{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "name": "NER_bert_bilstm_crf.ipynb",
      "provenance": [],
      "collapsed_sections": [],
      "authorship_tag": "ABX9TyM/WsCRoZp25rwCnGPKyabM",
      "include_colab_link": true
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "widgets": {
      "application/vnd.jupyter.widget-state+json": {
        "a70e8eaa27884bfcbe79b0d23714f4d8": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "state": {
            "_view_name": "HBoxView",
            "_dom_classes": [],
            "_model_name": "HBoxModel",
            "_view_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_view_count": null,
            "_view_module_version": "1.5.0",
            "box_style": "",
            "layout": "IPY_MODEL_a4b90e489c164a7fb5a265655b831724",
            "_model_module": "@jupyter-widgets/controls",
            "children": [
              "IPY_MODEL_5598043135754a73bd8d043e4ec9446d",
              "IPY_MODEL_3141e6a895c048e8ae9a616dd81ee3c6"
            ]
          }
        },
        "a4b90e489c164a7fb5a265655b831724": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "state": {
            "_view_name": "LayoutView",
            "grid_template_rows": null,
            "right": null,
            "justify_content": null,
            "_view_module": "@jupyter-widgets/base",
            "overflow": null,
            "_model_module_version": "1.2.0",
            "_view_count": null,
            "flex_flow": null,
            "width": null,
            "min_width": null,
            "border": null,
            "align_items": null,
            "bottom": null,
            "_model_module": "@jupyter-widgets/base",
            "top": null,
            "grid_column": null,
            "overflow_y": null,
            "overflow_x": null,
            "grid_auto_flow": null,
            "grid_area": null,
            "grid_template_columns": null,
            "flex": null,
            "_model_name": "LayoutModel",
            "justify_items": null,
            "grid_row": null,
            "max_height": null,
            "align_content": null,
            "visibility": null,
            "align_self": null,
            "height": null,
            "min_height": null,
            "padding": null,
            "grid_auto_rows": null,
            "grid_gap": null,
            "max_width": null,
            "order": null,
            "_view_module_version": "1.2.0",
            "grid_template_areas": null,
            "object_position": null,
            "object_fit": null,
            "grid_auto_columns": null,
            "margin": null,
            "display": null,
            "left": null
          }
        },
        "5598043135754a73bd8d043e4ec9446d": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "state": {
            "_view_name": "ProgressView",
            "style": "IPY_MODEL_af5446e2b301433fa930dea4fb85816f",
            "_dom_classes": [],
            "description": "Downloading: 100%",
            "_model_name": "FloatProgressModel",
            "bar_style": "success",
            "max": 433,
            "_view_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "value": 433,
            "_view_count": null,
            "_view_module_version": "1.5.0",
            "orientation": "horizontal",
            "min": 0,
            "description_tooltip": null,
            "_model_module": "@jupyter-widgets/controls",
            "layout": "IPY_MODEL_0d3e0de8b9824c70b2b026b64669b834"
          }
        },
        "3141e6a895c048e8ae9a616dd81ee3c6": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "state": {
            "_view_name": "HTMLView",
            "style": "IPY_MODEL_89fd61196dd648e0ad72abf63b8fb0e9",
            "_dom_classes": [],
            "description": "",
            "_model_name": "HTMLModel",
            "placeholder": "​",
            "_view_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "value": " 433/433 [00:00&lt;00:00, 1.35kB/s]",
            "_view_count": null,
            "_view_module_version": "1.5.0",
            "description_tooltip": null,
            "_model_module": "@jupyter-widgets/controls",
            "layout": "IPY_MODEL_370d74f69dcd4fb3a097bfb8667ac0c1"
          }
        },
        "af5446e2b301433fa930dea4fb85816f": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "state": {
            "_view_name": "StyleView",
            "_model_name": "ProgressStyleModel",
            "description_width": "initial",
            "_view_module": "@jupyter-widgets/base",
            "_model_module_version": "1.5.0",
            "_view_count": null,
            "_view_module_version": "1.2.0",
            "bar_color": null,
            "_model_module": "@jupyter-widgets/controls"
          }
        },
        "0d3e0de8b9824c70b2b026b64669b834": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "state": {
            "_view_name": "LayoutView",
            "grid_template_rows": null,
            "right": null,
            "justify_content": null,
            "_view_module": "@jupyter-widgets/base",
            "overflow": null,
            "_model_module_version": "1.2.0",
            "_view_count": null,
            "flex_flow": null,
            "width": null,
            "min_width": null,
            "border": null,
            "align_items": null,
            "bottom": null,
            "_model_module": "@jupyter-widgets/base",
            "top": null,
            "grid_column": null,
            "overflow_y": null,
            "overflow_x": null,
            "grid_auto_flow": null,
            "grid_area": null,
            "grid_template_columns": null,
            "flex": null,
            "_model_name": "LayoutModel",
            "justify_items": null,
            "grid_row": null,
            "max_height": null,
            "align_content": null,
            "visibility": null,
            "align_self": null,
            "height": null,
            "min_height": null,
            "padding": null,
            "grid_auto_rows": null,
            "grid_gap": null,
            "max_width": null,
            "order": null,
            "_view_module_version": "1.2.0",
            "grid_template_areas": null,
            "object_position": null,
            "object_fit": null,
            "grid_auto_columns": null,
            "margin": null,
            "display": null,
            "left": null
          }
        },
        "89fd61196dd648e0ad72abf63b8fb0e9": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "state": {
            "_view_name": "StyleView",
            "_model_name": "DescriptionStyleModel",
            "description_width": "",
            "_view_module": "@jupyter-widgets/base",
            "_model_module_version": "1.5.0",
            "_view_count": null,
            "_view_module_version": "1.2.0",
            "_model_module": "@jupyter-widgets/controls"
          }
        },
        "370d74f69dcd4fb3a097bfb8667ac0c1": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "state": {
            "_view_name": "LayoutView",
            "grid_template_rows": null,
            "right": null,
            "justify_content": null,
            "_view_module": "@jupyter-widgets/base",
            "overflow": null,
            "_model_module_version": "1.2.0",
            "_view_count": null,
            "flex_flow": null,
            "width": null,
            "min_width": null,
            "border": null,
            "align_items": null,
            "bottom": null,
            "_model_module": "@jupyter-widgets/base",
            "top": null,
            "grid_column": null,
            "overflow_y": null,
            "overflow_x": null,
            "grid_auto_flow": null,
            "grid_area": null,
            "grid_template_columns": null,
            "flex": null,
            "_model_name": "LayoutModel",
            "justify_items": null,
            "grid_row": null,
            "max_height": null,
            "align_content": null,
            "visibility": null,
            "align_self": null,
            "height": null,
            "min_height": null,
            "padding": null,
            "grid_auto_rows": null,
            "grid_gap": null,
            "max_width": null,
            "order": null,
            "_view_module_version": "1.2.0",
            "grid_template_areas": null,
            "object_position": null,
            "object_fit": null,
            "grid_auto_columns": null,
            "margin": null,
            "display": null,
            "left": null
          }
        },
        "8129fbf206d74a21a5544c2083c9c143": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "state": {
            "_view_name": "HBoxView",
            "_dom_classes": [],
            "_model_name": "HBoxModel",
            "_view_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_view_count": null,
            "_view_module_version": "1.5.0",
            "box_style": "",
            "layout": "IPY_MODEL_dfbaa556d6a94cb8836c2aaa08a3fb7c",
            "_model_module": "@jupyter-widgets/controls",
            "children": [
              "IPY_MODEL_e5a28f13f8894eccbe74663c86725e0a",
              "IPY_MODEL_39e4b03464b0441c85996bb590807705"
            ]
          }
        },
        "dfbaa556d6a94cb8836c2aaa08a3fb7c": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "state": {
            "_view_name": "LayoutView",
            "grid_template_rows": null,
            "right": null,
            "justify_content": null,
            "_view_module": "@jupyter-widgets/base",
            "overflow": null,
            "_model_module_version": "1.2.0",
            "_view_count": null,
            "flex_flow": null,
            "width": null,
            "min_width": null,
            "border": null,
            "align_items": null,
            "bottom": null,
            "_model_module": "@jupyter-widgets/base",
            "top": null,
            "grid_column": null,
            "overflow_y": null,
            "overflow_x": null,
            "grid_auto_flow": null,
            "grid_area": null,
            "grid_template_columns": null,
            "flex": null,
            "_model_name": "LayoutModel",
            "justify_items": null,
            "grid_row": null,
            "max_height": null,
            "align_content": null,
            "visibility": null,
            "align_self": null,
            "height": null,
            "min_height": null,
            "padding": null,
            "grid_auto_rows": null,
            "grid_gap": null,
            "max_width": null,
            "order": null,
            "_view_module_version": "1.2.0",
            "grid_template_areas": null,
            "object_position": null,
            "object_fit": null,
            "grid_auto_columns": null,
            "margin": null,
            "display": null,
            "left": null
          }
        },
        "e5a28f13f8894eccbe74663c86725e0a": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "state": {
            "_view_name": "ProgressView",
            "style": "IPY_MODEL_83a0fd94d4964ade902ff8abfeff4865",
            "_dom_classes": [],
            "description": "Downloading: 100%",
            "_model_name": "FloatProgressModel",
            "bar_style": "success",
            "max": 526681800,
            "_view_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "value": 526681800,
            "_view_count": null,
            "_view_module_version": "1.5.0",
            "orientation": "horizontal",
            "min": 0,
            "description_tooltip": null,
            "_model_module": "@jupyter-widgets/controls",
            "layout": "IPY_MODEL_e67d3527db684f97aa180ab9602c2155"
          }
        },
        "39e4b03464b0441c85996bb590807705": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "state": {
            "_view_name": "HTMLView",
            "style": "IPY_MODEL_03c8b75226dc4418a91a775153284949",
            "_dom_classes": [],
            "description": "",
            "_model_name": "HTMLModel",
            "placeholder": "​",
            "_view_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "value": " 527M/527M [00:08&lt;00:00, 62.4MB/s]",
            "_view_count": null,
            "_view_module_version": "1.5.0",
            "description_tooltip": null,
            "_model_module": "@jupyter-widgets/controls",
            "layout": "IPY_MODEL_d9db770455934f0a97d0f93117372bd6"
          }
        },
        "83a0fd94d4964ade902ff8abfeff4865": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "state": {
            "_view_name": "StyleView",
            "_model_name": "ProgressStyleModel",
            "description_width": "initial",
            "_view_module": "@jupyter-widgets/base",
            "_model_module_version": "1.5.0",
            "_view_count": null,
            "_view_module_version": "1.2.0",
            "bar_color": null,
            "_model_module": "@jupyter-widgets/controls"
          }
        },
        "e67d3527db684f97aa180ab9602c2155": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "state": {
            "_view_name": "LayoutView",
            "grid_template_rows": null,
            "right": null,
            "justify_content": null,
            "_view_module": "@jupyter-widgets/base",
            "overflow": null,
            "_model_module_version": "1.2.0",
            "_view_count": null,
            "flex_flow": null,
            "width": null,
            "min_width": null,
            "border": null,
            "align_items": null,
            "bottom": null,
            "_model_module": "@jupyter-widgets/base",
            "top": null,
            "grid_column": null,
            "overflow_y": null,
            "overflow_x": null,
            "grid_auto_flow": null,
            "grid_area": null,
            "grid_template_columns": null,
            "flex": null,
            "_model_name": "LayoutModel",
            "justify_items": null,
            "grid_row": null,
            "max_height": null,
            "align_content": null,
            "visibility": null,
            "align_self": null,
            "height": null,
            "min_height": null,
            "padding": null,
            "grid_auto_rows": null,
            "grid_gap": null,
            "max_width": null,
            "order": null,
            "_view_module_version": "1.2.0",
            "grid_template_areas": null,
            "object_position": null,
            "object_fit": null,
            "grid_auto_columns": null,
            "margin": null,
            "display": null,
            "left": null
          }
        },
        "03c8b75226dc4418a91a775153284949": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "state": {
            "_view_name": "StyleView",
            "_model_name": "DescriptionStyleModel",
            "description_width": "",
            "_view_module": "@jupyter-widgets/base",
            "_model_module_version": "1.5.0",
            "_view_count": null,
            "_view_module_version": "1.2.0",
            "_model_module": "@jupyter-widgets/controls"
          }
        },
        "d9db770455934f0a97d0f93117372bd6": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "state": {
            "_view_name": "LayoutView",
            "grid_template_rows": null,
            "right": null,
            "justify_content": null,
            "_view_module": "@jupyter-widgets/base",
            "overflow": null,
            "_model_module_version": "1.2.0",
            "_view_count": null,
            "flex_flow": null,
            "width": null,
            "min_width": null,
            "border": null,
            "align_items": null,
            "bottom": null,
            "_model_module": "@jupyter-widgets/base",
            "top": null,
            "grid_column": null,
            "overflow_y": null,
            "overflow_x": null,
            "grid_auto_flow": null,
            "grid_area": null,
            "grid_template_columns": null,
            "flex": null,
            "_model_name": "LayoutModel",
            "justify_items": null,
            "grid_row": null,
            "max_height": null,
            "align_content": null,
            "visibility": null,
            "align_self": null,
            "height": null,
            "min_height": null,
            "padding": null,
            "grid_auto_rows": null,
            "grid_gap": null,
            "max_width": null,
            "order": null,
            "_view_module_version": "1.2.0",
            "grid_template_areas": null,
            "object_position": null,
            "object_fit": null,
            "grid_auto_columns": null,
            "margin": null,
            "display": null,
            "left": null
          }
        },
        "35f1e18eb4ad460d83d70da2051671a8": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "state": {
            "_view_name": "HBoxView",
            "_dom_classes": [],
            "_model_name": "HBoxModel",
            "_view_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_view_count": null,
            "_view_module_version": "1.5.0",
            "box_style": "",
            "layout": "IPY_MODEL_48b24187237641df8f1b46ee90814013",
            "_model_module": "@jupyter-widgets/controls",
            "children": [
              "IPY_MODEL_1fb936169290464f80e42f36793c12be",
              "IPY_MODEL_4d4137f4e1c54de494ea1734b6a2964d"
            ]
          }
        },
        "48b24187237641df8f1b46ee90814013": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "state": {
            "_view_name": "LayoutView",
            "grid_template_rows": null,
            "right": null,
            "justify_content": null,
            "_view_module": "@jupyter-widgets/base",
            "overflow": null,
            "_model_module_version": "1.2.0",
            "_view_count": null,
            "flex_flow": null,
            "width": null,
            "min_width": null,
            "border": null,
            "align_items": null,
            "bottom": null,
            "_model_module": "@jupyter-widgets/base",
            "top": null,
            "grid_column": null,
            "overflow_y": null,
            "overflow_x": null,
            "grid_auto_flow": null,
            "grid_area": null,
            "grid_template_columns": null,
            "flex": null,
            "_model_name": "LayoutModel",
            "justify_items": null,
            "grid_row": null,
            "max_height": null,
            "align_content": null,
            "visibility": null,
            "align_self": null,
            "height": null,
            "min_height": null,
            "padding": null,
            "grid_auto_rows": null,
            "grid_gap": null,
            "max_width": null,
            "order": null,
            "_view_module_version": "1.2.0",
            "grid_template_areas": null,
            "object_position": null,
            "object_fit": null,
            "grid_auto_columns": null,
            "margin": null,
            "display": null,
            "left": null
          }
        },
        "1fb936169290464f80e42f36793c12be": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "state": {
            "_view_name": "ProgressView",
            "style": "IPY_MODEL_8951e2f1a68a4dd7aeded7fe92993eb8",
            "_dom_classes": [],
            "description": "Downloading: 100%",
            "_model_name": "FloatProgressModel",
            "bar_style": "success",
            "max": 213450,
            "_view_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "value": 213450,
            "_view_count": null,
            "_view_module_version": "1.5.0",
            "orientation": "horizontal",
            "min": 0,
            "description_tooltip": null,
            "_model_module": "@jupyter-widgets/controls",
            "layout": "IPY_MODEL_0bf82eb8f2bb4bdcb1001b858c84227c"
          }
        },
        "4d4137f4e1c54de494ea1734b6a2964d": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "state": {
            "_view_name": "HTMLView",
            "style": "IPY_MODEL_639994e3be4048e8adb59195bdce2e92",
            "_dom_classes": [],
            "description": "",
            "_model_name": "HTMLModel",
            "placeholder": "​",
            "_view_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "value": " 213k/213k [00:00&lt;00:00, 2.07MB/s]",
            "_view_count": null,
            "_view_module_version": "1.5.0",
            "description_tooltip": null,
            "_model_module": "@jupyter-widgets/controls",
            "layout": "IPY_MODEL_a0230b830e724ff7a989a5f4094c0131"
          }
        },
        "8951e2f1a68a4dd7aeded7fe92993eb8": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "state": {
            "_view_name": "StyleView",
            "_model_name": "ProgressStyleModel",
            "description_width": "initial",
            "_view_module": "@jupyter-widgets/base",
            "_model_module_version": "1.5.0",
            "_view_count": null,
            "_view_module_version": "1.2.0",
            "bar_color": null,
            "_model_module": "@jupyter-widgets/controls"
          }
        },
        "0bf82eb8f2bb4bdcb1001b858c84227c": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "state": {
            "_view_name": "LayoutView",
            "grid_template_rows": null,
            "right": null,
            "justify_content": null,
            "_view_module": "@jupyter-widgets/base",
            "overflow": null,
            "_model_module_version": "1.2.0",
            "_view_count": null,
            "flex_flow": null,
            "width": null,
            "min_width": null,
            "border": null,
            "align_items": null,
            "bottom": null,
            "_model_module": "@jupyter-widgets/base",
            "top": null,
            "grid_column": null,
            "overflow_y": null,
            "overflow_x": null,
            "grid_auto_flow": null,
            "grid_area": null,
            "grid_template_columns": null,
            "flex": null,
            "_model_name": "LayoutModel",
            "justify_items": null,
            "grid_row": null,
            "max_height": null,
            "align_content": null,
            "visibility": null,
            "align_self": null,
            "height": null,
            "min_height": null,
            "padding": null,
            "grid_auto_rows": null,
            "grid_gap": null,
            "max_width": null,
            "order": null,
            "_view_module_version": "1.2.0",
            "grid_template_areas": null,
            "object_position": null,
            "object_fit": null,
            "grid_auto_columns": null,
            "margin": null,
            "display": null,
            "left": null
          }
        },
        "639994e3be4048e8adb59195bdce2e92": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "state": {
            "_view_name": "StyleView",
            "_model_name": "DescriptionStyleModel",
            "description_width": "",
            "_view_module": "@jupyter-widgets/base",
            "_model_module_version": "1.5.0",
            "_view_count": null,
            "_view_module_version": "1.2.0",
            "_model_module": "@jupyter-widgets/controls"
          }
        },
        "a0230b830e724ff7a989a5f4094c0131": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "state": {
            "_view_name": "LayoutView",
            "grid_template_rows": null,
            "right": null,
            "justify_content": null,
            "_view_module": "@jupyter-widgets/base",
            "overflow": null,
            "_model_module_version": "1.2.0",
            "_view_count": null,
            "flex_flow": null,
            "width": null,
            "min_width": null,
            "border": null,
            "align_items": null,
            "bottom": null,
            "_model_module": "@jupyter-widgets/base",
            "top": null,
            "grid_column": null,
            "overflow_y": null,
            "overflow_x": null,
            "grid_auto_flow": null,
            "grid_area": null,
            "grid_template_columns": null,
            "flex": null,
            "_model_name": "LayoutModel",
            "justify_items": null,
            "grid_row": null,
            "max_height": null,
            "align_content": null,
            "visibility": null,
            "align_self": null,
            "height": null,
            "min_height": null,
            "padding": null,
            "grid_auto_rows": null,
            "grid_gap": null,
            "max_width": null,
            "order": null,
            "_view_module_version": "1.2.0",
            "grid_template_areas": null,
            "object_position": null,
            "object_fit": null,
            "grid_auto_columns": null,
            "margin": null,
            "display": null,
            "left": null
          }
        }
      }
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/debugk/NER_Covid19/blob/AddEval/NER_bert_bilstm_crf.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "NUZ7Zxv0zr1r",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 165
        },
        "outputId": "c83134ca-49a9-420f-cd52-db2a7a15ca39"
      },
      "source": [
        "import numpy as np\n",
        "import seaborn as sns\n",
        "import matplotlib.pyplot as plt\n",
        "\n",
        "from google.colab import drive\n",
        "drive.mount('/content/gdrive')"
      ],
      "execution_count": 1,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "/usr/local/lib/python3.6/dist-packages/statsmodels/tools/_testing.py:19: FutureWarning: pandas.util.testing is deprecated. Use the functions in the public API at pandas.testing instead.\n",
            "  import pandas.util.testing as tm\n"
          ],
          "name": "stderr"
        },
        {
          "output_type": "stream",
          "text": [
            "Go to this URL in a browser: https://accounts.google.com/o/oauth2/auth?client_id=947318989803-6bn6qk8qdgf4n4g3pfee6491hc0brc4i.apps.googleusercontent.com&redirect_uri=urn%3aietf%3awg%3aoauth%3a2.0%3aoob&response_type=code&scope=email%20https%3a%2f%2fwww.googleapis.com%2fauth%2fdocs.test%20https%3a%2f%2fwww.googleapis.com%2fauth%2fdrive%20https%3a%2f%2fwww.googleapis.com%2fauth%2fdrive.photos.readonly%20https%3a%2f%2fwww.googleapis.com%2fauth%2fpeopleapi.readonly\n",
            "\n",
            "Enter your authorization code:\n",
            "··········\n",
            "Mounted at /content/gdrive\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "hkLnG3wY0ytz",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 635
        },
        "outputId": "3697b3c1-2edc-4a58-9d24-0feb8ebef142"
      },
      "source": [
        "#install the amazing transformers package by huggingface\n",
        "!pip install transformers\n",
        "import transformers\n",
        "from transformers import BertTokenizer, BertConfig"
      ],
      "execution_count": 2,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "Collecting transformers\n",
            "\u001b[?25l  Downloading https://files.pythonhosted.org/packages/27/3c/91ed8f5c4e7ef3227b4119200fc0ed4b4fd965b1f0172021c25701087825/transformers-3.0.2-py3-none-any.whl (769kB)\n",
            "\r\u001b[K     |▍                               | 10kB 12.2MB/s eta 0:00:01\r\u001b[K     |▉                               | 20kB 1.6MB/s eta 0:00:01\r\u001b[K     |█▎                              | 30kB 2.2MB/s eta 0:00:01\r\u001b[K     |█▊                              | 40kB 2.5MB/s eta 0:00:01\r\u001b[K     |██▏                             | 51kB 2.0MB/s eta 0:00:01\r\u001b[K     |██▋                             | 61kB 2.2MB/s eta 0:00:01\r\u001b[K     |███                             | 71kB 2.5MB/s eta 0:00:01\r\u001b[K     |███▍                            | 81kB 2.7MB/s eta 0:00:01\r\u001b[K     |███▉                            | 92kB 2.9MB/s eta 0:00:01\r\u001b[K     |████▎                           | 102kB 2.7MB/s eta 0:00:01\r\u001b[K     |████▊                           | 112kB 2.7MB/s eta 0:00:01\r\u001b[K     |█████▏                          | 122kB 2.7MB/s eta 0:00:01\r\u001b[K     |█████▌                          | 133kB 2.7MB/s eta 0:00:01\r\u001b[K     |██████                          | 143kB 2.7MB/s eta 0:00:01\r\u001b[K     |██████▍                         | 153kB 2.7MB/s eta 0:00:01\r\u001b[K     |██████▉                         | 163kB 2.7MB/s eta 0:00:01\r\u001b[K     |███████▎                        | 174kB 2.7MB/s eta 0:00:01\r\u001b[K     |███████▊                        | 184kB 2.7MB/s eta 0:00:01\r\u001b[K     |████████                        | 194kB 2.7MB/s eta 0:00:01\r\u001b[K     |████████▌                       | 204kB 2.7MB/s eta 0:00:01\r\u001b[K     |█████████                       | 215kB 2.7MB/s eta 0:00:01\r\u001b[K     |█████████▍                      | 225kB 2.7MB/s eta 0:00:01\r\u001b[K     |█████████▉                      | 235kB 2.7MB/s eta 0:00:01\r\u001b[K     |██████████▎                     | 245kB 2.7MB/s eta 0:00:01\r\u001b[K     |██████████▋                     | 256kB 2.7MB/s eta 0:00:01\r\u001b[K     |███████████                     | 266kB 2.7MB/s eta 0:00:01\r\u001b[K     |███████████▌                    | 276kB 2.7MB/s eta 0:00:01\r\u001b[K     |████████████                    | 286kB 2.7MB/s eta 0:00:01\r\u001b[K     |████████████▍                   | 296kB 2.7MB/s eta 0:00:01\r\u001b[K     |████████████▉                   | 307kB 2.7MB/s eta 0:00:01\r\u001b[K     |█████████████▏                  | 317kB 2.7MB/s eta 0:00:01\r\u001b[K     |█████████████▋                  | 327kB 2.7MB/s eta 0:00:01\r\u001b[K     |██████████████                  | 337kB 2.7MB/s eta 0:00:01\r\u001b[K     |██████████████▌                 | 348kB 2.7MB/s eta 0:00:01\r\u001b[K     |███████████████                 | 358kB 2.7MB/s eta 0:00:01\r\u001b[K     |███████████████▍                | 368kB 2.7MB/s eta 0:00:01\r\u001b[K     |███████████████▊                | 378kB 2.7MB/s eta 0:00:01\r\u001b[K     |████████████████▏               | 389kB 2.7MB/s eta 0:00:01\r\u001b[K     |████████████████▋               | 399kB 2.7MB/s eta 0:00:01\r\u001b[K     |█████████████████               | 409kB 2.7MB/s eta 0:00:01\r\u001b[K     |█████████████████▌              | 419kB 2.7MB/s eta 0:00:01\r\u001b[K     |██████████████████              | 430kB 2.7MB/s eta 0:00:01\r\u001b[K     |██████████████████▎             | 440kB 2.7MB/s eta 0:00:01\r\u001b[K     |██████████████████▊             | 450kB 2.7MB/s eta 0:00:01\r\u001b[K     |███████████████████▏            | 460kB 2.7MB/s eta 0:00:01\r\u001b[K     |███████████████████▋            | 471kB 2.7MB/s eta 0:00:01\r\u001b[K     |████████████████████            | 481kB 2.7MB/s eta 0:00:01\r\u001b[K     |████████████████████▌           | 491kB 2.7MB/s eta 0:00:01\r\u001b[K     |████████████████████▉           | 501kB 2.7MB/s eta 0:00:01\r\u001b[K     |█████████████████████▎          | 512kB 2.7MB/s eta 0:00:01\r\u001b[K     |█████████████████████▊          | 522kB 2.7MB/s eta 0:00:01\r\u001b[K     |██████████████████████▏         | 532kB 2.7MB/s eta 0:00:01\r\u001b[K     |██████████████████████▋         | 542kB 2.7MB/s eta 0:00:01\r\u001b[K     |███████████████████████         | 552kB 2.7MB/s eta 0:00:01\r\u001b[K     |███████████████████████▍        | 563kB 2.7MB/s eta 0:00:01\r\u001b[K     |███████████████████████▉        | 573kB 2.7MB/s eta 0:00:01\r\u001b[K     |████████████████████████▎       | 583kB 2.7MB/s eta 0:00:01\r\u001b[K     |████████████████████████▊       | 593kB 2.7MB/s eta 0:00:01\r\u001b[K     |█████████████████████████▏      | 604kB 2.7MB/s eta 0:00:01\r\u001b[K     |█████████████████████████▋      | 614kB 2.7MB/s eta 0:00:01\r\u001b[K     |██████████████████████████      | 624kB 2.7MB/s eta 0:00:01\r\u001b[K     |██████████████████████████▍     | 634kB 2.7MB/s eta 0:00:01\r\u001b[K     |██████████████████████████▉     | 645kB 2.7MB/s eta 0:00:01\r\u001b[K     |███████████████████████████▎    | 655kB 2.7MB/s eta 0:00:01\r\u001b[K     |███████████████████████████▊    | 665kB 2.7MB/s eta 0:00:01\r\u001b[K     |████████████████████████████▏   | 675kB 2.7MB/s eta 0:00:01\r\u001b[K     |████████████████████████████▌   | 686kB 2.7MB/s eta 0:00:01\r\u001b[K     |█████████████████████████████   | 696kB 2.7MB/s eta 0:00:01\r\u001b[K     |█████████████████████████████▍  | 706kB 2.7MB/s eta 0:00:01\r\u001b[K     |█████████████████████████████▉  | 716kB 2.7MB/s eta 0:00:01\r\u001b[K     |██████████████████████████████▎ | 727kB 2.7MB/s eta 0:00:01\r\u001b[K     |██████████████████████████████▊ | 737kB 2.7MB/s eta 0:00:01\r\u001b[K     |███████████████████████████████ | 747kB 2.7MB/s eta 0:00:01\r\u001b[K     |███████████████████████████████▌| 757kB 2.7MB/s eta 0:00:01\r\u001b[K     |████████████████████████████████| 768kB 2.7MB/s eta 0:00:01\r\u001b[K     |████████████████████████████████| 778kB 2.7MB/s \n",
            "\u001b[?25hRequirement already satisfied: filelock in /usr/local/lib/python3.6/dist-packages (from transformers) (3.0.12)\n",
            "Collecting sentencepiece!=0.1.92\n",
            "\u001b[?25l  Downloading https://files.pythonhosted.org/packages/d4/a4/d0a884c4300004a78cca907a6ff9a5e9fe4f090f5d95ab341c53d28cbc58/sentencepiece-0.1.91-cp36-cp36m-manylinux1_x86_64.whl (1.1MB)\n",
            "\u001b[K     |████████████████████████████████| 1.1MB 15.2MB/s \n",
            "\u001b[?25hCollecting sacremoses\n",
            "\u001b[?25l  Downloading https://files.pythonhosted.org/packages/7d/34/09d19aff26edcc8eb2a01bed8e98f13a1537005d31e95233fd48216eed10/sacremoses-0.0.43.tar.gz (883kB)\n",
            "\u001b[K     |████████████████████████████████| 890kB 17.0MB/s \n",
            "\u001b[?25hRequirement already satisfied: packaging in /usr/local/lib/python3.6/dist-packages (from transformers) (20.4)\n",
            "Requirement already satisfied: dataclasses; python_version < \"3.7\" in /usr/local/lib/python3.6/dist-packages (from transformers) (0.7)\n",
            "Requirement already satisfied: tqdm>=4.27 in /usr/local/lib/python3.6/dist-packages (from transformers) (4.41.1)\n",
            "Collecting tokenizers==0.8.1.rc1\n",
            "\u001b[?25l  Downloading https://files.pythonhosted.org/packages/40/d0/30d5f8d221a0ed981a186c8eb986ce1c94e3a6e87f994eae9f4aa5250217/tokenizers-0.8.1rc1-cp36-cp36m-manylinux1_x86_64.whl (3.0MB)\n",
            "\u001b[K     |████████████████████████████████| 3.0MB 13.4MB/s \n",
            "\u001b[?25hRequirement already satisfied: requests in /usr/local/lib/python3.6/dist-packages (from transformers) (2.23.0)\n",
            "Requirement already satisfied: numpy in /usr/local/lib/python3.6/dist-packages (from transformers) (1.18.5)\n",
            "Requirement already satisfied: regex!=2019.12.17 in /usr/local/lib/python3.6/dist-packages (from transformers) (2019.12.20)\n",
            "Requirement already satisfied: six in /usr/local/lib/python3.6/dist-packages (from sacremoses->transformers) (1.15.0)\n",
            "Requirement already satisfied: click in /usr/local/lib/python3.6/dist-packages (from sacremoses->transformers) (7.1.2)\n",
            "Requirement already satisfied: joblib in /usr/local/lib/python3.6/dist-packages (from sacremoses->transformers) (0.16.0)\n",
            "Requirement already satisfied: pyparsing>=2.0.2 in /usr/local/lib/python3.6/dist-packages (from packaging->transformers) (2.4.7)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.6/dist-packages (from requests->transformers) (2020.6.20)\n",
            "Requirement already satisfied: chardet<4,>=3.0.2 in /usr/local/lib/python3.6/dist-packages (from requests->transformers) (3.0.4)\n",
            "Requirement already satisfied: idna<3,>=2.5 in /usr/local/lib/python3.6/dist-packages (from requests->transformers) (2.10)\n",
            "Requirement already satisfied: urllib3!=1.25.0,!=1.25.1,<1.26,>=1.21.1 in /usr/local/lib/python3.6/dist-packages (from requests->transformers) (1.24.3)\n",
            "Building wheels for collected packages: sacremoses\n",
            "  Building wheel for sacremoses (setup.py) ... \u001b[?25l\u001b[?25hdone\n",
            "  Created wheel for sacremoses: filename=sacremoses-0.0.43-cp36-none-any.whl size=893260 sha256=3c84a150967e754ac79a22a15e1108fbb3b90945e3f21c0e5624e3141fe41c81\n",
            "  Stored in directory: /root/.cache/pip/wheels/29/3c/fd/7ce5c3f0666dab31a50123635e6fb5e19ceb42ce38d4e58f45\n",
            "Successfully built sacremoses\n",
            "Installing collected packages: sentencepiece, sacremoses, tokenizers, transformers\n",
            "Successfully installed sacremoses-0.0.43 sentencepiece-0.1.91 tokenizers-0.8.1rc1 transformers-3.0.2\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "DGOzKE851TCt",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 278,
          "referenced_widgets": [
            "a70e8eaa27884bfcbe79b0d23714f4d8",
            "a4b90e489c164a7fb5a265655b831724",
            "5598043135754a73bd8d043e4ec9446d",
            "3141e6a895c048e8ae9a616dd81ee3c6",
            "af5446e2b301433fa930dea4fb85816f",
            "0d3e0de8b9824c70b2b026b64669b834",
            "89fd61196dd648e0ad72abf63b8fb0e9",
            "370d74f69dcd4fb3a097bfb8667ac0c1",
            "8129fbf206d74a21a5544c2083c9c143",
            "dfbaa556d6a94cb8836c2aaa08a3fb7c",
            "e5a28f13f8894eccbe74663c86725e0a",
            "39e4b03464b0441c85996bb590807705",
            "83a0fd94d4964ade902ff8abfeff4865",
            "e67d3527db684f97aa180ab9602c2155",
            "03c8b75226dc4418a91a775153284949",
            "d9db770455934f0a97d0f93117372bd6",
            "35f1e18eb4ad460d83d70da2051671a8",
            "48b24187237641df8f1b46ee90814013",
            "1fb936169290464f80e42f36793c12be",
            "4d4137f4e1c54de494ea1734b6a2964d",
            "8951e2f1a68a4dd7aeded7fe92993eb8",
            "0bf82eb8f2bb4bdcb1001b858c84227c",
            "639994e3be4048e8adb59195bdce2e92",
            "a0230b830e724ff7a989a5f4094c0131"
          ]
        },
        "outputId": "0e7be8df-71f8-4354-ff45-bfafb9b87034"
      },
      "source": [
        "from transformers import BertTokenizer, TFBertModel\n",
        "import tensorflow as tf\n",
        "\n",
        "tf_model = TFBertModel.from_pretrained('bert-base-cased')\n",
        "tokenizer = BertTokenizer.from_pretrained('bert-base-cased')"
      ],
      "execution_count": 3,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "application/vnd.jupyter.widget-view+json": {
              "model_id": "a70e8eaa27884bfcbe79b0d23714f4d8",
              "version_minor": 0,
              "version_major": 2
            },
            "text/plain": [
              "HBox(children=(FloatProgress(value=0.0, description='Downloading', max=433.0, style=ProgressStyle(description_…"
            ]
          },
          "metadata": {
            "tags": []
          }
        },
        {
          "output_type": "stream",
          "text": [
            "\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "display_data",
          "data": {
            "application/vnd.jupyter.widget-view+json": {
              "model_id": "8129fbf206d74a21a5544c2083c9c143",
              "version_minor": 0,
              "version_major": 2
            },
            "text/plain": [
              "HBox(children=(FloatProgress(value=0.0, description='Downloading', max=526681800.0, style=ProgressStyle(descri…"
            ]
          },
          "metadata": {
            "tags": []
          }
        },
        {
          "output_type": "stream",
          "text": [
            "\n"
          ],
          "name": "stdout"
        },
        {
          "output_type": "stream",
          "text": [
            "Some weights of the model checkpoint at bert-base-cased were not used when initializing TFBertModel: ['nsp___cls', 'mlm___cls']\n",
            "- This IS expected if you are initializing TFBertModel from the checkpoint of a model trained on another task or with another architecture (e.g. initializing a BertForSequenceClassification model from a BertForPretraining model).\n",
            "- This IS NOT expected if you are initializing TFBertModel from the checkpoint of a model that you expect to be exactly identical (initializing a BertForSequenceClassification model from a BertForSequenceClassification model).\n",
            "All the weights of TFBertModel were initialized from the model checkpoint at bert-base-cased.\n",
            "If your task is similar to the task the model of the ckeckpoint was trained on, you can already use TFBertModel for predictions without further training.\n"
          ],
          "name": "stderr"
        },
        {
          "output_type": "display_data",
          "data": {
            "application/vnd.jupyter.widget-view+json": {
              "model_id": "35f1e18eb4ad460d83d70da2051671a8",
              "version_minor": 0,
              "version_major": 2
            },
            "text/plain": [
              "HBox(children=(FloatProgress(value=0.0, description='Downloading', max=213450.0, style=ProgressStyle(descripti…"
            ]
          },
          "metadata": {
            "tags": []
          }
        },
        {
          "output_type": "stream",
          "text": [
            "\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "z9qqiHio_Z0j",
        "colab_type": "code",
        "colab": {}
      },
      "source": [
        "import nltk\n",
        "nltk.download('punkt')"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "HlMYjDbqK8iK",
        "colab_type": "text"
      },
      "source": [
        "# Word embedding"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "XYqfE68zlZiz",
        "colab_type": "code",
        "colab": {}
      },
      "source": [
        "\n",
        "#==========================================================================================\n",
        "def prepare_tokentags(data, max_length = 150, fdebug=False):\n",
        "    data_tags   = []\n",
        "    data_tokens = []\n",
        "\n",
        "    sentences = nltk.tokenize.sent_tokenize(data['text'])\n",
        "    entities  = sorted(data['entities'], key=lambda entry: entry['start'], reverse=True) # sort by the entry start point, reverse\n",
        "\n",
        "    # The target is the group of the words in top entry, i.e. papillomavirus -> \n",
        "    entry = entities.pop()\n",
        "    target_tokens = tokenizer.tokenize(entry['entity'])\n",
        "    target_token  = '_'.join(target_tokens)  \n",
        "    len_targets   = len(target_tokens)\n",
        "    \n",
        "    is_never_match = True\n",
        "\n",
        "    for sentence in sentences:\n",
        "        # init the sentence tags\n",
        "        sentence_tags = ['O']*max_length\n",
        "        # Add the special tokens.\n",
        "        sentence = \"[CLS] \" + sentence + \"[SEP]\" \n",
        "\n",
        "        tokens = tokenizer.tokenize(sentence)\n",
        "\n",
        "        if len(tokens) < max_length:\n",
        "            tokens += [\"[PAD]\"]*(max_length - len(tokens))\n",
        "        \n",
        "        i = 0\n",
        "\n",
        "        while i < min(len(tokens), max_length): # some len(tokens) > 150 \n",
        "            end_point = i+len_targets if (i+len_targets) < len(tokens) else len(tokens)\n",
        "            match_token = '_'.join(tokens[i:i+len_targets])\n",
        "\n",
        "            if match_token ==  target_token:\n",
        "                is_never_match = False\n",
        "\n",
        "                sentence_tags[i] = 'B-' + entry['type']\n",
        "\n",
        "                for j in range(1, len_targets):\n",
        "                    if i+j >= max_length: continue \n",
        "\n",
        "                    sentence_tags[i+j] = 'I-' + entry['type']\n",
        "\n",
        "                # update the position\n",
        "                i += len_targets \n",
        "\n",
        "                if entities:\n",
        "                    # remove the top entry, move to next entry\n",
        "                    entry = entities.pop()\n",
        "                    target_tokens = tokenizer.tokenize(entry['entity'])  \n",
        "                    target_token  = '_'.join(target_tokens)  \n",
        "                    len_targets   = len(target_tokens) \n",
        "                else:\n",
        "                    # entities is empty, stop loop\n",
        "                    i = len(tokens)\n",
        "            else:\n",
        "                  i += 1\n",
        "\n",
        "        if fdebug:\n",
        "            for token, tag in zip(tokens, sentence_tags):\n",
        "                print(\"{}\\t{}\".format(tag, token))\n",
        "        \n",
        "        data_tokens += [tokens]\n",
        "        data_tags   += [sentence_tags]           \n",
        "\n",
        "    if entities: \n",
        "        print(sentences)\n",
        "        print(\"unmatched tags: \", entities)\n",
        "    elif is_never_match:\n",
        "        print(sentences)\n",
        "        print(\"Only one tag and it is not matched: \", entry)\n",
        "\n",
        "    return (data_tokens, data_tags)\n",
        "\n",
        "\n",
        "#==========================================================================================\n",
        "def prepare_embedding(datas, max_length = 150, fdebug=False):\n",
        "    sentences = []\n",
        "    \n",
        "    for data in datas:\n",
        "        sentences += nltk.tokenize.sent_tokenize(data['text'])\n",
        "    \n",
        "    # it will extrat the same token as \"tokenizer.encode(sentence)\" or \"tokenizer.tokenize(sentence); tokenizer.convert_tokens_to_ids()\"\n",
        "    tf_inputs = tokenizer(sentences, padding=True, pad_to_multiple_of=max_length, return_attention_mask=True, return_tensors=\"tf\") \n",
        "\n",
        "    if fdebug:\n",
        "        print(tf_inputs)\n",
        "\n",
        "    tf_outputs = tf_model(tf_inputs)\n",
        "\n",
        "    # use the second-to-last layer for embedding.   \n",
        "    last_hidden_states = tf_outputs[0]\n",
        "\n",
        "    return last_hidden_states # tensorflow tensor"
      ],
      "execution_count": 21,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "CUT3c4jDzUA_",
        "colab_type": "text"
      },
      "source": [
        "# Word embedding test"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "z9KQnZaQzcyP",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "outputId": "e0d12840-5cdb-4d15-9079-406832669c2b"
      },
      "source": [
        "test_data = {\"text\": \"Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference\\tThe search for an HIV/AIDS vaccine is steadily moving ahead, generating and validating new concepts in terms of novel vectors for antigen delivery and presentation, new vaccine and adjuvant strategies, alternative approaches to design HIV-1 antigens for eliciting protective cross-neutralising antibodies, and identification of key mechanisms in HIV infection and modulation of the immune system. All these different perspectives are contributing to the unprecedented challenge of developing a protective HIV-1 vaccine.\", \n",
        "             \"entities\": [\n",
        "                          #{\"entity\": \"HIV vaccine\", \"type\": \"Drug\", \"start\": 35, \"end\": 46}, \n",
        "                          #{\"entity\": \"AIDS\", \"type\": \"Disease\", \"start\": 62, \"end\": 66}, \n",
        "                          #{\"entity\": \"HIV/AIDS vaccine\", \"type\": \"Drug\", \"start\": 109, \"end\": 125}, \n",
        "                          {\"entity\": \"vaccine\", \"type\": \"Drug\", \"start\": 118, \"end\": 125}, \n",
        "                          {\"entity\": \"vaccine\", \"type\": \"Drug\", \"start\": 260, \"end\": 267}, \n",
        "                          {\"entity\": \"HIV-1 antigens\", \"type\": \"Virus\", \"start\": 326, \"end\": 340}, \n",
        "                          {\"entity\": \"cross-neutralising antibodies\", \"type\": \"Chemical\", \"start\": 366, \"end\": 395}, \n",
        "                          {\"entity\": \"HIV infection\", \"type\": \"Phenotype\", \"start\": 437, \"end\": 450}, \n",
        "                          {\"entity\": \"HIV-1 vaccine\", \"type\": \"Drug\", \"start\": 596, \"end\": 609}]}\n",
        "\n",
        "\n",
        "test_tokens, test_tags = prepare_tokentags(test_data, fdebug=True) "
      ],
      "execution_count": 22,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "O\t[CLS]\n",
            "O\tProgress\n",
            "O\ttowards\n",
            "O\tdevelopment\n",
            "O\tof\n",
            "O\tan\n",
            "O\tHIV\n",
            "B-Drug\tvaccine\n",
            "O\t:\n",
            "O\treport\n",
            "O\tof\n",
            "O\tthe\n",
            "O\tAIDS\n",
            "O\tV\n",
            "O\t##ac\n",
            "O\t##cine\n",
            "O\t2009\n",
            "O\tConference\n",
            "O\tThe\n",
            "O\tsearch\n",
            "O\tfor\n",
            "O\tan\n",
            "O\tHIV\n",
            "O\t/\n",
            "O\tAIDS\n",
            "B-Drug\tvaccine\n",
            "O\tis\n",
            "O\tsteadily\n",
            "O\tmoving\n",
            "O\tahead\n",
            "O\t,\n",
            "O\tgenerating\n",
            "O\tand\n",
            "O\tvalid\n",
            "O\t##ating\n",
            "O\tnew\n",
            "O\tconcepts\n",
            "O\tin\n",
            "O\tterms\n",
            "O\tof\n",
            "O\tnovel\n",
            "O\tvectors\n",
            "O\tfor\n",
            "O\tanti\n",
            "O\t##gen\n",
            "O\tdelivery\n",
            "O\tand\n",
            "O\tpresentation\n",
            "O\t,\n",
            "O\tnew\n",
            "O\tvaccine\n",
            "O\tand\n",
            "O\tad\n",
            "O\t##ju\n",
            "O\t##vant\n",
            "O\tstrategies\n",
            "O\t,\n",
            "O\talternative\n",
            "O\tapproaches\n",
            "O\tto\n",
            "O\tdesign\n",
            "B-Virus\tHIV\n",
            "I-Virus\t-\n",
            "I-Virus\t1\n",
            "I-Virus\tanti\n",
            "I-Virus\t##gens\n",
            "O\tfor\n",
            "O\tel\n",
            "O\t##icit\n",
            "O\t##ing\n",
            "O\tprotective\n",
            "B-Chemical\tcross\n",
            "I-Chemical\t-\n",
            "I-Chemical\tneutral\n",
            "I-Chemical\t##ising\n",
            "I-Chemical\tantibodies\n",
            "O\t,\n",
            "O\tand\n",
            "O\tidentification\n",
            "O\tof\n",
            "O\tkey\n",
            "O\tmechanisms\n",
            "O\tin\n",
            "B-Phenotype\tHIV\n",
            "I-Phenotype\tinfection\n",
            "O\tand\n",
            "O\tm\n",
            "O\t##od\n",
            "O\t##ulation\n",
            "O\tof\n",
            "O\tthe\n",
            "O\timmune\n",
            "O\tsystem\n",
            "O\t.\n",
            "O\t[SEP]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[CLS]\n",
            "O\tAll\n",
            "O\tthese\n",
            "O\tdifferent\n",
            "O\tperspectives\n",
            "O\tare\n",
            "O\tcontributing\n",
            "O\tto\n",
            "O\tthe\n",
            "O\tunprecedented\n",
            "O\tchallenge\n",
            "O\tof\n",
            "O\tdeveloping\n",
            "O\ta\n",
            "O\tprotective\n",
            "B-Drug\tHIV\n",
            "I-Drug\t-\n",
            "I-Drug\t1\n",
            "I-Drug\tvaccine\n",
            "O\t.\n",
            "O\t[SEP]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n",
            "O\t[PAD]\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "4U5mgVj4-rQJ",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 35
        },
        "outputId": "0008a4af-ec23-422e-9731-ba86b3f4fa13"
      },
      "source": [
        "tokenizer.tokenize('HIV-1 antigens')"
      ],
      "execution_count": 23,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "['HIV', '-', '1', 'anti', '##gens']"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 23
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "YR_A8rBfz7Ar",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "outputId": "d6a3ef36-8385-4608-bae8-9feef7109d6f"
      },
      "source": [
        "test_embedding = prepare_embedding([test_data], fdebug=True)"
      ],
      "execution_count": 24,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "{'input_ids': <tf.Tensor: shape=(2, 150), dtype=int32, numpy=\n",
            "array([[  101, 12798,  2019,  1718,  1104,  1126,  9622, 20034,   131,\n",
            "         2592,  1104,  1103,  9837,   159,  7409, 15459,  1371,  3047,\n",
            "         1109,  3403,  1111,  1126,  9622,   120,  9837, 20034,  1110,\n",
            "        11383,  2232,  3075,   117, 12713,  1105,  9221,  3798,  1207,\n",
            "         8550,  1107,  2538,  1104,  2281, 21118,  1111,  2848,  4915,\n",
            "         6779,  1105,  8685,   117,  1207, 20034,  1105,  8050,  9380,\n",
            "        14194, 10700,   117,  4174,  8015,  1106,  1902,  9622,   118,\n",
            "          122,  2848, 21144,  1111,  8468, 22308,  1158,  9760,  2771,\n",
            "          118,  8795,  7131, 26491,   117,  1105,  9117,  1104,  2501,\n",
            "        10748,  1107,  9622,  8974,  1105,   182,  5412,  6856,  1104,\n",
            "         1103, 11650,  1449,   119,   102,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0],\n",
            "       [  101,  1398,  1292,  1472, 22168,  1132,  7773,  1106,  1103,\n",
            "        16789,  4506,  1104,  4297,   170,  9760,  9622,   118,   122,\n",
            "        20034,   119,   102,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0,     0,     0,     0,\n",
            "            0,     0,     0,     0,     0,     0]], dtype=int32)>, 'token_type_ids': <tf.Tensor: shape=(2, 150), dtype=int32, numpy=\n",
            "array([[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0],\n",
            "       [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]],\n",
            "      dtype=int32)>, 'attention_mask': <tf.Tensor: shape=(2, 150), dtype=int32, numpy=\n",
            "array([[1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,\n",
            "        1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,\n",
            "        1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,\n",
            "        1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,\n",
            "        1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0],\n",
            "       [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,\n",
            "        0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]],\n",
            "      dtype=int32)>}\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "cGDgMMyy0h71",
        "colab_type": "text"
      },
      "source": [
        "# Read training file"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "zFG16Iw2fjnU",
        "colab_type": "code",
        "colab": {}
      },
      "source": [
        "import json\n",
        "input_dir = \"/content/gdrive/My Drive/Covid19_data/\"\n",
        "\n",
        "f = open(input_dir+'new_train.json','r')\n",
        "datas = []\n",
        "for line in f:\n",
        "  datas.append(json.loads(line))"
      ],
      "execution_count": 10,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "3TwEFuZku0Hm",
        "colab_type": "code",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "outputId": "90c00e4c-e7a0-4bc5-fcba-6b4b8b71652c"
      },
      "source": [
        "train_tags = []\n",
        "\n",
        "for data in datas:\n",
        "    _, cur_tags = prepare_tokentags(data)\n",
        "    \n",
        "    train_tags += cur_tags"
      ],
      "execution_count": 25,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "['Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial\\tBimagrumab showed a good safety profile, relative to placebo, in individuals with inclusion body myositis but did not improve 6MWD.', 'The strengths of our study are that, to the best of our knowledge, it is the largest randomised controlled trial done in people with inclusion body myositis, and it provides important natural history data over 12 months.']\n",
            "unmatched tags:  [{'entity': 'inclusion body myositis', 'type': 'Disease', 'start': 413, 'end': 436}, {'entity': '6MWD', 'type': 'Gene', 'start': 274, 'end': 278}]\n",
            "['Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference\\tThe search for an HIV/AIDS vaccine is steadily moving ahead, generating and validating new concepts in terms of novel vectors for antigen delivery and presentation, new vaccine and adjuvant strategies, alternative approaches to design HIV-1 antigens for eliciting protective cross-neutralising antibodies, and identification of key mechanisms in HIV infection and modulation of the immune system.', 'All these different perspectives are contributing to the unprecedented challenge of developing a protective HIV-1 vaccine.']\n",
            "unmatched tags:  [{'entity': 'HIV-1 vaccine', 'type': 'Drug', 'start': 596, 'end': 609}, {'entity': 'HIV infection', 'type': 'Phenotype', 'start': 437, 'end': 450}, {'entity': 'cross-neutralising antibodies', 'type': 'Chemical', 'start': 366, 'end': 395}]\n",
            "['Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial\\tThe NOR-SWITCH trial showed that switching from infliximab originator to CT-P13 was not inferior to continued treatment with infliximab originator according to a prespecified non-inferiority margin of 15%.', 'The study was not powered to show non-inferiority in individual diseases.']\n",
            "unmatched tags:  [{'entity': 'infliximab', 'type': 'Gene', 'start': 318, 'end': 328}, {'entity': 'CT-P13', 'type': 'Gene', 'start': 266, 'end': 272}, {'entity': 'infliximab', 'type': 'Gene', 'start': 241, 'end': 251}]\n",
            "['Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial\\tIrinotecan–temozolomide–dinutuximab met protocol-defined criteria for selection as the combination meriting further study whereas irinotecan–temozolomide–temsirolimus did not.', 'Irinotecan–temozolomide–dinutuximab shows notable anti-tumour activity in patients with relapsed or refractory neuroblastoma.', 'Further evaluation of biomarkers in a larger cohort of patients might identify those most likely to respond to this chemoimmunotherapeutic regimen.']\n",
            "unmatched tags:  [{'entity': 'neuroblastoma', 'type': 'Disease', 'start': 455, 'end': 468}, {'entity': 'Irinotecan–temozolomide-dinutuximab', 'type': 'Drug', 'start': 344, 'end': 379}, {'entity': 'irinotecan-temozolomide-temsirolimus', 'type': 'Drug', 'start': 298, 'end': 334}]\n",
            "['DDT and DDE exposure in mothers and time to pregnancy in daughters\\tReproductive-tract anomalies after administration of the potent oestrogen, diethylstilboestrol, in pregnant women raised concerns about the reproductive effects of exposure to weakly oestrogenic environmental contaminants such as bis[4-chlorophenyl]-1,1,1-trichloroethane (p, p′-DDT) or its metabolites, such as bis[4-chlorophenyl]-1,1-dichloroethene (p, p′-DDE).', 'We measured p, p′-DDT and p, p′-DDE in preserved maternal serum samples drawn 1–3 days after delivery between 1960 and 1963.', 'We recorded time to pregnancy in 289 eldest daughters 28–31 years later.']\n",
            "unmatched tags:  [{'entity': 'DDE', 'type': 'ChemicalCompound', 'start': 463, 'end': 466}]\n",
            "[\"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial\\tGuselkumab, a human monoclonal antibody that specifically inhibits IL-23 by binding the cytokine's p19 subunit, was efficacious and demonstrated an acceptable benefit–risk profile in patients with active psoriatic arthritis who were naive to treatment with biologics.\", 'These data support the use of selective inhibition of IL-23 to treat psoriatic arthritis.']\n",
            "unmatched tags:  [{'entity': 'psoriatic arthritis', 'type': 'Disease', 'start': 482, 'end': 501}]\n",
            "['Dose recommendations for anticancer drugs in patients with renal or hepatic impairment\\tRenal or hepatic impairment is a common comorbidity for patients with cancer either because of the disease itself, toxicity of previous anticancer treatments, or because of other factors affecting organ function, such as increased age.', 'Because renal and hepatic function are among the main determinants of drug exposure, the pharmacokinetic profile might be altered for patients with cancer who have renal or hepatic impairment, necessitating dose adjustments.', 'Most anticancer drugs are dosed near their maximum tolerated dose and are characterised by a narrow therapeutic index.']\n",
            "unmatched tags:  [{'entity': 'cancer', 'type': 'Disease', 'start': 557, 'end': 563}, {'entity': 'hepatic impairment', 'type': 'Disease', 'start': 496, 'end': 514}, {'entity': 'cancer', 'type': 'Disease', 'start': 471, 'end': 477}, {'entity': 'cancer', 'type': 'Disease', 'start': 227, 'end': 233}, {'entity': 'cancer', 'type': 'Disease', 'start': 157, 'end': 163}]\n",
            "['An Effective CTL Peptide Vaccine for Ebola Zaire Based on Survivors’ CD8+ Targeting of a Particular Nucleocapsid Protein Epitope with Potential Implications for COVID-19 Vaccine Design\\tThe 2013-2016 West Africa EBOV epidemic was the biggest EBOV outbreak to date.', 'An analysis of virus-specific CD8+ T-cell immunity in 30 survivors showed that 26 of those individuals had a CD8+ response to at least one EBOV protein.', 'The dominant response (25/26 subjects) was specific to the EBOV nucleocapsid protein (NP).', 'It has been suggested that epitopes on the EBOV NP could form an important part of an effective T-cell vaccine for Ebola Zaire.', 'We show that a 9-amino-acid peptide NP44-52 (YQVNNLEEI) located in a conserved region of EBOV NP provides protection against morbidity and mortality after mouse adapted EBOV challenge.', 'A single vaccination in a C57BL/6 mouse using an adjuvanted microsphere peptide vaccine formulation containing NP44-52 is enough to confer immunity in mice.', 'Our work suggests that a peptide vaccine based on CD8+ T-cell immunity in EBOV survivors is conceptually sound and feasible.', 'Nucleocapsid proteins within SARS-CoV-2 contain multiple class I epitopes with predicted HLA restrictions consistent with broad population coverage.', 'A similar approach to a CTL vaccine design may be possible for that virus.']\n",
            "unmatched tags:  [{'entity': 'vaccine', 'type': 'Drug', 'start': 1280, 'end': 1287}, {'entity': 'HLA', 'type': 'Gene', 'start': 1192, 'end': 1195}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1132, 'end': 1142}, {'entity': 'Nucleocapsid proteins', 'type': 'Gene', 'start': 1103, 'end': 1124}]\n",
            "['Asthma\\tAsthma—one of the most common chronic, non-communicable diseases in children and adults—is characterised by variable respiratory symptoms and variable airflow limitation.', 'Asthma is a consequence of complex gene–environment interactions, with heterogeneity in clinical presentation and the type and intensity of airway inflammation and remodelling.', 'The goal of asthma treatment is to achieve good asthma control—ie, to minimise symptom burden and risk of exacerbations.', 'Anti-inflammatory and bronchodilator treatments are the mainstay of asthma therapy and are used in a stepwise approach.']\n",
            "unmatched tags:  [{'entity': 'asthma therapy', 'type': 'Disease', 'start': 544, 'end': 558}, {'entity': 'bronchodilator', 'type': 'Drug', 'start': 498, 'end': 512}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 434, 'end': 441}, {'entity': 'asthma', 'type': 'Phenotype', 'start': 403, 'end': 409}, {'entity': 'asthma', 'type': 'Phenotype', 'start': 367, 'end': 373}, {'entity': 'type', 'type': 'Gene', 'start': 296, 'end': 300}]\n",
            "['Comparisons of a Novel Air Sampling Filter Material, Wash Buffers and Extraction Methods in the Detection and Quantification of Influenza Virus\\tQuantification of aerosolized influenza virus is used for determining inhalation exposure.', 'Several bioaerosol samplers and analytical methods have been used; however, the detection and quantification of influenza virus among aerosol samples remains challenging.', 'Therefore, improved viral aerosol measurement methods are needed.', 'This study evaluated influenza virus recovery among three filter types polytetrafluoroethylene, polyvinylchloride and polystyrene.', 'Polytetrafluoroethylene, polyvinylchloride are fabricated filter materials and commonly used in the scientific literature to sample for viral aerosols.', 'A novel, electrospun polystyrene filter material may improve viral aerosol recovery during filter-based air sampling.', 'The filter materials were compared across the following conditions: treated with or without air, filter wash buffer (HBSS or PBS), and viral RNA extraction method (QIAamp Viral RNA Mini Kit or Trizol).', 'Twenty trials were completed in a chamber and samples were analyzed using RT-qPCR.', 'Viral recovery was significantly different (p-value < .0001) by filter type.', 'Polystyrene filter use resulted in recovery of the most viral RNA.', 'Air sampling did not affect the recovery of viral RNA from the filter materials (p-values > 0.05).', 'Viral RNA concentrations were significantly different across extraction methods for all comparisons (p-values < 0.05).', 'Our results demonstrated that the novel polystyrene filter material resulted in the highest concentration of extracted RNA compared to the commonly used polytetrafluoroethylene and polyvinylchloride, which we speculate may be related to the chemical composition of the filter material ( e.g.', ', polystyrene is an aromatic hydrocarbon whereas polytetrafluoroethylene and polyvinylchloride contain more polar, and thus potentially reactive, carbon-halogen bonds).', 'Air sampling did not have an effect on viral RNA recovery.', 'Using Hanks Balanced Salt Solution with QIAamp Viral RNA Mini Kit, and Phosphate-buffered saline with the Trizol extraction, resulted in the most viral RNA recovery.']\n",
            "unmatched tags:  [{'entity': 'viral RNA', 'type': 'Gene', 'start': 2186, 'end': 2195}, {'entity': 'Trizol extraction', 'type': 'Disease', 'start': 2146, 'end': 2163}, {'entity': 'Phosphate-buffered saline', 'type': 'Drug', 'start': 2111, 'end': 2136}, {'entity': 'RNA', 'type': 'Gene', 'start': 2093, 'end': 2096}, {'entity': 'QIAamp Viral RNA Mini Kit', 'type': 'Chemical', 'start': 2080, 'end': 2105}, {'entity': 'Hanks Balanced Salt Solution', 'type': 'Drug', 'start': 2046, 'end': 2074}, {'entity': 'viral RNA', 'type': 'Gene', 'start': 2020, 'end': 2029}, {'entity': 'carbon-halogen bonds', 'type': 'Chemical', 'start': 1958, 'end': 1978}, {'entity': 'polyvinylchloride', 'type': 'Drug', 'start': 1889, 'end': 1906}, {'entity': 'polytetrafluoroethylene', 'type': 'Drug', 'start': 1861, 'end': 1884}, {'entity': 'aromatic hydrocarbon', 'type': 'Drug', 'start': 1832, 'end': 1852}, {'entity': 'polystyrene', 'type': 'Drug', 'start': 1814, 'end': 1825}, {'entity': 'polyvinylchloride', 'type': 'Drug', 'start': 1701, 'end': 1718}, {'entity': 'polytetrafluoroethylene', 'type': 'Drug', 'start': 1673, 'end': 1696}, {'entity': 'RNA', 'type': 'Gene', 'start': 1639, 'end': 1642}, {'entity': 'polystyrene filter material', 'type': 'Drug', 'start': 1560, 'end': 1587}, {'entity': 'RNA', 'type': 'Gene', 'start': 1407, 'end': 1410}, {'entity': 'Viral RNA', 'type': 'Gene', 'start': 1401, 'end': 1410}, {'entity': 'viral RNA', 'type': 'Gene', 'start': 1346, 'end': 1355}, {'entity': 'RNA', 'type': 'Gene', 'start': 1297, 'end': 1300}, {'entity': 'viral RNA', 'type': 'Gene', 'start': 1291, 'end': 1300}, {'entity': 'Polystyrene filter', 'type': 'Drug', 'start': 1235, 'end': 1253}, {'entity': 'RT-qPCR', 'type': 'Gene', 'start': 1149, 'end': 1156}, {'entity': 'Trizol', 'type': 'Drug', 'start': 1066, 'end': 1072}, {'entity': 'QIAamp Viral RNA Mini Kit', 'type': 'Chemical', 'start': 1037, 'end': 1062}, {'entity': 'RNA', 'type': 'Gene', 'start': 1014, 'end': 1017}, {'entity': 'viral RNA', 'type': 'Gene', 'start': 1008, 'end': 1017}, {'entity': 'PBS', 'type': 'Gene', 'start': 998, 'end': 1001}, {'entity': 'HBSS', 'type': 'Chemical', 'start': 990, 'end': 994}, {'entity': 'polystyrene filter material', 'type': 'Drug', 'start': 776, 'end': 803}, {'entity': 'polyvinylchloride', 'type': 'Drug', 'start': 628, 'end': 645}]\n",
            "['Detection of Nucleocapsid Antibody to SARS-CoV-2 is More Sensitive than Antibody to Spike Protein in COVID-19 Patients\\tBackground: SARS-CoV-2, the cause of coronavirus disease 2019 (COVID-19), is associated with respiratory-related morbidity and mortality.', 'Assays to detect virus-specific antibodies are important to understand the prevalence of infection and the course of the immune response.', 'Methodology:  Quantitative measurements of plasma or serum antibodies by luciferase immunoprecipitation assay systems (LIPS) to the nucleocapsid and spike proteins were analyzed in 100 cross-sectional or longitudinal samples from SARS-CoV-2-infected patients.', 'A subset of samples was tested with and without heat inactivation.', 'Results: Fifteen or more days after symptom onset, antibodies against SARS-CoV-2 nucleocapsid protein showed 100% sensitivity and 100% specificity, while antibodies to spike protein were detected with 91% sensitivity and 100% specificity.', 'Neither antibody levels nor the rate of seropositivity were significantly reduced by heat inactivation of samples.', 'Analysis of daily samples from six patients with COVID-19 showed anti-nucleocapsid and spike antibodies appearing between day 8 to day 14 after initial symptoms.', 'Immunocompromised patients generally had a delayed antibody response to SARS-CoV-2 compared to immunocompetent patients.', 'Conclusions:  Antibody to the nucleocapsid protein of SARS-CoV-2 is more sensitive than spike protein antibody for detecting early infection.', 'Analyzing heat-inactivated samples by LIPS is a safe and sensitive method for detecting SARS-CoV-2 antibodies.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1596, 'end': 1606}, {'entity': 'early infection', 'type': 'Disease', 'start': 1490, 'end': 1505}, {'entity': 'spike protein', 'type': 'Gene', 'start': 1453, 'end': 1466}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1419, 'end': 1429}, {'entity': 'nucleocapsid protein', 'type': 'Gene', 'start': 1395, 'end': 1415}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1316, 'end': 1326}]\n",
            "['Site-specific analysis of the SARS-CoV-2 glycan shield\\tThe emergence of the betacoronavirus, SARS-CoV-2 that causes COVID-19, represents a significant threat to global human health.', 'Vaccine development is focused on the principal target of the humoral immune response, the spike (S) glycoprotein, that mediates cell entry and membrane fusion.', 'SARS-CoV-2 S gene encodes 22 N-linked glycan sequons per protomer, which likely play a role in immune evasion and occluding immunogenic protein epitopes.', 'Here, using a site-specific mass spectrometric approach, we reveal the glycan structures on a recombinant SARS-CoV-2 S immunogen.', 'This analysis enables mapping of the glycan-processing states across the trimeric viral spike.', 'We show how SARS-CoV-2 S glycans differ from typical host glycan processing, which may have implications in viral pathobiology and vaccine design.']\n",
            "unmatched tags:  [{'entity': 'vaccine', 'type': 'Drug', 'start': 853, 'end': 860}]\n",
            "['Maternal and child undernutrition: global and regional exposures and health consequences\\tMaternal and child undernutrition is highly prevalent in low-income and middle-income countries, resulting in substantial increases in mortality and overall disease burden.', 'In this paper, we present new analyses to estimate the effects of the risks related to measures of undernutrition, as well as to suboptimum breastfeeding practices on mortality and disease.', 'We estimated that stunting, severe wasting, and intrauterine growth restriction together were responsible for 2·2 million deaths and 21% of disability-adjusted life-years (DALYs) for children younger than 5 years.']\n",
            "unmatched tags:  [{'entity': 'DALYs', 'type': 'Chemical', 'start': 624, 'end': 629}, {'entity': 'wasting', 'type': 'Disease', 'start': 487, 'end': 494}, {'entity': 'undernutrition', 'type': 'Disease', 'start': 361, 'end': 375}, {'entity': 'middle-income countries', 'type': 'Disease', 'start': 161, 'end': 184}]\n",
            "['Analysis on the Clinical Characteristics of 36 Cases of Novel Coronavirus Pneumonia in Kunming\\tObjective: To analyze the clinical characteristics of patients with novel coronavirus pneumonia in Kunming City, and to study the correlation between nutritional status and immune function.', \"Methods: Clinical data of 36 patients with novel coronavirus pneumonia in isolation area of Kunming Third People's Hospital from January 31 to February 15, 2020 were collected, and the basic situation, clinical characteristics, laboratory examination and CT imaging characteristics were analyzed.\", 'Serum albumin (ALB), prealbumin (PAB), hypersensitive c-reactive protein (hs-crp), CD3T cells, CD4T cells, CD8T cells and normal control group were analyzed.', 'A simple linear regression analysis of the relationship between proalbumin and T cell subpopulation counts in the blood of patients.', 'Results: (1) The patients with new coronavirus pneumonia in Kunming were mainly of common type.', \"(2) 50% of the patients' first symptoms were fever and cough; (3) The total number of white blood cells in peripheral blood was normal or decreased in 23 cases (79%), and the lymphocyte count decreased in 5 cases (13.89%), without anemia.\", 'Hypersensitive c-reactive protein increased in 19 (52.78%) cases, and procalcitonin increased in 1 case.', 'Albumin decreased in 5 cases (13.89%), proalbumin decreased in 15 cases (41.67%), alanine transaminase increased slightly in 4 cases (11.11%), alanine transaminase increased slightly in 4 cases (11.11%), total bilirubin increased slightly in 11 cases (30.56%), and renal function and blood coagulation were normal.', 'Absolute value of CD3+T cells is with a decrease in 21 cases (58.3%), CD4+T in 28 cases (77.8%), CD8+T in 17 cases (47.2%), and CD4+/ CD8+ inverse in 6 cases (16.7%).', '(4) The prealbumin, CD3 T cells, CD4 T cells and CD8 T cells in the new coronavirus pneumonia group were significantly lower than those in the normal control group, and the hypersensitive c-reactive protein was higher than that in the normal control group.', '(5) The levels of PAB in the serum of the patients were linearly correlated with hs-crp, CD3 T cells, CD4 T cells and CD8 T cells, and the correlation coefficients were -0.474, 0.558, 0.467 and 0.613, respectively, showing statistical differences.', 'Conclusion: The clinical characteristics of the novel coronavirus pneumonia in Kunming are different from those in Wuhan.', 'The changes of serum proalbumin and T cell subsets are relatively obvious.', 'Changes in serum proalbumin may contribute to the early warning of novel coronavirus pneumonia.', 'The nutritional status of patients with common and mild pneumonia should be considered.']\n",
            "unmatched tags:  [{'entity': 'mild pneumonia', 'type': 'Disease', 'start': 2646, 'end': 2660}, {'entity': 'coronavirus pneumonia', 'type': 'Disease', 'start': 2572, 'end': 2593}]\n",
            "['Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study\\tGuselkumab, a novel anti-interleukin 23p19 antibody, significantly improved signs and symptoms of active psoriatic arthritis and was well tolerated during 44 weeks of treatment.', 'The results of this study support further development of guselkumab as a novel and comprehensive treatment in psoriatic arthritis.']\n",
            "unmatched tags:  [{'entity': 'psoriatic arthritis', 'type': 'Disease', 'start': 429, 'end': 448}]\n",
            "['Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors\\tAfter binding to the target cell, the transmembrane spike protein might change conformation by association between the HR1 and HR2 regions to form an oligomeric structure, leading to fusion between the viral and target-cell membranes.', 'At the prefusion intermediate state, CP-1 could bind to the HR1 region and interfere with the conformational changes, resulting in inhibition of SARS-CoV fusion with the target cells.', 'CP-1 might be modifiable to increase its anti-SARS-CoV activity and could be further developed as an antiviral agent for treatment or prophylaxis of SARS-CoV infection.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV', 'type': 'Virus', 'start': 750, 'end': 758}, {'entity': 'antiviral agent', 'type': 'Drug', 'start': 702, 'end': 717}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 647, 'end': 655}, {'entity': 'CP-1', 'type': 'Gene', 'start': 601, 'end': 605}]\n",
            "['Diet and risk of coronary heart disease and type 2 diabetes\\tA high intake of saturated fat is an important risk factor for coronary heart disease (CHD) and type 2 diabetes.', 'However the declining rates of CHD in many affluent societies and the steady increase in type 2 diabetes worldwide suggest that these important causes of serious morbidity and premature mortality have differing risk or protective factors worldwide.', 'Changed macronutrient composition, reduced cigarette smoking, and improved treatment of risk factors and acute cardiac events might explain the reduction in risk of CHD, whereas the increasing rates of obesity are probably the most important explanation for the increase in diabetes.']\n",
            "unmatched tags:  [{'entity': 'diabetes', 'type': 'Disease', 'start': 696, 'end': 704}, {'entity': 'obesity', 'type': 'Phenotype', 'start': 624, 'end': 631}, {'entity': 'type 2 diabetes', 'type': 'Disease', 'start': 262, 'end': 277}]\n",
            "['Hereditary spastic paraplegia: from diagnosis to emerging therapeutic approaches\\tHereditary spastic paraplegia (HSP) describes a heterogeneous group of genetic neurodegenerative diseases characterised by progressive spasticity of the lower limbs.', 'The pathogenic mechanism, associated clinical features, and imaging abnormalities vary substantially according to the affected gene and differentiating HSP from other genetic diseases associated with spasticity can be challenging.', 'Next generation sequencing-based gene panels are now widely available but have limitations and a molecular diagnosis is not made in most suspected cases.']\n",
            "unmatched tags:  [{'entity': 'gene', 'type': 'Gene', 'start': 511, 'end': 515}, {'entity': 'gene', 'type': 'Gene', 'start': 483, 'end': 487}, {'entity': 'spasticity', 'type': 'Phenotype', 'start': 447, 'end': 457}, {'entity': 'gene', 'type': 'Gene', 'start': 414, 'end': 418}, {'entity': 'HSP', 'type': 'Gene', 'start': 399, 'end': 402}, {'entity': 'gene', 'type': 'Gene', 'start': 374, 'end': 378}, {'entity': 'clinical features', 'type': 'Gene', 'start': 284, 'end': 301}, {'entity': 'spasticity', 'type': 'Phenotype', 'start': 216, 'end': 226}]\n",
            "['Global efforts toward the cure of childhood acute lymphoblastic leukaemia\\tImprovements in risk-directed treatment and supportive care, together with increased reliance on both national and international collaborative studies, have made childhood acute lymphoblastic leukaemia (ALL) one of the most curable human cancers.', 'Next-generation sequencing studies of leukaemia cells and the host germline provide new opportunities for precision medicine and thus potential improvements in the cure rate and quality of life of patients.', 'Efforts are underway to assess the global impact of childhood ALL and develop initiatives that can meet the long-term challenge of providing quality care to children with this disease worldwide and improving cure rates globally.']\n",
            "unmatched tags:  [{'entity': 'leukaemia cells', 'type': 'Disease', 'start': 359, 'end': 374}, {'entity': 'cancers', 'type': 'Disease', 'start': 312, 'end': 319}, {'entity': 'acute lymphoblastic leukaemia', 'type': 'Disease', 'start': 246, 'end': 275}, {'entity': 'childhood acute lymphoblastic leukaemia', 'type': 'Disease', 'start': 236, 'end': 275}]\n",
            "['Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study\\tUse of Swedish snus should be added to the list of tentative risk factors for pancreatic cancer.', 'We were unable to confirm any excess of oral or lung cancer in snus users.']\n",
            "unmatched tags:  [{'entity': 'snus', 'type': 'Chemical', 'start': 311, 'end': 315}]\n",
            "['Evolution and variation of 2019-novel coronavirus\\tBackground The current outbreak caused by novel coronavirus (2019-nCoV) in China has become a worldwide concern.', 'As of 28 January 2020, there were 4631 confirmed cases and 106 deaths, and 11 countries or regions were affected.', 'Methods We downloaded the genomes of 2019-nCoVs and similar isolates from the Global Initiative on Sharing Avian Influenza Database (GISAID and nucleotide database of the National Center for Biotechnology Information (NCBI).', 'Lasergene 7.0 and MEGA 6.0 softwares were used to calculate genetic distances of the sequences, to construct phylogenetic trees, and to align amino acid sequences.', 'Bayesian coalescent phylogenetic analysis, implemented in the BEAST software package, was used to calculate the molecular clock related characteristics such as the nucleotide substitution rate and the most recent common ancestor (tMRCA) of 2019-nCoVs.', 'Results An isolate numbered EPI_ISL_403928 showed different phylogenetic trees and genetic distances of the whole length genome, the coding sequences (CDS) of ployprotein (P), spike protein (S), and nucleoprotein (N) from other 2019-nCoVs.', 'There are 22, 4, 2 variations in P, S, and N at the level of amino acid residues.', 'The nucleotide substitution rates from high to low are 1·05 × 10 −2 (nucleotide substitutions/site/year, with 95% HPD interval being 6.27 × 10 −4 to 2.72 × 10 −2 ) for N, 5.34 × 10 −3 (5.10 × 10 −4 , 1.28 × 10 −2 ) for S, 1.69 × 10 −3 (3.94 × 10 −4 , 3.60 × 10 −3 ) for P, 1.65 × 10 −3 (4.47 × 10 −4 , 3.24 × 10 −3 ) for the whole genome, respectively.', 'At this nucleotide substitution rate, the most recent common ancestor (tMRCA) of 2019-nCoVs appeared about 0.253-0.594 year before the epidemic.', 'Conclusion Our analysis suggests that at least two different viral strains of 2019-nCoV are involved in this outbreak that might occur a few months earlier before it was officially reported.']\n",
            "unmatched tags:  [{'entity': '2019-nCoV', 'type': 'Virus', 'start': 1816, 'end': 1825}, {'entity': '2019-nCoV', 'type': 'Virus', 'start': 1674, 'end': 1683}, {'entity': 'tMRCA', 'type': 'Chemical', 'start': 1664, 'end': 1669}, {'entity': 'nucleotide substitution', 'type': 'Gene', 'start': 1601, 'end': 1624}, {'entity': 'HPD', 'type': 'Drug', 'start': 1354, 'end': 1357}, {'entity': 'nucleotide substitution', 'type': 'Gene', 'start': 1309, 'end': 1332}, {'entity': 'nucleotide substitution', 'type': 'Gene', 'start': 1244, 'end': 1267}, {'entity': 'amino acid residues', 'type': 'Chemical', 'start': 1219, 'end': 1238}, {'entity': '2019-nCoV', 'type': 'Virus', 'start': 1146, 'end': 1155}, {'entity': 'nucleoprotein (N)', 'type': 'Gene', 'start': 1117, 'end': 1134}, {'entity': 'spike protein', 'type': 'Gene', 'start': 1094, 'end': 1107}, {'entity': 'coding sequences', 'type': 'Gene', 'start': 1051, 'end': 1067}, {'entity': 'EPI_ISL_403928', 'type': 'Chemical', 'start': 946, 'end': 960}, {'entity': '2019-nCoV', 'type': 'Virus', 'start': 906, 'end': 915}, {'entity': 'tMRCA', 'type': 'Chemical', 'start': 896, 'end': 901}, {'entity': 'nucleotide substitution', 'type': 'Gene', 'start': 830, 'end': 853}, {'entity': 'construct', 'type': 'Gene', 'start': 601, 'end': 610}, {'entity': 'NCBI', 'type': 'Organization', 'start': 495, 'end': 499}, {'entity': 'National Center for Biotechnology Information', 'type': 'Organization', 'start': 448, 'end': 493}, {'entity': 'nucleotide database', 'type': 'Gene', 'start': 421, 'end': 440}]\n",
            "['Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial\\tIn patients with chronic migraine, erenumab 70 mg and 140 mg reduced the number of monthly migraine days with a safety profile similar to placebo, providing evidence that erenumab could be a potential therapy for migraine prevention.', 'Further research is needed to understand long-term efficacy and safety of erenumab, and the applicability of this study to real-world settings.']\n",
            "unmatched tags:  [{'entity': 'erenumab', 'type': 'Chemical', 'start': 447, 'end': 455}]\n",
            "['Detection of spreader nodes and ranking of interacting edges in Human-SARS-CoV protein interaction network\\tThe entire world has recently witnessed the commencement of coronavirus disease 19 (COVID-19) pandemic.', 'It is caused by a novel coronavirus (n-CoV) generally distinguished as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).', 'It has exploited human vulnerabilities to coronavirus outbreak.', 'SARS-CoV-2 promotes fatal chronic respiratory disease followed by multiple organ failure which ultimately puts an end to human life.', 'No proven vaccine for n-CoV is available till date in spite of significant research efforts worldwide.', 'International Committee on Taxonomy of Viruses (ICTV) has reached to a consensus that the virus SARS-CoV-2 is highly genetically similar to Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) outbreak of 2003.', 'It has been reported that SARS-CoV has ~89% genetic similarities with n-CoV.', 'With this hypothesis, the current work focuses on the identification of spreader nodes in SARS-CoV protein interaction network.', 'Various network characteristics like edge ratio, neighborhood density and node weight have been explored for defining a new feature spreadability index by virtue of which spreader nodes and edges are identified.', 'The selected top spreader nodes having high spreadability index have been also validated by Susceptible-Infected-Susceptible (SIS) disease model.', 'Initially, the proposed method is applied on a synthetic protein interaction network followed by SARS-CoV-human protein interaction network.', 'Hence, key spreader nodes and edges (ranked edges) are unmasked in SARS-CoV proteins and its connected level 1 and level 2 human proteins.', 'The new network attribute spreadability index along with generated SIS values of selected top spreader nodes when compared with the other network centrality based methodologies like Degree centrality (DC), Closeness centrality (CC), Local average centrality (LAC) and Betweeness centrality (BC) is found to perform relatively better than the existing-state-of-art.']\n",
            "unmatched tags:  [{'entity': 'BC', 'type': 'Drug', 'start': 1993, 'end': 1995}, {'entity': 'LAC', 'type': 'Gene', 'start': 1961, 'end': 1964}, {'entity': 'Closeness centrality', 'type': 'Organization', 'start': 1908, 'end': 1928}, {'entity': 'SIS', 'type': 'Gene', 'start': 1769, 'end': 1772}, {'entity': 'SARS-CoV proteins', 'type': 'Virus', 'start': 1630, 'end': 1647}, {'entity': 'SARS-CoV-human', 'type': 'Virus', 'start': 1519, 'end': 1528}, {'entity': 'SIS', 'type': 'Gene', 'start': 1402, 'end': 1405}, {'entity': 'SARS-CoV protein', 'type': 'Virus', 'start': 1026, 'end': 1042}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 885, 'end': 893}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 831, 'end': 839}, {'entity': 'Acute Respiratory Syndrome Coronavirus', 'type': 'Virus', 'start': 791, 'end': 829}, {'entity': 'genetically', 'type': 'Gene', 'start': 761, 'end': 772}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 740, 'end': 750}, {'entity': 'vaccine', 'type': 'Drug', 'start': 551, 'end': 558}, {'entity': 'chronic respiratory disease', 'type': 'Disease', 'start': 434, 'end': 461}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 408, 'end': 418}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 386, 'end': 397}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 331, 'end': 341}, {'entity': 'Acute Respiratory Syndrome Coronavirus', 'type': 'Virus', 'start': 289, 'end': 327}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 235, 'end': 246}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 191, 'end': 199}]\n",
            "['Primary biliary cirrhosis\\tPrimary biliary cirrhosis (PBC) is a chronic progressive disease, most often affecting women, characterised by progressive destruction of the small intrahepatic bile ducts with portal inflammation leading to fibrosis and cirrhosis.', 'There is a close association between PBC and antibodies to pyruvate dehydrogenase complex (antimitochondrial antibodies [AMA]).', 'The pathogenesis of PBC is unknown and there is no definitive drug treatment; liver transplantation is indicated for patients with intractable symptoms and for end-stage disease.']\n",
            "unmatched tags:  [{'entity': 'end-stage disease', 'type': 'Disease', 'start': 546, 'end': 563}, {'entity': 'PBC', 'type': 'Disease', 'start': 406, 'end': 409}, {'entity': 'PBC', 'type': 'Disease', 'start': 295, 'end': 298}, {'entity': 'cirrhosis', 'type': 'Disease', 'start': 247, 'end': 256}]\n",
            "['Death from heroin overdose: findings from hair analysis\\tAlthough our findings may be subject to selection bias, since suitable hair samples were available for only 37 of the 91 addicts who had died, these findings support the theory of high susceptibility to opioid overdose after periods of intentional or unintentional abstinence, due to loss of tolerance.', 'Medical staff running detoxification programmes should be aware of the risk inherent in relapse to heroin after a period of abstinence.', 'Moreover, occasional heroin use without a build-up of tolerance could also give a high risk of overdose.']\n",
            "unmatched tags:  [{'entity': 'overdose', 'type': 'Disease', 'start': 590, 'end': 598}, {'entity': 'heroin', 'type': 'Drug', 'start': 516, 'end': 522}]\n",
            "['Correlation Analysis Between Disease Severity and Inflammation-related Parameters in Patients with COVID-19 Pneumonia\\tAim: The new coronavirus pneumonia (COVID-19) outbreaking at the end of 2019 is highly contagious.', 'Crude mortality rate reached 49% in critical patients.', 'Inflammation matters on disease progression.', 'This study analyzed blood inflammation indicators among mild, severe and critical patients, helping to identify severe or critical patients early.', 'Methods: In this cross-sectional study, 100 patients were included and divided to mild, severe or critical groups.', 'Correlation of peripheral blood inflammation-related indicators with disease criticality was analyzed.', 'Cut-off values for critically ill patients were speculated through the ROC curve.', 'Results：Significantly, disease severity were associated with age (R=-0.564, P<0.001), interleukin-2 receptor (IL2R) (R=-0.534, P<0.001), interleukin-6 (IL-6) (R=-0.535, P<0.001), interleukin-8 (IL-8) (R=-0.308, P<0.001), interleukin-10 (IL-10) (R=-0.422, P<0.001), tumor necrosis factor α (TNFα) (R=-0.322, P<0.001), C-reactive protein (CRP) (R=-0.604, P<0.001), ferroprotein (R=-0.508, P<0.001), procalcitonin (R=-0.650, P<0.001), white cell counts (WBC) (R=-0.54, P<0.001), lymphocyte counts (LC) (R=-0.56, P<0.001), neutrophil count (NC) (R=-0.585, P<0.001) and eosinophil counts (EC) (R=-0.299, P=0.01).', 'Conclusion：With following parameters such as age >67.5 years, IL2R >793.5U/mL, CRP >30.7ng/mL, ferroprotein >2252μg/L, WBC>9.5*10^9/L or NC >7.305*10^9/L, the progress of COVID-19 to critical stage should be closely observed and possibly prevented.', 'Inflammation is closely related to severity of COVID-19, and IL-6, TNFα and IL-8 might be promising therapeutic targets.']\n",
            "unmatched tags:  [{'entity': 'IL-8', 'type': 'Gene', 'start': 1697, 'end': 1701}, {'entity': 'TNFα', 'type': 'Gene', 'start': 1688, 'end': 1692}, {'entity': 'IL-6', 'type': 'Gene', 'start': 1682, 'end': 1686}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1668, 'end': 1676}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1543, 'end': 1551}, {'entity': 'NC', 'type': 'Gene', 'start': 1509, 'end': 1511}, {'entity': 'ferroprotein', 'type': 'Chemical', 'start': 1467, 'end': 1479}, {'entity': 'IL2R', 'type': 'Gene', 'start': 1434, 'end': 1438}, {'entity': 'NC', 'type': 'Gene', 'start': 1301, 'end': 1303}, {'entity': 'procalcitonin', 'type': 'Gene', 'start': 1161, 'end': 1174}, {'entity': 'ferroprotein', 'type': 'Chemical', 'start': 1127, 'end': 1139}]\n",
            "['Typhoid conjugate vaccines: a new tool in the fight against antimicrobial resistance\\tTyphoid fever is an acute systemic infectious disease responsible for an estimated 12–20 million illnesses and over 150\\u2008000 deaths annually.', 'In March, 2018, a new recommendation was issued by WHO for the programmatic use of typhoid conjugate vaccines in endemic countries.', 'Health economic analyses of typhoid vaccines have informed funding decisions and national policies regarding vaccine rollout.', 'However, by focusing only on averted typhoid cases and their associated costs, traditional cost-effectiveness analyses might underestimate crucial benefits of typhoid vaccination programmes, because the potential effect of typhoid vaccines on the treatment of patients with non-specific acute febrile illnesses is not considered.']\n",
            "unmatched tags:  [{'entity': 'illnesses', 'type': 'Phenotype', 'start': 785, 'end': 794}, {'entity': 'typhoid vaccines', 'type': 'Drug', 'start': 707, 'end': 723}, {'entity': 'typhoid', 'type': 'Disease', 'start': 643, 'end': 650}, {'entity': 'typhoid', 'type': 'Disease', 'start': 521, 'end': 528}]\n",
            "['Cryo-EM structures of HKU2 and SADS-CoV spike glycoproteins and insights into coronavirus evolution\\tA new porcine coronavirus SADS-CoV was recently identified from suckling piglets with severe diarrhea in southern China and its genome sequence is most identical (~95% identity) to that of bat α-coronavirus HKU2.', 'It again indicates bats are the natural reservoir of many coronaviruses that have great potential for cross-species transmission to animals and humans by recombination and/or mutation.', 'Here we report the cryo-EM structures of HKU2 and SADS-CoV spike glycoprotein trimers at 2.38 Å and 2.83 Å resolution, respectively.', 'HKU2 and SADS-CoV spikes exhibit very high structural similarity, with subtle differences mainly distributed in the NTD and CTD of the S1 subunit responsible for cell attachment and receptor binding.', 'We systematically analyzed and compared the NTD, CTD, SD1 and SD2 domains of the S1 subunit and the S2 subunit of HKU2 spike with those of α-, β-, γ-, and δ-coronavirus spikes.', 'The results show that the NTD and CTD of HKU2/SADS-CoV are probably the most ancestral in the evolution of spike.', 'Although the S2 subunit mediating membrane fusion is highly conserved, the connecting region after fusion peptide in HKU2/SADS-CoV S2 subunit also adopts a conformation distinct from other coronaviruses.', 'These results structurally demonstrate a close evolutionary relationship between HKU2 /SADS-CoV and β-coronavirus spikes and provide new insights into the evolution and cross-species transmission of coronaviruses.']\n",
            "unmatched tags:  [{'entity': 'coronaviruses', 'type': 'Virus', 'start': 1525, 'end': 1538}, {'entity': 'β-coronavirus', 'type': 'Virus', 'start': 1426, 'end': 1439}, {'entity': 'SADS-CoV', 'type': 'Virus', 'start': 1413, 'end': 1421}]\n",
            "['A mechanistic population balance model to evaluate the impact of interventions on infectious disease outbreaks: Case for COVID19\\tInfectious diseases, especially when new and highly contagious, could be devastating producing epidemic outbreaks and pandemics.', 'Predicting the outcomes of such events in relation to possible interventions is crucial for societal and healthcare planning and forecasting of resource needs.', 'Deterministic and mechanistic models can capture the main known phenomena of epidemics while also allowing for a meaningful interpretation of results.', 'In this work a deterministic mechanistic population balance model was developed.', 'The model describes individuals in a population by infection stage and age group.', 'The population is treated as in a close well mixed community with no migrations.', 'Infection rates and clinical and epidemiological information govern the transitions between stages of the disease.', 'The present model provides a steppingstone to build upon and its current low complexity retains accessibility to non experts and policy makers to comprehend the variables and phenomena at play.', 'The impact of specific interventions on the outbreak time course, number of cases and outcome of fatalities were evaluated including that of available critical care.', 'Data available from the COVID19 outbreak as of early April 2020 was used.', 'Key findings in our results indicate that (i) universal social isolation measures appear effective in reducing total fatalities only if they are strict and the number of daily social interactions is reduced to very low numbers; (ii) selective isolation of only the elderly (at higher fatality risk) appears almost as effective in reducing total fatalities but at a much lower economic damage; (iii) an increase in the number of critical care beds could save up to eight lives per extra bed in a million population with the current parameters used; (iv) the use of protective equipment (PPE) appears effective to dramatically reduce total fatalities when implemented extensively and in a high degree; (v) infection recognition through random testing of the population, accompanied by subsequent (self) isolation of infected aware individuals, can dramatically reduce the total fatalities but only if conducted extensively to almost the entire population and sustained over time; (vi) ending isolation measures while R0 values remain above 1.0 (with a safety factor) renders the isolation measures useless and total fatality numbers return to values as if nothing was ever done; (vii) ending the isolation measures for only the population under 60 y/o at R0 values still above 1.0 increases total fatalities but only around half as much as if isolation ends for everyone; (viii) a threshold value, equivalent to that for R0, appears to exist for the daily fatality rate at which to end isolation measures, this is significant as the fatality rate is (unlike R0) very accurately known.', 'Any interpretation of these results for the COVID19 outbreak predictions and interventions should be considered only qualitatively at this stage due to the low confidence (lack of complete and valid data) on the parameter values available at the time of writing.', 'Any quantitative interpretation of the results must be accompanied with a critical discussion in terms of the model limitations and its frame of application.']\n",
            "unmatched tags:  [{'entity': 'COVID19', 'type': 'Chemical', 'start': 2992, 'end': 2999}, {'entity': 'R0', 'type': 'Organization', 'start': 2919, 'end': 2921}, {'entity': 'R0', 'type': 'Organization', 'start': 2782, 'end': 2784}, {'entity': 'fatalities', 'type': 'Disease', 'start': 2658, 'end': 2668}, {'entity': 'R0', 'type': 'Organization', 'start': 2616, 'end': 2618}, {'entity': 'R0', 'type': 'Organization', 'start': 2378, 'end': 2380}]\n",
            "['Prophylactic cranial irradiation for patients with lung cancer\\tThe incidence of brain metastases in patients with lung cancer has increased as a result of improved local and systemic control and better diagnosis from advances in brain imaging.', 'Because brain metastases are responsible for life-threatening symptoms and serious impairment of quality of life, resulting in shortened survival, prophylactic cranial irradiation has been proposed in both small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) to try to improve incidence of brain metastasis, survival, and eventually quality of life.']\n",
            "unmatched tags:  [{'entity': 'brain metastasis', 'type': 'Disease', 'start': 550, 'end': 566}, {'entity': 'NSCLC', 'type': 'Disease', 'start': 512, 'end': 517}]\n",
            "['Direct Measurement of Rates of Asymptomatic Infection and Clinical Care-Seeking for Seasonal Coronavirus\\tThe pandemic potential of the novel coronavirus (nCoV) that emerged in Wuhan, China, during December 2019 is strongly tied to the number and contagiousness of undocumented human infections.', 'Here we present findings from a proactive longitudinal sampling study of acute viral respiratory infections that documents rates of asymptomatic infection and clinical care seeking for seasonal coronavirus.', 'We find that the majority of infections are asymptomatic by most symptom definitions and that only 4% of individuals experiencing a seasonal coronavirus infection episode sought medical care for their symptoms.', 'These numbers indicate that a very high percentage of seasonal coronavirus infections are undocumented and provide a reference for understanding the spread of the emergent nCoV.']\n",
            "unmatched tags:  [{'entity': 'nCoV', 'type': 'Virus', 'start': 887, 'end': 891}, {'entity': 'coronavirus infections', 'type': 'Disease', 'start': 778, 'end': 800}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 644, 'end': 655}, {'entity': 'coronavirus infection', 'type': 'Disease', 'start': 644, 'end': 665}, {'entity': 'seasonal coronavirus', 'type': 'Virus', 'start': 635, 'end': 655}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 568, 'end': 575}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 548, 'end': 555}, {'entity': 'seasonal coronavirus', 'type': 'Virus', 'start': 480, 'end': 500}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 428, 'end': 435}, {'entity': 'viral respiratory infections', 'type': 'Disease', 'start': 374, 'end': 402}, {'entity': 'nCoV', 'type': 'Virus', 'start': 154, 'end': 158}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 141, 'end': 152}]\n",
            "['The Xs and Y of immune responses to viral vaccines\\tThe biological differences associated with the sex of an individual are a major source of variation, affecting immune responses to vaccination.', 'Compelling clinical data illustrate that men and women differ in their innate, humoral, and cell-mediated responses to viral vaccines.', 'Sex affects the frequency and severity of adverse effects of vaccination, including fever, pain, and inflammation.', 'Pregnancy can also substantially alter immune responses to vaccines.', 'Data from clinical trials and animal models of vaccine efficacy lay the groundwork for future studies aimed at identifying the biological mechanisms that underlie sex-specific responses to vaccines, including genetic and hormonal factors.']\n",
            "unmatched tags:  [{'entity': 'vaccines', 'type': 'Drug', 'start': 703, 'end': 711}, {'entity': 'vaccine', 'type': 'Drug', 'start': 561, 'end': 568}, {'entity': 'vaccines', 'type': 'Drug', 'start': 504, 'end': 512}, {'entity': 'pain', 'type': 'Phenotype', 'start': 421, 'end': 425}]\n",
            "['Enhancement of trans-cleavage activity of Cas12a with engineered crRNA enables amplified nucleic acid detection\\tThe CRISPR/Cas12a RNA-guided complexes have a tremendous potential for nucleic acid detection due to its ability to indiscriminately cleave ssDNA once bound to a target DNA.', 'However, the current CRISPR/Cas12a systems are limited to detecting DNA in a picomolar detection limit without an amplification step.', 'Here, we developed a platform with engineered crRNAs and optimized conditions that enabled us to detect DNA, DNA/RNA heteroduplex and methylated DNA with higher sensitivity, achieving a limit of detection of in femtomolar range without any target pre-amplification step.', 'By extending the 3’- or 5’-ends of the crRNA with different lengths of ssDNA, ssRNA, and phosphorothioate ssDNA, we discovered a new self-catalytic behavior and an augmented rate of LbCas12a-mediated collateral cleavage activity as high as 3.5-fold compared to the wild-type crRNA.', 'We applied this sensitive system to detect as low as 25 fM dsDNA from the PCA3 gene, an overexpressed biomarker in prostate cancer patients, in simulated urine over 6 hours.', 'The same platform was used to detect as low as ~700 fM cDNA from HIV, 290 fM RNA from HCV, and 370 fM cDNA from SARS-CoV-2, all within 30 minutes without a need for target amplification.', 'With isothermal amplification of SARS-CoV-2 RNA using RT-LAMP, the modified crRNAs were incorporated in a paper-based lateral flow assay that could detect the target with up to 23-fold higher sensitivity within 40-60 minutes.']\n",
            "unmatched tags:  [{'entity': 'crRNA', 'type': 'Chemical', 'start': 1410, 'end': 1415}, {'entity': 'RT-LAMP', 'type': 'Chemical', 'start': 1388, 'end': 1395}, {'entity': 'RNA', 'type': 'Gene', 'start': 1378, 'end': 1381}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1367, 'end': 1377}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1259, 'end': 1269}, {'entity': 'cDNA', 'type': 'Gene', 'start': 1249, 'end': 1253}, {'entity': 'HCV', 'type': 'Virus', 'start': 1233, 'end': 1236}, {'entity': 'RNA', 'type': 'Gene', 'start': 1224, 'end': 1227}, {'entity': 'HIV', 'type': 'Virus', 'start': 1212, 'end': 1215}, {'entity': 'DNA', 'type': 'Gene', 'start': 1203, 'end': 1206}, {'entity': 'cDNA', 'type': 'Gene', 'start': 1202, 'end': 1206}, {'entity': 'prostate cancer', 'type': 'Disease', 'start': 1088, 'end': 1103}, {'entity': 'PCA3 gene', 'type': 'Gene', 'start': 1047, 'end': 1056}, {'entity': 'dsDNA', 'type': 'Gene', 'start': 1032, 'end': 1037}, {'entity': 'crRNA', 'type': 'Chemical', 'start': 966, 'end': 971}, {'entity': 'wild-type', 'type': 'Drug', 'start': 956, 'end': 965}, {'entity': 'DNA', 'type': 'Gene', 'start': 799, 'end': 802}]\n",
            "['Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial\\tPatients with NSCLC of PS2 are a group of patients of unmet therapeutic need.', 'The PePS2 trial shows that pembrolizumab can be safely administered to these patients, with no increase in the risk of immune-related or other toxicities.', 'Efficacy outcomes are at least as good as those in patients with PS0–1 and the data provides clinicians with the confidence to incorporate pembrolizumab into the treatment pathway of patients with NSCLC of PS2.']\n",
            "unmatched tags:  [{'entity': 'PS2', 'type': 'Gene', 'start': 558, 'end': 561}, {'entity': 'NSCLC', 'type': 'Disease', 'start': 549, 'end': 554}, {'entity': 'pembrolizumab', 'type': 'Drug', 'start': 491, 'end': 504}, {'entity': 'toxicities', 'type': 'Disease', 'start': 340, 'end': 350}, {'entity': 'immune-related', 'type': 'Organization', 'start': 316, 'end': 330}, {'entity': 'pembrolizumab', 'type': 'Drug', 'start': 224, 'end': 237}]\n",
            "['Clinical features of coronavirus disease 2019 (COVID-19) in a cohort of patients with disability due to spinal cord injury\\tStudy design: Cohort study of patients with spinal cord injury (SCI) Objectives: To describe the clinical and analytical features of a Covid-19 infected cohort with SCI to contribute new knowledge for a more accurate diagnosis and to outline prevention measures.', 'Setting: This study was conducted at the National Hospital for Paraplegics (Toledo, Spain).', 'Methods: A cohort analysis of seven patients with SCI infected by Covid-19 was carried out.', 'Diagnosis was confirmed with reverse transcriptase polymerase chain reaction (RT-PCR) of nasal exudate or sputum samples.', 'Clinical, analytical and radiographic findings were registered.', 'Results: RT-PCR detected COVID-19 infection in all patients, affecting males and people with a cervical level of injury more often (5 out 7).', 'The average delay for diagnostic confirmation was 4 days (interquartile range, 1-10).', 'Fever was the most frequent symptom (6 out of 7).', 'The second most common symptom was asthenia (4 out of 7), followed by dyspnea, cough and expectoration (3 out of 7 for each symptom).', 'The MEWS score for Covid-19 severity rating was classified as severe in 5 out of 7.', 'All but one patient showed radiological alterations evident in chest X-Rays at the time of diagnosis.', 'All patients recovered gradually.', 'Conclusion: Our patients with SCI and Covid-19 infection exhibited fewer symptoms than the general population.', 'Furthermore, they presented similar or greater clinical severity.', 'The clinical evolution was not as pronounced as had been expected.', 'This study recommends close supervision of the SCI population to detect early compatible signs and symptoms of Covid-19 infection.']\n",
            "unmatched tags:  [{'entity': 'Covid-19', 'type': 'Disease', 'start': 1744, 'end': 1752}, {'entity': 'Covid-19', 'type': 'Disease', 'start': 1427, 'end': 1435}, {'entity': 'Covid-19', 'type': 'Disease', 'start': 1187, 'end': 1195}, {'entity': 'MEWS', 'type': 'Chemical', 'start': 1172, 'end': 1176}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 1158, 'end': 1165}, {'entity': 'cough', 'type': 'Phenotype', 'start': 1113, 'end': 1118}, {'entity': 'dyspnea', 'type': 'Phenotype', 'start': 1104, 'end': 1111}, {'entity': 'asthenia', 'type': 'Phenotype', 'start': 1069, 'end': 1077}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 1057, 'end': 1064}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 1012, 'end': 1019}, {'entity': 'Fever', 'type': 'Phenotype', 'start': 984, 'end': 989}, {'entity': 'injury', 'type': 'Disease', 'start': 869, 'end': 875}]\n",
            "['Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010\\tDespite the apparently small contribution of YLLs—with deaths in people with mental disorders coded to the physical cause of death and suicide coded to the category of injuries under self-harm—our findings show the striking and growing challenge that these disorders pose for health systems in developed and developing regions.', 'In view of the magnitude of their contribution, improvement in population health is only possible if countries make the prevention and treatment of mental and substance use disorders a public health priority.']\n",
            "unmatched tags:  [{'entity': 'substance use disorders', 'type': 'Disease', 'start': 618, 'end': 641}, {'entity': 'disorders', 'type': 'Disease', 'start': 388, 'end': 397}]\n",
            "['The neurotropic herpes viruses: herpes simplex and varicella-zoster\\tHerpes simplex viruses types 1 and 2 (HSV1 and HSV2) and varicella-zoster virus (VZV) establish latent infection in dorsal root ganglia for the entire life of the host.', 'From this reservoir they can reactivate to cause human morbidity and mortality.', 'Although the viruses vary in the clinical disorders they cause and in their molecular structure, they share several features that affect the course of infection of the human nervous system.', 'HSV1 is the causative agent of encephalitis, corneal blindness, and several disorders of the peripheral nervous system; HSV2 is responsible for meningoencephalitis in neonates and meningitis in adults.']\n",
            "unmatched tags:  [{'entity': 'meningitis', 'type': 'Phenotype', 'start': 687, 'end': 697}, {'entity': 'meningoencephalitis', 'type': 'Disease', 'start': 651, 'end': 670}, {'entity': 'HSV2', 'type': 'Gene', 'start': 627, 'end': 631}, {'entity': 'disorders', 'type': 'Disease', 'start': 583, 'end': 592}, {'entity': 'encephalitis', 'type': 'Disease', 'start': 538, 'end': 550}]\n",
            "['Comparative analyses of SAR-CoV2 genomes from different geographical locations and other coronavirus family genomes reveals unique features potentially consequential to host-virus interaction and pathogenesis\\tThe ongoing pandemic of the coronavirus disease 2019 (COVID - 19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2).', 'We have performed an integrated sequence-based analysis of SARS-CoV2 genomes from different geographical locations in order to identify its unique features absent in SARS-CoV and other related coronavirus family genomes, conferring unique infection, facilitation of transmission, virulence and immunogenic features to the virus.', 'The phylogeny of the genomes yields some interesting results.', 'Systematic gene level mutational analysis of the genomes has enabled us to identify several unique features of the SARS-CoV2 genome, which includes a unique mutation in the spike surface glycoprotein (A930V (24351C>T)) in the Indian SARS-CoV2, absent in other strains studied here.', 'We have also predicted the impact of the mutations in the spike glycoprotein function and stability, using computational approach.', 'To gain further insights into host responses to viral infection, we predict that antiviral host-miRNAs may be controlling the viral pathogenesis.', 'Our analysis reveals nine host miRNAs which can potentially target SARS-CoV2 genes.', 'Interestingly, the nine miRNAs do not have targets in SARS and MERS genomes.', 'Also, hsa-miR-27b is the only unique miRNA which has a target gene in the Indian SARS-CoV2 genome.', 'We also predicted immune epitopes in the genomes']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV', 'type': 'Virus', 'start': 1563, 'end': 1571}, {'entity': 'gene', 'type': 'Gene', 'start': 1544, 'end': 1548}, {'entity': 'miRNA', 'type': 'Gene', 'start': 1519, 'end': 1524}, {'entity': 'genomes', 'type': 'Gene', 'start': 1473, 'end': 1480}, {'entity': 'MERS', 'type': 'Disease', 'start': 1468, 'end': 1472}, {'entity': 'SARS', 'type': 'Disease', 'start': 1459, 'end': 1463}, {'entity': 'miRNAs', 'type': 'Gene', 'start': 1429, 'end': 1435}, {'entity': 'gene', 'type': 'Gene', 'start': 1398, 'end': 1402}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 1388, 'end': 1396}, {'entity': 'miRNAs', 'type': 'Gene', 'start': 1352, 'end': 1358}, {'entity': 'gene', 'type': 'Gene', 'start': 1312, 'end': 1316}, {'entity': 'host-miRNAs', 'type': 'Organization', 'start': 1266, 'end': 1277}, {'entity': 'antiviral', 'type': 'Virus', 'start': 1256, 'end': 1265}, {'entity': 'viral infection', 'type': 'Virus', 'start': 1223, 'end': 1238}, {'entity': 'strains', 'type': 'Disease', 'start': 1022, 'end': 1029}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 995, 'end': 1003}, {'entity': 'spike surface glycoprotein', 'type': 'Gene', 'start': 935, 'end': 961}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 877, 'end': 885}, {'entity': 'genomes', 'type': 'Gene', 'start': 811, 'end': 818}, {'entity': 'gene', 'type': 'Gene', 'start': 773, 'end': 777}, {'entity': 'genomes', 'type': 'Gene', 'start': 721, 'end': 728}, {'entity': 'genomes', 'type': 'Gene', 'start': 583, 'end': 590}, {'entity': 'coronavirus family', 'type': 'Virus', 'start': 564, 'end': 582}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 537, 'end': 545}, {'entity': 'genomes', 'type': 'Gene', 'start': 440, 'end': 447}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 430, 'end': 438}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 359, 'end': 367}, {'entity': 'acute respiratory syndrome coronavirus 2', 'type': 'Virus', 'start': 317, 'end': 357}, {'entity': 'infectious disease', 'type': 'Disease', 'start': 281, 'end': 299}]\n",
            "[\"Dementia associated with Parkinson's disease\\tDementia affects about 40% of patients with Parkinson's disease; the incidence of dementia in these patients is up to six times that in healthy people.\", 'Clinically, the prototype of dementia in PD is a dysexecutive syndrome.', 'Loss of cholinergic, dopaminergic, and noradrenergic innervation has been suggested to be the underlying neurochemical deficits.', 'Nigral pathology alone is probably not sufficient for the development of dementia.', 'Although there is some controversy with regard to the site and type of pathology involved, dementia is likely to be associated with the spread of pathology to other subcortical nuclei, the limbic system, and the cerebral cortex.']\n",
            "unmatched tags:  [{'entity': 'dementia', 'type': 'Disease', 'start': 572, 'end': 580}, {'entity': 'type', 'type': 'Gene', 'start': 544, 'end': 548}, {'entity': 'dementia', 'type': 'Disease', 'start': 471, 'end': 479}, {'entity': 'dopaminergic', 'type': 'Drug', 'start': 290, 'end': 302}]\n",
            "['The changing face of diabetes complications\\tThe global increase in type 2 diabetes prevalence is well documented, but international trends in complications of type 2 diabetes are less clear.', 'The available data suggest large reductions in classic complications of type 2 diabetes in high-income countries over the past 20 years, predominantly reductions in myocardial infarction, stroke, amputations, and mortality.', 'These trends might be accompanied by less obvious, but still important, changes in the character of morbidity in people with diabetes.']\n",
            "unmatched tags:  [{'entity': 'diabetes', 'type': 'Disease', 'start': 540, 'end': 548}, {'entity': 'stroke', 'type': 'Disease', 'start': 379, 'end': 385}, {'entity': 'myocardial infarction', 'type': 'Disease', 'start': 356, 'end': 377}]\n",
            "['Mantle-cell lymphoma\\tDuring the past decade, mantle-cell lymphoma has been established as a new disease entity.', 'The normal counterparts of the cells forming this malignant lymphoma are found in the mantle zone of the lymph node, a thin layer surrounding the germinal follicles.', 'These cells have small to medium-sized nuclei, are commonly indented or cleaved, and stain positively with CD5, CD20, cyclin D1, and FMC7 antibodies.', 'Because of its morphological appearance and a resemblance to other low-grade lymphomas, many of which grow slowly, this lymphoma was initially thought to be an indolent tumour, but its natural course was not thoroughly investigated until the 1990s, when the']\n",
            "unmatched tags:  [{'entity': 'tumour', 'type': 'Disease', 'start': 597, 'end': 603}, {'entity': 'lymphoma', 'type': 'Disease', 'start': 548, 'end': 556}, {'entity': 'lymphoma', 'type': 'Disease', 'start': 505, 'end': 513}, {'entity': 'low-grade lymphomas', 'type': 'Disease', 'start': 495, 'end': 514}, {'entity': 'FMC7', 'type': 'Gene', 'start': 411, 'end': 415}, {'entity': 'cyclin D1', 'type': 'Gene', 'start': 396, 'end': 405}, {'entity': 'CD20', 'type': 'Gene', 'start': 390, 'end': 394}, {'entity': 'CD5', 'type': 'Gene', 'start': 385, 'end': 388}, {'entity': 'stain', 'type': 'Disease', 'start': 363, 'end': 368}, {'entity': 'malignant lymphoma', 'type': 'Disease', 'start': 162, 'end': 180}]\n",
            "['Adverse health consequences of the Iraq War\\tThe adverse health consequences of the Iraq War (2003–11) were profound.', 'We conclude that at least 116\\u2008903 Iraqi non-combatants and more than 4800 coalition military personnel died over the 8-year course.', 'Many Iraqi civilians were injured or became ill because of damage to the health-supporting infrastructure of the country, and about 5 million were displaced.', 'More than 31\\u2008000 US military personnel were injured and a substantial percentage of those deployed suffered post-traumatic stress disorder, traumatic brain injury, and other neuropsychological disorders and their concomitant psychosocial problems.']\n",
            "unmatched tags:  [{'entity': 'psychosocial problems', 'type': 'Disease', 'start': 632, 'end': 653}, {'entity': 'neuropsychological disorders', 'type': 'Disease', 'start': 581, 'end': 609}, {'entity': 'traumatic brain injury', 'type': 'Disease', 'start': 547, 'end': 569}, {'entity': 'post-traumatic stress disorder', 'type': 'Disease', 'start': 515, 'end': 545}]\n",
            "['Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial\\tPentavalent rotavirus vaccine is effective against severe rotavirus gastroenteritis in the first 2 years of life in African countries with high mortality in infants younger than 5 years.', \"We support WHO's recommendation for adoption of rotavirus vaccine into national expanded programmes on immunisation in Africa.\"]\n",
            "unmatched tags:  [{'entity': 'national', 'type': 'Organization', 'start': 452, 'end': 460}, {'entity': 'rotavirus vaccine', 'type': 'Drug', 'start': 429, 'end': 446}]\n",
            "['Experiences of hearing voices: analysis of a novel phenomenological survey\\tThis study is, to our knowledge, the largest mixed-methods investigation of auditory hallucination phenomenology so far.', 'Our survey was completed by a diverse sample of people who hear voices with various diagnoses and clinical histories.', 'Our findings both overlap with past large-sample investigations of auditory hallucination and suggest potentially important new findings about the association between acoustic perception and thought, somatic and multisensorial features of auditory hallucinations, and the link between auditory hallucinations and characterological entities.']\n",
            "unmatched tags:  [{'entity': 'auditory hallucinations', 'type': 'Phenotype', 'start': 599, 'end': 622}, {'entity': 'auditory hallucinations', 'type': 'Phenotype', 'start': 553, 'end': 576}, {'entity': 'auditory hallucination', 'type': 'Phenotype', 'start': 381, 'end': 403}]\n",
            "['Single-cell analysis of human lung epithelia reveals concomitant expression of the SARS-CoV-2 receptor ACE2 with multiple virus receptors and scavengers in alveolar type II cells\\tThe novel coronavirus SARS-CoV-2 was identified as the causative agent of the ongoing pandemic COVID 19.', 'COVID-19-associated deaths are mainly attributed to severe pneumonia and respiratory failure.', 'Recent work demonstrated that SARS-CoV-2 binds to angiotensin converting enzyme 2 (ACE2) in the lung.', 'To better understand ACE2 abundance and expression patterns in the lung we interrogated our in-house single-cell RNA-sequencing dataset containing 70,085 EPCAM+ lung epithelial cells from paired normal and lung adenocarcinoma tissues.', 'Transcriptomic analysis revealed a diverse repertoire of airway lineages that included alveolar type I and II, bronchioalveolar, club/secretory, quiescent and proliferating basal, ciliated and malignant cells as well as rare populations such as ionocytes.', 'While the fraction of lung epithelial cells expressing ACE2 was low (1.7% overall), alveolar type II (AT2, 2.2% ACE2 +) cells exhibited highest levels of ACE2 expression among all cell subsets.', 'Further analysis of the AT2 compartment (n = 27,235 cells) revealed a number of genes co-expressed with ACE2 that are important for lung pathobiology including those associated with chronic obstructive pulmonary disease (COPD; HHIP ), pneumonia and infection ( FGG and C4BPA ) as well as malarial/bacterial ( CD36 ) and viral ( DMBT1 ) scavenging which, for the most part, were increased in smoker versus light or non-smoker cells.', 'Notably, DMBT1 was highly expressed in AT2 cells relative to other lung epithelial subsets and its expression positively correlated with ACE2 .', 'We describe a population of ACE2 -positive AT2 cells that co-express pathogen (including viral) receptors (e.g.', 'DMBT1 ) with crucial roles in host defense thus comprising plausible phenotypic targets for treatment of COVID-19.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 1958, 'end': 1966}, {'entity': 'DMBT1', 'type': 'Gene', 'start': 1853, 'end': 1858}, {'entity': 'receptors', 'type': 'Gene', 'start': 1837, 'end': 1846}, {'entity': 'co-express', 'type': 'Organization', 'start': 1799, 'end': 1809}, {'entity': 'AT2 cells', 'type': 'Gene', 'start': 1784, 'end': 1793}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1769, 'end': 1773}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1734, 'end': 1738}, {'entity': 'AT2 cells', 'type': 'Gene', 'start': 1636, 'end': 1645}, {'entity': 'DMBT1', 'type': 'Gene', 'start': 1606, 'end': 1611}, {'entity': 'light', 'type': 'Gene', 'start': 1570, 'end': 1575}, {'entity': 'DMBT1', 'type': 'Gene', 'start': 1493, 'end': 1498}, {'entity': 'CD36', 'type': 'Gene', 'start': 1474, 'end': 1478}, {'entity': 'C4BPA', 'type': 'Gene', 'start': 1434, 'end': 1439}, {'entity': 'FGG', 'type': 'Gene', 'start': 1426, 'end': 1429}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 1400, 'end': 1409}, {'entity': 'HHIP', 'type': 'Gene', 'start': 1392, 'end': 1396}, {'entity': 'chronic obstructive pulmonary disease', 'type': 'Disease', 'start': 1347, 'end': 1384}]\n",
            "['Non-psychotic mental disorders in the perinatal period\\tMental disorders are among the most common morbidities of pregnancy and the postnatal period, and can have adverse effects on the mother, her child, and family.', 'This Series paper summarises the evidence about epidemiology, risk factors, identification, and interventions for non-psychotic mental disorders.', 'Although the phenomenology and risk factors for perinatal mental disorders are largely similar to those for the disorders at other times, treatment considerations differ during pregnancy and breastfeeding.']\n",
            "unmatched tags:  [{'entity': 'disorders', 'type': 'Disease', 'start': 474, 'end': 483}, {'entity': 'disorders', 'type': 'Disease', 'start': 427, 'end': 436}, {'entity': 'perinatal mental disorders', 'type': 'Disease', 'start': 410, 'end': 436}]\n",
            "['Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs\\tAngiogenesis is essential for tumour growth, invasion, and metastasis.', 'Tumour blood vessels show many differences from normal vessels and are not genetically unstable, so they form a potentially key area for therapy of all types of cancer including leukaemias.', 'Here we review current knowledge on the multiple pathways controlling tumour angiogenesis and assess which are the most clinically relevant.', 'We also review the clinical evidence that angiogenesis affects the behaviour of cancer.', 'Retrospective studies on intratumoral vascularisation suggest that it is an independent prognostic factor that merits prospective validation.']\n",
            "unmatched tags:  [{'entity': 'cancer', 'type': 'Disease', 'start': 601, 'end': 607}, {'entity': 'tumour angiogenesis', 'type': 'Disease', 'start': 450, 'end': 469}, {'entity': 'leukaemias', 'type': 'Disease', 'start': 368, 'end': 378}, {'entity': 'cancer', 'type': 'Disease', 'start': 351, 'end': 357}, {'entity': 'genetically', 'type': 'Gene', 'start': 265, 'end': 276}, {'entity': 'Tumour blood vessels', 'type': 'Disease', 'start': 190, 'end': 210}]\n",
            "['The bat influenza H17N10 can be neutralized by broadly-neutralizing monoclonal antibodies and its neuraminidase can facilitate viral egress\\tThe diversity of subtypes within the Influenza A virus genus has recently expanded with the identification of H17N10 and H18N11 from bats.', 'In order to further study the tropism and zoonotic potential of these viruses, we have successfully produced lentiviral pseudotypes bearing both haemagglutinin H17 and neuraminidase N10.', 'These pseudotypes were shown to be efficiently neutralized by the broadly-neutralizing monoclonal antibodies CR9114 and FI6.', 'Our studies also confirm previous reports that H17 does not use sialic acid as its cellular receptor, as pseudotypes bearing the H17 envelope glycoprotein are released into the cell supernatant in the absence of NA.', 'However, we demonstrate that N10 facilitates heterosubtypic (H5 and H7) influenza HA-bearing pseudotype release in the absence of another source of NA, significantly increasing luciferase pseudotype production titres.', 'Despite this, N10 shows no activity in the enzyme-linked lectin assay used for traditional sialidases.', 'These findings suggest that this protein plays an important role in viral egress, but is perhaps involved in further accessory roles in the bat influenza lifecycle that are yet to be discovered.', 'Thus we show the lentiviral pseudotype system is a useful research tool, and amenable for investigation of bat influenza tropism, restriction and sero-epidemiology, without the constraints or safety issues with producing a replication-competent virus, to which the human population is naïve.', 'Significance statement Influenza virus is responsible for mortality and morbidity across the globe; human populations are constantly at risk of newly emerging strains from the aquatic bird reservoir which harbors most of the subtypes of influenza A (H1-H16).', 'Recently identified subtypes (H17N10, H18N11) from bats have broadened the reservoir from which potential pandemic strains of influenza can emerge.', 'To evaluate the potential for these novel subtypes to cross over into human populations, their ability to establish an infection, in addition to the extent of cross-reactive immunity established by human seasonal strains needs to be investigated.', 'This study highlights a novel platform for the study of the bat H17 and N10 envelope glycoproteins, using a lentiviral pseudotype system.', 'Following the generation of this pseudotype it was employed in cell entry and microneutralization assays.', 'These showed that two well-characterised monoclonal antibodies (mAb) which target avian and human influenza subtypes will also neutralize H17.', 'Furthermore the data presented in this study show a novel aspect of the N10 glycoprotein in its ability to facilitate the budding of pseudotypes bearing different influenza HAs.']\n",
            "unmatched tags:  [{'entity': 'influenza', 'type': 'Disease', 'start': 2819, 'end': 2828}, {'entity': 'N10 glycoprotein', 'type': 'Gene', 'start': 2728, 'end': 2744}, {'entity': 'H17', 'type': 'Gene', 'start': 2651, 'end': 2654}, {'entity': 'influenza', 'type': 'Disease', 'start': 2611, 'end': 2620}, {'entity': 'mAb', 'type': 'Gene', 'start': 2577, 'end': 2580}, {'entity': 'monoclonal antibodies', 'type': 'Drug', 'start': 2554, 'end': 2575}, {'entity': 'lentiviral', 'type': 'Drug', 'start': 2377, 'end': 2387}, {'entity': 'protein', 'type': 'Gene', 'start': 2359, 'end': 2366}, {'entity': 'H17', 'type': 'Gene', 'start': 2333, 'end': 2336}, {'entity': 'seasonal strains', 'type': 'Organization', 'start': 2226, 'end': 2242}, {'entity': 'influenza', 'type': 'Disease', 'start': 2000, 'end': 2009}, {'entity': 'strains', 'type': 'Disease', 'start': 1989, 'end': 1996}, {'entity': 'H17N10', 'type': 'Gene', 'start': 1904, 'end': 1910}, {'entity': 'H1-H16', 'type': 'Gene', 'start': 1865, 'end': 1871}, {'entity': 'influenza A', 'type': 'Drug', 'start': 1852, 'end': 1863}, {'entity': 'strains', 'type': 'Disease', 'start': 1774, 'end': 1781}, {'entity': 'Influenza virus', 'type': 'Virus', 'start': 1638, 'end': 1653}, {'entity': 'replication-competent virus', 'type': 'Gene', 'start': 1546, 'end': 1573}, {'entity': 'influenza', 'type': 'Disease', 'start': 1434, 'end': 1443}, {'entity': 'bat influenza tropism', 'type': 'Drug', 'start': 1430, 'end': 1451}, {'entity': 'lentiviral', 'type': 'Drug', 'start': 1340, 'end': 1350}, {'entity': 'bat influenza', 'type': 'Drug', 'start': 1268, 'end': 1281}, {'entity': 'protein', 'type': 'Gene', 'start': 1161, 'end': 1168}, {'entity': 'sialidases', 'type': 'Gene', 'start': 1116, 'end': 1126}, {'entity': 'luciferase', 'type': 'Gene', 'start': 984, 'end': 994}, {'entity': 'influenza', 'type': 'Disease', 'start': 879, 'end': 888}]\n",
            "['A prospect on the use of antiviral drugs to control local outbreaks of COVID-19\\tBackground: Current outbreaks of COVID-19 are threatening the health care systems of several countries around the world.', 'Control measures, based on isolation and quarantine, have been shown to decrease and delay the burden of the ongoing epidemic.', 'With respect to the ongoing COVID-19 epidemic, recent modelling work shows that this intervention technique may be inadequate to control local outbreaks, even when perfect isolation is assumed.', 'Furthermore, the effect of  infectiousness prior to symptom onset combined with a significant proportion of asymptomatic infectees further complicates the use of contact tracing.', 'Antivirals, which decrease the viral load and reduce the infectiousness, could be integrated in the control measures in order to augment the feasibility of controlling the epidemic.', 'Methods: Using a simulation-based model of viral transmission we tested the efficacy of different intervention measures for the control of COVID-19.', 'For individuals that were identified through contact tracing, we evaluate two procedures: monitoring individuals for symptoms onset and testing of individuals.', 'Moreover, we investigate the effect of a potent antiviral compound on the contact tracing process.', 'Findings: The use of an antiviral drug, in combination with contact tracing, quarantine and isolation, results in a significant decrease of the final size, the peak incidence, and increases the probability that the outbreak will fade out.', 'Interpretation: For an infectious disease in which presymptomatic infections are plausible, an intervention measure based on contact tracing performs better when realized together with testing instead of monitoring, provided that the test is able to detect infections during the incubation period.', 'In addition, in all tested scenarios, the model highlights the benefits of the administration of an antiviral drug in addition to quarantine, isolation and contact tracing.', 'The resulting control measure, could be an effective strategy to control local and re-emerging outbreaks of COVID-19.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2110, 'end': 2118}, {'entity': 'antiviral drug', 'type': 'Drug', 'start': 1929, 'end': 1943}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 1585, 'end': 1592}, {'entity': 'presymptomatic infections', 'type': 'Disease', 'start': 1582, 'end': 1607}, {'entity': 'infectious disease', 'type': 'Disease', 'start': 1554, 'end': 1572}, {'entity': 'antiviral drug', 'type': 'Drug', 'start': 1316, 'end': 1330}, {'entity': 'antiviral compound', 'type': 'Chemical', 'start': 1240, 'end': 1258}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1022, 'end': 1030}, {'entity': 'Antivirals', 'type': 'Drug', 'start': 701, 'end': 711}]\n",
            "['Cleft lip and palate\\tClefts of the lip and palate are generally divided into two groups, isolated cleft palate and cleft lip with or without cleft palate, representing a heterogeneous group of disorders affecting the lips and oral cavity.', 'These defects arise in about 1·7 per 1000 liveborn babies, with ethnic and geographic variation.', 'Effects on speech, hearing, appearance, and psychology can lead to longlasting adverse outcomes for health and social integration.', 'Typically, children with these disorders need multidisciplinary care from birth to adulthood and have higher morbidity and mortality throughout life than do unaffected individuals.']\n",
            "unmatched tags:  [{'entity': 'disorders', 'type': 'Disease', 'start': 498, 'end': 507}]\n",
            "['Active surveillance: towards a new paradigm in the management of early prostate cancer\\tProstate cancer is the only human cancer that is curable but which commonly does not need to be cured.', 'Active surveillance is a new strategy that aims to individualise therapy by selecting only those men with significant cancers for curative therapy.', 'Patients with favourable tumour characteristics are closely monitored using serum prostate specific antigen (PSA) concentrations and repeat prostate biopsies.', 'The choice between radical treatment and continued observation is based on evidence of disease progression, defined in terms of the PSA doubling time, and “upgrading” at repeat biopsy.']\n",
            "unmatched tags:  [{'entity': 'serum prostate specific antigen', 'type': 'Gene', 'start': 414, 'end': 445}, {'entity': 'tumour', 'type': 'Disease', 'start': 363, 'end': 369}]\n",
            "['Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial\\tFilgotinib is efficacious and safe for the treatment of patients with active ankylosing spondylitis who have not responded to first-line pharmacological therapy with NSAIDs.', 'Further investigation of filgotinib for ankylosing spondylitis is warranted.']\n",
            "unmatched tags:  [{'entity': 'ankylosing spondylitis', 'type': 'Disease', 'start': 406, 'end': 428}, {'entity': 'filgotinib', 'type': 'Drug', 'start': 391, 'end': 401}]\n",
            "['Human monkeypox: an emerging zoonosis\\tHuman monkeypox is a rare viral zoonosis endemic to central and western Africa that has recently emerged in the USA.', 'Laboratory diagnosis is important because the virus can cause disease that is clinically indistinguishable from other pox-like illnesses, particularly smallpox and chickenpox.', 'Although the natural animal reservoir of the monkeypox virus is unknown, rodents are the probable source of its introduction into the USA.', 'A clear understanding of the virulence and transmissibility of human monkeypox has been limited by inconsistencies in epidemiological investigations.']\n",
            "unmatched tags:  [{'entity': 'monkeypox', 'type': 'Disease', 'start': 539, 'end': 548}, {'entity': 'monkeypox virus', 'type': 'Virus', 'start': 376, 'end': 391}, {'entity': 'chickenpox', 'type': 'Disease', 'start': 319, 'end': 329}, {'entity': 'smallpox', 'type': 'Disease', 'start': 306, 'end': 314}, {'entity': 'illnesses', 'type': 'Phenotype', 'start': 282, 'end': 291}]\n",
            "['Moderate and severe traumatic brain injury in adults\\tTraumatic brain injury (TBI) is a major health and socioeconomic problem that affects all societies.', 'In recent years, patterns of injury have been changing, with more injuries, particularly contusions, occurring in older patients.', 'Blast injuries have been identified as a novel entity with specific characteristics.', 'Traditional approaches to the classification of clinical severity are the subject of debate owing to the widespread policy of early sedation and ventilation in more severely injured patients, and are being supplemented with structural and functional neuroimaging.']\n",
            "unmatched tags:  [{'entity': 'Blast injuries', 'type': 'Disease', 'start': 284, 'end': 298}, {'entity': 'contusions', 'type': 'Disease', 'start': 243, 'end': 253}, {'entity': 'injury', 'type': 'Disease', 'start': 183, 'end': 189}, {'entity': 'societies', 'type': 'Organization', 'start': 143, 'end': 152}]\n",
            "['Global strategies to prevent bacterial pneumonia in adults with HIV disease\\tWe examined the peer-reviewed literature on the burden of bacterial pneumonia and the effectiveness of interventions for its prevention among HIV-infected adults in developed and developing countries.', 'Bacterial pneumonia rates were up to 25-fold higher among HIV-infected adults than in the general community, with rates increasing as CD4+ T-cell count decreases.', 'In developed countries, cohort studies showed that highly active antiretroviral therapy (HAART) had the most consistent effect on reducing pneumonia.']\n",
            "unmatched tags:  [{'entity': 'pneumonia', 'type': 'Disease', 'start': 579, 'end': 588}, {'entity': 'HIV-infected', 'type': 'Disease', 'start': 335, 'end': 347}]\n",
            "['Genome based Evolutionary study of SARS-CoV-2 towards the Prediction of Epitope Based Chimeric Vaccine\\tSARS-CoV-2 is known to infect the neurological, respiratory, enteric, and hepatic systems of human and has already become an unprecedented threat to global healthcare system.', 'COVID-19, the most serious public condition caused by SARS-CoV-2 leads the world to an uncertainty alongside thousands of regular death scenes.', 'Unavailability of specific therapeutics or approved vaccine has made the recovery of COVI-19 more troublesome and challenging.', 'The present in silico study aimed to predict a novel chimeric vaccines by simultaneously targeting four major structural proteins via the establishment of ancestral relationship among different strains of coronaviruses.', 'Conserved regions from the homologous protein sets of spike glycoprotein (S), membrane protein (M), envelope protein and nucleocapsid protein (N) were identified through multiple sequence alignment.', 'The phylogeny analyses of whole genome stated that four proteins (S, E, M and N) reflected the close ancestral relation of SARS-CoV-2 to SARS-COV-1 and bat coronavirus.', 'Numerous immunogenic epitopes (both T cell and B cell) were generated from the common fragments which were further ranked on the basis of antigenicity, transmembrane topology, conservancy level, toxicity and allergenicity pattern and population coverage analysis.', 'Top putative epitopes were combined with appropriate adjuvants and linkers to construct a novel multiepitope subunit vaccine against COVID-19.', 'The designed constructs were characterized based on physicochemical properties, allergenicity, antigenicity and solubility which revealed the superiority of construct V3 in terms safety and efficacy.', 'Essential molecular dynamics and Normal Mode analysis confirmed minimal deformability of the refined model at molecular level.', 'In addition, disulfide engineering was investigated to accelerate the stability of the protein.', 'Molecular docking study ensured high binding affinity between construct V3 and HLA cells, as well as with different host receptors.', 'Microbial expression and translational efficacy of the constructs were checked using pET28a(+) vector of E. coli strain K12.', 'The development of preventive measures to combat COVID-19 infections might be aided the present study.', 'However, the in vivo and in vitro validation might be ensured with wet lab trials using model animals for the implementation of the presented data.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2273, 'end': 2281}, {'entity': 'combat', 'type': 'Disease', 'start': 2266, 'end': 2272}, {'entity': 'constructs', 'type': 'Gene', 'start': 2154, 'end': 2164}, {'entity': 'host receptors', 'type': 'Gene', 'start': 2083, 'end': 2097}, {'entity': 'construct V3', 'type': 'Gene', 'start': 2029, 'end': 2041}, {'entity': 'protein', 'type': 'Gene', 'start': 1958, 'end': 1965}, {'entity': 'construct V3', 'type': 'Gene', 'start': 1701, 'end': 1713}, {'entity': 'constructs', 'type': 'Gene', 'start': 1557, 'end': 1567}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1534, 'end': 1542}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1518, 'end': 1525}, {'entity': 'bat coronavirus', 'type': 'Virus', 'start': 1120, 'end': 1135}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1091, 'end': 1101}, {'entity': 'proteins', 'type': 'Gene', 'start': 1024, 'end': 1032}, {'entity': 'protein', 'type': 'Gene', 'start': 1024, 'end': 1031}, {'entity': 'nucleocapsid protein', 'type': 'Gene', 'start': 890, 'end': 910}, {'entity': 'protein', 'type': 'Gene', 'start': 878, 'end': 885}, {'entity': 'envelope protein', 'type': 'Gene', 'start': 869, 'end': 885}]\n",
            "['Inhibition of SARS-CoV-2 (previously 2019-nCoV)Â\\xa0infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion\\tThe recent outbreak of coronavirus disease (COVID-19) caused by SARS-CoV-2 infection in Wuhan, China has posed a serious threat to global public health.', 'To develop specific anti-coronavirus therapeutics and prophylactics, the molecular mechanism that underlies viral infection must first be defined.', 'Therefore, we herein established a SARS-CoV-2 spike (S) protein-mediated cellâ\\x80\\x93cell fusion assay and found that SARS-CoV-2 showed a superior plasma membrane fusion capacity compared to that of SARS-CoV.', 'We solved the X-ray crystal structure of six-helical bundle (6-HB) core of the HR1 and HR2 domains in the SARS-CoV-2 S protein S2 subunit, revealing that several mutated amino acid residues in the HR1 domain may be associated with enhanced interactions with the HR2 domain.', 'We previously developed a pan-coronavirus fusion inhibitor, EK1, which targeted the HR1 domain and could inhibit infection by divergent human coronaviruses tested, including SARS-CoV and MERS-CoV.', 'Here we generated a series of lipopeptides derived from EK1 and found that EK1C4 was the most potent fusion inhibitor against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection with IC50s of 1.3 and 15.8â\\x80\\x89nM, about 241- and 149-fold more potent than the original EK1 peptide, respectively.', 'EK1C4 was also highly effective against membrane fusion and infection of other human coronavirus pseudoviruses tested, including SARS-CoV and MERS-CoV, as well as SARSr-CoVs, and potently inhibited the replication of 5 live human coronaviruses examined, including SARS-CoV-2.', 'Intranasal application of EK1C4 before or after challenge with HCoV-OC43 protected mice from infection, suggesting that EK1C4 could be used for prevention and treatment of infection by the currently circulating SARS-CoV-2 and other emerging SARSr-CoVs.']\n",
            "unmatched tags:  [{'entity': 'SARSr-CoVs', 'type': 'Virus', 'start': 1999, 'end': 2009}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1969, 'end': 1979}, {'entity': 'EK1', 'type': 'Disease', 'start': 1878, 'end': 1881}, {'entity': 'mice', 'type': 'Gene', 'start': 1841, 'end': 1845}, {'entity': 'HCoV-OC43', 'type': 'Virus', 'start': 1821, 'end': 1830}, {'entity': 'EK1', 'type': 'Disease', 'start': 1784, 'end': 1787}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1746, 'end': 1756}, {'entity': 'coronaviruses', 'type': 'Virus', 'start': 1712, 'end': 1725}, {'entity': 'SARSr-CoVs', 'type': 'Virus', 'start': 1645, 'end': 1655}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 1624, 'end': 1632}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 1611, 'end': 1619}, {'entity': 'coronavirus pseudoviruses', 'type': 'Virus', 'start': 1567, 'end': 1592}, {'entity': 'EK1', 'type': 'Disease', 'start': 1482, 'end': 1485}, {'entity': 'EK1 peptide', 'type': 'Chemical', 'start': 1455, 'end': 1466}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1296, 'end': 1306}, {'entity': 'fusion inhibitor', 'type': 'Drug', 'start': 1271, 'end': 1287}, {'entity': 'EK1', 'type': 'Disease', 'start': 1245, 'end': 1248}, {'entity': 'EK1', 'type': 'Disease', 'start': 1226, 'end': 1229}, {'entity': 'lipopeptides', 'type': 'Gene', 'start': 1200, 'end': 1212}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 1160, 'end': 1168}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 1147, 'end': 1155}, {'entity': 'coronaviruses', 'type': 'Virus', 'start': 1115, 'end': 1128}, {'entity': 'HR1', 'type': 'Gene', 'start': 1057, 'end': 1060}, {'entity': 'EK1', 'type': 'Disease', 'start': 1033, 'end': 1036}, {'entity': 'fusion inhibitor', 'type': 'Drug', 'start': 1015, 'end': 1031}, {'entity': 'pan-coronavirus', 'type': 'Virus', 'start': 999, 'end': 1014}, {'entity': 'HR2 domain', 'type': 'Disease', 'start': 961, 'end': 971}]\n",
            "['Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19\\tIn 2015, the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) reached the Republic of Korea through nosocomial transmission and was the largest epidemic outside of the Arabian Peninsula.', 'To date, despite various strategies to identify CoV interventions, only limited therapeutic options are available.', 'To address these unmet medical needs, we used a South Korean MERS-CoV clinical isolate and screened 5,406 compounds, including United States Food and Drug Administration (FDA)-approved drugs and bioactive molecules, for their activity against the isolate.', 'The primary assay confirmed 221 hits by dose-response curve analysis and identified 54 hits with a therapeutic index (TI) greater than 6.', 'Time-of-addition studies with 12 FDA-approved drugs demonstrated that 8 and 4 therapeutics act on the early and late stages of the viral life cycle, respectively.', 'Among the drugs were e.g., three cardiotonic agents (ouabain, digitoxin, digoxin) with a TI greater than 100, an anti-malaria drug (atovaquone; TI >34), an inhalable corticosteroid (ciclesonide; TI >6), etc.', 'Together, our results identify potential therapeutic options for treating MERS-CoV infections and could provide a basis for agents against a wider range of coronavirus-related illnesses, including the currently emerging Coronavirus Disease 2019 (COVID-19) outbreak.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 1457, 'end': 1465}, {'entity': 'CoV', 'type': 'Virus', 'start': 1290, 'end': 1293}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 1285, 'end': 1293}, {'entity': 'ciclesonide', 'type': 'Drug', 'start': 1185, 'end': 1196}, {'entity': 'inhalable corticosteroid', 'type': 'Drug', 'start': 1159, 'end': 1183}, {'entity': 'atovaquone', 'type': 'Drug', 'start': 1135, 'end': 1145}, {'entity': 'anti-malaria drug', 'type': 'Drug', 'start': 1116, 'end': 1133}, {'entity': 'digoxin', 'type': 'Drug', 'start': 1076, 'end': 1083}, {'entity': 'digitoxin', 'type': 'Drug', 'start': 1065, 'end': 1074}, {'entity': 'ouabain', 'type': 'Drug', 'start': 1056, 'end': 1063}, {'entity': 'cardiotonic agents', 'type': 'Drug', 'start': 1036, 'end': 1054}, {'entity': 'compounds', 'type': 'Drug', 'start': 552, 'end': 561}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 507, 'end': 515}, {'entity': 'CoV', 'type': 'Virus', 'start': 379, 'end': 382}]\n",
            "['Reperfusion therapy for STEMI: is there still a role for thrombolysis in the era of primary percutaneous coronary intervention?', 'In the past ten years, primary percutaneous coronary intervention (PCI) has replaced thrombolysis as the revascularisation strategy for many patients presenting with ST-segment elevation myocardial infarction (STEMI).', 'However, delivery of primary PCI within evidence-based timeframes is challenging, and health-care provision varies substantially worldwide.', 'Consequently, even with the ideal circumstances of rapid initial diagnosis, long transfer delays to the catheter laboratory can occur.', \"These delays are detrimental to outcomes for patients and can be exaggerated by variations in timing of patients' presentation and diagnosis.\"]\n",
            "unmatched tags:  [{'entity': 'era', 'type': 'Gene', 'start': 691, 'end': 694}, {'entity': 'STEMI', 'type': 'Disease', 'start': 338, 'end': 343}, {'entity': 'ST-segment elevation myocardial infarction', 'type': 'Disease', 'start': 294, 'end': 336}]\n",
            "['Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study\\tGlobally spreading lineages expressing invasive serotypes have an important role in serotype replacement, and emerging non-vaccine serotypes associated with different pneumococcal lineages in different countries might be explained by local antibiotic-selective pressures.', 'Continued genomic surveillance of the dynamics of the pneumococcal population with increased geographical representation in the post-vaccine period will generate further knowledge for optimising future vaccine design.']\n",
            "unmatched tags:  [{'entity': 'vaccine', 'type': 'Drug', 'start': 672, 'end': 679}]\n",
            "['Kinetic Analysis of Bacteriophage Sf6 Binding to Outer Membrane Protein A Using Whole Virions\\tFor successful infection, viruses must recognize their respective host cells.', 'A common mechanism of host recognition by viruses is to utilize a portion of the host cell as a receptor.', 'Bacteriophage Sf6, which infects Shigella flexneri , uses lipopolysaccharide as a primary receptor and then requires interaction with a secondary receptor, a role that can be fulfilled by either outer membrane proteins (Omp) A or C. Our previous work showed that specific residues in the loops of OmpA mediate Sf6 infection.', 'To better understand Sf6 interactions with OmpA loop variants, we determined the kinetics of these interactions through the use of biolayer interferometry, an optical biosensing technique that yields data similar to surface plasmon resonance.', 'Here, we successfully tethered whole Sf6 virions, determined the binding constant of Sf6 to OmpA to be 36 nM.', 'Additionally, we showed that Sf6 bound to five variant OmpAs and the resulting kinetic parameters varied only slightly.', 'Based on these data, we propose a model in which Sf6: Omp receptor recognition is not solely based on kinetics, but likely also on the ability of an Omp to induce a conformational change that results in productive infection.']\n",
            "unmatched tags:  [{'entity': 'productive infection', 'type': 'Disease', 'start': 1279, 'end': 1299}, {'entity': 'Omp', 'type': 'Gene', 'start': 1225, 'end': 1228}, {'entity': 'receptor', 'type': 'Gene', 'start': 1134, 'end': 1142}, {'entity': 'Omp', 'type': 'Gene', 'start': 1130, 'end': 1133}, {'entity': 'Sf6', 'type': 'Organization', 'start': 1125, 'end': 1128}, {'entity': 'OmpAs', 'type': 'Gene', 'start': 1011, 'end': 1016}, {'entity': 'Sf6', 'type': 'Organization', 'start': 985, 'end': 988}, {'entity': 'OmpA', 'type': 'Drug', 'start': 938, 'end': 942}, {'entity': 'Sf6', 'type': 'Organization', 'start': 931, 'end': 934}, {'entity': 'Sf6', 'type': 'Organization', 'start': 883, 'end': 886}, {'entity': 'OmpA', 'type': 'Drug', 'start': 646, 'end': 650}, {'entity': 'Sf6', 'type': 'Organization', 'start': 624, 'end': 627}, {'entity': 'Sf6', 'type': 'Organization', 'start': 588, 'end': 591}, {'entity': 'OmpA', 'type': 'Drug', 'start': 575, 'end': 579}, {'entity': 'Omp', 'type': 'Gene', 'start': 498, 'end': 501}, {'entity': 'outer membrane proteins', 'type': 'Gene', 'start': 473, 'end': 496}, {'entity': 'receptor', 'type': 'Gene', 'start': 424, 'end': 432}, {'entity': 'primary receptor', 'type': 'Gene', 'start': 360, 'end': 376}, {'entity': 'lipopolysaccharide', 'type': 'Drug', 'start': 336, 'end': 354}, {'entity': 'Sf6', 'type': 'Organization', 'start': 292, 'end': 295}, {'entity': 'Bacteriophage Sf6', 'type': 'Virus', 'start': 278, 'end': 295}, {'entity': 'receptor', 'type': 'Gene', 'start': 268, 'end': 276}]\n",
            "['The genetic landscape of the epileptic encephalopathies of infancy and childhood\\tEpileptic encephalopathies of infancy and childhood comprise a large, heterogeneous group of severe epilepsies characterised by several seizure types, frequent epileptiform activity on EEG, and developmental slowing or regression.', 'The encephalopathies include many age-related electroclinical syndromes with specific seizure types and EEG features.', 'With the molecular revolution, the number of known monogenic determinants underlying the epileptic encephalopathies has grown rapidly.', 'De-novo dominant mutations are frequently identified; somatic mosaicism and recessive disorders are also seen.']\n",
            "unmatched tags:  [{'entity': 'recessive disorders', 'type': 'Disease', 'start': 641, 'end': 660}, {'entity': 'De-novo', 'type': 'Organization', 'start': 565, 'end': 572}, {'entity': 'epileptic encephalopathies', 'type': 'Disease', 'start': 519, 'end': 545}, {'entity': 'monogenic', 'type': 'Disease', 'start': 481, 'end': 490}, {'entity': 'encephalopathies', 'type': 'Disease', 'start': 316, 'end': 332}]\n",
            "['Genetic therapies for inherited neuromuscular disorders\\tInherited neuromuscular disorders encompass a broad group of genetic conditions, and the discovery of these underlying genes has expanded greatly in the past three decades.', 'The discovery of such genes has enabled more precise diagnosis of these disorders and the development of specific therapeutic approaches that target the genetic basis and pathophysiological pathways.', 'Such translational research has led to the approval of two genetic therapies by the US Food and Drug Administration: eteplirsen for Duchenne muscular dystrophy and nusinersen for spinal muscular atrophy, which are both antisense oligonucleotides that modify pre-mRNA splicing.']\n",
            "unmatched tags:  [{'entity': 'antisense oligonucleotides', 'type': 'Gene', 'start': 648, 'end': 674}, {'entity': 'spinal muscular atrophy', 'type': 'Phenotype', 'start': 608, 'end': 631}, {'entity': 'nusinersen', 'type': 'Drug', 'start': 593, 'end': 603}, {'entity': 'Duchenne muscular dystrophy', 'type': 'Disease', 'start': 561, 'end': 588}, {'entity': 'disorders', 'type': 'Disease', 'start': 301, 'end': 310}]\n",
            "['Peripheral neuropathy\\tPeripheral neuropathy is a common neurological problem.', 'Because the presentation of neuropathy is variable and the causes are disparate, a logical and sequential clinical approach is necessary for evaluation and management.', \"Through a combination of clinical findings, electrodiagnostic tests, and laboratory investigations tailored to individual patients' circumstances, most neuropathies can be categorised by subtype and aetiology.\", 'Such classification allows rational assessment of prognosis and treatment options.']\n",
            "unmatched tags:  [{'entity': 'neuropathies', 'type': 'Disease', 'start': 398, 'end': 410}, {'entity': 'clinical findings', 'type': 'Phenotype', 'start': 271, 'end': 288}]\n",
            "['Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin\\tSince the SARS outbreak 18 years ago, a large number of severe acute respiratory syndrome related coronaviruses (SARSr-CoV) have been discovered in their natural reservoir host, bats.', 'Previous studies indicated that some of those bat SARSr-CoVs have the potential to infect humans.', 'Here we report the identification and characterization of a novel coronavirus (nCoV-2019) which caused an epidemic of acute respiratory syndrome in humans, in Wuhan, China.', 'The epidemic, started from December 12th, 2019, has caused 198 laboratory confirmed infections with three fatal cases by January 20th, 2020.', 'Full-length genome sequences were obtained from five patients at the early stage of the outbreak.', 'They are almost identical to each other and share 79.5% sequence identify to SARS-CoV.', 'Furthermore, it was found that nCoV-2019 is 96% identical at the whole genome level to a bat coronavirus.', 'The pairwise protein sequence analysis of seven conserved non-structural proteins show that this virus belongs to the species of SARSr-CoV.', 'The nCoV-2019 virus was then isolated from the bronchoalveolar lavage fluid of a critically ill patient, which can be neutralized by sera from several patients.', 'Importantly, we have confirmed that this novel CoV uses the same cell entry receptor, ACE2, as SARS-CoV.']\n",
            "unmatched tags:  [{'entity': 'CoV', 'type': 'Virus', 'start': 1409, 'end': 1412}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1395, 'end': 1399}, {'entity': 'cell entry receptor', 'type': 'Gene', 'start': 1374, 'end': 1393}, {'entity': 'CoV', 'type': 'Virus', 'start': 1356, 'end': 1359}, {'entity': 'critically ill', 'type': 'Phenotype', 'start': 1228, 'end': 1242}, {'entity': 'nCoV-2019', 'type': 'Organization', 'start': 1151, 'end': 1160}, {'entity': 'CoV', 'type': 'Virus', 'start': 1141, 'end': 1144}, {'entity': 'SARS', 'type': 'Disease', 'start': 1135, 'end': 1139}, {'entity': 'SARSr-CoV', 'type': 'Virus', 'start': 1135, 'end': 1144}, {'entity': 'non-structural proteins', 'type': 'Gene', 'start': 1064, 'end': 1087}, {'entity': 'bat coronavirus', 'type': 'Virus', 'start': 989, 'end': 1004}, {'entity': 'nCoV-2019', 'type': 'Organization', 'start': 931, 'end': 940}, {'entity': 'CoV', 'type': 'Virus', 'start': 894, 'end': 897}, {'entity': 'SARS-CoV.  ', 'type': 'Virus', 'start': 889, 'end': 900}]\n",
            "['Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence\\tThe lifestyle factors of physical activity, sedentary behaviour, and diet are increasingly being studied for their associations with cancer.', 'Physical activity is inversely associated with and sedentary behaviour is positively (and independently) associated with an increased risk of more than ten types of cancer, including colorectal cancer (and advanced adenomas), endometrial cancers, and breast cancer.', 'The most consistent dietary risk factor for premalignant and invasive breast cancer is alcohol, whether consumed during early or late adult life, even at low levels.']\n",
            "unmatched tags:  [{'entity': 'alcohol', 'type': 'Drug', 'start': 588, 'end': 595}, {'entity': 'cancer', 'type': 'Disease', 'start': 578, 'end': 584}]\n",
            "['Will COVID-19 pandemic diminish by summer-monsoon in India?', 'Lesson from the first lockdown\\tThe novel Coronavirus (2019-nCoV) was identified in Wuhan, Hubei Province, China, in December 2019 and has created a medical emergency worldwide.', 'It has spread rapidly to multiple countries and has been declared a pandemic by the World Health Organization.', 'In India, it is already reported more than 18 thousand cases and more than 600 deaths due to Coronavirus disease 2019 (COVID-19) till April 20, 2020.', 'Previous studies on various viral infections like influenza have supported an epidemiological hypothesis that the cold and dry (low absolute humidity) environments favor the survival and spread of droplet-mediated viral diseases.', 'These viral transmissions found attenuated in warm and humid (high absolute humidity) environments.', 'However, the role of temperature, humidity, and absolute humidity in the transmission of COVID-19 has not yet been well established.', 'Therefore the study to investigate the meteorological condition for incidence and spread of COVID-19 infection, to predict the epidemiology of the infectious disease, and to provide a scientific basis for prevention and control measures against the new disease is required for India.', 'In this work, we analyze the local weather patterns of the Indian region affected by the COVID-19 virus for March and April months, 2020.', 'We have investigated the effect of meteorological parameters like Temperature, relative humidity, and absolute humidity on the rate of spread of COVID-19 using daily confirm cases in India.', 'We have used daily averaged meteorological data for the last three years (2017-2019) for March and April month and the same for the year 2020 for March 1 to April 15.', 'We found a positive association (Pearsons r=0.56) between temperature and daily COVID-19 cases over India.', 'We found a negative association of humidity (RH and AH) with daily COVID-19 Cases (Persons r=-0.62, -0.37).', 'We have also investigated the role of aerosol in spreading the pandemic across India because its possible airborne nature.', 'For this, we have investigated the association of aerosols (AOD) and other pollutions (NO2) with COVID-19 cases during the study period and also during the first lockdown period (25 March-15 April) in India.', 'We found a negative association in March when there were few cases, but in April, it shows positive association when the number of cases is more (for AOD it was r=-0.41 and r=0.28 respectively).', 'During the lockdown period, aerosols (AOD) and other pollutants (NO2; an indicator of PM2.5) reduced sharply with a percentage drop of about 36 and 37, respectively.', 'This reduction may have reduced the risk for COVID-19 through air transmission due to the unavailability of aerosol particles as a base.', 'HYSPLIT forward trajectory model also shows that surface aerosols may travel up to 4 km according to wind and direction within three h of its generation.', 'If coronavirus becomes airborne as suggested by many studies, then it may have a higher risk of transmission by aerosols particles.', 'So relaxing in the lockdown and environmental rules in terms of pollutant emissions from power plants, factories, and other facilities would be a wrong choice and could result in more COVID-19 incidences and deaths in India.', 'Therefore the current study, although limited, suggests that it is doubtful that the spread of COVID-19 would slow down in India due to meteorological factors, like high temperature and high humidity.', 'Because a large number of cases have already been reported in the range of high Tem, high Relative, and high absolute humidity regions of India.', 'Thus our results in no way suggest that COVID-19 would not spread in warm, humid regions or during summer/monsoon.', 'So effective public health interventions should be implemented across India to slow down the transmission of COVID-19.', 'If COVID-19 is indeed sensitive to environmental factors, it could be tested in the coming summer-monsoon for India.', 'So the only summer is not going to help India until monsoon is coming.', 'Only government mitigations strategies would be helpful, whether its lockdown, aggressive and strategic testing, medical facilities, imposing social distancing, encouraging to use face mask or monitoring by a mobile application (Aarogya Setu).']\n",
            "unmatched tags:  [{'entity': 'government', 'type': 'Organization', 'start': 4068, 'end': 4078}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 3878, 'end': 3886}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 3865, 'end': 3873}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 3681, 'end': 3689}, {'entity': 'Tem', 'type': 'Disease', 'start': 3576, 'end': 3579}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 3390, 'end': 3398}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 3254, 'end': 3262}, {'entity': 'pollutant', 'type': 'Chemical', 'start': 3134, 'end': 3143}, {'entity': 'airborne', 'type': 'Drug', 'start': 2961, 'end': 2969}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 2941, 'end': 2952}, {'entity': 'wind', 'type': 'Phenotype', 'start': 2885, 'end': 2889}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2692, 'end': 2700}, {'entity': 'NO2', 'type': 'Gene', 'start': 2546, 'end': 2549}, {'entity': 'pollutants', 'type': 'Chemical', 'start': 2534, 'end': 2544}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2175, 'end': 2183}, {'entity': 'NO2', 'type': 'Gene', 'start': 2165, 'end': 2168}, {'entity': 'airborne', 'type': 'Drug', 'start': 2061, 'end': 2069}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1914, 'end': 1922}]\n",
            "['Rupture of silicone-gel breast implants: causes, sequelae, and diagnosis\\tSilicone-gel-filled breast implants have been widely used for breast augmentation and reconstruction after mastectomy.', 'The rate of implant rupture and its sequelae are not known.', 'We review the frequency, causes, sequelae, and detection of implant rupture.', 'Materials testing of removed implants provides evidence that as implants age in vivo, they weaken and may rupture.', 'Sequelae of rupture include migration of gel accompanied by inflammation and silicone granuloma formation.', 'The role of free silicone gel in relation to idiopathic or atypical connective tissue disease is not clear.']\n",
            "unmatched tags:  [{'entity': 'connective tissue disease', 'type': 'Disease', 'start': 619, 'end': 644}, {'entity': 'free silicone gel', 'type': 'Drug', 'start': 563, 'end': 580}, {'entity': 'silicone granuloma', 'type': 'Disease', 'start': 521, 'end': 539}]\n",
            "['Prevalence of malnutrition and analysis of related factors in elderly patients with COVID-19 in Wuhan, China\\tTo evaluate the prevalence of malnutrition and its related factors in elderly patients with COVID-19 in Wuhan, China.In a cross-sectional study, we evaluated the nutritional status of elderly inpatients with COVID-19 using the Mini Nutritional Assessment (MNA).', 'Based on MNA scores, patients were divided into non-malnutrition group (MNAâ\\x80\\x89â\\x89¥â\\x80\\x8924), the group with risk of malnutrition (MNA 17â\\x80\\x9323.5) and malnutrition group (MNA score < 17).', 'Regression analysis was conducted to screen for risk factors for malnutrition.A total of 182 patients were included in the study, of which 27.5% were in the group with malnutrition risk and 52.7% were in the malnutrition group.', 'There were statistical differences in the incidence of comorbid diabetes mellitus, body mass index (BMI), calf circumference,albumin, hemoglobin, and lymphocyte counts among the three groups.', 'Further regression analysis suggested that combined diabetes, low calf circumference, and low albumin were independent risk factors for malnutrition.The prevalence of malnutrition in elderly patients with COVID-19 was high, and nutritional support should be strengthened during treatment, especially for those with diabetes mellitus, low calf circumference, or low albumin.']\n",
            "unmatched tags:  [{'entity': 'albumin', 'type': 'Gene', 'start': 1338, 'end': 1345}, {'entity': 'diabetes mellitus', 'type': 'Disease', 'start': 1288, 'end': 1305}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1178, 'end': 1186}, {'entity': 'malnutrition', 'type': 'Disease', 'start': 1140, 'end': 1152}, {'entity': 'malnutrition', 'type': 'Disease', 'start': 1109, 'end': 1121}, {'entity': 'albumin', 'type': 'Gene', 'start': 1067, 'end': 1074}, {'entity': 'diabetes', 'type': 'Disease', 'start': 1025, 'end': 1033}]\n",
            "['Crystal structure of the giant panda MHC class I complex: first insights into the viral peptide presentation profile in the bear family\\tThe viral cytotoxic T lymphocyte (CTL) epitope peptides presented by classical MHC-I molecules require the assembly of a peptide-MHC-I- β 2m (aka pMHC-I) trimolecular complex for TCR recognition, which is the critical activation link for triggering antiviral T cell immunity.', 'Ursidae includes 5 genera and 8 species; however, research on T cell immunology in this family, especially structural immunology, is lacking.', 'In this study, the structure of the key trimolecular complex pMHC-1 (aka pAime-128), which binds a peptide from canine distemper virus, was solved for the first time using giant panda as a representative species of Ursidae.', 'The structural characteristics of the giant panda pMHC-I complex, including the unique pockets in the peptide-binding groove (PBG), were analyzed in detail.', 'Comparing the panda pMHC-I to others in the bear family and extending the comparison to other mammals revealed distinct features.', 'The interaction between MHC-I and β 2m, the features of pAime-128 involved in TCR docking and CD8 binding, the anchor sites in the PBG, and the CTL epitopes of potential viruses that infect pandas were concretely clarified.', 'Unique features of pMHC-I viral antigen presentation in the panda were revealed by solving the three-dimensional structure of pAime-128.', 'The distinct characteristics of pAime-128 indicate an unusual event that emerged during the evolution of the MHC system in the bear family.', 'These results provide a new platform for research on panda CTL immunity and the design of vaccines for application in the bear family.', 'IMPORTANCE Ursidae includes 5 genera and 8 species; however, the study of its immunology, especially structural immunology, is extremely rare to date.', 'In this paper, we first crystallized the key complex pMHC-I, taking the giant panda as its representative species.', 'Structural characteristics of the giant panda pMHC-I complexes, contains the unique pockets of PBG were analyzed in detail.', 'Comparison of the panda pMHC-I in the bear family and other mammals, almost definite features was displayed.', 'Meanwhile, the interaction between HC and LV, the unique features of pMHC-I in the CD8 binding and TCR docking, validation of anchor site in the PBG, and epitopes of potential viruses infected with the pandas, were concretely clarified.', 'These unique characteristics of pMHC-I clearly indicate an unusual situation during the evolution of MHC molecules in the endangered pandas.', 'These results also provide a novel platform for further study of panda T cell immunology and vaccines.']\n",
            "unmatched tags:  [{'entity': 'vaccines', 'type': 'Drug', 'start': 2671, 'end': 2679}, {'entity': 'panda', 'type': 'Gene', 'start': 2643, 'end': 2648}, {'entity': 'pandas', 'type': 'Disease', 'start': 2570, 'end': 2576}, {'entity': 'MHC molecules', 'type': 'Gene', 'start': 2538, 'end': 2551}, {'entity': 'MHC-I', 'type': 'Gene', 'start': 2470, 'end': 2475}, {'entity': 'pMHC-I', 'type': 'Gene', 'start': 2469, 'end': 2475}, {'entity': 'pandas', 'type': 'Disease', 'start': 2402, 'end': 2408}, {'entity': 'PBG', 'type': 'Drug', 'start': 2345, 'end': 2348}, {'entity': 'pMHC-I', 'type': 'Gene', 'start': 2269, 'end': 2275}, {'entity': 'HC', 'type': 'Gene', 'start': 2235, 'end': 2237}, {'entity': 'MHC-I', 'type': 'Gene', 'start': 2116, 'end': 2121}, {'entity': 'pMHC-I', 'type': 'Gene', 'start': 2115, 'end': 2121}, {'entity': 'panda', 'type': 'Gene', 'start': 2109, 'end': 2114}, {'entity': 'PBG', 'type': 'Drug', 'start': 2062, 'end': 2065}, {'entity': 'pMHC-I', 'type': 'Gene', 'start': 2013, 'end': 2019}, {'entity': 'panda', 'type': 'Gene', 'start': 2007, 'end': 2012}, {'entity': 'giant', 'type': 'Disease', 'start': 2001, 'end': 2006}, {'entity': 'panda', 'type': 'Gene', 'start': 1930, 'end': 1935}, {'entity': 'giant', 'type': 'Disease', 'start': 1924, 'end': 1929}, {'entity': 'MHC-I', 'type': 'Gene', 'start': 1906, 'end': 1911}, {'entity': 'pMHC-I', 'type': 'Gene', 'start': 1905, 'end': 1911}, {'entity': 'vaccines', 'type': 'Drug', 'start': 1656, 'end': 1664}, {'entity': 'panda', 'type': 'Gene', 'start': 1619, 'end': 1624}, {'entity': 'HC', 'type': 'Gene', 'start': 1536, 'end': 1538}, {'entity': 'pAime-128', 'type': 'Chemical', 'start': 1458, 'end': 1467}, {'entity': 'pAime-128', 'type': 'Chemical', 'start': 1415, 'end': 1424}, {'entity': 'panda', 'type': 'Gene', 'start': 1349, 'end': 1354}, {'entity': 'pMHC-I', 'type': 'Gene', 'start': 1308, 'end': 1314}, {'entity': 'pandas', 'type': 'Disease', 'start': 1255, 'end': 1261}, {'entity': 'PBG', 'type': 'Drug', 'start': 1196, 'end': 1199}, {'entity': 'pAime-128', 'type': 'Chemical', 'start': 1121, 'end': 1130}, {'entity': 'MHC-I', 'type': 'Gene', 'start': 1089, 'end': 1094}, {'entity': 'pMHC-I', 'type': 'Gene', 'start': 955, 'end': 961}, {'entity': 'panda', 'type': 'Gene', 'start': 949, 'end': 954}, {'entity': 'PBG', 'type': 'Drug', 'start': 904, 'end': 907}, {'entity': 'MHC-I', 'type': 'Gene', 'start': 829, 'end': 834}, {'entity': 'pMHC-I', 'type': 'Gene', 'start': 828, 'end': 834}, {'entity': 'panda', 'type': 'Gene', 'start': 822, 'end': 827}, {'entity': 'giant', 'type': 'Disease', 'start': 816, 'end': 821}, {'entity': 'panda', 'type': 'Gene', 'start': 732, 'end': 737}, {'entity': 'giant', 'type': 'Disease', 'start': 726, 'end': 731}, {'entity': 'distemper virus', 'type': 'Virus', 'start': 673, 'end': 688}, {'entity': 'peptide', 'type': 'Gene', 'start': 653, 'end': 660}, {'entity': 'pAime-128', 'type': 'Chemical', 'start': 627, 'end': 636}, {'entity': 'pMHC-I', 'type': 'Gene', 'start': 282, 'end': 288}, {'entity': 'MHC-I', 'type': 'Gene', 'start': 215, 'end': 220}, {'entity': 'peptides', 'type': 'Gene', 'start': 183, 'end': 191}]\n",
            "['“Identification and enrichment of SECReTE\\tcis -acting RNA motifs play a major role in regulating many aspects of RNA biology including posttranscriptional processing, nuclear export, RNA localization, translation and degradation.', 'Here we analyzed the genomes of SARS-CoV-2 and other single-strand RNA (ssRNA) viruses for the presence of a unique cis RNA element called SECReTE.', 'This motif consists of 10 or more consecutive triplet nucleotide repeats where a pyrimidine nucleotide (C or U) in present every third base, and which we identified in mRNAs encoding secreted proteins in bacteria, yeast, and humans.', 'This motif facilitates mRNA localization to the endoplasmic reticulum (ER), along with the enhanced translation and secretion of translated protein.', 'We now examined for SECReTE presence in Group IV and V RNA viruses, the former including the Coronaviridae , like SARS-CoV-2 and other positive (+)ssRNA viruses, and the latter consisting of negative (-) ssRNA viruses.', 'Interestingly, the SARS-CoV-2 genome contains 40 SECReTE motifs at an abundance of ~1.3 SECReTEs/kilobase (kb).', 'Moreover, all ssRNA viruses we examined contain multiple copies of this motif and appears in (+)ssRNA viruses as non-random in occurrence and independent of genome length.', 'Importantly, (+)ssRNA viruses ( e.g.', 'Coronaviruses and Hepaciviruses), which utilize ER membranes to create double membrane vesicles to serve as viral replication centers (VRCs), contain more SECReTE motifs per kb as compared to (−)ssRNA viruses ( e.g .', 'Rabies, Mumps, and Influenza), that replicate in the nucleus or the cytoplasm, or other (+)ssRNA viruses ( e.g .', 'Enteroviruses and Flaviviruses) which employ different organellar membranes.', 'As predicted by our earlier work, SECReTE sequences are mostly found in membranal or ER-associated/secreted proteins.', 'Thus, we propose that SECReTE motifs could be important for the efficient translation and secretion of secreted viral proteins, as well as for VRC formation.', 'Future studies of SECReTE function and identification of SECReTE-binding proteins could provide new drug targets to treat COVID-19 and other (+)ssRNA related diseases.']\n",
            "unmatched tags:  [{'entity': 'diseases', 'type': 'Disease', 'start': 2141, 'end': 2149}, {'entity': 'RNA', 'type': 'Gene', 'start': 2129, 'end': 2132}, {'entity': 'ssRNA', 'type': 'Gene', 'start': 2127, 'end': 2132}, {'entity': '(+)ssRNA', 'type': 'Gene', 'start': 2124, 'end': 2132}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2105, 'end': 2113}, {'entity': 'protein', 'type': 'Gene', 'start': 2056, 'end': 2063}, {'entity': 'SECReTE-binding proteins', 'type': 'Gene', 'start': 2040, 'end': 2064}, {'entity': 'VRC', 'type': 'Organization', 'start': 1968, 'end': 1971}, {'entity': 'viral proteins', 'type': 'Gene', 'start': 1937, 'end': 1951}, {'entity': 'protein', 'type': 'Gene', 'start': 1815, 'end': 1822}, {'entity': 'Flaviviruses', 'type': 'Virus', 'start': 1648, 'end': 1660}, {'entity': 'Enteroviruses', 'type': 'Virus', 'start': 1630, 'end': 1643}, {'entity': '(+)ssRNA viruses', 'type': 'Virus', 'start': 1605, 'end': 1621}, {'entity': 'Influenza', 'type': 'Disease', 'start': 1536, 'end': 1545}, {'entity': 'Mumps', 'type': 'Disease', 'start': 1525, 'end': 1530}, {'entity': 'Rabies', 'type': 'Disease', 'start': 1517, 'end': 1523}, {'entity': 'RNA', 'type': 'Gene', 'start': 1497, 'end': 1500}, {'entity': 'ssRNA', 'type': 'Gene', 'start': 1495, 'end': 1500}, {'entity': 'ssRNA viruses', 'type': 'Virus', 'start': 1495, 'end': 1508}, {'entity': '(−)ssRNA viruses', 'type': 'Virus', 'start': 1492, 'end': 1508}, {'entity': 'VRC', 'type': 'Organization', 'start': 1435, 'end': 1438}, {'entity': 'ER', 'type': 'Gene', 'start': 1348, 'end': 1350}, {'entity': 'Hepaciviruses', 'type': 'Virus', 'start': 1318, 'end': 1331}, {'entity': 'Coronaviruses', 'type': 'Virus', 'start': 1300, 'end': 1313}, {'entity': 'ssRNA viruses', 'type': 'Virus', 'start': 1279, 'end': 1292}, {'entity': '(+)ssRNA viruses', 'type': 'Virus', 'start': 1276, 'end': 1292}, {'entity': 'RNA', 'type': 'Gene', 'start': 1189, 'end': 1192}, {'entity': '(+)ssRNA viruses', 'type': 'Virus', 'start': 1184, 'end': 1200}, {'entity': 'ssRNA viruses', 'type': 'Virus', 'start': 1105, 'end': 1118}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 998, 'end': 1008}, {'entity': 'RNA', 'type': 'Gene', 'start': 966, 'end': 969}, {'entity': 'ssRNA', 'type': 'Gene', 'start': 964, 'end': 969}, {'entity': 'ssRNA viruses', 'type': 'Virus', 'start': 964, 'end': 977}, {'entity': '(+)ssRNA viruses', 'type': 'Virus', 'start': 904, 'end': 920}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 874, 'end': 884}, {'entity': 'Coronaviridae', 'type': 'Virus', 'start': 853, 'end': 866}, {'entity': 'RNA', 'type': 'Gene', 'start': 815, 'end': 818}, {'entity': 'V RNA viruses', 'type': 'Virus', 'start': 813, 'end': 826}, {'entity': 'protein', 'type': 'Gene', 'start': 751, 'end': 758}, {'entity': 'ER', 'type': 'Gene', 'start': 682, 'end': 684}, {'entity': 'mRNA', 'type': 'Gene', 'start': 634, 'end': 638}, {'entity': 'protein', 'type': 'Gene', 'start': 570, 'end': 577}, {'entity': 'RNA', 'type': 'Gene', 'start': 547, 'end': 550}, {'entity': 'mRNAs', 'type': 'Gene', 'start': 546, 'end': 551}, {'entity': 'pyrimidine nucleotide', 'type': 'Gene', 'start': 459, 'end': 480}, {'entity': 'triplet nucleotide repeats', 'type': 'Gene', 'start': 424, 'end': 450}]\n",
            "['Incubation periods of acute respiratory viral infections: a systematic review\\tKnowledge of the incubation period is essential in the investigation and control of infectious disease, but statements of incubation period are often poorly referenced, inconsistent, or based on limited data.', 'In a systematic review of the literature on nine respiratory viral infections of public-health importance, we identified 436 articles with statements of incubation period and 38 with data for pooled analysis.', 'We fitted a log-normal distribution to pooled data and found the median incubation period to be 5·6 days (95% CI 4·8–6·3) for adenovirus, 3·2 days (95% CI 2·8–3·7) for human coronavirus, 4·0 days (95% CI 3·6–4·4) for severe acute respiratory syndrome coronavirus, 1·4 days (95% CI 1·3–1·5) for influenza A, 0·6 days (95% CI 0·5–0·6) for influenza B, 12·5 days (95% CI 11·8–13·3) for measles, 2·6 days (95% CI 2·1–3·1) for parainfluenza, 4·4 days (95% CI 3·9–4·9) for respiratory syncytial virus, and 1·9 days (95% CI 1·4–2·4) for rhinovirus.']\n",
            "unmatched tags:  [{'entity': 'rhinovirus', 'type': 'Virus', 'start': 1026, 'end': 1036}, {'entity': 'respiratory syncytial virus', 'type': 'Virus', 'start': 963, 'end': 990}, {'entity': 'parainfluenza', 'type': 'Disease', 'start': 918, 'end': 931}]\n",
            "['Isolation and sequencing of AGO-bound RNAs reveals characteristics of mammalian stem-loop processing\\tMicroRNA precursors (pre-miRNAs) are short hairpin RNAs that are rapidly processed into mature microRNAs (miRNAs) in the cytoplasm.', 'Due to their low abundance in cells, sequencing-based studies of pre-miRNAs have been limited.', 'We successfully enriched for and deep sequenced pre-miRNAs in human cells by capturing these RNAs during their interaction with Argonaute (AGO) proteins.', 'Using this approach, we detected > 350 pre-miRNAs in human cells and > 250 pre-miRNAs in a reanalysis of a similar study in mouse cells.', 'We uncovered widespread trimming and non-templated additions to the 3’ ends of pre- and mature miRNAs.', 'Additionally, we created an index for microRNA precursor processing efficiency.', 'This analysis revealed a subset of pre-miRNAs that produce low levels of mature miRNAs despite abundant precursors, including an annotated miRNA in the 5’ UTR of the DiGeorge syndrome critical region 8 mRNA transcript.', 'This led us to search for AGO-associated stem-loops originating from other mRNA species, which identified hundreds of putative pre-miRNAs derived from human and mouse mRNAs.', 'In summary, we provide a wealth of information on mammalian pre-miRNAs, and identify novel microRNA and microRNA-like elements localized in mRNAs.']\n",
            "unmatched tags:  [{'entity': 'mRNAs', 'type': 'Gene', 'start': 1335, 'end': 1340}, {'entity': 'microRNA', 'type': 'Gene', 'start': 1286, 'end': 1294}, {'entity': 'RNAs', 'type': 'Gene', 'start': 1261, 'end': 1265}, {'entity': 'miRNAs', 'type': 'Gene', 'start': 1259, 'end': 1265}, {'entity': 'pre-miRNAs', 'type': 'Gene', 'start': 1255, 'end': 1265}, {'entity': 'mRNAs', 'type': 'Gene', 'start': 1188, 'end': 1193}, {'entity': 'RNAs', 'type': 'Gene', 'start': 1154, 'end': 1158}, {'entity': 'pre-miRNAs', 'type': 'Gene', 'start': 1148, 'end': 1158}, {'entity': 'mRNA', 'type': 'Gene', 'start': 1096, 'end': 1100}, {'entity': 'transcript', 'type': 'Gene', 'start': 1009, 'end': 1019}, {'entity': 'mRNA', 'type': 'Gene', 'start': 1004, 'end': 1008}, {'entity': 'DiGeorge syndrome', 'type': 'Disease', 'start': 968, 'end': 985}, {'entity': 'UTR', 'type': 'Gene', 'start': 957, 'end': 960}, {'entity': 'miRNA', 'type': 'Gene', 'start': 941, 'end': 946}, {'entity': 'precursors', 'type': 'Gene', 'start': 906, 'end': 916}, {'entity': 'miRNAs', 'type': 'Gene', 'start': 882, 'end': 888}, {'entity': 'miRNA', 'type': 'Gene', 'start': 882, 'end': 887}, {'entity': 'RNAs', 'type': 'Gene', 'start': 843, 'end': 847}, {'entity': 'pre-miRNAs', 'type': 'Gene', 'start': 837, 'end': 847}, {'entity': 'microRNA', 'type': 'Gene', 'start': 760, 'end': 768}, {'entity': 'miRNAs', 'type': 'Gene', 'start': 714, 'end': 720}, {'entity': 'RNAs', 'type': 'Gene', 'start': 563, 'end': 567}, {'entity': 'miRNAs', 'type': 'Gene', 'start': 561, 'end': 567}, {'entity': 'pre-miRNAs', 'type': 'Gene', 'start': 557, 'end': 567}, {'entity': 'pre-miRNAs', 'type': 'Gene', 'start': 521, 'end': 531}, {'entity': 'proteins', 'type': 'Gene', 'start': 472, 'end': 480}, {'entity': 'Argonaute', 'type': 'Gene', 'start': 456, 'end': 465}, {'entity': 'RNAs', 'type': 'Gene', 'start': 421, 'end': 425}, {'entity': 'RNAs', 'type': 'Gene', 'start': 382, 'end': 386}, {'entity': 'miRNAs', 'type': 'Gene', 'start': 380, 'end': 386}, {'entity': 'miRNA', 'type': 'Gene', 'start': 380, 'end': 385}, {'entity': 'pre-miRNAs', 'type': 'Gene', 'start': 376, 'end': 386}, {'entity': 'pre-miRNAs', 'type': 'Gene', 'start': 298, 'end': 308}, {'entity': 'RNAs', 'type': 'Gene', 'start': 209, 'end': 213}, {'entity': 'miRNAs', 'type': 'Gene', 'start': 207, 'end': 213}]\n",
            "['Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58\\u2008209 women with breast cancer and 101\\u2008986 women without the disease\\tEight out of nine women who develop breast cancer do not have an affected mother, sister, or daughter.', 'Although women who have first-degree relatives with a history of breast cancer are at increased risk of the disease, most will never develop breast cancer, and most who do will be aged over 50 when their cancer is diagnosed.', 'In countries where breast cancer is common, the lifetime excess incidence of breast cancer is 5·5% for women with one affected first-degree relative and 13·3% for women with two.']\n",
            "unmatched tags:  [{'entity': 'cancer', 'type': 'Disease', 'start': 592, 'end': 598}, {'entity': 'breast cancer', 'type': 'Disease', 'start': 585, 'end': 598}]\n",
            "['Molecular Docking Reveals the Potential of Aliskiren, Dipyridamole, Mopidamol, Rosuvastatin, Rolitetracycline and Metamizole to Inhibit COVID-19 Virus Main Protease\\tDrug repurposing is a fast way to rapidly discover a drug for clinical use.', 'In such circumstances of the spreading of the highly contagious COVID-19, searching for already known drugs is a worldwide demand.', 'In this study, many drugs were evaluated by molecular docking.', 'Among the test compounds, aliskiren (the best), dipyridamole, mopidamol and rosuvastatin showed higher energies of binding than that of the co-crystallized ligand N3 with COVID-19 main protease M']\n",
            "unmatched tags:  [{'entity': 'rosuvastatin', 'type': 'Drug', 'start': 512, 'end': 524}, {'entity': 'mopidamol', 'type': 'Drug', 'start': 498, 'end': 507}, {'entity': 'dipyridamole', 'type': 'Drug', 'start': 484, 'end': 496}, {'entity': 'aliskiren', 'type': 'Drug', 'start': 462, 'end': 471}, {'entity': 'test compounds', 'type': 'Drug', 'start': 446, 'end': 460}, {'entity': 'drug', 'type': 'Drug', 'start': 393, 'end': 397}]\n",
            "['Psychiatric disorders and violent reoffending: a national cohort study of convicted prisoners in Sweden\\tCertain psychiatric disorders are associated with a substantially increased hazard of violent reoffending.', 'Because these disorders are prevalent and mostly treatable, improvements to prison mental health services could counteract the cycle of reoffending and improve both public health and safety.', 'National violence prevention strategies should consider the role of prison health.']\n",
            "unmatched tags:  [{'entity': 'National', 'type': 'Organization', 'start': 402, 'end': 410}]\n",
            "['Trends in diagnosis and treatment for people with dementia in the UK from 2005 to 2015: a longitudinal retrospective cohort study\\tOver the 10 years studied, there is evidence of a sustained positive change in diagnosis rates of dementia and in the quality of drug treatment provided to those diagnosed.', 'The prescription of antidementia drugs more than doubled and the prescription of potentially hazardous antipsychotics halved after the introduction of national dementia strategies.', 'These data support the formulation and delivery of national policy to improve the quality of care for people with dementia.']\n",
            "unmatched tags:  [{'entity': 'dementia', 'type': 'Disease', 'start': 598, 'end': 606}, {'entity': 'national dementia', 'type': 'Disease', 'start': 454, 'end': 471}, {'entity': 'antipsychotics', 'type': 'Drug', 'start': 406, 'end': 420}]\n",
            "['Primary ciliary dyskinesia in the genomics age\\tPrimary ciliary dyskinesia is a genetically and clinically heterogeneous syndrome.', 'Impaired function of motile cilia causes failure of mucociliary clearance.', 'Patients typically present with neonatal respiratory distress of unknown cause and then continue to have a daily wet cough, recurrent chest infections, perennial rhinosinusitis, otitis media with effusion, and bronchiectasis.', 'Approximately 50% of patients have situs inversus, and infertility is common.', 'While understanding of the underlying genetics and disease mechanisms have substantially advanced in recent years, there remains a paucity of evidence for treatment.']\n",
            "unmatched tags:  [{'entity': 'bronchiectasis', 'type': 'Disease', 'start': 415, 'end': 429}, {'entity': 'otitis media', 'type': 'Disease', 'start': 383, 'end': 395}, {'entity': 'perennial rhinosinusitis', 'type': 'Disease', 'start': 357, 'end': 381}, {'entity': 'chest infections', 'type': 'Disease', 'start': 339, 'end': 355}, {'entity': 'wet cough', 'type': 'Phenotype', 'start': 318, 'end': 327}, {'entity': 'respiratory distress', 'type': 'Phenotype', 'start': 246, 'end': 266}, {'entity': 'genetically', 'type': 'Gene', 'start': 79, 'end': 90}]\n",
            "['Future directions of acute ischaemic stroke therapy\\tFor several years, the only therapy with proven efficacy for acute ischaemic stroke was alteplase, which is approved for use within 4·5 h after stroke onset in many countries, but only within 3 h in the USA.', 'However, the recanalisation rate with alteplase is modest.', 'Several trials have shown substantial clinical benefit of neurothrombectomy within 6 h of ischaemic stroke onset, which has initiated a new era of acute stroke therapy.', 'As neurothrombectomy becomes part of standard practice, additional trials will be needed to determine the best way to organise delivery of this care.']\n",
            "unmatched tags:  [{'entity': 'stroke', 'type': 'Disease', 'start': 472, 'end': 478}, {'entity': 'ischaemic stroke', 'type': 'Disease', 'start': 409, 'end': 425}, {'entity': 'alteplase', 'type': 'Gene', 'start': 298, 'end': 307}, {'entity': 'stroke', 'type': 'Disease', 'start': 196, 'end': 202}]\n",
            "['Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis\\tTreatment of the neuronal ceroid lipofuscinoses, also known as Batten disease, is at the start of a new era because of diagnostic and therapeutic advances relevant to this group of inherited neurodegenerative and life-limiting disorders that affect children.', 'Diagnosis has improved with the use of comprehensive DNA-based tests that simultaneously screen for many genes.', 'The identification of disease-causing mutations in 13 genes provides a basis for understanding the molecular mechanisms underlying neuronal ceroid lipofuscinoses, and for the development of targeted therapies.']\n",
            "unmatched tags:  [{'entity': 'era', 'type': 'Gene', 'start': 661, 'end': 664}, {'entity': 'lipofuscinoses', 'type': 'Drug', 'start': 607, 'end': 621}, {'entity': 'era', 'type': 'Gene', 'start': 290, 'end': 293}, {'entity': 'era', 'type': 'Gene', 'start': 225, 'end': 228}, {'entity': 'diagnostic', 'type': 'Chemical', 'start': 208, 'end': 218}, {'entity': 'era', 'type': 'Gene', 'start': 193, 'end': 196}, {'entity': 'Batten disease', 'type': 'Disease', 'start': 152, 'end': 166}, {'entity': 'lipofuscinoses', 'type': 'Drug', 'start': 122, 'end': 136}]\n",
            "['New Epidemiological Model Suggestions Revealing Size of Epidemics Based on the COVID-19 Pandemic Example: Wavelength Models\\tThe main purpose of the study is to introduce the wavelength models developed to measure the size of outbreaks based on the COVID-19 example.', 'In this way, the wavelengths of the outbreaks can be calculated, ensuring that the outbreaks are valid, reliable and easy to follow at the national and international level.', 'Wavelength models consist of approved case, death, recovered case and net wavelength models.', 'Thus, the size of the outbreak can be measured both individually and as a whole.', 'COVID-19 cases of 181 countries were used to demonstrate the application of the models.', 'The prominent findings in the applied wavelength models are as follows: the countries with the highest case wavelength are USA, Italy, Spain and Germany, respectively.', 'However, Italy ranks first in the death wavelength, followed by Spain, the USA and France.', 'On the other hand, China has taken the first place in the recovered case wavelength.', 'This country was followed by Spain and Germany and Italy, respectively.', 'Based on all these wavelength models mentioned, net wavelength lengths are calculated.', 'According to the findings of net wavelengths obtained, Canada ranked first, followed by United Kingdom, USA and Italy, respectively.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 613, 'end': 621}]\n",
            "['Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial\\tNanoliposomal irinotecan in combination with fluorouracil and folinic acid extends survival with a manageable safety profile in patients with metastatic pancreatic ductal adenocarcinoma who previously received gemcitabine-based therapy.', 'This agent represents a new treatment option for this population.']\n",
            "unmatched tags:  [{'entity': 'metastatic pancreatic ductal adenocarcinoma', 'type': 'Disease', 'start': 335, 'end': 378}, {'entity': 'folinic acid', 'type': 'Drug', 'start': 255, 'end': 267}, {'entity': 'fluorouracil', 'type': 'Drug', 'start': 238, 'end': 250}]\n",
            "['In-silico immune cell deconvolution of the airway proteomes of infants with pneumonia reveals a link between reduced airway eosinophils and an increased risk of mortality\\tRationale Pneumonia is a leading cause of mortality in infants and young children.', 'The mechanisms that lead to mortality in these children are poorly understood.', 'Studies of the cellular immunology of the infant airway have traditionally been hindered by the limited sample volumes available from the young, frail children who are admitted to hospital with pneumonia.', 'This is further compounded by the relatively low frequencies of certain immune cell phenotypes that are thought to be critical to the clinical outcome of pneumonia.', 'To address this, we developed a novel in-silico deconvolution method for inferring the frequencies of immune cell phenotypes in the airway of children with different survival outcomes using proteomic data.', 'Methods Using high-resolution mass spectrometry, we identified > 1,000 proteins expressed in the airways of children who were admitted to hospital with clinical pneumonia.', '61 of these children were discharged from hospital and survived for more than 365 days after discharge, while 19 died during admission.', 'We used machine learning by random forest to derive protein features that could be used to deconvolve immune cell phenotypes in paediatric airway samples.', 'We applied these phenotype-specific signatures to identify airway-resident immune cell phenotypes that were differentially enriched by survival status and validated the findings using a large retrospective pneumonia cohort.', 'Main Results We identified immune-cell phenotype classification features for 33 immune cell types.', 'Eosinophil-associated features were significantly elevated in airway samples obtained from pneumonia survivors and were downregulated in children who subsequently died.', 'To confirm these results, we analyzed clinical parameters from >10,000 children who had been admitted with pneumonia in the previous 10 years.', 'The results of this retrospective analysis mirrored airway deconvolution data and showed that survivors had significantly elevated eosinophils at admission compared to fatal pneumonia.', 'Conclusions Using a proteomics bioinformatics approach, we identify airway eosinophils as a critical factor for pneumonia survival in infants and young children.']\n",
            "unmatched tags:  [{'entity': 'pneumonia', 'type': 'Disease', 'start': 2304, 'end': 2313}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 2181, 'end': 2190}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 1971, 'end': 1980}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 1786, 'end': 1795}]\n",
            "['Dengue and dengue haemorrhagic fever\\tThe incidence and geographical distribution of dengue have greatly increased in recent years.', 'Dengue is an acute mosquito-transmitted viral disease characterised by fever, headache, muscle and joint pains, rash, nausea, and vomiting.', \"Some infections result in dengue haemorrhagic fever (DHF), a syndrome that in its most severe form can threaten the patient's life, primarily through increased vascular permeability and shock.\", 'The case fatality rate in patients with dengue shock syndrome can be as high as 44%.']\n",
            "unmatched tags:  [{'entity': 'dengue shock syndrome', 'type': 'Disease', 'start': 504, 'end': 525}, {'entity': 'syndrome', 'type': 'Disease', 'start': 332, 'end': 340}, {'entity': 'dengue haemorrhagic fever', 'type': 'Disease', 'start': 297, 'end': 322}, {'entity': 'vomiting', 'type': 'Phenotype', 'start': 261, 'end': 269}, {'entity': 'nausea', 'type': 'Phenotype', 'start': 249, 'end': 255}, {'entity': 'rash', 'type': 'Phenotype', 'start': 243, 'end': 247}, {'entity': 'headache', 'type': 'Phenotype', 'start': 209, 'end': 217}, {'entity': 'fever', 'type': 'Phenotype', 'start': 202, 'end': 207}]\n",
            "['Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries\\tThese time trends show a compelling need for more effective lifestyle management of patients with coronary heart disease.', 'Despite a substantial increase in antihypertensive and lipid-lowering drugs, blood pressure management remained unchanged, and almost half of all patients remain above the recommended lipid targets.', 'To salvage the acutely ischaemic myocardium without addressing the underlying causes of the disease is futile; we need to invest in prevention.']\n",
            "unmatched tags:  [{'entity': 'lipid-lowering drugs', 'type': 'Drug', 'start': 311, 'end': 331}, {'entity': 'antihypertensive', 'type': 'Drug', 'start': 290, 'end': 306}, {'entity': 'coronary heart disease', 'type': 'Disease', 'start': 232, 'end': 254}, {'entity': 'II', 'type': 'Gene', 'start': 95, 'end': 97}]\n",
            "[\"Measuring Iran's success in achieving Millennium Development Goal 4: a systematic analysis of under-5 mortality at national and subnational levels from 1990 to 2015\\tIran and most of its provinces achieved MDG 4 and SDG 3 (target 2) goals by 2015.\", 'However, at the subnational level in some provinces, there is substantial inequity.', 'Local policy makers should use effective strategies to accelerate the reduction of child mortality for these provinces by 2030.', 'Possible recommendations for such strategies include enhancing the level of education and health literacy among women, tackling sex discrimination, and improving incomes for families.']\n",
            "unmatched tags:  [{'entity': 'national', 'type': 'Organization', 'start': 266, 'end': 274}, {'entity': 'SDG 3', 'type': 'Drug', 'start': 215, 'end': 220}, {'entity': 'MDG', 'type': 'Gene', 'start': 205, 'end': 208}]\n",
            "['Dangers of vaccine refusal near the herd immunity threshold: a modelling study\\tAs vaccination makes preventable illness rarer, for some diseases, it also increases the expected severity of each case.', 'Because estimates of case risks rely on data for severity generated during a pre-vaccine era they underestimate negative outcomes in the modern post-vaccine epidemiological landscape.', \"Physicians and parents should understand when making decisions about their children's health and safety that remaining unvaccinated in a predominantly vaccine-protected community exposes their children to the most severe possible outcomes for many preventable diseases.\"]\n",
            "unmatched tags:  [{'entity': 'preventable diseases', 'type': 'Disease', 'start': 632, 'end': 652}, {'entity': 'vaccine', 'type': 'Drug', 'start': 349, 'end': 356}]\n",
            "[\"Predictions, role of interventions and effects of a historic national lockdown in India's response to the COVID-19 pandemic: data science call to arms\\tImportance: India has taken strong and early public health measures for arresting the spread of the COVID-19 epidemic.\", 'With only 536 COVID-19 cases and 11 fatalities, India - a democracy of 1.34 billion people - took the historic decision of a 21-day national lockdown on March 25.', 'The lockdown was further extended to May 3, soon after the analysis of this paper was completed.', 'Objective: To study the short- and long-term impact of an initial 21-day lockdown on the total number of COVID-19 cases in India compared to other less severe non-pharmaceutical interventions using epidemiological forecasting models and Bayesian estimation algorithms; to compare effects of hypothetical durations of lockdown from an epidemiological perspective; to study alternative explanations for slower growth rate of the virus outbreak in India, including exploring the association of the number of cases and average monthly temperature; and finally, to outline the pivotal role of reliable and transparent data, reproducible data science methods, tools and products as we reopen the country and prepare for a post lock-down phase of the pandemic.', 'Design, Setting, and Participants: We use the daily data on the number of COVID-19 cases, of recovered and of deaths from March 1 until April 7, 2020 from the 2019 Novel Coronavirus Visual Dashboard operated by the Johns Hopkins University Center for Systems Science and Engineering (JHU CSSE).', 'Additionally, we use COVID-19 incidence counts data from Kaggle and the monthly average temperature of major cities across the world from Wikipedia.', 'Main Outcome and Measures: The current time-series data on daily proportions of cases and removed (recovered and death combined) from India are analyzed using an extended version of the standard SIR (susceptible, infected, and removed) model.', 'The eSIR model incorporates time-varying transmission rates that help us predict the effect of lockdown compared to other hypothetical interventions on the number of cases at future time points.', 'A Markov Chain Monte Carlo implementation of this model provided predicted proportions of the cases at future time points along with credible intervals (CI).', \"Results: Our predicted cumulative number of COVID-19 cases in India on April 30 assuming a 1-week delay in people's adherence to a 21-day lockdown (March 25 - April 14) and a gradual, moderate resumption of daily activities after April 14 is 9,181 with upper 95% CI of 72,245.\", 'In comparison, the predicted cumulative number of cases under \"no intervention\" and \"social distancing and travel bans without lockdown\" are 358 thousand and 46 thousand (upper 95% CI of nearly 2.3 million and 0.3 million) respectively.', 'An effective lockdown can prevent roughly 343 thousand (upper 95% CI 1.8 million) and 2.4 million (upper 95% CI 38.4 million) COVID-19 cases nationwide compared to social distancing alone by May 15 and June 15, respectively.', 'When comparing a 21-day lockdown with a hypothetical lockdown of longer duration, we find that 28-, 42-, and 56-day lockdowns can approximately prevent 238 thousand (upper 95% CI 2.3 million), 622 thousand (upper 95% CI 4.3 million), 781 thousand (upper 95% CI 4.6 million) cases by June 15, respectively.', 'We find some suggestive evidence that the COVID-19 incidence rates worldwide are negatively associated with temperature in a crude unadjusted analysis with Pearson correlation estimates [95% confidence interval] between average monthly temperature and total monthly incidence around the world being -0.185 [-0.548, 0.236] for January, -0.110 [-0.362, 0.157] for February, and -0.173 [-0.314, -0.026] for March.', 'Conclusions and Relevance: The lockdown, if implemented correctly in the end, has a high chance of reducing the total number of COVID-19 cases in the short term, and buy India invaluable time to prepare its healthcare and disease monitoring system.', 'Our analysis shows we need to have some measures of suppression in place after the lockdown for the best outcome.', 'We cannot heavily rely on the hypothetical prevention governed by meteorological factors such as temperature based on current evidence.', 'From an epidemiological perspective, a longer lockdown between 42-56 days is preferable.', 'However, the lockdown comes at a tremendous price to social and economic health through a contagion process not dissimilar to that of the coronavirus itself.', 'Data can play a defining role as we design post-lockdown testing, reopening and resource allocation strategies.', 'Software: Our contribution to data science includes an interactive and dynamic app (covind19.org) with short- and long-term projections updated daily that can help inform policy and practice related to COVID-19 in India.', 'Anyone can visualize the observed data for India and create predictions under hypothetical scenarios with quantification of uncertainties.', 'We make our prediction codes freely available (https://github.com/umich-cphds/cov-ind-19) for reproducible science and for other COVID-19 affected countries to use them for their prediction and data visualization work.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 5135, 'end': 5143}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 4848, 'end': 4856}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 4513, 'end': 4524}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 3915, 'end': 3923}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 3416, 'end': 3424}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2969, 'end': 2977}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2373, 'end': 2381}, {'entity': 'credible intervals', 'type': 'Gene', 'start': 2303, 'end': 2321}, {'entity': 'Wikipedia', 'type': 'Chemical', 'start': 1719, 'end': 1728}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1602, 'end': 1610}, {'entity': 'CSSE', 'type': 'Disease', 'start': 1574, 'end': 1578}, {'entity': 'JHU', 'type': 'Organization', 'start': 1570, 'end': 1573}]\n",
            "['Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study\\tOur estimate of respiratory and cardiovascular mortality associated with the 2009 pandemic influenza A H1N1 was 15 times higher than reported laboratory-confirmed deaths.', 'Although no estimates of sCFRs were available from Africa and southeast Asia, a disproportionate number of estimated pandemic deaths might have occurred in these regions.', 'Therefore, efforts to prevent influenza need to effectively target these regions in future pandemics.']\n",
            "unmatched tags:  [{'entity': 'influenza', 'type': 'Disease', 'start': 506, 'end': 515}]\n",
            "['Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications\\tBackground The COVID-19 pandemic caused by SARS-CoV-2 coronavirus threatens global public health.', 'Currently, neutralizing antibodies (NAbs) versus this virus are expected to correlate with recovery and protection of this disease.', 'However, the characteristics of these antibodies have not been well studied in association with the clinical manifestations in patients.', 'Methods  Plasma collected from 175 COVID-19 recovered patients with mild symptoms were screened using a safe and sensitive pseudotyped-lentiviral-vector-based neutralization assay.', 'Spike-binding antibody in plasma were determined by ELISA using RBD, S1, and S2 proteins of SARS-CoV-2.', 'The levels and the time course of SARS-CoV-2-specific NAbs and the spike-binding antibodies were monitored at the same time.', 'Findings  SARS-CoV-2 NAbs were unable to cross-reactive with SARS-CoV virus.', 'SARS-CoV-2-specific NAbs were detected in patients from day 10-15 after the onset of the disease and remained thereafter.', 'The titers of NAb among these patients correlated with the spike-binding antibodies targeting S1, RBD, and S2 regions.', 'The titers of NAbs were variable in different patients.', 'Elderly and middle-age patients had significantly higher plasma NAb titers (P<0.0001) and spike-binding antibodies (P=0.0003) than young patients.', 'Notably, among these patients, there were ten patients whose NAb titers were under the detectable level of our assay (ID50: < 40); while in contrast, two patients, showed very high titers of NAb, with ID50 :15989 and 21567 respectively.', 'The NAb titers were positive correlated with plasma CRP levels but negative correlated with the lymphocyte counts of patients at the time of admission, indicating an association between humoral response and cellular immune response.', 'Interpretation The variations of SARS-CoV-2 specific NAbs in recovered COVID-19 patients may raise the concern about the role of NAbs on disease progression.', 'The correlation of NAb titers with age, lymphocyte counts, and blood CRP levels suggested that the interplay between virus and host immune response in coronavirus infections should be further explored for the development of effective vaccine against SARS-CoV-2 virus.', 'Furthermore, titration of NAb is helpful prior to the use of convalescent plasma for prevention or treatment.', 'Funding Ministry of Science and Technology of China, National Natural Science Foundation of China, Shanghai Municipal Health Commission, and Chinese Academy of Medical Sciences']\n",
            "unmatched tags:  [{'entity': 'NAb', 'type': 'Chemical', 'start': 2331, 'end': 2334}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 2287, 'end': 2297}, {'entity': 'vaccine', 'type': 'Drug', 'start': 2271, 'end': 2278}, {'entity': 'coronavirus infections', 'type': 'Disease', 'start': 2188, 'end': 2210}, {'entity': 'NAb', 'type': 'Chemical', 'start': 2056, 'end': 2059}, {'entity': 'NAb', 'type': 'Chemical', 'start': 2008, 'end': 2011}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1950, 'end': 1958}, {'entity': 'NAb', 'type': 'Chemical', 'start': 1932, 'end': 1935}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1912, 'end': 1922}, {'entity': 'NAb', 'type': 'Chemical', 'start': 1649, 'end': 1652}, {'entity': 'NAb', 'type': 'Chemical', 'start': 1599, 'end': 1602}, {'entity': 'NAb', 'type': 'Chemical', 'start': 1469, 'end': 1472}, {'entity': 'NAb', 'type': 'Chemical', 'start': 1325, 'end': 1328}, {'entity': 'NAb', 'type': 'Chemical', 'start': 1219, 'end': 1222}, {'entity': 'RBD', 'type': 'Gene', 'start': 1184, 'end': 1187}, {'entity': 'S1', 'type': 'Gene', 'start': 1180, 'end': 1182}, {'entity': 'NAb', 'type': 'Chemical', 'start': 1100, 'end': 1103}, {'entity': 'NAb', 'type': 'Chemical', 'start': 984, 'end': 987}, {'entity': 'SARS-CoV virus', 'type': 'Virus', 'start': 948, 'end': 962}, {'entity': 'NAb', 'type': 'Chemical', 'start': 908, 'end': 911}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 897, 'end': 907}, {'entity': 'NAb', 'type': 'Chemical', 'start': 815, 'end': 818}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 749, 'end': 759}, {'entity': 'S2 proteins', 'type': 'Gene', 'start': 734, 'end': 745}, {'entity': 'S1', 'type': 'Gene', 'start': 726, 'end': 728}]\n",
            "['TIM-1 Serves as a Nonredundant Receptor for Ebola Virus, Enhancing Viremia and Pathogenesis\\tBackground.', 'T cell immunoglobulin mucin domain-1 (TIM-1) is a phosphatidylserine (PS) receptor, mediating filovirus entry into cells through interactions with PS on virions.', 'TIM-1 expression has been implicated in Ebola virus (EBOV) pathogenesis; however, it remains unclear whether this is due to TIM-1 serving as a filovirus receptor in vivo or, as others have suggested, TIM-1 induces a cytokine storm elicited by T cell/virion interactions.', 'Here, we use a BSL2 model virus that expresses EBOV glycoprotein and demonstrate the importance of TIM-1 as a virus receptor late during in vivo infection.', 'Methodology/Principal findings.', 'We used an infectious, recombinant vesicular stomatitis virus expressing EBOV glycoprotein (EBOV GP/rVSV) to assess the role of TIM-1 during in vivo infection.', 'TIM-1-sufficient or TIM-1-deficient BALB/c interferon α/β receptor -/- mice were challenged with EBOV GP/rVSV-GFP or G/rVSV-GFP.', 'While G/rVSV caused profound morbidity and mortality in both mouse strains, TIM-1-deficient mice had significantly better survival than TIM-1-expressing mice following EBOV GP/rVSV challenge.', 'EBOV GP/rVSV load in spleen was high and unaffected by expression of TIM-1.', 'However, infectious virus in serum, liver, kidney and adrenal gland was reduced late in infection in the TIM-1-deficient mice, suggesting that virus entry via this receptor contributes to virus load.', 'Consistent with higher virus loads, proinflammatory chemokines trended higher in organs from infected TIM-1-sufficient mice compared to the TIM-1-deficient mice, but proinflammatory cytokines were more modestly affected.', 'To assess the role of T cells in EBOV GP/rVSV pathogenesis, T cells were depleted in TIM-1-sufficient and -deficient mice and the mice were challenged with virus.', 'Depletion of T cells did not alter the pathogenic consequences of virus infection.', 'Conclusions.', 'Our studies provide evidence that at late times during EBOV GP/rVSV infection, TIM-1 increased virus load and associated mortality, consistent with an important role of this receptor in virus entry.', 'This work suggests that inhibitors which block TIM-1/virus interaction may serve as effective antivirals, reducing virus load at late times during EBOV infection.', 'Author summary T cell immunoglobulin mucin domain-1 (TIM-1) is one of a number of phosphatidylserine (PS) receptors that mediate clearance of apoptotic bodies by binding PS on the surface of dead or dying cells.', 'Enveloped viruses mimic apoptotic bodies by exposing PS on the outer leaflet of the viral membrane.', 'While TIM-1 has been shown to serve as an adherence factor/receptor for filoviruses in tissue culture, limited studies have investigated the role of TIM-1 as a receptor in vivo.', 'Here, we sought to determine if TIM-1 was critical for Ebola virus glycoprotein-mediated infection using a BSL2 model virus.', 'We demonstrate that loss of TIM-1 expression results in decreased virus load late during infection and significantly reduced virus-elicited mortality.', 'These findings provide evidence that TIM-1 serves as an important receptor for Ebola virus in vivo.', 'Blocking TIM-1/EBOV interactions may be effective antiviral strategy to reduce viral load and pathogenicity at late times of EBOV infection.']\n",
            "unmatched tags:  [{'entity': 'EBOV infection', 'type': 'Disease', 'start': 3315, 'end': 3329}, {'entity': 'EBOV', 'type': 'Virus', 'start': 3205, 'end': 3209}, {'entity': 'TIM-1', 'type': 'Gene', 'start': 3199, 'end': 3204}, {'entity': 'Ebola virus', 'type': 'Virus', 'start': 3169, 'end': 3180}, {'entity': 'receptor', 'type': 'Gene', 'start': 3156, 'end': 3164}, {'entity': 'TIM-1', 'type': 'Gene', 'start': 3127, 'end': 3132}, {'entity': 'TIM-1', 'type': 'Gene', 'start': 2967, 'end': 2972}, {'entity': 'Ebola virus', 'type': 'Virus', 'start': 2869, 'end': 2880}, {'entity': 'TIM-1', 'type': 'Gene', 'start': 2846, 'end': 2851}, {'entity': 'receptor', 'type': 'Gene', 'start': 2796, 'end': 2804}, {'entity': 'TIM-1', 'type': 'Gene', 'start': 2785, 'end': 2790}, {'entity': 'filoviruses', 'type': 'Virus', 'start': 2708, 'end': 2719}, {'entity': 'receptor', 'type': 'Gene', 'start': 2695, 'end': 2703}, {'entity': 'TIM-1', 'type': 'Gene', 'start': 2642, 'end': 2647}, {'entity': 'PS', 'type': 'Gene', 'start': 2589, 'end': 2591}, {'entity': 'Enveloped viruses', 'type': 'Virus', 'start': 2536, 'end': 2553}, {'entity': 'PS', 'type': 'Gene', 'start': 2494, 'end': 2496}, {'entity': 'receptor', 'type': 'Gene', 'start': 2430, 'end': 2438}, {'entity': 'PS', 'type': 'Gene', 'start': 2426, 'end': 2428}, {'entity': 'phosphatidylserine', 'type': 'Drug', 'start': 2406, 'end': 2424}, {'entity': 'TIM-1', 'type': 'Gene', 'start': 2377, 'end': 2382}, {'entity': 'Author summary T cell immunoglobulin mucin domain-1', 'type': 'Gene', 'start': 2324, 'end': 2375}, {'entity': 'EBOV infection', 'type': 'Disease', 'start': 2308, 'end': 2322}, {'entity': 'antivirals', 'type': 'Drug', 'start': 2255, 'end': 2265}, {'entity': 'TIM-1', 'type': 'Gene', 'start': 2208, 'end': 2213}, {'entity': 'receptor', 'type': 'Gene', 'start': 2136, 'end': 2144}, {'entity': 'TIM-1', 'type': 'Gene', 'start': 2041, 'end': 2046}, {'entity': 'EBOV', 'type': 'Virus', 'start': 2017, 'end': 2021}, {'entity': 'virus infection', 'type': 'Disease', 'start': 1932, 'end': 1947}, {'entity': 'mice', 'type': 'Gene', 'start': 1833, 'end': 1837}, {'entity': 'mice', 'type': 'Gene', 'start': 1820, 'end': 1824}, {'entity': 'EBOV', 'type': 'Virus', 'start': 1736, 'end': 1740}, {'entity': 'TIM-1-deficient mice', 'type': 'Gene', 'start': 1622, 'end': 1642}, {'entity': 'mice', 'type': 'Gene', 'start': 1601, 'end': 1605}, {'entity': 'chemokines', 'type': 'Gene', 'start': 1534, 'end': 1544}, {'entity': 'receptor', 'type': 'Gene', 'start': 1446, 'end': 1454}, {'entity': 'TIM-1-deficient mice', 'type': 'Gene', 'start': 1387, 'end': 1407}, {'entity': 'infectious virus', 'type': 'Disease', 'start': 1291, 'end': 1307}, {'entity': 'TIM-1', 'type': 'Gene', 'start': 1275, 'end': 1280}, {'entity': 'EBOV', 'type': 'Virus', 'start': 1206, 'end': 1210}, {'entity': 'EBOV', 'type': 'Virus', 'start': 1182, 'end': 1186}, {'entity': 'mice', 'type': 'Gene', 'start': 1167, 'end': 1171}, {'entity': 'TIM-1-deficient mice', 'type': 'Gene', 'start': 1090, 'end': 1110}, {'entity': 'EBOV', 'type': 'Virus', 'start': 982, 'end': 986}, {'entity': 'mice', 'type': 'Gene', 'start': 956, 'end': 960}, {'entity': 'receptor', 'type': 'Gene', 'start': 943, 'end': 951}, {'entity': 'TIM-1', 'type': 'Gene', 'start': 853, 'end': 858}, {'entity': 'EBOV', 'type': 'Virus', 'start': 817, 'end': 821}, {'entity': 'EBOV glycoprotein', 'type': 'Organization', 'start': 798, 'end': 815}, {'entity': 'recombinant vesicular stomatitis virus', 'type': 'Virus', 'start': 748, 'end': 786}, {'entity': 'receptor', 'type': 'Gene', 'start': 653, 'end': 661}, {'entity': 'virus receptor', 'type': 'Gene', 'start': 647, 'end': 661}, {'entity': 'TIM-1', 'type': 'Gene', 'start': 636, 'end': 641}, {'entity': 'EBOV glycoprotein', 'type': 'Organization', 'start': 584, 'end': 601}]\n",
            "['Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study\\tBenralizumab at 20 mg and 100 mg doses seemed to reduce asthma exacerbations in adults with uncontrolled eosinophilic asthma and baseline blood eosinophils of at least 300 cells per μL, possibly due to targeting of the interleukin 5 receptor rather than interleukin 5 ligand.', 'Further investigation of benralizumab treatment in phase 3 studies is warranted.']\n",
            "unmatched tags:  [{'entity': 'benralizumab', 'type': 'Drug', 'start': 463, 'end': 475}, {'entity': 'ligand', 'type': 'Chemical', 'start': 430, 'end': 436}, {'entity': 'interleukin 5', 'type': 'Gene', 'start': 416, 'end': 429}, {'entity': 'interleukin 5 receptor', 'type': 'Gene', 'start': 381, 'end': 403}, {'entity': 'eosinophilic asthma', 'type': 'Disease', 'start': 267, 'end': 286}, {'entity': 'asthma', 'type': 'Phenotype', 'start': 218, 'end': 224}, {'entity': 'Benralizumab', 'type': 'Drug', 'start': 162, 'end': 174}]\n",
            "['First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study\\tFirst-line pembrolizumab has antitumour activity and acceptable tolerability in cisplatin-ineligible patients with urothelial cancer, most of whom were elderly, had poor prognostic factors, or had serious comorbidities.', 'In view of this result, pembrolizumab has become a new treatment option for patients who are cisplatin-ineligible or not suitable candidates for chemotherapy.', 'Pembrolizumab in the first-line setting is being further assessed in the phase 3 KEYNOTE-361 trial ( ClinicalTrials.gov ,  NCT02335424 ).']\n",
            "unmatched tags:  [{'entity': 'Pembrolizumab', 'type': 'Gene', 'start': 564, 'end': 577}]\n",
            "['On the interactions of the receptor-binding domain of SARS-CoV-1 and SARS-CoV-2 spike proteins with monoclonal antibodies and the receptor ACE2\\tA new betacoronavirus named SARS-CoV-2 has emerged as a new threat to global health and economy.', 'A promising target for both diagnosis and therapeutics treatments of the new disease named COVID-19 is the coronavirus (CoV) spike (S) glycoprotein.', 'By constant-pH Monte Carlo simulations and the PROCEEDpKa method, we have mapped the electrostatic epitopes for four monoclonal antibodies and the angiotensin-converting enzyme 2 (ACE2) on both SARS-CoV-1 and the new SARS-CoV-2 S receptor binding domain (RBD) proteins.', 'We also calculated free energy of interactions and shown that the S RBD proteins from both SARS viruses binds to ACE2 with similar affinities.', 'However, the affinity between the S RBD protein from the new SARS-CoV-2 and ACE2 is higher than for any studied antibody previously found complexed with SARS-CoV-1.', 'Based on physical chemical analysis and free energies estimates, we can shed some light on the involved molecular recognition processes, their clinical aspects, the implications for drug developments, and suggest structural modifications on the CR3022 antibody that would improve its binding affinities for SARS-CoV-2 and contribute to address the ongoing international health crisis.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1275, 'end': 1285}, {'entity': 'CR3022 antibody', 'type': 'Gene', 'start': 1213, 'end': 1228}, {'entity': 'ACE2', 'type': 'Gene', 'start': 879, 'end': 883}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 864, 'end': 874}]\n",
            "['Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society—\\tInspired by unprecedented improvements in human health and development in recent decades, our world has embarked on a quest that only a generation ago would have been considered unreachable—achieving sustainable health and development for all.', \"Improving the health and wellbeing of the world's people is at the core of the Sustainable Development Goals (SDGs), reflected in targets that call for ending the epidemics of AIDS, tuberculosis, and malaria; achieving enormous improvements in maternal and child health; and tackling the growing burden of non-communicable diseases (NCDs).\"]\n",
            "unmatched tags:  [{'entity': 'non-communicable diseases', 'type': 'Disease', 'start': 690, 'end': 715}, {'entity': 'malaria', 'type': 'Disease', 'start': 584, 'end': 591}, {'entity': 'tuberculosis', 'type': 'Disease', 'start': 566, 'end': 578}, {'entity': 'AIDS', 'type': 'Disease', 'start': 560, 'end': 564}, {'entity': 'SDGs', 'type': 'Gene', 'start': 494, 'end': 498}]\n",
            "['The Use of Adjuvant Therapy in Preventing Progression to Severe Pneumonia in Patients with Coronavirus Disease 2019: A Multicenter Data Analysis\\tABSTRACT IMPORTANCE Coronavirus disease 2019 (COVID-19) is a global pandemic associated with high mortality and effective treatment to prevent clinical deterioration to severe pneumonia has not yet been well clarified.', 'OBJECTIVE To investigate the role of several adjuvant treatments in preventing severe pneumonia in patients with COVID-19.', \"DESIGN, SETTING, AND PARTICIPANTS Multicenter, retrospective cohort study of 564 consecutively hospitalized patients with confirmed COVID-19 at Third Xiangya Hospital of Central South University, Changsha Public Health Treatment Center, First Hospital of Yueyang, Junshan People's Hospital of Yueyang, Central Hospital of Shaoyang, Central Hospital of Xiangtan, Second Hospital of Changde, Central Hospital of Loudi, and First Affiliated Hospital of University of South China in Hunan province from January 17, 2020 to February 28, 2020; The final date of follow-up was March 15, 2020.\", 'EXPOSURES Nonspecific antivirals (arbidol, lopinavir/ritonavir, and interferon α), antihypertensives, and chloroquine.', 'MAIN OUTCOMES AND MEASURES The development of severe COVID-19 pneumonia; Demographic, epidemiological, clinical, laboratory, radiological, and treatment data were collected and analyzed.', 'RESULTS Of 564 patients, the median age was 47 years (interquartile range, 36-58 years), and 284 (50.4%) patients were men.', 'Sixty-nine patients (12.2%) developed severe pneumonia.', 'Patients who developed severe pneumonia were older (median age of 59 and 45 years, respectively), and more patients had comorbidities including hypertension (30.4% and 12.3%, respectively), diabetes (17.4% and 6.7%, respectively), and cardiovascular disease (8.7% and 3.2%, respectively) and presented with fever (84.1% and 60.4%, respectively) and shortness of breath (10.1% and 3.8%, respectively) compared with those who did not.', 'Nonspecific antiviral therapy did not prevent clinical progression to severe pneumonia, although fewer hypertensive patients on angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers (ACEI/ARB) therapy developed severe pneumonia in contrast with those on non-ACEI/ARB antihypertensive therapy (1 of 16 [6.3%] patients and 16 of 49 [32.7%] patients, respectively [difference, 26.4%; 95% CI, 1.5% to 41.3%]).', 'Multivariate logistic regression analysis showed that hypertension without receiving ACEI/ARB therapy was an independent risk factor (odds ratio [OR], 2.07; 95% CI, 1.07 to 4.00) for developing severe pneumonia irrespective of age.', 'Besides, none of patients treated with chloroquine developed severe pneumonia, though without significance (difference, 12.0%; 95% CI, -3.5% to 30.0%) by propensity score matching.', 'CONCLUSIONS AND RELEVANCE Hypertensive patients on ACEI or ARB may be protective from severe pneumonia in COVID-19 and hence these therapies should not be ceased unless there is a strong indication or further epidemiological evidence.', 'Though none of the current antiviral and immunoregulation therapy showed benefit in preventing COVID-19 progression, chloroquine deserved further investigation.']\n",
            "unmatched tags:  [{'entity': 'chloroquine', 'type': 'Drug', 'start': 3184, 'end': 3195}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 3162, 'end': 3170}, {'entity': 'antiviral', 'type': 'Virus', 'start': 3094, 'end': 3103}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2938, 'end': 2946}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 2925, 'end': 2934}, {'entity': 'ACEI', 'type': 'Chemical', 'start': 2883, 'end': 2887}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 2719, 'end': 2728}, {'entity': 'chloroquine', 'type': 'Drug', 'start': 2690, 'end': 2701}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 2620, 'end': 2629}, {'entity': 'ACEI', 'type': 'Chemical', 'start': 2504, 'end': 2508}, {'entity': 'hypertension', 'type': 'Disease', 'start': 2473, 'end': 2485}, {'entity': 'ACEI', 'type': 'Chemical', 'start': 2271, 'end': 2275}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 2231, 'end': 2240}, {'entity': 'ACEI', 'type': 'Chemical', 'start': 2196, 'end': 2200}, {'entity': 'angiotensin-receptor blockers', 'type': 'Drug', 'start': 2165, 'end': 2194}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 2070, 'end': 2079}, {'entity': 'antiviral', 'type': 'Virus', 'start': 2005, 'end': 2014}, {'entity': 'shortness of breath', 'type': 'Phenotype', 'start': 1909, 'end': 1928}, {'entity': 'fever', 'type': 'Phenotype', 'start': 1867, 'end': 1872}, {'entity': 'cardiovascular disease', 'type': 'Disease', 'start': 1795, 'end': 1817}, {'entity': 'diabetes', 'type': 'Disease', 'start': 1750, 'end': 1758}, {'entity': 'hypertension', 'type': 'Disease', 'start': 1704, 'end': 1716}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 1590, 'end': 1599}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 1549, 'end': 1558}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 1254, 'end': 1263}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1245, 'end': 1253}, {'entity': 'chloroquine', 'type': 'Drug', 'start': 1179, 'end': 1190}, {'entity': 'antihypertensives', 'type': 'Drug', 'start': 1156, 'end': 1173}, {'entity': 'interferon', 'type': 'Gene', 'start': 1141, 'end': 1151}, {'entity': 'lopinavir/ritonavir', 'type': 'Drug', 'start': 1116, 'end': 1135}]\n",
            "['High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial\\tIn this phase 2 study, HCO-HD did not improve clinical outcomes for patients with de novo multiple myeloma and myeloma cast nephropathy who required haemodialysis for acute kidney injury and who received a bortezomib-based chemotherapy regimen relative to those receiving HF-HD.', 'These results do not support proceeding to a phase 3 study for HCO-HD in these patients.']\n",
            "unmatched tags:  [{'entity': 'acute kidney injury', 'type': 'Disease', 'start': 339, 'end': 358}]\n",
            "['Alpha-ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication\\tThe main protease of coronaviruses and the 3C protease of enteroviruses share a similar active-site architecture and a unique requirement for glutamine in the P1 position of the substrate.', 'Because of their unique specificity and essential role in viral polyprotein processing, these proteases are suitable targets for the development of antiviral drugs.', 'In order to obtain near-equipotent, broad-spectrum antivirals against alphacoronaviruses, betacoronaviruses, and enteroviruses, we pursued structure-based design of peptidomimetic α-ketoamides as inhibitors of main and 3C proteases.', 'Six crystal structures of protease:inhibitor complexes were determined as part of this study.', 'Compounds synthesized were tested against the recombinant proteases as well as in viral replicons and virus-infected cell cultures; most of them were not cell-toxic.', 'Optimization of the P2 substituent of the α-ketoamides proved crucial for achieving near-equipotency against the three virus genera.', 'The best near-equipotent inhibitors, 11u (P2 = cyclopentylmethyl) and 11r (P2 = cyclohexylmethyl), display low-micromolar EC 50 values against enteroviruses, alphacoronaviruses, and betacoronaviruses in cell cultures.', 'In Huh7 cells, 11r exhibits three-digit picomolar activity against Middle East Respiratory Syndrome coronavirus.']\n",
            "unmatched tags:  [{'entity': 'coronavirus', 'type': 'Virus', 'start': 1387, 'end': 1398}, {'entity': 'Middle East Respiratory Syndrome coronavirus', 'type': 'Virus', 'start': 1354, 'end': 1398}, {'entity': 'Huh7 cells', 'type': 'Gene', 'start': 1290, 'end': 1300}, {'entity': 'betacoronaviruses', 'type': 'Virus', 'start': 1251, 'end': 1268}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 1232, 'end': 1243}, {'entity': 'coronaviruses', 'type': 'Virus', 'start': 1232, 'end': 1245}, {'entity': 'alphacoronaviruses', 'type': 'Virus', 'start': 1227, 'end': 1245}, {'entity': 'enteroviruses', 'type': 'Virus', 'start': 1212, 'end': 1225}, {'entity': 'low-micromolar', 'type': 'Gene', 'start': 1176, 'end': 1190}, {'entity': 'virus genera', 'type': 'Virus', 'start': 1055, 'end': 1067}, {'entity': 'viral replicons', 'type': 'Gene', 'start': 852, 'end': 867}, {'entity': 'proteases', 'type': 'Gene', 'start': 828, 'end': 837}, {'entity': 'recombinant proteases', 'type': 'Gene', 'start': 816, 'end': 837}, {'entity': 'protease', 'type': 'Gene', 'start': 702, 'end': 710}, {'entity': '3C proteases', 'type': 'Gene', 'start': 662, 'end': 674}, {'entity': 'structure-based design', 'type': 'Gene', 'start': 582, 'end': 604}, {'entity': 'enteroviruses', 'type': 'Virus', 'start': 556, 'end': 569}]\n",
            "['Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV\\tSince 2002, beta coronaviruses (CoV) have caused three zoonotic outbreaks, SARS-CoV in 2002â\\x80\\x932003, MERS-CoV in 2012, and the newly emerged SARS-CoV-2 in late 2019.', 'However, little is currently known about the biology of SARS-CoV-2.', 'Here, using SARS-CoV-2 S protein pseudovirus system, we confirm that human angiotensin converting enzyme 2 (hACE2) is the receptor for SARS-CoV-2, find that SARS-CoV-2 enters 293/hACE2 cells mainly through endocytosis, that PIKfyve, TPC2, and cathepsin L are critical for entry, and that SARS-CoV-2 S protein is less stable than SARS-CoV S. Polyclonal anti-SARS S1 antibodies T62 inhibit entry of SARS-CoV S but not SARS-CoV-2 S pseudovirions.', 'Further studies using recovered SARS and COVID-19 patientsâ\\x80\\x99 sera show limited cross-neutralization, suggesting that recovery from one infection might not protect against the other.', 'Our results present potential targets for development of drugs and vaccines for SARS-CoV-2.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1054, 'end': 1064}, {'entity': 'vaccines', 'type': 'Drug', 'start': 1041, 'end': 1049}, {'entity': 'cross-neutralization', 'type': 'Disease', 'start': 871, 'end': 891}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 832, 'end': 840}, {'entity': 'SARS', 'type': 'Disease', 'start': 823, 'end': 827}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 763, 'end': 773}, {'entity': 'CoV', 'type': 'Virus', 'start': 749, 'end': 752}, {'entity': 'SARS-CoV S', 'type': 'Virus', 'start': 744, 'end': 754}, {'entity': 'SARS', 'type': 'Disease', 'start': 704, 'end': 708}, {'entity': 'Polyclonal', 'type': 'Gene', 'start': 688, 'end': 698}, {'entity': 'SARS-CoV S', 'type': 'Virus', 'start': 676, 'end': 686}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 635, 'end': 645}, {'entity': 'cathepsin L', 'type': 'Gene', 'start': 590, 'end': 601}, {'entity': 'TPC2', 'type': 'Gene', 'start': 580, 'end': 584}, {'entity': 'PIKfyve', 'type': 'Gene', 'start': 571, 'end': 578}, {'entity': 'hACE2', 'type': 'Chemical', 'start': 526, 'end': 531}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 504, 'end': 514}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 482, 'end': 492}, {'entity': 'receptor', 'type': 'Gene', 'start': 469, 'end': 477}, {'entity': 'hACE2', 'type': 'Chemical', 'start': 455, 'end': 460}, {'entity': 'angiotensin converting enzyme 2', 'type': 'Gene', 'start': 422, 'end': 453}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 359, 'end': 369}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 335, 'end': 345}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 254, 'end': 264}, {'entity': 'CoV', 'type': 'Virus', 'start': 219, 'end': 222}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 214, 'end': 222}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 189, 'end': 197}, {'entity': 'CoV', 'type': 'Virus', 'start': 146, 'end': 149}]\n",
            "['Neurological disorders caused by inherited ion-channel mutations\\tSeveral neurological diseases-including neuromuscular disorders, movement disorders, migraine, and epilepsy-are caused by inherited mutations of ion channels.', 'The list of these “channelopathies” is expanding rapidly, as is the phenotypic range associated with each channel.', 'At present the best understood channelopathies are those that affect muscle-fibre excitability.', 'These channelopathies produce a range of disorders which include: periodic paralysis, myotonias, malignant hyperthermia, and congenital myasthenic syndromes.']\n",
            "unmatched tags:  [{'entity': 'congenital myasthenic syndromes', 'type': 'Disease', 'start': 560, 'end': 591}, {'entity': 'hyperthermia', 'type': 'Phenotype', 'start': 542, 'end': 554}, {'entity': 'periodic paralysis', 'type': 'Disease', 'start': 501, 'end': 519}, {'entity': 'disorders', 'type': 'Disease', 'start': 476, 'end': 485}, {'entity': 'channelopathies', 'type': 'Disease', 'start': 441, 'end': 456}, {'entity': 'channelopathies', 'type': 'Disease', 'start': 370, 'end': 385}, {'entity': 'channelopathies', 'type': 'Disease', 'start': 243, 'end': 258}, {'entity': 'ion channels', 'type': 'Gene', 'start': 210, 'end': 222}, {'entity': 'migraine', 'type': 'Disease', 'start': 150, 'end': 158}]\n",
            "['Effects of resective surgery for left-sided intracranial tumours on language function: a prospective study\\tResective surgery for left-sided intracranial tumours significantly improves language function in dysphasic patients, and is unlikely to impair language functions in non-dysphasic patients.', 'Dysphasia and its response to resective surgery are related to the tumour neuropathology.']\n",
            "unmatched tags:  [{'entity': 'tumour', 'type': 'Disease', 'start': 364, 'end': 370}, {'entity': 'Dysphasia', 'type': 'Disease', 'start': 297, 'end': 306}, {'entity': 'dysphasic', 'type': 'Disease', 'start': 277, 'end': 286}, {'entity': 'impair', 'type': 'Disease', 'start': 244, 'end': 250}]\n",
            "['Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial\\tMore than 90% of patients with locally advanced unresectable progressive pigmented villonodular synovitis achieved disease control with 12 weeks of nilotinib treatment.', 'These results indicate that CSF1R tyrosine kinase inhibitors have anti-tumour activity with manageable toxicity in patients with inoperable progressive pigmented villonodular synovitis.', 'Randomised trials investigating the efficacy of nilotinib for patients with unresectable pigmented villonodular synovitis are warranted.']\n",
            "unmatched tags:  [{'entity': 'unresectable pigmented villonodular synovitis', 'type': 'Disease', 'start': 548, 'end': 593}, {'entity': 'nilotinib', 'type': 'Drug', 'start': 520, 'end': 529}, {'entity': 'Randomised trials', 'type': 'Organization', 'start': 472, 'end': 489}, {'entity': 'synovitis', 'type': 'Disease', 'start': 461, 'end': 470}, {'entity': 'pigmented villonodular synovitis', 'type': 'Disease', 'start': 438, 'end': 470}]\n",
            "['Dihydroartemisinin–piperaquine resistance in\\tDihydroartemisinin–piperaquine failures are caused by both artemisinin and piperaquine resistance, and commonly occur in places where dihydroartemisinin–piperaquine has been used in the private sector.', 'In Cambodia, artesunate plus mefloquine may be a viable option to treat dihydroartemisinin–piperaquine failures, and a more effective first-line ACT in areas where dihydroartemisinin–piperaquine failures are common.', 'The use of single low-dose primaquine to eliminate circulating gametocytes is needed in areas where artemisinin and ACT resistance is prevalent.']\n",
            "unmatched tags:  [{'entity': 'artemisinin', 'type': 'Drug', 'start': 563, 'end': 574}, {'entity': 'primaquine', 'type': 'Drug', 'start': 490, 'end': 500}, {'entity': 'piperaquine', 'type': 'Drug', 'start': 430, 'end': 441}, {'entity': 'dihydroartemisinin', 'type': 'Drug', 'start': 411, 'end': 429}, {'entity': 'piperaquine', 'type': 'Drug', 'start': 338, 'end': 349}, {'entity': 'artemisinin', 'type': 'Drug', 'start': 326, 'end': 337}, {'entity': 'dihydroartemisinin', 'type': 'Drug', 'start': 319, 'end': 337}, {'entity': 'mefloquine', 'type': 'Drug', 'start': 276, 'end': 286}, {'entity': 'artesunate', 'type': 'Drug', 'start': 260, 'end': 270}, {'entity': 'piperaquine', 'type': 'Drug', 'start': 198, 'end': 209}, {'entity': 'dihydroartemisinin', 'type': 'Drug', 'start': 179, 'end': 197}]\n",
            "['Prediabetes: a high-risk state for diabetes development\\tPrediabetes (intermediate hyperglycaemia) is a high-risk state for diabetes that is defined by glycaemic variables that are higher than normal, but lower than diabetes thresholds.', '5–10% of people per year with prediabetes will progress to diabetes, with the same proportion converting back to normoglycaemia.', 'Prevalence of prediabetes is increasing worldwide and experts have projected that more than 470 million people will have prediabetes by 2030.', 'Prediabetes is associated with the simultaneous presence of insulin resistance and β-cell dysfunction—abnormalities that start before glucose changes are detectable.']\n",
            "unmatched tags:  [{'entity': 'glucose changes', 'type': 'Drug', 'start': 641, 'end': 656}, {'entity': 'Prediabetes', 'type': 'Disease', 'start': 507, 'end': 518}]\n",
            "['Viral CNS infections in children from a malaria-endemic area of Malawi: a prospective cohort study\\tViral CNS infections are an important cause of hospital admission and death in children in Malawi, including in children whose coma might be attributed solely to cerebral malaria.', 'Interaction between viral infection and parasitaemia could increase disease severity.']\n",
            "unmatched tags:  [{'entity': 'parasitaemia', 'type': 'Disease', 'start': 319, 'end': 331}, {'entity': 'viral infection', 'type': 'Virus', 'start': 299, 'end': 314}, {'entity': 'cerebral malaria', 'type': 'Disease', 'start': 261, 'end': 277}, {'entity': 'coma', 'type': 'Disease', 'start': 226, 'end': 230}]\n",
            "['Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study\\tA single episode of falciparum or vivax malaria in the first trimester of pregnancy can cause miscarriage.', 'No additional toxic effects associated with artesunate treatment occurred in early pregnancy.', 'Prospective studies should now be done to assess the safety and efficacy of artemisinin combination treatments in early pregnancy.']\n",
            "unmatched tags:  [{'entity': 'early pregnancy', 'type': 'Disease', 'start': 449, 'end': 464}, {'entity': 'artemisinin', 'type': 'Drug', 'start': 411, 'end': 422}, {'entity': 'early pregnancy', 'type': 'Disease', 'start': 318, 'end': 333}, {'entity': 'artesunate', 'type': 'Drug', 'start': 285, 'end': 295}, {'entity': 'malaria', 'type': 'Disease', 'start': 174, 'end': 181}, {'entity': 'vivax', 'type': 'Disease', 'start': 168, 'end': 173}]\n",
            "['Anticytokine autoantibodies in infectious diseases: pathogenesis and mechanisms\\tAutoantibodies to cytokines occur in many different conditions and situations and can cause a wide range of disease, including pulmonary alveolar proteinosis, disseminated non-tuberculous mycobacterial disease, pure red-cell aplasia, and chronic mucocutaneous candidiasis.', 'Anticytokine autoantibodies may also develop against exogenously administered cytokines, sometimes diminishing their effects or inhibiting the activity of the endogenous cytokine.', 'Unlike primary congenital immunodeficiencies, autoantibodies may develop over time, wax and wane, and may change in titre or avidity.']\n",
            "unmatched tags:  [{'entity': 'autoantibodies', 'type': 'Gene', 'start': 579, 'end': 593}, {'entity': 'primary congenital immunodeficiencies', 'type': 'Disease', 'start': 540, 'end': 577}]\n",
            "['Modulation of cytochrome P450 activity: implications for cancer therapy\\tAlthough metabolism mediated by cytochrome P450 isoenzymes is known to play a major part in the biotransformation of anticancer agents in vivo, few clinical studies have investigated activity of cytochrome P450s and therapeutic outcome in people with cancer.', 'Variability between individuals in the pharmacokinetics of cancer chemotherapy has important consequences in terms of therapeutic efficacy and safety.', 'We discuss here the effect of drug metabolism mediated by cytochrome P450 on therapeutic outcome.']\n",
            "unmatched tags:  [{'entity': 'cytochrome P450', 'type': 'Gene', 'start': 540, 'end': 555}, {'entity': 'cancer', 'type': 'Disease', 'start': 390, 'end': 396}]\n",
            "['High transmissibility of COVID-19 near symptom onset\\tBackground The dynamics of coronavirus disease 2019 (COVID-19) transmissibility after symptom onset remains unknown.', 'Methods We conducted a prospective case-ascertained study on laboratory-confirmed COVID-19 cases and their contacts.', 'Secondary clinical attack rate (considering symptomatic cases only) was analyzed for different exposure windows after symptom onset of index cases and for different exposure settings.', 'Results Thirty-two confirmed patients were enrolled and 12 paired data (index-secondary cases) were identified among the 1,043 contacts.', 'The secondary clinical attack rate was 0.9% (95% CI 0.5-1.7%).', 'The attack rate was higher among those whose exposure to index cases started within five days of symptom onset (2.4%, 95% CI 1.1-4.5%) than those who were exposed later (zero case from 605 close contacts, 95% CI 0-0.61%).', 'The attack rate was also higher among household contacts (13.6%, 95% CI 4.7-29.5%) and non-household family contacts (8.5%, 95% CI 2.4-20.3%) than that in healthcare or other settings.', 'The higher secondary clinical attack rate for contacts near symptom onset remained when the analysis was restricted to household and family contacts.', 'There was a trend of increasing attack rate with the age of contacts (p for trend < 0.001).', 'Conclusions High transmissibility of COVID-19 near symptom onset suggests that finding and isolating symptomatic patients alone may not suffice to contain the epidemic, and more generalized social distancing measures are required.', 'Rapid reduction of transmissibility over time implies that prolonged hospitalization of mild cases might not be necessary in large epidemics.']\n",
            "unmatched tags:  [{'entity': 'symptom', 'type': 'Phenotype', 'start': 1424, 'end': 1431}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 1374, 'end': 1381}]\n",
            "['Non-coding RNAs with essential roles in neurodegenerative disorders\\tThe importance of various classes of regulatory non-protein-coding RNA molecules (ncRNAs) in the normal functioning of the CNS is becoming increasingly evident.', 'ncRNAs are involved in neuronal cell specification and patterning during development, but also in higher cognitive processes, such as structural plasticity and memory formation in the adult brain.', 'We discuss advances in understanding of the function of ncRNAs in the CNS, with a focus on the potential involvement of specific species, such as microRNAs, endogenous small interfering RNAs, long intergenic non-coding RNAs, and natural antisense transcripts, in various neurodegenerative disorders.']\n",
            "unmatched tags:  [{'entity': 'long intergenic non-coding RNAs', 'type': 'Gene', 'start': 618, 'end': 649}, {'entity': 'RNAs', 'type': 'Gene', 'start': 612, 'end': 616}, {'entity': 'small interfering', 'type': 'Gene', 'start': 594, 'end': 611}, {'entity': 'microRNAs', 'type': 'Gene', 'start': 572, 'end': 581}, {'entity': 'RNAs', 'type': 'Gene', 'start': 484, 'end': 488}, {'entity': 'ncRNAs', 'type': 'Gene', 'start': 482, 'end': 488}]\n",
            "['identification of potential inhibitors against human 2’-5’-oligoadenylate synthetase (OAS) proteins\\tAs part of the type I IFN signaling, the 2’-5’- oligoadenylate synthetase (OAS) proteins have been involved in the progression of several non-viral diseases.', 'Notably, OAS has been correlated with immune-modulatory functions that promote chronic inflammatory conditions, autoimmune disorders, cancer, and infectious diseases.', 'In spite of this, OAS enzymes have been ignored as drug targets, and to date, there are no reports of compounds that can inhibit their activity.', 'In this study, we have used homology modeling and virtual high-throughput screening to identify potential inhibitors of the human proteins OAS1, OAS2, and OAS3.', 'Altogether, we have found 37 molecules that could exert a competitive inhibition in the ATP binding sites of OAS proteins, independently of the activation state of the enzyme.', 'This latter characteristic, which might be crucial for a versatile inhibitor, was observed in compounds interacting with the residues Asp75, Asp77, Gln229, and Tyr230 in OAS1, and their equivalents in OAS2 and OAS3.', 'Although there was little correlation between specific chemical fragments and particular interactions, intermolecular contacts with OAS catalytic triad and other critical amino acids were mainly promoted by heterocycles with π electrons and hydrogen bond acceptors.', 'In conclusion, this study provides a potential set of OAS inhibitors as well as valuable information for their design, development, and optimization.']\n",
            "unmatched tags:  [{'entity': 'OAS', 'type': 'Disease', 'start': 1443, 'end': 1446}, {'entity': 'π electrons', 'type': 'Chemical', 'start': 1348, 'end': 1359}, {'entity': 'amino acids', 'type': 'Gene', 'start': 1294, 'end': 1305}, {'entity': 'OAS', 'type': 'Disease', 'start': 1255, 'end': 1258}, {'entity': 'OAS3', 'type': 'Gene', 'start': 1117, 'end': 1121}, {'entity': 'OAS', 'type': 'Disease', 'start': 1108, 'end': 1111}, {'entity': 'OAS2', 'type': 'Gene', 'start': 1108, 'end': 1112}, {'entity': 'OAS1', 'type': 'Gene', 'start': 1077, 'end': 1081}, {'entity': 'Gln229', 'type': 'Gene', 'start': 1055, 'end': 1061}, {'entity': 'Asp77', 'type': 'Gene', 'start': 1048, 'end': 1053}, {'entity': 'compounds', 'type': 'Drug', 'start': 1001, 'end': 1010}, {'entity': 'enzyme', 'type': 'Gene', 'start': 899, 'end': 905}]\n",
            "['Acute hepatitis C and HIV coinfection\\tHepatitis C is a common infection worldwide, but acute infection is often asymptomatic and difficult to diagnose.', 'People coinfected with HIV and hepatitis C might progress to chronic liver disease more quickly.', 'We present a case of a man infected with HIV with sexually acquired acute hepatitis C and discuss the immunology, natural history, and epidemiology of acute hepatitis C and coinfection with HIV.', 'Several recent reports have documented acute hepatitis C among men who have sex with men who engage in high risk sexual practices and often have concomitant genital ulcer disease.']\n",
            "unmatched tags:  [{'entity': 'genital ulcer disease', 'type': 'Disease', 'start': 601, 'end': 622}, {'entity': 'acute hepatitis C', 'type': 'Disease', 'start': 483, 'end': 500}, {'entity': 'HIV', 'type': 'Virus', 'start': 439, 'end': 442}]\n",
            "['Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial\\tPnCRM7 vaccine prevents vaccine serotype invasive pneumococcal disease even in a high risk population.', 'Other regions with similar disease burden should consider including this vaccine in the routine childhood vaccine schedule.']\n",
            "unmatched tags:  [{'entity': 'vaccine', 'type': 'Drug', 'start': 328, 'end': 335}, {'entity': 'vaccine', 'type': 'Drug', 'start': 295, 'end': 302}]\n",
            "['Secret science: tobacco industry research on smoking behaviour and cigarette toxicity\\tA lack of scientific data remains the principal obstacle to regulating cigarette toxicity.', 'In particular, there is an immediate need to improve our understanding of the interaction between smoking behaviour and product design, and its influence on cigarette deliveries.', 'This article reviews internal tobacco industry documents on smoking behaviour research undertaken by Imperial Tobacco Limited (ITL) and British-American Tobacco (BAT).', 'BAT documents indicate that smokers vary their puffing behaviour to regulate nicotine levels and compensate for low-yield cigarettes by smoking them more intensely.']\n",
            "unmatched tags:  [{'entity': 'nicotine', 'type': 'Drug', 'start': 601, 'end': 609}, {'entity': 'ITL', 'type': 'Gene', 'start': 483, 'end': 486}]\n",
            "['Proofreading-deficient coronaviruses adapt over long-term passage for increased fidelity and fitness without reversion of exoribonuclease-inactivating mutations\\tThe coronavirus (CoV) RNA genome is the largest among single-stranded positive sense RNA viruses.', 'CoVs encode a proofreading 3′→5′exoribonuclease within nonstructural protein 14 (nsp14-ExoN) that is responsible for CoV high-fidelity replication.', 'Alanine substitution of ExoN catalytic residues [ExoN(-)] in SARS-CoV and murine hepatitis virus (MHV) disrupts ExoN activity, yielding viable mutant viruses with defective replication, up to 20-fold decreased fidelity, and increased susceptibility to nucleoside analogs.', 'To test the stability of the ExoN(-) genotype and phenotype, we passaged MHV-ExoN(-) 250 times in cultured cells (P250), in parallel with WT-MHV.', 'Compared to MHV-ExoN(-) P3, MHV-ExoN(-) P250 demonstrated enhanced replication, reduced susceptibility to nucleoside analogs, and increased competitive fitness.', 'However, passage did not select for complete or partial reversion at the ExoN-inactivating mutations.', 'We identified novel amino acid changes within the RNA-dependent RNA polymerase (nsp12-RdRp) and nsp14 of MHV-ExoN(-) P250 that partially account for the observed changes in replication, susceptibility to nucleoside analogs, and competitive fitness observed in the passaged virus population, indicating that additional determinants can compensate for the activities of nsp14-ExoN.', 'Our results suggest that while selection favors restoration of replication fidelity in ExoN(-) CoVs, there may be a significant barrier to ExoN(-) reversion.', 'These results also support the hypothesis that high-fidelity replication is linked to CoV fitness and identify additional candidate proteins that may regulate CoV replication fidelity.', 'IMPORTANCE Unique among RNA viruses, CoVs encode a proofreading exoribonuclease (ExoN) in nsp14 that mediates high-fidelity RNA genome replication.', 'Proofreading-deficient CoVs with disrupted ExoN activity [ExoN(-)] are either non-viable or have significant defects in replication, RNA synthesis, fidelity, fitness, and virulence.', 'In this study, we show that ExoN(-) murine hepatitis virus can adapt over long-term passage for increased replication and fitness without reverting the ExoN-inactivating mutations.', 'Passage-adapted ExoN(-) mutants also demonstrate increasing resistance to nucleoside analogs that is only partially explained by secondary mutations in nsp12 and nsp14.', 'These data suggest that enhanced resistance to nucleoside analogs is mediated by the interplay of multiple replicase proteins and support the proposed link between CoV fidelity and fitness.']\n",
            "unmatched tags:  [{'entity': 'CoV', 'type': 'Virus', 'start': 2655, 'end': 2658}, {'entity': 'proteins', 'type': 'Gene', 'start': 2608, 'end': 2616}, {'entity': 'nucleoside analogs', 'type': 'Gene', 'start': 2538, 'end': 2556}, {'entity': 'nsp12', 'type': 'Disease', 'start': 2474, 'end': 2479}, {'entity': 'nucleoside analogs', 'type': 'Gene', 'start': 2396, 'end': 2414}, {'entity': 'ExoN(-)', 'type': 'Gene', 'start': 2338, 'end': 2345}, {'entity': 'adapt', 'type': 'Drug', 'start': 2330, 'end': 2335}, {'entity': 'adapt', 'type': 'Drug', 'start': 2204, 'end': 2209}, {'entity': 'hepatitis virus', 'type': 'Virus', 'start': 2184, 'end': 2199}, {'entity': 'murine', 'type': 'Drug', 'start': 2177, 'end': 2183}, {'entity': 'ExoN(-)', 'type': 'Gene', 'start': 2169, 'end': 2176}, {'entity': 'RNA', 'type': 'Gene', 'start': 2092, 'end': 2095}, {'entity': 'ExoN(-)', 'type': 'Gene', 'start': 2017, 'end': 2024}, {'entity': 'ExoN', 'type': 'Gene', 'start': 2002, 'end': 2006}, {'entity': 'CoVs', 'type': 'Virus', 'start': 1982, 'end': 1986}, {'entity': 'high-fidelity RNA', 'type': 'Organization', 'start': 1921, 'end': 1938}, {'entity': 'ExoN', 'type': 'Gene', 'start': 1892, 'end': 1896}, {'entity': 'proofreading exoribonuclease', 'type': 'Gene', 'start': 1862, 'end': 1890}, {'entity': 'CoVs', 'type': 'Virus', 'start': 1848, 'end': 1852}, {'entity': 'RNA viruses', 'type': 'Virus', 'start': 1835, 'end': 1846}, {'entity': 'CoV', 'type': 'Virus', 'start': 1785, 'end': 1788}]\n",
            "['Prediction of SARS-CoV-2 epitopes across 9360 HLA class I alleles\\tElucidating antiviral CD8 T lymphocyte responses to SARS-CoV-2 may shed light on the heterogeneity of clinical outcomes and inform vaccine or therapeutic approaches.', 'To facilitate the evaluation of antiviral CD8 T cell responses to SARS-CoV-2, we generated a publicly accessible database of epitopes predicted to bind any class I HLA protein across the entire SARS-CoV-2 proteome.', 'While a subset of epitopes from earlier betacoronaviruses, such as SARS-CoV (SARS), have been validated experimentally, validation systems are often biased toward specific HLA haplotypes (notably HLA-A*02:01) that only account for a fraction of the haplotypes of individuals affected by the SARS-CoV-2 pandemic.', 'To enable evaluation of epitopes across individuals with a variety of HLA haplotypes, we computed the predicted binding affinities between 9-mer peptides derived from the annotated SARS-CoV-2 peptidome across 9,360 MHC class I HLA-A, -B, and -C alleles.', 'There were 6,748 unique combinations of peptides and HLA alleles (pMHCs) with a predicted binding affinity of less than 500nM, including 1,103 unique peptides and 1,022 HLA alleles, spanning 11 annotated superfamilies.', 'These peptides were derived from all 11 proteins spanning the SARS-CoV-2 peptidome, including peptides that have previously been validated experimentally.', 'We also show evidence that these previously validated epitopes may be relevant in other HLA contexts.', 'This complete dataset is available publicly: gs://pici-covid19-data-resources/mhci/peptide_predictions.']\n",
            "unmatched tags:  [{'entity': 'HLA', 'type': 'Gene', 'start': 1475, 'end': 1478}, {'entity': 'peptides', 'type': 'Gene', 'start': 1326, 'end': 1334}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1294, 'end': 1304}, {'entity': 'proteins', 'type': 'Gene', 'start': 1272, 'end': 1280}, {'entity': 'peptides', 'type': 'Gene', 'start': 1238, 'end': 1246}]\n",
            "['Cancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies\\tCancer/testis tumour-associated antigens (C/T TAA) were the first human tumour-associated antigens to be characterised at the molecular level.', 'Specific genes are expressed in the testis and in tumours of varying histological origin.', 'The tissue expression pattern supports the notion that these antigens could be targets for active specific immunotherapy.', 'Specific serological reagents have been developed and have helped to clarify biochemical characteristics of C/T TAA and to assess their distribution within clinical tumour samples.']\n",
            "unmatched tags:  [{'entity': 'TAA', 'type': 'Drug', 'start': 566, 'end': 569}, {'entity': 'tumours', 'type': 'Disease', 'start': 292, 'end': 299}]\n",
            "['Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial\\tIn immunologically naive patients whole-virus vaccine produced better responses than subunit vaccine.', 'Two doses of subunit or whole virus vaccine would leave a large proportion of the naive population (⩽32 years) unprotected against A/Hong Kong/1073/99 (H9N2).', 'Primed patients should be protected with a single dose of either vaccine.']\n",
            "unmatched tags:  [{'entity': 'vaccine', 'type': 'Drug', 'start': 466, 'end': 473}]\n",
            "['Evidence for influenza B virus hemagglutinin adaptation to the human host: high cleavability, acid-stability and preference for cool temperature\\tInfluenza A virus (IAV) and influenza B virus (IBV) cause yearly epidemics with significant morbidity and mortality.', 'When zoonotic IAVs enter the human population, the viral hemagglutinin (HA) requires adaptation to achieve sustained virus transmission.', 'In contrast, IBV has been circulating in humans, its only host, for a long period of time.', 'Whether this entailed adaptation of IBV HA to the human airways is unknown.', 'To address this question, we compared seasonal IAV (A/H1N1 and A/H3N2) and IBV viruses (B/Victoria and B/Yamagata lineage) with regard to host-dependent activity of HA as the mediator of membrane fusion during viral entry.', 'We first investigated proteolytic activation of HA, by covering all type II transmembrane serine protease (TTSP) and kallikrein enzymes, many of which proved present in human respiratory epithelium.', 'Compared to IAV, the IBV HA0 precursor is cleaved by a broader panel of TTSPs and activated with much higher efficiency.', 'Accordingly, knockdown of a single protease, TMPRSS2, was sufficient to abrogate spread of IAV but not IBV in human respiratory epithelial cells.', 'Second, the HA fusion pH proved similar for IBV and human-adapted IAVs (one exception being HA of 1918 IAV).', 'Third, IBV HA exhibited higher expression at 33°C, a temperature required for membrane fusion by B/Victoria HA.', 'This indicates pronounced adaptation of IBV HA to the mildly acidic pH and cooler temperature of human upper airways.', 'These distinct and intrinsic features of IBV HA are compatible with extensive host-adaptation during prolonged circulation of this respiratory virus in the human population.', 'Importance Influenza epidemics are caused by influenza A (IAV) and influenza B (IBV) viruses.', 'IBV causes substantial disease, however it is far less studied than IAV.', 'While IAV originates from animal reservoirs, IBV circulates in humans only.', 'Virus spread requires that the viral hemagglutinin (HA) is active and sufficiently stable in human airways.', 'We here resolve how these mechanisms differ between IBV and IAV.', 'Whereas human IAVs rely on one particular protease for HA activation, this is not the case for IBV.', 'Superior activation of IBV by several proteases should enhance shedding of infectious particles.', 'IBV HA exhibits acid-stability and a preference for 33°C, indicating pronounced adaptation to the human upper airways, where the pH is mildly acidic and a cooler temperature exists.', 'These adaptive features are rationalized by the long existence of IBV in humans, and may have broader relevance for understanding the biology and evolution of respiratory viruses.']\n",
            "unmatched tags:  [{'entity': 'respiratory viruses', 'type': 'Virus', 'start': 2722, 'end': 2741}, {'entity': 'IBV', 'type': 'Gene', 'start': 2629, 'end': 2632}, {'entity': 'acidic', 'type': 'Chemical', 'start': 2523, 'end': 2529}, {'entity': 'HA', 'type': 'Gene', 'start': 2385, 'end': 2387}, {'entity': 'IBV', 'type': 'Gene', 'start': 2381, 'end': 2384}, {'entity': 'infectious particles', 'type': 'Gene', 'start': 2359, 'end': 2379}, {'entity': 'proteases', 'type': 'Gene', 'start': 2322, 'end': 2331}, {'entity': 'IBV', 'type': 'Gene', 'start': 2307, 'end': 2310}, {'entity': 'IBV', 'type': 'Gene', 'start': 2279, 'end': 2282}, {'entity': 'HA', 'type': 'Gene', 'start': 2239, 'end': 2241}, {'entity': 'protease', 'type': 'Gene', 'start': 2226, 'end': 2234}, {'entity': 'IAVs', 'type': 'Chemical', 'start': 2198, 'end': 2202}, {'entity': 'IAV', 'type': 'Organization', 'start': 2179, 'end': 2182}, {'entity': 'IBV', 'type': 'Gene', 'start': 2171, 'end': 2174}, {'entity': 'HA', 'type': 'Gene', 'start': 2063, 'end': 2065}, {'entity': 'IBV', 'type': 'Gene', 'start': 1980, 'end': 1983}, {'entity': 'IAV', 'type': 'Organization', 'start': 1941, 'end': 1944}, {'entity': 'IAV', 'type': 'Organization', 'start': 1930, 'end': 1933}, {'entity': 'IBV', 'type': 'Gene', 'start': 1862, 'end': 1865}, {'entity': 'IBV', 'type': 'Gene', 'start': 1848, 'end': 1851}, {'entity': 'influenza B', 'type': 'Disease', 'start': 1835, 'end': 1846}, {'entity': 'IAV', 'type': 'Organization', 'start': 1826, 'end': 1829}, {'entity': 'influenza A', 'type': 'Drug', 'start': 1813, 'end': 1824}, {'entity': 'Influenza epidemics', 'type': 'Disease', 'start': 1779, 'end': 1798}, {'entity': 'respiratory virus', 'type': 'Virus', 'start': 1725, 'end': 1742}, {'entity': 'HA', 'type': 'Gene', 'start': 1639, 'end': 1641}, {'entity': 'IBV', 'type': 'Gene', 'start': 1635, 'end': 1638}, {'entity': 'acidic', 'type': 'Chemical', 'start': 1537, 'end': 1543}, {'entity': 'HA', 'type': 'Gene', 'start': 1520, 'end': 1522}, {'entity': 'IBV', 'type': 'Gene', 'start': 1516, 'end': 1519}, {'entity': 'HA', 'type': 'Gene', 'start': 1472, 'end': 1474}, {'entity': 'HA', 'type': 'Gene', 'start': 1375, 'end': 1377}, {'entity': 'IBV', 'type': 'Gene', 'start': 1371, 'end': 1374}, {'entity': 'IAV', 'type': 'Organization', 'start': 1358, 'end': 1361}, {'entity': 'HA', 'type': 'Gene', 'start': 1347, 'end': 1349}, {'entity': 'IAVs', 'type': 'Chemical', 'start': 1321, 'end': 1325}, {'entity': 'IBV', 'type': 'Gene', 'start': 1299, 'end': 1302}, {'entity': 'HA', 'type': 'Gene', 'start': 1267, 'end': 1269}, {'entity': 'IBV', 'type': 'Gene', 'start': 1212, 'end': 1215}, {'entity': 'IAV', 'type': 'Organization', 'start': 1200, 'end': 1203}, {'entity': 'TMPRSS2', 'type': 'Gene', 'start': 1154, 'end': 1161}, {'entity': 'protease', 'type': 'Gene', 'start': 1144, 'end': 1152}, {'entity': 'TTSPs', 'type': 'Gene', 'start': 1060, 'end': 1065}, {'entity': 'HA', 'type': 'Gene', 'start': 1013, 'end': 1015}, {'entity': 'IBV', 'type': 'Gene', 'start': 1009, 'end': 1012}, {'entity': 'IAV', 'type': 'Organization', 'start': 1000, 'end': 1003}, {'entity': 'enzymes', 'type': 'Gene', 'start': 917, 'end': 924}, {'entity': 'kallikrein', 'type': 'Gene', 'start': 906, 'end': 916}]\n",
            "['A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV\\tThe outbreak of COVID-19, which is caused by SARS-CoV-2 virus, continues to spread globally, but there is currently very little understanding of the epitopes on the virus.', 'In this study, we have determined the crystal structure of the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein in complex with CR3022, a neutralizing antibody previously isolated from a convalescent SARS patient.', 'CR3022 targets a highly conserved epitope that enables cross-reactive binding between SARS-CoV-2 and SARS-CoV.', 'Structural modeling further demonstrates that the binding site can only be accessed when at least two RBDs on the trimeric S protein are in the “up” conformation.', 'Overall, this study provides structural and molecular insight into the antigenicity of SARS-CoV-2.', 'ONE SENTENCE SUMMARY Structural study of a cross-reactive SARS antibody reveals a conserved epitope on the SARS-CoV-2 receptor-binding domain.']\n",
            "unmatched tags:  [{'entity': 'receptor-binding domain', 'type': 'Gene', 'start': 988, 'end': 1011}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 977, 'end': 987}, {'entity': 'SARS', 'type': 'Disease', 'start': 928, 'end': 932}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 858, 'end': 868}, {'entity': 'RBDs', 'type': 'Gene', 'start': 710, 'end': 714}, {'entity': 'SARS-CoV.', 'type': 'Virus', 'start': 598, 'end': 607}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 583, 'end': 593}, {'entity': 'CR3022', 'type': 'Gene', 'start': 497, 'end': 503}, {'entity': 'SARS', 'type': 'Disease', 'start': 483, 'end': 487}, {'entity': 'neutralizing antibody', 'type': 'Gene', 'start': 421, 'end': 442}, {'entity': 'CR3022', 'type': 'Gene', 'start': 411, 'end': 417}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 366, 'end': 376}, {'entity': 'RBD', 'type': 'Gene', 'start': 354, 'end': 357}, {'entity': 'receptor-binding domain', 'type': 'Gene', 'start': 329, 'end': 352}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 139, 'end': 149}]\n",
            "['Variation in Aerosol Production Across Oxygen Delivery Devices in Spontaneously Breathing Human Subjects\\tWe sought to assess whether HHFNC results in greater production of aerosolized particles than 6 liters per minute nasal cannula, using state-of-the-art techniques of aerosol measurement, in spontaneously breathing human volunteers in a simulated hospital room.', 'For each volunteer, we first measured background aerosol levels in the room immediately prior to testing.', 'We then measured aerosol levels while the healthy volunteer laid in bed - - with the head of bed at 30 degrees - - wearing the following oxygen delivery devices: (a) 6L/min nasal canula (NC) with humidification; (b) non-re-breather mask (NRB) with 15L/min gas flow, non-humidified; (c) HHFNC with 30L/min gas flow; (d) HHFNC with 60L/min gas flow.', 'Two scanning mobility particle sizing (SMPS) systems (TSI 3080/3030, TSI 3080/3750) were used to measure aerosols 10 to 500 nanometer (nm) in size for each of the oxygen delivery devices.', 'There was no variation in aerosol level within patients between room air, 6 L/min NC, 15 L/min NRB, 30 L/min HHFNC, and 60 L/min HHFNC, regardless of coughing.']\n",
            "unmatched tags:  [{'entity': 'coughing', 'type': 'Phenotype', 'start': 1161, 'end': 1169}, {'entity': 'NC', 'type': 'Gene', 'start': 1143, 'end': 1145}, {'entity': 'NC', 'type': 'Gene', 'start': 1123, 'end': 1125}, {'entity': 'NC', 'type': 'Gene', 'start': 1093, 'end': 1095}, {'entity': 'TSI', 'type': 'Gene', 'start': 890, 'end': 893}, {'entity': 'TSI', 'type': 'Gene', 'start': 875, 'end': 878}, {'entity': 'NC', 'type': 'Gene', 'start': 795, 'end': 797}, {'entity': 'NC', 'type': 'Gene', 'start': 762, 'end': 764}, {'entity': 'NC', 'type': 'Gene', 'start': 660, 'end': 662}, {'entity': 'bed', 'type': 'Disease', 'start': 566, 'end': 569}, {'entity': 'bed', 'type': 'Disease', 'start': 541, 'end': 544}]\n",
            "['Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015\\tSeveral challenges to improving reproductive health lie ahead in the SDG era.', 'Countries should establish or renew systems for collection and timely dissemination of health data; expand coverage and improve quality of family planning services, including access to contraception and safe abortion to address high adolescent fertility; invest in improving health system capacity, including coverage of routine reproductive health care and of more advanced obstetric care—including EmOC; adapt health systems and data collection systems to monitor and reverse the increase in indirect, other direct, and late maternal deaths, especially in high SDI locations; and examine their own performance with respect to their SDI level, using that information to formulate strategies to improve performance and ensure optimum reproductive health of their population.']\n",
            "unmatched tags:  [{'entity': 'era', 'type': 'Gene', 'start': 528, 'end': 531}, {'entity': 'era', 'type': 'Gene', 'start': 326, 'end': 329}]\n",
            "['Occult hepatitis B\\tWorldwide, chronic hepatitis B virus (HBV) infection is the primary cause of cirrhosis and hepatocellular carcinoma and is one of the ten leading causes of death.', 'Traditionally, people with chronic HBV infection have been identified with blood tests for HBV antigens and antibodies.', 'Recently, another group of patients with chronic HBV infection has been identified by sensitive, molecular testing for HBV DNA.', 'Members of this group are often referred to as having occult hepatitis B because they are HBV-DNA positive, but hepatitis B surface antigen negative.']\n",
            "unmatched tags:  [{'entity': 'hepatitis B surface antigen', 'type': 'Disease', 'start': 542, 'end': 569}, {'entity': 'HBV-DNA', 'type': 'Gene', 'start': 520, 'end': 527}]\n",
            "['Low plasma arginine concentrations in children with cerebral malaria and decreased nitric oxide production\\tNitric oxide (NO) production and mononuclear cell NO synthase 2 (NOS2) expression are high in healthy Tanzanian children but low in those with cerebral malaria.', 'Factors that downregulate NOS2 also diminish factors involved in cellular uptake and biosynthesis of L-arginine, the substrate for NO synthesis.', 'We therefore postulated that L-arginine concentrations would be low in individuals with cerebral malaria.', 'We measured concentrations of L-arginine in cryopreserved plasma samples from Tanzanian children with and without malaria.']\n",
            "unmatched tags:  [{'entity': 'malaria', 'type': 'Disease', 'start': 633, 'end': 640}, {'entity': 'L-arginine', 'type': 'Gene', 'start': 549, 'end': 559}, {'entity': 'cerebral malaria', 'type': 'Disease', 'start': 501, 'end': 517}, {'entity': 'arginine', 'type': 'Gene', 'start': 444, 'end': 452}, {'entity': 'L-arginine', 'type': 'Gene', 'start': 442, 'end': 452}, {'entity': 'L-arginine', 'type': 'Gene', 'start': 369, 'end': 379}]\n",
            "['Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study\\tBackground: Hydroxychloroquine has recently received Emergency Use Authorization by the FDA and is currently prescribed in combination with azithromycin for COVID-19 pneumonia.', 'We studied the safety of hydroxychloroquine, alone and in combination with azithromycin.', 'Methods: New user cohort studies were conducted including 16 severe adverse events (SAEs).', 'Rheumatoid arthritis patients aged 18+ and initiating hydroxychloroquine were compared to those initiating sulfasalazine and followed up over 30 days.', 'Self-controlled case series (SCCS) were conducted to further establish safety in wider populations.', 'Separately, SAEs associated with hydroxychloroquine-azithromycin (compared to hydroxychloroquine-amoxicillin) were studied.', 'Data comprised 14 sources of claims data or electronic medical records from Germany, Japan, Netherlands, Spain, UK, and USA.', 'Propensity score stratification and calibration using negative control outcomes were used to address confounding.', 'Cox models were fitted to estimate calibrated hazard ratios (CalHRs) according to drug use.', 'Estimates were pooled where I2<40%.', 'Results: Overall, 956,374 and 310,350 users of hydroxychloroquine and sulfasalazine, and 323,122 and 351,956 users of hydroxychloroquine-azithromycin and hydroxychloroquine-amoxicillin were included.', 'No excess risk of SAEs was identified when 30-day hydroxychloroquine and sulfasalazine use were compared.', 'SCCS confirmed these findings.', 'However, when azithromycin was added to hydroxychloroquine, we observed an increased risk of 30-day cardiovascular mortality (CalHR2.19 [1.22-3.94]), chest pain/angina (CalHR 1.15 [95% CI 1.05-1.26]), and heart failure (CalHR 1.22 [95% CI 1.02-1.45])  Conclusions: Short-term hydroxychloroquine treatment is safe, but addition of azithromycin may induce heart failure and cardiovascular mortality, potentially due to synergistic effects on QT length.', 'We call for caution if such combination is to be used in the management of Covid-19.']\n",
            "unmatched tags:  [{'entity': 'Covid-19', 'type': 'Disease', 'start': 2157, 'end': 2165}, {'entity': 'heart failure', 'type': 'Phenotype', 'start': 1985, 'end': 1998}, {'entity': 'azithromycin', 'type': 'Drug', 'start': 1961, 'end': 1973}, {'entity': 'hydroxychloroquine', 'type': 'Drug', 'start': 1907, 'end': 1925}, {'entity': 'heart failure', 'type': 'Phenotype', 'start': 1836, 'end': 1849}, {'entity': 'hydroxychloroquine', 'type': 'Drug', 'start': 1671, 'end': 1689}, {'entity': 'azithromycin', 'type': 'Drug', 'start': 1645, 'end': 1657}, {'entity': 'sulfasalazine', 'type': 'Drug', 'start': 1567, 'end': 1580}, {'entity': 'hydroxychloroquine', 'type': 'Drug', 'start': 1544, 'end': 1562}]\n",
            "['Tension-type headache: current research and clinical management\\tTension-type headache (TTH) is the most common form of headache, and chronic tension-type headache (CTTH) is one of the most neglected and difficult types of headache to treat.', 'The pathogenesis of TTH is multifactorial and varies between forms and individuals.', 'Peripheral mechanisms (myofascial nociception) and central mechanisms (sensitisation and inadequate endogenous pain control) are intermingled: the former predominate in infrequent and frequent TTH, whereas the latter predominate in CTTH.', 'Acute therapy is effective for episodes of TTH, whereas preventive treatment—which is indicated for frequent and chronic TTH—is, on average, not effective.']\n",
            "unmatched tags:  [{'entity': 'TTH', 'type': 'Organization', 'start': 684, 'end': 687}, {'entity': 'TTH', 'type': 'Organization', 'start': 606, 'end': 609}, {'entity': 'TTH', 'type': 'Organization', 'start': 558, 'end': 561}, {'entity': 'TTH', 'type': 'Organization', 'start': 518, 'end': 521}, {'entity': 'TTH', 'type': 'Organization', 'start': 261, 'end': 264}, {'entity': 'headache', 'type': 'Phenotype', 'start': 222, 'end': 230}, {'entity': 'TTH', 'type': 'Organization', 'start': 165, 'end': 168}, {'entity': 'chronic tension-type headache', 'type': 'Disease', 'start': 133, 'end': 162}]\n",
            "['Poststroke dementia\\tDementia is one of the major causes of dependency after stroke.', 'The prevalence of poststroke dementia (PSD)—defined as any dementia occurring after stroke—is likely to increase in the future.', 'In community-based studies, the prevalence of PSD in stroke survivors is about 30% and the incidence of new onset dementia after stroke increases from 7% after 1 year 48% after 25 years.', 'Having a stroke doubles the risk of dementia.', 'Patient-related variables associated with an increased risk of PSD are increasing age, low education level, dependency before stroke, prestroke cognitive decline without dementia, diabetes mellitus, atrial fibrillation, myocardial infarction, epileptic seizures, sepsis, cardiac arrhythmias, congestive heart failure, silent cerebral infarcts, global and medial-temporal-lobe atrophy, and white-matter changes.']\n",
            "unmatched tags:  [{'entity': 'silent cerebral infarcts', 'type': 'Disease', 'start': 763, 'end': 787}, {'entity': 'congestive heart failure', 'type': 'Disease', 'start': 737, 'end': 761}, {'entity': 'sepsis', 'type': 'Disease', 'start': 708, 'end': 714}, {'entity': 'epileptic seizures', 'type': 'Disease', 'start': 688, 'end': 706}, {'entity': 'myocardial infarction', 'type': 'Disease', 'start': 665, 'end': 686}, {'entity': 'diabetes mellitus', 'type': 'Disease', 'start': 625, 'end': 642}, {'entity': 'dementia', 'type': 'Disease', 'start': 615, 'end': 623}, {'entity': 'prestroke', 'type': 'Disease', 'start': 579, 'end': 588}, {'entity': 'stroke', 'type': 'Disease', 'start': 571, 'end': 577}, {'entity': 'PSD', 'type': 'Gene', 'start': 508, 'end': 511}, {'entity': 'dementia', 'type': 'Disease', 'start': 435, 'end': 443}, {'entity': 'stroke', 'type': 'Disease', 'start': 408, 'end': 414}, {'entity': 'stroke', 'type': 'Disease', 'start': 341, 'end': 347}, {'entity': 'dementia', 'type': 'Disease', 'start': 326, 'end': 334}, {'entity': 'stroke', 'type': 'Disease', 'start': 265, 'end': 271}, {'entity': 'PSD', 'type': 'Gene', 'start': 258, 'end': 261}, {'entity': 'stroke', 'type': 'Disease', 'start': 168, 'end': 174}, {'entity': 'dementia', 'type': 'Disease', 'start': 143, 'end': 151}, {'entity': 'PSD', 'type': 'Gene', 'start': 123, 'end': 126}, {'entity': 'dementia', 'type': 'Disease', 'start': 113, 'end': 121}, {'entity': 'stroke', 'type': 'Disease', 'start': 106, 'end': 112}, {'entity': 'stroke', 'type': 'Disease', 'start': 76, 'end': 82}]\n",
            "['Advances in oral immunomodulating therapies in relapsing multiple sclerosis\\tOral treatment options for disease-modifying therapy in relapsing multiple sclerosis have substantially increased over the past decade with four approved oral compounds now available: fingolimod, dimethyl fumarate, teriflunomide, and cladribine.', 'Although these immunomodulating therapies are all orally administered, and thus convenient for patients, they have different modes of action.', 'These distinct mechanisms of action allow better adaption of treatments according to individual comorbidities and offer different mechanisms of treatment such as inhibition of immune cell trafficking versus immune cell depletion, thereby substantially expanding the available treatment options.']\n",
            "unmatched tags:  [{'entity': 'cladribine', 'type': 'Gene', 'start': 310, 'end': 320}, {'entity': 'teriflunomide', 'type': 'Drug', 'start': 291, 'end': 304}, {'entity': 'dimethyl fumarate', 'type': 'Drug', 'start': 272, 'end': 289}, {'entity': 'fingolimod', 'type': 'Drug', 'start': 260, 'end': 270}, {'entity': 'oral compounds', 'type': 'Drug', 'start': 230, 'end': 244}]\n",
            "['Causes of massive tropical splenomegaly in Ghana\\tB-lymphoproliferative disorders are a previously unrecognised cause of massive tropical splenomegaly.', 'This finding has major implications for management of massive splenomegaly.', 'Diagnosis of the less common causes of this disorder is usually straightforward, but differentiating between B-lymphoproliferative disorders and HMS can be difficult.', 'HMS is associated with younger age, a higher proportion of women, and lower absolute lymphocyte counts than lymphoproliferative disorders.']\n",
            "unmatched tags:  [{'entity': 'lymphoproliferative disorders', 'type': 'Disease', 'start': 502, 'end': 531}, {'entity': 'younger age', 'type': 'Gene', 'start': 417, 'end': 428}, {'entity': 'HMS', 'type': 'Disease', 'start': 394, 'end': 397}]\n",
            "['New genes in inflammatory bowel disease: lessons for complex diseases?', \"The chronic inflammatory bowel diseases Crohn's disease and ulcerative colitis are common causes of gastrointestinal disease in northern Europe, affecting as many as one in 250 people.\", 'Although mortality is low, morbidity associated with these diseases is substantial.', 'We review the recent advances in the genetics of inflammatory bowel disease, with particular emphasis on the data that have been generated since the discovery of the']\n",
            "unmatched tags:  [{'entity': 'inflammatory bowel disease', 'type': 'Disease', 'start': 389, 'end': 415}, {'entity': 'diseases', 'type': 'Disease', 'start': 315, 'end': 323}, {'entity': 'gastrointestinal disease', 'type': 'Disease', 'start': 171, 'end': 195}, {'entity': 'ulcerative colitis', 'type': 'Disease', 'start': 131, 'end': 149}]\n",
            "['Difficulties and strategies of HIV diagnosis\\tHIV infection is commonly diagnosed by detection of antibodies (anti-HIV) by ELISA or agglutination.', 'Reactive results are confirmed by western blot (immunoblot) or further specific tests such as competitive ELISA, which, when evaluated quantitatively, allow the differentiation of HIV types and partially subtypes.', 'Detection of infection of newborn babies, characterisation of individual strains for subtyping and forensic identification, and therapeutic monitoring are the domain of nucleic-acid-based assays.']\n",
            "unmatched tags:  [{'entity': 'strains', 'type': 'Disease', 'start': 433, 'end': 440}]\n",
            "['Fetal HLA typing in β thalassaemia: implications for haemopoietic stem-cell transplantation\\tStem-cell transplantation can cure β thalassaemia.', 'We aimed to assess whether fetal HLA typing done early in the pregnancy of couples who were at risk of β thalassaemia could provide an alternative to pregnancy termination if the prospect of a bone-marrow transplantation from a family member was available.', 'In our clinic in Sardinia, we did fetal HLA typing for 49 couples at risk of having a baby with β thalassaemia.', 'Two affected children were born and successfully received a transplantation from a family donor.']\n",
            "unmatched tags:  [{'entity': 'thalassaemia', 'type': 'Disease', 'start': 498, 'end': 510}]\n",
            "['Primary nervous-system lymphoma\\tPrimary nervous-system lymphoma is a rare type of non-Hodgkin lymphoma, which is confined to the nervous system.', 'This disease is managed quite differently from the usual treatment of either primary brain tumours or systemic non-Hodgkin lymphoma.', 'Although whole-brain radiotherapy results in responses in more than 90% of cases, this treatment is associated with high relapse rates and with delayed neurotoxicity in elderly patients.', 'Firstgeneration chemotherapy regimens used successfully in systemic non-Hodgkin lymphoma (eg cyclophosphamide, adriamycin, vincristine, and prednisone) are ineffective in primary nervoussystem lymphoma, partly because of the blood–brain barrier.']\n",
            "unmatched tags:  [{'entity': 'primary nervoussystem lymphoma', 'type': 'Disease', 'start': 636, 'end': 666}, {'entity': 'prednisone', 'type': 'Drug', 'start': 605, 'end': 615}, {'entity': 'vincristine', 'type': 'Drug', 'start': 588, 'end': 599}, {'entity': 'adriamycin', 'type': 'Drug', 'start': 576, 'end': 586}, {'entity': 'cyclophosphamide', 'type': 'Drug', 'start': 558, 'end': 574}]\n",
            "['Advances in technology for management of type 1 diabetes\\tTechnological advances have had a major effect on the management of type 1 diabetes.', 'In addition to blood glucose meters, devices used by people with type 1 diabetes include insulin pumps, continuous glucose monitors, and, most recently, systems that combine both a pump and a monitor for algorithm-driven automation of insulin delivery.', 'In the next 5 years, as many advances are expected in technology for the management of diabetes as there have been in the past 5 years, with improvements in continuous glucose monitoring and more available choices of systems that automate insulin delivery.']\n",
            "unmatched tags:  [{'entity': 'diabetes', 'type': 'Disease', 'start': 482, 'end': 490}]\n",
            "['Worldwide application of prevention science in adolescent health\\tThe burden of morbidity and mortality from non-communicable disease has risen worldwide and is accelerating in low-income and middle-income countries, whereas the burden from infectious diseases has declined.', 'Since this transition, the prevention of non-communicable disease as well as communicable disease causes of adolescent mortality has risen in importance.', 'Problem behaviours that increase the short-term or long-term likelihood of morbidity and mortality, including alcohol, tobacco, and other drug misuse, mental health problems, unsafe sex, risky and unsafe driving, and violence are largely preventable.']\n",
            "unmatched tags:  [{'entity': 'violence', 'type': 'Disease', 'start': 645, 'end': 653}, {'entity': 'risky', 'type': 'Gene', 'start': 615, 'end': 620}, {'entity': 'alcohol', 'type': 'Drug', 'start': 538, 'end': 545}, {'entity': 'Problem behaviours', 'type': 'Disease', 'start': 428, 'end': 446}, {'entity': 'risen', 'type': 'Drug', 'start': 407, 'end': 412}]\n",
            "['Genetic predisposition to testicular germ-cell tumours\\tTesticular germ-cell tumours (TGCT) are the most common neoplasm in young men.', 'Various studies have suggested the existence of an inherited predisposition to development of these tumours.', 'Genome-wide screens subsequently provided evidence of a TGCT susceptibility gene on chromosome Xq27 (']\n",
            "unmatched tags:  [{'entity': 'chromosome Xq27', 'type': 'Disease', 'start': 327, 'end': 342}, {'entity': 'susceptibility gene', 'type': 'Gene', 'start': 304, 'end': 323}, {'entity': 'TGCT', 'type': 'Disease', 'start': 299, 'end': 303}, {'entity': 'tumours', 'type': 'Disease', 'start': 234, 'end': 241}, {'entity': 'young men', 'type': 'Chemical', 'start': 123, 'end': 132}]\n",
            "['Towards metabolic biomarkers of insulin resistance and type 2 diabetes: progress from the metabolome\\tThe complex aetiology of type 2 diabetes makes effective screening, diagnosis and prognosis a substantial challenge for the physician.', 'The rapidly developing area of metabolomics, which uses analytical techniques such as mass spectrometry and nuclear magnetic resonance, has emerged as a promising approach to identify biomarkers of diabetes and the insulin-resistant state that precedes overt pathology.', 'Initial successes with metabolomic studies have indicated potential biomarkers for insulin resistance and for identifying people at risk of developing diabetes, with particular focus on aminoacids and lipid metabolism.']\n",
            "unmatched tags:  [{'entity': 'aminoacids', 'type': 'Gene', 'start': 692, 'end': 702}, {'entity': 'diabetes', 'type': 'Disease', 'start': 657, 'end': 665}]\n",
            "['Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review\\tTuberculosis continues to kill 1·4 million people annually.', 'During the past 5 years, an alarming increase in the number of patients with multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis has been noted, particularly in eastern Europe, Asia, and southern Africa.', 'Treatment outcomes with available treatment regimens for drug-resistant tuberculosis are poor.', 'Although substantial progress in drug development for tuberculosis has been made, scientific progress towards development of interventions for prevention and improvement of drug treatment outcomes have lagged behind.']\n",
            "unmatched tags:  [{'entity': 'tuberculosis', 'type': 'Disease', 'start': 537, 'end': 549}]\n",
            "['The legal determinants of health: harnessing the power of law for global health and sustainable development\\tHealth risks in the 21st century are beyond the control of any government in any country.', 'In an era of globalisation, promoting public health and equity requires cooperation and coordination both within and among states.', 'Law can be a powerful tool for advancing global health, yet it remains substantially underutilised and poorly understood.', \"Working in partnership, public health lawyers and health professionals can become champions for evidence-based laws to ensure the public's health and safety.\"]\n",
            "unmatched tags:  [{'entity': 'public health lawyers', 'type': 'Gene', 'start': 475, 'end': 496}, {'entity': 'partnership', 'type': 'Organization', 'start': 462, 'end': 473}]\n",
            "['Omsk haemorrhagic fever\\tOmsk haemorrhagic fever is an acute viral disease prevalent in some regions of western Siberia in Russia.', 'The symptoms of this disease include fever, headache, nausea, severe muscle pain, cough, and moderately severe haemorrhagic manifestations.', 'A third of patients develop pneumonia, nephrosis, meningitis, or a combination of these complications.', 'The only treatments available are for control of symptoms.', 'No specific vaccine has been developed, although the vaccine against tick-borne encephalitis might provide a degree of protection against Omsk haemorrhagic fever virus.']\n",
            "unmatched tags:  [{'entity': 'Omsk haemorrhagic fever virus', 'type': 'Virus', 'start': 570, 'end': 599}, {'entity': 'tick-borne encephalitis', 'type': 'Disease', 'start': 501, 'end': 524}, {'entity': 'vaccine', 'type': 'Drug', 'start': 485, 'end': 492}, {'entity': 'vaccine', 'type': 'Drug', 'start': 444, 'end': 451}, {'entity': 'meningitis', 'type': 'Phenotype', 'start': 320, 'end': 330}, {'entity': 'nephrosis', 'type': 'Disease', 'start': 309, 'end': 318}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 298, 'end': 307}, {'entity': 'cough', 'type': 'Phenotype', 'start': 212, 'end': 217}, {'entity': 'muscle pain', 'type': 'Phenotype', 'start': 199, 'end': 210}, {'entity': 'nausea', 'type': 'Phenotype', 'start': 184, 'end': 190}, {'entity': 'headache', 'type': 'Phenotype', 'start': 174, 'end': 182}, {'entity': 'fever', 'type': 'Phenotype', 'start': 167, 'end': 172}]\n",
            "['Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)\\tProgression-free survival with IRIS is not inferior to that with FOLFIRI in patients receiving second-line chemotherapy for metastatic colorectal cancer.', 'Treatment with IRIS could be an additional therapeutic option for second-line chemotherapy in metastatic colorectal cancer.']\n",
            "unmatched tags:  [{'entity': 'metastatic colorectal cancer', 'type': 'Disease', 'start': 459, 'end': 487}]\n",
            "['Pulmonary sarcoidosis\\tSarcoidosis is a granulomatous disease of unknown cause, occurs worldwide and has a highly variable prevalence.', 'The disease is typically dominant in the lungs, although it can affect virtually any organ and is unpredictable in its clinical course.', 'The severity of pulmonary sarcoidosis ranges from incidentally discovered radiographic abnormalities in asymptomatic patients to a chronic progressive disease that is refractory to treatment.', 'Mortality from sarcoidosis appears to have increased in the past three decades, with respiratory failure being the most common cause of sarcoidosis-related death.']\n",
            "unmatched tags:  [{'entity': 'respiratory failure', 'type': 'Disease', 'start': 547, 'end': 566}, {'entity': 'sarcoidosis', 'type': 'Disease', 'start': 477, 'end': 488}]\n",
            "['Association of inflammatory markers with the severity of COVID-19\\tBackground: The ongoing worldwide epidemic of Coronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has posed a huge threat to global public health.', 'However, with regard to the effects of inflammatory markers on the severity of COVID-19, studies have reported associations that vary in strength and direction.', 'Aims: In the meta-analysis, we aimed to provide an overview of the association of inflammatory markers with severity of COVID-19.', 'Methods: The following databases were searched: PubMed, Embase, Cochrane Library, Wanfang database and CNKI (China National Knowledge Infrastructure) database until March 20, 2020.', 'Weighted mean difference (WMD) and 95% confidence intervals (CIs) were pooled using random or fixed-effects models.', 'Results: A total of 16 studies were included in our analysis comprising of 3962 patients with COVID-19.', 'Random-effects results demonstrated that patients with COVID-19 in non-severe group had lower levels for CRP (WMD\\u2009=\\u2009-41.78\\u2009mg/l, 95% CI\\u2009=\\u2009[-52.43, -31.13], P\\u2009<\\u20090.001), PCT (WMD\\u2009=\\u2009-0.13\\u2009ng/ml, 95% CI\\u2009=\\u2009[-0.20, -0.05], P\\u2009<\\u20090.001), IL-6 (WMD\\u2009=\\u2009-21.32\\u2009ng/l, 95% CI\\u2009=\\u2009[-28.34, -14.31], P\\u2009<\\u20090.001), ESR (WMD\\u2009=\\u2009-8.40\\u2009mm/h, 95% CI\\u2009=\\u2009[-14.32, -2.48], P\\u2009=\\u20090.005), SAA (WMD\\u2009=\\u2009-43.35 μg/ml, 95% CI\\u2009=\\u2009[-80.85, -5.85], P\\u2009=\\u20090.020) and serum ferritin (WMD\\u2009=\\u2009-398.80\\u2009mg/l, 95% CI\\u2009=\\u2009[-625.89, -171.71], P\\u2009<\\u20090.001), compared with those in severe group.', 'Moreover, survivors had lower level for IL-6 than non-survivors with COVID-19 (WMD\\u2009=\\u2009-4.80\\u2009ng/ml, 95% CI\\u2009=\\u2009[-5.87, -3.73], P\\u2009<\\u20090.001).', 'These results were consistent through sensitivity analysis and publication bias assessment.', 'Conclusions: The meta-analysis highlights the association of inflammatory markers with the severity of COVID-19.', 'Measurement of inflammatory markers might help clinicians to monitor and evaluate the severity and prognosis of COVID-19.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 1951, 'end': 1959}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1829, 'end': 1837}, {'entity': 'WMD', 'type': 'Gene', 'start': 1577, 'end': 1580}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1567, 'end': 1575}, {'entity': 'IL-6', 'type': 'Gene', 'start': 1538, 'end': 1542}, {'entity': 'WMD', 'type': 'Gene', 'start': 1400, 'end': 1403}, {'entity': 'WMD', 'type': 'Gene', 'start': 1323, 'end': 1326}]\n",
            "['Common mental disorders in postconflict settings\\tResearch into postconflict psychiatric sequelae in low-income countries has been focused largely on symptoms rather than on full psychiatric diagnostic assessment.', 'We assessed 3048 respondents from postconflict communities in Algeria, Cambodia, Ethiopia, and Palestine with the aim of establishing the prevalence of mood disorder, somatoform disorder, post-traumatic stress disorder (PTSD), and other anxiety disorders.', 'PTSD and other anxiety disorders were the most frequent problems.', 'In three countries, PTSD was the most likely disorder in individuals exposed to violence associated with armed conflict, but such violence was a common risk factor for various disorders and comorbidity combinations in different settings.']\n",
            "unmatched tags:  [{'entity': 'disorders', 'type': 'Disease', 'start': 711, 'end': 720}, {'entity': 'violence', 'type': 'Disease', 'start': 665, 'end': 673}, {'entity': 'violence', 'type': 'Disease', 'start': 615, 'end': 623}, {'entity': 'PTSD', 'type': 'Disease', 'start': 555, 'end': 559}]\n",
            "['A consideration of publication-derived immune-related associations in Coronavirus and related lung damaging diseases\\tThe severe acute respiratory syndrome virus SARS-CoV-2, a close\\trelative of the SARS-CoV virus, is the cause of recent COVID-19 pandemic affecting, to date, over a 2 million individuals across the globe and demonstrating relatively high rates of infection and mortality.', 'A third virus, the H5N1, responsible for avian influenza, has caused infection with some clinical similarities to those in COVID-19 infections.', 'Cytokines, small proteins that modulate immune responses, have been directly implicated in some of the severe responses seen in COVID-19 patients, e.g.', 'cytokine storms.', 'Understanding the immune processes related to COVID-19, and other similar infections, could help identify diagnostic markers and therapeutic targets.', 'Here we examine data of cytokine, immune cell types, and disease associations captured from biomedical literature associated with coronavirus, SARS, and H5N1 influenza, with the objective of identifying potentially useful relationships and areas for future research.', 'Cytokine and cell-type associations captured from MeSH terms linked to thousands of PubMed abstracts, has identified differing patterns of associations between the three corpuses of abstracts (coronavirus, SARS, or H5N1 influenza).', 'Clustering of cytokine-disease co-occurrences in the context of coronavirus has identified compelling clusters of co-morbidities and symptoms, some of which already known to be linked to COVID-19.', 'Finally, network analysis identified sub-networks of cytokines and immune cell types associated with different manifestations, co-morbidities and symptoms of coronavirus, SARS, and H5N1.', 'Systematic review of research in medicine is essential to facilitate evidence-based choices about health interventions.', 'In a fast moving pandemic the approach taken here will identify trends and enable rapid comparison to the literature of related diseases.']\n",
            "unmatched tags:  [{'entity': 'diseases', 'type': 'Disease', 'start': 1982, 'end': 1990}, {'entity': 'H5N1', 'type': 'Disease', 'start': 1728, 'end': 1732}, {'entity': 'SARS', 'type': 'Disease', 'start': 1718, 'end': 1722}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 1705, 'end': 1716}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1537, 'end': 1545}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 1414, 'end': 1425}]\n",
            "['Dispelling the myths surrounding radiotherapy for treatment of cutaneous melanoma\\tThe role of radiotherapy is well established in the management of most locally advanced and metastatic cancers; however, there has been reluctance to extend this role to melanoma.', 'The reasons can be traced historically to in-vitro and in-vivo data suggesting that melanomas are resistant to radiation.', 'Current findings indicate that these cancers have a wide range of sensitivity to radiation that overlaps extensively with those for common epithelial cancers: indeed, some melanomas show high sensitivity to radiation.']\n",
            "unmatched tags:  [{'entity': 'melanomas', 'type': 'Disease', 'start': 556, 'end': 565}, {'entity': 'cancers', 'type': 'Disease', 'start': 534, 'end': 541}, {'entity': 'cancers', 'type': 'Disease', 'start': 421, 'end': 428}]\n",
            "['Velopharyngeal incompetence and chromosome 22q11 deletion\\tChromosome 22q11 deletion gives rise to various phenotypes, including cardiac malformations, velopharyngeal abnormalities, absent thymus, and neurological defects.', 'We assessed, in a prospective study, chromosome 22q11 deletion in 50 of 144 patients with velopharyngeal incompetence in the absence of overt clefting.', '18 (12·5% of the whole cohort and 36% of patients tested for the deletion) had the 22q11 deletion.', 'This frequency differs from an estimated population prevalence of 0·025% and suggests a need for screening for the 22q11 deletion in these patients.']\n",
            "unmatched tags:  [{'entity': '22q11 deletion', 'type': 'Disease', 'start': 588, 'end': 602}, {'entity': '22q11 deletion', 'type': 'Disease', 'start': 457, 'end': 471}, {'entity': 'velopharyngeal incompetence', 'type': 'Disease', 'start': 312, 'end': 339}]\n",
            "['Public financing of health in developing countries: a cross-national systematic analysis\\tTo address the negative effect of DAH on domestic government health spending, we recommend strong standardised monitoring of government health expenditures and government spending in other health-related sectors; establishment of collaborative targets to maintain or increase the share of government expenditures going to health; investment in the capacity of developing countries to effectively receive and use DAH; careful assessment of the risks and benefits of expanded DAH to non-governmental sectors; and investigation of the use of global price subsidies or product transfers as mechanisms for DAH.']\n",
            "unmatched tags:  [{'entity': 'DAH', 'type': 'Drug', 'start': 690, 'end': 693}]\n",
            "['Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial\\tThe substantial boost in intestinal immunity conferred by a supplementary dose of IPV given to children younger than 5 years who had previously received OPV shows a potential role for this vaccine in immunisation activities to accelerate eradication and prevent outbreaks of poliomyelitis.']\n",
            "unmatched tags:  [{'entity': 'poliomyelitis', 'type': 'Disease', 'start': 458, 'end': 471}, {'entity': 'vaccine', 'type': 'Drug', 'start': 372, 'end': 379}, {'entity': 'OPV', 'type': 'Drug', 'start': 336, 'end': 339}]\n",
            "['Anaemia after enalapril in a child with nephrotic syndrome\\tA girl aged 7 years with focal segmental glomerulosclerosis and nephrotic syndrome failed to respond to prednisolone for 7 weeks, and to prednisolone with cyclophosphamide for a further 8 weeks Blood pressure was normal and oedema was controlled with diuretics Creatinine had increased from 30 μmol/L to 50 μmol/L, and the urine protein/creatinine ratio from 2400 mg/mmol to 4000 mg/mmol From week 10 to week 40, creatinine rose from 30 μmol/L to 85 μmol/L and the urine albumin/creatinine ratio fluctuated between 2000 mg/mmol and 4000 mg/mmol She was started on enalapril 2·5 mg twice daily After 3 months, enalapril was discontinued because her haemoglobin had fallen from 127 g/L to 62 g/L with haematocrit of 0·16, but with normal ferritin, folate, and vitamin B']\n",
            "unmatched tags:  [{'entity': 'folate', 'type': 'Drug', 'start': 805, 'end': 811}, {'entity': 'haemoglobin', 'type': 'Drug', 'start': 707, 'end': 718}, {'entity': 'enalapril', 'type': 'Gene', 'start': 668, 'end': 677}, {'entity': 'enalapril', 'type': 'Gene', 'start': 623, 'end': 632}]\n",
            "['Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis\\tOur retrospective cohort study in US Medicare beneficiaries shows that, in people 65 years of age and older, high-dose inactivated influenza vaccine was significantly more effective than standard-dose vaccine in prevention of influenza-related medical encounters.', 'Additionally, the large population in our study enabled us to show, for the first time, a significant reduction in influenza-related hospital admissions in high-dose compared to standard-dose vaccine recipients, an outcome not shown in randomised studies.']\n",
            "unmatched tags:  [{'entity': 'vaccine', 'type': 'Drug', 'start': 646, 'end': 653}]\n",
            "['Current and future perspectives in the management of juvenile idiopathic arthritis\\tThe treatment of juvenile idiopathic arthritis has improved tremendously in the past 20 years as a result of appropriate legislative initiatives, large international collaborative networks, and the availability of new potent medications.', 'Despite these considerable advances, a sizable proportion of patients are still resistant to treatment.', 'Further improvement will stem from a better definition of the disease entities under the broad term juvenile idiopathic arthritis (which includes all forms of arthritis with disease onset before the age of 16 years); the discovery of laboratory and imaging biomarkers that could help the tuning of therapy; smoother implementation of clinical trials; more standardised links between academia, regulatory authorities, and patient organisations for the planning of future trials; and the availability of new drugs that selectively target molecules or pathways involved in inflammation.']\n",
            "unmatched tags:  [{'entity': 'academia', 'type': 'Organization', 'start': 808, 'end': 816}, {'entity': 'arthritis', 'type': 'Disease', 'start': 584, 'end': 593}, {'entity': 'juvenile idiopathic arthritis', 'type': 'Disease', 'start': 525, 'end': 554}, {'entity': 'disease entities', 'type': 'Disease', 'start': 487, 'end': 503}]\n",
            "['Diabetes: a 21st century challenge\\tThe number of people with diabetes worldwide has more than doubled during the past 20 years.', 'One of the most worrying features of this rapid increase is the emergence of type 2 diabetes in children, adolescents, and young adults.', 'Although the role of traditional risk factors for type 2 diabetes (eg, genetic, lifestyle, and behavioural risk factors) has been given attention, recent research has focused on identifying the contributions of epigenetic mechanisms and the effect of the intrauterine environment.']\n",
            "unmatched tags:  [{'entity': 'behavioural risk factors', 'type': 'Chemical', 'start': 360, 'end': 384}]\n",
            "['Disease X: accelerating the development of medical countermeasures for the next pandemic\\tWHO has listed several priority diseases with epidemic potential for which there are no, or insufficient, medical countermeasures.', 'In response, the Bill & Melinda Gates Foundation (with support from PricewaterhouseCoopers) coordinated subject matter experts to create a preparedness plan for Disease X.', 'Disease X is caused by Pathogen X, an infectious agent that is not currently known to cause human disease, but an aetiologic agent of a future outbreak with epidemic or pandemic potential.', 'We have identified crucial areas for acceleration in medical countermeasure product development and international coordination.']\n",
            "unmatched tags:  [{'entity': 'human disease', 'type': 'Disease', 'start': 484, 'end': 497}, {'entity': 'Disease X', 'type': 'Disease', 'start': 392, 'end': 401}]\n",
            "['Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial\\t6 months of atorvastatin improved cough on a quality-of-life scale in patients with bronchiectasis.', 'Multicentre studies are now needed to assess whether long-term statin treatment can reduce exacerbations.']\n",
            "unmatched tags:  [{'entity': 'statin', 'type': 'Drug', 'start': 247, 'end': 253}, {'entity': 'bronchiectasis', 'type': 'Disease', 'start': 168, 'end': 182}, {'entity': 'quality-of-life scale', 'type': 'Phenotype', 'start': 129, 'end': 150}]\n",
            "['Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study\\tRe-exposure to varicella-zoster virus via contact with children seems to protect latently infected individuals against zoster.', 'Reduction of childhood varicella by vaccination might lead to increased incidence of adult zoster.', 'Vaccination of the elderly (if effective) should be considered in countries with childhood varicella vaccination programmes.']\n",
            "unmatched tags:  [{'entity': 'varicella', 'type': 'Disease', 'start': 427, 'end': 436}]\n",
            "['3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial\\tIn this trial, we provide results for 3 years of treatment, with the limitation that withdrawn individuals were not followed up after discontinuation.', 'Liraglutide 3·0 mg might provide health benefits in terms of reduced risk of diabetes in individuals with obesity and prediabetes.']\n",
            "unmatched tags:  [{'entity': 'prediabetes', 'type': 'Disease', 'start': 430, 'end': 441}, {'entity': 'obesity', 'type': 'Phenotype', 'start': 418, 'end': 425}, {'entity': 'diabetes', 'type': 'Disease', 'start': 389, 'end': 397}]\n",
            "['Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis\\tThe identification of factors that can affect the efficacy of immunomodulatory drugs in relapsing-remitting multiple sclerosis (MS) is important.', 'For the available interferon-beta products, neutralising antibodies (NAb) have been shown to affect treatment efficacy.', 'In June, 2009, a panel of experts in MS and NAbs to interferon-beta therapy convened in Amsterdam, Netherlands, under the auspices of the Neutralizing Antibodies on Interferon beta in Multiple Sclerosis consortium, a European-based project of the 6th Framework Programme of the European Commission, to review and discuss data on NAbs and their practical consequences for the treatment of patients with MS on interferon beta.']\n",
            "unmatched tags:  [{'entity': 'interferon beta', 'type': 'Gene', 'start': 791, 'end': 806}, {'entity': 'NAb', 'type': 'Chemical', 'start': 712, 'end': 715}, {'entity': 'Multiple Sclerosis', 'type': 'Disease', 'start': 567, 'end': 585}, {'entity': 'Interferon beta', 'type': 'Gene', 'start': 548, 'end': 563}, {'entity': 'Amsterdam', 'type': 'Disease', 'start': 471, 'end': 480}, {'entity': 'interferon-beta therapy', 'type': 'Gene', 'start': 435, 'end': 458}]\n",
            "[\"Rethinking good cholesterol: a clinicians' guide to understanding HDL\\tLow HDL cholesterol dyslipidaemia affects about half of people with type 2 diabetes and represents a major independent risk factor for atherosclerotic cardiovascular disease.\", 'The “good cholesterol” label was coined decades ago on the basis of a presumed causal role of HDL cholesterol in atherosclerotic cardiovascular disease.', 'However, this view has been challenged by the negative results of several studies of HDL cholesterol-raising drugs, creating a paradox for clinicians regarding the value of HDL cholesterol as a risk biomarker and therapeutic target, and seemingly contradicting decades of evidence substantiating an inverse relation between HDL cholesterol and cardiovascular disease risk.']\n",
            "unmatched tags:  [{'entity': 'cardiovascular disease', 'type': 'Disease', 'start': 742, 'end': 764}, {'entity': 'HDL cholesterol', 'type': 'Drug', 'start': 722, 'end': 737}]\n",
            "[\"HIV infection and neoplasia\\tHIV infection predisposes to several neoplastic conditions, especially non-Hodgkin lymphoma (NHL) and Kaposi's sarcoma (KS), and also intraepithelial cervical neoplasia (CIN) and anal neoplasia (AIN) (but not cervical or anal invasive cancer) and possibly seminoma.\", 'For neoplasias associated with oncogenic human viruses (ie, some NHL, CIN, AIN, and probably KS) the role of HIV is most probably linked to its immunosuppressive effect and interference with immune-mediated tumour surveillance.', 'HIV-1, through its regulatory protein']\n",
            "unmatched tags:  [{'entity': 'HIV-1', 'type': 'Virus', 'start': 522, 'end': 527}, {'entity': 'HIV', 'type': 'Virus', 'start': 403, 'end': 406}, {'entity': 'AIN', 'type': 'Disease', 'start': 369, 'end': 372}, {'entity': 'CIN', 'type': 'Disease', 'start': 364, 'end': 367}, {'entity': 'oncogenic human viruses', 'type': 'Virus', 'start': 325, 'end': 348}, {'entity': 'neoplasias', 'type': 'Disease', 'start': 298, 'end': 308}, {'entity': 'seminoma', 'type': 'Disease', 'start': 284, 'end': 292}]\n",
            "['Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study\\tTivantinib did not improve overall survival compared with placebo in patients with MET-high advanced hepatocellular carcinoma previously treated with sorafenib.', 'Although this METIV-HCC trial was negative, the study shows the feasibility of doing integral tissue biomarker studies in patients with advanced hepatocellular carcinoma.', 'Additional randomised studies are needed to establish whether MET inhibition could be a potential therapy for some subsets of patients with advanced hepatocellular carcinoma.']\n",
            "unmatched tags:  [{'entity': 'hepatocellular carcinoma', 'type': 'Disease', 'start': 646, 'end': 670}, {'entity': 'advanced hepatocellular carcinoma', 'type': 'Disease', 'start': 637, 'end': 670}, {'entity': 'MET', 'type': 'Gene', 'start': 559, 'end': 562}, {'entity': 'advanced hepatocellular carcinoma', 'type': 'Disease', 'start': 462, 'end': 495}, {'entity': 'MET', 'type': 'Gene', 'start': 340, 'end': 343}, {'entity': 'sorafenib', 'type': 'Drug', 'start': 315, 'end': 324}, {'entity': 'hepatocellular carcinoma', 'type': 'Disease', 'start': 266, 'end': 290}, {'entity': 'advanced hepatocellular carcinoma', 'type': 'Disease', 'start': 257, 'end': 290}]\n",
            "['Effectiveness of interventions targeting air travellers for delaying local outbreaks of SARS-CoV-2\\tBackground: We evaluated if interventions aimed at air travellers can delay local SARS-CoV-2 community transmission in a previously unaffected country.', 'Methods: We simulated infected air travellers arriving into countries with no sustained SARS-CoV-2 transmission or other introduction routes from affected regions.', 'We assessed the effectiveness of syndromic screening at departure and/or arrival & traveller sensitisation to the COVID-2019-like symptoms with the aim to trigger rapid self-isolation and reporting on symptom onset to enable contact tracing.', 'We assumed that syndromic screening would reduce the number of infected arrivals and that traveller sensitisation reduces the average number of secondary cases.', 'We use stochastic simulations to account for uncertainty in both arrival and secondary infections rates, and present sensitivity analyses on arrival rates of infected travellers and the effectiveness of traveller sensitisation.', 'We report the median expected delay achievable in each scenario and an inner 50% interval.', 'Results: Under baseline assumptions, introducing exit and entry screening in combination with traveller sensitisation can delay a local SARS-CoV-2 outbreak by 8 days (50% interval: 3-14 days) when the rate of importation is 1 infected traveller per week at time of introduction.', 'The additional benefit of entry screening is small if exit screening is effective: the combination of only exit screening and traveller sensitisation can delay an outbreak by 7 days (50% interval: 2-13 days).', 'In the absence of screening, with less effective sensitisation, or a higher rate of importation, these delays shrink rapidly to less than 4 days.', 'Conclusion: Syndromic screening and traveller sensitisation in combination may have marginally delayed SARS-CoV-2 outbreaks in unaffected countries.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1875, 'end': 1885}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1274, 'end': 1284}, {'entity': 'secondary infections', 'type': 'Disease', 'start': 895, 'end': 915}]\n",
            "['Advances in β-cell replacement therapy for the treatment of type 1 diabetes\\tThe main goal of treatment for type 1 diabetes is to control glycaemia with insulin therapy to reduce disease complications.', 'For some patients, technological approaches to insulin delivery are inadequate, and allogeneic islet transplantation is a safe alternative for those patients who have had severe hypoglycaemia complicated by impaired hypoglycaemia awareness or glycaemic lability, or who already receive immunosuppressive drugs for a kidney transplant.', 'Since 2000, intrahepatic islet transplantation has proven efficacious in alleviating the burden of labile diabetes and preventing complications related to diabetes, whether or not a previous kidney transplant is present.']\n",
            "unmatched tags:  [{'entity': 'diabetes', 'type': 'Disease', 'start': 691, 'end': 699}, {'entity': 'diabetes', 'type': 'Disease', 'start': 642, 'end': 650}, {'entity': 'hypoglycaemia', 'type': 'Disease', 'start': 417, 'end': 430}]\n",
            "['Daytime urinary incontinence in children and adolescents\\tDaytime urinary incontinence is common in the paediatric population and affects approximately 7–10% of children (aged 5–13 years).', 'Several subtypes of daytime incontinence, which are classified according to their relation to the storage and voiding phases of bladder function, exist.', 'Risk factors for these subtypes of incontinence can be genetic, demographic, environmental, behavioural, or physical.', 'Therefore, treatment is multidisciplinary and needs an adequate diagnosis to be successful.', 'Urotherapy is the first-line treatment for all types of daytime incontinence.']\n",
            "unmatched tags:  [{'entity': 'daytime incontinence', 'type': 'Disease', 'start': 607, 'end': 627}]\n",
            "['A binning tool to reconstruct viral haplotypes from assembled contigs\\tMotivation Infections by RNA viruses such as Influenza, HIV still pose a serious threat to human health despite extensive research on viral diseases.', 'One challenge for producing effective prevention and treatment strategies is high intra-species genetic diversity.', 'As different strains may have different biological properties, characterizing the genetic diversity is thus important to vaccine and drug design.', 'Next-generation sequencing technology enables comprehensive characterization of both known and novel strains and has been widely adopted for sequencing viral populations.', 'However, genome-scale reconstruction of haplotypes is still a challenging problem.', 'In particular, haplotype assembly programs often produce contigs rather than full genomes.', 'As a mutation in one gene can mask the phenotypic effects of a mutation at another locus, clustering these contigs into genome-scale haplotypes is still needed.', 'Results We developed a contig binning tool, VirBin, which clusters contigs into different groups so that each group represents a haplotype.', 'Commonly used features based on sequence composition and contig coverage cannot effectively distinguish viral haplotypes because of their high sequence similarity and heterogeneous sequencing coverage for RNA viruses.', 'VirBin applied prototype-based clustering to cluster regions that are more likely to contain mutations specific to a haplotype.', 'The tool was tested on multiple simulated sequencing data with different haplotype abundance distributions and contig sizes, and also on mock quasispecies sequencing data.', 'The benchmark results with other contig binning tools demonstrated the superior sensitivity and precision of VirBin in contig binning for viral haplotype reconstruction.', 'Availability  https://github.com/chjiao/VirBin Contact  yannisun{at}cityu.edu.hk']\n",
            "unmatched tags:  [{'entity': 'VirBin', 'type': 'Chemical', 'start': 1855, 'end': 1861}, {'entity': 'VirBin', 'type': 'Chemical', 'start': 1754, 'end': 1760}, {'entity': 'binning tool', 'type': 'Gene', 'start': 1685, 'end': 1697}, {'entity': 'VirBin', 'type': 'Chemical', 'start': 1345, 'end': 1351}, {'entity': 'RNA viruses', 'type': 'Virus', 'start': 1332, 'end': 1343}, {'entity': 'gene', 'type': 'Gene', 'start': 1300, 'end': 1304}, {'entity': 'contigs', 'type': 'Organization', 'start': 1054, 'end': 1061}, {'entity': 'VirBin', 'type': 'Chemical', 'start': 1031, 'end': 1037}, {'entity': 'binning tool', 'type': 'Gene', 'start': 1017, 'end': 1029}, {'entity': 'genome-scale', 'type': 'Organization', 'start': 946, 'end': 958}, {'entity': 'contigs', 'type': 'Organization', 'start': 933, 'end': 940}, {'entity': 'gene', 'type': 'Gene', 'start': 847, 'end': 851}, {'entity': 'genomes', 'type': 'Gene', 'start': 817, 'end': 824}, {'entity': 'contigs', 'type': 'Organization', 'start': 792, 'end': 799}, {'entity': 'genome-scale', 'type': 'Organization', 'start': 661, 'end': 673}, {'entity': 'strains', 'type': 'Disease', 'start': 582, 'end': 589}, {'entity': 'gene', 'type': 'Gene', 'start': 486, 'end': 490}, {'entity': 'vaccine', 'type': 'Drug', 'start': 456, 'end': 463}, {'entity': 'gene', 'type': 'Gene', 'start': 417, 'end': 421}]\n",
            "['Emergency surgery in the era of molecular treatment of solid tumours\\tIn the advancing era of molecular therapy of solid tumours, emergency treatment of complications, such as bowel perforation, haemorrhage, and tumour rupture, is likely to evolve into one of the main challenges of surgical oncology.', 'These complications might be caused by disease progression from resistance to therapy, side-effects of therapy on normal vasculature, and therapeutic induction of excessively responding tumours.', 'This Review outlines the probability and management of emergency operations during molecularly targeted therapy of solid tumours.']\n",
            "unmatched tags:  [{'entity': 'solid tumours', 'type': 'Disease', 'start': 611, 'end': 624}, {'entity': 'era', 'type': 'Gene', 'start': 602, 'end': 605}, {'entity': 'era', 'type': 'Gene', 'start': 563, 'end': 566}, {'entity': 'tumours', 'type': 'Disease', 'start': 487, 'end': 494}, {'entity': 'era', 'type': 'Gene', 'start': 441, 'end': 444}, {'entity': 'era', 'type': 'Gene', 'start': 406, 'end': 409}, {'entity': 'era', 'type': 'Gene', 'start': 381, 'end': 384}, {'entity': 'tumour rupture', 'type': 'Disease', 'start': 211, 'end': 225}, {'entity': 'bowel perforation', 'type': 'Disease', 'start': 175, 'end': 192}, {'entity': 'tumours', 'type': 'Disease', 'start': 120, 'end': 127}, {'entity': 'solid tumours', 'type': 'Disease', 'start': 114, 'end': 127}]\n",
            "[\"Aetiological diagnosis of ischaemic stroke in young adults\\tDespite improvements in diagnosis and treatment, ischaemic stroke in young adults remains a catastrophic event from the patients' perspective.\", 'Stroke can cause death, disability, and hamper quality of life.', 'For the neurologist treating a young adult with suspected ischaemic stroke, the diagnostic challenge is to identify its cause.', 'Contemporary neuroimaging of the brain and its vessels, and a comprehensive cardiac assessment, will enable identification of the most frequent causes of stroke in this age group: cardioembolism and arterial dissection.']\n",
            "unmatched tags:  [{'entity': 'arterial dissection', 'type': 'Disease', 'start': 592, 'end': 611}, {'entity': 'stroke', 'type': 'Disease', 'start': 547, 'end': 553}, {'entity': 'ischaemic stroke', 'type': 'Disease', 'start': 324, 'end': 340}, {'entity': 'Stroke', 'type': 'Disease', 'start': 202, 'end': 208}]\n",
            "['De novo 3D models of SARS-CoV-2 RNA elements and small-molecule-binding RNAs to guide drug discovery\\tThe rapid spread of COVID-19 motivates development of antivirals targeting conserved molecular machinery of the SARS-CoV-2 virus.', 'The SARS-CoV-2 genome includes conserved RNA elements that offer potential targets for RNA-targeting small-molecule drugs, but 3D structures of most of these elements have not been experimentally characterized.', 'Here, we provide a dataset called ‘FARFAR2-SARS-CoV-2’, a collection of 3D coordinates modeled using Rosetta’s FARFAR2 algorithm, including de novo models for thirteen RNA elements in SARS-CoV-2 and homology models for a fourteenth.', 'These elements comprise SL1, SL2, SL3, SL4, SL5, putative SL6 and SL7 in the extended 5′ UTR, as well as the entire extended 5′ UTR; the frameshifting element (FSE) from the SARS-CoV-2 ORF1a/b gene and a putative dimer of FSE; and the extended pseudoknot, hypervariable region, and the s2m of the 3′ UTR, as well as the entire 3′ UTR.', 'For five of these elements (SL1, SL2, SL3, FSE, s2m), convergence of lowest predicted energy structures supports their accuracy in capturing low energy states that might be targeted for small molecule binding.', 'To aid efforts to discover small molecule RNA binders guided by computational models, we provide a second benchmarking dataset called ‘FARFAR2-Apo-Riboswitch’, which consists of similarly prepared Rosetta-FARFAR2 models for RNA riboswitch aptamer regions that bind small molecules.', 'Both datasets include up to 400 3D models for each RNA element, which may facilitate drug discovery approaches targeting dynamic ensembles of low-energy excited states of RNA molecules.']\n",
            "unmatched tags:  [{'entity': 'RNA', 'type': 'Gene', 'start': 1673, 'end': 1676}, {'entity': 'RNA', 'type': 'Gene', 'start': 1553, 'end': 1556}, {'entity': 'RNA element', 'type': 'Chemical', 'start': 1553, 'end': 1564}, {'entity': 'small molecules', 'type': 'Drug', 'start': 1485, 'end': 1500}, {'entity': 'RNA riboswitch', 'type': 'Gene', 'start': 1444, 'end': 1458}, {'entity': 'RNA', 'type': 'Gene', 'start': 1262, 'end': 1265}, {'entity': 'small molecule RNA', 'type': 'Drug', 'start': 1247, 'end': 1265}, {'entity': 'SL3', 'type': 'Gene', 'start': 1048, 'end': 1051}, {'entity': 'SL2', 'type': 'Gene', 'start': 1043, 'end': 1046}, {'entity': 'SL1', 'type': 'Gene', 'start': 1038, 'end': 1041}, {'entity': 'elements', 'type': 'Chemical', 'start': 1028, 'end': 1036}, {'entity': 'UTR', 'type': 'Gene', 'start': 1005, 'end': 1008}, {'entity': '3′ UTR', 'type': 'Gene', 'start': 1002, 'end': 1008}, {'entity': '3′ UTR', 'type': 'Gene', 'start': 972, 'end': 978}, {'entity': 'hypervariable region', 'type': 'Gene', 'start': 931, 'end': 951}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 849, 'end': 859}, {'entity': 'UTR', 'type': 'Gene', 'start': 803, 'end': 806}, {'entity': 'UTR', 'type': 'Gene', 'start': 764, 'end': 767}, {'entity': 'SL6', 'type': 'Gene', 'start': 733, 'end': 736}, {'entity': 'SL4', 'type': 'Gene', 'start': 714, 'end': 717}, {'entity': 'SL3', 'type': 'Gene', 'start': 709, 'end': 712}, {'entity': 'SL2', 'type': 'Gene', 'start': 704, 'end': 707}, {'entity': 'SL1', 'type': 'Gene', 'start': 699, 'end': 702}, {'entity': 'elements', 'type': 'Chemical', 'start': 681, 'end': 689}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 626, 'end': 636}]\n",
            "['Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics\\tMany papers are emerging that describe the in vitro antiviral activity of drugs that may be repurposed for therapy or chemoprophylaxis against SARS-CoV-2.', 'However, no comprehensive evaluation of these molecules in the context of the achievable plasma pharmacokinetics after administration of approved doses and schedules to humans has been conducted.', 'Moreover, most publications have focussed on 50% maximum effective concentrations (EC50), which may be an insufficiently robust indicator of antiviral activity because of marked differences in the slope of the concentration-response curve between drugs.', 'Accordingly, in vitro anti-SARS-CoV-2 activity data was digitised from all available publications up to 13th April 2020 and used to recalculate an EC90 value for each drug.', 'EC90 values were then expressed as a ratio to the achievable maximum plasma concentrations (Cmax) reported for each drug after administration of the approved dose to humans (Cmax/EC90 ratio).', 'Only 14 of the analysed drugs achieved a Cmax/EC90 ratio above 1 meaning that plasma Cmax concentrations exceeded those necessary to inhibit 90% of SARS-CoV-2 replication.', 'A more in-depth assessment of these drugs demonstrated that only nitazoxanide, nelfinavir, tipranavir (boosted with ritonavir) and sulfadoxine achieved plasma concentrations above their anti-SARS-CoV-2 activity across their entire approved dosing interval at their approved human dose.', 'For all drugs reported, the unbound lung to plasma tissue partition coefficient (KpUlung) was also simulated and used along with reported Cmax and fraction unbound in plasma to derive a lung Cmax/EC50  as a better indicator of potential human efficacy (lung Cmax/EC90 ratio was also calculable for a limited number of drugs).', 'Using this parameter hydroxychloroquine, chloroquine, mefloquine, atazanavir (boosted with ritonavir), tipranavir (boosted with ritonavir), ivermectin, azithromycin and lopinavir (boosted with ritonavir) were all predicted to achieve lung concentrations over 10-fold higher than their reported EC50.', 'This analysis was not possible for nelfinavir because insufficient data were available to calculate KpUlung but nitozoxanide and sulfadoxine were also predicted to exceed their reported EC50 by 3.1- and 1.5-fold in lung, respectively.', 'The antiviral activity data reported to date is of variable quality and conducted under different conditions by different investigators.', 'However, this analysis has prioritised candidates with the best chance for success in therapy or chemoprevention of Covid-19 based upon the currently available in vitro activity and human plasma pharmacokinetic data.', 'Future studies should focus on EC90 values and discuss findings in the context of achievable exposures in humans, especially within target compartments such as the lung, in order to maximise the potential for success of proposed human clinical trials.']\n",
            "unmatched tags:  [{'entity': 'EC90', 'type': 'Gene', 'start': 2867, 'end': 2871}, {'entity': 'Covid-19', 'type': 'Disease', 'start': 2735, 'end': 2743}, {'entity': 'EC50', 'type': 'Gene', 'start': 2433, 'end': 2437}, {'entity': 'sulfadoxine', 'type': 'Drug', 'start': 2376, 'end': 2387}, {'entity': 'nelfinavir', 'type': 'Drug', 'start': 2282, 'end': 2292}, {'entity': 'EC50', 'type': 'Gene', 'start': 2241, 'end': 2245}, {'entity': 'ritonavir', 'type': 'Drug', 'start': 2140, 'end': 2149}, {'entity': 'lopinavir', 'type': 'Drug', 'start': 2116, 'end': 2125}, {'entity': 'azithromycin', 'type': 'Drug', 'start': 2099, 'end': 2111}, {'entity': 'ivermectin', 'type': 'Drug', 'start': 2087, 'end': 2097}, {'entity': 'ritonavir', 'type': 'Drug', 'start': 2075, 'end': 2084}, {'entity': 'tipranavir', 'type': 'Drug', 'start': 2050, 'end': 2060}, {'entity': 'ritonavir', 'type': 'Drug', 'start': 2038, 'end': 2047}, {'entity': 'atazanavir', 'type': 'Drug', 'start': 2013, 'end': 2023}, {'entity': 'mefloquine', 'type': 'Drug', 'start': 2001, 'end': 2011}, {'entity': 'chloroquine', 'type': 'Drug', 'start': 1988, 'end': 1999}, {'entity': 'hydroxychloroquine', 'type': 'Drug', 'start': 1968, 'end': 1986}, {'entity': 'drug', 'type': 'Drug', 'start': 1939, 'end': 1943}, {'entity': 'EC90', 'type': 'Gene', 'start': 1884, 'end': 1888}, {'entity': 'EC50', 'type': 'Gene', 'start': 1817, 'end': 1821}, {'entity': 'drug', 'type': 'Drug', 'start': 1629, 'end': 1633}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1526, 'end': 1536}, {'entity': 'sulfadoxine', 'type': 'Drug', 'start': 1466, 'end': 1477}, {'entity': 'ritonavir', 'type': 'Drug', 'start': 1451, 'end': 1460}, {'entity': 'tipranavir', 'type': 'Drug', 'start': 1426, 'end': 1436}, {'entity': 'nelfinavir', 'type': 'Drug', 'start': 1414, 'end': 1424}, {'entity': 'nitazoxanide', 'type': 'Drug', 'start': 1400, 'end': 1412}, {'entity': 'drug', 'type': 'Drug', 'start': 1371, 'end': 1375}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1311, 'end': 1321}, {'entity': 'EC90', 'type': 'Gene', 'start': 1209, 'end': 1213}, {'entity': 'drug', 'type': 'Drug', 'start': 1187, 'end': 1191}, {'entity': 'EC90', 'type': 'Gene', 'start': 1150, 'end': 1154}, {'entity': 'drug', 'type': 'Drug', 'start': 1087, 'end': 1091}, {'entity': 'EC90', 'type': 'Gene', 'start': 971, 'end': 975}, {'entity': 'drug', 'type': 'Drug', 'start': 965, 'end': 969}, {'entity': 'EC90', 'type': 'Gene', 'start': 945, 'end': 949}, {'entity': 'digitised', 'type': 'Drug', 'start': 854, 'end': 863}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 825, 'end': 835}]\n",
            "['Early epidemiological and clinical manifestations of COVID-19 in Japan\\tBackground: Severe acute respiratory syndrome coronaviruses -2 (SARS-COV2) named as COVID-19 had spread worldwide and leading to 1,210,956 confirmed cases and 67,594 deaths Methods: A data of 1192 confirmed cases and 43 deaths due to COVID-19 in Japan collected from the Ministry of Health, Labour and Welfare of Japan and analysed for different epidemiological parameters and their clinical manifestations.', 'We used Clauset-Newman-Moore (CNM) clustering algorithm to develop web-network of confirmed cases to identified clusters of community transmission.', 'Results: Out of 1192 confirmed cases, 90.60% were symptomatic and 9.39% were asymptomatic.', 'The prevalence of COVID19 in males was 56.29% and 43.20 % in females.', 'The mean interval (SD) from symptom onset to diagnosis was 6-22.6 days while mean interval (SD) from contact to onset of symptoms was 5-19.5 days.', 'People of age range 40-79 were more infected and deaths median age was 80.', 'The main symptoms were fever, dry cough, fatigue and pneumonia.', 'The main infected cities were Tokyo (195/1192, 16.35%), Hokkaido (160/1192 13.42%), Aichi (150/1192, 12.58%) and Osaka (145/1192, 12.16%).', 'Only 2.34% cases had travel history from Wuhan China and Osaka music concert was identify as main cluster for community transmission.', 'While 556 (46.64%) cases were clinically diagnosed and 557 (46.72%) were confirmed by using RT-PCR.', 'Conclusions: Other than, declare emergency Japan need to change their approach of diagnosing COVID-19, as asymptomatic cases prevalence is high and maybe it is reason for current sudden increase of cases.', 'Screening centre should be establish away from hospitals, which are treating positive cases.']\n",
            "unmatched tags:  [{'entity': 'symptom', 'type': 'Phenotype', 'start': 1556, 'end': 1563}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1542, 'end': 1550}, {'entity': 'Aichi', 'type': 'Chemical', 'start': 1159, 'end': 1164}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 1064, 'end': 1073}, {'entity': 'dry cough', 'type': 'Phenotype', 'start': 1041, 'end': 1050}, {'entity': 'fever', 'type': 'Phenotype', 'start': 1034, 'end': 1039}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 817, 'end': 824}, {'entity': 'COVID19', 'type': 'Chemical', 'start': 737, 'end': 744}]\n",
            "['Cardioembolic stroke: an update\\tEmbolism of cardiac origin accounts for about one fifth of ischaemic strokes.', 'Strokes due to cardioembolism are in general severe and prone to early recurrence.', 'The risk of long term recurrence and mortality are high after a cardio-embolic stroke.', 'Cardioembolism can be reliably predicted on clinical grounds but is difficult to document.', 'MRI, transcranial doppler, echocardiogram, Holter monitoring, and electrophysiological studies increase our ability to identify the source of cardioembolism.', 'Non-valvular atrial fibrillation is the commonest cause of cardioembolic stroke.']\n",
            "unmatched tags:  [{'entity': 'stroke', 'type': 'Disease', 'start': 602, 'end': 608}, {'entity': 'stroke', 'type': 'Disease', 'start': 272, 'end': 278}]\n",
            "['Risk of drug-induced Long QT Syndrome associated with the use of repurposed COVID-19 drugs: a systematic review\\tBackground: The World Health Organization first declared SARS-CoV-2 (COVID-19) a pandemic on March 11, 2020.', 'There are currently no vaccines or therapeutic agents proven efficacious to treat COVID-19.', 'So, whether existing approved drugs could be repurposed and used off-label for the treatment of novel COVID-19 disease is being explored.', 'Methods: A thorough literature search was performed to gather information on the pharmacological properties and toxicity of 6 drugs (azithromycin, chloroquine, favipiravir, hydroxychloroquine, lopinavir/ritonavir, remdesivir) proposed to be repurposed to treat COVID-19.', 'Researchers emphasized affinity of these drugs to block the rapid component of the delayed rectifier cardiac potassium current (IKr) encoded by the human ether-a-go-go gene (hERG), their propensity to prolong cardiac repolarization (QT interval) and cause torsade de pointes (TdP).', 'Risk of drug-induced Long QT Syndrome (LQTS) for these drugs was quantified by comparing six indices used to assess such risk and by querying the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System database with specific key words.', 'Data are also provided to compare the level of risk for drug-induced LQTS by these drugs to 23 other, well-recognized, torsadogenic compounds.', 'Results: Estimators of LQTS risk levels indicated a very-high or high risk for all COVID-19 repurposed drugs except for azithromycin, although cases of TdP have been reported following the administration of this drug.', 'There was an excellent agreement among the various indices used to assess risk of drug-induced LQTS for the six repurposed drugs and the 23 torsadogenic compounds.', 'Conclusion: The risk-benefit assessment for the use of repurposed drugs to treat COVID-19 is complicated since benefits are currently anticipated, not proven.', 'Mandatory monitoring of the QT interval shall be performed as such monitoring is possible for hospitalized patients or by the use of biodevices for outpatients initiated on these drugs.']\n",
            "unmatched tags:  [{'entity': 'drug', 'type': 'Drug', 'start': 2118, 'end': 2122}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1861, 'end': 1869}, {'entity': 'drug', 'type': 'Drug', 'start': 1846, 'end': 1850}, {'entity': 'drug', 'type': 'Drug', 'start': 1739, 'end': 1743}, {'entity': 'drug', 'type': 'Drug', 'start': 1610, 'end': 1614}, {'entity': 'azithromycin', 'type': 'Drug', 'start': 1518, 'end': 1530}, {'entity': 'drug', 'type': 'Drug', 'start': 1501, 'end': 1505}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1481, 'end': 1489}, {'entity': 'drug', 'type': 'Drug', 'start': 1338, 'end': 1342}, {'entity': 'drug', 'type': 'Drug', 'start': 1059, 'end': 1063}, {'entity': 'torsade de pointes', 'type': 'Disease', 'start': 978, 'end': 996}, {'entity': 'hERG', 'type': 'Gene', 'start': 896, 'end': 900}, {'entity': 'ether-a-go-go gene', 'type': 'Gene', 'start': 876, 'end': 894}, {'entity': 'IKr', 'type': 'Gene', 'start': 850, 'end': 853}, {'entity': 'drug', 'type': 'Drug', 'start': 763, 'end': 767}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 712, 'end': 720}, {'entity': 'remdesivir', 'type': 'Chemical', 'start': 665, 'end': 675}, {'entity': 'lopinavir/ritonavir', 'type': 'Drug', 'start': 644, 'end': 663}, {'entity': 'hydroxychloroquine', 'type': 'Drug', 'start': 624, 'end': 642}, {'entity': 'favipiravir', 'type': 'Drug', 'start': 611, 'end': 622}, {'entity': 'chloroquine', 'type': 'Drug', 'start': 598, 'end': 609}, {'entity': 'azithromycin', 'type': 'Drug', 'start': 584, 'end': 596}, {'entity': 'drug', 'type': 'Drug', 'start': 577, 'end': 581}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 415, 'end': 423}, {'entity': 'drug', 'type': 'Drug', 'start': 343, 'end': 347}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 303, 'end': 311}, {'entity': 'therapeutic agents', 'type': 'Drug', 'start': 256, 'end': 274}]\n",
            "['Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches\\tInclusion body myositis is the most common acquired muscle disease in older individuals, and its prevalence varies among countries and ethnic groups.', 'The aetiology and pathogenesis of sporadic inclusion body myositis are still poorly understood; however genetic factors, ageing, and environmental triggers might all have a role.', 'Unlike other inflammatory myopathies, sporadic inclusion body myositis causes slowly progressing muscular weakness and atrophy, it has a distinctive pattern of muscle involvement, and is unresponsive to conventional forms of immunotherapy.']\n",
            "unmatched tags:  [{'entity': 'muscular weakness', 'type': 'Phenotype', 'start': 523, 'end': 540}]\n",
            "['Type 2 diabetes in adolescents: a severe phenotype posing major clinical challenges and public health burden\\tType 2 diabetes in adolescence manifests as a severe progressive form of diabetes that frequently presents with complications, responds poorly to treatment, and results in rapid progression of microvascular and macrovascular complications.', 'Although overall still a rare disease, adolescent type 2 diabetes now poses major challenges to paediatric and adult diabetes services in many countries.', 'Therapeutic options are heavily curtailed by a dearth of knowledge about the condition, with low numbers of participants and poor trial recruitment impeding research.']\n",
            "unmatched tags:  [{'entity': 'recruitment', 'type': 'Disease', 'start': 639, 'end': 650}, {'entity': 'diabetes services', 'type': 'Disease', 'start': 466, 'end': 483}, {'entity': 'type 2 diabetes', 'type': 'Disease', 'start': 399, 'end': 414}]\n",
            "['Ophthalmologic evidence against the interpersonal transmission of 2019 novel coronavirus through conjunctiva\\tBackground: The emerging 2019 novel coronavirus (2019−nCoV) has pushed several countries into state of emergency all over the world.', 'The possible transmission of 2019−nCoV by conjunctiva is controversial and has substantial public health implications.', 'Methods: A retrospective cohort study was initiated to investigate the possible transmission of 2019−nCoV through aerosol contact with conjunctiva.', 'We enrolled 67 cases of confirmed or suspected cases of novel coronavirus pneumonia (NCP) during 17−28 Jan 2020.', 'Nasopharyngeal and conjunctival swabs were collected for real time RT-PCR analysis to detect 2019−nCoV.', 'Results: 63 patients were identified as laboratory−confirmed NCP and the remaining four were suspected NCP.', 'Conjunctival swab samples from one NCP patient yielded positive PCR results and two NCP patients yielded probable positive PCR results.', 'None of the three patients had ocular symptoms.', 'The only one NCP patient with conjunctivitis as the first symptom had negative conjunctival sac 2019−nCoV test.', 'Conjunctival swab samples from the four suspected cases of NCIP were negative.', 'Conclusion: 2019−nCoV can be detected in the conjunctival sac of patients with NCP.', 'Through clinical analysis, viral transmission via the conjunctival route was not supported by the data.', 'Good clinical protection can effectively cut off the transmission path.']\n",
            "unmatched tags:  [{'entity': 'NCIP', 'type': 'Chemical', 'start': 1189, 'end': 1193}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 1076, 'end': 1083}]\n",
            "['Childhood obesity\\tWorldwide prevalence of childhood obesity has increased greatly during the past three decades.', 'The increasing occurrence in children of disorders such as type 2 diabetes is believed to be a consequence of this obesity epidemic.', 'Much progress has been made in understanding of the genetics and physiology of appetite control and from these advances, elucidation of the causes of some rare obesity syndromes.', 'However, these rare disorders have so far taught us few lessons about prevention or reversal of obesity in most children.']\n",
            "unmatched tags:  [{'entity': 'obesity', 'type': 'Phenotype', 'start': 521, 'end': 528}, {'entity': 'disorders', 'type': 'Disease', 'start': 445, 'end': 454}, {'entity': 'obesity', 'type': 'Phenotype', 'start': 406, 'end': 413}, {'entity': 'obesity', 'type': 'Phenotype', 'start': 228, 'end': 235}]\n",
            "['Identification and Referral to Improve Safety (IRIS) of women experiencing domestic violence with a primary care training and support programme: a cluster randomised controlled trial\\tA training and support programme targeted at primary care clinicians and administrative staff improved referral to specialist domestic violence agencies and recorded identification of women experiencing domestic violence.', 'Our findings reduce the uncertainty about the benefit of training and support interventions in primary care settings for domestic violence and show that screening of women patients for domestic violence is not a necessary condition for improved identification and referral to advocacy services.']\n",
            "unmatched tags:  [{'entity': 'domestic violence', 'type': 'Disease', 'start': 590, 'end': 607}, {'entity': 'domestic violence', 'type': 'Disease', 'start': 526, 'end': 543}, {'entity': 'domestic violence', 'type': 'Disease', 'start': 386, 'end': 403}]\n",
            "['Scrutinizing the SARS-CoV-2 protein information for the designing an effective vaccine encompassing both the T-cell and B-cell epitopes\\tNovel SARS coronavirus (SARS-CoV-2) has caused a pandemic condition world-wide and has been declared as public health emergency of International concern by WHO in a very short span of time.', 'The community transmission of this highly infectious virus has severely affected various parts of China, Italy, Spain and USA among others.', 'The prophylactic solution against SARS-CoV-2 infection is challenging due to the high mutation rate of its RNA genome.', 'Herein, we exploited a next generation vaccinology approach to construct a multi-epitope vaccine candidate against SARS-CoV-2 with high antigenicity, safety and efficacy to combat this deadly infectious agent.', 'The whole proteome was scrutinized for the screening of highly conserved, antigenic, non-allergen and non-toxic epitopes having high population coverage that can elicit both humoral and cellular mediated immune response against COVID-19 infection.', 'These epitopes along with four different adjuvants were utilized to construct a multi-epitope vaccine candidate that can generate strong immunological memory response having high efficacy in humans.', 'Various physiochemical analyses revealed the formation of a stable vaccine product having a high propensity to form a protective solution against the detrimental SARS-CoV-2 strain with high efficacy.', 'The vaccine candidate interacted with immunological receptor TLR3 with high affinity depicting the generation of innate immunity.', 'Further, the codon optimization and in silico expression show the plausibility of the high expression and easy purification of the vaccine product.', 'Thus, this present study provides an initial platform of the rapid generation of an efficacious protective vaccine for combating COVID-19.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 1849, 'end': 1857}, {'entity': 'combat', 'type': 'Disease', 'start': 1839, 'end': 1845}, {'entity': 'protective vaccine', 'type': 'Drug', 'start': 1816, 'end': 1834}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1703, 'end': 1710}, {'entity': 'TLR3', 'type': 'Gene', 'start': 1503, 'end': 1507}, {'entity': 'immunological receptor', 'type': 'Gene', 'start': 1480, 'end': 1502}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1446, 'end': 1453}]\n",
            "['Cognitive functioning and health-related quality of life in patients with newly diagnosed primary CNS lymphoma: a systematic review\\tIncidence of primary CNS lymphoma (PCNSL) is increasing, while prognosis is improving as treatments advance.', 'However, declined cognitive functioning remains a major challenge in the treatment of PCNSL.', 'This cognitive decline, in conjunction with other symptoms caused by the disease or its treatment, or both, can compromise health-related quality of life (HRQOL).', 'The aim of this Review was to give a comprehensive overview on cognitive functioning and HRQOL for patients with PCNSL, including an evaluation of patient-related and treatment-related factors that can influence cognitive functioning and HRQOL.']\n",
            "unmatched tags:  [{'entity': 'treatment-related factors', 'type': 'Disease', 'start': 664, 'end': 689}, {'entity': 'PCNSL', 'type': 'Disease', 'start': 610, 'end': 615}, {'entity': 'PCNSL', 'type': 'Disease', 'start': 327, 'end': 332}, {'entity': 'PCNSL', 'type': 'Disease', 'start': 167, 'end': 172}]\n",
            "['Evaluation of recombinant nucleocapsid and spike proteins for serological diagnosis of novel coronavirus disease 2019 (COVID-19)\\tBackground: The colloidal gold immunochromatography assay (GICA) is a rapid diagnostic tool for novel coronavirus disease 2019 (COVID-19) infections.', 'However, with significant numbers of false negatives, improvements to GICA are needed.', 'Methods: Six recombinant HCoV-19 nucleocapsid and spike proteins were prepared and evaluated.', 'The optimal proteins were employed to develop a sandwich-format GICA strip to detect total antibodies (IgM and IgG) against HCoV-19.', 'GICA performance was assessed with comparison of viral RNA detection.', 'Results: Recombinant HCoV-19 proteins were obtained, including three prokaryotically expressed rN, rN1, rN2 nucleocapsid proteins, and three eukaryotically expressed rS1, rS-RBD, rS-RBD-mFc spike proteins.', 'The recombinant proteins with the highest ELISA titers (rS1 and rS-RBD-mFc) against coronavirus-specific IgM and IgG were chosen for GICA development.', 'The GICA  has a sensitivity and specificity of 86.89% (106/122) and 99.39% (656/660), respectively.', 'Furthermore, 65.63% (21/32) of the clinically confirmed but RT-PCR negative samples were GICA positive.', 'Conclusions: The eukaryotically-expressed spike proteins (rS1and rS-RBD-mFc) are more suitable than the prokaryotically expressed nucleocapsid proteins for HCoV-19 serological diagnosis.', 'The GICA sandwich used to detect total antibodies is a powerful complement to the current standard RNA-based tests.']\n",
            "unmatched tags:  [{'entity': 'total antibodies', 'type': 'Gene', 'start': 1444, 'end': 1460}, {'entity': 'GICA', 'type': 'Chemical', 'start': 1415, 'end': 1419}, {'entity': 'nucleocapsid proteins', 'type': 'Gene', 'start': 1354, 'end': 1375}, {'entity': 'rS1', 'type': 'Disease', 'start': 1282, 'end': 1285}, {'entity': 'proteins', 'type': 'Gene', 'start': 1272, 'end': 1280}, {'entity': 'spike proteins', 'type': 'Gene', 'start': 1266, 'end': 1280}, {'entity': 'GICA', 'type': 'Chemical', 'start': 1209, 'end': 1213}, {'entity': 'GICA', 'type': 'Chemical', 'start': 1024, 'end': 1028}, {'entity': 'GICA', 'type': 'Chemical', 'start': 1002, 'end': 1006}, {'entity': 'rS1', 'type': 'Disease', 'start': 925, 'end': 928}, {'entity': 'recombinant proteins', 'type': 'Gene', 'start': 873, 'end': 893}, {'entity': 'proteins', 'type': 'Gene', 'start': 859, 'end': 867}, {'entity': 'spike proteins', 'type': 'Gene', 'start': 853, 'end': 867}, {'entity': 'rS1', 'type': 'Disease', 'start': 829, 'end': 832}, {'entity': 'eukaryotically expressed', 'type': 'Gene', 'start': 804, 'end': 828}, {'entity': 'rN2 nucleocapsid proteins', 'type': 'Gene', 'start': 767, 'end': 792}, {'entity': 'rN1', 'type': 'Gene', 'start': 762, 'end': 765}, {'entity': 'rN', 'type': 'Gene', 'start': 758, 'end': 760}, {'entity': 'proteins', 'type': 'Gene', 'start': 692, 'end': 700}, {'entity': 'viral RNA', 'type': 'Gene', 'start': 642, 'end': 651}]\n",
            "['The case for replacing live oral polio vaccine with inactivated vaccine in the Americas\\tBefore the development of the inactivated poliovirus vaccine (IPV) and live oral poliovirus vaccine (OPV), sporadic outbreaks of poliomyelitis were reported to cause as many as 18\\u2008000 cases of paralysis and over 3000 deaths in the USA alone.']\n",
            "unmatched tags:  [{'entity': 'poliomyelitis', 'type': 'Disease', 'start': 217, 'end': 230}, {'entity': 'OPV', 'type': 'Drug', 'start': 189, 'end': 192}]\n",
            "['Eye examination for early diagnosis of disseminated tuberculosis in patients with AIDS\\tChoroidal tuberculosis is present in 5–20% of patients with disseminated tuberculosis, and point-of-care dilated binocular indirect ophthalmoscopy eye examination can provide immediate diagnosis.', 'In geographical areas of high tuberculosis prevalence and in susceptible patients (CD4 counts less than 200 cells per μL) detection of choroidal granulomas should be accepted as evidence of disseminated tuberculosis.', 'With training and proper support, eye screening can be done by HIV/AIDS clinicians, allowing early tuberculosis treatment.']\n",
            "unmatched tags:  [{'entity': 'tuberculosis', 'type': 'Disease', 'start': 599, 'end': 611}, {'entity': 'HIV/AIDS', 'type': 'Disease', 'start': 563, 'end': 571}, {'entity': 'disseminated tuberculosis', 'type': 'Disease', 'start': 473, 'end': 498}, {'entity': 'tuberculosis', 'type': 'Disease', 'start': 313, 'end': 325}]\n",
            "['Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients\\tSummary Background The novel coronavirus (CoV) severe acute respiratory syndrome (SARS)-CoV-2 outbreak started at the end of 2019 in Wuhan, China, and spread over 100 countries.', 'SARS-CoV-2 uses the membrane protein Angiotensin I converting enzyme 2(ACE2) as a cell entry receptor.', 'Indeed, it was reported that the balance of Renin-Angiotensin System (RAS), regulated by both ACE and ACE2, was altered in COVID-19 patients.', 'It is controversial, however, whether commonly used anti-hypertensive drugs Angiotensin I converting enzyme inhibitor (ACEI) and Angiotensin II receptor blocker (ARB) shall be continued in the confirmed COVID-19 patients.', 'This study was designed to investigate any difference in disease severity between COVID-19 patients with hypertension comorbidity.', 'The included COVID-19 patients used ACEI, ARB, calcium channel blockers (CCB), beta blockers (BB), or thiazide to treat preexisting hypertension prior to the hospital were compared to patients who did not take any of those drugs.', 'Methods  In this multicentre retrospective study, clinical data of 511 COVID-19 patients were analyzed.', 'Patients were categorized into six sub-groups of hypertension comorbidity based on treatment using one of anti-hypertension drugs (ACEI, ARB, CCB, BB, thiazide), or none.', 'A meta-analysis was performed to evaluate the use of ACEI and ARB associated with pneumonia using published studies.', 'Findings  Among the elderly (age>65) COVID-19 patients with hypertension comorbidity, the risk of COVID-19-S (severe disease) was significantly decreased in patients who took ARB drugs prior to hospitalization compared to patients who took no drugs (OR=0.343, 95% CI 0.128-0.916, p=0.025).', 'The meta-analysis showed that ARB use has positive effects associated with morbidity and mortality of pneumonia.', 'Interpretation  Elderly (age>65) COVID-19 patients with hypertension comorbidity who are taking ARB anti-hypertension drugs may be less likely to develop severe lung disease compared to patients who take no anti-hypertension drugs.', 'Funding  National Natural Science Foundation of China, Chinese Academy of Medical Sciences']\n",
            "unmatched tags:  [{'entity': 'hypertension', 'type': 'Disease', 'start': 2142, 'end': 2154}, {'entity': 'anti-hypertension drugs', 'type': 'Drug', 'start': 2137, 'end': 2160}, {'entity': 'lung disease', 'type': 'Disease', 'start': 2091, 'end': 2103}, {'entity': 'anti-hypertension drugs', 'type': 'Drug', 'start': 2030, 'end': 2053}, {'entity': 'hypertension', 'type': 'Disease', 'start': 1986, 'end': 1998}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1963, 'end': 1971}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 1917, 'end': 1926}, {'entity': 'ARB drugs', 'type': 'Drug', 'start': 1700, 'end': 1709}, {'entity': 'severe disease', 'type': 'Disease', 'start': 1635, 'end': 1649}, {'entity': 'hypertension', 'type': 'Disease', 'start': 1585, 'end': 1597}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1562, 'end': 1570}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 1489, 'end': 1498}, {'entity': 'ACEI', 'type': 'Chemical', 'start': 1460, 'end': 1464}, {'entity': 'thiazide', 'type': 'Drug', 'start': 1387, 'end': 1395}, {'entity': 'CCB', 'type': 'Drug', 'start': 1378, 'end': 1381}, {'entity': 'ACEI', 'type': 'Chemical', 'start': 1367, 'end': 1371}, {'entity': 'anti-hypertension drugs', 'type': 'Drug', 'start': 1342, 'end': 1365}, {'entity': 'hypertension', 'type': 'Disease', 'start': 1285, 'end': 1297}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1203, 'end': 1211}, {'entity': 'hypertension', 'type': 'Disease', 'start': 1033, 'end': 1045}, {'entity': 'thiazide', 'type': 'Drug', 'start': 1003, 'end': 1011}, {'entity': 'beta blockers', 'type': 'Drug', 'start': 980, 'end': 993}, {'entity': 'CCB', 'type': 'Drug', 'start': 974, 'end': 977}, {'entity': 'calcium channel blockers', 'type': 'Drug', 'start': 948, 'end': 972}, {'entity': 'ACEI', 'type': 'Chemical', 'start': 937, 'end': 941}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 914, 'end': 922}, {'entity': 'hypertension', 'type': 'Disease', 'start': 875, 'end': 887}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 852, 'end': 860}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 751, 'end': 759}, {'entity': 'Angiotensin II receptor blocker', 'type': 'Drug', 'start': 677, 'end': 708}, {'entity': 'ACEI', 'type': 'Chemical', 'start': 667, 'end': 671}, {'entity': 'Angiotensin I', 'type': 'Gene', 'start': 624, 'end': 637}, {'entity': 'anti-hypertensive drugs', 'type': 'Drug', 'start': 600, 'end': 623}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 529, 'end': 537}, {'entity': 'ACE2', 'type': 'Gene', 'start': 508, 'end': 512}, {'entity': 'RAS', 'type': 'Drug', 'start': 476, 'end': 479}, {'entity': 'cell entry receptor', 'type': 'Gene', 'start': 385, 'end': 404}]\n",
            "['Human African trypanosomiasis\\tHuman African trypanosomiasis (sleeping sickness) is a parasitic infection that almost invariably progresses to death unless treated.', 'Human African trypanosomiasis caused devastating epidemics during the 20th century.', 'Thanks to sustained and coordinated efforts over the past 15 years, the number of reported cases has fallen to an historically low level.', 'Fewer than 3000 cases were reported in 2015, and the disease is targeted for elimination by WHO.', 'Despite these recent successes, the disease is still endemic in parts of sub-Saharan Africa, where it is a considerable burden on rural communities, most notably in central Africa.']\n",
            "unmatched tags:  [{'entity': 'Human African trypanosomiasis', 'type': 'Disease', 'start': 164, 'end': 193}, {'entity': 'parasitic infection', 'type': 'Disease', 'start': 85, 'end': 104}]\n",
            "['Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine\\tThe Strategic Advisory Group of Experts (SAGE) on Immunization advises WHO on global policies for vaccines.', 'In April, 2016, SAGE issued recommendations on the use of the first licenced dengue vaccine, CYD-TDV.', 'In November, 2017, a retrospective analysis of clinical trial data, stratifying participants according to their dengue serostatus before the first vaccine dose, showed that although in high seroprevalence settings the vaccine provides overall population benefit, there was an excess risk of severe dengue in seronegative vaccinees.']\n",
            "unmatched tags:  [{'entity': 'vaccine', 'type': 'Drug', 'start': 641, 'end': 648}, {'entity': 'dengue', 'type': 'Disease', 'start': 618, 'end': 624}, {'entity': 'vaccine', 'type': 'Drug', 'start': 538, 'end': 545}, {'entity': 'vaccine', 'type': 'Drug', 'start': 467, 'end': 474}, {'entity': 'dengue serostatus', 'type': 'Disease', 'start': 432, 'end': 449}]\n",
            "['Classification of Coronavirus Images using Shrunken Features\\tNecessary screenings must be performed to control the spread of the Corona Virus (COVID-19) in daily life and to make a preliminary diagnosis of suspicious cases.', 'The long duration of pathological laboratory tests and the wrong test results led the researchers to focus on different fields.', 'Fast and accurate diagnoses are essential for effective interventions with COVID-19.', 'The information obtained by using X-ray and Computed Tomography (CT) images is vital in making clinical diagnoses.', 'Therefore it was aimed to develop a machine learning method for the detection of viral epidemics by analyzing X-ray images.', 'In this study, images belonging to 6 situations, including coronavirus images, are classified.', 'Since the number of images in the dataset is deficient and unbalanced, it is more convenient to analyze these images with hand-crafted feature extraction methods.', 'For this purpose, firstly, all the images in the dataset are extracted with the help of four feature extraction algorithms.', 'These extracted features are combined in raw form.', 'The unbalanced data problem is eliminated by producing feature vectors with the SMOTE algorithm.', 'Finally, the feature vector is reduced in size by using a stacked auto-encoder and principal component analysis to remove interconnected features in the feature vector.', 'According to the obtained results, it is seen that the proposed method has leveraging performance, especially in order to make the diagnosis of COVID-19 in a short time and effectively.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 1519, 'end': 1527}]\n",
            "[\"Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study\\tContinuous delivery of levodopa-carbidopa with an intestinal gel offers a promising option for control of advanced Parkinson's disease with motor complications.\", 'Benefits noted with intestinal gel delivery were of a greater magnitude than were those obtained with medical therapies to date, and our study is, to our knowledge, the first demonstration of the benefit of continuous levodopa delivery in a double-blind controlled study.']\n",
            "unmatched tags:  [{'entity': 'levodopa', 'type': 'Gene', 'start': 556, 'end': 564}]\n",
            "['Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment\\tGH treatment did not affect the incidence of type 1 diabetes mellitus in any age group.', 'We postulate that the higher than expected incidence of type 2 diabetes mellitus with GH treatment may be an acceleration of the disorder in predisposed individuals.']\n",
            "unmatched tags:  [{'entity': 'GH', 'type': 'Gene', 'start': 299, 'end': 301}]\n",
            "['Antiviral combinations for severe influenza\\tObservational data suggest that the treatment of influenza infection with neuraminidase inhibitors decreases progression to more severe illness, especially when treatment is started soon after symptom onset.', 'However, even early treatment might fail to prevent complications in some patients, particularly those infected with novel viruses such as the 2009 pandemic influenza A H1N1, avian influenza A H5N1 virus subtype, or the avian influenza A H7N9 virus subtype.', 'Furthermore, treatment with one antiviral drug might promote the development of antiviral resistance, especially in immunocompromised hosts and critically ill patients.']\n",
            "unmatched tags:  [{'entity': 'critically ill', 'type': 'Phenotype', 'start': 654, 'end': 668}, {'entity': 'antiviral drug', 'type': 'Drug', 'start': 542, 'end': 556}, {'entity': 'influenza A H7N9 virus subtype', 'type': 'Virus', 'start': 478, 'end': 508}]\n",
            "['Posterior cortical atrophy\\tPosterior cortical atrophy (PCA) is a neurodegenerative syndrome that is characterised by progressive decline in visuospatial, visuoperceptual, literacy, and praxic skills.', \"The progressive neurodegeneration affecting parietal, occipital, and occipitotemporal cortices that underlies PCA is attributable to Alzheimer's disease in most patients.\", 'However, alternative underlying causes, including dementia with Lewy bodies, corticobasal degeneration, and prion disease, have also been identified, and not all patients with PCA have atrophy on clinical imaging.']\n",
            "unmatched tags:  [{'entity': 'PCA', 'type': 'Gene', 'start': 547, 'end': 550}, {'entity': 'prion disease', 'type': 'Disease', 'start': 479, 'end': 492}, {'entity': 'corticobasal degeneration', 'type': 'Disease', 'start': 448, 'end': 473}, {'entity': 'dementia', 'type': 'Disease', 'start': 421, 'end': 429}, {'entity': \"Alzheimer's disease\", 'type': 'Disease', 'start': 333, 'end': 352}, {'entity': 'PCA', 'type': 'Gene', 'start': 310, 'end': 313}, {'entity': 'visuoperceptual', 'type': 'Phenotype', 'start': 154, 'end': 169}, {'entity': 'PCA', 'type': 'Gene', 'start': 55, 'end': 58}]\n",
            "['approach for designing of a multi-epitope based vaccine against novel Coronavirus (SARS-COV-2)\\tA novel Coronavirus (SARS-COV-2) has now become a global pandemic.', 'Considering the severity of infection and the associated mortalities, there is an urgent need to develop an effective preventive measure against this virus.', 'In this study, we have designed a novel vaccine construct using computational strategies.', 'Spike (S) glycoprotein is the major antigenic component that trigger the host immune responses.', 'Detailed investigation of S protein with various immunoinformatics tools enabled us to identify 5 MHC I and 5 MHC II B-cell derived T-cell epitopes with VaxiJen score > 1 and IC 50 value < 100nM.', 'These epitopes were joined with a suitable adjuvant and appropriate linkers to form a multi-epitope based vaccine construct.', 'Further, in silico testing of the vaccine construct for its antigenicity, allergenicity, solubility, and other physicochemical properties showed it to be safe and immunogenic.', 'Suitable tertiary structure of the vaccine protein was generated using 3Dpro of SCRATCH suite, refined with GalaxyRefine, and validated with ProSA, PROCHECK, and ERRAT server.', 'Finally, molecular docking studies were performed to ensure a favorable binding affinity between the vaccine construct and TLR3 receptor.', 'The designed multi-epitope vaccine showed potential to elicit specific immune responses against the SARS-COV-2.', 'However, further wet lab validation is necessary to confirm the actual effectiveness, safety and immunogenic potency of the vaccine construct against derived in this study.']\n",
            "unmatched tags:  [{'entity': 'vaccine construct', 'type': 'Gene', 'start': 1552, 'end': 1569}, {'entity': 'wet lab', 'type': 'Gene', 'start': 1445, 'end': 1452}, {'entity': 'SARS-COV-2', 'type': 'Virus', 'start': 1416, 'end': 1426}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1343, 'end': 1350}, {'entity': 'multi-epitope vaccine', 'type': 'Gene', 'start': 1329, 'end': 1350}, {'entity': 'TLR3 receptor', 'type': 'Gene', 'start': 1301, 'end': 1314}, {'entity': 'vaccine construct', 'type': 'Gene', 'start': 1279, 'end': 1296}, {'entity': 'ERRAT', 'type': 'Gene', 'start': 1164, 'end': 1169}, {'entity': 'GalaxyRefine', 'type': 'Chemical', 'start': 1110, 'end': 1122}, {'entity': 'SCRATCH', 'type': 'Disease', 'start': 1082, 'end': 1089}, {'entity': 'vaccine protein', 'type': 'Drug', 'start': 1037, 'end': 1052}, {'entity': 'vaccine construct', 'type': 'Gene', 'start': 860, 'end': 877}, {'entity': 'vaccine construct', 'type': 'Gene', 'start': 807, 'end': 824}, {'entity': 'multi-epitope', 'type': 'Gene', 'start': 787, 'end': 800}]\n",
            "['Vitamin D and solar ultraviolet radiation in the risk and treatment of tuberculosis\\tImproved understanding of the association between tuberculosis and vitamin D is needed to inform clinical practice.', 'Vitamin D has both immunostimulatory and immunosuppressive effects relevant to human antimycobacterial responses.', 'Ultraviolet radiation, the main source of vitamin D, also induces immunomodulation and could affect the relation between vitamin D and tuberculosis.', 'Clinical trials of vitamin D supplementation in patients with tuberculosis have produced largely negative results, prompting the review of dosing regimens—an explanation for low 25-hydroxyvitamin D status in patients with active tuberculosis is also needed.']\n",
            "unmatched tags:  [{'entity': 'active tuberculosis', 'type': 'Disease', 'start': 685, 'end': 704}]\n",
            "['Integrated analyses of single-cell atlases reveal age, gender, and smoking status associations with cell type-specific expression of mediators of SARS-CoV-2 viral entry and highlights inflammatory programs in putative target cells\\tThe COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, creates an urgent need for identifying molecular mechanisms that mediate viral entry, propagation, and tissue pathology.', 'Cell membrane bound angiotensin-converting enzyme 2 (ACE2) and associated proteases, transmembrane protease serine 2 (TMPRSS2) and Cathepsin L (CTSL), were previously identified as mediators of SARS-CoV2 cellular entry.', 'Here, we assess the cell type-specific RNA expression of ACE2 , TMPRSS2 , and CTSL through an integrated analysis of 107 single-cell and single-nucleus RNA-Seq studies, including 22 lung and airways datasets (16 unpublished), and 85 datasets from other diverse organs.', 'Joint expression of ACE2 and the accessory proteases identifies specific subsets of respiratory epithelial cells as putative targets of viral infection in the nasal passages, airways, and alveoli.', 'Cells that co-express ACE2 and proteases are also identified in cells from other organs, some of which have been associated with COVID-19 transmission or pathology, including gut enterocytes, corneal epithelial cells, cardiomyocytes, heart pericytes, olfactory sustentacular cells, and renal epithelial cells.', 'Performing the first meta-analyses of scRNA-seq studies, we analyzed 1,176,683 cells from 282 nasal, airway, and lung parenchyma samples from 164 donors spanning fetal, childhood, adult, and elderly age groups, associate increased levels of ACE2 , TMPRSS2 , and CTSL in specific cell types with increasing age, male gender, and smoking, all of which are epidemiologically linked to COVID-19 susceptibility and outcomes.', 'Notably, there was a particularly low expression of ACE2 in the few young pediatric samples in the analysis.', 'Further analysis reveals a gene expression program shared by ACE2 + TMPRSS2 + cells in nasal, lung and gut tissues, including genes that may mediate viral entry, subtend key immune functions, and mediate epithelial-macrophage cross-talk.', 'Amongst these are IL6, its receptor and co-receptor, IL1R , TNF response pathways, and complement genes.', 'Cell type specificity in the lung and airways and smoking effects were conserved in mice.', 'Our analyses suggest that differences in the cell type-specific expression of mediators of SARS-CoV-2 viral entry may be responsible for aspects of COVID-19 epidemiology and clinical course, and point to putative molecular pathways involved in disease susceptibility and pathogenesis.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2525, 'end': 2533}, {'entity': 'mediators', 'type': 'Drug', 'start': 2455, 'end': 2464}, {'entity': 'cell', 'type': 'Gene', 'start': 2422, 'end': 2426}, {'entity': 'mice', 'type': 'Gene', 'start': 2371, 'end': 2375}, {'entity': 'complement genes', 'type': 'Gene', 'start': 2269, 'end': 2285}, {'entity': 'TNF', 'type': 'Gene', 'start': 2242, 'end': 2245}, {'entity': 'IL1R', 'type': 'Gene', 'start': 2235, 'end': 2239}, {'entity': 'receptor', 'type': 'Gene', 'start': 2225, 'end': 2233}, {'entity': 'receptor', 'type': 'Gene', 'start': 2209, 'end': 2217}, {'entity': 'IL6', 'type': 'Gene', 'start': 2200, 'end': 2203}, {'entity': 'cell', 'type': 'Gene', 'start': 2022, 'end': 2026}, {'entity': 'TMPRSS2', 'type': 'Gene', 'start': 2012, 'end': 2019}, {'entity': 'ACE2', 'type': 'Gene', 'start': 2005, 'end': 2009}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1887, 'end': 1891}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1797, 'end': 1805}, {'entity': 'cell', 'type': 'Gene', 'start': 1694, 'end': 1698}, {'entity': 'CTSL', 'type': 'Gene', 'start': 1677, 'end': 1681}, {'entity': 'TMPRSS2', 'type': 'Gene', 'start': 1663, 'end': 1670}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1656, 'end': 1660}, {'entity': 'cell', 'type': 'Gene', 'start': 1494, 'end': 1498}, {'entity': 'cell', 'type': 'Gene', 'start': 1408, 'end': 1412}, {'entity': 'cell', 'type': 'Gene', 'start': 1380, 'end': 1384}, {'entity': 'cell', 'type': 'Gene', 'start': 1316, 'end': 1320}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1234, 'end': 1242}, {'entity': 'cell', 'type': 'Gene', 'start': 1169, 'end': 1173}, {'entity': 'proteases', 'type': 'Gene', 'start': 1136, 'end': 1145}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1127, 'end': 1131}, {'entity': 'co-express', 'type': 'Organization', 'start': 1116, 'end': 1126}, {'entity': 'viral infection', 'type': 'Virus', 'start': 1044, 'end': 1059}, {'entity': 'cell', 'type': 'Gene', 'start': 1015, 'end': 1019}, {'entity': 'proteases', 'type': 'Gene', 'start': 951, 'end': 960}, {'entity': 'ACE2', 'type': 'Gene', 'start': 928, 'end': 932}, {'entity': 'cell', 'type': 'Gene', 'start': 767, 'end': 771}, {'entity': 'CTSL', 'type': 'Gene', 'start': 717, 'end': 721}, {'entity': 'TMPRSS2', 'type': 'Gene', 'start': 703, 'end': 710}, {'entity': 'ACE2', 'type': 'Gene', 'start': 696, 'end': 700}, {'entity': 'RNA', 'type': 'Gene', 'start': 678, 'end': 681}, {'entity': 'cell', 'type': 'Gene', 'start': 659, 'end': 663}, {'entity': 'cell', 'type': 'Gene', 'start': 623, 'end': 627}, {'entity': 'mediators', 'type': 'Drug', 'start': 600, 'end': 609}, {'entity': 'CTSL', 'type': 'Gene', 'start': 563, 'end': 567}, {'entity': 'Cathepsin L', 'type': 'Gene', 'start': 550, 'end': 561}, {'entity': 'TMPRSS2', 'type': 'Gene', 'start': 537, 'end': 544}, {'entity': 'transmembrane protease serine 2', 'type': 'Gene', 'start': 504, 'end': 535}, {'entity': 'associated proteases', 'type': 'Gene', 'start': 482, 'end': 502}, {'entity': 'ACE2', 'type': 'Gene', 'start': 472, 'end': 476}]\n",
            "['Primary brain tumours in adults\\tPrimary CNS tumours refer to a heterogeneous group of tumours arising from cells within the CNS, and can be benign or malignant.', 'Malignant primary brain tumours remain among the most difficult cancers to treat, with a 5 year overall survival no greater than 35%.', 'The most common malignant primary brain tumours in adults are gliomas.', 'Recent advances in molecular biology have improved understanding of glioma pathogenesis, and several clinically significant genetic alterations have been described.', 'A number of these (']\n",
            "unmatched tags:  [{'entity': 'gliomas', 'type': 'Disease', 'start': 357, 'end': 364}]\n",
            "['Rotavirus vaccines: viral shedding and risk of transmission\\tRotavirus causes gastroenteritis in almost all children by 5 years of age.', 'Immunity to rotavirus is incomplete, with potential for recurrent infections occurring throughout life.', 'Live rotavirus vaccines have been developed for the protection of children from severe wildtype rotavirus infections.', 'Transmission of vaccine virus strains from vaccinated children to unvaccinated contacts harbours the potential for herd immunity, but also the risk of vaccine-derived disease in immunocompromised contacts.']\n",
            "unmatched tags:  [{'entity': 'strains', 'type': 'Disease', 'start': 387, 'end': 394}, {'entity': 'vaccine virus', 'type': 'Virus', 'start': 373, 'end': 386}]\n",
            "['Familial intracranial aneurysms\\tOur results demonstrate a high prevalence of incidental intracranial aneurysms among first-degree relatives aged 30 years or older of patients with the condition and indicate that the risk of having an aneurysm is about four times higher for a close relative than for someone from the general population.', 'Also, polycystic kidney disease families are a small fraction of the familial intracranial aneurysm families.']\n",
            "unmatched tags:  [{'entity': 'familial intracranial aneurysm', 'type': 'Disease', 'start': 406, 'end': 436}]\n",
            "['Human papillomavirus and cervical cancer\\tCervical cancer is the second most common cancer in women worldwide, and knowledge regarding its cause and pathogenesis is expanding rapidly.', 'Persistent infection with one of about 15 genotypes of carcinogenic human papillomavirus (HPV) causes almost all cases.', 'There are four major steps in cervical cancer development: infection of metaplastic epithelium at the cervical transformation zone, viral persistence, progression of persistently infected epithelium to cervical precancer, and invasion through the basement membrane of the epithelium.']\n",
            "unmatched tags:  [{'entity': 'cancer', 'type': 'Disease', 'start': 517, 'end': 523}, {'entity': 'cervical precancer', 'type': 'Disease', 'start': 505, 'end': 523}, {'entity': 'cervical cancer', 'type': 'Disease', 'start': 333, 'end': 348}, {'entity': 'HPV', 'type': 'Gene', 'start': 273, 'end': 276}, {'entity': 'carcinogenic human papillomavirus', 'type': 'Virus', 'start': 238, 'end': 271}]\n",
            "['Clinical challenges in mechanical ventilation\\tMechanical ventilation supports gas exchange and alleviates the work of breathing when the respiratory muscles are overwhelmed by an acute pulmonary or systemic insult.', 'Although mechanical ventilation is not generally considered a treatment for acute respiratory failure per se, ventilator management warrants close attention because inappropriate ventilation can result in injury to the lungs or respiratory muscles and worsen morbidity and mortality.', 'Key clinical challenges include averting intubation in patients with respiratory failure with non-invasive techniques for respiratory support; delivering lung-protective ventilation to prevent ventilator-induced lung injury; maintaining adequate gas exchange in severely hypoxaemic patients; avoiding the development of ventilator-induced diaphragm dysfunction; and diagnosing and treating the many pathophysiological mechanisms that impair liberation from mechanical ventilation.']\n",
            "unmatched tags:  [{'entity': 'impair', 'type': 'Disease', 'start': 933, 'end': 939}, {'entity': 'ventilator-induced lung injury', 'type': 'Disease', 'start': 692, 'end': 722}]\n",
            "['Inhibition of SARS-CoV-2 infection (previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion\\tThe recent outbreak of coronavirus disease (COVID-19) caused by SARS-CoV-2 infection in Wuhan, China has posed a serious threat to global public health.', 'To develop specific anti-coronavirus therapeutics and prophylactics, the molecular mechanism that underlies viral infection must first be confirmed.', 'Therefore, we herein used a SARS-CoV-2 spike (S) protein-mediated cell-cell fusion assay and found that SARS-CoV-2 showed plasma membrane fusion capacity superior to that of SARS-CoV.', 'We solved the X-ray crystal structure of six-helical bundle (6-HB) core of the HR1 and HR2 domains in SARS-CoV-2 S protein S2 subunit, revealing that several mutated amino acid residues in the HR1 domain may be associated with enhanced interactions with HR2 domain.', 'We previously developed a pan-coronavirus fusion inhibitor, EK1, which targeted HR1 domain and could inhibit infection by divergent human coronaviruses tested, including SARS-CoV and MERS-CoV.', 'We then generated a series of lipopeptides and found that the EK1C4 was the most potent fusion inhibitor against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection with IC 50 s of 1.3 and 15.8 nM, about 241- and 149-fold more potent than that of EK1 peptide, respectively.', 'EK1C4 was also highly effective against membrane fusion and infection of other human coronavirus pseudoviruses tested, including SARS-CoV and MERS-CoV, as well as SARSr-CoVs, potently inhibiting replication of 4 live human coronaviruses, including SARS-CoV-2.', 'Intranasal application of EK1C4 before or after challenge with HCoV-OC43 protected mice from infection, suggesting that EK1C4 could be used for prevention and treatment of infection by currently circulating SARS-CoV-2 and emerging SARSr-CoVs.']\n",
            "unmatched tags:  [{'entity': 'SARSr-CoVs', 'type': 'Virus', 'start': 1924, 'end': 1934}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1900, 'end': 1910}, {'entity': 'EK1', 'type': 'Disease', 'start': 1813, 'end': 1816}, {'entity': 'mice', 'type': 'Gene', 'start': 1776, 'end': 1780}, {'entity': 'HCoV-OC43', 'type': 'Virus', 'start': 1756, 'end': 1765}, {'entity': 'EK1', 'type': 'Disease', 'start': 1719, 'end': 1722}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1681, 'end': 1691}, {'entity': 'coronaviruses', 'type': 'Virus', 'start': 1656, 'end': 1669}, {'entity': 'SARSr-CoVs', 'type': 'Virus', 'start': 1596, 'end': 1606}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 1575, 'end': 1583}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 1562, 'end': 1570}, {'entity': 'coronavirus pseudoviruses', 'type': 'Virus', 'start': 1518, 'end': 1543}, {'entity': 'EK1', 'type': 'Disease', 'start': 1433, 'end': 1436}, {'entity': 'EK1 peptide', 'type': 'Chemical', 'start': 1406, 'end': 1417}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1252, 'end': 1262}, {'entity': 'fusion inhibitor', 'type': 'Drug', 'start': 1227, 'end': 1243}, {'entity': 'EK1', 'type': 'Disease', 'start': 1201, 'end': 1204}, {'entity': 'lipopeptides', 'type': 'Gene', 'start': 1169, 'end': 1181}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 1129, 'end': 1137}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 1116, 'end': 1124}, {'entity': 'coronaviruses', 'type': 'Virus', 'start': 1084, 'end': 1097}, {'entity': 'HR1', 'type': 'Gene', 'start': 1026, 'end': 1029}, {'entity': 'EK1', 'type': 'Disease', 'start': 1006, 'end': 1009}, {'entity': 'fusion inhibitor', 'type': 'Drug', 'start': 988, 'end': 1004}, {'entity': 'pan-coronavirus', 'type': 'Virus', 'start': 972, 'end': 987}, {'entity': 'HR2 domain', 'type': 'Disease', 'start': 934, 'end': 944}]\n",
            "['GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study\\tThe addition of ATLG to standard GVHD prophylaxis improves the probability of surviving without disease relapse and cGVHD after myeloablative peripheral blood stem-cell transplantation from an HLA-identical sibling donor for patients with acute leukaemia in remission.', 'Further additional benefits are better QoL and shorter immunosuppressive treatment compared with standard GVHD prophylaxis without ATLG.', 'Therefore, in this setting, ATLG plus standard GVHD prophylaxis should be preferred over the standard GVHD prophylaxis alone.']\n",
            "unmatched tags:  [{'entity': 'GVHD', 'type': 'Disease', 'start': 791, 'end': 795}, {'entity': 'GVHD', 'type': 'Disease', 'start': 736, 'end': 740}, {'entity': 'GVHD', 'type': 'Disease', 'start': 658, 'end': 662}, {'entity': 'immunosuppressive treatment', 'type': 'Drug', 'start': 607, 'end': 634}, {'entity': 'QoL', 'type': 'Phenotype', 'start': 591, 'end': 594}]\n",
            "['Insights and challenges in tuberculosis vaccine development\\tTuberculosis kills more people than any other pathogen and the need for a universally effective vaccine has never been greater.', 'An effective vaccine will be a key tool in achieving the targets set by WHO in the End TB Strategy.', 'Tuberculosis vaccine development is difficult and slow.', 'Substantial progress has been made in research and development of tuberculosis vaccines in the past 20 years, and two clinical trial results from 2018 provide reason for optimism.', 'However, many challenges to the successful licensure and deployment of an effective tuberculosis vaccine remain.']\n",
            "unmatched tags:  [{'entity': 'vaccine', 'type': 'Drug', 'start': 621, 'end': 628}, {'entity': 'tuberculosis vaccine', 'type': 'Drug', 'start': 608, 'end': 628}, {'entity': 'tuberculosis vaccines', 'type': 'Drug', 'start': 410, 'end': 431}, {'entity': 'vaccine', 'type': 'Drug', 'start': 301, 'end': 308}, {'entity': 'Tuberculosis', 'type': 'Disease', 'start': 288, 'end': 300}]\n",
            "['Diabetes, hyperglycaemia, and acute ischaemic stroke\\tDiabetes and ischaemic stroke often arise together.', 'People with diabetes have more than double the risk of ischaemic stroke after correction for other risk factors, relative to individuals without diabetes.', 'Multifactorial treatment of risk factors for stroke—in particular, lifestyle factors, hypertension, and dyslipidaemia—will prevent a substantial number of these disabling strokes.', 'Hyperglycaemia occurs in 30–40% of patients with acute ischaemic stroke, also in individuals without a known history of diabetes.']\n",
            "unmatched tags:  [{'entity': 'diabetes', 'type': 'Disease', 'start': 560, 'end': 568}, {'entity': 'stroke', 'type': 'Disease', 'start': 505, 'end': 511}, {'entity': 'acute ischaemic stroke', 'type': 'Disease', 'start': 489, 'end': 511}, {'entity': 'Hyperglycaemia', 'type': 'Disease', 'start': 440, 'end': 454}, {'entity': 'strokes', 'type': 'Disease', 'start': 431, 'end': 438}, {'entity': 'dyslipidaemia', 'type': 'Disease', 'start': 364, 'end': 377}, {'entity': 'hypertension', 'type': 'Disease', 'start': 346, 'end': 358}]\n",
            "['Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV\\tLiver disease is a leading cause of morbidity and mortality among people with HIV, and in this era of safer and more effective hepatitis C therapy, non-alcoholic fatty liver disease (NAFLD) could soon emerge as the most common liver disease in this population.', 'NAFLD is common among patients with HIV, and might be more likely to progress to non-alcoholic steatohepatitis (NASH) and NAFLD-related fibrosis or cirrhosis in these patients than in individuals without HIV.', 'Several mechanisms of NAFLD pathogenesis are postulated to explain the disease severity in patients with HIV; these mechanisms include the influence of the gut microbiome, and also metabolic, genetic, and immunological factors.']\n",
            "unmatched tags:  [{'entity': 'HIV', 'type': 'Virus', 'start': 664, 'end': 667}, {'entity': 'NAFLD', 'type': 'Disease', 'start': 581, 'end': 586}, {'entity': 'era', 'type': 'Gene', 'start': 562, 'end': 565}, {'entity': 'HIV', 'type': 'Virus', 'start': 554, 'end': 557}, {'entity': 'cirrhosis', 'type': 'Disease', 'start': 498, 'end': 507}, {'entity': 'non-alcoholic steatohepatitis', 'type': 'Disease', 'start': 431, 'end': 460}, {'entity': 'HIV', 'type': 'Virus', 'start': 386, 'end': 389}, {'entity': 'NAFLD', 'type': 'Disease', 'start': 350, 'end': 355}]\n",
            "[\"Abatacept treatment for patients with early active primary Sjögren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)\\tOn the basis of this trial, we cannot recommend abatacept treatment as standard of care to reduce systemic disease activity in patients with primary Sjögren's syndrome.\", 'Further studies should evaluate whether patients with specific clinical manifestations and biological characteristics might benefit from abatacept treatment.']\n",
            "unmatched tags:  [{'entity': 'abatacept', 'type': 'Gene', 'start': 479, 'end': 488}]\n",
            "['Radiological surveillance of interval breast cancers in screening programmes\\tInterval breast cancers—those diagnosed after a negative mammographic screen and before the next scheduled screen—are an important indicator of the potential effectiveness of population screening for breast cancer.', 'Although the incidence of interval cancers is usually monitored, radiological surveillance is not undertaken routinely in most screening programmes.', 'Here, we describe radiological surveillance of interval breast cancers and discuss methodological difficulties in the radiological review process and in the categorisation of interval cancers as false-negative, true, or occult.']\n",
            "unmatched tags:  [{'entity': 'interval cancers', 'type': 'Disease', 'start': 616, 'end': 632}, {'entity': 'interval breast cancers', 'type': 'Disease', 'start': 488, 'end': 511}]\n",
            "['New horizons for stroke prevention: PROGRESS and HOPE\\tInhibitors of angiotensin-converting enzyme (ACE) act by blocking the conversion of angiotensin I to angiotensin II, which is catalysed by this enzyme.', 'ACE inhibitors also prevent the breakdown of bradykinin, a potent vasodepressor agent, and prevent the effects of angiotensin II, which include increase in blood pressure, peripheral vasoconstriction, and stimulation of aldosterone secretion from the adronal cortex.', 'Physiological and pathological studies have shown that ACE inhibitors have beneficial effects, such as increasing vascular compliance, regression of periarteriolar collagen area, improvement of coronary reserve, and regression of resistance-artery structure and left-ventricular hypertrophy.']\n",
            "unmatched tags:  [{'entity': 'beneficial effects', 'type': 'Chemical', 'start': 548, 'end': 566}, {'entity': 'angiotensin II', 'type': 'Gene', 'start': 320, 'end': 334}, {'entity': 'vasodepressor agent', 'type': 'Disease', 'start': 272, 'end': 291}, {'entity': 'bradykinin', 'type': 'Gene', 'start': 251, 'end': 261}, {'entity': 'enzyme', 'type': 'Gene', 'start': 198, 'end': 204}, {'entity': 'angiotensin II', 'type': 'Gene', 'start': 155, 'end': 169}]\n",
            "['IFITM proteins inhibit HIV-1 protein synthesis\\tInterferon induced transmembrane proteins (IFITMs) inhibit the cellular entry of a broad range of viruses, but it has been suspected that for HIV-1 IFITMs may also inhibit a post-integration replicative step.', 'We show that IFITM expression reduces HIV-1 viral protein synthesis by preferentially excluding viral mRNA transcripts from translation and thereby restricts viral production.', 'Codon-optimization of proviral DNA rescues viral translation, implying that IFITM-mediated restriction requires recognition of viral RNA elements.', 'In addition, we find that expression of the viral accessory protein Nef can help overcome the IFITM-mediated inhibition of virus production.', 'Our studies identify a novel role for IFITMs in inhibiting HIV replication at the level of translation, but show that the effects can be overcome by the lentiviral protein Nef.']\n",
            "unmatched tags:  [{'entity': 'Nef', 'type': 'Gene', 'start': 892, 'end': 895}, {'entity': 'lentiviral protein', 'type': 'Gene', 'start': 873, 'end': 891}, {'entity': 'HIV', 'type': 'Virus', 'start': 779, 'end': 782}, {'entity': 'IFITM', 'type': 'Chemical', 'start': 758, 'end': 763}, {'entity': 'Nef', 'type': 'Gene', 'start': 647, 'end': 650}, {'entity': 'viral accessory protein', 'type': 'Gene', 'start': 623, 'end': 646}, {'entity': 'viral RNA elements', 'type': 'Chemical', 'start': 559, 'end': 577}, {'entity': 'IFITM-mediated restriction', 'type': 'Organization', 'start': 508, 'end': 534}, {'entity': 'proviral', 'type': 'Virus', 'start': 454, 'end': 462}, {'entity': 'Codon-optimization', 'type': 'Organization', 'start': 432, 'end': 450}, {'entity': 'transcripts', 'type': 'Gene', 'start': 363, 'end': 374}, {'entity': 'mRNA', 'type': 'Gene', 'start': 358, 'end': 362}]\n",
            "['Differential COVID-19-attributable mortality and BCG vaccine use in countries\\tWhile mortality attributable to COVID-19 has devastated global health systems and economies, striking regional differences have been observed.', 'The Bacille Calmette Guerin (BCG) vaccine has previously been shown to have non-specific protective effects on infections, as well as long-term efficacy against tuberculosis.', 'Using publicly available data we built a simple log-linear regression model to assess the association of BCG use and COVID-19-attributable mortality per 1 million population after adjusting for confounders including country economic status (GDP per capita), and proportion of elderly among the population.', 'The timing of country entry into the pandemic epidemiological trajectory was aligned by plotting time since the 100th reported case.', 'Countries with economies classified as lower-middle-income, upper-middle-income and high-income countries (LMIC, UMIC, HIC) had median crude COVID-19 log-mortality of 0.4 (Interquartile Range (IQR) 0.1, 0.4), 0.7 (IQR 0.2, 2.2) and 5.5 (IQR 1.6,  13.9), respectively.', 'COVID-19-attributable mortality among BCG-using countries was 5.8 times lower [95% CI 1.8-19.0] than in non BCG-using countries.', 'Notwithstanding limitations due to testing constraints in LMICs, case ascertainment bias and a plausible rise of cases as countries progress along the epidemiological trajectory, these analyses provide intriguing observations that urgently warrant mobilization of resources for prospective randomized interventional studies and institution of systematic disease surveillance, particularly in LMICs.']\n",
            "unmatched tags:  [{'entity': 'LMIC', 'type': 'Gene', 'start': 1624, 'end': 1628}, {'entity': 'systematic disease', 'type': 'Disease', 'start': 1575, 'end': 1593}, {'entity': 'case ascertainment', 'type': 'Gene', 'start': 1297, 'end': 1315}]\n",
            "['Polycystic ovary syndrome and endometrial carcinoma\\tAn association between polycystic ovary syndrome (PCOS) and endometrial carcinoma was first suggested in 1949, 14 years after the original description of the syndrome.', 'Since then several studies have been published that seem to support this association.', 'The prescription of hormonal treatment to reduce the risk of this complication is supported by the Guidelines for Good Clinical Practice of the Royal College of Obstetricians and Gynaecologists, UK, the Health Information website of the National Library of Medicine, USA, and in textbooks of gynaecological oncology.']\n",
            "unmatched tags:  [{'entity': 'syndrome', 'type': 'Disease', 'start': 210, 'end': 218}, {'entity': 'endometrial carcinoma', 'type': 'Disease', 'start': 112, 'end': 133}]\n",
            "['Comparative efficacy of low-dose versus standard-dose azithromycin for patients with yaws: a randomised non-inferiority trial in Ghana and Papua New Guinea\\tIn this study, low-dose azithromycin did not meet the prespecified non-inferiority margin compared with standard-dose azithromycin in achieving clinical and serological cure in PCR-confirmed active yaws.', 'Only a single participant (with presumed latent yaws) had definitive serological failure.', 'This work suggests that 20 mg/kg of azithromycin is probably effective against yaws, but further data are needed.']\n",
            "unmatched tags:  [{'entity': 'yaws', 'type': 'Disease', 'start': 529, 'end': 533}]\n",
            "['Testicular germ cell tumours\\tTesticular germ cell tumours are at the crossroads of developmental and neoplastic processes.', 'Their cause has not been fully elucidated but differences in incidences suggest that a combination of genetic and environment factors are involved, with environmental factors predominating early in life.', 'Substantial progress has been made in understanding genetic susceptibility in the past 5 years on the basis of the results of large genome-wide association studies.', 'Testicular germ cell tumours are highly sensitive to radiotherapy and chemotherapy and hence have among the best outcomes of all tumours.']\n",
            "unmatched tags:  [{'entity': 'tumours', 'type': 'Disease', 'start': 621, 'end': 628}, {'entity': 'Testicular germ cell tumours', 'type': 'Disease', 'start': 492, 'end': 520}]\n",
            "['A simple ecological model captures the transmission pattern of the coronavirus COVID-19 outbreak in China\\tThe rapid spread of the 2019 novel coronavirus (COVID-19), initially reported in the city of Wuhan in China, and quickly transmitted to the entire nation and beyond, has become an international public health emergency.', 'Estimating the final number of infection cases and the turning point (time with the fastest spreading rate) is crucial to assessing and improving the national and international control measures currently being applied.', 'In this paper we develop a simple model based on infectious growth with a time-varying infection rate, and estimate the final number of infections and the turning point using data updated daily from 3 February 2020, when China escalated its initial public health measures, to 10 February.', 'Our model provides an extremely good fit to the existing data and therefore a reasonable estimate of the time-varying infection rate that has largely captured the transmission pattern of this epidemic outbreak.', 'Our estimation suggests that (i) the final number of infections in China could reach 78,000 with an upper 95% confidence limit of 88,880; (ii) the turning point of the fastest spread was on the 4th or the 5th of February; and (iii) the projected period for the end of the outbreak (i.e., when 95% of the final predicted number of infection is reached) will be the 24th of February, with an upper 95% confidence limit on the 19th of March.', 'This suggests that the current control measures in China are excellent, and more than sufficient to contain the spread of this highly infectious novel coronavirus, and that the application of such measures could be considered internationally for the global control of this outbreak.']\n",
            "unmatched tags:  [{'entity': 'national', 'type': 'Organization', 'start': 1714, 'end': 1722}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 1634, 'end': 1645}, {'entity': 'turning point', 'type': 'Chemical', 'start': 1191, 'end': 1204}, {'entity': 'turning point', 'type': 'Chemical', 'start': 699, 'end': 712}, {'entity': 'national', 'type': 'Organization', 'start': 493, 'end': 501}]\n",
            "['Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein\\tAlthough isolated amyloid fibrils are stable in vitro, AA amyloid deposits exist in a state of dynamic turnover, and outcome is favourable in AA amyloidosis when the SAA concentration is maintained below 10 mg/L.', 'The potential for amyloid to regress and for the function of amyloidotic organs to recover support therapeutic strategies to decrease the supply of amyloid fibril precursor proteins in amyloidosis generally.']\n",
            "unmatched tags:  [{'entity': 'amyloidosis', 'type': 'Disease', 'start': 518, 'end': 529}, {'entity': 'amyloid', 'type': 'Gene', 'start': 481, 'end': 488}, {'entity': 'amyloid', 'type': 'Gene', 'start': 394, 'end': 401}, {'entity': 'amyloid', 'type': 'Gene', 'start': 351, 'end': 358}]\n",
            "['Colorectal cancer\\tSeveral decades ago, colorectal cancer was infrequently diagnosed.', \"Nowadays, it is the world's fourth most deadly cancer with almost 900\\u2008000 deaths annually.\", 'Besides an ageing population and dietary habits of high-income countries, unfavourable risk factors such as obesity, lack of physical exercise, and smoking increase the risk of colorectal cancer.', 'Advancements in pathophysiological understanding have increased the array of treatment options for local and advanced disease leading to individual treatment plans.']\n",
            "unmatched tags:  [{'entity': 'colorectal cancer', 'type': 'Disease', 'start': 353, 'end': 370}]\n",
            "['Sudden hyposmia as a prevalent symptom of COVID-19 infection.', 'Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has recently caused a pandemic that has involved Italy as the second worldwide nation in terms of infected patients and deaths.', 'The clinical manifestation of Covid-19 ranges from asymptomatic carrier status to severe pneumonia.', 'Asymptomatic individuals in Covid-19 are those who are carriers of the virus but do not show clinical symptoms and are able to transmit the disease in the same degree as symptomatic carriers.', 'In order to contain contagions is of supreme importance to identify asymptomatic patients because this subpopulation is one of the main factors contributing to the spread of this disease.', 'We report on six Italian patients with COVID-19 who presented sudden hyposmia as the only or most prominent disease manifestation, without upper or lower respiratory tract involvement or other major features of the disease.', 'A supra-threshold olfaction test confirmed the hyposmia in all patients.', 'The onset of hyposmia during a Covid-19 outbreak should be considered as a warning sign of an infection that requires a diagnostic test for Covid-19']\n",
            "unmatched tags:  [{'entity': 'Covid-19', 'type': 'Disease', 'start': 1061, 'end': 1069}, {'entity': 'hyposmia', 'type': 'Phenotype', 'start': 1043, 'end': 1051}, {'entity': 'hyposmia', 'type': 'Phenotype', 'start': 1004, 'end': 1012}, {'entity': 'disease manifestation', 'type': 'Disease', 'start': 841, 'end': 862}, {'entity': 'hyposmia', 'type': 'Phenotype', 'start': 802, 'end': 810}, {'entity': 'sudden hyposmia', 'type': 'Phenotype', 'start': 795, 'end': 810}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 772, 'end': 780}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 614, 'end': 621}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 523, 'end': 530}, {'entity': 'clinical symptoms', 'type': 'Phenotype', 'start': 446, 'end': 463}, {'entity': 'Covid-19', 'type': 'Disease', 'start': 381, 'end': 389}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 354, 'end': 361}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 341, 'end': 350}]\n",
            "['Epidemic Landscape and Forecasting of SARS-CoV-2 in India\\tBACKGROUND India was one of the countries to institute strict measures for SARS-CoV-2 control in early phase.', 'Since, then, the epidemic growth trajectory was slow before registering an explosion of cases due to local cluster transmissions.', 'METHODS We estimated growth rate and doubling time of SARS-CoV-2 for India and high burden states using crowd sourced time series data.', 'Further, we also estimated Basic Reproductive Number (R0) and time dependent reproductive number (Rt) using serial intervals from the data.', 'We compared the R0 estimated from five different methods and R0 from SB was further used in analysis.', 'We modified standard SIR models to SIRD model to accommodate deaths using R0 with the Sequential Bayesian method (SBM) for simulation in SIRD models.', 'RESULTS On an average, 2.8 individuals were infected by an index case.', 'The mean serial interval was 3.9 days.', 'The R0 estimated from different methods ranged from 1.43 to 1.85.', 'The mean time to recovery was 14, SD 5.3 days.', 'Daily epidemic growth rate of India was 0.16 [95%CI; 0.14, 0.17] with a doubling time of 4.30 days [95%CI; 3.96, 4.70].', 'From the SIRD model, it can be deduced that the peak of SARS-CoV-2 in India will be around mid-July to early August 2020 with around 12.5% likely to be infected at peak time of incidence.', 'CONCLUSIONS The pattern of spread of SARS-CoV-2 in India is suggestive of community transmission.', 'There is a need to increase fund for infectious disease research and epidemiologic studies.', 'All the current gains may be reversed rapidly if air travel and social mixing resumes rapidly.', 'For the time being, these must be resumed only in a phased manner, and should be back to normal levels only after we are prepared to deal with the disease with efficient tools like vaccine or a medicine.']\n",
            "unmatched tags:  [{'entity': 'vaccine', 'type': 'Drug', 'start': 1827, 'end': 1834}, {'entity': 'infectious disease', 'type': 'Disease', 'start': 1496, 'end': 1514}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1398, 'end': 1408}, {'entity': 'mid-July', 'type': 'Gene', 'start': 1263, 'end': 1271}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1228, 'end': 1238}, {'entity': 'R0', 'type': 'Organization', 'start': 943, 'end': 945}]\n",
            "['Serial interval and generation interval for respectively the imported and local infectors estimated using reported contact-tracing data of COVID-19 in China\\tBackgrounds: The emerging virus, COVID-19, has caused a massive outbreak worldwide.', 'Based on the publicly available contact-tracing data, we identified 337 transmission chains from 10 provinces in China and estimated the serial interval (SI) and generation interval (GI) of COVID-19 in China.', 'Methods: Inspired by possibly different values of the time-varying reproduction number for the imported cases and the local cases in China, we divided all transmission events into three subsets: imported (the zeroth generation) infecting 1st-generation locals, 1st-generation locals infecting 2nd-generation locals, and others transmissions among 2+ generations.', 'The corresponding SI (GI) is respectively denoted as  $\\\\mbox{SI}^{0}_{1}$ ($\\\\mbox{GI}^{0}_{1}$), $\\\\mbox{SI}^{1}_{2}$ ($\\\\mbox{GI}^{1}_{2}$), and $\\\\mbox{SI}^{2+}_{3+}$ ($\\\\mbox{GI}^{2+}_{3+}$).', 'A Bayesian approach with doubly interval-censored likelihood is employed to fit the lognormal, gamma, and Weibull distribution function of the SI and GI using the identified 337 transmission chains.', 'Findings: It is found that the estimated $\\\\mbox{SI}^{0}_{1}$ = 6.27 (95%CI : 5.62 - 6.98), $\\\\mbox{SI}^{1}_{2}$ = 5.92 (95%CI : 5.27 - 6.66),  $\\\\mbox{SI}^{2+}_{3+}$ = 4.36 (95%CI : 3.65 - 5.20), and $\\\\mbox{GI}^{0}_{1}$ = 8.15 (95%CI : 6.73 - 9.91), $\\\\mbox{GI}^{1}_{2}$ = 5.26 (95%CI : 4.25 - 6.69), $\\\\mbox{GI}^{2+}_{3+}$ = 3.85 (95%CI : 2.18 - 6.72), thus overall both SI and GI decrease when generation increases.']\n",
            "unmatched tags:  [{'entity': 'GI', 'type': 'Gene', 'start': 1578, 'end': 1580}, {'entity': 'SI', 'type': 'Gene', 'start': 1571, 'end': 1573}, {'entity': 'GI', 'type': 'Gene', 'start': 1508, 'end': 1510}]\n",
            "['Stroke epidemiology, prevention, and management strategies at a regional level: Latin America and the Caribbean\\tStroke is a major health problem in Latin American and Caribbean countries.', 'In this paper, we review the epidemiology, aetiology, and management of stroke in the region based on a systematic search of articles published in Spanish, Portuguese, and English.', 'Stroke mortality is higher than in developed countries but rates are declining.', 'Population-based studies show variations in incidence of strokes: lower rates of ischaemic stroke and similar rates of intracranial haemorrhages, compared with other regions.']\n",
            "unmatched tags:  [{'entity': 'intracranial haemorrhages', 'type': 'Disease', 'start': 568, 'end': 593}]\n",
            "['Synonymous mutations and the molecular evolution of SARS-Cov-2 origins\\tHuman severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is most closely related, by average genetic distance, to two coronaviruses isolated from bats, RaTG13 and RmYN02.', 'However, there is a segment of high amino acid similarity between human SARS-CoV-2 and a pangolin isolated strain, GD410721, in the receptor binding domain (RBD) of the spike protein, a pattern that can be caused by either recombination or by convergent amino acid evolution driven by natural selection.', 'We perform a detailed analysis of the synonymous divergence, which is less likely to be affected by selection than amino acid divergence, between human SARS-CoV-2 and related strains.', 'We show that the synonymous divergence between the bat derived viruses and SARS-CoV-2 is larger than between GD410721 and SARS-CoV-2 in the RBD, providing strong additional support for the recombination hypothesis.', 'However, the synonymous divergence between pangolin strain and SARS-CoV-2 is also relatively high, which is not consistent with a recent recombination between them, instead it suggests a recombination into RaTG13.', 'We also find a 14-fold increase in the d N / d S ratio from the lineage leading to SARS-CoV-2 to the strains of the current pandemic, suggesting that the vast majority of non-synonymous mutations currently segregating within the human strains have a negative impact on viral fitness.', 'Finally, we estimate that the time to the most recent common ancestor of SARS-CoV-2 and RaTG13 or RmYN02 based on synonymous divergence, is 51.71 years (95% C.I., 28.11-75.31) and 37.02 years (95% C.I., 18.19-55.85), respectively.']\n",
            "unmatched tags:  [{'entity': 'd', 'type': 'Drug', 'start': 1631, 'end': 1632}, {'entity': 'd', 'type': 'Drug', 'start': 1578, 'end': 1579}, {'entity': 'd', 'type': 'Drug', 'start': 1562, 'end': 1563}, {'entity': 'RmYN02', 'type': 'Gene', 'start': 1551, 'end': 1557}, {'entity': 'RaTG13', 'type': 'Gene', 'start': 1541, 'end': 1547}, {'entity': 'd', 'type': 'Drug', 'start': 1539, 'end': 1540}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1526, 'end': 1536}, {'entity': 'strains', 'type': 'Disease', 'start': 1404, 'end': 1411}, {'entity': 'd', 'type': 'Drug', 'start': 1296, 'end': 1297}, {'entity': 'strains', 'type': 'Disease', 'start': 1270, 'end': 1277}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1252, 'end': 1262}, {'entity': 'd', 'type': 'Drug', 'start': 1244, 'end': 1245}, {'entity': 'd', 'type': 'Drug', 'start': 1214, 'end': 1215}, {'entity': 'd', 'type': 'Drug', 'start': 1208, 'end': 1209}, {'entity': 'd', 'type': 'Drug', 'start': 1190, 'end': 1191}, {'entity': 'd', 'type': 'Drug', 'start': 1180, 'end': 1181}, {'entity': 'RaTG13', 'type': 'Gene', 'start': 1161, 'end': 1167}, {'entity': 'd', 'type': 'Drug', 'start': 1126, 'end': 1127}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1018, 'end': 1028}, {'entity': 'd', 'type': 'Drug', 'start': 1016, 'end': 1017}, {'entity': 'd', 'type': 'Drug', 'start': 979, 'end': 980}, {'entity': 'd', 'type': 'Drug', 'start': 904, 'end': 905}, {'entity': 'd', 'type': 'Drug', 'start': 903, 'end': 904}, {'entity': 'd', 'type': 'Drug', 'start': 890, 'end': 891}, {'entity': 'RBD', 'type': 'Gene', 'start': 880, 'end': 883}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 862, 'end': 872}, {'entity': 'd', 'type': 'Drug', 'start': 860, 'end': 861}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 815, 'end': 825}, {'entity': 'd', 'type': 'Drug', 'start': 813, 'end': 814}, {'entity': 'd', 'type': 'Drug', 'start': 801, 'end': 802}, {'entity': 'd', 'type': 'Drug', 'start': 795, 'end': 796}, {'entity': 'd', 'type': 'Drug', 'start': 768, 'end': 769}, {'entity': 'strains', 'type': 'Disease', 'start': 731, 'end': 738}, {'entity': 'd', 'type': 'Drug', 'start': 729, 'end': 730}, {'entity': 'd', 'type': 'Drug', 'start': 721, 'end': 722}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 708, 'end': 718}, {'entity': 'd', 'type': 'Drug', 'start': 682, 'end': 683}, {'entity': 'amino acid', 'type': 'Gene', 'start': 671, 'end': 681}, {'entity': 'd', 'type': 'Drug', 'start': 651, 'end': 652}, {'entity': 'd', 'type': 'Drug', 'start': 605, 'end': 606}, {'entity': 'd', 'type': 'Drug', 'start': 576, 'end': 577}, {'entity': 'd', 'type': 'Drug', 'start': 569, 'end': 570}, {'entity': 'd', 'type': 'Drug', 'start': 527, 'end': 528}, {'entity': 'amino acid', 'type': 'Gene', 'start': 506, 'end': 516}, {'entity': 'd', 'type': 'Drug', 'start': 463, 'end': 464}, {'entity': 'spike protein', 'type': 'Gene', 'start': 421, 'end': 434}, {'entity': 'RBD', 'type': 'Gene', 'start': 409, 'end': 412}, {'entity': 'd', 'type': 'Drug', 'start': 401, 'end': 402}, {'entity': 'd', 'type': 'Drug', 'start': 396, 'end': 397}, {'entity': 'd', 'type': 'Drug', 'start': 357, 'end': 358}, {'entity': 'd', 'type': 'Drug', 'start': 337, 'end': 338}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 324, 'end': 334}, {'entity': 'amino acid', 'type': 'Gene', 'start': 288, 'end': 298}, {'entity': 'RmYN02', 'type': 'Gene', 'start': 244, 'end': 250}, {'entity': 'd', 'type': 'Drug', 'start': 242, 'end': 243}, {'entity': 'RaTG13', 'type': 'Gene', 'start': 233, 'end': 239}, {'entity': 'd', 'type': 'Drug', 'start': 220, 'end': 221}, {'entity': 'coronaviruses', 'type': 'Virus', 'start': 199, 'end': 212}, {'entity': 'd', 'type': 'Drug', 'start': 182, 'end': 183}, {'entity': 'd', 'type': 'Drug', 'start': 160, 'end': 161}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 126, 'end': 136}, {'entity': 'acute respiratory syndrome coronavirus 2', 'type': 'Virus', 'start': 84, 'end': 124}]\n",
            "['Prostate cancer\\tIn developed countries, prostate cancer is the second most frequently diagnosed cancer, and the third most common cause of death from cancer in men.', 'Apart from age and ethnic origin, a positive family history is probably the strongest known risk factor.', 'Clinically, prostate cancer is diagnosed as local or advanced, and treatments range from surveillance to radical local treatment or androgen-deprivation treatment.', 'Androgen deprivation reduces symptoms in about 70–80% of patients with advanced prostate cancer, but most tumours relapse within 2 years to an incurable androgen-independent state.']\n",
            "unmatched tags:  [{'entity': 'tumours relapse', 'type': 'Disease', 'start': 540, 'end': 555}, {'entity': 'cancer', 'type': 'Disease', 'start': 523, 'end': 529}]\n",
            "['Subclinical thyroid disease\\tSubclinical thyroid diseases—subclinical hyperthyroidism and subclinical hypothyroidism—are common clinical entities that encompass mild degrees of thyroid dysfunction.', 'The clinical significance of mild thyroid overactivity and underactivity is uncertain, which has led to controversy over the appropriateness of diagnostic testing and possible treatment.', 'In this Seminar, we discuss the definition, epidemiology, differential diagnoses, risks of progression to overt thyroid disease, potential effects on various health outcomes, and management of subclinical hyperthyroidism and subclinical hypothyroidism.']\n",
            "unmatched tags:  [{'entity': 'subclinical hypothyroidism', 'type': 'Disease', 'start': 609, 'end': 635}, {'entity': 'subclinical hyperthyroidism', 'type': 'Disease', 'start': 577, 'end': 604}, {'entity': 'thyroid disease', 'type': 'Disease', 'start': 496, 'end': 511}]\n",
            "['Use of bednets given free to pregnant women in Kenya\\tIn 2001, UNICEF procured 70\\u2008000 bednets and insecticide treatments to be distributed free to pregnant women attending antenatal clinics in 35 (of 69) districts in Kenya.', '1 year later, we interviewed 294 pregnant women who had received a free net.', '267 (91%) nets had remained in the target homesteads, and only one of the nets had been sold.', 'In a district with high malarial transmission, 93 (84%) of 111 women who had not previously been sleeping under a bednet had used the net while pregnant, and 97 (91%) of the 107 surviving babies were also protected; in another district, which had low transmission, 73 (58%) of 126 women used the nets during pregnancy and 91 (80%) of 114 infants were protected by the nets.']\n",
            "unmatched tags:  [{'entity': 'nets', 'type': 'Gene', 'start': 762, 'end': 766}, {'entity': 'nets', 'type': 'Gene', 'start': 690, 'end': 694}, {'entity': 'surviving', 'type': 'Gene', 'start': 572, 'end': 581}, {'entity': 'malarial', 'type': 'Drug', 'start': 418, 'end': 426}, {'entity': 'nets', 'type': 'Gene', 'start': 374, 'end': 378}, {'entity': 'nets', 'type': 'Gene', 'start': 310, 'end': 314}, {'entity': 'insecticide', 'type': 'Chemical', 'start': 97, 'end': 108}, {'entity': 'nets', 'type': 'Gene', 'start': 88, 'end': 92}]\n",
            "['A comprehensive annotation and differential expression analysis of short and long non-coding RNAs in 16 bat genomes\\tAlthough bats are increasingly becoming the focus of scientific studies due to their unique properties, these exceptional animals are still among the least studied mammals.', 'Assembly quality and completeness of bat genomes vary a lot and especially non-coding RNA (ncRNA) annotations are incomplete or simply missing.', 'Accordingly, standard bioinformatics pipelines for gene expression analysis often ignore ncRNAs such as microRNAs or long antisense RNAs.', 'The main cause of this problem is the use of incomplete genome annotations.', 'We present a complete screening for ncRNAs within 16 bat genomes.', 'NcRNAs affect a remarkable variety of vital biological functions, including gene expression regulation, RNA processing, RNA interference and, as recently described, regulatory processes in viral infections.', 'Within all investigated bat assemblies we annotated 667 ncRNA families including 162 snoRNAs and 193 miRNAs as well as rRNAs, tRNAs, several snRNAs and IncRNAs, and other structural ncRNA elements.', 'We validated our ncRNA candidates by six RNA-Seq data sets and show significant expression patterns that have never been described before in a bat species on such a large scale.', 'Our annotations will be usable as a resource (Electronic Supplement) for deeper studying of bat evolution, ncRNAs repertoire, gene expression and regulation, ecology, and important host-virus interactions.', 'Supplementary information is available at rna.uni-jena.de/supplements/bats , the Open Science Framework ( doi.org/10.17605/OSF.IO/4CMDN ), and GitHub ( github.com/rnajena/bats_ncrna ).']\n",
            "unmatched tags:  [{'entity': 'GitHub', 'type': 'Organization', 'start': 1645, 'end': 1651}, {'entity': 'ncRNAs', 'type': 'Gene', 'start': 1403, 'end': 1409}, {'entity': 'RNAs', 'type': 'Gene', 'start': 1075, 'end': 1079}, {'entity': 'IncRNAs', 'type': 'Gene', 'start': 1072, 'end': 1079}, {'entity': 'snRNAs', 'type': 'Gene', 'start': 1061, 'end': 1067}, {'entity': 'RNAs', 'type': 'Gene', 'start': 1047, 'end': 1051}, {'entity': 'tRNAs', 'type': 'Gene', 'start': 1046, 'end': 1051}, {'entity': 'rRNAs', 'type': 'Gene', 'start': 1039, 'end': 1044}, {'entity': 'RNAs', 'type': 'Gene', 'start': 1023, 'end': 1027}, {'entity': 'miRNAs', 'type': 'Gene', 'start': 1021, 'end': 1027}, {'entity': 'snoRNAs', 'type': 'Gene', 'start': 1005, 'end': 1012}, {'entity': 'viral infections', 'type': 'Disease', 'start': 902, 'end': 918}, {'entity': 'RNAs', 'type': 'Gene', 'start': 715, 'end': 719}, {'entity': 'NcRNAs', 'type': 'Gene', 'start': 713, 'end': 719}, {'entity': 'genomes', 'type': 'Gene', 'start': 704, 'end': 711}, {'entity': 'ncRNAs', 'type': 'Gene', 'start': 683, 'end': 689}, {'entity': 'RNAs', 'type': 'Gene', 'start': 565, 'end': 569}]\n",
            "['The International Health Regulations 10 years on: the governing framework for global health security\\tFundamental revisions to the International Health Regulations in 2005 were meant to herald a new era of global health security and cooperation.', 'Yet, 10 years later, the International Health Regulations face criticism, particularly after the west African Ebola epidemic.', 'Several high-level panels']\n",
            "unmatched tags:  [{'entity': 'era', 'type': 'Gene', 'start': 374, 'end': 377}, {'entity': 'Ebola', 'type': 'Disease', 'start': 355, 'end': 360}, {'entity': 'era', 'type': 'Gene', 'start': 236, 'end': 239}]\n",
            "['Optimization of Microbiological Laboratory Detection Strategy for Patients in A Designated Hospital Treating Novel Coronavirus Pneumonia in Anhui Province\\tNovel coronavirus pneumonia (NCP) is an emerging, highly contagious community acquired pneumonia (CAP) caused by severe acute respiratory syndrome  coronavirus 2 (SARS-CoV-2).', 'Highly efficient and accurate microbiological laboratory assay is essential to confirm the SARS-CoV-2 infection, rule out other pathogens that can cause CAP, and monitor secondary infections.', 'Here, we enrolled and provide microbiological analysis for 129 suspected and 52 transferred confirmed NCP patients hospitalized in the First Affiliated Hospital of University of Science and Technology of China (USTC) from Jan 21 to Feb 29, 2020.', 'By analyzing the dual swab samples (sputum and pharyngeal) from 129 suspected patients with realtime RT-PCR, we confirmed 33 SARS-CoV-2 infections, with two co-infection cases with adenovirus or rhinovirus.', 'We also used multiplex PCR to detect 13 common respiratory tract pathogens in 96 non-NCP patients, and found that 30 patients (31.25%) were infected with at least one respiratory tract pathogen that may cause CAP.', 'Further, we performed bacterial and fungal cultures as well as fungal serologic tests and found that there is no secondary bacterial/fungal infections in confirmed NCP patients.', 'Our studies suggest that, during the epidemic of NCP in Anhui province, there was a certain proportion of infection and co-infection of other common pathogens of CAP, and the secondary bacterial and fungal infection is not detectable in NCP patients.', 'In comparison with SARS-CoV-2 detection alone, this optimized strategy combining multiple pathogen detection for identification of NCP and other CAP patients as well as cultures and serologic tests for confirmed patients increases the diagnosis efficiency and facilitates the personalized medication.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1638, 'end': 1648}, {'entity': 'fungal infection', 'type': 'Phenotype', 'start': 1567, 'end': 1583}, {'entity': 'co-infection', 'type': 'Disease', 'start': 1488, 'end': 1500}]\n",
            "['Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial\\tEarly treatment with glatiramer acetate is efficacious in delaying conversion to clinically definite multiple sclerosis in patients presenting with clinically isolated syndrome and brain lesions detected by MRI.']\n",
            "unmatched tags:  [{'entity': 'brain lesions', 'type': 'Disease', 'start': 382, 'end': 395}]\n",
            "['Malaria control in Afghanistan: progress and challenges\\tFrom the 1950s until 1979 malaria control in Afghanistan was implemented through a vertical programme managed by the government, but little of the original programme remained functional by the early 1990s.', 'Delivery of basic health care including malaria diagnosis and treatment was done by non-governmental organisations (NGOs) and UN agencies, which organised cross-border operations from Pakistan and Iran and placed much less emphasis on vertical programming.', 'From 1992 the situation in the east of Afghanistan became stable enough to allow the establishment of a network of NGO-supported clinics and to introduce standardised training and monitoring of microscopists and clinical staff, coordinated by a lead agency specialising in malaria.']\n",
            "unmatched tags:  [{'entity': 'malaria', 'type': 'Disease', 'start': 792, 'end': 799}, {'entity': 'agency', 'type': 'Organization', 'start': 769, 'end': 775}]\n",
            "['Monitoring and surveillance of chronic non-communicable diseases: progress and capacity in high-burden countries\\tThe burden of chronic, non-communicable diseases in low-income and middle-income countries is increasing.', 'We outline a framework for monitoring of such diseases and review the mortality burden and the capacity of countries to respond to them.', 'We show data from WHO data sources and published work for prevalence of tobacco use, overweight, and cause-specific mortality in 23 low-income and middle-income countries with a high burden of non-communicable disease.', 'Data for national capacity for chronic disease prevention and control were generated from a global assessment that was done in WHO member states in 2009–10.']\n",
            "unmatched tags:  [{'entity': 'chronic disease', 'type': 'Disease', 'start': 606, 'end': 621}, {'entity': 'non-communicable disease', 'type': 'Disease', 'start': 549, 'end': 573}, {'entity': 'middle-income countries', 'type': 'Disease', 'start': 503, 'end': 526}, {'entity': 'low-income', 'type': 'Gene', 'start': 488, 'end': 498}, {'entity': 'overweight', 'type': 'Phenotype', 'start': 441, 'end': 451}]\n",
            "['Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a\\tOlaparib tablet maintenance treatment provided a significant progression-free survival improvement with no detrimental effect on quality of life in patients with platinum-sensitive, relapsed ovarian cancer and a']\n",
            "unmatched tags:  [{'entity': 'ovarian cancer', 'type': 'Disease', 'start': 298, 'end': 312}]\n",
            "['Environmental, genetic, and molecular features of prostate cancer\\tProstate cancer is the sixth most common cancer in the world and the third leading cause of cancer in men.', 'The increase in the understanding of prostate carcinogenesis over the past 15 years has helped to define crucial steps in the natural history of the disease, namely initiation and progression to androgen independence.', 'This heterogeneous disease encompasses a range of environmental and familial factors, which provides strong support for the use of chemopreventive strategies.', 'Most patients with advanced prostate cancer are treated with androgendeprivation therapy, which leads to a striking regression of androgen-responsive cancer cells.']\n",
            "unmatched tags:  [{'entity': 'cancer', 'type': 'Disease', 'start': 700, 'end': 706}, {'entity': 'androgen', 'type': 'Drug', 'start': 611, 'end': 619}, {'entity': 'prostate cancer', 'type': 'Disease', 'start': 578, 'end': 593}, {'entity': 'heterogeneous disease', 'type': 'Disease', 'start': 396, 'end': 417}, {'entity': 'androgen', 'type': 'Drug', 'start': 368, 'end': 376}]\n",
            "['Smallpox vaccine and its stockpile in 2005\\tSmallpox vaccine was the most important tool in the successful eradication of smallpox.', 'In 1980, this achievement made it possible for all nations to cease smallpox vaccination.', 'However, the threat of smallpox bioterrorism has made it necessary to reconsider the need for vaccination.', 'Over the past 3 years, many nations have set up action plans for use in the event of such an attack.', 'The setting up of these plans was not simple.', 'Several factors needed to be considered, including the judgement of risk, vaccine complications, conventional vaccines versus new vaccines, optimal stockpile of smallpox vaccine, and its use for different target populations in different emergency situations.']\n",
            "unmatched tags:  [{'entity': 'smallpox', 'type': 'Disease', 'start': 636, 'end': 644}, {'entity': 'smallpox vaccine', 'type': 'Drug', 'start': 636, 'end': 652}, {'entity': 'vaccines', 'type': 'Drug', 'start': 605, 'end': 613}, {'entity': 'vaccines', 'type': 'Drug', 'start': 585, 'end': 593}, {'entity': 'vaccine', 'type': 'Drug', 'start': 549, 'end': 556}, {'entity': 'smallpox bioterrorism', 'type': 'Disease', 'start': 244, 'end': 265}]\n",
            "['Optimum timing of treatment for hepatitis C infection relative to liver transplantation\\tThe approval of direct-acting antiviral agents that may be given orally in an interferon-free regimen has greatly changed the landscape of treatment for hepatitis C virus (HCV) infection, especially for patients with the most severe disease, who have decompensated cirrhosis, or who are waiting for or have undergone liver transplantation.', 'Treatment with interferon proved to be ineffective and poorly tolerated because of high risks of infection and transplant rejection.', 'The availability of new drugs poses new questions about the optimum time to give treatment to prevent HCV recurrence, taking into account efficacy, tolerance, and drug–drug interactions.']\n",
            "unmatched tags:  [{'entity': 'drug', 'type': 'Drug', 'start': 729, 'end': 733}, {'entity': 'drug', 'type': 'Drug', 'start': 724, 'end': 728}]\n",
            "['Hydroxychloroquine for the management of COVID-19: Hope or Hype?', 'A Systematic review of the current evidence\\tPurpose: The COVID-19 Pandemic has literally left the world breathless in the chase for Pharmacotherapy.', 'With the vaccine approval likely more than a year away and novel drugs in early clinical trials, repurposing of existing drugs takes the center stage.', 'A potential drug discussed both in geopolitical and global scientific community is hydroxychloroquine (HCQ).', 'We intend to systematically weigh and analyze the existing evidence of HCQ in the light of published and pre-print data available so far.', 'Methods: PubMed Ovid MEDLINE, EMBASE, Google scholar databases and official clinical trial Registries of the United States, China, WHO ICTRP were electronically searched for studies for the use of HCQ in patients with COVID-19.', 'Pre-proof article repositories like MedRxiv, BioRxiv, and ChemRxiv were also included in the search.', 'The literature was critically appraised.', 'Results: Total 71 articles were available as of 15 th April of which articles of relevance (three invitro studies, two open label non-randomized trials, two open label randomized control trials, one follow-up study, three reviews, ten short communications) and 88 clinical trials registered in three clinical trial registries were analyzed.', 'HCQ seems to be efficient in inhibiting of SARS CoV-2 in in-vitro cell lines; there is lack of strong evidence from human studies.', 'Conclusions: The in-vitro cell culture based data of viral inhibition does not suffice for the use of hydroxychloroquine in the patients with COVID-19.', 'Currently literature shows inadequate, low level evidence in human studies.', 'Scarcity of safety and efficacy data warrants medical communities, health care agencies and governments across the world against the widespread use of HCQ in COVID-19 prophylaxis and treatment, until robust evidence becomes available.', 'Keywords: Hydroxychloroquine, SARS-CoV-2, COVID-19, Corona virus, nCov2, systematic review']\n",
            "unmatched tags:  [{'entity': 'Corona virus', 'type': 'Disease', 'start': 1969, 'end': 1981}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1959, 'end': 1967}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1947, 'end': 1957}, {'entity': 'Hydroxychloroquine', 'type': 'Drug', 'start': 1927, 'end': 1945}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1840, 'end': 1848}, {'entity': 'HCQ', 'type': 'Drug', 'start': 1833, 'end': 1836}, {'entity': 'governments', 'type': 'Organization', 'start': 1774, 'end': 1785}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1596, 'end': 1604}, {'entity': 'hydroxychloroquine', 'type': 'Drug', 'start': 1556, 'end': 1574}, {'entity': 'SARS', 'type': 'Disease', 'start': 1366, 'end': 1370}, {'entity': 'HCQ', 'type': 'Drug', 'start': 1323, 'end': 1326}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 830, 'end': 838}, {'entity': 'HCQ', 'type': 'Drug', 'start': 809, 'end': 812}, {'entity': 'EMBASE', 'type': 'Chemical', 'start': 642, 'end': 648}, {'entity': 'pre-print', 'type': 'Chemical', 'start': 579, 'end': 588}, {'entity': 'HCQ', 'type': 'Drug', 'start': 545, 'end': 548}, {'entity': 'HCQ', 'type': 'Drug', 'start': 468, 'end': 471}, {'entity': 'hydroxychloroquine', 'type': 'Drug', 'start': 448, 'end': 466}, {'entity': 'drug', 'type': 'Drug', 'start': 377, 'end': 381}]\n",
            "['Peripheral nervous system involvement in patients with cancer\\tInvolvement of the peripheral nervous system (PNS) is common in patients with cancer and any part, including motor neurons, sensory ganglia, nerve roots, plexuses, cranial and peripheral nerves, and neuromuscular junctions, can be affected.', 'Different mechanisms can initiate damage associated with cancer-related PNS disorders.', 'These include tumour infiltration, toxicity of treatments, metabolic and nutritional perturbations, cachexia, virus infections, and paraneoplastic neurological syndromes.', 'The type of cancer, lymphoma, or solid tumour is a further determinant of a PNS disorder.']\n",
            "unmatched tags:  [{'entity': 'PNS disorder', 'type': 'Disease', 'start': 637, 'end': 649}, {'entity': 'solid tumour', 'type': 'Disease', 'start': 594, 'end': 606}, {'entity': 'lymphoma', 'type': 'Disease', 'start': 581, 'end': 589}, {'entity': 'cancer', 'type': 'Disease', 'start': 573, 'end': 579}, {'entity': 'paraneoplastic neurological syndromes', 'type': 'Disease', 'start': 522, 'end': 559}, {'entity': 'virus infections', 'type': 'Disease', 'start': 500, 'end': 516}]\n",
            "['Insights into Cross-species Evolution of Novel Human Coronavirus 2019-nCoV and Defining Immune Determinants for Vaccine Development\\tNovel Coronavirus (nCoV) outbreak in the city of Wuhan, China during December 2019, has now spread to various countries across the globe triggering a heightened containment effort.', 'This human pathogen is a member of betacoronavirus genus carrying 30 kilobase of single positive-sense RNA genome.', 'Understanding the evolution, zoonotic transmission, and source of this novel virus would help accelerating containment and prevention efforts.', 'The present study reported detailed analysis of 2019-nCoV genome evolution and potential candidate peptides for vaccine development.', 'This nCoV genotype might have been evolved from a bat-CoV by accumulating non-synonymous mutations, indels, and recombination events.', 'Structural proteins Spike (S), and Membrane (M) had extensive mutational changes, whereas Envelope (E) and Nucleocapsid (N) proteins were very conserved suggesting differential selection pressures exerted on 2019-nCoV during evolution.', 'Interestingly, 2019-nCoV Spike protein contains a 39 nucleotide sequence insertion relative to SARS-like bat-SL-CoVZC45/2017.', 'Furthermore, we identified eight high binding affinity (HBA) CD4 T-cell epitopes in the S, E, M and N proteins, which can be commonly recognized by HLA-DR alleles of Asia and Asia-Pacific Region population.', 'These immunodominant epitopes can be incorporated in universal subunit CoV vaccine.', 'Diverse HLA types and variations in the epitope binding affinity may contribute to the wide range of immunopathological outcomes of circulating virus in humans.', 'Our findings emphasize the requirement for continuous surveillance of CoV strains in live animal markets to better understand the viral adaptation to human host and to develop practical solutions to prevent the emergence of novel pathogenic CoV strains.']\n",
            "unmatched tags:  [{'entity': 'circulating virus', 'type': 'Gene', 'start': 1623, 'end': 1640}, {'entity': 'subunit CoV vaccine', 'type': 'Drug', 'start': 1470, 'end': 1489}, {'entity': 'alleles', 'type': 'Gene', 'start': 1355, 'end': 1362}, {'entity': 'N proteins', 'type': 'Gene', 'start': 1300, 'end': 1310}, {'entity': 'HBA', 'type': 'Gene', 'start': 1256, 'end': 1259}, {'entity': 'nCoV', 'type': 'Virus', 'start': 1094, 'end': 1098}, {'entity': '2019-nCoV', 'type': 'Virus', 'start': 1089, 'end': 1098}, {'entity': '2019-nCoV', 'type': 'Virus', 'start': 1046, 'end': 1055}, {'entity': 'Nucleocapsid (N) proteins', 'type': 'Gene', 'start': 945, 'end': 970}, {'entity': 'Structural proteins', 'type': 'Gene', 'start': 838, 'end': 857}, {'entity': 'nCoV', 'type': 'Virus', 'start': 709, 'end': 713}, {'entity': 'vaccine', 'type': 'Drug', 'start': 683, 'end': 690}, {'entity': 'peptides', 'type': 'Gene', 'start': 670, 'end': 678}, {'entity': '2019-nCoV', 'type': 'Virus', 'start': 619, 'end': 628}, {'entity': 'betacoronavirus genus', 'type': 'Virus', 'start': 348, 'end': 369}, {'entity': 'nCoV', 'type': 'Virus', 'start': 151, 'end': 155}, {'entity': 'Coronavirus', 'type': 'Virus', 'start': 138, 'end': 149}]\n",
            "['Beyond registration—measuring the public-health potential of new treatments for malaria in Africa\\tMalaria claims over one million lives a year in some of the poorest countries of the world.', 'Affected populations and governments cannot afford to pay for expensive new therapies.', 'Most antimalarial treatments are purchased from local shops and administered in the home.', 'These factors make for a complex set of requirements for any new treatment for malaria if a substantial reduction in mortality is ever to be achieved.', 'Thankfully there are several treatments being developed, mostly within public–private partnerships.']\n",
            "unmatched tags:  [{'entity': 'private partnerships', 'type': 'Organization', 'start': 596, 'end': 616}]\n",
            "['Epidemiology and Transmission of COVID-19 in Shenzhen China: Analysis of 391 cases and 1,286 of their close contacts\\tBackground Rapid spread of SARS-CoV-2 in Wuhan prompted heightened surveillance in Shenzhen and elsewhere in China.', 'The resulting data provide a rare opportunity to measure key metrics of disease course, transmission, and the impact of control.', 'Methods The Shenzhen CDC identified 391 SARS-CoV-2 cases from January 14 to February 12, 2020 and 1286 close contacts.', 'We compare cases identified through symptomatic surveillance and contact tracing, and estimate the time from symptom onset to confirmation, isolation, and hospitalization.', 'We estimate metrics of disease transmission and analyze factors influencing transmission risk.', 'Findings Cases were older than the general population (mean age 45) and balanced between males (187) and females (204).', 'Ninety-one percent had mild or moderate clinical severity at initial assessment.', 'Three have died, 225 have recovered (median time to recovery is 21 days).', 'Cases were isolated on average 4.6 days after developing symptoms; contact tracing reduced this by 1.9 days.', 'Household contacts and those travelling with a case where at higher risk of infection (ORs 6 and 7) than other close contacts.', 'The household secondary attack rate was 15%, and children were as likely to be infected as adults.', 'The observed reproductive number was 0.4, with a mean serial interval of 6.3 days.', 'Interpretation Our data on cases as well as their infected and uninfected close contacts provide key insights into SARS-CoV-2 epidemiology.', 'This work shows that heightened surveillance and isolation, particularly contact tracing, reduces the time cases are infectious in the community, thereby reducing R. Its overall impact, however, is uncertain and highly dependent on the number of asymptomatic cases.', 'We further show that children are at similar risk of infection as the general population, though less likely to have severe symptoms; hence should be considered in analyses of transmission and control.']\n",
            "unmatched tags:  [{'entity': 'symptom', 'type': 'Phenotype', 'start': 1828, 'end': 1835}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1556, 'end': 1566}, {'entity': 'household secondary attack rate', 'type': 'Chemical', 'start': 1263, 'end': 1294}, {'entity': 'ORs', 'type': 'Drug', 'start': 1219, 'end': 1222}]\n",
            "[\"Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth\\tHIV protease inhibitors are antiretroviral drugs that block the enzyme required for production of infectious viral particles.\", 'Although these agents have been designed to selectively bind to the catalytic site of HIV protease, evidence indicates that other cellular and microbial enzymes and pathways are also affected.', \"It has been reported that patients treated with highly active anti-retroviral therapy (HAART) containing a protease inhibitor may be at reduced risk of Kaposi's sarcoma (KS) and some types of non-Hodgkin lymphomas; some disease regressions have also been described.\"]\n",
            "unmatched tags:  [{'entity': 'non-Hodgkin lymphomas', 'type': 'Disease', 'start': 586, 'end': 607}, {'entity': \"Kaposi's sarcoma\", 'type': 'Disease', 'start': 546, 'end': 562}, {'entity': 'protease inhibitor', 'type': 'Drug', 'start': 501, 'end': 519}, {'entity': 'enzymes', 'type': 'Gene', 'start': 354, 'end': 361}, {'entity': 'HIV protease', 'type': 'Gene', 'start': 287, 'end': 299}, {'entity': 'enzyme', 'type': 'Gene', 'start': 139, 'end': 145}]\n",
            "['CHOP and IRE1α-XBP1/JNK signaling promote Newcastle Disease Virus induced apoptosis and benefit virus proliferation\\tNewcastle disease virus (NDV) causes severe infectious disease in poultry, and selectively kills tumor cells by inducing apoptosis.', 'In this report, we revealed the mechanisms underlying NDV-induced apoptosis via investigation of endoplasmic reticulum (ER) stress-related unfolded protein response (UPR) in HeLa cells.', 'We found that NDV infection induced the expression of pro-apoptotic transcription factor CHOP via PKR-eIF2α pathway.', 'Knock down and exogenous expression studies showed that CHOP promoted cell apoptosis by down-regulation of anti-apoptotic protein BCL-2 and MCL-1, promotion of pro-apoptotic JNK and p38 signaling, and suppression of pro-survival AKT signaling.', 'Meanwhile, CHOP facilitated NDV proliferation.', 'Furthermore, virus infection activated IRE1α, another ER stress sensor, thereby promoting the mRNA splicing of XBP1 and resulting in the translation of transcription factor XBP1s.', 'XBP1s entered into cell nucleus, promoted the expression of ER chaperones and components of ER associated degradation (ERAD).', 'Exogenous expression of XBP1s helped IBV proliferation, and silence of XBP1s reduced virus proliferation.', 'Meanwhile, exogenous expression and knock down studies demonstrated that IRE1α activated pro-apoptotic JNK signaling, promoted apoptosis and inflammation.', 'In conclusion, our current study demonstrates that the induction of CHOP and activation of IRE1α-XBP1/JNK signaling cascades promote apoptosis and benefit NDV proliferation.', 'IMPORTANCE It is well known that NDV kills host animal and tumor cells by inducing cell apoptosis.', 'Although several studies investigate the apoptotic phenomena in NDV-infected tumor cells, the molecular mechanisms underlying this oncolytic virus induced apoptosis is not well understood yet.', 'In this study, we focus on characterization of the ER stress responses in NDV-infected tumor cells, and find that virus induces apoptosis by up-regulation or activation of several unfolded protein responses (UPR) related transcription factors and signaling: such as ATF4, CHOP and XBP1s, and pro-apoptotic kinases (IRE1α, JNK, p38).', 'Moreover, activation of these transcription factors and signaling cascades helps virus proliferation.', 'Our study dissects the UPR induced apoptosis in NDV-infected tumor cells, and provides the evidence that UPR favors NDV proliferation.']\n",
            "unmatched tags:  [{'entity': 'NDV', 'type': 'Virus', 'start': 2426, 'end': 2429}, {'entity': 'transcription factors', 'type': 'Gene', 'start': 2238, 'end': 2259}, {'entity': 'p38', 'type': 'Gene', 'start': 2202, 'end': 2205}, {'entity': 'JNK', 'type': 'Gene', 'start': 2197, 'end': 2200}, {'entity': 'IRE1α', 'type': 'Gene', 'start': 2190, 'end': 2195}, {'entity': 'pro-apoptotic kinases', 'type': 'Gene', 'start': 2167, 'end': 2188}, {'entity': 'XBP1s', 'type': 'Chemical', 'start': 2156, 'end': 2161}, {'entity': 'ATF4', 'type': 'Gene', 'start': 2141, 'end': 2145}, {'entity': 'transcription factors', 'type': 'Gene', 'start': 2096, 'end': 2117}, {'entity': 'ER', 'type': 'Gene', 'start': 1926, 'end': 1928}, {'entity': 'oncolytic virus', 'type': 'Virus', 'start': 1813, 'end': 1828}, {'entity': 'NDV', 'type': 'Virus', 'start': 1616, 'end': 1619}, {'entity': 'NDV', 'type': 'Virus', 'start': 1564, 'end': 1567}, {'entity': 'JNK', 'type': 'Gene', 'start': 1511, 'end': 1514}, {'entity': 'XBP1', 'type': 'Gene', 'start': 1506, 'end': 1510}, {'entity': 'JNK', 'type': 'Gene', 'start': 1357, 'end': 1360}, {'entity': 'pro-apoptotic', 'type': 'Gene', 'start': 1343, 'end': 1356}, {'entity': 'IRE1α', 'type': 'Gene', 'start': 1327, 'end': 1332}, {'entity': 'XBP1s', 'type': 'Chemical', 'start': 1219, 'end': 1224}, {'entity': 'silence', 'type': 'Disease', 'start': 1208, 'end': 1215}, {'entity': 'IBV', 'type': 'Gene', 'start': 1185, 'end': 1188}, {'entity': 'XBP1s', 'type': 'Chemical', 'start': 1172, 'end': 1177}, {'entity': 'ER', 'type': 'Gene', 'start': 1141, 'end': 1143}, {'entity': 'ER', 'type': 'Gene', 'start': 1114, 'end': 1116}, {'entity': 'chaperones', 'type': 'Gene', 'start': 1085, 'end': 1095}, {'entity': 'ER', 'type': 'Gene', 'start': 1082, 'end': 1084}, {'entity': 'XBP1s', 'type': 'Chemical', 'start': 1022, 'end': 1027}, {'entity': 'XBP1s', 'type': 'Chemical', 'start': 1015, 'end': 1020}, {'entity': 'transcription factor', 'type': 'Gene', 'start': 994, 'end': 1014}, {'entity': 'XBP1', 'type': 'Gene', 'start': 953, 'end': 957}, {'entity': 'mRNA', 'type': 'Gene', 'start': 936, 'end': 940}, {'entity': 'ER', 'type': 'Gene', 'start': 896, 'end': 898}, {'entity': 'IRE1α', 'type': 'Gene', 'start': 881, 'end': 886}, {'entity': 'virus infection', 'type': 'Disease', 'start': 855, 'end': 870}, {'entity': 'NDV', 'type': 'Virus', 'start': 823, 'end': 826}, {'entity': 'AKT', 'type': 'Gene', 'start': 780, 'end': 783}, {'entity': 'p38 signaling', 'type': 'Gene', 'start': 733, 'end': 746}, {'entity': 'JNK', 'type': 'Gene', 'start': 725, 'end': 728}, {'entity': 'pro-apoptotic', 'type': 'Gene', 'start': 711, 'end': 724}, {'entity': 'MCL-1', 'type': 'Gene', 'start': 691, 'end': 696}, {'entity': 'BCL-2', 'type': 'Gene', 'start': 681, 'end': 686}]\n",
            "['A Mini Review on Current Clinical and Research Findings for Children Suffering from COVID-19\\tBackground: As the novel coronavirus triggering COVID-19 has broken out in Wuhan, China and spread rapidly worldwide, it threatens the lives of thousands of people and poses a global threat on the economies of the entire world.', 'However, infection with COVID-19 is currently rare in children.', 'Objective To discuss the latest findings and research focus on the basis of characteristics of children confirmed with COVID-19, and provide an insight into the future treatment and research direction.', 'Methods: We searched the terms \"COVID-19 OR coronavirus OR SARS-CoV-2\" AND \"Pediatric OR children\" on PubMed, Embase, Cochrane library, NIH, CDC, and CNKI.', 'The authors also reviewed the guidelines published on Chinese CDC and Chinese NHC.', 'Results: We included 25 published literature references related to the epidemiology, clinical manifestation, accessary examination, treatment, and prognosis of pediatric patients with COVID-19.', 'Conclusion: The numbers of children with COVID‐19 pneumonia infection are small, and most of them come from family aggregation.', 'Symptoms are mainly mild or even asymptomatic, which allow children to be a risk factor for transmission.', 'Thus, strict epidemiological history screening is needed for early diagnosis and segregation.', 'This holds especially for infants, who are more susceptible to infection than other age groups in pediatric age, but have most likely subtle and unspecific symptoms.', 'They need to be paid more attention to.', 'CT examination is a necessity for screening the suspected cases, because most of the pediatric patients are mild cases, and plain chest X-ray do not usually show the lesions or the detailed features.', 'Therefore, early chest CT examination combined with pathogenic detection is a recommended clinical diagnosis scheme in children.', 'The risk factors which may suggest severe or critical progress for children are: Fast respiratory rate and/or; lethargy and drowsiness mental state and/or; lactate progressively increasing and/or; imaging showed bilateral or multi lobed infiltration, pleural effusion or rapidly expending of lesions in a short period of time and/or; less than 3 months old or those who underly diseases.', 'For those critical pediatric patients with positive SARS-CoV-2 diagnosis, polypnea may be the most common symptom.', 'For treatment, the elevated PCT seen in children in contrast to adults suggests that the underlying coinfection/secondary infection may be more common in pediatric patients and appropriate antibacterial treatment should be considered.', 'Once cytokine storm is found in these patients, anti-autoimmune or blood-purifying therapy should be given in time.', 'Furthermore, effective isolation measures and appropriate psychological comfort need to be provided timely.']\n",
            "unmatched tags:  [{'entity': 'cytokine storm', 'type': 'Gene', 'start': 2629, 'end': 2643}, {'entity': 'antibacterial treatment', 'type': 'Drug', 'start': 2578, 'end': 2601}, {'entity': 'coinfection/secondary infection', 'type': 'Disease', 'start': 2489, 'end': 2520}, {'entity': 'PCT', 'type': 'Disease', 'start': 2417, 'end': 2420}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 2380, 'end': 2387}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 2326, 'end': 2336}, {'entity': 'diseases', 'type': 'Disease', 'start': 2264, 'end': 2272}, {'entity': 'lactate', 'type': 'Drug', 'start': 2042, 'end': 2049}]\n",
            "['Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study\\tThe reduction in radiation dose-response for risk of thyroid cancer after childhood exposure to thyroid doses higher than 30 Gy is consistent with a cell-killing effect.', \"Standard long-term follow-up of patients who have had Hodgkin's lymphoma for detection of thyroid cancer should also be undertaken for survivors of any cancer during childhood who received radiotherapy to the thorax or head and neck region.\"]\n",
            "unmatched tags:  [{'entity': 'cancer', 'type': 'Disease', 'start': 446, 'end': 452}, {'entity': 'thyroid cancer', 'type': 'Disease', 'start': 384, 'end': 398}, {'entity': \"Hodgkin's lymphoma\", 'type': 'Disease', 'start': 348, 'end': 366}]\n",
            "['Repurposed Single Inhibitor for Serine Protease and Spike Glycoproteins of SAR-CoV-2\\tIn this research, structure of SARS-CoV-2 spike glycoprotein S1 and S2 along with TMPRSS2, TMPRSS4, TMPRSS11A, TMPRSS11D and TMPRSS11E serine protease (which activates S1 and S2) are used for docking with repurposed inhibitor drug molecules.', 'We searched for a universally active drug molecule which binds with glycoproteins and serine protease with binding energy above a pre-set threshold value, thus single handedly inhibits the virus glycoprotein interaction with ACE-II receptor on human cell preventing the virus RNA transfer to human cell.', 'Through data analysis performed on binding energies of the selected repurposed inhibitors, we found out five molecules to have high binding energies on both spike glycoproteins and serine protease, while showing less variance in their binding energies.', 'Among these five, Edoxaban is an FDA approved commercially available drug molecule.', 'Hence, high binding molecular inhibitors for spike glycoprotein and serine protease for treatment of SARS-CoV-2 were identified.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1069, 'end': 1079}, {'entity': 'serine protease', 'type': 'Gene', 'start': 1036, 'end': 1051}, {'entity': 'spike glycoprotein', 'type': 'Gene', 'start': 1013, 'end': 1031}, {'entity': 'Edoxaban', 'type': 'Drug', 'start': 902, 'end': 910}, {'entity': 'serine protease', 'type': 'Gene', 'start': 812, 'end': 827}, {'entity': 'spike glycoproteins', 'type': 'Drug', 'start': 788, 'end': 807}, {'entity': 'virus RNA transfer', 'type': 'Gene', 'start': 597, 'end': 615}, {'entity': 'serine protease', 'type': 'Gene', 'start': 413, 'end': 428}, {'entity': 'glycoproteins', 'type': 'Drug', 'start': 395, 'end': 408}, {'entity': 'S1', 'type': 'Gene', 'start': 253, 'end': 255}, {'entity': 'serine protease', 'type': 'Gene', 'start': 220, 'end': 235}]\n",
            "['Comparative analysis of gene expression in virulent and attenuated strains of infectious bronchitis virus at sub-codon resolution\\tInfectious bronchitis virus (IBV) is a member of the genus Gammacoronavirus and the causative agent of avian infectious bronchitis.', 'IBV has a single-stranded, positive-sense RNA genome ~27 kb in length and, like all coronaviruses, produces a set of sub-genomic messenger RNAs (sgmRNAs) synthesised via the viral polymerase.', 'Here, we used RNA sequencing (RNASeq) and ribosome profiling (RiboSeq) to delineate gene expression in the IBV M41-CK and Beau-CK strains at sub-codon resolution.', 'Quantification of reads flanking the programmed ribosomal frameshifting (PRF) signal at the genomic RNA ORF1a/ORF1b junction revealed that PRF in IBV is highly efficient (33–40%), consistent with in vitro measurements.', 'Triplet phasing of the profiling data allowed precise determination of reading frames and revealed the translation of two intergenic genes (4b and 4c on sgmRNA4), which are widely conserved across IBV isolates.', 'RNASeq revealed two novel transcription junction sites in the attenuated Beau-CK strain, one of which would generate a sgmRNA encoding a ribosomally occupied ORF in the viral 3’ untranslated region (dORF).', 'Within IBV transcripts, the nucleocapsid (N) protein was unexpectedly found to be inefficiently translated, despite being an abundant structural component of mature IBV virions.', 'Finally, we demonstrate that the host cell response to IBV occurs primarily at the level of transcription, with a global up-regulation of immune-related mRNA transcripts following infection, and comparatively modest changes in the translation efficiencies of host genes.', 'IMPORTANCE IBV is a major avian pathogen and presents a substantial economic burden to the poultry industry.', 'Improved vaccination strategies are urgently needed to curb the global spread of this pathogen, and the development of suitable vaccine candidates will be aided by an improved understanding of IBV molecular biology.', 'Our high-resolution data have enabled a precise study of transcription and translation in both pathogenic and attenuated forms of IBV, and expand our understanding of gammacoronaviral gene expression.', 'We demonstrate that gene expression shows considerable intra-species variation, with single nucleotide polymorphisms associated with altered production of sgmRNA transcripts, and our RiboSeq data sets enabled us to uncover novel ribosomally occupied ORFs in both strains.', 'We also identify numerous cellular genes and gene networks that are differentially expressed during virus infection, giving insights into the host cell reponse to IBV infection.']\n",
            "unmatched tags:  [{'entity': 'IBV', 'type': 'Gene', 'start': 2663, 'end': 2666}, {'entity': 'virus infection', 'type': 'Disease', 'start': 2600, 'end': 2615}, {'entity': 'strains', 'type': 'Disease', 'start': 2491, 'end': 2498}, {'entity': 'ORFs', 'type': 'Gene', 'start': 2478, 'end': 2482}, {'entity': 'ribosomally occupied', 'type': 'Organization', 'start': 2457, 'end': 2477}, {'entity': 'RiboSeq', 'type': 'Chemical', 'start': 2411, 'end': 2418}, {'entity': 'transcripts', 'type': 'Gene', 'start': 2390, 'end': 2401}, {'entity': 'mRNA', 'type': 'Gene', 'start': 2385, 'end': 2389}, {'entity': 'IBV', 'type': 'Gene', 'start': 2157, 'end': 2160}, {'entity': 'IBV', 'type': 'Gene', 'start': 2004, 'end': 2007}, {'entity': 'candidates', 'type': 'Gene', 'start': 1947, 'end': 1957}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1939, 'end': 1946}, {'entity': 'IBV', 'type': 'Gene', 'start': 1713, 'end': 1716}, {'entity': 'transcripts', 'type': 'Gene', 'start': 1589, 'end': 1600}, {'entity': 'mRNA', 'type': 'Gene', 'start': 1584, 'end': 1588}, {'entity': 'immune-related', 'type': 'Organization', 'start': 1569, 'end': 1583}, {'entity': 'IBV', 'type': 'Gene', 'start': 1486, 'end': 1489}, {'entity': 'IBV', 'type': 'Gene', 'start': 1418, 'end': 1421}, {'entity': 'nucleocapsid', 'type': 'Gene', 'start': 1281, 'end': 1293}, {'entity': 'transcripts', 'type': 'Gene', 'start': 1264, 'end': 1275}, {'entity': 'IBV', 'type': 'Gene', 'start': 1260, 'end': 1263}, {'entity': 'dORF', 'type': 'Gene', 'start': 1246, 'end': 1250}, {'entity': 'viral 3’ untranslated region', 'type': 'Gene', 'start': 1216, 'end': 1244}, {'entity': 'ORF', 'type': 'Gene', 'start': 1205, 'end': 1208}, {'entity': 'ribosomally occupied', 'type': 'Organization', 'start': 1184, 'end': 1204}, {'entity': 'mRNA', 'type': 'Gene', 'start': 1168, 'end': 1172}, {'entity': 'Beau-CK', 'type': 'Chemical', 'start': 1120, 'end': 1127}, {'entity': 'IBV', 'type': 'Gene', 'start': 1033, 'end': 1036}, {'entity': 'mRNA', 'type': 'Gene', 'start': 991, 'end': 995}, {'entity': 'profiling', 'type': 'Gene', 'start': 859, 'end': 868}, {'entity': 'IBV', 'type': 'Gene', 'start': 763, 'end': 766}, {'entity': 'PRF', 'type': 'Gene', 'start': 756, 'end': 759}, {'entity': 'ORF', 'type': 'Gene', 'start': 727, 'end': 730}, {'entity': 'ORF', 'type': 'Gene', 'start': 721, 'end': 724}, {'entity': 'PRF', 'type': 'Gene', 'start': 690, 'end': 693}, {'entity': 'strains', 'type': 'Disease', 'start': 584, 'end': 591}, {'entity': 'Beau-CK', 'type': 'Chemical', 'start': 576, 'end': 583}, {'entity': 'M41-CK', 'type': 'Gene', 'start': 565, 'end': 571}, {'entity': 'IBV', 'type': 'Gene', 'start': 561, 'end': 564}, {'entity': 'RiboSeq', 'type': 'Chemical', 'start': 516, 'end': 523}, {'entity': 'profiling', 'type': 'Gene', 'start': 505, 'end': 514}]\n",
            "['Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation\\t2019-nCov has caused more than 80 deaths as of 27 January 2020 in China, and infection cases have been reported in more than 10 countries.', 'However, there is no approved drug to treat the disease.', '2019-nCov M pro is a potential drug target to combat the virus.', 'We built homology models based on SARS M pro structures, and docked 1903 small molecule drugs to the models.', 'Based on the docking score and the 3D similarity of the binding mode to the known M pro ligands, 4 drugs were selected for binding free energy calculations.', 'Both MM/GBSA and SIE methods voted for nelfinavir, with the binding free energy of −24.69±0.52 kcal/mol and −9.42±0.04 kcal/mol, respectively.', 'Therefore, we suggested that nelfinavir might be a potential inhibitor against 2019-nCov M pro .']\n",
            "unmatched tags:  [{'entity': '2019-nCov', 'type': 'Virus', 'start': 939, 'end': 948}, {'entity': 'nelfinavir', 'type': 'Drug', 'start': 889, 'end': 899}, {'entity': 'nelfinavir', 'type': 'Drug', 'start': 756, 'end': 766}, {'entity': 'SIE', 'type': 'Organization', 'start': 734, 'end': 737}, {'entity': 'drug', 'type': 'Drug', 'start': 659, 'end': 663}, {'entity': 'M pro ligands', 'type': 'Chemical', 'start': 642, 'end': 655}]\n",
            "['Targeting of MEK in lung cancer therapeutics\\tThe MAP-kinase pathway, consisting of the kinases RAS, RAF, MEK, and ERK, is crucial for cell proliferation, inhibition of apoptosis, and migration of cells.', 'Direct inhibition of RAS is not yet possible, whereas inhibition of RAF is already established in malignant melanoma and under investigation in non-small-cell lung cancer (NSCLC).', 'Due to their structure and function, the MEK proteins are attractive targets for cancer therapy and are also under investigation in NSCLC.', 'We discuss strategies of targeting the RAS-RAF-MEK-ERK pathway with emphasis on MEK inhibition, either alone or in combination with other targets or conventional chemotherapy.']\n",
            "unmatched tags:  [{'entity': 'MEK', 'type': 'Gene', 'start': 602, 'end': 605}, {'entity': 'RAS-RAF-MEK-ERK pathway', 'type': 'Gene', 'start': 561, 'end': 584}, {'entity': 'NSCLC', 'type': 'Disease', 'start': 515, 'end': 520}, {'entity': 'MEK', 'type': 'Gene', 'start': 424, 'end': 427}, {'entity': 'NSCLC', 'type': 'Disease', 'start': 375, 'end': 380}, {'entity': 'lung cancer', 'type': 'Disease', 'start': 362, 'end': 373}, {'entity': 'malignant melanoma', 'type': 'Disease', 'start': 301, 'end': 319}, {'entity': 'RAF', 'type': 'Gene', 'start': 271, 'end': 274}]\n",
            "['Rotavirus vaccines against diarrhoeal disease\\tRotaviruses are responsible for more diarrhoea!', 'disease-associated mortality than any other single agent.', 'Vaccination may therefore hold the key to combating diarrhoea!', 'disease worldwide.', 'Natural immunity to rotavirus infection indicates that rather than protection from reinfection such immunity gives rise to less severe and less frequent attacks of diarrhoea.', 'Early attempts to design a rotavirus vaccine with bovine rotavirus failed because of poor efficacy in some developing countries.', 'Research into rhesus rotavirus, particularly the high-titre rhesus rotavirus tetravalent (RRV-TV) vaccine, has given slightly better results.']\n",
            "unmatched tags:  [{'entity': 'vaccine', 'type': 'Drug', 'start': 636, 'end': 643}, {'entity': 'rhesus rotavirus', 'type': 'Drug', 'start': 598, 'end': 614}, {'entity': 'rhesus rotavirus', 'type': 'Drug', 'start': 552, 'end': 568}, {'entity': 'poor efficacy', 'type': 'Chemical', 'start': 494, 'end': 507}]\n",
            "['Pulmonary radiological change of COVID-19 patients with 99mTc-MDP treatment\\tBackground: As increasing cases of COVID-19 around world, urgent need for effective COVID-19-specific therapeutic drugs is necessary; therefore, we conducted a pilot randomized-controlled study to evaluate the efficacy of 99mTc-MDP for COVID-19 therapeutic treatment.', 'Methods: A total of 21 mild patients with COVID-19 were enrolled in this pilot RCT from February 2020 through March 2020, and then were assigned, in a 1:1 ratio, into control (11 patients) and 99mTc-MDP group (10 patients).', 'Patients in the control group received routine treatment and patients assigned to the 99mTc-MDP group received a combination of routine treatment and an administration of 99mTc-MDP injection of 5ml/day.', 'Both of the patients in the control and 99mTc-MDP groups were treated for 7 days with the primary end point of CT-based radiological pulmonary changes during 7-day follow-up.', 'Findings: From baseline to the day 7, 8 (80%) of 10 mild patients in the 99mTc-MDP group had a significant radiological improvement in lung and a decline in inflammatory infiltration, whereas only 1 (9.1%) of 11 patients in the control group had a radiological improvement in lung.', 'None of the patients in the 99mTc-MDP group had disease progression from mild to severe, as well as an inflammatory cytokine storm, and 2 mild patients (18.2%) in the control group developed severe.', 'During days 7 through 14, the number of patients with radiological improvement in the 99mTc-MDP group remained consistent, and only 1 additional case (22%) in the control group were reported.', 'Conclusion: In this randomized pilot study, 99mTc-MDP had an effective inhibitory effect on the inflammatory disease progression for the therapy of COVID-19, and it can accelerate the absorption of pulmonary inflammation in a short period of time during the process of treatment.']\n",
            "unmatched tags:  [{'entity': 'pulmonary inflammation', 'type': 'Disease', 'start': 1819, 'end': 1841}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1769, 'end': 1777}, {'entity': 'inflammatory disease', 'type': 'Disease', 'start': 1717, 'end': 1737}, {'entity': '99mTc-MDP', 'type': 'Drug', 'start': 1665, 'end': 1674}, {'entity': '99mTc-MDP group', 'type': 'Drug', 'start': 1515, 'end': 1530}]\n",
            "['Occupational lung diseases: from old and novel exposures to effective preventive strategies\\tOccupational exposure is an important, global cause of respiratory disease.', 'Unlike many other non-communicable lung diseases, the proximal causes of many occupational lung diseases are well understood and they should be amenable to control with use of established and effective approaches.', 'Therefore, the risks arising from exposure to silica and asbestos are well known, as are the means of their prevention.', 'Although the incidence of occupational lung disease has decreased in many countries, in parts of the world undergoing rapid economic transition and population growth—often with large informal and unregulated workforces—occupational exposures continue to impose a heavy burden of disease.']\n",
            "unmatched tags:  [{'entity': 'occupational lung disease', 'type': 'Disease', 'start': 528, 'end': 553}]\n",
            "['Memory boundaries: opening a window inspired by reconsolidation to treat anxiety, trauma-related, and addiction disorders\\tPioneering research over the past two decades has shown that memories are far more malleable than we once thought, thereby highlighting the potential for new clinical avenues for treatment of psychopathology.', 'We first briefly review the historical foundation of memory reconsolidation—a concept that refers to hypothetical processes that occur when a memory is retrieved and restored.', 'Then, we provide an overview of the basic research on memory reconsolidation that has been done with humans and other animals, focusing on models of fear, anxiety-related disorders, and addiction, from the perspective that they all involve disorders of memory.']\n",
            "unmatched tags:  [{'entity': 'disorders', 'type': 'Disease', 'start': 747, 'end': 756}]\n",
            "['Pelvic organ prolapse\\tPelvic organ prolapse is downward descent of female pelvic organs, including the bladder, uterus or post-hysterectomy vaginal cuff, and the small or large bowel, resulting in protrusion of the vagina, uterus, or both.', 'Prolapse development is multifactorial, with vaginal child birth, advancing age, and increasing body-mass index as the most consistent risk factors.', 'Vaginal delivery, hysterectomy, chronic straining, normal ageing, and abnormalities of connective tissue or connective-tissue repair predispose some women to disruption, stretching, or dysfunction of the levator ani complex, connective-tissue attachments of the vagina, or both, resulting in prolapse.']\n",
            "unmatched tags:  [{'entity': 'prolapse', 'type': 'Disease', 'start': 681, 'end': 689}, {'entity': 'dysfunction', 'type': 'Disease', 'start': 574, 'end': 585}]\n",
            "['Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial\\tBuccal midazolam is at least as effective as rectal diazepam in the acute treatment of seizures.', 'Administration via the mouth is more socially acceptable and convenient and may become the preferred treatment for long seizures that occur outside hospital.']\n",
            "unmatched tags:  [{'entity': 'long seizures', 'type': 'Phenotype', 'start': 334, 'end': 347}, {'entity': 'seizures', 'type': 'Phenotype', 'start': 209, 'end': 217}, {'entity': 'diazepam', 'type': 'Drug', 'start': 174, 'end': 182}]\n",
            "['Survival after bone marrow transplantation from cytomegalovirus seropositive sibling donors\\tHLA-A2-restricted T cells show peptide-specific activity against cytomegalovirus and leukaemia cells.', 'We retrospectively analysed the influence of donor cytomegalovirus serostatus on the outcome of 103 consecutive patients who had leukaemia and who received bone-marrow transplants from HLA-identical sibling donors.', 'We found that donor cytomegalovirus seropositivity significantly improved overall survival (p=0.02) as a result of lower relapse incidence (p=0.035) in HLA-A2-positive but not HLA-A2-negative recipients.']\n",
            "unmatched tags:  [{'entity': 'seropositivity', 'type': 'Disease', 'start': 445, 'end': 459}]\n",
            "['DeepTracer: Predicting Backbone Atomic Structure from High Resolution Cryo-EM Density Maps of Protein Complexes\\tMotivation Accurately determining the atomic structure of proteins represents a fundamental problem in the field of structural bioinformatics.', 'A solution would be significant as protein structure information could be utilized in the medical field, e.g.', 'in the development of vaccines for new viruses.', 'This paper focuses on predicting the protein structure based on 3D images of the proteins captured through cryogenic electron microscopes (cryo-EM).', 'A fully automated computationally efficient protein structure prediction method would be particularly beneficial in the field of cryo-EM as the technology allows researchers to photograph multiple large protein complexes in a single study, which means that a fast prediction method could allow for a high throughput of derived protein structures.', 'We present a deep learning approach, DeepTracer, for predicting locations of the backbone atoms, secondary structure elements, and the amino acid types.', 'In order to connect the predicted amino acids into chains, we applied a modified traveling salesman algorithm.', 'Results We trained our deep learning model on experimental cryo-EM density maps and tested it on a set of 50 density maps.', 'We found that our new approach predicted protein structures with an average RMSD value of 1.18 and a coverage of 87.5%.', 'Furthermore, we detected secondary structure information for 87.2% of amino acids correctly.', 'We also showed preliminarily that 25.2% of amino acid types could be predicted directly from the 3D cryo-EM density map, considering 20 different types in total.', 'Finally, we noted that the prediction runtime of DeepTracer is significantly improved compared to other methods.', 'It predicts a large protein complex structure of more than 30,000 amino acids in only 2 hours.', 'Availability The repository of this project will be published.', 'Contact  dongsi{at}uw.edu Supplementary information Supplementary data will be available at Bioinformatics online.']\n",
            "unmatched tags:  [{'entity': 'amino acids', 'type': 'Gene', 'start': 1850, 'end': 1861}, {'entity': 'protein complex', 'type': 'Gene', 'start': 1804, 'end': 1819}, {'entity': 'DeepTracer', 'type': 'Disease', 'start': 1720, 'end': 1730}, {'entity': 'cryo-EM', 'type': 'Gene', 'start': 1609, 'end': 1616}, {'entity': 'amino acid types', 'type': 'Gene', 'start': 1552, 'end': 1568}, {'entity': 'amino acids', 'type': 'Gene', 'start': 1486, 'end': 1497}, {'entity': 'protein structures', 'type': 'Gene', 'start': 1337, 'end': 1355}, {'entity': 'cryo-EM', 'type': 'Gene', 'start': 1232, 'end': 1239}, {'entity': 'amino acids', 'type': 'Gene', 'start': 1096, 'end': 1107}, {'entity': 'amino acid types', 'type': 'Gene', 'start': 1044, 'end': 1060}, {'entity': 'DeepTracer', 'type': 'Disease', 'start': 946, 'end': 956}]\n",
            "['LONG-TERM CLINICAL OUTCOMES IN SURVIVORS OF CORONAVIRUS OUTBREAKS AFTER HOSPITALISATION OR ICU ADMISSION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF FOLLOW-UP STUDIES\\tObjective: To determine the long-term clinical problems in adult survivors of coronavirus (CoV) infection [Coronavirus disease 2019 (COVID-19), Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS)] after hospitalisation or Intensive Care Unit (ICU) admission.', 'Design: Systematic review and meta-analysis of the literature.', 'Data sources: Ovid MEDLINE, EMBASE, CINAHL Plus and PsycINFO were searched using the strategy: (Coronavirus OR Coronavirus Infections OR COVID OR SARS virus OR Severe acute respiratory syndrome OR MERS OR Middle east respiratory syndrome) AND (Follow-up OR Follow-up studies OR Prevalence).', 'Original studies reporting the clinical outcomes of adult survivors of coronavirus outbreaks two months after discharge or three months after admission were included.', 'The quality of the studies was assessed using the Oxford Centre for Evidence-Based Medicine (OCEBM) 2009 Level of Evidence Tool.', 'Meta-analysis was conducted to derive pooled estimates of prevalence and severity for different outcomes at time points up to 6 months follow-up and beyond 6 months follow-up.', 'Results: The search yielded 1169 studies of which 28 were included in this review.', 'There were 15 Level 1b, 8 Level 2b, 2 Level 3b and 3 Level 4 studies by OCEBM grading.', 'Pooled analysis of studies revealed that complications commonly observed were impaired diffusing capacity for carbon monoxide (DLCO) [prevalence of 27.26%, 95% CI 14.87 to 44.57] and reduced exercise capacity [(6-minute walking distance (6MWD) mean 461m, 95% CI 449.66 to 472.71] at 6 months with limited improvement beyond 6 months.', 'Coronavirus survivors had considerable prevalence of psychological disorders such as post-traumatic stress disorder (PTSD) [38.80%, CI 30.93 to 47.31], depression [33.20%, CI 19.80 to 50.02] and anxiety [30.04%, CI 10.44 to 61.26) beyond 6 months.', 'These complications were accompanied by low Short Form 36 (SF-36) scores at 6 months and beyond indicating reduced quality of life which is present long-term.', 'Conclusions: The long term clinical problems in survivors of CoV infections (SARS and MERS) after hospitalisation or Intensive Care Unit (ICU) admission include respiratory dysfunction, reduced exercise capacity, psychological problems such as PTSD, depression and anxiety, and reduced quality of life.', 'Critical care, rehabilitation and mental health services should anticipate a high prevalence of these problems following COVID-19 and ensure their adequate and timely management with the aim of restoring premorbid quality of life.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2619, 'end': 2627}, {'entity': 'depression', 'type': 'Disease', 'start': 2445, 'end': 2455}, {'entity': 'PTSD', 'type': 'Disease', 'start': 2439, 'end': 2443}, {'entity': 'MERS', 'type': 'Disease', 'start': 2281, 'end': 2285}, {'entity': 'SARS', 'type': 'Disease', 'start': 2272, 'end': 2276}, {'entity': 'depression', 'type': 'Disease', 'start': 1940, 'end': 1950}, {'entity': 'PTSD', 'type': 'Disease', 'start': 1905, 'end': 1909}, {'entity': 'post-traumatic stress disorder', 'type': 'Disease', 'start': 1873, 'end': 1903}, {'entity': 'psychological disorders', 'type': 'Disease', 'start': 1841, 'end': 1864}, {'entity': 'Coronavirus', 'type': 'Virus', 'start': 1788, 'end': 1799}, {'entity': '6MWD', 'type': 'Gene', 'start': 1692, 'end': 1696}, {'entity': 'carbon monoxide', 'type': 'Chemical', 'start': 1564, 'end': 1579}, {'entity': 'Level', 'type': 'Drug', 'start': 1420, 'end': 1425}, {'entity': 'Level', 'type': 'Drug', 'start': 1405, 'end': 1410}, {'entity': 'Level', 'type': 'Drug', 'start': 1393, 'end': 1398}, {'entity': 'Level', 'type': 'Drug', 'start': 1381, 'end': 1386}, {'entity': 'Level', 'type': 'Drug', 'start': 1083, 'end': 1088}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 882, 'end': 893}, {'entity': 'Middle east respiratory syndrome', 'type': 'Disease', 'start': 725, 'end': 757}, {'entity': 'MERS', 'type': 'Disease', 'start': 717, 'end': 721}, {'entity': 'acute respiratory syndrome', 'type': 'Disease', 'start': 687, 'end': 713}, {'entity': 'SARS', 'type': 'Disease', 'start': 666, 'end': 670}, {'entity': 'COVID', 'type': 'Virus', 'start': 657, 'end': 662}, {'entity': 'Coronavirus Infections', 'type': 'Disease', 'start': 631, 'end': 653}, {'entity': 'Coronavirus', 'type': 'Virus', 'start': 616, 'end': 627}]\n",
            "['Field trial of a locally produced, killed, oral cholera vaccine in Vietnam\\tThese findings suggest that oral killed whole-cell vaccines can confer substantial protection against El Tor cholera in young children, who are at highest risk of cholera in endemic settings.', 'An inexpensive, locally produced, and effective oral cholera vaccine may be within reach of the limited health-care budgets of poor countries with endemic cholera, if our findings can be replicated in a randomised double-blind trial.']\n",
            "unmatched tags:  [{'entity': 'cholera', 'type': 'Drug', 'start': 422, 'end': 429}, {'entity': 'endemic cholera', 'type': 'Disease', 'start': 414, 'end': 429}]\n",
            "['Efficacy and tolerability of triple drug therapy with albendazole, pyrantel pamoate, and oxantel pamoate compared with albendazole plus oxantel pamoate, pyrantel pamoate plus oxantel pamoate, and mebendazole plus pyrantel pamoate and oxantel pamoate against hookworm infections in school-aged children in Laos: a randomised, single-blind trial\\tTDT with albendazole, pyrantel pamoate, and oxantel pamoate could make a difference, in particular in the context of soil-transmitted helminth elimination.', 'Pyrantel pamoate might be a useful alternative to prevent benzimidazole resistance; however, larger trials are needed to confirm this finding.']\n",
            "unmatched tags:  [{'entity': 'benzimidazole resistance', 'type': 'Drug', 'start': 558, 'end': 582}, {'entity': 'pamoate', 'type': 'Drug', 'start': 509, 'end': 516}, {'entity': 'Pyrantel pamoate', 'type': 'Drug', 'start': 500, 'end': 516}, {'entity': 'oxantel pamoate', 'type': 'Drug', 'start': 388, 'end': 403}, {'entity': 'pamoate', 'type': 'Drug', 'start': 375, 'end': 382}, {'entity': 'pyrantel pamoate', 'type': 'Drug', 'start': 366, 'end': 382}, {'entity': 'albendazole', 'type': 'Drug', 'start': 353, 'end': 364}, {'entity': 'TDT', 'type': 'Gene', 'start': 344, 'end': 347}, {'entity': 'school-aged children', 'type': 'Gene', 'start': 281, 'end': 301}, {'entity': 'hookworm infections', 'type': 'Disease', 'start': 258, 'end': 277}, {'entity': 'oxantel pamoate', 'type': 'Drug', 'start': 234, 'end': 249}, {'entity': 'pamoate', 'type': 'Drug', 'start': 222, 'end': 229}, {'entity': 'pyrantel pamoate', 'type': 'Drug', 'start': 213, 'end': 229}, {'entity': 'mebendazole', 'type': 'Drug', 'start': 196, 'end': 207}, {'entity': 'oxantel pamoate', 'type': 'Drug', 'start': 175, 'end': 190}, {'entity': 'pamoate', 'type': 'Drug', 'start': 162, 'end': 169}]\n",
            "['Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial\\tReduction in heart rate with ivabradine does not improve cardiac outcomes in all patients with stable coronary artery disease and left-ventricular systolic dysfunction, but could be used to reduce the incidence of coronary artery disease outcomes in a subgroup of patients who have heart rates of 70 bpm or greater.']\n",
            "unmatched tags:  [{'entity': 'coronary artery disease', 'type': 'Disease', 'start': 382, 'end': 405}]\n",
            "['Challenges and controversies in management of pancreatic neuroendocrine tumours in patients with MEN1\\tMultiple endocrine neoplasia type 1 (MEN1), an autosomal dominant disorder, is characterised by the occurrence of pancreatic neuroendocrine tumours (P-NETs) in association with parathyroid and pituitary tumours.', 'P-NETs, which include gastrinomas, insulinomas, and non-functioning tumours, occur in more than 80% of MEN1 patients and account for 50% of disease-specific deaths.', 'However, there is no consensus about the optimal methods for detecting and treating P-NETs in MEN1 patients, and extrapolations from approaches used in patients with non-familial (sporadic) P-NETs require caution because of differences, such as the younger age of onset, multi-focality of P-NETs, and concomitant presence of other tumours in MEN1 patients.']\n",
            "unmatched tags:  [{'entity': 'MEN1', 'type': 'Gene', 'start': 821, 'end': 825}, {'entity': 'tumours', 'type': 'Disease', 'start': 810, 'end': 817}, {'entity': 'younger age', 'type': 'Gene', 'start': 728, 'end': 739}, {'entity': 'MEN1', 'type': 'Gene', 'start': 573, 'end': 577}, {'entity': 'MEN1', 'type': 'Gene', 'start': 417, 'end': 421}, {'entity': 'tumours', 'type': 'Disease', 'start': 382, 'end': 389}, {'entity': 'non-functioning tumours', 'type': 'Disease', 'start': 366, 'end': 389}, {'entity': 'insulinomas', 'type': 'Disease', 'start': 349, 'end': 360}, {'entity': 'gastrinomas', 'type': 'Disease', 'start': 336, 'end': 347}, {'entity': 'pituitary tumours', 'type': 'Disease', 'start': 295, 'end': 312}]\n",
            "['All-in-One Dual CRISPR-Cas12a (AIOD-CRISPR) Assay: A Case for Rapid, Ultrasensitive and Visual Detection of Novel Coronavirus SARS-CoV-2 and HIV virus\\tA recent outbreak of novel coronavirus (SARS-CoV-2), the causative agent of COVID-19, has spread rapidly all over the world.', 'Human immunodeficiency virus (HIV) is another deadly virus and causes acquired immunodeficiency syndrome (AIDS).', 'Rapid and early detection of these viruses will facilitate early intervention and reduce disease transmission risk.', 'Here, we present an A ll- I n- O ne D ual CRISPR -Cas12a (termed “AIOD-CRISPR”) assay method for simple, rapid, ultrasensitive, one-pot, and visual detection of coronavirus SARS-CoV-2 and HIV virus.', 'In our AIOD CRISPR assay, a pair of crRNAs was introduced to initiate dual CRISPR-Cas12a detection and improve detection sensitivity.', 'The AIOD-CRISPR assay system was successfully utilized to detect nucleic acids (DNA and RNA) of SARS-CoV-2 and HIV with a sensitivity of few copies.', 'Also, it was evaluated by detecting HIV-1 RNA extracted from human plasma samples, achieving a comparable sensitivity with real-time RT-PCR method.', 'Thus, our method has a great potential for developing next-generation point-of-care molecular diagnostics.']\n",
            "unmatched tags:  [{'entity': 'HIV-1 RNA', 'type': 'Virus', 'start': 1023, 'end': 1032}, {'entity': 'HIV', 'type': 'Virus', 'start': 949, 'end': 952}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 934, 'end': 944}, {'entity': 'RNA', 'type': 'Gene', 'start': 926, 'end': 929}, {'entity': 'DNA', 'type': 'Gene', 'start': 918, 'end': 921}, {'entity': 'nucleic acids', 'type': 'Gene', 'start': 903, 'end': 916}]\n",
            "['Uncommon primary mediastinal tumours\\tThe mediastinum is a unique anatomic area containing several structures and pluripotent cells that allow for the development of a range of tumours.', 'Uncommon neoplasms of the mediastinum account for less than 10% of all mediastinal masses and include primary thymic carcinomas, neuroendocrine carcinomas, germ-cell tumours (GCTs), lymphomas, and neurogenic, endocrine, and mesenchymal tumours.', 'Primary thymic carcinomas and neuroendocrine carcinomas, although rare, are highly malignant lesions.', 'GCTs are thought to derive from primitive germ cells and can be classified in seminomatous and non-seminomatous GCTs.']\n",
            "unmatched tags:  [{'entity': 'GCTs', 'type': 'Gene', 'start': 644, 'end': 648}, {'entity': 'GCTs', 'type': 'Gene', 'start': 532, 'end': 536}, {'entity': 'neuroendocrine carcinomas', 'type': 'Disease', 'start': 460, 'end': 485}, {'entity': 'Primary thymic carcinomas', 'type': 'Disease', 'start': 430, 'end': 455}]\n",
            "[\"Pisa syndrome in Parkinson's disease and parkinsonism: clinical features, pathophysiology, and treatment\\tPisa syndrome is defined as a reversible lateral bending of the trunk with a tendency to lean to one side.\", \"It is a frequent and often disabling complication of Parkinson's disease, and has also been described in several atypical forms of parkinsonism and in neurodegenerative and psychiatric disorders after drug exposure and surgical procedures.\", 'Although no consistent diagnostic criteria for Pisa syndrome are available, most investigations have adopted an arbitrary cutoff of at least 10° of lateral flexion for the diagnosis of the syndrome.']\n",
            "unmatched tags:  [{'entity': 'syndrome', 'type': 'Disease', 'start': 641, 'end': 649}, {'entity': 'Pisa syndrome', 'type': 'Disease', 'start': 499, 'end': 512}, {'entity': 'psychiatric disorders', 'type': 'Disease', 'start': 385, 'end': 406}, {'entity': 'parkinsonism', 'type': 'Disease', 'start': 343, 'end': 355}]\n",
            "[\"Factitious disorders and malingering: challenges for clinical assessment and management\\tCompared with other psychiatric disorders, diagnosis of factitious disorders is rare, with identification largely dependent on the systematic collection of relevant information, including a detailed chronology and scrutiny of the patient's medical record.\", 'Management of such disorders ideally requires a team-based approach and close involvement of the primary care doctor.', 'As deception is a key defining component of factitious disorders, diagnosis has important implications for young children, particularly when identified in women and health-care workers.']\n",
            "unmatched tags:  [{'entity': 'factitious disorders', 'type': 'Disease', 'start': 506, 'end': 526}, {'entity': 'disorders', 'type': 'Disease', 'start': 363, 'end': 372}]\n",
            "['Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial\\tOral doxycycline is as efficient as intravenous ceftriaxone for the treatment of European adults with Lyme neuroborreliosis.']\n",
            "unmatched tags:  [{'entity': 'Lyme neuroborreliosis', 'type': 'Disease', 'start': 249, 'end': 270}, {'entity': 'ceftriaxone', 'type': 'Drug', 'start': 195, 'end': 206}]\n",
            "['Effectiveness of interventions for diagnosis and treatment of tuberculosis in hard-to-reach populations in countries of low and medium tuberculosis incidence: a systematic review\\tTuberculosis is over-represented in hard-to-reach (underserved) populations in high-income countries of low tuberculosis incidence.', 'The mainstay of tuberculosis care is early detection of active tuberculosis (case finding), contact tracing, and treatment completion.', 'We did a systematic review with a scoping component of relevant studies published between 1990 and 2015 to update and extend previous National Institute for Health and Care Excellence (NICE) reviews on the effectiveness of interventions for identifying and managing tuberculosis in hard-to-reach populations.']\n",
            "unmatched tags:  [{'entity': 'tuberculosis', 'type': 'Disease', 'start': 712, 'end': 724}]\n",
            "['Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome\\tMetabolic syndrome is a cluster of metabolic abnormalities that identifies people at risk of diabetes and cardiovascular disease, whereas non-alcoholic fatty liver disease (NAFLD) is defined as a disorder with excess fat in the liver due to non-alcoholic causes.', 'Two key components of metabolic syndrome, glucose and triglycerides, are overproduced by the fatty liver.', 'The liver is therefore a key determinant of metabolic abnormalities.', 'The prevalence of both metabolic syndrome and NAFLD increases with obesity.']\n",
            "unmatched tags:  [{'entity': 'obesity', 'type': 'Phenotype', 'start': 590, 'end': 597}, {'entity': 'NAFLD', 'type': 'Disease', 'start': 569, 'end': 574}, {'entity': 'metabolic syndrome', 'type': 'Disease', 'start': 546, 'end': 564}, {'entity': 'fatty liver', 'type': 'Disease', 'start': 441, 'end': 452}, {'entity': 'triglycerides', 'type': 'Drug', 'start': 402, 'end': 415}, {'entity': 'glucose', 'type': 'Drug', 'start': 390, 'end': 397}, {'entity': 'metabolic syndrome', 'type': 'Disease', 'start': 370, 'end': 388}, {'entity': 'non-alcoholic', 'type': 'Disease', 'start': 326, 'end': 339}, {'entity': 'fat', 'type': 'Drug', 'start': 302, 'end': 305}, {'entity': 'NAFLD', 'type': 'Disease', 'start': 258, 'end': 263}]\n",
            "['COVID-19 pandemic scenario in India compared to China and rest of the world: a data driven and model analysis\\tThe COVID-19 is a rapidly spreading respiratory illness caused with the infection of SARS-CoV-2.', 'The COVID-19 data from India was compared with China and rest of the world.', 'The average values of daily growth rate (DGR), case recovery rate (CRR), case fatality rate (CFR), serial interval (SI) of COVID-19 in India was 17%, 8.25%, and 1.87%, and 5.76 days respectively, as of April 9, 2020.', 'The data driven estimates of basic reproduction number (R0), average reproduction number (R) and effective reproduction number (Re) were 1.03, 1.73, and 1.35, respectively.', 'The results of exponential and SIR model showed higher estimates of R0, R and Re.', 'The data driven as well as estimated COVID-19 cases reflect the growing nature of the epidemic in India and world excluding China, whereas the same in China reveal the involved population became infected with the disease and moved into the recovered stage.', 'The epidemic size of India was estimated to be ~30,284 (as of April 15, 2020 with 12,370 infectious cases) with an estimated end of the epidemic on June 9, 2020.', 'The Re values in India before and after lockdown were 1.62 and 1.37 respectively, with SI 5.52 days and 5.98 days, respectively, as of April 17, 2020, reflecting the effectiveness of lockdown strategies.', 'Beyond April 17, 2020, our estimate of 24,431 COVID-19 infected cases with lockdown is 78% lower compared to the 112,042 case estimates in absence of lockdown, on April 27, 2020.', 'To early end of the COVID-19 epidemic, strong social distancing is important.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 1577, 'end': 1585}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1424, 'end': 1432}, {'entity': 'SI', 'type': 'Gene', 'start': 1261, 'end': 1263}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 792, 'end': 800}]\n",
            "['Acute pancreatitis\\tAcute pancreatitis is an inflammatory disease of the pancreas.', 'Acute abdominal pain is the most common symptom, and increased concentrations of serum amylase and lipase confirm the diagnosis.', 'Pancreatic injury is mild in 80% of patients, who recover without complications.', 'The remaining patients have a severe disease with local and systemic complications.', 'Gallstone migration into the common bile duct and alcohol abuse are the most frequent causes of pancreatitis in adults.', 'About 15–25% of pancreatitis episodes are of unknown origin.']\n",
            "unmatched tags:  [{'entity': 'pancreatitis', 'type': 'Disease', 'start': 512, 'end': 524}, {'entity': 'pancreatitis', 'type': 'Disease', 'start': 472, 'end': 484}, {'entity': 'alcohol abuse', 'type': 'Disease', 'start': 426, 'end': 439}, {'entity': 'Pancreatic injury', 'type': 'Disease', 'start': 211, 'end': 228}, {'entity': 'lipase', 'type': 'Gene', 'start': 181, 'end': 187}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 122, 'end': 129}, {'entity': 'Acute abdominal pain', 'type': 'Phenotype', 'start': 82, 'end': 102}]\n",
            "['Comparative outcomes of rectal cancer surgery between elderly and non-elderly patients: a systematic review\\tElderly people represent almost all patients diagnosed with and treated for rectal cancer, and this trend is likely to become more apparent in the future.', 'Surgical management and treatment decisions for this disease are becoming increasingly complex, but only a few reports deal specifically with older patients.', 'In this systematic review, we provide an overview of published studies of outcomes after curative surgery for rectal cancer in elderly people (>70 years).', 'We identified 48 studies providing information about postoperative results, survival, surgical approach, stoma formation, functional results, and quality of life after rectal resection for cancer.']\n",
            "unmatched tags:  [{'entity': 'cancer', 'type': 'Disease', 'start': 765, 'end': 771}]\n",
            "['An ecological study of socioeconomic predictors in detection of COVID-19 cases across neighborhoods in New York City\\tAbstract Background: New York City was the first major urban center of the COVID-19 pandemic in the USA.', 'Cases are clustered in the city, with certain neighborhoods experiencing more cases than others.', 'We investigate whether potential socioeconomic factors can explain between-neighborhood variation in the number of detected COVID-19 cases.', 'Methods: Data were collected from 177 Zip Code Tabulation Areas (ZCTA) in New York City (99.9% of the population).', 'We fit multiple Bayesian Besag-York-Mollié (BYM) mixed models using positive COVID-19 tests as the outcome and a set of 10 representative economic, demographic, and health-care associated ZCTA-level parameters as potential predictors.', 'The BYM model includes both spatial and nonspatial random effects to account for clustering and overdispersion.', 'Results: Multiple different regression approaches indicated a consistent, statistically significant association between detected COVID-19 cases and dependent (under 18 or 65+ years old) population, male to female ratio, and median household income.', 'In the final model, we found that an increase of only 1% in dependent population is associated with a 2.5% increase in detected COVID-19 cases (95% confidence interval (CI): 1.6% to 3.4%, p < 0.0005).', 'An increase of 1 male per 100 females is associated with a 1.0% (95% CI: 0.6% to 1.5%, p < 0.0005) increases in detected cases.', 'A decrease of $10,000 median household income is associated with a 2.5% (95% CI: 1.0% to 4.1% p = 0.002) increase in detected COVID-19 cases.', 'Conclusions: Our findings indicate associations between neighborhoods with a large dependent population, those with a high proportion of males, and low-income neighborhoods and detected COVID-19 cases.', 'Given the elevated mortality in aging populations, the study highlights the importance of public health management during and after the current COVID-19 pandemic.', 'Further work is warranted to fully understand the mechanisms by which these factors may have affected the number of detected cases, either in terms of the true number of cases or access to testing.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 1990, 'end': 1998}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1830, 'end': 1838}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1627, 'end': 1635}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1300, 'end': 1308}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1052, 'end': 1060}]\n",
            "['Impact of Social Distancing Measures on COVID-19 Healthcare Demand in Central Texas\\tA novel coronavirus (SARS-CoV-2) emerged in Wuhan, China in late 2019 and rapidly spread worldwide.', 'In the absence of effective antiviral drugs and vaccines, well-targeted social distancing measures are essential for mitigating the COVID-19 pandemic, reducing strain on local health systems, and preventing mortality.', 'Here, we provide a quantitative assessment of the efficacy of social distancing to slow COVID-19 transmission and reduce hospital surge, depending on the timing and extent of the measures imposed for a metropolitan region and its health care systems.', 'We built a granular mathematical model of COVID-19 transmission that incorporated age-specific and risk-stratified heterogeneity, estimates for the transmission, and severity of COVID-19 using current best evidence.', 'We performed thousands of stochastic simulations of COVID-19 transmission in the Austin-Round Rock Metropolitan Area to project the impact of school closures coupled with social distancing measures that were estimated to reduce non-household contacts by 0%, 25%, 50%, 75% or 90%.', 'We compare early versus late implementation and estimate the number of COVID-19 hospitalizations, ICU patients, ventilator needs and deaths through mid-August, 2020.', 'We queried local emergency services and hospital systems to estimate total hospital bed, ICU, and ventilator capacity for the region.', 'We expected COVID-19 hospital beds and ICU requirements would surpass local capacity by mid-May if no intervention was taken.', 'Assuming a four-day epidemic doubling time, school closures alone would be expected to reduce peak hospitalizations by only 18% and cumulative deaths by less than 3%.', 'Immediate social distancing measures that reduced non-household contacts by over 75%, such as stay-at-home orders and closing of non-essential businesses, would be required to ensure that COVID-19 cases do not overwhelm local hospital surge capacity.', 'Peak ICU bed demand prior to mid August 2020 would be expected to be reduced from 2,121 (95% CI: 2,018-2,208) with no intervention to 698 (95% CI: 204-1,100) with 75% social distancing and 136 (95% CI: 38-308) with 90% social distancing; current ICU bed capacity was estimated at 680.', 'A two-week delay in implementation of such measures is projected to accelerate a local ICU bed shortage by four weeks.', 'School closures alone hardly impact the epidemic curve.', 'Immediate social distancing measures that reduce non-household contacts by over 75% were required to ensure that COVID-19 cases do not overwhelm local hospital surge capacity.', 'These findings helped inform the Stay Home-Work Safe order enacted by the city of Austin, Texas on March 24, 2020 as a means of mitigating the emerging COVID-19 epidemic.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2781, 'end': 2789}, {'entity': 'Austin', 'type': 'Drug', 'start': 2711, 'end': 2717}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2566, 'end': 2574}, {'entity': 'bed', 'type': 'Disease', 'start': 2369, 'end': 2372}, {'entity': 'bed', 'type': 'Disease', 'start': 2243, 'end': 2246}]\n",
            "['RNA-dependent RNA polymerase speed and fidelity are not the only determinants of the mechanism or efficiency of recombination\\tUsing the RNA-dependent RNA polymerase (RdRp) from poliovirus (PV) as our model system, we have shown that Lys-359 in motif-D functions as a general acid in the mechanism of nucleotidyl transfer.', 'A K359H (KH) RdRp derivative is slow and faithful relative to wild-type enzyme.', 'In the context of the virus, RdRp-coding sequence evolves, selecting for the following substitutions: I331F (IF, motif-C) and P356S (PS, motif-D).', 'We have evaluated IF-KH, PS-KH, and IF-PS-KH viruses and enzymes.', 'The speed and fidelity of each double mutant are equivalent.', 'Each exhibits a unique recombination phenotype, with IF-KH being competent for copy-choice recombination and PS-KH being competent for forced-copy-choice recombination.', 'Although the IF-PS-KH RdRp exhibits biochemical properties within twofold of wild type, the virus is impaired substantially for recombination in cells.', 'We conclude that there are biochemical properties of the RdRp in addition to speed and fidelity that determine the mechanism and efficiency of recombination.', 'The interwoven nature of speed, fidelity, the undefined property suggested here, and recombination makes it impossible to attribute a single property of the RdRp to fitness.', 'However, the derivatives described here may permit elucidation of the importance of recombination on the fitness of the viral population in a background of constant polymerase speed and fidelity.', 'Significance The availability of a “universal” method to create attenuated viruses for use as vaccine strains would permit a rapid response to outbreaks of newly emerging viruses.', 'Targeting RdRp fidelity has emerged as such a universal approach.', 'However, because polymerase fidelity and speed are inextricably linked, the effort to attribute the attenuated phenotype to a single biochemical property of the RdRp may be futile.', 'Here, we show that this circumstance is even more complex.', 'We provide evidence for the existence of a biochemical parameter that combines with fidelity and speed to govern the mechanism and/or efficiency of recombination.', 'We conclude that the field will be served best by continued emphasis on discovery of manipulatable functions of the RdRp instead of debating the importance of individual properties.']\n",
            "unmatched tags:  [{'entity': 'polymerase fidelity', 'type': 'Gene', 'start': 1788, 'end': 1807}, {'entity': 'vaccine strains', 'type': 'Drug', 'start': 1619, 'end': 1634}, {'entity': 'polymerase', 'type': 'Gene', 'start': 1494, 'end': 1504}, {'entity': 'wild type', 'type': 'Gene', 'start': 922, 'end': 931}, {'entity': 'PS-KH', 'type': 'Gene', 'start': 861, 'end': 866}, {'entity': 'PS-KH', 'type': 'Gene', 'start': 785, 'end': 790}, {'entity': 'enzymes', 'type': 'Gene', 'start': 606, 'end': 613}, {'entity': 'PS-KH', 'type': 'Gene', 'start': 588, 'end': 593}, {'entity': 'PS-KH', 'type': 'Gene', 'start': 574, 'end': 579}, {'entity': 'PS', 'type': 'Gene', 'start': 535, 'end': 537}, {'entity': 'P356S', 'type': 'Disease', 'start': 528, 'end': 533}, {'entity': 'motif-C', 'type': 'Organization', 'start': 515, 'end': 522}, {'entity': 'I331F', 'type': 'Chemical', 'start': 504, 'end': 509}, {'entity': 'enzyme', 'type': 'Gene', 'start': 394, 'end': 400}, {'entity': 'wild-type', 'type': 'Drug', 'start': 384, 'end': 393}, {'entity': 'nucleotidyl transfer', 'type': 'Gene', 'start': 300, 'end': 320}, {'entity': 'Lys-359', 'type': 'Gene', 'start': 233, 'end': 240}, {'entity': 'PV', 'type': 'Drug', 'start': 189, 'end': 191}]\n",
            "['Lessons from the skin—cutaneous features of familial cancer\\tAs the molecular basis of disease continues to be elucidated, familial cancer syndromes, which consist of a range of neoplastic and non-neoplastic features, are emerging.', 'The usual pathway of referral to a genetics clinic or familial cancer centre is via an oncologist, when high-risk features that suggest a possible hereditary basis for the presenting cancer are recognised.', 'Traditionally, these high-risk features include more than two family members with similar cancers over two or more generations, a young age of onset, and more than one synchronous or metachronous tumour.']\n",
            "unmatched tags:  [{'entity': 'young age', 'type': 'Disease', 'start': 567, 'end': 576}, {'entity': 'cancers', 'type': 'Disease', 'start': 527, 'end': 534}, {'entity': 'cancer', 'type': 'Disease', 'start': 414, 'end': 420}, {'entity': 'cancer', 'type': 'Disease', 'start': 294, 'end': 300}, {'entity': 'familial cancer centre', 'type': 'Disease', 'start': 285, 'end': 307}, {'entity': 'non-neoplastic', 'type': 'Disease', 'start': 192, 'end': 206}]\n",
            "['Treatment of postmenopausal osteoporosis\\tThe aim of treatment of postmenopausal osteoporosis is to reduce the frequency of vertebral and non-vertebral fractures (especially at the hip), which are responsible for morbidity associated with the disease.', 'Results of large placebo controlled trials have shown that alendronate, raloxifene, risedronate, the 1–34 fragment of parathyroid hormone, and nasal calcitonin, greatly reduce the risk of vertebral fractures.', 'Furthermore, a large reduction of non-vertebral fractures has been shown for alendronate, risedronate, and the 1–34 fragment of parathyroid hormone.']\n",
            "unmatched tags:  [{'entity': 'parathyroid hormone', 'type': 'Drug', 'start': 588, 'end': 607}, {'entity': 'risedronate', 'type': 'Drug', 'start': 550, 'end': 561}, {'entity': 'alendronate', 'type': 'Drug', 'start': 537, 'end': 548}, {'entity': 'non-vertebral fractures', 'type': 'Disease', 'start': 494, 'end': 517}, {'entity': 'vertebral fractures', 'type': 'Disease', 'start': 439, 'end': 458}, {'entity': 'nasal calcitonin', 'type': 'Drug', 'start': 394, 'end': 410}, {'entity': 'parathyroid hormone', 'type': 'Drug', 'start': 369, 'end': 388}, {'entity': 'risedronate', 'type': 'Drug', 'start': 335, 'end': 346}, {'entity': 'raloxifene', 'type': 'Drug', 'start': 323, 'end': 333}, {'entity': 'alendronate', 'type': 'Drug', 'start': 310, 'end': 321}, {'entity': 'hip', 'type': 'Gene', 'start': 180, 'end': 183}, {'entity': 'non-vertebral fractures', 'type': 'Disease', 'start': 137, 'end': 160}]\n",
            "['Protection of Rhesus Macaque from SARS-Coronavirus challenge by recombinant adenovirus vaccine\\tA recombinant adenovirus vaccine against the SARS Coronavirus (SARS-CoV) was constructed, which contains fragments from the S, N, and Orf8 genes.', 'Rhesus Macaques immunized with the recombinant adenovirus generated antigen-specific humoral and cellular response.', 'Furthermore, the vaccine provided significant protection against subsequent live SARS-CoV challenge.', 'In contrast, three out of four monkeys immunized with placebo suffered severe alveolar damage and pulmonary destruction.']\n",
            "unmatched tags:  [{'entity': 'pulmonary destruction', 'type': 'Disease', 'start': 556, 'end': 577}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 438, 'end': 446}, {'entity': 'vaccine', 'type': 'Drug', 'start': 374, 'end': 381}, {'entity': 'antigen-specific', 'type': 'Gene', 'start': 309, 'end': 325}, {'entity': 'recombinant adenovirus', 'type': 'Virus', 'start': 276, 'end': 298}, {'entity': 'Orf8', 'type': 'Gene', 'start': 229, 'end': 233}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 158, 'end': 166}]\n",
            "['Getting to zero quickly in the 2019-nCov epidemic with vaccines or rapid testing\\tAny plan for stopping the ongoing 2019-nCov epidemic must be based on a quantitative understanding of the proportion of the at-risk population that needs to be protected by effective control measures in order for transmission to decline sufficiently and quickly enough for the epidemic to end.', 'Using an SEIR-type transmission model, we contrasted two alternate strategies by modeling the proportion of the population that needs to be protected from infection by one-time vaccination (assuming 100% effectiveness) or by testing with isolation and treatment of individuals within six, 24, or 48 hours of symptom onset.', 'If R is currently 2.2, vaccination at the herd immunity coverage of 55% would drive R just below 1, but transmission could persist for years.', 'Over 80% of coverage is required to end the epidemic in 6 months with population-wide vaccination.', 'The epidemic could be ended in just under a year if testing with isolation and treatment reached 80% of symptomatically infected patients within 24 hours of symptom onset (assuming 10% asymptomatic transmission).', 'The epidemic could be ended in six months if testing with isolation and treatment reached 90% of symptomatic patients.', 'If 90% of symptomatic patients could be tested within six hours of symptoms appearing, the epidemic could be ended in under four months.']\n",
            "unmatched tags:  [{'entity': 'symptom', 'type': 'Phenotype', 'start': 1281, 'end': 1288}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 1249, 'end': 1256}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 1125, 'end': 1132}]\n",
            "['Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review\\tAlthough patient-reported outcomes (PROs), such as health-related quality of life, are important endpoints in randomised controlled trials (RCTs), there is little consensus about the analysis, interpretation, and reporting of these data.', 'We did a systematic review to assess the variability, quality, and standards of PRO data analyses in advanced breast cancer RCTs.', 'We searched PubMed for English language articles published in peer-reviewed journals between Jan 1, 2001, and Oct 30, 2017.', 'Eligible articles were those that reported PRO results from RCTs of adult patients with advanced breast cancer receiving anti-cancer treatments with reported sample sizes of at least 50 patients—66 RCTs met the selection criteria.']\n",
            "unmatched tags:  [{'entity': 'RCTs', 'type': 'Chemical', 'start': 846, 'end': 850}, {'entity': 'anti-cancer treatments', 'type': 'Drug', 'start': 769, 'end': 791}, {'entity': 'advanced breast cancer', 'type': 'Disease', 'start': 736, 'end': 758}]\n",
            "['Population genomics insights into the recent evolution of SARS-CoV-2\\tThe current coronavirus disease 2019 (COVID-19) pandemic is caused by the SARS-CoV-2 virus and is still spreading rapidly worldwide.', 'Full-genome-sequence computational analysis of the SARS-CoV-2 genome will allow us to understand the recent evolutionary events and adaptability mechanisms more accurately, as there is still neither effective therapeutic nor prophylactic strategy.', 'In this study, we used population genetics analysis to infer the mutation rate and plausible recombination events that may have contributed to the evolution of the SARS-CoV-2 virus.', 'Furthermore, we localized targets of recent and strong positive selection.', 'The genomic regions that appear to be under positive selection are largely co-localized with regions in which recombination from non-human hosts appeared to have taken place in the past.', 'Our results suggest that the pangolin coronavirus genome may have contributed to the SARS-CoV-2 genome by recombination with the bat coronavirus genome.', 'However, we find evidence for additional recombination events that involve coronavirus genomes from other hosts, i.e., Hedgehog and Sparrow.', 'Even though recombination events within human hosts cannot be directly assessed, due to the high similarity of SARS-CoV-2 genomes, we infer that recombinations may have recently occurred within human hosts using a linkage disequilibrium analysis.', 'In addition, we employed an Approximate Bayesian Computation approach to estimate the parameters of a demographic scenario involving an exponential growth of the size of the SARS-CoV-2 populations that have infected European, Asian and Northern American cohorts, and we demonstrated that a rapid exponential growth in population size can support the observed polymorphism patterns in SARS-CoV-2 genomes.']\n",
            "unmatched tags:  [{'entity': 'genomes', 'type': 'Gene', 'start': 1830, 'end': 1837}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1819, 'end': 1829}, {'entity': 'exponential growth', 'type': 'Organization', 'start': 1731, 'end': 1749}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1609, 'end': 1619}, {'entity': 'exponential growth', 'type': 'Organization', 'start': 1571, 'end': 1589}, {'entity': 'genomes', 'type': 'Gene', 'start': 1310, 'end': 1317}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1299, 'end': 1309}, {'entity': 'genomes', 'type': 'Gene', 'start': 1134, 'end': 1141}]\n",
            "[\"Diagnosis of Alzheimer's disease with cerebrospinal fluid tau protein and aspartate aminotransferase\\tIn Alzheimer's disease neuronal degeneration leads to the release of the microtubule-associated protein tau into the extracellular space and cerebrospinal fluid (CSF).\", \"CSF tau concentration is substantially increased compared with controls in mild Alzheimer's disease and in other forms of dementia,\"]\n",
            "unmatched tags:  [{'entity': 'dementia', 'type': 'Disease', 'start': 391, 'end': 399}, {'entity': \"mild Alzheimer's disease\", 'type': 'Disease', 'start': 344, 'end': 368}]\n",
            "['The effect of BCG vaccination on COVID-19 examined by a statistical approach: no positive results from the Diamond Princess and cross-national differences previously reported by world-wide comparisons are flawed in several ways\\tRecently, the controversial hypothesis that BCG (Bacillus Calmette-Guerin) vaccination reduces infection or severity of COVID-19 has been proposed.', 'The present study examined this hypothesis using statistical approaches based on the public data.', 'Three approaches were utilized: 1) comparing the infection and mortality ratio of people on the cruise ship Diamond Princess, 2) comparing the number of mortalities among nations, and 3) comparing the maximum daily increase rate of total mortalities among nations.', 'The result of 1) showed that there is no significant difference in infection per person onboard and mortality-infection between Japanese citizens vs. other nationalities and BCG obligatory nations vs. non-BCG obligatory nations on the Diamond Princess.', 'The result of 2) showed that the number of mortalities among nations is similar to the previous studies, but this analysis also considered the timing of COVID-19 arrival in each nation.', 'After correcting for arrival time, previously reported effect of BCG vaccination on decreasing total mortality disappeared.', 'This is because nations that lack BCG vaccination are concentrated in Western Europe, which is near an epicenter of COVID-19.', 'Therefore some previous reports are now considered to be affected by this artifact; the result may have been flawed by on-land dispersal from an epicenter.', 'However, some results showed weakly significant differences in the number of deaths at a particular time among BCG obligatory and non-BCG nations (especially the use of Japanese BCG strain Tokyo 172).', 'However, these results are affected by the results of three countries and the effect of BCG vaccination remains inconclusive.', 'The result of 3) showed that the maximum daily increasing rate in death among nations showed no significant difference among BCG vaccination policies.', 'In the present study, although some results showed statistically significant differences among BCG vaccination policies, they may be affected by the impact of various other factors, such as national infection-control policies, social distancing, behavioral changes of people, possible previous local epidemics of closely related viruses, or inter-population differences in ACE2 or other genetic polymorphism.', 'Further research is needed to better understand the underlying cause of the observed differences in infection and mortality of the disease among nations.', 'Nevertheless, our results show that the effect of BCG vaccination, if any, can be masked by many other factors.', 'Therefore, the possible effect might be relatively small.', 'In fact, in Japan, where almost all citizens have been vaccinated, COVID-19 cases are constantly increasing.', 'Given the importance of peoples behavior in preventing viral propagation, the spread of optimism triggered by this hypothesis would be harmful to BCG vaccination nations.']\n",
            "unmatched tags:  [{'entity': 'nation', 'type': 'Organization', 'start': 3066, 'end': 3072}, {'entity': 'nation', 'type': 'Organization', 'start': 3059, 'end': 3065}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2862, 'end': 2870}, {'entity': 'nation', 'type': 'Organization', 'start': 2684, 'end': 2690}, {'entity': 'nation', 'type': 'Organization', 'start': 2616, 'end': 2622}, {'entity': 'ACE2', 'type': 'Gene', 'start': 2435, 'end': 2439}, {'entity': 'nation', 'type': 'Organization', 'start': 2252, 'end': 2258}, {'entity': 'nation', 'type': 'Organization', 'start': 2166, 'end': 2172}, {'entity': 'nation', 'type': 'Organization', 'start': 2045, 'end': 2051}, {'entity': 'nation', 'type': 'Organization', 'start': 1989, 'end': 1995}, {'entity': 'nation', 'type': 'Organization', 'start': 1882, 'end': 1888}, {'entity': 'BCG strain Tokyo 172', 'type': 'Drug', 'start': 1762, 'end': 1782}, {'entity': 'nation', 'type': 'Organization', 'start': 1722, 'end': 1728}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1418, 'end': 1426}, {'entity': 'nation', 'type': 'Organization', 'start': 1345, 'end': 1351}, {'entity': 'nation', 'type': 'Organization', 'start': 1318, 'end': 1324}, {'entity': 'nation', 'type': 'Organization', 'start': 1252, 'end': 1258}, {'entity': 'nation', 'type': 'Organization', 'start': 1170, 'end': 1176}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1145, 'end': 1153}, {'entity': 'nation', 'type': 'Organization', 'start': 1053, 'end': 1059}, {'entity': 'Diamond Princess', 'type': 'Chemical', 'start': 974, 'end': 990}, {'entity': 'nation', 'type': 'Organization', 'start': 959, 'end': 965}, {'entity': 'nation', 'type': 'Organization', 'start': 928, 'end': 934}, {'entity': 'nation', 'type': 'Organization', 'start': 895, 'end': 901}, {'entity': 'nation', 'type': 'Organization', 'start': 730, 'end': 736}, {'entity': 'nation', 'type': 'Organization', 'start': 645, 'end': 651}, {'entity': 'Diamond Princess', 'type': 'Chemical', 'start': 582, 'end': 598}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 348, 'end': 356}, {'entity': 'nation', 'type': 'Organization', 'start': 308, 'end': 314}, {'entity': 'nation', 'type': 'Organization', 'start': 134, 'end': 140}]\n",
            "['The worldwide emergence of plasmid-mediated quinolone resistance\\tFluoroquinolone resistance is emerging in Gram-negative pathogens worldwide.', 'The traditional understanding that quinolone resistance is acquired only through mutation and transmitted only vertically does not entirely account for the relative ease with which resistance develops in exquisitely susceptible organisms, or for the very strong association between resistance to quinolones and to other agents.', 'The recent discovery of plasmid-mediated horizontally transferable genes encoding quinolone resistance might shed light on these phenomena.']\n",
            "unmatched tags:  [{'entity': 'quinolone resistance', 'type': 'Drug', 'start': 552, 'end': 572}]\n",
            "['Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective\\tIn the past decade, many tyrosine-kinase inhibitors have been introduced in oncology and haemato-oncology.', 'Because this new class of drugs is extensively used, serious drug–drug interactions are an increasing risk.', 'In this Review, we give a comprehensive overview of known or suspected drug–drug interactions between tyrosine-kinase inhibitors and other drugs.', 'We discuss all haemato-oncological and oncological tyrosine-kinase inhibitors that had been approved by Aug 1, 2013, by the US Food and Drug Administration or the European Medicines Agency.']\n",
            "unmatched tags:  [{'entity': 'European Medicines Agency', 'type': 'Chemical', 'start': 603, 'end': 628}, {'entity': 'Drug', 'type': 'Drug', 'start': 576, 'end': 580}, {'entity': 'tyrosine-kinase inhibitors', 'type': 'Drug', 'start': 491, 'end': 517}, {'entity': 'drug', 'type': 'Drug', 'start': 433, 'end': 437}, {'entity': 'tyrosine-kinase inhibitors', 'type': 'Drug', 'start': 396, 'end': 422}]\n",
            "['Spermatozoal RNA profiles of normal fertile men\\tThe microarray data from testes and spermatozoa (pooled and individual) were concordant, supporting the view that a spermatozoal mRNA fingerprint can be obtained from normal fertile men.', 'Thus, profiling can be used to monitor past events—ie, gene expression of spermatogenesis.', 'Moreover, the data suggest that, in addition to delivering the paternal genome, spermatozoa provide the zygote with a unique suite of paternal mRNAs.', 'Ejaculate spermatozoa can now be used as a non-invasive proxy for investigations of testis-specific infertility.']\n",
            "unmatched tags:  [{'entity': 'mRNAs', 'type': 'Gene', 'start': 469, 'end': 474}, {'entity': 'profiling', 'type': 'Gene', 'start': 241, 'end': 250}]\n",
            "['Effect of detailed fetal echocardiography as part of routine prenatal ultrasonographic screening on detection of congenital heart disease\\tInclusion of detailed fetal echocardiography as a screening examination has a substantial effect on detection of congenital heart disease since a major proportion of prenatally detectable cases occur in a low-risk population.']\n",
            "unmatched tags:  [{'entity': 'low-risk', 'type': 'Gene', 'start': 343, 'end': 351}]\n",
            "['Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study\\tIn patients with atrial fibrillation anticoagulated after recent ischaemic stroke or transient ischaemic attack, cerebral microbleed presence is independently associated with symptomatic intracranial haemorrhage risk and could be used to inform anticoagulation decisions.', 'Large-scale collaborative observational cohort analyses are needed to refine and validate intracranial haemorrhage risk scores incorporating cerebral microbleeds to identify patients at risk of net harm from oral anticoagulation.']\n",
            "unmatched tags:  [{'entity': 'intracranial haemorrhage', 'type': 'Disease', 'start': 580, 'end': 604}, {'entity': 'intracranial haemorrhage', 'type': 'Disease', 'start': 405, 'end': 429}]\n",
            "['Prevention of early episodes of otitis media by pneumococcal vaccines might reduce progression to complex disease\\tOtitis media is a common childhood infection of the middle ear and a major cause of morbidity.', 'This multifactorial disease manifests as a spectrum of clinical syndromes from uncomplicated acute otitis media to more complex recurrent and chronic cases (frequently polymicrobial), with the major pathogens involved being']\n",
            "unmatched tags:  [{'entity': 'polymicrobial', 'type': 'Disease', 'start': 377, 'end': 390}]\n",
            "['Diagnosis of adult tuberculous meningitis by use of clinical and laboratory features\\tThis study suggests that simple clinical and laboratory data can help in the diagnosis of adults with tuberculous meningitis.', 'Although the usefulness of the diagnostic rule will vary depending on the prevalence of tuberculosis and HIV-1 infection, we suggest it be applied to adults with meningitis and a low cerebrospinal fluid glucose, particularly in settings with limited microbiological resources.']\n",
            "unmatched tags:  [{'entity': 'meningitis', 'type': 'Phenotype', 'start': 373, 'end': 383}]\n",
            "[\"Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial\\tThis trial did not demonstrate an improvement in overall survival for etirinotecan pegol compared to treatment of physician's choice in patients with heavily pre-treated advanced breast cancer.\", 'The toxicity profile noted in the etirinotecan pegol group differed from that in the control group.', 'In view of the frequency of cross-resistance and overlapping toxicities noted with many available drugs and the need for effective drugs in highly refractory disease, etirinotecan pegol may warrant further research in some subgroups of patients.']\n",
            "unmatched tags:  [{'entity': 'subgroups', 'type': 'Virus', 'start': 755, 'end': 764}, {'entity': 'pegol', 'type': 'Chemical', 'start': 712, 'end': 717}, {'entity': 'etirinotecan', 'type': 'Drug', 'start': 699, 'end': 711}, {'entity': 'toxicities', 'type': 'Disease', 'start': 593, 'end': 603}, {'entity': 'pegol', 'type': 'Chemical', 'start': 479, 'end': 484}, {'entity': 'etirinotecan', 'type': 'Drug', 'start': 466, 'end': 478}]\n",
            "[\"Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study\\tAD is a common cause of SCI, naMCI, and aMCI and is associated with cognitive decline in patients with naMCI or aMCI.\", 'Patients with SCI might be in the early stages of AD, and cognitive decline might become apparent only after longer follow-up.']\n",
            "unmatched tags:  [{'entity': 'aMCI', 'type': 'Organization', 'start': 320, 'end': 324}]\n",
            "['Neutralising antibodies to SARS coronavirus 2 in Scottish blood donors - a pilot study of the value of serology to determine population exposure\\tBackground.', 'The extent of spread of SARS coronavirus 2 (SARS-CoV-2) in the UK and elsewhere is unknown because typically only symptomatic individuals are diagnosed.', 'We performed a serological study of recent blood donors in Scotland to detect antibodies to SARS-CoV-2 as a marker of past infection.', 'Methods.', 'A pseudotyped SARS-CoV-2 virus microneutralisation assay was used to detect neutralising antibodies to SARS-CoV-2.', 'The study group comprised samples from 1000 blood donors collected in Scotland during March, 2020.', 'Controls were collected from 100 donors in Scotland during 2019.', 'Findings.', 'All samples collected on the 17th March, 2020 (n=500) were negative in the pseudotyped SARS-CoV-2 virus microneutralisation assay.', 'Neutralising antibodies were detected in 5 of the 500 samples collected 21st to 23rd March; one further sample was reactive in an anti-spike ELISA.', 'Interpretation.', 'Although we cannot use the rise in numbers seropositive to infer the contemporary seroprevalence or the growth rate of the epidemic, we note that they are consistent with frequency of reported diagnosed infections and SARS-CoV-2-associated deaths reported in that time period in Scotland, given that seroconversion takes up to 2-3 weeks.', 'It should also be noted that blood donors are not representative of the general population; in particular, those with a history of recent respiratory infections are deferred.', 'Finally, it is unknown what proportion of infected individuals seroconvert and become reactive in the assays used.', 'Serial follow up studies are needed to track infection and seroconversion in this and other similar populations However, these data indicate that sero-surveys of blood banks can serve as a useful tool for tracking the emergence and progression of an epidemic like the current SARS-CoV-2 outbreak.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1947, 'end': 1957}, {'entity': 'respiratory infections', 'type': 'Disease', 'start': 1519, 'end': 1541}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 832, 'end': 842}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 558, 'end': 568}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 469, 'end': 479}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 402, 'end': 412}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 201, 'end': 211}]\n",
            "['Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China\\tSummary Background The pneumonia caused by the 2019 novel coronavirus (SARS-CoV-2) is a highly infectious disease, which was occurred in Wuhan, Hubei Province, China in December 2019.', 'As of February 13, 2020, a total of 59883 cases of COVID-19 in China have been confirmed and 1368 patients have died from the disease.', 'However, the clinical characteristics of the dyed patients were still not clearly clarified.', 'This study aims to summarize the clinical characteristics of death cases with COVID-19 and to identify critically ill patients of COVID-19 early and reduce their mortality.', 'Methods The clinical records, laboratory findings and radiologic assessments included chest X-ray or computed tomography were extracted from electronic medical records of 25 died patients with COVID-19 in Renmin Hospital of Wuhan University from Jan 14 to Feb 13, 2020.', 'Two experienced clinicians reviewed and abstracted the data.', 'Findings The mean age of the dead was 71.48  years, the average course of the disease was 10.56  days, all patients eventually died of respiratory failure.', 'All of those who died had underlying diseases, the most common of which was hypertension (16/25, 64%), followed by diabetes (10/25, 40%), heart diseases (8/25, 32%), kidney diseases (5/25, 20%), cerebral infarction (4/25, 16%), chronic obstructive pulmonary disease (COPD, 2/25, 8%), malignant tumors (2/25, 8%) and acute pancreatitis (1/25, 4%).', 'The most common organ damage outside the lungs was the heart, followed by kidney and liver.', \"In the patients' last examination before death, white blood cell and neutrophil counts were elevated in 17 patients (17/25, 68%) and 18 patients (18/25, 72%), lymphocyte counts were decreased in 22  patients (22/25, 88%).\", \"Most patients' PCT, CRP and SAA levels were elevated, the percentages were 90.5% (19/21), 85% (19/20) and 100% (21/21) respectively.\", 'The levels of the last test of neutrophils (15/16, 93.8%), PCT (11/11, 100%), CRP (11/13, 84.6%), cTnI (8/9, 88.9%), D-Dimer (11/12, 91.6%) and LDH (9/9, 100%) were increased as compared to the first test, while the levels of lymphocytes were decreased (14/16, 87.5%).', 'Interpretation The age and underlying diseases (hypertension, diabetes, etc.)', 'were the most important risk factors for death of COVID-19 pneumonia.', 'Bacterial infections may play an important role in promoting the death of patients.', 'Malnutrition was common to severe patients.', 'Multiple organ dysfunction can be observed, the most common organ damage  was lung, followed by heart, kidney and liver.', 'The rising of neutrophils, SAA, PCT, CRP, cTnI, D-Dimer and LDH levels can be used as indicators of disease progression, as well as the decline of lymphocytes counts.']\n",
            "unmatched tags:  [{'entity': 'indicators', 'type': 'Chemical', 'start': 2783, 'end': 2793}, {'entity': 'LDH', 'type': 'Gene', 'start': 2757, 'end': 2760}, {'entity': 'cTnI', 'type': 'Gene', 'start': 2739, 'end': 2743}, {'entity': 'PCT', 'type': 'Disease', 'start': 2729, 'end': 2732}, {'entity': 'SAA', 'type': 'Gene', 'start': 2724, 'end': 2727}, {'entity': 'Malnutrition', 'type': 'Disease', 'start': 2532, 'end': 2544}, {'entity': 'Bacterial infections', 'type': 'Disease', 'start': 2448, 'end': 2468}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 2437, 'end': 2446}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2428, 'end': 2436}, {'entity': 'diabetes', 'type': 'Disease', 'start': 2362, 'end': 2370}, {'entity': 'hypertension', 'type': 'Disease', 'start': 2348, 'end': 2360}, {'entity': 'diseases', 'type': 'Disease', 'start': 2338, 'end': 2346}, {'entity': 'LDH', 'type': 'Gene', 'start': 2173, 'end': 2176}, {'entity': 'cTnI', 'type': 'Gene', 'start': 2127, 'end': 2131}, {'entity': 'PCT', 'type': 'Disease', 'start': 2088, 'end': 2091}, {'entity': 'SAA', 'type': 'Gene', 'start': 1924, 'end': 1927}, {'entity': 'PCT', 'type': 'Disease', 'start': 1911, 'end': 1914}, {'entity': 'acute pancreatitis', 'type': 'Disease', 'start': 1551, 'end': 1569}, {'entity': 'malignant tumors', 'type': 'Disease', 'start': 1519, 'end': 1535}, {'entity': 'chronic obstructive pulmonary disease', 'type': 'Disease', 'start': 1463, 'end': 1500}]\n",
            "['Sporadic and familial hemiplegic migraine: pathophysiological mechanisms, clinical characteristics, diagnosis, and management\\tHemiplegic migraine is a rare form of migraine with aura that involves motor aura (weakness).', 'This type of migraine can occur as a sporadic or a familial disorder.', 'Familial forms of hemiplegic migraine are dominantly inherited.', 'Data from genetic studies have implicated mutations in genes that encode proteins involved in ion transportation.', 'However, at least a quarter of the large families affected and most sporadic cases do not have a mutation in the three genes known to be implicated in this disorder, suggesting that other genes are still to be identified.']\n",
            "unmatched tags:  [{'entity': 'ion transportation', 'type': 'Organization', 'start': 448, 'end': 466}, {'entity': 'proteins', 'type': 'Gene', 'start': 427, 'end': 435}, {'entity': 'hemiplegic migraine', 'type': 'Disease', 'start': 308, 'end': 327}]\n",
            "['Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study\\tWe noted no significant difference in clinical outcome between patients with HIV and uninfected controls with NSCLC.', 'Survival after curative surgical resection in early-stage patients was similar in HIV-infected individuals and uninfected controls.', 'These data suggest that HIV status should not affect therapeutic decision making in NSCLC.']\n",
            "unmatched tags:  [{'entity': 'NSCLC', 'type': 'Disease', 'start': 480, 'end': 485}, {'entity': 'era', 'type': 'Gene', 'start': 451, 'end': 454}, {'entity': 'HIV', 'type': 'Virus', 'start': 420, 'end': 423}, {'entity': 'HIV-infected', 'type': 'Disease', 'start': 346, 'end': 358}, {'entity': 'NSCLC', 'type': 'Disease', 'start': 257, 'end': 262}, {'entity': 'HIV', 'type': 'Virus', 'start': 224, 'end': 227}]\n",
            "['COVID-19: Modelling Local Transmission and Morbidity effects to provide an estimate of overall Relative Healthcare Resource Impact by General Practice Granularity\\tIntroduction Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the name given to the 2019 novel coronavirus.', 'COVID-19 is the name given to the disease associated with the virus.', 'SARS-CoV-2 is a new strain of coronavirus that has not been previously identified in humans.', 'Methods Two key factors were analysed which when multiplied together would give an estimate of relative demand on healthcare utilisation.', 'These factors were case incidence and case morbidity.', 'GP Practice data was used as this provided the most geographically granular source of published public population data.', 'To analyse case incidence, the latest values for indicators that could be associated with infection transmission rates were collected from the Office of National Statistics (ONS) and Quality Outcome Framework (QOF) sources.', 'These included population density, % age >16 at fulltime work/education, % age over 60, % BME ethnicity, social deprivation as IMD 2019, Location as latitude/longitude, and patient engagement as % self-confident in their own long term condition management.', 'Average case morbidity was calculated by applying the international mortality Odds Ratio to the local population relevant age and disease prevalences and then summing and dividing by the equivalent national figure.', 'To provide a comparative measure of overall healthcare resource impact, individual GP practice impact scores were compared against the median practice.', 'Results The case incidence regression is a dynamic situation with the significance of specific factors moderating over time as the balance between external infection, community transmission and impact of mitigation measures feeds through to the number of cases.', 'It showed that currently Urban, % Working and age >60 were the strongest determinants of case incidence.', 'The local population comorbidity remains unchanged.', 'The range of relative HC impact was wide with 80% of practices falling between 20%-250% of the national median.', 'Once practice population numbers were included it showed that the top 33% of GP practices supporting 45% of the patient population would require 68% of COVID-19 healthcare resources.', 'The model provides useful information about the relative impact of Covid-19 on healthcare workload at GP practice granularity in all parts of England.', 'Conclusion Covid-19 is impacting on the utilisation of health and social care resources across the country.', 'This model provides a method for predicting relative local levels of disease burden based on defined criteria and thereby providing a method for targeting limited (and perhaps soon to be scarce) care resources to optimise national, regional and local responses to the COVID-19 outbreak.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2859, 'end': 2867}, {'entity': 'national', 'type': 'Organization', 'start': 2813, 'end': 2821}, {'entity': 'Covid-19', 'type': 'Disease', 'start': 2493, 'end': 2501}, {'entity': 'GP', 'type': 'Gene', 'start': 2433, 'end': 2435}, {'entity': 'Covid-19', 'type': 'Disease', 'start': 2398, 'end': 2406}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2300, 'end': 2308}, {'entity': 'GP', 'type': 'Gene', 'start': 2225, 'end': 2227}, {'entity': 'national median', 'type': 'Organization', 'start': 2127, 'end': 2142}]\n",
            "['Structure of dimeric full-length human ACE2 in complex with B\\tAngiotensin-converting enzyme 2 (ACE2) is the surface receptor for SARS coronavirus (SARS-CoV), directly interacting with the spike glycoprotein (S protein).', 'ACE2 is also suggested to be the receptor for the new coronavirus (2019-nCoV), which is causing a serious epidemic in China manifested with severe respiratory syndrome.', 'B 0 AT1 (SLC6A19) is a neutral amino acid transporter whose surface expression in intestinal cells requires ACE2.', 'Here we present the 2.9 Å resolution cryo-EM structure of full-length human ACE2 in complex with B 0 AT1.', 'The complex, assembled as a dimer of ACE2-B 0 AT1 heterodimers, exhibits open and closed conformations due to the shifts of the peptidase domains (PDs) of ACE2.', 'A newly resolved Collectrin-like domain (CLD) on ACE2 mediates homo-dimerization.', 'Structural modelling suggests that the ACE2-B 0 AT1 complex can bind two S proteins simultaneously, providing important clues to the molecular basis for coronavirus recognition and infection.']\n",
            "unmatched tags:  [{'entity': 'coronavirus', 'type': 'Virus', 'start': 1005, 'end': 1016}, {'entity': 'S proteins', 'type': 'Gene', 'start': 925, 'end': 935}, {'entity': 'B 0 AT1', 'type': 'Gene', 'start': 896, 'end': 903}, {'entity': 'ACE2', 'type': 'Gene', 'start': 819, 'end': 823}, {'entity': 'CLD', 'type': 'Disease', 'start': 811, 'end': 814}, {'entity': 'Collectrin-like domain', 'type': 'Gene', 'start': 787, 'end': 809}, {'entity': 'ACE2', 'type': 'Gene', 'start': 764, 'end': 768}, {'entity': 'PDs', 'type': 'Gene', 'start': 756, 'end': 759}, {'entity': 'B 0 AT1', 'type': 'Gene', 'start': 651, 'end': 658}, {'entity': 'B 0 AT1', 'type': 'Gene', 'start': 600, 'end': 607}, {'entity': 'ACE2', 'type': 'Gene', 'start': 579, 'end': 583}, {'entity': 'ACE2', 'type': 'Gene', 'start': 497, 'end': 501}, {'entity': 'neutral amino acid transporter', 'type': 'Gene', 'start': 412, 'end': 442}, {'entity': 'SLC6A19', 'type': 'Gene', 'start': 398, 'end': 405}, {'entity': 'B 0 AT1', 'type': 'Gene', 'start': 389, 'end': 396}, {'entity': 'respiratory syndrome', 'type': 'Disease', 'start': 367, 'end': 387}, {'entity': '2019-nCoV', 'type': 'Virus', 'start': 287, 'end': 296}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 274, 'end': 285}, {'entity': 'receptor', 'type': 'Gene', 'start': 253, 'end': 261}, {'entity': 'ACE2', 'type': 'Gene', 'start': 220, 'end': 224}, {'entity': 'S protein', 'type': 'Gene', 'start': 208, 'end': 217}, {'entity': 'spike glycoprotein', 'type': 'Gene', 'start': 188, 'end': 206}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 147, 'end': 155}]\n",
            "['Forecasting COVID-19 impact on hospital bed-days, ICU-days, ventilator-days and deaths by US state in the next 4 months\\tKey Points  Question: Assuming social distancing measures are maintained, what are the forecasted gaps in available health service resources and number of deaths from the COVID-19 pandemic for each state in the United States?', 'Findings: Using a statistical model, we predict excess demand will be 64,175 (95% UI 7,977 to 251,059) total beds and 17,380 (95% UI 2,432 to 57,955) ICU beds at the peak of COVID-19.', 'Peak ventilator use is predicted to be 19,481 (95% UI 9,767 to 39,674) ventilators.', 'Peak demand will be in the second week of April.', 'We estimate 81,114 (95% UI 38,242 to 162,106) deaths in the United States from COVID-19 over the next 4 months.', 'Meaning: Even with social distancing measures enacted and sustained, the peak demand for hospital services due to the COVID-19 pandemic is likely going to exceed capacity substantially.', 'Alongside the implementation and enforcement of social distancing measures, there is an urgent need to develop and implement plans to reduce non-COVID-19 demand for and temporarily increase capacity of health facilities.', 'Abstract  Importance: This study presents the first set of estimates of predicted health service utilization and deaths due to COVID-19 by day for the next 4 months for each state in the US.', 'Objective: To determine the extent and timing of deaths and excess demand for hospital services due to COVID-19 in the US.', 'Design, Setting, and Participants: This study used data on confirmed COVID-19  deaths by day from WHO websites and local and national governments; data on hospital capacity and utilization for US states; and observed COVID-19 utilization data from select locations to develop a statistical model forecasting deaths and hospital utilization against capacity by state for the US over the next 4 months.', 'Exposure(s): COVID-19.', 'Main outcome(s) and measure(s): Deaths, bed and ICU occupancy, and ventilator use.', 'Results: Compared to licensed capacity and average annual occupancy rates, excess demand from COVID-19 at the peak of the pandemic in the second week of April is predicted to be 64,175 (95% UI 7,977 to 251,059) total beds and 17,380 (95% UI 2,432 to 57,955) ICU beds.', 'At the peak of the pandemic, ventilator use is predicted to be 19,481 (95% UI 9,767 to 39,674).', 'The date of peak excess demand by state varies from the second week of April through May.', 'We estimate that there will a total of 81,114 (95% UI 38,242 to 162,106) deaths from COVID-19 over the next 4 months in the US.', 'Deaths from COVID-19 are estimated to drop below 10 deaths per day between May 31 and June 6.', 'Conclusions and Relevance: In addition to a large number of deaths from COVID-19, the epidemic in the US will place a load well beyond the current capacity of hospitals to manage, especially for ICU care.', 'These estimates can help inform the development and implementation of strategies to mitigate this gap, including reducing non-COVID-19 demand for services and temporarily increasing system capacity.', 'These are urgently needed given that peak volumes are estimated to be only three weeks away.', 'The estimated excess demand on hospital systems is predicated on the enactment of social distancing measures in all states that have not done so already within the next week and maintenance of these measures throughout the epidemic, emphasizing the importance of implementing, enforcing, and maintaining these measures to mitigate hospital system overload and prevent deaths.']\n",
            "unmatched tags:  [{'entity': 'overload', 'type': 'Disease', 'start': 3543, 'end': 3551}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 3030, 'end': 3038}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2771, 'end': 2779}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2613, 'end': 2621}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2558, 'end': 2566}, {'entity': 'bed', 'type': 'Disease', 'start': 2281, 'end': 2284}, {'entity': 'bed', 'type': 'Disease', 'start': 2236, 'end': 2239}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2113, 'end': 2121}, {'entity': 'bed', 'type': 'Disease', 'start': 1975, 'end': 1978}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1924, 'end': 1932}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1726, 'end': 1734}, {'entity': 'national governments', 'type': 'Organization', 'start': 1634, 'end': 1654}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1578, 'end': 1586}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1487, 'end': 1495}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1318, 'end': 1326}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1111, 'end': 1119}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 898, 'end': 906}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 745, 'end': 753}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 523, 'end': 531}]\n",
            "['Emerging viral respiratory tract infections—environmental risk factors and transmission\\tThe past decade has seen the emergence of several novel viruses that cause respiratory tract infections in human beings, including Middle East respiratory syndrome coronavirus (MERS-CoV) in Saudi Arabia, an H7N9 influenza A virus in eastern China, a swine-like influenza H3N2 variant virus in the USA, and a human adenovirus 14p1 also in the USA.', 'MERS-CoV and H7N9 viruses are still a major worldwide public health concern.', 'The pathogenesis and mode of transmission of MERS-CoV and H7N9 influenza A virus are poorly understood, making it more difficult to implement intervention and preventive measures.']\n",
            "unmatched tags:  [{'entity': 'H7N9 influenza A virus', 'type': 'Virus', 'start': 570, 'end': 592}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 557, 'end': 565}, {'entity': 'H7N9 viruses', 'type': 'Virus', 'start': 448, 'end': 460}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 435, 'end': 443}, {'entity': 'H7N9 influenza A virus', 'type': 'Virus', 'start': 295, 'end': 317}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 265, 'end': 273}, {'entity': 'Middle East respiratory syndrome coronavirus', 'type': 'Virus', 'start': 219, 'end': 263}]\n",
            "['Realtime 2-5A kinetics suggests interferons β and λ evade global arrest of translation by RNase L\\tCells of all mammals recognize double-stranded RNA (dsRNA) as a foreign material.', 'In response, they release interferons (IFNs) and activate a ubiquitously expressed pseudokinase/endoribonuclease RNase L. RNase L executes regulated RNA decay and halts global translation.', 'Here we developed a biosensor for 2’,5’-oligoadenylate (2-5A), the natural activator of RNase L. We found that 2-5A was acutely synthesized by cells in response to dsRNA sensing, which immediately triggered cellular RNA cleavage by RNase L and arrested host protein synthesis.', 'However, translation-arrested cells still transcribed IFN-stimulated genes (ISGs) and secreted IFNs of types I and III (IFN-β and IFN-λ).', 'Our data suggests that IFNs escape from the action of RNase L on translation.', 'We propose that 2-5A/RNase L pathway serves to rapidly and accurately suppress basal protein synthesis, preserving privileged production of defense proteins of the innate immune system.', 'Significance RNase L is a mammalian enzyme that can stop global protein synthesis during interferon response.', 'Cells must balance the need to make interferons (which are proteins) with the risk to lose cell-wide translation due to RNase L. This balance can most simply be achieved if RNase L was activated late in the interferon response.', 'However, we show by engineering a biosensor for the RNase L pathway, that on the contrary, RNase L activation precedes interferon synthesis.', 'Further, translation of interferons evades the action of RNase L. Our data suggest that RNase L facilitates a switch of protein synthesis from homeostasis to specific needs of innate immune signaling.']\n",
            "unmatched tags:  [{'entity': 'innate immune signaling', 'type': 'Chemical', 'start': 1703, 'end': 1726}, {'entity': 'RNase L', 'type': 'Gene', 'start': 1615, 'end': 1622}, {'entity': 'RNase L', 'type': 'Gene', 'start': 1584, 'end': 1591}, {'entity': 'interferons', 'type': 'Gene', 'start': 1551, 'end': 1562}, {'entity': 'RNase L', 'type': 'Gene', 'start': 1477, 'end': 1484}, {'entity': 'RNase L', 'type': 'Gene', 'start': 1438, 'end': 1445}, {'entity': 'RNase L', 'type': 'Gene', 'start': 1331, 'end': 1338}, {'entity': 'RNase L', 'type': 'Gene', 'start': 1278, 'end': 1285}, {'entity': 'proteins', 'type': 'Gene', 'start': 1217, 'end': 1225}, {'entity': 'interferons', 'type': 'Gene', 'start': 1194, 'end': 1205}, {'entity': 'enzyme', 'type': 'Gene', 'start': 1084, 'end': 1090}, {'entity': 'RNase L', 'type': 'Gene', 'start': 1061, 'end': 1068}, {'entity': 'proteins', 'type': 'Gene', 'start': 1010, 'end': 1018}, {'entity': 'RNase L', 'type': 'Gene', 'start': 883, 'end': 890}, {'entity': 'RNase L', 'type': 'Gene', 'start': 838, 'end': 845}, {'entity': 'IFNs', 'type': 'Gene', 'start': 807, 'end': 811}, {'entity': 'IFN-λ', 'type': 'Gene', 'start': 776, 'end': 781}, {'entity': 'IFN-β', 'type': 'Gene', 'start': 766, 'end': 771}, {'entity': 'IFNs', 'type': 'Gene', 'start': 741, 'end': 745}, {'entity': 'ISGs', 'type': 'Chemical', 'start': 722, 'end': 726}, {'entity': 'IFN-stimulated genes', 'type': 'Gene', 'start': 700, 'end': 720}, {'entity': 'RNase L', 'type': 'Gene', 'start': 601, 'end': 608}, {'entity': 'RNA', 'type': 'Gene', 'start': 585, 'end': 588}, {'entity': 'dsRNA', 'type': 'Gene', 'start': 533, 'end': 538}, {'entity': 'RNase L', 'type': 'Gene', 'start': 457, 'end': 464}, {'entity': 'RNA', 'type': 'Gene', 'start': 329, 'end': 332}, {'entity': 'RNase L', 'type': 'Gene', 'start': 302, 'end': 309}, {'entity': 'RNase L', 'type': 'Gene', 'start': 293, 'end': 300}]\n",
            "['Altered polarization of PAR-2 signaling during airway epithelial remodeling\\tBackground Protease-activated receptor 2 (PAR-2) is activated by proteases involved in allergy and triggers airway epithelial secretion and inflammation.', 'PAR-2 is normally expressed basolaterally in differentiated nasal ciliated cells.', 'Objective We tested if epithelial remodeling during diseases characterized by loss of cilia and squamous metaplasia may alter PAR-2 polarization.', 'Methods Endogenous PAR-2 responses were measured by live cell calcium and cilia imaging, measurement of fluid secretion, and quantification of cytokines.', 'We utilized airway squamous cell lines, primary differentiated air-liquid interface cultures, and tissue explants.', 'Cells were exposed to disease-related modifiers that alter epithelial morphology, including IL-13, cigarette smoke condensate, and retinoic acid deficiency.', 'We used concentrations and exposure times that altered epithelial morphology without causing breakdown of the epithelial barrier, likely reflecting early disease states.', 'Results PAR-2 signaling in airway squamous cells activated calcium and inflammatory responses.', 'Squamous cells cultured at air liquid interface (ALI) responded to PAR-2 agonists applied both apically and basolaterally.', 'Primary well-differentiated nasal epithelial ALI cultures responded only to basolateral PAR-2 stimulation.', 'Primary cultures exposed to IL-13, cigarette smoke condensate, or reduced retinoic acid responded to both apical and basolateral PAR-2 stimulation.', 'Nasal polyp tissue, but not control middle turbinate, exhibited apical calcium responses to PAR-2 stimulation.', 'However, isolated ciliated cells from both polyp and turbinate maintained basolateral PAR-2 polarization.', 'Conclusions Squamous metaplasia and/or loss of cilia enhances apical PAR-2 responses.', 'Altered PAR-2 polarization in dedifferentiated or remodeled epithelia may contribute to increased sensitivity to inhaled protease allergens in inflammatory airway diseases.']\n",
            "unmatched tags:  [{'entity': 'inflammatory airway diseases', 'type': 'Disease', 'start': 1973, 'end': 2001}, {'entity': 'inhaled protease allergens', 'type': 'Gene', 'start': 1943, 'end': 1969}, {'entity': 'dedifferentiated', 'type': 'Disease', 'start': 1860, 'end': 1876}, {'entity': 'PAR-2', 'type': 'Gene', 'start': 1838, 'end': 1843}, {'entity': 'PAR-2', 'type': 'Gene', 'start': 1813, 'end': 1818}, {'entity': 'basolateral PAR-2', 'type': 'Gene', 'start': 1712, 'end': 1729}, {'entity': 'PAR-2', 'type': 'Gene', 'start': 1619, 'end': 1624}, {'entity': 'calcium', 'type': 'Drug', 'start': 1598, 'end': 1605}, {'entity': 'Nasal polyp tissue', 'type': 'Disease', 'start': 1527, 'end': 1545}, {'entity': 'basolateral PAR-2', 'type': 'Gene', 'start': 1496, 'end': 1513}, {'entity': 'retinoic acid', 'type': 'Drug', 'start': 1453, 'end': 1466}]\n",
            "['Rickets\\tRickets, once thought vanquished, is reappearing.', 'In some less developed countries it hardly went away.', 'This seminar reviews the effects of genes, stage of development, and environment on clinical expression of the disease.', 'Rickets can be secondary to disorders of the gut, pancreas, liver, kidney, or metabolism; however, it is mostly due to nutrient deficiency and we concentrate on this form.', \"Although calcium deficiency contributes in communities where little cows' milk is consumed, deficiency of vitamin D is the main cause.\"]\n",
            "unmatched tags:  [{'entity': 'vitamin D', 'type': 'Drug', 'start': 510, 'end': 519}]\n",
            "['Limited SARS-CoV-2 diversity within hosts and following passage in cell culture\\tSince the first reports of pneumonia associated with a novel coronavirus (COVID-19) emerged in Wuhan, Hubei province, China, there have been considerable efforts to sequence the causative virus, SARS-CoV-2 (also referred to as hCoV-19) and to make viral genomic information available quickly on shared repositories.', 'As of 30 March 2020, 7,680 consensus sequences have been shared on GISAID, the principal repository for SARS-CoV-2 genetic information.', 'These sequences are primarily consensus sequences from clinical and passaged samples, but few reports have looked at diversity of virus populations within individual hosts or cultures.', 'Understanding such diversity is essential to understanding viral evolutionary dynamics.', 'Here, we characterize within-host viral diversity from a primary isolate and passaged samples, all originally deriving from an individual returning from Wuhan, China, who was diagnosed with COVID-19 and subsequently sampled in Wisconsin, United States.', 'We use a metagenomic approach with Oxford Nanopore Technologies (ONT) GridION in combination with Illumina MiSeq to capture minor within-host frequency variants ≥1%.', 'In a clinical swab obtained from the day of hospital presentation, we identify 15 single nucleotide variants (SNVs) ≥1% frequency, primarily located in the largest gene – ORF1a.', 'While viral diversity is low overall, the dominant genetic signatures are likely secondary to population size changes, with some evidence for mild purifying selection throughout the genome.', 'We see little to no evidence for positive selection or ongoing adaptation of SARS-CoV-2 within cell culture or in the primary isolate evaluated in this study.', 'Author Summary Within-host variants are critical for addressing molecular evolution questions, identifying selective pressures imposed by vaccine-induced immunity and antiviral therapeutics, and characterizing interhost dynamics, including the stringency and character of transmission bottlenecks.', 'Here, we sequenced SARS-CoV-2 viruses isolated from a human host and from cell culture on three distinct Vero cell lines using Illumina and ONT technologies.', 'We show that SARS-CoV-2 consensus sequences can remain stable through at least two serial passages on Vero 76 cells, suggesting SARS-CoV-2 can be propagated in cell culture in preparation for in-vitro and in-vivo studies without dramatic alterations of its genotype.', 'However, we emphasize the need to deep-sequence viral stocks prior to use in experiments to characterize sub-consensus diversity that may alter outcomes.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 2335, 'end': 2345}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 2220, 'end': 2230}, {'entity': 'ONT', 'type': 'Organization', 'start': 2189, 'end': 2192}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 2068, 'end': 2078}, {'entity': 'bottlenecks', 'type': 'Organization', 'start': 2036, 'end': 2047}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1669, 'end': 1679}, {'entity': 'gene', 'type': 'Gene', 'start': 1453, 'end': 1457}, {'entity': 'ORF1a', 'type': 'Gene', 'start': 1395, 'end': 1400}, {'entity': 'gene', 'type': 'Gene', 'start': 1388, 'end': 1392}, {'entity': 'ONT', 'type': 'Organization', 'start': 1123, 'end': 1126}, {'entity': 'Oxford Nanopore Technologies', 'type': 'Organization', 'start': 1093, 'end': 1121}]\n",
            "['Malaria vaccine developments\\tLarge gains in the reduction of malaria mortality in the early 20th century were lost in subsequent decades.', 'Malaria now kills 2–3 million people yearly.', 'Implementation of malaria control technologies such as insecticide-treated bednets and chemotherapy could reduce mortality substantially, but an effective malaria vaccine is also needed.', 'Advances in vaccine technology and immunology are being used to develop malaria subunit vaccines.', 'Novel approaches that might yield effective vaccines for other diseases are being evaluated first in malaria.']\n",
            "unmatched tags:  [{'entity': 'malaria', 'type': 'Disease', 'start': 569, 'end': 576}, {'entity': 'diseases', 'type': 'Disease', 'start': 531, 'end': 539}]\n",
            "['Effectiveness and Safety of Glucocorticoids to Treat COVID-19: A Rapid Review and Meta-Analysis\\tBackground: Glucocorticoids are widely used in the treatment of various pulmonary inflammatory diseases, but they are also often accompanied by significant adverse reactions.', 'Published guidelines point out that low dose and short duration systemic glucocorticoid therapy may be considered for patients with rapidly progressing COVID-19 while the evidence is still limited.', 'Methods: We comprehensively searched electronic databases and supplemented the screening by conducting a manual search.', 'We included RCTs and cohort studies evaluating the effectiveness and safety of glucocorticoids in children and adults with COVID-19, SARS and MERS, and conducted meta-analyses of the main indicators that were identified in the studies.', 'Results: Our search retrieved 23 studies, including one RCT and 22 cohort studies, with a total of 13,815 patients.', 'In adults with COVID-19, the use of systemic glucocorticoid did not reduce mortality (RR=2.00, 95% CI: 0.69 to 5.75, I =90.9%) or the duration of lung inflammation (WMD=-1 days, 95% CI: -2.91 to 0.91), while a significant reduction was found in the duration of fever (WMD=-3.23 days, 95% CI: -3.56 to -2.90).', 'In patients with SARS, glucocorticoids also did not reduce the mortality (RR=1.52, 95% CI: 0.89 to 2.60, I =84.6%), duration of fever (WMD=0.82 days, 95% CI: -2.88 to 4.52, I =97.9%) or duration of lung inflammation absorption (WMD=0.95 days, 95% CI: -7.57 to 9.48, I =94.6%).', 'The use of systemic glucocorticoid therapy prolonged the duration of hospital stay in all patients (COVID-19, SARS and MERS).', 'Conclusions: Glucocorticoid therapy was found to reduce the duration of fever, but not mortality, duration of hospitalization or lung inflammation absorption.', 'Long-term use of high-dose glucocorticoids increased the risk of adverse reactions such as coinfections, so routine use of systemic glucocorticoids for patients with COVID-19 cannot be recommend.', 'Keywords: COVID-19; glucocorticoids; meta-analysis; rapid review']\n",
            "unmatched tags:  [{'entity': 'glucocorticoids', 'type': 'Drug', 'start': 2028, 'end': 2043}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2018, 'end': 2026}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1978, 'end': 1986}, {'entity': 'glucocorticoids', 'type': 'Drug', 'start': 1944, 'end': 1959}]\n",
            "['Oral sucrose as an analgesic drug for procedural pain in newborn infants: a randomised controlled trial\\tOur data suggest that oral sucrose does not significantly affect activity in neonatal brain or spinal cord nociceptive circuits, and therefore might not be an effective analgesic drug.', 'The ability of sucrose to reduce clinical observational scores after noxious events in newborn infants should not be interpreted as pain relief.']\n",
            "unmatched tags:  [{'entity': 'sucrose', 'type': 'Drug', 'start': 304, 'end': 311}]\n",
            "[\"Heparan sulphate proteoglycans in Alzheimer's disease and amyloid‐related disorders\\tProteoglycans are associated with all kinds of amyloid deposits in the human body.\", \"These complex macromolecules, in particular heparan sulphate proteoglycans, have also been implicated in several features of the pathogenesis of Alzheimer's disease (AD), including the genesis of senile plaques, cerebrovascular amyloid, and neurofibrillary tangles.\", 'In this review we focus on the role of proteoglycans and glycosaminoglycans in amyloidogenesis in general and in AD in particular.', 'Heparan sulphate proteoglycans may promote amyloid-β peptide (Aβ) or tau fibrillisation on the one hand, and provide resistance against proteolytic breakdown on the other.']\n",
            "unmatched tags:  [{'entity': 'fibrillisation', 'type': 'Gene', 'start': 637, 'end': 651}, {'entity': 'tau', 'type': 'Gene', 'start': 633, 'end': 636}, {'entity': 'amyloid-β peptide', 'type': 'Gene', 'start': 607, 'end': 624}, {'entity': 'proteoglycans', 'type': 'Gene', 'start': 581, 'end': 594}, {'entity': 'genesis', 'type': 'Gene', 'start': 520, 'end': 527}, {'entity': 'glycosaminoglycans', 'type': 'Drug', 'start': 490, 'end': 508}, {'entity': 'proteoglycans', 'type': 'Gene', 'start': 472, 'end': 485}, {'entity': 'genesis', 'type': 'Gene', 'start': 352, 'end': 359}]\n",
            "['Early surveillance and public health emergency disposal measures between novel coronavirus disease 2019 and avian influenza in China: a case-comparison study\\tBackground: The novel coronavirus disease 2019 (COVID-19) outbreak is spreading rapidly throughout China and the world.', 'Hence, early surveillance and public health emergency disposal are considered crucial to curb this emerging infectious disease.', 'However, studies that investigated the early surveillance and public health emergency disposal for the prevention and control of the COVID-19 outbreak in China are relatively few.', 'We aimed to compare the strengths and weaknesses of early surveillance and public health emergency disposal for prevention and control between COVID-19 and H7N9 avian influenza, which was commended by the international community, in China.', 'Methods: A case-comparison study was conducted using a set of six key time nodes to form a reference framework for evaluating early surveillance and public health emergency disposal between H7N9 avian influenza (2013) in Shanghai, China and COVID-19 in Wuhan, China.', 'Findings: A report to the local Center for Disease Control and Prevention, China, for the first hospitalized patient was sent after 6 and 20 days for H7N9 avian influenza and COVID-19, respectively.', 'In contrast, the pathogen was identified faster in the case of COVID-19 than in the case of H7N9 avian influenza (12 days vs. 31 days).', 'The government response regarding COVID-19 was 10 days later than that regarding avian influenza.', 'The entire process of early surveillance and public health emergency disposal lasted 5 days longer in COVID-19 than in H7N9 avian influenza (46 days vs. 41 days).', 'Conclusions: The identification of the unknown pathogen improved in China between the outbreaks of avian influenza and COVID-19.', \"The longer emergency disposal period in the case of COVID-19 could be attributed to the government's slower response to the epidemic.\", 'Improving public health emergency management could lessen the adverse social effects of emerging infectious diseases and public health crisis in the future.']\n",
            "unmatched tags:  [{'entity': 'infectious diseases', 'type': 'Disease', 'start': 2049, 'end': 2068}, {'entity': \"government's\", 'type': 'Organization', 'start': 1906, 'end': 1918}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1870, 'end': 1878}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1808, 'end': 1816}, {'entity': 'influenza', 'type': 'Disease', 'start': 1794, 'end': 1803}, {'entity': 'avian influenza', 'type': 'Disease', 'start': 1788, 'end': 1803}, {'entity': 'H7N9 avian influenza', 'type': 'Virus', 'start': 1645, 'end': 1665}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1628, 'end': 1636}, {'entity': 'influenza', 'type': 'Disease', 'start': 1515, 'end': 1524}, {'entity': 'avian influenza', 'type': 'Disease', 'start': 1509, 'end': 1524}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1462, 'end': 1470}, {'entity': 'government response', 'type': 'Organization', 'start': 1432, 'end': 1451}, {'entity': 'avian influenza', 'type': 'Disease', 'start': 1389, 'end': 1404}]\n",
            "[\"Lewy body dementias\\tThe broad importance of dementia is undisputed, with Alzheimer's disease justifiably getting the most attention.\", \"However, dementia with Lewy bodies and Parkinson's disease dementia, now called Lewy body dementias, are the second most common type of degenerative dementia in patients older than 65 years.\", 'Despite this, Lewy body dementias receive little attention and patients are often misdiagnosed, leading to less than ideal management.', 'Over the past 10 years, considerable effort has gone into improving diagnostic accuracy by refining diagnostic criteria and using imaging and other biomarkers.']\n",
            "unmatched tags:  [{'entity': 'Lewy body dementias', 'type': 'Disease', 'start': 338, 'end': 357}]\n",
            "['Ovarian transposition in prepubescent and adolescent girls with cancer\\tOvarian transposition was the first procedure proposed to preserve fertility in girls with cancer and is indicated for patients with tumours requiring pelvic radiation at doses of 42·0–58·4 Gy, much higher doses than those that can induce loss of ovarian function (4–20 Gy).', 'Ovarian transposition is usually done after neoadjuvant chemotherapy and is completed by minimally invasive surgery or open surgery in case of concomitant resection of the abdominal tumour.', \"According to the type of tumour, the ovaries are moved and placed in the paracolic gutters when the radiation field reaches the midline (for medulloblastoma or urogenital rhabdomyosarcoma), contralaterally to the tumour (for pelvic sarcomas), or in line with the iliac crests (for Hodgkin's lymphoma).\"]\n",
            "unmatched tags:  [{'entity': \"Hodgkin's lymphoma\", 'type': 'Disease', 'start': 817, 'end': 835}, {'entity': 'pelvic sarcomas', 'type': 'Disease', 'start': 761, 'end': 776}, {'entity': 'tumour', 'type': 'Disease', 'start': 749, 'end': 755}, {'entity': 'urogenital rhabdomyosarcoma', 'type': 'Disease', 'start': 696, 'end': 723}]\n",
            "['Exploring Conformational Transition of 2019 Novel Coronavirus Spike Glycoprotein Between Its Closed and Open States Using Molecular Dynamics Simulations\\tSince its first recorded appearance in December 2019, a novel coronavirus (SARS-CoV-2) causing the disease COVID-19 has resulted in more than 2,000,000 infections and 128,000 deaths.', 'Currently there is no proven treatment for COVID-19 and there is an urgent need for the development of vaccines and therapeutics.', 'Coronavirus spike glycoproteins play a critical role in coronavirus entry into the host cells, as they provide host cell recognition and membrane fusion between virus and host cell.', 'Thus, they emerged as popular and promising drug targets.', 'Crystal structures of spike protein in its closed and open states were resolved very recently in March 2020.', 'These structures comprise 77% of the sequence and provide almost the complete protein structure.', 'Based on down and up positions of receptor binding domain (RBD), spike protein can be in a receptor inaccessible closed or receptor accessible open state, respectively.', 'Starting from closed and open state crystal structures, and also 16 intermediate conformations, an extensive set of all-atom molecular dynamics (MD) simulations in the presence of explicit water and ions were performed.', 'Simulations show that in its down position, RBD has significantly lower mobility compared to its up position; probably caused by the 6 interdomain salt bridges of RBD in down position compared to 3 in up position.', 'Free energy landscapes based on MD simulations revealed a semi-open state located between closed and open states.', 'Minimum energy pathway between down and up positions comprised a gradual salt bridge switching mechanism.', 'Furthermore, although significantly lower than open state, ACE2 binding surface of RBD contained a partial solvent accessibility in its closed state.']\n",
            "unmatched tags:  [{'entity': 'solvent', 'type': 'Chemical', 'start': 1842, 'end': 1849}, {'entity': 'RBD', 'type': 'Gene', 'start': 1818, 'end': 1821}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1794, 'end': 1798}, {'entity': 'ions', 'type': 'Chemical', 'start': 1677, 'end': 1681}, {'entity': 'ions', 'type': 'Chemical', 'start': 1557, 'end': 1561}, {'entity': 'RBD', 'type': 'Gene', 'start': 1464, 'end': 1467}, {'entity': 'RBD', 'type': 'Gene', 'start': 1345, 'end': 1348}, {'entity': 'ions', 'type': 'Chemical', 'start': 1308, 'end': 1312}, {'entity': 'ions', 'type': 'Chemical', 'start': 1280, 'end': 1284}, {'entity': 'water', 'type': 'Drug', 'start': 1270, 'end': 1275}, {'entity': 'ions', 'type': 'Chemical', 'start': 1237, 'end': 1241}, {'entity': 'ions', 'type': 'Chemical', 'start': 1171, 'end': 1175}, {'entity': 'receptor', 'type': 'Gene', 'start': 1035, 'end': 1043}, {'entity': 'receptor', 'type': 'Gene', 'start': 1003, 'end': 1011}, {'entity': 'spike protein', 'type': 'Gene', 'start': 977, 'end': 990}, {'entity': 'RBD', 'type': 'Gene', 'start': 971, 'end': 974}, {'entity': 'receptor', 'type': 'Gene', 'start': 946, 'end': 954}, {'entity': 'ions', 'type': 'Chemical', 'start': 938, 'end': 942}, {'entity': 'protein structure', 'type': 'Gene', 'start': 893, 'end': 910}, {'entity': 'spike protein', 'type': 'Gene', 'start': 728, 'end': 741}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 522, 'end': 533}, {'entity': 'Coronavirus spike glycoproteins', 'type': 'Gene', 'start': 466, 'end': 497}, {'entity': 'vaccines', 'type': 'Drug', 'start': 439, 'end': 447}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 379, 'end': 387}, {'entity': 'ions', 'type': 'Chemical', 'start': 311, 'end': 315}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 260, 'end': 268}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 228, 'end': 238}]\n",
            "['Identification of a pangolin niche for a 2019-nCoV-like coronavirus through an extensive meta-metagenomic search\\tIn numerous instances, tracking the biological significance of a nucleic acid sequence can be augmented through the identification of environmental niches in which the sequence of interest is present.', 'Many metagenomic datasets are now available, with deep sequencing of samples from diverse biological niches.', 'While any individual metagenomic dataset can be readily queried using web-based tools, meta-searches through all such datasets are less accessible.', 'In this brief communication, we demonstrate such a meta-meta-genomic approach, examining close matches to the Wuhan coronavirus 2019-nCoV in all high-throughput sequencing datasets in the NCBI Sequence Read Archive accessible with the keyword \"virome\".', 'In addition to the homology to bat coronaviruses observed in descriptions of the 2019-nCoV sequence (F. Wu et al.', '2020, Nature, doi.org/10.1038/s41586-020-2008-3; P. Zhou et al.', '2020, Nature, doi.org/10.1038/s41586-020-2012-7), we note a strong homology to numerous sequence reads in a metavirome dataset generated from the lungs of deceased Pangolins reported by Liu et al.', '(Viruses 11:11, 2019, http://doi.org/10.3390/v11110979).', 'Our observations are relevant to discussions of the derivation of 2019-nCoV and illustrate the utility and limitations of meta-metagenomic search tools in effective and rapid characterization of potentially significant nucleic acid sequences.']\n",
            "unmatched tags:  [{'entity': '2019-nCoV', 'type': 'Virus', 'start': 1327, 'end': 1336}, {'entity': 'Viruses', 'type': 'Virus', 'start': 1204, 'end': 1211}]\n",
            "['Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial\\tAtorvastatin 10 mg daily is safe and efficacious in reducing the risk of first cardiovascular disease events, including stroke, in patients with type 2 diabetes without high LDL-cholesterol.', 'No justification is available for having a particular threshold level of LDL-cholesterol as the sole arbiter of which patients with type 2 diabetes should receive statins.', 'The debate about whether all people with this disorder warrant statin treatment should now focus on whether any patients are at sufficiently low risk for this treatment to be withheld.']\n",
            "unmatched tags:  [{'entity': 'statin', 'type': 'Drug', 'start': 614, 'end': 620}, {'entity': 'statins', 'type': 'Drug', 'start': 542, 'end': 549}, {'entity': 'type 2 diabetes', 'type': 'Disease', 'start': 511, 'end': 526}, {'entity': 'LDL-cholesterol', 'type': 'Drug', 'start': 452, 'end': 467}, {'entity': 'LDL-cholesterol', 'type': 'Drug', 'start': 362, 'end': 377}, {'entity': 'type 2 diabetes', 'type': 'Disease', 'start': 333, 'end': 348}, {'entity': 'stroke', 'type': 'Disease', 'start': 308, 'end': 314}, {'entity': 'cardiovascular disease', 'type': 'Disease', 'start': 267, 'end': 289}, {'entity': 'Atorvastatin', 'type': 'Drug', 'start': 188, 'end': 200}]\n",
            "['Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments\\tAntithrombotic drugs, which include antiplatelet and anticoagulant therapies, prevent and treat many cardiovascular disorders and, as such, are some of the most commonly prescribed drugs worldwide.', 'The first drugs designed to inhibit platelets or coagulation factors, such as the antiplatelet clopidogrel and the anticoagulant warfarin, significantly reduced the risk of thrombotic events at the cost of increased bleeding in patients.', 'However, both clopidogrel and warfarin have some pharmacological limitations including interpatient variability in antithrombotic effects in part due to the metabolism, interactions (eg, drug, environment, and genetic), or targets of the drugs.']\n",
            "unmatched tags:  [{'entity': 'drug', 'type': 'Drug', 'start': 776, 'end': 780}, {'entity': 'drug', 'type': 'Drug', 'start': 725, 'end': 729}, {'entity': 'warfarin', 'type': 'Drug', 'start': 568, 'end': 576}, {'entity': 'clopidogrel', 'type': 'Drug', 'start': 552, 'end': 563}, {'entity': 'anticoagulant warfarin', 'type': 'Drug', 'start': 415, 'end': 437}, {'entity': 'clopidogrel', 'type': 'Drug', 'start': 395, 'end': 406}, {'entity': 'antiplatelet clopidogrel', 'type': 'Drug', 'start': 382, 'end': 406}, {'entity': 'coagulation factors', 'type': 'Gene', 'start': 349, 'end': 368}, {'entity': 'drug', 'type': 'Drug', 'start': 310, 'end': 314}, {'entity': 'drug', 'type': 'Drug', 'start': 283, 'end': 287}, {'entity': 'cardiovascular disorders', 'type': 'Disease', 'start': 203, 'end': 227}, {'entity': 'anticoagulant therapies', 'type': 'Drug', 'start': 155, 'end': 178}]\n",
            "['Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study\\tTherapeutic warfarin is associated with reduced severity of ischaemic stroke at presentation and reduced disability or death at discharge in patients with atrial fibrillation.', 'Antiplatelet treatment is associated with a more modest reduction than warfarin in baseline stroke severity.']\n",
            "unmatched tags:  [{'entity': 'stroke', 'type': 'Disease', 'start': 414, 'end': 420}, {'entity': 'warfarin', 'type': 'Drug', 'start': 393, 'end': 401}]\n",
            "['Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial\\tIn patients with early rheumatoid arthritis in whom methotrexate treatment failed, addition of a tumour necrosis factor antagonist to methotrexate monotherapy is clinically superior to addition of conventional disease-modifying antirheumatic drugs.']\n",
            "unmatched tags:  [{'entity': 'disease-modifying antirheumatic drugs', 'type': 'Drug', 'start': 409, 'end': 446}, {'entity': 'methotrexate', 'type': 'Drug', 'start': 333, 'end': 345}, {'entity': 'tumour necrosis factor antagonist', 'type': 'Gene', 'start': 296, 'end': 329}, {'entity': 'methotrexate', 'type': 'Drug', 'start': 251, 'end': 263}]\n",
            "['Oral cholera vaccines: use in clinical practice\\tCholera continues to occur globally, particularly in sub-Saharan Africa and Asia.', 'Oral cholera vaccines have been developed and have now been used for several years, primarily in traveller populations.', 'The licensure in the European Union of a killed whole cell cholera vaccine combined with the recombinant B subunit of cholera toxin (rCTB-WC) has stimulated interest in protection against cholera.', 'Because of the similarity between cholera toxin and the heat-labile toxin of']\n",
            "unmatched tags:  [{'entity': 'heat-labile toxin', 'type': 'Gene', 'start': 503, 'end': 520}, {'entity': 'cholera toxin', 'type': 'Gene', 'start': 481, 'end': 494}, {'entity': 'cholera', 'type': 'Drug', 'start': 438, 'end': 445}, {'entity': 'cholera toxin', 'type': 'Gene', 'start': 368, 'end': 381}, {'entity': 'vaccine', 'type': 'Drug', 'start': 317, 'end': 324}, {'entity': 'cholera', 'type': 'Drug', 'start': 309, 'end': 316}]\n",
            "['Impact of anti-vaccine movements on pertussis control: the untold story\\tTo assess the impact of anti-vaccine movements that targeted pertussis whole-cell vaccines, we compared pertussis incidence in countries where high coverage with diphtheria-tetanus-pertussis vaccines (DTP) was maintained (Hungary, the former East Germany, Poland, and the USA) with countries where immunisation was disrupted by antivaccine movements (Sweden, Japan, UK, The Russian Federation, Ireland, Italy, the former West Germany, and Australia).', 'Pertussis incidence was 10 to 100 times lower in countries where high vaccine coverage was maintained than in countries where immunisation programs were compromised by anti-vaccine movements.']\n",
            "unmatched tags:  [{'entity': 'vaccine', 'type': 'Drug', 'start': 696, 'end': 703}, {'entity': 'vaccine', 'type': 'Drug', 'start': 593, 'end': 600}, {'entity': 'Pertussis', 'type': 'Disease', 'start': 523, 'end': 532}, {'entity': 'vaccine', 'type': 'Drug', 'start': 404, 'end': 411}]\n",
            "['Aerosol drug delivery: developments in device design and clinical use\\tAerosolised drugs are prescribed for use in a range of inhaler devices and systems.', 'Delivering drugs by inhalation requires a formulation that can be successfully aerosolised and a delivery system that produces a useful aerosol of the drug; the particles or droplets need to be of sufficient size and mass to be carried to the distal lung or deposited on proximal airways to give rise to a therapeutic effect.', 'Patients and caregivers must use and maintain these aerosol drug delivery devices correctly.']\n",
            "unmatched tags:  [{'entity': 'drug', 'type': 'Drug', 'start': 540, 'end': 544}]\n",
            "['High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa\\tIt has been reported that ACE2 is the main host cell receptor of 2019-nCoV and plays a crucial role in the entry of virus into the cell to cause the final infection.', 'To investigate the potential route of 2019-nCov infection on the mucosa of oral cavity, bulk RNA-seq profiles from two public databases including The Cancer Genome Atlas (TCGA) and Functional Annotation of The Mammalian Genome Cap Analysis of Gene Expression (FANTOM5 CAGE) dataset were collected.', 'RNA-seq profiling data of 13 organ types with para-carcinoma normal tissues from TCGA and 14 organ types with normal tissues from FANTOM5 CAGE were analyzed in order to explore and validate the expression of ACE2 on the mucosa of oral cavity.', 'Further, single-cell transcriptomes from an independent data generated in-house were used to identify and confirm the ACE2-expressing cell composition and proportion in oral cavity.', 'The results demonstrated that the ACE2 expressed on the mucosa of oral cavity.', 'Interestingly, this receptor was highly enriched in epithelial cells of tongue.', 'Preliminarily, those findings have explained the basic mechanism that the oral cavity is a potentially high risk for 2019-nCoV infectious susceptibility and provided a piece of evidence for the future prevention strategy in dental clinical practice as well as daily life.']\n",
            "unmatched tags:  [{'entity': '2019-nCoV', 'type': 'Virus', 'start': 1250, 'end': 1259}, {'entity': 'cell', 'type': 'Gene', 'start': 1116, 'end': 1120}, {'entity': 'receptor', 'type': 'Gene', 'start': 1073, 'end': 1081}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1008, 'end': 1012}, {'entity': 'cell', 'type': 'Gene', 'start': 926, 'end': 930}, {'entity': 'cell', 'type': 'Gene', 'start': 808, 'end': 812}, {'entity': 'ACE2', 'type': 'Gene', 'start': 757, 'end': 761}, {'entity': 'CAGE', 'type': 'Gene', 'start': 687, 'end': 691}, {'entity': 'FANTOM5', 'type': 'Gene', 'start': 679, 'end': 686}, {'entity': 'para-carcinoma', 'type': 'Gene', 'start': 595, 'end': 609}, {'entity': 'CAGE', 'type': 'Gene', 'start': 519, 'end': 523}, {'entity': 'FANTOM5', 'type': 'Gene', 'start': 511, 'end': 518}]\n",
            "['Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial\\tDeferoxamine mesylate was safe.', 'However, the primary result showed that further study of the efficacy of deferoxamine mesylate with anticipation that the drug would significantly improve the chance of good clinical outcome (ie, mRS score of 0–2) at day 90 would be futile.']\n",
            "unmatched tags:  [{'entity': 'drug', 'type': 'Drug', 'start': 302, 'end': 306}, {'entity': 'mesylate', 'type': 'Drug', 'start': 266, 'end': 274}]\n",
            "['Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and economic impact\\tEffective cervical cancer control requires a comprehensive strategy.', 'Even with HPV vaccination, radiotherapy treatment scale-up remains essential and produces large health benefits and a strong return on investment to countries at different levels of development.']\n",
            "unmatched tags:  [{'entity': 'era', 'type': 'Gene', 'start': 289, 'end': 292}, {'entity': 'HPV', 'type': 'Gene', 'start': 265, 'end': 268}, {'entity': 'cervical cancer', 'type': 'Disease', 'start': 196, 'end': 211}, {'entity': 'middle-income countries', 'type': 'Disease', 'start': 110, 'end': 133}, {'entity': 'low-income', 'type': 'Gene', 'start': 95, 'end': 105}, {'entity': 'papillomavirus vaccination', 'type': 'Drug', 'start': 65, 'end': 91}]\n",
            "['Triple-negative breast cancer: therapeutic options\\tTriple-negative breast cancers are defined by a lack of expression of oestrogen, progesterone, and ERBB2 receptors.', 'This subgroup accounts for 15% of all types of breast cancer and for a higher percentage of breast cancer arising in African and African-American women who are premenopausal.', 'Because of the absence of specific treatment guidelines for this subgroup, triple-negative breast cancers are managed with standard treatment; however, such treatment leaves them associated with a high rate of local and systemic relapse.']\n",
            "unmatched tags:  [{'entity': 'triple-negative breast cancers', 'type': 'Disease', 'start': 417, 'end': 447}, {'entity': 'breast cancer', 'type': 'Disease', 'start': 259, 'end': 272}, {'entity': 'breast cancer', 'type': 'Disease', 'start': 214, 'end': 227}, {'entity': 'ERBB2 receptors', 'type': 'Gene', 'start': 150, 'end': 165}, {'entity': 'progesterone', 'type': 'Drug', 'start': 132, 'end': 144}]\n",
            "[\"Bullying in the family: sibling bullying\\tSibling relationships have a substantial and lasting effect on children's development.\", 'Many siblings experience some occasional conflict, however, up to 40% are exposed to sibling bullying every week, a repeated and harmful form of intrafamilial aggression.', 'We review evidence on the precursors, factors relating to peer bullying, and mental health consequences of sibling bullying.', 'Parenting quality and behaviour are the intrafamilial factors most strongly associated with bullying between siblings.']\n",
            "unmatched tags:  [{'entity': 'bullying', 'type': 'Disease', 'start': 516, 'end': 524}, {'entity': 'sibling bullying', 'type': 'Disease', 'start': 406, 'end': 422}, {'entity': 'bullying', 'type': 'Disease', 'start': 362, 'end': 370}]\n",
            "['A Library of Nucleotide Analogues Terminate RNA Synthesis Catalyzed by Polymerases of Coronaviruses Causing SARS and COVID-19\\tSARS-CoV-2, a member of the coronavirus family, is responsible for the current COVID-19 worldwide pandemic.', 'We previously demonstrated that five nucleotide analogues inhibit the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), including the active triphosphate forms of Sofosbuvir, Alovudine, Zidovudine, Tenofovir alafenamide and Emtricitabine.', 'We report here the evaluation of a library of additional nucleoside triphosphate analogues with a variety of structural and chemical features as inhibitors of the RdRps of SARS-CoV and SARS-CoV-2.', 'These features include modifications on the sugar (2′ or 3′ modifications, carbocyclic, acyclic, or dideoxynucleotides) or on the base.', 'The goal is to identify nucleotide analogues that not only terminate RNA synthesis catalyzed by these coronavirus RdRps, but also have the potential to resist the viruses′ exonuclease activity.', 'We examined these nucleotide analogues with regard to their ability to be incorporated by the RdRps in the polymerase reaction and then prevent further incorporation.', 'While all 11 molecules tested displayed incorporation, 6 exhibited immediate termination of the polymerase reaction (Carbovir triphosphate, Ganciclovir triphosphate, Stavudine triphosphate, Entecavir triphosphate, 3′-O-methyl UTP and Biotin-16-dUTP), 2 showed delayed termination (Cidofovir diphosphate and 2′-O-methyl UTP), and 3 did not terminate the polymerase reaction (2′-fluoro-dUTP, 2′-amino-dUTP and Desthiobiotin-16-UTP).', 'The coronavirus genomes encode an exonuclease that apparently requires a 2′-OH group to excise mismatched bases at the 3′-terminus.', 'In this study, all of the nucleoside triphosphate analogues we evaluated form Watson-Crick-like base pairs.', 'All the nucleotide analogues which demonstrated termination either lack a 2′-OH, have a blocked 2′-OH, or show delayed termination.', 'These nucleotides may thus have the potential to resist exonuclease activity, a property that we will investigate in the future.', 'Furthermore, prodrugs of five of these nucleotide analogues (Brincidofovir/Cidofovir, Abacavir, Valganciclovir/Ganciclovir, Stavudine and Entecavir) are FDA approved for other viral infections, and their safety profile is well known.', 'Thus, they can be evaluated rapidly as potential therapies for COVID-19.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2394, 'end': 2402}, {'entity': 'viral infections', 'type': 'Disease', 'start': 2273, 'end': 2289}, {'entity': 'Entecavir', 'type': 'Drug', 'start': 2235, 'end': 2244}, {'entity': 'Stavudine', 'type': 'Gene', 'start': 2221, 'end': 2230}, {'entity': 'Valganciclovir/Ganciclovir', 'type': 'Drug', 'start': 2193, 'end': 2219}, {'entity': 'Abacavir', 'type': 'Gene', 'start': 2183, 'end': 2191}, {'entity': 'Brincidofovir/Cidofovir', 'type': 'Drug', 'start': 2158, 'end': 2181}, {'entity': 'nucleotide analogues', 'type': 'Gene', 'start': 2136, 'end': 2156}, {'entity': 'exonuclease', 'type': 'Gene', 'start': 2024, 'end': 2035}, {'entity': 'nucleotides', 'type': 'Gene', 'start': 1974, 'end': 1985}, {'entity': 'nucleotide analogues', 'type': 'Gene', 'start': 1844, 'end': 1864}, {'entity': 'nucleoside triphosphate', 'type': 'Gene', 'start': 1754, 'end': 1777}, {'entity': 'exonuclease', 'type': 'Gene', 'start': 1630, 'end': 1641}, {'entity': 'genomes', 'type': 'Gene', 'start': 1612, 'end': 1619}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 1600, 'end': 1611}, {'entity': 'UTP', 'type': 'Gene', 'start': 1590, 'end': 1593}, {'entity': 'UTP', 'type': 'Gene', 'start': 1565, 'end': 1568}, {'entity': 'UTP', 'type': 'Gene', 'start': 1550, 'end': 1553}, {'entity': 'UTP', 'type': 'Gene', 'start': 1484, 'end': 1487}, {'entity': 'Cidofovir diphosphate', 'type': 'Gene', 'start': 1446, 'end': 1467}, {'entity': 'Biotin-16-dUTP', 'type': 'Gene', 'start': 1399, 'end': 1413}, {'entity': 'UTP', 'type': 'Gene', 'start': 1391, 'end': 1394}, {'entity': 'Entecavir', 'type': 'Drug', 'start': 1355, 'end': 1364}, {'entity': 'Stavudine', 'type': 'Gene', 'start': 1331, 'end': 1340}, {'entity': 'Ganciclovir triphosphate', 'type': 'Gene', 'start': 1305, 'end': 1329}, {'entity': 'Carbovir triphosphate', 'type': 'Gene', 'start': 1282, 'end': 1303}, {'entity': 'nucleotide analogues', 'type': 'Gene', 'start': 1016, 'end': 1036}, {'entity': 'exonuclease', 'type': 'Gene', 'start': 976, 'end': 987}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 906, 'end': 917}, {'entity': 'RNA', 'type': 'Gene', 'start': 873, 'end': 876}, {'entity': 'nucleotide analogues', 'type': 'Gene', 'start': 828, 'end': 848}, {'entity': 'dideoxynucleotides', 'type': 'Gene', 'start': 768, 'end': 786}, {'entity': 'acyclic', 'type': 'Drug', 'start': 756, 'end': 763}, {'entity': 'carbocyclic', 'type': 'Drug', 'start': 743, 'end': 754}, {'entity': 'sugar', 'type': 'Drug', 'start': 712, 'end': 717}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 656, 'end': 666}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 643, 'end': 651}, {'entity': 'chemical', 'type': 'Chemical', 'start': 595, 'end': 603}, {'entity': 'nucleoside triphosphate', 'type': 'Gene', 'start': 528, 'end': 551}, {'entity': 'Emtricitabine', 'type': 'Gene', 'start': 456, 'end': 469}, {'entity': 'Tenofovir alafenamide', 'type': 'Gene', 'start': 430, 'end': 451}, {'entity': 'Zidovudine', 'type': 'Drug', 'start': 418, 'end': 428}, {'entity': 'Alovudine', 'type': 'Gene', 'start': 407, 'end': 416}]\n",
            "['Estimating required lockdown cycles before immunity to SARS-CoV-2: Model-based analyses of susceptible population sizes, S0, in seven European countries including the UK and Ireland\\tBackground: Following stringent social distancing measures, some European countries are beginning to report a slowed or negative rate of growth of daily case numbers testing positive for the novel coronavirus.', 'The notion that the first wave of infection is close to its peak begs the question of whether future peaks or second waves are likely.', 'We sought to determine the current size of the effective (i.e.', 'susceptible) population for seven European countries - to estimate immunity levels following this first wave.', 'We compare these numbers to the total population sizes of these countries, in order to investigate the potential for future peaks.', 'Methods: We used Bayesian model inversion to estimate epidemic parameters from the reported case and death rates from seven countries using data from late January 2020 to April 5th 2020.', 'Two distinct generative model types were employed: first a continuous time dynamical-systems implementation of a Susceptible-Exposed-Infectious-Recovered (SEIR) model and second: a partially observable Markov Decision Process (MDP) or hidden Markov model (HMM) implementation of an SEIR model.', 'Both models parameterise the size of the initial susceptible population (S0), as well as epidemic parameters.', 'Parameter estimation (data fitting) was performed using a standard Bayesian scheme (variational Laplace) designed to allow for latent unobservable states and uncertainty in model parameters.', 'Results: Both models recapitulated the dynamics of transmissions and disease as given by case and death rates.', 'The peaks of the current waves were predicted to be in the past for four countries (Italy, Spain, Germany and Switzerland) and to emerge in 0.5-2 weeks in Ireland and 1-3 weeks in the UK.', 'For France one model estimated the peak within the past week and the other in the future in two weeks.', 'Crucially, Maximum a posteriori (MAP) estimates of S0 for each country indicated effective population sizes of below 20% (of total population size), under both the continuous time and HMM models.', 'Using for all countries, with a Bayesian weighted average across all seven countries and both models, we estimated that 6.4% of the total population would be immune.', 'From the two models the maximum percentage of the effective population was estimated at 19.6% of the total population for the UK, 16.7% for Ireland, 11.4% for Italy, 12.8% for Spain, 18.8% for France, 4.7% for Germany and 12.9% for Switzerland.', 'Conclusion: Our results indicate that after the current wave, a large proportion of the total population will remain without immunity.', 'This suggests that in the absence of strong seasonal effects, new medications or more comprehensive contact tracing, a further set of epidemic waves in different geographic centres are likely.', 'These findings may have implications for exit strategies from any lockdown stage.']\n",
            "unmatched tags:  [{'entity': 'wave', 'type': 'Gene', 'start': 2905, 'end': 2909}, {'entity': 'medications', 'type': 'Drug', 'start': 2828, 'end': 2839}, {'entity': 'wave', 'type': 'Gene', 'start': 2683, 'end': 2687}, {'entity': 'wave', 'type': 'Gene', 'start': 1752, 'end': 1756}, {'entity': 'MDP', 'type': 'Gene', 'start': 1246, 'end': 1249}]\n",
            "['Mental health status among family members of health care workers in Ningbo, China during the Coronavirus Disease 2019 (COVID-19) outbreak: a Cross-sectional Study\\tBackground: So far, the psychological impact of COVID-19 epidemic among family members of Health care workers (HCWs) in China has been neglected.', 'The present cross-sectional study aimed to investigate the mental health status and related factors of families of HCWs in Designated Hospitals in Ningbo, China.', 'Method: Family members of HCWs working in five designated hospitals in Ningbo, China were recruited between February 10th and 20th, 2020.', 'Information on demographic variables, the COVID-19-related events in the lives, knowledge of COVID-19 and the working status of family members (that is, HCWs) was collected using online self-administered questionnaires.', 'The mental health status were assessed using the Chinese version of Patient Health Questionnare-9 (PHQ-9) and Chinese version of Generalized Anxiety Disorder-7 (GAD-7 ).', 'Multivariable logistic regression analyses were conducted to identify the main factors associated with the mental health conditions.', 'Results: A total of 822 participants completed questionnaires correctly.', '(response rate of 95.80% ).', 'The overall prevalence of GAD and depressive symptoms were 33.73%, and 29.35%, respectively.', 'More times (hours) to focus on the COVID-19 (OR=1.215, 95%CI:1.061-1.391), family members (that is, HCWs) directly contact with confirmed or suspected COVID-19 patients (OR=1.477, 95%CI:1.069-2.040) were risk factors for GAD, while higher participants self-reported safety score for protective equipment of HCWs (OR=0.807, 95%CI:0.700-0.930) was a protective factor.', 'More times (hours) to focus on the COVID-19 (OR=1.215, 95%CI:1.061-1.391), longer average working times per week for family members (that is, HCWs) (OR=1.017, 95%CI:1.005-1.029), being parents and other next of kin of HCWs were risk factors for depressive symptoms (OR=3.526, 95%CI:1.609-7.728 and OR=1.639, 95%CI:1.096-2.451, respectively).', 'In addition, compared with participants who were HCWs, participants who were enterprise workers and were more likely to develop depressive symptoms(OR=1.750, 95%CI:1.104-2.776), while who were government employees or institutions employees were less likely to suffer depressive symptoms (OR=0.529, 95%CI:0.286-0.977).', 'Conclusions: Psychological responses to COVID-19 have been dramatic among family members of HCWs during the rising phase of the outbreak.', 'Our findings provide strong evidence to pay more attention on the mental health status of this vulnerable but often unseen populations during COVID-19 epidemic.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2634, 'end': 2642}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2394, 'end': 2402}, {'entity': 'depressive symptoms', 'type': 'Phenotype', 'start': 2303, 'end': 2322}, {'entity': 'depressive symptoms', 'type': 'Phenotype', 'start': 2164, 'end': 2183}, {'entity': 'depressive symptoms', 'type': 'Phenotype', 'start': 1939, 'end': 1958}, {'entity': 'kin', 'type': 'Gene', 'start': 1905, 'end': 1908}, {'entity': 'kin', 'type': 'Gene', 'start': 1787, 'end': 1790}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1729, 'end': 1737}, {'entity': 'GAD', 'type': 'Gene', 'start': 1548, 'end': 1551}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1478, 'end': 1486}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1362, 'end': 1370}, {'entity': 'depressive symptoms', 'type': 'Phenotype', 'start': 1268, 'end': 1287}, {'entity': 'GAD', 'type': 'Gene', 'start': 1260, 'end': 1263}, {'entity': 'Multivariable logistic regression analyses', 'type': 'Gene', 'start': 1000, 'end': 1042}]\n",
            "['Peptide antibiotics\\tThe era of the “classical antibiotic” may be over.', 'The emergence of resistance has seen to that.', 'Yet no truly novel class of antibacterial agent has come on the market in the past 30 years.', 'Currently there is great interest in peptide antibiotics, especially the cationic peptides.', 'Thousands of such molecules have been synthesised and just a few are entering clinical trials.', 'Because they kill bacteria quickly by the physical disruption of cell membranes, peptide antibiotics may not face the rapid emergence of resistance.']\n",
            "unmatched tags:  [{'entity': 'antibiotic', 'type': 'Drug', 'start': 486, 'end': 496}, {'entity': 'antibiotics', 'type': 'Drug', 'start': 486, 'end': 497}, {'entity': 'peptide antibiotics', 'type': 'Gene', 'start': 478, 'end': 497}, {'entity': 'peptide', 'type': 'Gene', 'start': 292, 'end': 299}, {'entity': 'cationic peptides', 'type': 'Gene', 'start': 283, 'end': 300}, {'entity': 'peptide antibiotics', 'type': 'Gene', 'start': 247, 'end': 266}, {'entity': 'antibacterial agent', 'type': 'Drug', 'start': 145, 'end': 164}, {'entity': 'antibiotic', 'type': 'Drug', 'start': 46, 'end': 56}]\n",
            "[\"Part II: Treatment of primary malignant non-Wilms' renal tumours in children\\tRenal-cell carcinoma, clear-cell sarcoma, (congenital) mesoblastic nephroma, rhabdoid tumour, and renal medullary carcinoma form a heterogeneous group of childhood renal malignancies known as non-Wilms' tumours.\", 'Progress has been slow in improving the management of these tumours to decrease morbidity and increase survival.', 'However, greater cooperation between national and international centres should engender specialisation, and an increased knowledge of the molecular biology of these tumours will inevitably lead to substantial progress over the next decade.']\n",
            "unmatched tags:  [{'entity': 'tumours', 'type': 'Disease', 'start': 567, 'end': 574}, {'entity': 'national', 'type': 'Organization', 'start': 457, 'end': 465}]\n",
            "['A model to estimate bed demand for COVID-19 related hospitalization\\tAs of March 23, 2020 there have been over 354,000 confirmed cases of coronavirus disease 2019 (COVID-19) in over 180 countries, the World Health Organization characterized COVID-19 as a pandemic, and the United States (US) announced a national state of emergency.1, 2, 3 In parts of China and Italy the demand for intensive care (IC) beds was higher than the number of available beds.4, 5 We sought to build an accessible interactive model that could facilitate hospital capacity planning in the presence of significant uncertainty about the proportion of the population that is COVID-19+ and the rate at which COVID-19 is spreading in the population.', 'Our approach was to design a tool with parameters that hospital leaders could adjust to reflect their local data and easily modify to conduct sensitivity analyses.', 'We developed a model to facilitate hospital planning with estimates of the number of Intensive Care (IC) beds, Acute Care (AC) beds, and ventilators necessary to accommodate patients who require hospitalization for COVID-19 and how these compare to the available resources.', 'Inputs to the model include estimates of the characteristics of the patient population and hospital capacity.', 'We deployed this model as an interactive online tool.6 The model is implemented in R 3.5, RStudio, RShiny 1.4.0 and Python 3.7.', 'The parameters used may be modified as data become available, for use at other institutions, and to generate sensitivity analyses.', 'We illustrate the use of the model by estimating the demand generated by COVID-19+ arrivals for a hypothetical acute care medical center.', 'The model calculated that the number of patients requiring an IC bed would equal the number of IC beds on Day 23, the number of patients requiring a ventilator would equal the number of ventilators available on Day 27,  and the number of patients requiring an AC bed and coverage by the Medicine Service would equal the capacity of the Medicine service on Day 21.', 'In response to the COVID-19 epidemic, hospitals must understand their current and future capacity to care for patients with severe illness.', 'While there is significant uncertainty around the parameters used to develop this model, the analysis is based on transparent logic and starts from observed data to provide a robust basis of projections for hospital managers.', 'The model demonstrates the need and provides an approach to address critical questions about staffing patterns for IC and AC, and equipment capacity such as ventilators.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2052, 'end': 2060}, {'entity': 'AC bed', 'type': 'Disease', 'start': 1928, 'end': 1934}, {'entity': 'bed', 'type': 'Disease', 'start': 1766, 'end': 1769}, {'entity': 'bed', 'type': 'Disease', 'start': 1733, 'end': 1736}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1603, 'end': 1611}, {'entity': 'RStudio', 'type': 'Gene', 'start': 1359, 'end': 1366}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1100, 'end': 1108}, {'entity': 'bed', 'type': 'Disease', 'start': 1012, 'end': 1015}, {'entity': 'bed', 'type': 'Disease', 'start': 990, 'end': 993}]\n",
            "['Characterisation of the transcriptome and proteome of SARS-CoV-2 using direct RNA sequencing and tandem mass spectrometry reveals evidence for a cell passage induced in-frame deletion in the spike glycoprotein that removes the furin-like cleavage site\\tDirect RNA sequencing using an Oxford Nanopore MinION characterised the transcriptome of SARS-CoV-2 grown in Vero E6 cells.', 'This cell line is being widely used to propagate the novel coronavirus.', 'The viral transcriptome was analysed using a recently developed ORF-centric pipeline.', 'This revealed the pattern of viral transcripts, (i.e.', 'subgenomic mRNAs), generally fitted the predicted replication and transcription model for coronaviruses.', 'A 24 nt in-frame deletion was detected in subgenomic mRNAs encoding the spike (S) glycoprotein.', 'This feature was identified in over half of the mapped transcripts and was predicted to remove a proposed furin cleavage site from the S glycoprotein.', 'This motif directs cleavage of the S glycoprotein into functional subunits during virus entry or exit.', 'Cleavage of the S glycoprotein can be a barrier to zoonotic coronavirus transmission and affect viral pathogenicity.', 'Allied to this transcriptome analysis, tandem mass spectrometry was used to identify over 500 viral peptides and 44 phosphopeptides, covering almost all of the proteins predicted to be encoded by the SARS-CoV-2 genome, including peptides unique to the deleted variant of the S glycoprotein.', 'Detection of an apparently viable deletion in the furin cleavage site of the S glycoprotein reinforces the point that this and other regions of SARS-CoV-2 proteins may readily mutate.', 'This is of clear significance given the interest in the S glycoprotein as a potential vaccine target and the observation that the furin cleavage site likely contributes strongly to the pathogenesis and zoonosis of this virus.', 'The viral genome sequence should be carefully monitored during the growth of viral stocks for research, animal challenge models and, potentially, in clinical samples.', 'Such variations may result in different levels of virulence, morbidity and mortality.']\n",
            "unmatched tags:  [{'entity': 'zoonosis', 'type': 'Disease', 'start': 1837, 'end': 1845}, {'entity': 'furin', 'type': 'Gene', 'start': 1765, 'end': 1770}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1721, 'end': 1728}, {'entity': 'S glycoprotein', 'type': 'Gene', 'start': 1691, 'end': 1705}, {'entity': 'proteins', 'type': 'Gene', 'start': 1606, 'end': 1614}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1595, 'end': 1605}, {'entity': 'S glycoprotein', 'type': 'Gene', 'start': 1528, 'end': 1542}, {'entity': 'furin', 'type': 'Gene', 'start': 1501, 'end': 1506}, {'entity': 'S glycoprotein', 'type': 'Gene', 'start': 1435, 'end': 1449}, {'entity': 'peptides', 'type': 'Gene', 'start': 1389, 'end': 1397}]\n",
            "['Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial\\tThe 9vHPV vaccine prevents infection, cytological abnormalities, high-grade lesions, and cervical procedures related to HPV 31, 33, 45, 52, and 58.', 'Both the 9vHPV vaccine and qHPV vaccine had a similar immunogenicity profile with respect to HPV 6, 11, 16, and 18.', 'Vaccine efficacy was sustained for up to 6 years.', 'The 9vHPV vaccine could potentially provide broader coverage and prevent 90% of cervical cancer cases worldwide.']\n",
            "unmatched tags:  [{'entity': 'cervical cancer', 'type': 'Disease', 'start': 552, 'end': 567}, {'entity': 'HPV', 'type': 'Gene', 'start': 478, 'end': 481}, {'entity': 'Vaccine', 'type': 'Drug', 'start': 422, 'end': 429}, {'entity': 'HPV', 'type': 'Gene', 'start': 399, 'end': 402}, {'entity': 'qHPV vaccine', 'type': 'Gene', 'start': 333, 'end': 345}, {'entity': 'HPV', 'type': 'Gene', 'start': 317, 'end': 320}, {'entity': 'HPV', 'type': 'Gene', 'start': 278, 'end': 281}]\n",
            "['Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1\\tNeurofibromatosis type 1 (NF1) is a familial tumour syndrome.', 'Malignant tumours can arise in the nervous and non-nervous system in either childhood or adulthood, with malignant peripheral nerve sheath tumours being most common.', 'Rhabdomyosarcoma and neuroblastoma are paediatric neoplasms that are more common in children with NF1 than in those without the syndrome.', 'Gastrointestinal stromal tumours, somatostatinomas, breast cancer, and phaeochromocytomas are seen in adults with NF1.', 'Several pathways are thought to be involved in the development of tumours associated with NF1: rat sarcoma viral oncogene homologue (RAS)–mitogen activated protein kinase (MAPK), mammalian target of rapamycin (mTOR), and P21 protein (Cdc42/Rac)–activated kinase 1 (PAK1).']\n",
            "unmatched tags:  [{'entity': 'PAK1', 'type': 'Gene', 'start': 830, 'end': 834}, {'entity': 'P21 protein', 'type': 'Gene', 'start': 786, 'end': 797}, {'entity': 'mTOR', 'type': 'Gene', 'start': 775, 'end': 779}, {'entity': 'rapamycin', 'type': 'Drug', 'start': 764, 'end': 773}, {'entity': 'activated protein kinase', 'type': 'Gene', 'start': 711, 'end': 735}, {'entity': 'viral oncogene homologue', 'type': 'Gene', 'start': 672, 'end': 696}, {'entity': 'sarcoma', 'type': 'Disease', 'start': 664, 'end': 671}, {'entity': 'NF1', 'type': 'Gene', 'start': 655, 'end': 658}, {'entity': 'tumours', 'type': 'Disease', 'start': 631, 'end': 638}, {'entity': 'NF1', 'type': 'Gene', 'start': 560, 'end': 563}, {'entity': 'phaeochromocytomas', 'type': 'Disease', 'start': 517, 'end': 535}, {'entity': 'breast cancer', 'type': 'Disease', 'start': 498, 'end': 511}, {'entity': 'somatostatinomas', 'type': 'Disease', 'start': 480, 'end': 496}, {'entity': 'tumours', 'type': 'Disease', 'start': 471, 'end': 478}, {'entity': 'Gastrointestinal stromal tumours', 'type': 'Disease', 'start': 446, 'end': 478}, {'entity': 'syndrome', 'type': 'Disease', 'start': 436, 'end': 444}, {'entity': 'NF1', 'type': 'Gene', 'start': 406, 'end': 409}, {'entity': 'neuroblastoma', 'type': 'Disease', 'start': 329, 'end': 342}, {'entity': 'Rhabdomyosarcoma', 'type': 'Disease', 'start': 308, 'end': 324}, {'entity': 'malignant peripheral nerve sheath tumours', 'type': 'Disease', 'start': 247, 'end': 288}, {'entity': 'nervous', 'type': 'Phenotype', 'start': 193, 'end': 200}]\n",
            "['Presentation and management of intravascular large B-cell lymphoma\\tIntravascular large B-cell lymphoma (IVLBCL) is a rare disease entity of non-Hodgkin lymphoma according to the current WHO classification.', 'This rare form of B-cell lymphoma is characterised by selective growth of tumour cells in the lumina of small vessels of various organs.', 'Strange characteristics of IVLBCL, including the absence of marked lymphoadenopathy and the usually aggressive clinical behaviour, result in the delay of timely and accurate diagnosis and fatal complications.', 'Thus, the prognosis of IVLBCL is extremely poor.']\n",
            "unmatched tags:  [{'entity': 'lymphoadenopathy', 'type': 'Disease', 'start': 410, 'end': 426}, {'entity': 'B-cell lymphoma', 'type': 'Disease', 'start': 224, 'end': 239}, {'entity': 'non-Hodgkin lymphoma', 'type': 'Disease', 'start': 140, 'end': 160}]\n",
            "['Decoding the lethal effect of\\tBackground COVID-19 is a disease with global public health emergency that have shook the world since its’ first detection in China in December, 2019.', 'Severe acute respiratory syndrome Coronavirus 2 ( SARS-CoV-2 ) is the pathogen responsible behind this pandemic.', 'The lethality of different viral strains is found to vary in different geographical locations but the molecular mechanism is yet to be known.', 'Methods Available data of whole genome sequencing of different viral strains published by different countries were retrieved and then analysed using Multiple Sequence Alignment and Pair-wise Sequence Alignment leading to Phylogenetic tree construction.', 'Each location and the corresponding genetic variations were screened in depth.', 'Then the variations are analysed at protein level giving special emphasis on Non Synonymous amino acid substitutions.', 'The fatality rates in different countries were matched against the mutation number, rarity of the nucleotide alterations and functional impact of the Non Synonymous changes at protein level, separately and in combination.', 'Findings All the viral strains have been found to evolve from the viral strain of Taiwan (MT192759) which is 100% identical with the ancestor SARS-CoV-2 sequences of Wuhan (NC 045512.2; submitted on 5 th Jan, 2020).', 'Transition from C to T (C>T) is the most frequent mutation in this viral genome and mutations A>T, G>A, T>A are the rarest ones, found in countries with maximum fatality rate i.e Italy, Spain and Sweden.', '20 Non Synonymous mutations are located in viral genome spanning Orf1ab polyprotein, Surface glycoprotein, Nucleocapsid protein etc.', 'The functional effect on the structure and function of the protein can favourably or unfavourably interact with the host body.', 'Interpretation The fatality outcome depends on three important factors (a) number of mutation (b) rarity of the allelic variation and (c) functional consequence of the mutation at protein level.', 'The molecular divergence, evolved from the ancestral strain (S) lead to extremely lethal (E), lethal(L) and non lethal (N) strains with the involvement of an Intermediate strain(I).']\n",
            "unmatched tags:  [{'entity': 'strains', 'type': 'Disease', 'start': 2105, 'end': 2112}, {'entity': 'protein', 'type': 'Gene', 'start': 1967, 'end': 1974}, {'entity': 'protein', 'type': 'Gene', 'start': 1719, 'end': 1726}]\n",
            "['Non-alcoholic fatty liver disease and the interface between primary and secondary care\\tNon-alcoholic fatty liver disease (NAFLD) has a prevalence of 25–30% in unselected populations and has become the main reason for referrals to hepatology services.', 'From the perspective of liver disease, NAFLD has a high prevalence but low severity.', 'Screening studies in people at risk for NAFLD have shown a prevalence of advanced fibrosis of 5%, which underlines the need for robust pathways for risk stratification in primary care, with subsequent referrals as required.', 'In this Review, we discuss the interface between primary and secondary care with regards to risk stratification and management of patients with NAFLD.']\n",
            "unmatched tags:  [{'entity': 'NAFLD', 'type': 'Disease', 'start': 704, 'end': 709}, {'entity': 'NAFLD', 'type': 'Disease', 'start': 376, 'end': 381}, {'entity': 'NAFLD', 'type': 'Disease', 'start': 290, 'end': 295}]\n",
            "['Primary dystonia and dystonia-plus syndromes: clinical characteristics, diagnosis, and pathogenesis\\tThe dystonias are a heterogeneous group of hyperkinetic movement disorders characterised by involuntary sustained muscle contractions that lead to abnormal postures and repetitive movements.', 'Dystonia syndromes represent common movement disorders and yet are often misdiagnosed or unrecognised.', 'In recent years, there have been substantial advances in the understanding of the spectrum of clinical features that encompass dystonia syndromes, from severe generalised childhood dystonia that is often genetic in origin, to adult-onset focal dystonias and rarer forms of secondary dystonias, to dystonia as a feature of other types of CNS dysfunction.']\n",
            "unmatched tags:  [{'entity': 'dystonia', 'type': 'Phenotype', 'start': 691, 'end': 699}]\n",
            "['Caution on Kidney Dysfunctions of COVID-19 Patients\\tSummary Background: To date, large amounts of epidemiological and case study data have been available for the Coronavirus Disease 2019 (COVID-19), which suggested that the mortality was related to not just respiratory complications.', 'Here, we specifically analyzed kidney functions in COVID-19 patients and their relations to mortality.', 'Methods: In this multi-centered, retrospective, observational study, we included 193 adult patients with laboratory-confirmed COVID-19 from 2 hospitals in Wuhan, 1 hospital in Huangshi (Hubei province, 83 km from Wuhan) and 1 hospital in Chongqing (754 km from Wuhan).', 'Demographic data, symptoms, laboratory values, comorbidities, treatments, and clinical outcomes were all collected, including data regarding to kidney functions.', 'Data were compared among three groups: non-severe COVID-19 patients (128), severe COVID-19 patients (65) and a control group of other pneumonia (28).', 'For the data from computed tomographic (CT) scans, we also included a control group of healthy subjects (110 cases, without abnormalities in the lung and without kidney diseases).', 'The primary outcome was a common presence of kidney dysfunctions in COVID-19 patients and the occurrence of acute kidney injury (AKI) in a fraction of COVID-19 patients.', 'Secondary outcomes included a survival analysis of COVID-19 patients in conditions of AKI or comorbid chronic illnesses.', 'Findings: We included 193 COVID-19 patients (128 non-severe, 65 severe (including 32 non-survivors), between January 6th and February 21th,2020; the final date of follow-up was March 4th, 2020) and 28 patients of other pneumonia (15 of viral pneumonia, 13 of mycoplasma pneumonia) before the COVID-19 outbreak.', 'On hospital admission, a remarkable fraction of patients had signs of kidney dysfunctions, including 59% with proteinuria, 44% with hematuria, 14% with increased levels of blood urea nitrogen, and 10% with increased levels of serum creatinine, although mild but worse than that in cases with other pneumonia.', 'While these kidney dysfunctions might not be readily diagnosed as AKI at admission, over the progress during hospitalization they could be gradually worsened and diagnosed as AKI.', 'A univariate Cox regression analysis showed that proteinuria, hematuria, and elevated levels of blood urea nitrogen, serum creatinine, uric acid as well as D-dimer were significantly associated with the death of COVID-19 patients respectively.', 'Importantly, the Cox regression analysis also suggested that COVID-19 patients that developed AKI had a ~5.3-times mortality risk of those without AKI, much higher than that of comorbid chronic illnesses (~1.5 times risk of those without comorbid chronic illnesses).', 'Interpretation: To prevent fatality in such conditions, we suggested a high degree of caution in monitoring the kidney functions of severe COVID-19 patients regardless of the past disease history.', 'In addition, upon day-by-day monitoring, clinicians should consider any potential interventions to protect kidney functions at the early stage of the disease and renal replacement therapies in severely ill patients, particularly for those with strong inflammatory reactions or a cytokine storm.', 'Funding: None.']\n",
            "unmatched tags:  [{'entity': 'cytokine storm', 'type': 'Gene', 'start': 3228, 'end': 3242}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2891, 'end': 2899}, {'entity': 'comorbid chronic illnesses', 'type': 'Disease', 'start': 2723, 'end': 2749}, {'entity': 'comorbid chronic illnesses', 'type': 'Disease', 'start': 2662, 'end': 2688}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2546, 'end': 2554}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2453, 'end': 2461}, {'entity': 'uric acid', 'type': 'Drug', 'start': 2376, 'end': 2385}, {'entity': 'hematuria', 'type': 'Phenotype', 'start': 2303, 'end': 2312}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 2050, 'end': 2059}]\n",
            "['Tuberculosis: from prehistory to Robert Koch, as revealed by ancient DNA\\tDuring the past 10 years palaeomicrobiology, a new scientific discipline, has developed.', 'The study of ancient pathogens by direct detection of their DNA has answered several historical questions and shown changes to pathogens over time.', 'However, ancient DNA (aDNA) continues to be controversial and great care is needed to provide valid data.', 'Here we review the most successful application of the technology, which is the study of tuberculosis.', 'This has provided direct support for the current theory of']\n",
            "unmatched tags:  [{'entity': 'tuberculosis', 'type': 'Disease', 'start': 504, 'end': 516}]\n",
            "['Developmental neurotoxicity of industrial chemicals\\tNeurodevelopmental disorders such as autism, attention deficit disorder, mental retardation, and cerebral palsy are common, costly, and can cause lifelong disability.', 'Their causes are mostly unknown.', 'A few industrial chemicals (eg, lead, methylmercury, polychlorinated biphenyls [PCBs], arsenic, and toluene) are recognised causes of neurodevelopmental disorders and subclinical brain dysfunction.', 'Exposure to these chemicals during early fetal development can cause brain injury at doses much lower than those affecting adult brain function.']\n",
            "unmatched tags:  [{'entity': 'brain injury', 'type': 'Disease', 'start': 519, 'end': 531}, {'entity': 'chemicals', 'type': 'Chemical', 'start': 468, 'end': 477}, {'entity': 'subclinical brain dysfunction', 'type': 'Disease', 'start': 419, 'end': 448}, {'entity': 'neurodevelopmental disorders', 'type': 'Disease', 'start': 386, 'end': 414}, {'entity': 'toluene', 'type': 'Drug', 'start': 352, 'end': 359}, {'entity': 'arsenic', 'type': 'Drug', 'start': 339, 'end': 346}, {'entity': 'PCBs', 'type': 'Drug', 'start': 332, 'end': 336}, {'entity': 'polychlorinated biphenyls', 'type': 'Drug', 'start': 305, 'end': 330}, {'entity': 'methylmercury', 'type': 'Drug', 'start': 290, 'end': 303}]\n",
            "['Glycomic analysis of host-response reveals high mannose as a key mediator of influenza severity\\tInfluenza virus infections cause a wide variety of outcomes, from mild disease to 3-5 million cases of severe illness and ~290,000-645,000 deaths annually worldwide.', 'The molecular mechanisms underlying these disparate outcomes are currently unknown.', 'Glycosylation within the human host plays a critical role in influenza virus biology.', 'However, the impact these modifications have on the severity of influenza disease has not been examined.', 'Herein, we profile the glycomic host responses to influenza virus infection as a function of disease severity using a ferret model and our lectin microarray technology.', 'We identify the glycan epitope high mannose as a marker of influenza virus-induced pathogenesis and severity of disease outcome.', 'Induction of high mannose is dependent upon the unfolded protein response (UPR) pathway, a pathway previously shown to associate with lung damage and severity of influenza virus infection.', 'Also, the mannan-binding lectin (MBL2), an innate immune lectin that negatively impacts influenza outcomes, recognizes influenza virus-infected cells in a high mannose dependent manner.', 'Together, our data argue that the high mannose motif is an infection-associated molecular pattern on host cells that may guide immune responses leading to the concomitant damage associated with severity.']\n",
            "unmatched tags:  [{'entity': 'damage', 'type': 'Gene', 'start': 1381, 'end': 1387}, {'entity': 'high mannose', 'type': 'Drug', 'start': 1244, 'end': 1256}, {'entity': 'mannose', 'type': 'Drug', 'start': 1184, 'end': 1191}, {'entity': 'high mannose', 'type': 'Drug', 'start': 1179, 'end': 1191}, {'entity': 'influenza virus-infected cells', 'type': 'Chemical', 'start': 1143, 'end': 1173}, {'entity': 'influenza', 'type': 'Disease', 'start': 1112, 'end': 1121}, {'entity': 'MBL2', 'type': 'Gene', 'start': 1057, 'end': 1061}, {'entity': 'mannan-binding lectin', 'type': 'Gene', 'start': 1034, 'end': 1055}]\n",
            "['Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial\\tAddition of diaphragm pacing to standard care with non-invasive ventilation was associated with decreased survival in patients with ALS.', 'Our results suggest that diaphragmatic pacing should not be used as a routine treatment for patients with ALS in respiratory failure.']\n",
            "unmatched tags:  [{'entity': 'respiratory failure', 'type': 'Disease', 'start': 435, 'end': 454}]\n",
            "['Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection\\tPlasmablastic lymphoma of the oral cavity is a form of non-Hodgkin lymphoma (NHL) and was first described in 1997.', 'We describe a case of plasmablastic lymphoma in an HIV-infected patient who presented with an expanding oral lesion and symptoms of a toothache.', 'We review all cases of plasmablastic lymphoma that have been reported in the literature.', 'Plasmablastic lymphoma is strongly associated with immunodeficiency, and most particularly, with HIV infection.', 'The pathophysiological origin of plasmablastic lymphoma has not been fully characterised, but the presence of Epstein-Barr virus (EBV) has often been documented in biopsy specimens, supporting a role for EBV in the pathogenesis of this lymphoma.']\n",
            "unmatched tags:  [{'entity': 'lymphoma', 'type': 'Disease', 'start': 801, 'end': 809}, {'entity': 'EBV', 'type': 'Virus', 'start': 769, 'end': 772}, {'entity': 'EBV', 'type': 'Virus', 'start': 695, 'end': 698}, {'entity': 'Epstein-Barr virus', 'type': 'Virus', 'start': 675, 'end': 693}, {'entity': 'lymphoma', 'type': 'Disease', 'start': 612, 'end': 620}, {'entity': 'plasmablastic lymphoma', 'type': 'Disease', 'start': 598, 'end': 620}, {'entity': 'HIV infection', 'type': 'Phenotype', 'start': 550, 'end': 563}, {'entity': 'immunodeficiency', 'type': 'Phenotype', 'start': 504, 'end': 520}, {'entity': 'Plasmablastic lymphoma', 'type': 'Disease', 'start': 453, 'end': 475}, {'entity': 'lymphoma', 'type': 'Disease', 'start': 401, 'end': 409}, {'entity': 'plasmablastic lymphoma', 'type': 'Disease', 'start': 387, 'end': 409}, {'entity': 'toothache', 'type': 'Disease', 'start': 353, 'end': 362}]\n",
            "['The state of vaccine safety science: systematic reviews of the evidence\\tThis Review updates the scientific evidence assessing possible causal associations of adverse events following immunisation (AEFI) compiled in the 2012 report from the Institute of Medicine and the 2014 report from the Agency for Healthcare Research and Quality.', 'For 12 of 46 AEFI examined, a causal relationship has been established with at least one vaccine currently routinely recommended to the general USA population: anaphylaxis, arthralgia or arthritis (mild, acute, and transient, not chronic), deltoid bursitis (when vaccine is administered improperly), disseminated varicella infection (in immune deficient individuals for whom the varicella vaccine is contraindicated), encephalitis, febrile seizures, Guillain-Barré syndrome, hepatitis (in immune deficient individuals for whom the varicella vaccine is contraindicated), herpes zoster, immune thrombocytopenic purpura, meningitis, and syncope.']\n",
            "unmatched tags:  [{'entity': 'syncope', 'type': 'Phenotype', 'start': 969, 'end': 976}, {'entity': 'meningitis', 'type': 'Phenotype', 'start': 953, 'end': 963}, {'entity': 'immune thrombocytopenic purpura', 'type': 'Disease', 'start': 920, 'end': 951}, {'entity': 'herpes zoster', 'type': 'Disease', 'start': 905, 'end': 918}]\n",
            "[\"Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study\\tOur data support a continuum of disorders within inflammatory bowel disease, much better explained by three groups (ileal Crohn's disease, colonic Crohn's disease, and ulcerative colitis) than by Crohn's disease and ulcerative colitis as currently defined.\", \"Disease location is an intrinsic aspect of a patient's disease, in part genetically determined, and the major driver to changes in disease behaviour over time.\"]\n",
            "unmatched tags:  [{'entity': 'genetically', 'type': 'Gene', 'start': 434, 'end': 445}, {'entity': \"patient's disease\", 'type': 'Disease', 'start': 407, 'end': 424}, {'entity': 'Disease', 'type': 'Disease', 'start': 362, 'end': 369}, {'entity': 'ulcerative colitis', 'type': 'Disease', 'start': 321, 'end': 339}]\n",
            "['Early management of severe traumatic brain injury\\tSevere traumatic brain injury remains a major health-care problem worldwide.', 'Although major progress has been made in understanding of the pathophysiology of this injury, this has not yet led to substantial improvements in outcome.', 'In this report, we address present knowledge and its limitations, research innovations, and clinical implications.', 'Improved outcomes for patients with severe traumatic brain injury could result from progress in pharmacological and other treatments, neural repair and regeneration, optimisation of surgical indications and techniques, and combination and individually targeted treatments.']\n",
            "unmatched tags:  [{'entity': 'traumatic brain injury', 'type': 'Disease', 'start': 440, 'end': 462}, {'entity': 'clinical implications', 'type': 'Chemical', 'start': 374, 'end': 395}, {'entity': 'injury', 'type': 'Disease', 'start': 213, 'end': 219}]\n",
            "['Prediction of late seizures after ischaemic stroke with a novel prognostic model (the SeLECT score): a multivariable prediction model development and validation study\\tThis easily applied instrument was shown to be a good predictor of the risk of late seizures after stroke in three external validation cohorts and is freely available as a smartphone app.', 'The SeLECT score has the potential to identify individuals at high risk of seizures and is a step towards more personalised medicine.', 'It can inform the selection of an enriched population for antiepileptogenic treatment trials and will guide the recruitment for biomarker studies of epileptogenesis.']\n",
            "unmatched tags:  [{'entity': 'recruitment', 'type': 'Disease', 'start': 601, 'end': 612}, {'entity': 'seizures', 'type': 'Phenotype', 'start': 430, 'end': 438}]\n",
            "['Cellular senescence limits acute lung injury induced by mechanical ventilation\\tDifferent forms of lung injury can activate senescence pathways.', 'Senescence has been involved in chronic lung diseases, but its role in the acute phase is less known.', 'Acute lung injury activates a large variety of pathogenetic mechanisms that can lead to respiratory insufficiency.', 'In some cases, mechanical ventilation may help to maintain gas exchange, but positive airway pressures can cause regional overdistension of alveolar units and further damage.', 'Here, we report that acute lung injury and alveolar overstretching activate a lung senescent program aimed to limit apoptosis.', 'A systematic pooling of transcriptomic data from animal models of lung injury demonstrates the enrichment of a specific senescence signature.', 'In a clinically relevant, murine model of acid aspiration and mechanical ventilation, we observed the activation of the Tp53/Cdkn1a (p21) senescence pathway, increases in senescence-associated heterochromatin foci in alveolar cells and markers of DNA damage, chromatin reorganization and changes in the nuclear envelope.', 'Autopsy samples from lungs of critically ill patients showed the increase in senescence-associated heterochromatin foci.', 'Cell stretch per se was also able to activate the senescence response in an ex-vivo model.', 'Absence of Cdkn1a decreased the senescent response, but worsened lung injury by a significant increase in apoptosis.', 'In opposite, treatment with lopinavir/ritonavir led to Cdkn1a overexpression and ameliorated cell apoptosis and lung injury.', 'Collectively, these results suggest that acute injury promotes lung senescence.', 'This response plays a protective role against acute lung injury in the short term, but its long-term consequences remain unexplored.']\n",
            "unmatched tags:  [{'entity': 'acute lung injury', 'type': 'Disease', 'start': 1706, 'end': 1723}, {'entity': 'acute injury', 'type': 'Disease', 'start': 1621, 'end': 1633}, {'entity': 'lung injury', 'type': 'Disease', 'start': 1567, 'end': 1578}, {'entity': 'Cdkn1a', 'type': 'Gene', 'start': 1510, 'end': 1516}, {'entity': 'lopinavir/ritonavir', 'type': 'Drug', 'start': 1483, 'end': 1502}, {'entity': 'lung injury', 'type': 'Disease', 'start': 1403, 'end': 1414}, {'entity': 'Cdkn1a', 'type': 'Gene', 'start': 1349, 'end': 1355}, {'entity': 'critically ill', 'type': 'Phenotype', 'start': 1156, 'end': 1170}, {'entity': 'damage', 'type': 'Gene', 'start': 1056, 'end': 1062}, {'entity': 'Cdkn1a', 'type': 'Gene', 'start': 930, 'end': 936}]\n",
            "['Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma\\tAn immunophenotypically aberrant clonal intraepithelial T-cell population (similar to that of most cases of enteropathy-associated T-cell lymphoma) can be found in up to 75% of patients with refractory coeliac sprue; its identification by simple diagnostic techniques represents a marker of poor outcome (including occurrence of overt T-cell lymphoma).', 'We suggest that refractory sprue associated with an aberrant clonal IEL may be the missing link between coeliac disease and T-cell lymphoma and may be classified as cryptic enteropathy-associated T-cell lymphoma.']\n",
            "unmatched tags:  [{'entity': 'cryptic enteropathy-associated T-cell lymphoma', 'type': 'Disease', 'start': 596, 'end': 642}, {'entity': 'T-cell lymphoma', 'type': 'Disease', 'start': 555, 'end': 570}, {'entity': 'coeliac disease', 'type': 'Disease', 'start': 535, 'end': 550}, {'entity': 'sprue', 'type': 'Disease', 'start': 458, 'end': 463}]\n",
            "[\"Tracking progress towards universal childhood immunisation and the impact of global initiatives: a systematic analysis of three-dose diphtheria, tetanus, and pertussis immunisation coverage\\tSurvey-based DTP3 immunisation coverage has improved more gradually and not to the level suggested by countries' official reports or WHO and UNICEF estimates.\", 'There is an urgent need for independent and contestable monitoring of health indicators in an era of global initiatives that are target-oriented and disburse funds based on performance.']\n",
            "unmatched tags:  [{'entity': 'era', 'type': 'Gene', 'start': 443, 'end': 446}, {'entity': 'UNICEF', 'type': 'Organization', 'start': 331, 'end': 337}, {'entity': 'era', 'type': 'Gene', 'start': 224, 'end': 227}]\n",
            "['Projecting the Spread of COVID19 for Germany\\tWe model the evolution of the number of individuals that are reported to be sick with COVID-19 in Germany.', 'Our theoretical framework builds on a continuous time Markov chain with four states: healthy without infection, sick, healthy after recovery or after infection but without symptoms and dead.', 'Our quantitative solution matches the number of sick individuals up to the most recent observation and ends with a share of sick individuals following from infection rates and sickness probabilities.', 'We employ this framework to study inter alia the expected peak of the number of sick individuals in a scenario without public regulation of social contacts.', 'We also study the effects of public regulations.', 'For all scenarios we report the expected end of the CoV-2 epidemic.', 'We have four general findings: First, current epidemiological thinking implies that the long-run effects of the epidemic only depend on the aggregate long-run infection rate and on the individual risk to turn sick after an infection.', 'Any measures by individuals and the public therefore only influence the dynamics of spread of CoV-2.', 'Second, predictions about the duration and level of the epidemic must strongly distinguish between the officially reported numbers (Robert Koch Institut, RKI) and actual numbers of sick individuals.', 'Third, given the current (scarce) medical knowledge about long-run infection rate and individual risks to turn sick, any prediction on the length (duration in months) and strength (e.g.', 'maximum numbers of sick individuals on a given day) is subject to a lot of uncertainty.', 'Our predictions therefore offer robustness analyses that provide ranges on how long the epidemic will last and how strong it will be.', 'Fourth, public interventions that are already in place and that are being discussed can lead to more and less severe outcomes of the epidemic.', 'If an intervention takes place too early, the epidemic can actually be stronger than with an intervention that starts later.', 'Interventions should therefore be contingent on current infection rates in regions or countries.', 'Concerning predictions about COVID-19 in Germany, we find that the long-run number of sick individuals (that are reported to the RKI), once the epidemic is over, will lie between 500 thousand and 5 million individuals.', 'While this seems to be an absurdly large range for a precise projection, this reflects the uncertainty about the long-run infection rate in Germany.', 'If we assume that Germany will follow the good scenario of Hubei (and we are even a bit more conservative given discussions about data quality), we will end up with 500 thousand sick individuals over the entire epidemic.', 'If by contrast we believe (as many argue) that once the epidemic is over 70% of the population will have been infected (and thereby immune), we will end up at 5 million cases.', 'Defining the end of the epidemic by less than 100 newly reported sick individuals per day, we find a large variation depending on the effectiveness of governmental pleas and regulations to reduce social contacts.', 'An epidemic that is not influenced by public health measures would end mid June 2020.', 'With public health measures lasting for few weeks, the end is delayed by around one month or two.', 'The advantage of the delay, however, is to reduce the peak number of individuals that are simultaneously sick.', 'When we believe in long-run infection rates of 70%, this number is equally high for all scenarios we went through and well above 1 million.', 'When we can hope for the Hubei-scenario, the maximum number of sick individuals will be around 200 thousand \\x93only\\x94.', 'Whatever value of the range of long-run infection rates we want to assume, the epidemic will last at least until June, with extensive and potentially future public health measures, it will last until July.', 'In the worst case, it will last until end of August.', 'We emphasize that all projections are subject to uncertainty and permanent monitoring of observed incidences are taken into account to update the projection.', 'The most recent projections are available at https://www.macro.economics.uni-mainz.de/corona-blog/.']\n",
            "unmatched tags:  [{'entity': 'sick', 'type': 'Phenotype', 'start': 3603, 'end': 3607}, {'entity': 'sick', 'type': 'Phenotype', 'start': 3394, 'end': 3398}, {'entity': 'governmental pleas', 'type': 'Organization', 'start': 3043, 'end': 3061}, {'entity': 'sick', 'type': 'Phenotype', 'start': 2957, 'end': 2961}, {'entity': 'sick', 'type': 'Phenotype', 'start': 2672, 'end': 2676}, {'entity': 'RKI', 'type': 'Gene', 'start': 2255, 'end': 2258}, {'entity': 'sick', 'type': 'Phenotype', 'start': 2212, 'end': 2216}]\n",
            "['The prognosis of common mental disorders in adolescents: a 14-year prospective cohort study\\tEpisodes of adolescent mental disorder often precede mental disorders in young adults.', 'However, many such disorders, especially when brief in duration, are limited to the teenage years, with further symptom remission common in the late 20s.', 'The resolution of many adolescent disorders gives reason for optimism that interventions that shorten the duration of episodes could prevent much morbidity later in life.']\n",
            "unmatched tags:  [{'entity': 'disorders', 'type': 'Disease', 'start': 367, 'end': 376}]\n",
            "['Computational Design of Peptides to Block Binding of the SARS-CoV-2 Spike Protein to Human ACE2\\tThe outbreak of COVID-19 has now become a global pandemic and it continues to spread rapidly worldwide, severely threatening lives and economic stability.', 'Making the problem worse, there is no specific antiviral drug that can be used to treat COVID-19 to date.', 'SARS-CoV-2 initiates its entry into human cells by binding to angiotensin-converting enzyme 2 (hACE2) via the receptor binding domain (RBD) of its spike protein.', 'Therefore, molecules that can block SARS-CoV-2 from binding to hACE2 may potentially prevent the virus from entering human cells and serve as an effective antiviral drug.', 'Based on this idea, we designed a series of peptides that can strongly bind to SARS-CoV-2 RBD in computational experiments.', 'Specifically, we first constructed a 31-mer peptidic scaffold by linking two fragments grafted from hACE2 (a.a. 22-44 and 351-357) with a linker glycine, and then redesigned the peptide sequence to enhance its binding affinity to SARS-CoV-2 RBD.', 'Compared with several computational studies that failed to identify that SARS-CoV-2 shows higher binding affinity for hACE2 than SARS-CoV, our protein design scoring function, EvoEF2, makes a correct identification, which is consistent with the recently reported experimental data, implying its high accuracy.', 'The top designed peptide binders exhibited much stronger binding potency to hACE2 than the wild-type (−53.35 vs. −46.46 EvoEF2 energy unit for design and wild-type, respectively).', 'The extensive and detailed computational analyses support the high reasonability of the designed binders, which not only recapitulated the critical native binding interactions but also introduced new favorable interactions to enhance binding.', 'Due to the urgent situation created by COVID-19, we share these computational data to the community, which should be helpful to develop potential antiviral peptide drugs to combat this pandemic.']\n",
            "unmatched tags:  [{'entity': 'combat', 'type': 'Disease', 'start': 1966, 'end': 1972}, {'entity': 'antiviral peptide drugs', 'type': 'Drug', 'start': 1939, 'end': 1962}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1832, 'end': 1840}, {'entity': 'wild-type', 'type': 'Drug', 'start': 1524, 'end': 1533}, {'entity': 'wild-type', 'type': 'Drug', 'start': 1461, 'end': 1470}, {'entity': 'hACE2', 'type': 'Chemical', 'start': 1446, 'end': 1451}, {'entity': 'peptide', 'type': 'Gene', 'start': 1387, 'end': 1394}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 1189, 'end': 1197}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1179, 'end': 1183}, {'entity': 'hACE2', 'type': 'Chemical', 'start': 1178, 'end': 1183}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1133, 'end': 1143}, {'entity': 'RBD', 'type': 'Gene', 'start': 1055, 'end': 1058}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1044, 'end': 1054}, {'entity': 'peptide', 'type': 'Gene', 'start': 992, 'end': 999}, {'entity': 'hACE2', 'type': 'Chemical', 'start': 914, 'end': 919}, {'entity': 'RBD', 'type': 'Gene', 'start': 780, 'end': 783}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 769, 'end': 779}, {'entity': 'peptides', 'type': 'Gene', 'start': 734, 'end': 742}, {'entity': 'antiviral drug', 'type': 'Drug', 'start': 674, 'end': 688}]\n",
            "['Emergence and control of infectious diseases in China\\tInfectious diseases remain the major causes of morbidity and mortality in China despite substantial progress in their control.', 'China is a major contributor to the worldwide infectious disease burden because of its population size.', 'The association of China with the rest of the world through travel and trade means that events in the country can affect distant populations.', 'The ecological interaction of people with animals in China favours the emergence of new microbial threats.', 'The public-health system has to be prepared to deal with the challenges of newly emerging infectious diseases and at the same time try to control existing diseases.']\n",
            "unmatched tags:  [{'entity': 'diseases', 'type': 'Disease', 'start': 689, 'end': 697}, {'entity': 'infectious diseases', 'type': 'Disease', 'start': 624, 'end': 643}]\n",
            "['Topical azithromycin for the prevention of Lyme borreliosis: a randomised, placebo-controlled, phase 3 efficacy trial\\tTopical azithromycin was well tolerated and had a good safety profile.', 'Inclusion of asymptomatic seroconversion into the primary efficacy analysis led to no prevention effect with topical azithromycin.', 'Adequately powered studies assessing only erythema migrans should be considered.', 'A subgroup analysis in this study suggested that topical azithromycin reduces erythema migrans after bites of infected ticks.']\n",
            "unmatched tags:  [{'entity': 'bites', 'type': 'Disease', 'start': 502, 'end': 507}, {'entity': 'erythema migrans', 'type': 'Disease', 'start': 479, 'end': 495}, {'entity': 'azithromycin', 'type': 'Drug', 'start': 458, 'end': 470}]\n",
            "['Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries\\tIn 2018, WHO issued guidelines for the diagnosis, prevention, and management of HIV-related cryptococcal disease.', 'Two strategies are recommended to reduce the high mortality associated with HIV-related cryptococcal meningitis in low-income and middle-income countries (LMICs): optimised combination therapies for confirmed meningitis cases and cryptococcal antigen screening programmes for ambulatory people living with HIV who access care.', \"WHO's preferred therapy for the treatment of HIV-related cryptococcal meningitis in LMICs is 1 week of amphotericin B plus flucytosine, and the alternative therapy is 2 weeks of fluconazole plus flucytosine.\"]\n",
            "unmatched tags:  [{'entity': 'flucytosine', 'type': 'Gene', 'start': 785, 'end': 796}, {'entity': 'fluconazole', 'type': 'Drug', 'start': 768, 'end': 779}, {'entity': 'flucytosine', 'type': 'Gene', 'start': 713, 'end': 724}, {'entity': 'amphotericin B', 'type': 'Drug', 'start': 693, 'end': 707}, {'entity': 'cryptococcal meningitis', 'type': 'Disease', 'start': 647, 'end': 670}, {'entity': 'HIV-related', 'type': 'Disease', 'start': 635, 'end': 646}, {'entity': 'HIV', 'type': 'Virus', 'start': 569, 'end': 572}, {'entity': 'meningitis', 'type': 'Phenotype', 'start': 472, 'end': 482}, {'entity': 'middle-income countries', 'type': 'Disease', 'start': 393, 'end': 416}]\n",
            "['COVID-19: Projecting the impact in Rohingya refugee camps and beyond\\tBackground: COVID-19 could have even more dire consequences among refugees living in camps than in general populations.', 'Bangladesh has confirmed COVID-19 cases and hosts almost 1 million Rohingya refugees from Myanmar with 600,000 concentrated in Kutupalong-Balukhali Expansion Site.', 'Projections of the potential COVID-19 infection burden, epidemic speed, and healthcare needs in such settings are critical to inform preparedness planning.', 'Methods: To explore the potential impact of the introduction of SARS-CoV-2 in Kutupalong-Balukhali Expansion Site, we used a stochastic disease transmission model with parameters derived from emerging literature.', 'We considered three scenarios with different assumptions about the transmission potential of SARS-CoV-2.', 'We estimated the number and daily rate of infections, hospitalizations, deaths, and healthcare needs expected under each scenario.', 'Findings: A large-scale outbreak is highly likely after a single introduction of the virus into the camp across scenarios with 65-95% of simulations leading to at least 1,000 infections.', 'Estimated infections range from 119-504 between low and high transmission scenarios in the first 30 days; and between 424,798 and 543,647 in 12 months.', 'Hospitalization needs exceeded the existing hospitalization capacity of 340 beds after 58-139 days between the low and high transmission scenarios.', 'Estimated deaths range from 1,647-2,109 between low and high transmission scenarios.', 'Interpretation: A COVID-19 epidemic in a refugee settlement may have profound consequences, requiring unrealistically large increases in healthcare capacity and infrastructure.', 'Detailed and realistic planning for the worst in Kutupalong-Balukhali and all refugee camps worldwide must begin now.', 'Plans should consider novel and radical strategies to reduce infectious contacts and fill health worker gaps while recognizing that refugees may not have access to national health systems.', 'As global resources to fight this pandemic become scarce, displaced persons must not be forgotten.']\n",
            "unmatched tags:  [{'entity': 'gaps', 'type': 'Gene', 'start': 1935, 'end': 1939}, {'entity': 'camp', 'type': 'Gene', 'start': 1799, 'end': 1803}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1554, 'end': 1562}, {'entity': 'camp', 'type': 'Gene', 'start': 1062, 'end': 1066}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 817, 'end': 827}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 575, 'end': 585}, {'entity': 'settings', 'type': 'Disease', 'start': 454, 'end': 462}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 382, 'end': 390}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 214, 'end': 222}]\n",
            "['Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1–2 study\\tThese data show that melflufen is active in patients with relapsed and refractory multiple myeloma and tolerable in most patients.', 'These results show the feasibility of this regimen and support the initiation of additional clinical studies of melflufen in multiple myeloma, both in combination with dexamethasone as well as in triplet regimens with additional classes of drugs.']\n",
            "unmatched tags:  [{'entity': 'dexamethasone', 'type': 'Drug', 'start': 441, 'end': 454}, {'entity': 'multiple myeloma', 'type': 'Disease', 'start': 398, 'end': 414}]\n",
            "['Initial symptom severity of bipolar I disorder and the efficacy of olanzapine: a meta-analysis of individual participant data from five placebo-controlled studies\\tBenefits of olanzapine can be expected for patients across the full spectrum of symptom severity who are likely to be treated for acute mania.', 'Less severely ill patients seem to benefit less in terms of olanzapine efficacy, but still experience the same side-effects as more severely ill patients.', 'Thus, clinicians and patients should carefully consider the benefit-to-risk ratio of olanzapine and its additional, prophylactic effect against relapse in the long term.', 'The generalisability of these results to other antipsychotics, trial designs, and medical conditions remains to be established.']\n",
            "unmatched tags:  [{'entity': 'antipsychotics', 'type': 'Drug', 'start': 678, 'end': 692}, {'entity': 'olanzapine', 'type': 'Drug', 'start': 546, 'end': 556}]\n",
            "['Human, Nonhuman Primate, and Bat Cells Are Broadly Susceptible to Tibrovirus Particle Cell Entry\\tIn 2012, the genome of a novel rhabdovirus, Bas-Congo virus, was discovered in the acute-phase serum of a Congolese patient with presumed viral hemorrhagic fever.', 'In the absence of a replicating virus isolate, fulfilling Koch’s postulates to determine whether Bas-Congo virus is indeed a human virus and/or pathogen has been impossible.', 'However, experiments with vesiculoviral particles pseudotyped with Bas-Congo glycoprotein suggested that Bas-Congo virus particles can enter cells from multiple animals, including humans.', 'In 2015, genomes of two related viruses, Ekpoma virus 1 and Ekpoma virus 2, were detected in human sera in Nigeria.', 'Isolates could not be obtained.', 'Phylogenetic analyses led to the classification of Bas-Congo virus, Ekpoma virus 1, and Ekpoma virus 2 in the same genus, Tibrovirus , together with five biting midge-borne rhabdoviruses (i.e., Beatrice Hill virus, Bivens Arm virus, Coastal Plains virus, Sweetwater Branch virus, and Tibrogargan virus) not known to infect humans.', 'Using individual recombinant vesiculoviruses expressing the glycoproteins of all eight known tibroviruses and more than 75 cell lines representing different animal species, we demonstrate that the glycoproteins of all tibroviruses can mediate vesiculovirus particle entry into human, bat, nonhuman primate, cotton rat, boa constrictor, and Asian tiger mosquito cells.', 'Using four of five isolated authentic tibroviruses (i.e., Bivens Arm virus, Coastal Plains virus, Sweetwater Branch virus, and Tibrogargan virus), our experiments indicate that many cell types may be partially resistant to tibrovirus replication after virion cell entry.', 'Consequently, experimental data solely obtained from experiments using tibrovirus surrogate systems (e.g., vesiculoviral pseudotypes, recombinant vesiculoviruses) cannot be used to predict whether Bas-Congo virus, or any other tibrovirus, infects humans.']\n",
            "unmatched tags:  [{'entity': 'tibrovirus', 'type': 'Virus', 'start': 1967, 'end': 1977}, {'entity': 'Bas-Congo virus', 'type': 'Virus', 'start': 1937, 'end': 1952}]\n",
            "['Association between genetic variation in the gene for insulin-like growth factor-l and low birthweight\\tLow birthweight is associated with later risk of type 2 diabetes and related disorders.', 'We aimed to show that a polymorphism in the gene for insulin-like growth factor-l, which has proved to raise risk of type 2 diabetes and myocardial infarction, is associated with low birthweight.', 'We recorded birthweight and obtained DNA for 463 adults.', 'Individuals who did not have the wild-type allele of the polymorphism had a 215 g lower birthweight than those homozygous for this allele (95% Cl −411 to −10).']\n",
            "unmatched tags:  [{'entity': 'allele', 'type': 'Gene', 'start': 575, 'end': 581}, {'entity': 'allele', 'type': 'Gene', 'start': 487, 'end': 493}, {'entity': 'wild-type', 'type': 'Drug', 'start': 477, 'end': 486}, {'entity': 'DNA', 'type': 'Gene', 'start': 424, 'end': 427}, {'entity': 'myocardial infarction', 'type': 'Disease', 'start': 328, 'end': 349}, {'entity': 'type 2 diabetes', 'type': 'Disease', 'start': 308, 'end': 323}, {'entity': 'insulin-like growth factor-l', 'type': 'Gene', 'start': 244, 'end': 272}, {'entity': 'gene', 'type': 'Gene', 'start': 235, 'end': 239}]\n",
            "['A Multi-hospital Study in Wuhan, China：Protective Effects of Non-menopause and Female Hormones on SARS-CoV-2 infection\\tObjective To determine the correlation between menstruation status/sex hormones and prognosis of COVID-19, and to identify potential protective factors for female patients.', 'Design, Setting, and Participants A cross-sectional study of COVID-19 patients who were hospitalized at Tongji and Mobile Cabin Hospitals from Jan 28, 2020 to March 8, 2020.', 'Sex differences in severity and composite endpoints (admission to intensive care unit (ICU), use of mechanical ventilation, or death) of COVID-19 patients were compared.', 'The correlation analysis and cox/logistic regression modeling of menstruation status/sex hormones and prognosis were conducted.', 'Correlation between cytokines related to immunity and inflammation and disease severity or estradiol (E2) was revealed.Results Chi square test indicated significant differences in distribution of composite endpoints (p<0.01) and disease severity (p=0.05) between male and female patients (n=1902).', '435 female COVID-19 patients with menstruation records were recruited.', 'By the end of Mar 8, 111 patients recovered and discharged (25.3%).', 'Multivariate Cox regression model adjusted for age and severity indicated that post-menopausal patients show the greater risk of hospitalization time than non-menopausal patients (relative hazard [RH], 1.91; 95% confidence interval [CI], 1.06-3.46)Logistic regression model showed that higher AMH as a control for age increases the risk of severity of COVID-19 (HR=0.146, 95%CI= (0.026-0.824) p=0.029).', 'E2 showed protective effect against disease severity (HR=0.335, 95%CI= (0.105-1.070), p=0.046).In the Mann-Whitney U test, the higher levels of IL6 and IL8 were found in severe group (p=0.040, 0.033).The higher levels of IL2R, IL6, IL8 and IL10 were also observed in patients with composite end points(p＜0.001,＜0.001, =0.009, = 0.040).E2 levels were negatively correlated with IL2R, IL6, IL8 and TNFα in luteal phase (Pearson Correlation=-0.592, -0.558, -0.545, -0.623; p=0.033, 0.048, 0.054, 0.023) and with C3 in follicular phase (Pearson Correlation=-0.651; p=0.030).', 'Conclusions and Relevance Menopause is an independent risk factor for COVID-19.', 'E2 and AMH are negatively correlated with COVID-19 severity probably due to their regulation of cytokines related to immunity and inflammation.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2297, 'end': 2305}, {'entity': 'AMH', 'type': 'Gene', 'start': 2262, 'end': 2265}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2245, 'end': 2253}, {'entity': 'Pearson', 'type': 'Disease', 'start': 2137, 'end': 2144}, {'entity': 'C3', 'type': 'Gene', 'start': 2113, 'end': 2115}]\n",
            "['Divergent associations of height with cardiometabolic disease and cancer: epidemiology, pathophysiology, and global implications\\tAmong chronic non-communicable diseases, cardiometabolic diseases and cancer are the most important causes of morbidity and mortality worldwide.', 'Although high BMI and waist circumference, as estimates of total and abdominal fat mass, are now accepted as predictors of the increasing incidence of these diseases, adult height, which also predicts mortality, has been neglected.', 'Interestingly, increasing evidence suggests that height is associated with lower cardiometabolic risk, but higher cancer risk, associations supported by mendelian randomisation studies.']\n",
            "unmatched tags:  [{'entity': 'cancer', 'type': 'Disease', 'start': 620, 'end': 626}]\n",
            "['In-Silico evidence for two receptors based strategy of SARS-CoV-2\\tWe propose a novel numerical method able to determine efficiently and effectively the relationship of complementarity between portions of protein surfaces.', 'This innovative and general procedure, based on the representation of the molecular iso-electron density surface in terms of 2D Zernike polynomials, allows the rapid and quantitative assessment of the geometrical shape complementarity between interacting proteins, that was unfeasible with previous methods.', 'We first tested the method with a large dataset of known protein complexes obtaining an overall area under the ROC curve of 0.76 in the blind recognition of binding sites and then applied it to investigate the features of the interaction between the Spike protein of SARS-CoV-2 and human cellular receptors.', 'Our results indicate that SARS-CoV-2 uses a dual strategy: its spike protein could also interact with sialic acid receptors of the cells in the upper airways, in addition to the known interaction with Angiotensin-converting enzyme 2.']\n",
            "unmatched tags:  [{'entity': 'Angiotensin-converting enzyme 2', 'type': 'Gene', 'start': 1039, 'end': 1070}]\n",
            "['Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial\\tThese preliminary data suggest that ruxolitinib is active, well tolerated, and manageable in the outpatient setting in patients with secondary haemophagocytic lymphohistiocytosis.', 'Given the paucity of effective, non-myelosuppressive therapies, these preliminary findings have important therapeutic implications for patients with haemophagocytic lymphohistiocytosis and other cytokine-release syndromes and warrant further investigation.']\n",
            "unmatched tags:  [{'entity': 'cytokine-release syndromes', 'type': 'Disease', 'start': 499, 'end': 525}]\n",
            "['Demographics and concomitant disorders in heart failure\\tChronic heart failure is an increasingly common cause of premature death and poor quality of life.', 'Community-based epidemiological studies have provided much-needed information on the demography of chronic heart failure, providing insight into its influence on public health.', 'In most patients, chronic heart failure is accompanied by a range of concomitant disorders that both contribute to the cause of the disease and have a key role in its progression and response to treatment.', 'Information on the most common comorbidities in chronic heart failure-ischaemic heart disease, hypertension, and diabetes mellitus-is presented for prespecified subgroups in the reports of many large-scale, multicentre trials; despite their limitations, these subanalyses provide guidance in therapeutic decision-making.']\n",
            "unmatched tags:  [{'entity': 'subgroups', 'type': 'Virus', 'start': 699, 'end': 708}, {'entity': 'diabetes mellitus-is', 'type': 'Disease', 'start': 651, 'end': 671}, {'entity': 'hypertension', 'type': 'Disease', 'start': 633, 'end': 645}, {'entity': 'chronic heart failure-ischaemic heart disease', 'type': 'Disease', 'start': 586, 'end': 631}]\n",
            "['Rare uterine cancers\\tThe most common malignant tumour of the uterus is endometrioid endometrial cancer.', 'However, many less common malignant diseases also develop in the uterus, including both carcinomas and sarcomas.', 'Most notable of these tumours are papillary serous carcinomas, clear-cell carcinomas, carcinosarcomas, stromal sarcomas, and leiomyosarcomas.', 'These less common cancers can be aggressive, and account for a greatly disproportionate amount of deaths from uterine cancers.', 'Because they are uncommon, physicians will usually have seen only a few cases, and randomised data to guide treatment often do not exist.']\n",
            "unmatched tags:  [{'entity': 'uterine cancers', 'type': 'Disease', 'start': 469, 'end': 484}, {'entity': 'cancers', 'type': 'Disease', 'start': 377, 'end': 384}, {'entity': 'leiomyosarcomas', 'type': 'Disease', 'start': 342, 'end': 357}, {'entity': 'sarcomas', 'type': 'Disease', 'start': 328, 'end': 336}, {'entity': 'stromal sarcomas', 'type': 'Disease', 'start': 320, 'end': 336}, {'entity': 'carcinosarcomas', 'type': 'Disease', 'start': 303, 'end': 318}]\n",
            "['Vascular cognitive impairment\\tCerebrovascular disease is the second most common cause of acquired cognitive impairment and dementia and contributes to cognitive decline in the neurodegenerative dementias.', \"The current narrow definitions of vascular dementia should be broadened to recognise the important part cerebrovascular disease plays in several cognitive disorders, including the hereditary vascular dementias, multi-infarct dementia, post-stroke dementia, subcortical ischaemic vascular disease and dementia, mild cognitive impairment, and degenerative dementias (including Alzheimer's disease, frontotemporal dementia, and dementia with Lewy bodies).\"]\n",
            "unmatched tags:  [{'entity': 'dementia', 'type': 'Disease', 'start': 630, 'end': 638}, {'entity': 'frontotemporal dementia', 'type': 'Disease', 'start': 601, 'end': 624}, {'entity': \"Alzheimer's disease\", 'type': 'Disease', 'start': 580, 'end': 599}, {'entity': 'dementia', 'type': 'Disease', 'start': 559, 'end': 567}, {'entity': 'mild cognitive impairment', 'type': 'Disease', 'start': 515, 'end': 540}, {'entity': 'dementia', 'type': 'Disease', 'start': 505, 'end': 513}, {'entity': 'dementia', 'type': 'Disease', 'start': 452, 'end': 460}, {'entity': 'multi-infarct dementia', 'type': 'Disease', 'start': 416, 'end': 438}, {'entity': 'dementia', 'type': 'Disease', 'start': 405, 'end': 413}, {'entity': 'hereditary vascular dementias', 'type': 'Disease', 'start': 385, 'end': 414}, {'entity': 'cognitive disorders', 'type': 'Disease', 'start': 350, 'end': 369}, {'entity': 'cerebrovascular disease', 'type': 'Disease', 'start': 309, 'end': 332}]\n",
            "['Identification of a Novel Base J Binding Protein Complex Involved in RNA Polymerase II Transcription Termination in Trypanosomes\\tBase J, β-D-glucosyl-hydroxymethyluracil, is a modification of thymine DNA base involved in RNA Polymerase (Pol) II transcription termination in kinetoplastid protozoa.', 'Little is understood regarding how specific thymine residues are targeted for J-modification or the mechanism of J regulated transcription termination.', 'To identify proteins involved in J-synthesis, we expressed a tagged version of the J-glucosyltransferase (JGT) in Leishmania tarentolae , and identified four co-purified proteins by mass spectrometry: protein phosphatase (PP1), a homolog of Wdr82, a potential PP1 regulatory protein (PNUTS) and a protein containing a J-DNA binding domain (named JBP3).', 'Gel shift studies indicate JBP3 is a J-DNA binding protein.', 'Reciprocal tagging, co-IP and sucrose gradient analyses indicate PP1, JGT, JBP3, Wdr82 and PNUTS form a multimeric complex in kinetoplastids, similar to the mammalian PTW/PP1 complex involved in transcription termination via PP1 mediated dephosphorylation of Pol II.', 'Using RNAi and analysis of Pol II termination by RNA-seq and RT-PCR, we demonstrate that ablation of PNUTS, JBP3 and Wdr82 lead to defects in Pol II termination at the 3’-end of polycistronic gene arrays in Trypanosoma brucei .', 'Mutants also contain increased antisense RNA levels upstream of promoters, suggesting an additional role of the complex in regulating termination of bi-directional transcription.', 'In addition, PNUTS loss causes derepression of silent Variant Surface Glycoprotein genes important for host immune evasion.', 'Our results provide the first direct mechanistic link between base J and regulation of Pol II termination and suggest a novel molecular model for the role of the CTD of Pol II in terminating polycistronic transcription in trypanosomatids.', 'Author Summary  Trypanosoma brucei is an early-diverged parasitic protozoan that causes African sleeping sickness in humans.', 'The genome of T. brucei is organized into polycistronic gene clusters that contain multiple genes that are co-transcribed from a single promoter.', 'We have recently described the presence of a modified DNA base J and variant of histone H3 (H3.V) at transcription termination sites within gene clusters where the loss of base J and H3.V leads to read-through transcription and the expression of downstream genes.', 'We now identify a novel stable multimeric complex containing a J binding protein (JBP3), base J glucosyltransferase (JGT), PP1 phosphatase, PP1 interactive-regulatory protein (PNUTS) and Wdr82, which we refer to as PJW/PP1.', 'A similar complex (PTW/PP1) has been shown to be involved in Pol II termination in humans and yeast.', 'We demonstrate that PNUTS, JBP3 and Wdr82 mutants lead to read-through transcription in T. brucei .', 'Our data suggest the PJW/PP1 complex regulates termination by recruitment to termination sites via JBP3-base J interactions and dephosphorylation of specific proteins (including Pol II and termination factors) by PP1.', 'These findings significantly expand our understanding of mechanisms underlying transcription termination in eukaryotes, including divergent organisms that utilize polycistronic transcription and novel epigenetic marks such as base J and H3.V.', 'The studies also provide the first direct mechanistic link between J modification of DNA at termination sites and regulated Pol II termination and gene expression in kinetoplastids.']\n",
            "unmatched tags:  [{'entity': 'Pol II', 'type': 'Gene', 'start': 3445, 'end': 3451}, {'entity': 'DNA', 'type': 'Gene', 'start': 3406, 'end': 3409}, {'entity': 'base J', 'type': 'Gene', 'start': 3304, 'end': 3310}, {'entity': 'PP1', 'type': 'Gene', 'start': 3073, 'end': 3076}, {'entity': 'termination factors', 'type': 'Gene', 'start': 3049, 'end': 3068}, {'entity': 'Pol II', 'type': 'Gene', 'start': 3038, 'end': 3044}, {'entity': 'proteins', 'type': 'Gene', 'start': 3018, 'end': 3026}, {'entity': 'base J', 'type': 'Gene', 'start': 2964, 'end': 2970}, {'entity': 'JBP3-base J', 'type': 'Gene', 'start': 2959, 'end': 2970}, {'entity': 'recruitment', 'type': 'Disease', 'start': 2922, 'end': 2933}, {'entity': 'PP1', 'type': 'Gene', 'start': 2885, 'end': 2888}, {'entity': 'Wdr82', 'type': 'Gene', 'start': 2796, 'end': 2801}, {'entity': 'JBP3', 'type': 'Gene', 'start': 2787, 'end': 2791}, {'entity': 'PNUTS', 'type': 'Gene', 'start': 2780, 'end': 2785}, {'entity': 'Pol II', 'type': 'Gene', 'start': 2720, 'end': 2726}, {'entity': 'PP1', 'type': 'Gene', 'start': 2682, 'end': 2685}, {'entity': 'PP1', 'type': 'Gene', 'start': 2654, 'end': 2657}, {'entity': 'Wdr82', 'type': 'Gene', 'start': 2622, 'end': 2627}, {'entity': 'PNUTS', 'type': 'Gene', 'start': 2611, 'end': 2616}, {'entity': 'protein', 'type': 'Gene', 'start': 2602, 'end': 2609}, {'entity': 'PP1', 'type': 'Gene', 'start': 2575, 'end': 2578}, {'entity': 'PP1 phosphatase', 'type': 'Gene', 'start': 2558, 'end': 2573}, {'entity': 'JGT', 'type': 'Gene', 'start': 2552, 'end': 2555}]\n",
            "['Dysfunctional B-cell responses during HIV-1 infection: implication for influenza vaccination and highly active antiretroviral therapy\\tAlthough HIV-1 infection does not directly target B cells, B-cell numbers are reduced and their function is impaired during HIV infection.', 'Antibody titres against antigens previously encountered through vaccination or natural infection are low in patients with HIV.', 'Intrinsic B-cell defects might be involved in the impairment of humoral immunity during early HIV infection.', 'Abnormal T-cell activation and the altered expression of molecules involved in the B-cell homing process cause dysfunctional interaction between T and B cells in the germinal centres of lymphoid tissues, which might impair B-cell responses during HIV infection.']\n",
            "unmatched tags:  [{'entity': 'HIV infection', 'type': 'Phenotype', 'start': 756, 'end': 769}, {'entity': 'impair', 'type': 'Disease', 'start': 725, 'end': 731}, {'entity': 'HIV infection', 'type': 'Phenotype', 'start': 494, 'end': 507}]\n",
            "['Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study\\tOur findings show that if the option of surgery was based theoretically on galectin-3 expression alone, only 134 thyroid operations would have been done in 465 patients; therefore a large proportion (71%) of unnecessary thyroid surgical procedures could be avoided, although a number of galectin-3-negative cancers could be potentially missed.', 'The galectin-3 test proposed here does not replace conventional FNA cytology, but represents a complementary diagnostic method for those follicular nodules that remain indeterminate.']\n",
            "unmatched tags:  [{'entity': 'galectin-3 test', 'type': 'Gene', 'start': 519, 'end': 534}, {'entity': 'thyroid', 'type': 'Gene', 'start': 391, 'end': 398}]\n",
            "['Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review\\tThis systematic review of population-based studies of the incidence and early (21 days to 1 month) case fatality of stroke is based on studies published from 1970 to 2008.', \"Stroke incidence (incident strokes only) and case fatality from 21 days to 1 month post-stroke were analysed by four decades of study, two country income groups (high-income countries and low to middle income countries, in accordance with the World Bank's country classification) and, when possible, by stroke pathological type: ischaemic stroke, primary intracerebral haemorrhage, and subarachnoid haemorrhage.\"]\n",
            "unmatched tags:  [{'entity': 'subarachnoid haemorrhage', 'type': 'Disease', 'start': 670, 'end': 694}, {'entity': 'ischaemic stroke', 'type': 'Disease', 'start': 613, 'end': 629}, {'entity': 'stroke', 'type': 'Disease', 'start': 587, 'end': 593}]\n",
            "['Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial\\tAdjuvant capecitabine remains one of the standard treatments for stage III colorectal cancer in Japan; S-1 is not recommended.']\n",
            "unmatched tags:  [{'entity': 'S-1', 'type': 'Drug', 'start': 281, 'end': 284}]\n",
            "['Diabetic neuropathy: clinical manifestations and current treatments\\tDiabetic peripheral neuropathy is a prevalent, disabling disorder.', 'The most common manifestation is distal symmetrical polyneuropathy (DSP), but many patterns of nerve injury can occur.', 'Currently, the only effective treatments are glucose control and pain management.', 'While glucose control substantially decreases the development of neuropathy in those with type 1 diabetes, the effect is probably much smaller in those with type 2 diabetes.', 'Evidence supports the use of specific anticonvulsants and antidepressants for pain management in patients with diabetic peripheral neuropathy.']\n",
            "unmatched tags:  [{'entity': 'peripheral neuropathy', 'type': 'Disease', 'start': 630, 'end': 651}, {'entity': 'antidepressants', 'type': 'Drug', 'start': 568, 'end': 583}, {'entity': 'anticonvulsants', 'type': 'Drug', 'start': 548, 'end': 563}, {'entity': 'type 2 diabetes', 'type': 'Disease', 'start': 493, 'end': 508}, {'entity': 'type 1 diabetes', 'type': 'Disease', 'start': 426, 'end': 441}, {'entity': 'neuropathy', 'type': 'Disease', 'start': 401, 'end': 411}, {'entity': 'glucose control', 'type': 'Chemical', 'start': 342, 'end': 357}, {'entity': 'glucose control', 'type': 'Chemical', 'start': 299, 'end': 314}, {'entity': 'nerve injury', 'type': 'Disease', 'start': 230, 'end': 242}, {'entity': 'DSP', 'type': 'Drug', 'start': 203, 'end': 206}]\n",
            "['Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial\\tThe 10-years vaccine efficacy observed, suggests that a two-dose schedule of varicella vaccine provided optimum long-term protection for the prevention of varicella by offering individual protection against all severities of disease and leading to a potential reduction in transmission, as observed in the US experience with universal mass vaccination.']\n",
            "unmatched tags:  [{'entity': 'varicella', 'type': 'Disease', 'start': 385, 'end': 394}, {'entity': 'varicella vaccine', 'type': 'Drug', 'start': 307, 'end': 324}, {'entity': 'vaccine', 'type': 'Drug', 'start': 243, 'end': 250}, {'entity': 'vaccine', 'type': 'Drug', 'start': 132, 'end': 139}]\n",
            "['Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies\\tEven in the late ART era, survival during the first 3 years of ART continues to improve, which probably reflects transition to less toxic antiretroviral drugs, improved adherence, prophylactic measures, and management of comorbidity.', 'Prognostic models and life expectancy estimates should be updated to account for these improvements.']\n",
            "unmatched tags:  [{'entity': 'antiretroviral drugs', 'type': 'Drug', 'start': 270, 'end': 290}]\n",
            "['Challenges of infectious diseases in the USA\\tIn the USA, infectious diseases continue to exact a substantial toll on health and health-care resources.', 'Endemic diseases such as chronic hepatitis, HIV, and other sexually transmitted infections affect millions of individuals and widen health disparities.', 'Additional concerns include health-care-associated and foodborne infections—both of which have been targets of broad prevention efforts, with success in some areas, yet major challenges remain.', 'Although substantial progress in reduction of the burden of vaccine-preventable diseases has been made, continued cases and outbreaks of these diseases persist, driven by various contributing factors.']\n",
            "unmatched tags:  [{'entity': 'diseases', 'type': 'Disease', 'start': 640, 'end': 648}, {'entity': 'diseases', 'type': 'Disease', 'start': 577, 'end': 585}, {'entity': 'HIV', 'type': 'Virus', 'start': 195, 'end': 198}, {'entity': 'chronic hepatitis', 'type': 'Disease', 'start': 176, 'end': 193}, {'entity': 'Endemic diseases', 'type': 'Disease', 'start': 151, 'end': 167}]\n",
            "['Molecular diagnostics in paediatric glial tumours\\tGlial tumours in children have distinct patterns of epigenetic alteration, chromosomal structure, and gene and protein expression that differentiate them from their histological counterparts in adults.', 'Understanding paediatric gliomas at the molecular level provides important prognostic and therapeutic insights, such as which genetic alterations confer a favourable response to adjuvant therapy, or which signalling pathways might be amenable to specific molecularly targeted agents.', 'For clinicians, the ultimate goal is to individualise therapeutic regimens on the basis of the molecular fingerprint of a particular tumour and the prognosis conferred by this profile.']\n",
            "unmatched tags:  [{'entity': 'tumour', 'type': 'Disease', 'start': 669, 'end': 675}, {'entity': 'gene', 'type': 'Gene', 'start': 378, 'end': 382}, {'entity': 'gliomas', 'type': 'Disease', 'start': 277, 'end': 284}, {'entity': 'gene', 'type': 'Gene', 'start': 152, 'end': 156}]\n",
            "['Effectiveness of national and subnational infection prevention and control interventions in high-income and upper-middle-income countries: a systematic review\\tEvidence-based guidance for national infection prevention and control (IPC) programmes is needed to support national and global capacity building to reduce health-care-associated infection and antimicrobial resistance.', 'In this systematic review we investigate evidence on the effectiveness of IPC interventions implemented at national or subnational levels to inform the development of WHO guidelines on the core components of national IPC programmes.', 'We searched CENTRAL, CINAHL, Embase, MEDLINE, and WHO IRIS databases for publications between Jan 1, 2000, and April 19, 2017.']\n",
            "unmatched tags:  [{'entity': 'IPC', 'type': 'Gene', 'start': 595, 'end': 598}, {'entity': 'national', 'type': 'Organization', 'start': 586, 'end': 594}, {'entity': 'national', 'type': 'Organization', 'start': 500, 'end': 508}, {'entity': 'national', 'type': 'Organization', 'start': 485, 'end': 493}, {'entity': 'IPC', 'type': 'Gene', 'start': 452, 'end': 455}, {'entity': 'health-care-associated infection', 'type': 'Disease', 'start': 315, 'end': 347}, {'entity': 'national', 'type': 'Organization', 'start': 267, 'end': 275}, {'entity': 'IPC', 'type': 'Gene', 'start': 230, 'end': 233}, {'entity': 'national', 'type': 'Organization', 'start': 187, 'end': 195}, {'entity': 'upper-middle-income countries', 'type': 'Gene', 'start': 108, 'end': 137}]\n",
            "['Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial\\tAt 12 month follow-up, both very thin strut drug-eluting stents with dissimilar biodegradable polymer coatings (eluting either everolimus or sirolimus) were non-inferior to the durable polymer stent (eluting zotarolimus) in treating allcomers with a high proportion of patients with acute coronary syndromes.', 'The absence of a loss of 1 year safety and efficacy with the use of these two biodegradable polymer-coated stents is a prerequisite before assessing their potential longer-term benefits.']\n",
            "unmatched tags:  [{'entity': 'longer-term', 'type': 'Chemical', 'start': 713, 'end': 724}]\n",
            "['Unique properties of Zika NS2B-NS3pro complexes as decoded by experiments and MD simulations\\tZika virus can be passed from a pregnant woman to her fetus, thus leading to birth defects including more than microcephaly.', 'It has been recently estimated that one-third of the world population will be infected by Zika, but unfortunately no vaccine or medicine is available so far.', 'Zika NS2B-NS3pro is essential for its replication and thus represents an attractive target for drug discovery/design.', 'Here we characterized conformation, catalysis, inhibition and dynamics of linked and unlinked Zika NS2B-NS3pro complexes by both experiments and MD simulations.', 'The results unveil the unique properties of Zika NS2B-NS3pro which are very different from Dengue one.', 'Particularly, CD and NMR studies indicate that unlike Dengue, the C-terminal region of Zika NS2B with a significant sequence variation is highly disordered in the open conformation.', 'Indeed, MD simulations reveal that up to 100 ns, the Dengue NS2B C-terminus constantly has close contacts with its NS3pro domain.', 'By a sharp contrast, the Zika NS2B C-terminus loses the contacts with its NS3pro domain after 10 ns, further forming a short β-sheet characteristic of the closed conformation at 30 ns.', 'Furthermore, we found that a small molecule, previously identified as an active site inhibitor for other flaviviral NS2B-NS3pro, inhibited Zika NS2B-NS3pro potently in an allosteric manner.', 'Our study provides the first insight into the dynamics of Zika NS2B-NS3pro and further deciphers that it is susceptible to allosteric inhibition, which thus bears critical implications for the future development of therapeutic allosteric inhibitors.']\n",
            "unmatched tags:  [{'entity': 'Zika NS2B-NS3pro', 'type': 'Gene', 'start': 1503, 'end': 1519}, {'entity': 'Zika NS2B-NS3pro', 'type': 'Gene', 'start': 1394, 'end': 1410}, {'entity': 'flaviviral', 'type': 'Virus', 'start': 1360, 'end': 1370}, {'entity': 'small molecule', 'type': 'Drug', 'start': 1284, 'end': 1298}, {'entity': 'Zika NS2B', 'type': 'Gene', 'start': 1095, 'end': 1104}, {'entity': 'Zika NS2B C-terminus', 'type': 'Gene', 'start': 1095, 'end': 1115}, {'entity': 'Dengue', 'type': 'Disease', 'start': 993, 'end': 999}, {'entity': 'Zika NS2B', 'type': 'Gene', 'start': 845, 'end': 854}, {'entity': 'Dengue', 'type': 'Disease', 'start': 812, 'end': 818}, {'entity': 'Dengue', 'type': 'Disease', 'start': 746, 'end': 752}, {'entity': 'Zika NS2B-NS3pro', 'type': 'Gene', 'start': 699, 'end': 715}, {'entity': 'NS2B-NS3pro complexes', 'type': 'Gene', 'start': 593, 'end': 614}, {'entity': 'Zika', 'type': 'Virus', 'start': 588, 'end': 592}, {'entity': 'Zika NS2B-NS3pro', 'type': 'Gene', 'start': 376, 'end': 392}, {'entity': 'vaccine', 'type': 'Drug', 'start': 335, 'end': 342}, {'entity': 'Zika', 'type': 'Virus', 'start': 308, 'end': 312}]\n",
            "['Epidemiology and outcomes of osteoporotic fractures\\tBone mass declines and the risk of fractures increases as people age, especially as women pass through the menopause.', \"Hip fractures, the most serious outcome of osteoporosis, are becoming more frequent than before because the world's population is ageing and because the frequency of hip fractures is increasing by 1–3% per year in most areas of the world.\", 'Rates of hip fracture vary more widely from region to region than does the prevalance of vertebral fractures.', 'Low bone density and previous fractures are risk factors for almost all types of fracture, but each type of fracture also has its own unique risk factors.']\n",
            "unmatched tags:  [{'entity': 'fractures', 'type': 'Disease', 'start': 549, 'end': 558}, {'entity': 'vertebral fractures', 'type': 'Disease', 'start': 498, 'end': 517}]\n",
            "['Development of a malaria vaccine\\tDevelopment of an effective malaria vaccine poses a major scientific challenge both in the laboratory and in the field.', 'Such a vaccine is necessary because of the massive disease burden of malaria in the developing world, the global spread of drug resistance, and the difficulty of sustainable control of the mosquito vector.', 'Animal models have shown the immunological feasibility of vaccines targeted against different stages of parasite development, and studies in human volunteers have shown that a recombinant protein vaccine can protect against challenge with the homologous strain of parasite.']\n",
            "unmatched tags:  [{'entity': 'homologous strain', 'type': 'Gene', 'start': 602, 'end': 619}]\n",
            "['Maternal and early onset neonatal bacterial sepsis: burden and strategies for prevention in sub-Saharan Africa\\tMaternal and child health are high priorities for international development.', 'Through a Review of published work, we show substantial gaps in current knowledge on incidence (cases per live births), aetiology, and risk factors for both maternal and early onset neonatal bacterial sepsis in sub-Saharan Africa.', 'Although existing published data suggest that sepsis causes about 10% of all maternal deaths and 26% of neonatal deaths, these are likely to be considerable underestimates because of methodological limitations.']\n",
            "unmatched tags:  [{'entity': 'methodological limitations', 'type': 'Gene', 'start': 602, 'end': 628}]\n",
            "['Robust neutralization assay based on SARS-CoV-2 S-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressed BHK21 cells\\tThe global pandemic of Coronavirus disease 2019 (COVID-19) is a disaster for human society.', 'A convenient and reliable in vitro neutralization assay is very important for the development of neutralizing antibodies, vaccines and other inhibitors.', 'In this study, G protein-deficient vesicular stomatitis virus (VSVdG) bearing full-length and truncated spike (S) protein of SARS-CoV-2 were evaluated.', 'The virus packaging efficiency of VSV-SARS-CoV-2-Sdel18 (S with C-terminal 18 amino acid truncation) is much higher than VSV-SARS-CoV-2-S. A neutralization assay for antibody screening and serum neutralizing titer quantification was established based on VSV-SARS-CoV-2-Sdel18 pseudovirus and human angiotensin-converting enzyme 2 (ACE2) overexpressed BHK21 cell (BHK21-hACE2).', 'The experimental results can be obtained by automatically counting EGFP positive cell number at 12 hours after infection, making the assay convenient and high-throughput.', 'The serum neutralizing titer of COVID-19 convalescent patients measured by VSV-SARS-CoV-2-Sdel18 pseudovirus assay has a good correlation with live SARS-CoV-2 assay.', 'Seven neutralizing monoclonal antibodies targeting receptor binding domain (RBD) of SARS-CoV-2-S were obtained.', 'This efficient and reliable pseudovirus assay model could facilitate the development of new drugs and vaccines.']\n",
            "unmatched tags:  [{'entity': 'vaccines', 'type': 'Drug', 'start': 1463, 'end': 1471}, {'entity': 'RBD', 'type': 'Gene', 'start': 1325, 'end': 1328}, {'entity': 'neutralizing monoclonal antibodies', 'type': 'Gene', 'start': 1255, 'end': 1289}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1231, 'end': 1241}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1115, 'end': 1123}, {'entity': 'EGFP', 'type': 'Gene', 'start': 979, 'end': 983}]\n",
            "['CT imaging of chronic obstructive pulmonary disease: insights, disappointments, and promise\\tCT imaging is a readily quantifiable tool that can provide in-vivo assessments of lung structure in conditions such as chronic obstructive pulmonary disease (COPD).', 'The information extracted from these data has been used in many clinical, epidemiological, and genetic investigations for patient stratification and prognostication, and to determine intermediate endpoints for clinical trials.', 'Although these efforts have informed our understanding of the heterogeneity of pulmonary disease in smokers, they have not yet translated into new treatments for COPD or the personalisation of patient care.']\n",
            "unmatched tags:  [{'entity': 'personalisation', 'type': 'Disease', 'start': 658, 'end': 673}]\n",
            "['Consent to thrombolysis in acute ischaemic stroke: from trial to practice\\tThrombolysis with intravenous alteplase for acute ischaemic stroke, which is already in clinical use in the USA and Canada, has recently been approved in the European Union.', 'Until now, the use of alteplase has been limited to research or “off label” therapy in most of Europe.', 'Despite the growing importance of this therapy and the many guidelines for use and comments on its effects, there is a lack of information about informed consent.', 'The process of obtaining informed consent in the therapeutic decision process allows the patients to express their point of view on the risk-to-benefit ratio of thrombolytic therapy, on the different outcomes of stroke, and on the effect of thrombolysis.']\n",
            "unmatched tags:  [{'entity': 'stroke', 'type': 'Disease', 'start': 726, 'end': 732}, {'entity': 'alteplase', 'type': 'Gene', 'start': 270, 'end': 279}]\n",
            "['Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: a meta-analysis of test-negative design case-control studies\\tOur findings show that in elderly people, irrespective of vaccine match, seasonal influenza vaccination is effective against laboratory confirmed influenza during epidemic seasons.', 'Efforts should be renewed worldwide to further increase uptake of the influenza vaccine in the elderly population.']\n",
            "unmatched tags:  [{'entity': 'influenza vaccine', 'type': 'Drug', 'start': 394, 'end': 411}, {'entity': 'influenza', 'type': 'Disease', 'start': 289, 'end': 298}, {'entity': 'influenza', 'type': 'Disease', 'start': 225, 'end': 234}, {'entity': 'vaccine', 'type': 'Drug', 'start': 201, 'end': 208}]\n",
            "['Neurodevelopment and ages of onset in depressive disorders\\tHow and why do clinical depressive disorders emerge in adolescence?', 'In this Personal View, we present a neurodevelopmental theory to address causes for adolescent onsets of clinical depressive disorders.', 'We argue that theories should account for three perplexing aspects of depressive disorders in adolescence: the episodic nature of depression; differences between sexes in rates of depression across development; and age-differentiated onsets.', 'We consider how theories such as psychosocial acceleration, heterochronic brain development, dual-process models, glucocorticoid vulnerability hypothesis linked to early life stress, and epigenetic and genetic susceptibility might explain some aspects of adolescent depressive disorders.']\n",
            "unmatched tags:  [{'entity': 'depressive disorders', 'type': 'Disease', 'start': 771, 'end': 791}, {'entity': 'life stress', 'type': 'Disease', 'start': 675, 'end': 686}, {'entity': 'glucocorticoid', 'type': 'Drug', 'start': 619, 'end': 633}, {'entity': 'depression', 'type': 'Disease', 'start': 443, 'end': 453}]\n",
            "['Periodontal diseases\\tThe periodontal diseases are highly prevalent and can affect up to 90% of the worldwide population.', 'Gingivitis, the mildest form of periodontal disease, is caused by the bacterial biofilm (dental plaque) that accumulates on teeth adjacent to the gingiva (gums).', 'However, gingivitis does not affect the underlying supporting structures of the teeth and is reversible.', 'Periodontitis results in loss of connective tissue and bone support and is a major cause of tooth loss in adults.', 'In addition to pathogenic microorganisms in the biofilm, genetic and environmental factors, especially tobacco use, contribute to the cause of these diseases.']\n",
            "unmatched tags:  [{'entity': 'diseases', 'type': 'Disease', 'start': 651, 'end': 659}, {'entity': 'Periodontitis', 'type': 'Disease', 'start': 388, 'end': 401}, {'entity': 'gingivitis', 'type': 'Disease', 'start': 292, 'end': 302}, {'entity': 'dental plaque', 'type': 'Disease', 'start': 210, 'end': 223}, {'entity': 'periodontal disease', 'type': 'Disease', 'start': 153, 'end': 172}]\n",
            "['Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial\\tTreatment with oral amoxicillin for 3-days was equally as effective as treatment for 5 days in children with non-severe pneumonia.', 'The most important risk factor for treatment failure was non-compliance, which was also associated with longer duration of therapy.', 'Published online July 23, 2002 http://image.thelancet.com/extras/01art7461web.pdf']\n",
            "unmatched tags:  [{'entity': 'non-severe pneumonia', 'type': 'Organization', 'start': 242, 'end': 262}]\n",
            "['MicrobioLink: An integrated computational pipeline to infer functional effects of microbiome-host interactions\\tMicrobiome-host interactions play significant roles in health and in various diseases including auto-immune disorders.', 'Uncovering these inter-kingdom cross-talks propels our understanding of disease pathogenesis, and provides useful leads on potential therapeutic targets.', 'Despite the biological significance of microbe-host interactions, there is a big gap in understanding the downstream effects of these interactions on host processes.', 'Computational methods are expected to fill this gap by generating, integrating and prioritizing predictions - as experimental detection remains challenging due to feasibility issues.', 'Here, we present MicrobioLink, a computational pipeline to integrate predicted interactions between microbial and host proteins together with host molecular networks.', 'Using the concept of network diffusion, MicrobioLink can analyse how microbial proteins in a certain context are influencing cellular processes by modulating gene or protein expression.', 'We demonstrated the applicability of the pipeline using a case study.', 'We used gut metaproteomic data from Crohns disease patients and healthy controls to uncover the mechanisms by which the microbial proteins can modulate host genes which belong to biological processes implicated in disease pathogenesis.', 'MicrobioLink, which is agnostic of the microbial protein sources (bacterial, viral etc), is freely available on GitHub (https://github.com/korcsmarosgroup/HMIpipeline).']\n",
            "unmatched tags:  [{'entity': 'GitHub', 'type': 'Organization', 'start': 1504, 'end': 1510}, {'entity': 'gene', 'type': 'Gene', 'start': 1383, 'end': 1387}, {'entity': 'gene', 'type': 'Gene', 'start': 1313, 'end': 1317}, {'entity': 'microbial proteins', 'type': 'Gene', 'start': 1276, 'end': 1294}, {'entity': 'Crohns disease', 'type': 'Disease', 'start': 1192, 'end': 1206}, {'entity': 'gene', 'type': 'Gene', 'start': 1058, 'end': 1062}, {'entity': 'microbial proteins', 'type': 'Gene', 'start': 969, 'end': 987}, {'entity': 'host proteins', 'type': 'Gene', 'start': 847, 'end': 860}, {'entity': 'gene', 'type': 'Gene', 'start': 605, 'end': 609}]\n",
            "['Socioeconomic aspects of neglected tropical diseases\\tAlthough many examples of highly cost-effective interventions to control neglected tropical diseases exist, our understanding of the full economic effect that these diseases have on individuals, households, and nations needs to be improved to target interventions more effectively and equitably.', \"We review data for the effect of neglected tropical diseases on a population's health and economy.\", 'We also present evidence on the costs, cost-effectiveness, and financing of strategies to monitor, control, or reduce morbidity and mortality associated with these diseases.']\n",
            "unmatched tags:  [{'entity': 'diseases', 'type': 'Disease', 'start': 612, 'end': 620}]\n",
            "['Performance of late pregnancy biometry for gestational age dating in low-income and middle-income countries: a prospective, multicountry, population-based cohort study from the WHO Alliance for Maternal and Newborn Health Improvement (AMANHI) Study Group\\tIncorporation of TCD and the use of new formulas in late pregnancy ultrasound scans could improve the accuracy of gestational age estimation in both appropriate-for-gestational-age and small-for-gestational-age infants in LMICs.', 'Given the high rates of small-for-gestational-age infants in LMICs, these results might be especially relevant.', 'Validation of this new formula in other LMIC populations is needed to establish whether the accuracy of the late pregnancy ultrasound can be narrowed to within approximately 2 weeks.']\n",
            "unmatched tags:  [{'entity': 'LMIC', 'type': 'Gene', 'start': 636, 'end': 640}]\n",
            "['Prophage genomics reveals patterns in phage genome organization and replication\\tTemperate phage genomes are highly variable mosaic collections of genes that infect a bacterial host, integrate into the host’s genome or replicate as low copy number plasmids, and are regulated to switch from the lysogenic to lytic cycles to generate new virions and escape their host.', 'Genomes from most Bacterial phyla contain at least one or more prophages.', 'We updated our PhiSpy algorithm to improve detection of prophages and to provide a web-based framework for PhiSpy.', 'We have used this algorithm to identify 36,488 prophage regions from 11,941 bacterial genomes, including almost 600 prophages with no known homology to any proteins.', 'Transfer RNA genes were abundant in the prophages, many of which alleviate the limits of translation efficiency due to host codon bias and presumably enable phages to surpass the normal capacity of the hosts’ translation machinery.', 'We identified integrase genes in 15,765 prophages (43% of the prophages).', 'The integrase was routinely located at either end of the integrated phage genome, and was used to orient and align prophage genomes to reveal their underlying organization.', 'The conserved genome alignments of phages recapitulate early, middle, and late gene order in transcriptional control of phage genes, and demonstrate that gene order, presumably selected by transcription timing and/or coordination among functional modules has been stably conserved throughout phage evolution.']\n",
            "unmatched tags:  [{'entity': 'phage', 'type': 'Virus', 'start': 1493, 'end': 1498}, {'entity': 'phage genes', 'type': 'Virus', 'start': 1321, 'end': 1332}, {'entity': 'phages', 'type': 'Virus', 'start': 1236, 'end': 1242}, {'entity': 'genomes', 'type': 'Gene', 'start': 1152, 'end': 1159}, {'entity': 'prophage', 'type': 'Virus', 'start': 1143, 'end': 1151}, {'entity': 'phage', 'type': 'Virus', 'start': 1096, 'end': 1101}, {'entity': 'integrase', 'type': 'Gene', 'start': 1032, 'end': 1041}, {'entity': 'phage', 'type': 'Virus', 'start': 1019, 'end': 1024}, {'entity': 'phages', 'type': 'Virus', 'start': 1019, 'end': 1025}, {'entity': 'prophages', 'type': 'Virus', 'start': 1016, 'end': 1025}, {'entity': 'prophages', 'type': 'Virus', 'start': 994, 'end': 1003}, {'entity': 'integrase genes', 'type': 'Gene', 'start': 968, 'end': 983}, {'entity': 'phage', 'type': 'Virus', 'start': 879, 'end': 884}, {'entity': 'phages', 'type': 'Virus', 'start': 879, 'end': 885}, {'entity': 'phages', 'type': 'Virus', 'start': 765, 'end': 771}, {'entity': 'prophages', 'type': 'Virus', 'start': 762, 'end': 771}, {'entity': 'Transfer RNA genes', 'type': 'Gene', 'start': 722, 'end': 740}, {'entity': 'proteins', 'type': 'Gene', 'start': 712, 'end': 720}, {'entity': 'prophages', 'type': 'Virus', 'start': 672, 'end': 681}, {'entity': 'genomes', 'type': 'Gene', 'start': 642, 'end': 649}, {'entity': 'prophage regions', 'type': 'Virus', 'start': 603, 'end': 619}]\n",
            "['Transmission and epidemiological characteristics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infected Pneumonia (COVID-19): preliminary evidence obtained in comparison with 2003-SARS\\tObjectives: Latest epidemic data of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infected Pneumonia (COVID-19) was collected and a detailed statistical analysis was carried out to make comparison with 2003-SARS in order to provide scientific reference for the prevention and control of COVID-19.', 'Methods: The information of COVID-19 and 2003-SARS from websites of NHCPRC and the World Health Organization was collected, and then the transmission dynamics of the two kinds of infectious diseases were analyzed.', 'The information of 853 confirmed COVID-19 patients obtained from the website of health committees of 18 provinces.', 'A descriptive epidemiological analysis method was employed to carefully analyze the epidemic characteristics.', 'Subsequently, the COVID-19 epidemic data in Wuhan and other inland regions of China was analyzed separately and compared.', 'A multivariate function model was constructed based on the confirmed COVID-19 case data.', 'Results: The growth rate of new cases and deaths of COVID-19 were significantly faster than those of 2003-SARS.', 'The number of confirmed cases in Wuhan and other inland areas both showed increasing trends.', '853 confirmed COVID-19 cases aged 1 months to 94 years and the average age was (45.05 ± 17.22) years.', 'The gender ratio (M: F) was 1.12: 1.', 'Conclusions: The fatality rate of COVID-19 is lower than that of 2003-SARS and the cure rate is higher.', 'The age of COVID-19 patients is mainly concentrated in the 30-50 years old (60.61%).', 'The harm of the first-generation COVID-19 patients is higher than that of secondary cases.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 1731, 'end': 1739}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1624, 'end': 1632}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1543, 'end': 1551}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1384, 'end': 1392}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1217, 'end': 1225}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1145, 'end': 1153}, {'entity': 'inland regions', 'type': 'Gene', 'start': 1014, 'end': 1028}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 972, 'end': 980}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 762, 'end': 770}, {'entity': 'infectious diseases', 'type': 'Disease', 'start': 694, 'end': 713}, {'entity': 'NHCPRC', 'type': 'Chemical', 'start': 583, 'end': 589}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 543, 'end': 551}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 505, 'end': 513}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 320, 'end': 328}, {'entity': 'Pneumonia', 'type': 'Disease', 'start': 309, 'end': 318}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 288, 'end': 298}, {'entity': 'Coronavirus 2', 'type': 'Virus', 'start': 273, 'end': 286}]\n",
            "['A unifying structural and functional model of the coronavirus replication organelle: tracking down RNA synthesis\\tZoonotic coronavirus (CoV) infections, like those responsible for the current SARS-CoV-2 epidemic, cause grave international public health concern.', 'In infected cells, the CoV RNA-synthesizing machinery associates with modified endoplasmic reticulum membranes that are transformed into the viral replication organelle (RO).', 'While double-membrane vesicles (DMVs) appear to be a pan -coronavirus RO element, studies to date describe an assortment of additional coronavirus-induced membrane structures.', 'Despite much speculation, it remains unclear which RO element(s) accommodate viral RNA synthesis.', 'Here we provide detailed 2D and 3D analyses of CoV ROs and show that diverse CoVs essentially induce the same membrane modifications, including the small open double-membrane spherules (DMSs) previously thought to be restricted to gamma- and delta-CoV infections and proposed as sites of replication.', 'Metabolic labelling of newly-synthesized viral RNA followed by quantitative EM autoradiography revealed abundant viral RNA synthesis associated with DMVs in cells infected with the beta-CoVs MERS-CoV and SARS-CoV, and the gamma-CoV infectious bronchitis virus.', 'RNA synthesis could not be linked to DMSs or any other cellular or virus-induced structure.', 'Our results provide a unifying model of the CoV RO and clearly establish DMVs as the central hub for viral RNA synthesis and a potential drug target in coronavirus infection.']\n",
            "unmatched tags:  [{'entity': 'coronavirus infection', 'type': 'Disease', 'start': 1516, 'end': 1537}, {'entity': 'viral RNA', 'type': 'Gene', 'start': 1465, 'end': 1474}, {'entity': 'DMVs', 'type': 'Chemical', 'start': 1437, 'end': 1441}, {'entity': 'RO', 'type': 'Gene', 'start': 1412, 'end': 1414}, {'entity': 'CoV', 'type': 'Virus', 'start': 1408, 'end': 1411}, {'entity': 'RNA', 'type': 'Gene', 'start': 1272, 'end': 1275}, {'entity': 'CoV', 'type': 'Virus', 'start': 1239, 'end': 1242}, {'entity': 'gamma-CoV infectious bronchitis virus', 'type': 'Virus', 'start': 1233, 'end': 1270}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 1215, 'end': 1223}, {'entity': 'CoV', 'type': 'Virus', 'start': 1207, 'end': 1210}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 1202, 'end': 1210}, {'entity': 'beta-CoVs', 'type': 'Virus', 'start': 1192, 'end': 1201}]\n",
            "['Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue\\tThe liver is susceptible to the toxic effects of many cytotoxic or immunosuppressive treatments.', 'However, in carriers of hepatitis B virus (HBV) and, less frequently, of hepatitis C virus, liver damage due to reactivation of viral replication can occur after withdrawal of immuno-suppressive drugs.', 'These reactivations, which are associated with fulminant forms of hepatitis in up to 25% of cases, are observed both in symptom-free chronic carriers of hepatitis B surface antigen and in patients who have chronic hepatitis B or C and concurrent haematological tumours or solid neoplasms or who have received transplants.']\n",
            "unmatched tags:  [{'entity': 'solid neoplasms', 'type': 'Disease', 'start': 681, 'end': 696}]\n",
            "['Molecular and genetic pathways in penile cancer\\tPenile cancer is a rare malignancy affecting more than 400 men per year in the UK.', 'Studies on the aetiopathogenesis of this cancer have focused on its association with the human papilloma virus; however, there have also been several studies on the genetic and molecular changes that occur.', 'Human papilloma virus has shown differential levels of prevalence in association with different types of penile cancer.', 'The virus seems to act as a trigger for this disease via its oncogenes.', 'We review this process, and assess the independent genetic events that occur in penile cancer.']\n",
            "unmatched tags:  [{'entity': 'cancer', 'type': 'Disease', 'start': 617, 'end': 623}, {'entity': 'penile cancer', 'type': 'Disease', 'start': 610, 'end': 623}, {'entity': 'oncogenes', 'type': 'Gene', 'start': 519, 'end': 528}, {'entity': 'penile cancer', 'type': 'Disease', 'start': 443, 'end': 456}, {'entity': 'Human papilloma virus', 'type': 'Virus', 'start': 338, 'end': 359}, {'entity': 'papilloma virus', 'type': 'Virus', 'start': 226, 'end': 241}, {'entity': 'cancer', 'type': 'Disease', 'start': 172, 'end': 178}]\n",
            "['Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis\\tHPV16 is by far the most carcinogenic HPV type in the anus, with enrichment of HPV16 even from high-grade lesions to anal cancer, both in individuals who are HIV negative and those who are HIV positive.', 'Nevertheless, the fraction of anal cancer attributable to HPV16 is smaller in the HIV-positive population.']\n",
            "unmatched tags:  [{'entity': 'HIV-positive', 'type': 'Gene', 'start': 421, 'end': 433}, {'entity': 'HPV16', 'type': 'Gene', 'start': 397, 'end': 402}]\n",
            "['A hidden gene in astroviruses encodes a cell-permeabilizing protein involved in virus release\\tHuman astroviruses are small nonenveloped viruses with positive-sense single-stranded RNA genomes that contain three main open reading frames: ORF1a, ORF1b and ORF2.', 'Astroviruses cause acute gastroenteritis in children worldwide and have been associated with encephalitis and meningitis in immunocompromised individuals.', 'Through comparative genomic analysis of >400 astrovirus sequences, we identified a conserved “ORFX” overlapping the capsid-encoding ORF2 in genogroup I, III and IV astroviruses.', 'ORFX appears to be subject to purifying selection, consistent with it encoding a functional protein product, termed XP.', 'Using ribosome profiling of cells infected with human astrovirus 1, we confirm initiation at the ORFX AUG. XP-knockout astroviruses are strongly attenuated and after passaging can partly restore viral titer via pseudo-reversions, thus demonstrating that XP plays an important role in virus growth.', 'To further investigate XP, we developed an astrovirus replicon system.', 'We demonstrate that XP has only minor effects on RNA replication and structural protein production.', 'Instead, XP associates with the plasma membrane with an extracellular N-terminus topology and promotes efficient virus release.', 'Using two different assays, we show that expression of human or related astrovirus XPs leads to cell permeabilization, suggesting a viroporin-like activity.', 'The discovery of XP advances our knowledge of these important human viruses and opens a new direction of research into astrovirus replication and pathogenesis.']\n",
            "unmatched tags:  [{'entity': 'astrovirus', 'type': 'Virus', 'start': 1586, 'end': 1596}, {'entity': 'cell permeabilization', 'type': 'Chemical', 'start': 1406, 'end': 1427}, {'entity': 'astrovirus', 'type': 'Virus', 'start': 1382, 'end': 1392}, {'entity': 'structural protein production', 'type': 'Gene', 'start': 1151, 'end': 1180}, {'entity': 'RNA', 'type': 'Gene', 'start': 1131, 'end': 1134}, {'entity': 'astrovirus', 'type': 'Virus', 'start': 1054, 'end': 1064}, {'entity': 'astroviruses', 'type': 'Virus', 'start': 832, 'end': 844}, {'entity': 'ORFX', 'type': 'Gene', 'start': 810, 'end': 814}, {'entity': 'astrovirus', 'type': 'Virus', 'start': 767, 'end': 777}]\n",
            "['Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial\\tVaccination of pregnant women with trivalent inactivated influenza vaccine in Mali—a poorly resourced country with high infant mortality—was technically and logistically feasible and protected infants from laboratory-confirmed influenza for 4 months.', 'With adequate financing to procure the vaccine, implementation will parallel the access to antenatal care and immunisation coverage of pregnant women with tetanus toxoid.']\n",
            "unmatched tags:  [{'entity': 'tetanus toxoid', 'type': 'Gene', 'start': 596, 'end': 610}, {'entity': 'vaccine', 'type': 'Drug', 'start': 480, 'end': 487}, {'entity': 'influenza', 'type': 'Disease', 'start': 417, 'end': 426}, {'entity': 'vaccine', 'type': 'Drug', 'start': 257, 'end': 264}]\n",
            "['Prostate cancer diagnosis and management\\tProstate cancer is the most common cancer in men in many western countries, and the second leading cause of cancer deaths in men.', 'The number of deaths is likely to continue rising over the next 10 to 15 years.', 'In the USA, prostate cancer is estimated to cost $1·5 billion per year in direct medical expenses.', 'In addition to the burden of suffering, therefore, it is a major public-health issue.', 'The aetiology is unknown, though racial and geographical differences, dietary fat, and hereditary factors are all implicated.']\n",
            "unmatched tags:  [{'entity': 'dietary fat', 'type': 'Drug', 'start': 506, 'end': 517}]\n",
            "['Invoking human rights to reduce maternal deaths\\tMaternal health is one of the most neglected issues of our time, especially in the developing world, where the UN estimates that every year, nearly half a million women die from mostly preventable, pregnancy-related causes.', 'By contrast with treatment for HIV/AIDS, human rights are only just beginning to be applied to safe motherhood.', 'In this article, we describe how human rights are being invoked, nationally and internationally, to encourage governments to promote the human rights of women during pregnancy and childbirth.']\n",
            "unmatched tags:  [{'entity': 'governments', 'type': 'Organization', 'start': 494, 'end': 505}]\n",
            "[\"The production and use of cells as therapeutic agents in neurodegenerative diseases\\tAlthough progressive neurodegenerative diseases have very different and highly specific causes, the dysfunction or loss of a vulnerable group of neurons is common to all these disorders and may allow the development of similar therapeutic approaches to the treatment of diseases such as amyotrophic lateral sclerosis, Parkinson's disease, and Huntington's disease.\", 'When a disease is diagnosed, the first step is to instigate protective measures to prevent further degeneration.', 'However, most patients are symptom-free until almost all of the vulnerable cells have become dysfunctional or have died.']\n",
            "unmatched tags:  [{'entity': 'dysfunction', 'type': 'Disease', 'start': 655, 'end': 666}, {'entity': \"Huntington's disease\", 'type': 'Disease', 'start': 427, 'end': 447}, {'entity': \"Parkinson's disease\", 'type': 'Disease', 'start': 402, 'end': 421}, {'entity': 'amyotrophic lateral sclerosis', 'type': 'Disease', 'start': 371, 'end': 400}, {'entity': 'diseases', 'type': 'Disease', 'start': 354, 'end': 362}]\n",
            "['Definition of intervention points in prediabetes\\tWith respect to clinical phenotype and pathophysiology, prediabetes is akin to diabetes.', 'Prediabetes is prevalent in the global population, and those affected are at high risk of progression to overt diabetes, and also at risk of cardiovascular disease (CVD).', 'Progression to diabetes can occur because of worsening insulin resistance, β-cell dysfunction, or both, but the timecourse can be non-linear and, therefore, unpredictable.', 'Intervention—by lifestyle modification, glucose-lowering drugs, or a combination—can postpone deterioration of glucose control, but effects of intervention are variable and can be transient.']\n",
            "unmatched tags:  [{'entity': 'glucose control', 'type': 'Chemical', 'start': 592, 'end': 607}, {'entity': 'diabetes', 'type': 'Disease', 'start': 324, 'end': 332}, {'entity': 'CVD', 'type': 'Disease', 'start': 303, 'end': 306}, {'entity': 'cardiovascular disease', 'type': 'Disease', 'start': 279, 'end': 301}, {'entity': 'diabetes', 'type': 'Disease', 'start': 249, 'end': 257}]\n",
            "['4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease\\tA genetic predisposition to produce high concentrations of PAI-1 is associated with poor outcome of meningococcal sepsis.', 'This finding suggests that impaired fibrinolysis is an important factor in the pathophysiology of meningococcal sepsis.']\n",
            "unmatched tags:  [{'entity': 'meningococcal sepsis', 'type': 'Disease', 'start': 331, 'end': 351}, {'entity': 'meningococcal sepsis', 'type': 'Disease', 'start': 211, 'end': 231}, {'entity': 'PAI-1', 'type': 'Gene', 'start': 170, 'end': 175}]\n",
            "['Ovarian ageing, follicle depletion, and cancer: a hypothesis for the aetiology of epithelial ovarian cancer involving follicle depletion\\tThe association between ovarian cancer risk and reproductive factors has been well established, and two main theories, incessant ovulation and gonadotropin stimulation, have been proposed to explain the mechanism.', 'Recent studies using animal models of ovarian tumorigenesis, and analysis of ovarian tissues from prophylactic oophorectomies, suggest that depletion of ovarian follicles might underlie the epidemiological findings linking reproductive history and ovarian cancer risk.']\n",
            "unmatched tags:  [{'entity': 'ovarian cancer', 'type': 'Disease', 'start': 599, 'end': 613}, {'entity': 'ovarian tumorigenesis', 'type': 'Disease', 'start': 389, 'end': 410}]\n",
            "['30 years of second-generation antiseizure medications: impact and future perspectives\\tSince 1989, 18 second-generation antiseizure medications have reached the market, resulting in a greatly increased range of treatment options for patients and prescribers.', '30 years have passed and now is the time for an appraisal of the effect of these medications on clinical outcomes.', 'Every antiseizure medication needs to be assessed individually, but overall second-generation drugs are less likely to cause pharmacokinetic interactions than their older counterparts.', 'Some second-generation antiseizure medications have shown advantages in tolerability and safety, particularly in the treatment of older patients and women of childbearing potential.']\n",
            "unmatched tags:  [{'entity': 'antiseizure medication', 'type': 'Phenotype', 'start': 581, 'end': 603}, {'entity': 'second-generation', 'type': 'Drug', 'start': 563, 'end': 580}, {'entity': 'second-generation drugs', 'type': 'Drug', 'start': 449, 'end': 472}, {'entity': 'antiseizure medication', 'type': 'Phenotype', 'start': 379, 'end': 401}, {'entity': 'medications', 'type': 'Drug', 'start': 339, 'end': 350}, {'entity': 'medications', 'type': 'Drug', 'start': 131, 'end': 142}]\n",
            "['Frequency of protein Z deficiency in patients with ischaemic stroke\\tProthrombotic phenotype has been described in protein- Z deficient mice, but the thrombotic risk associated with protein Z deficiency in human beings is unknown.', 'We saw a protein Z plasma concentration deficiency of about 20% in 169 patients, from two hospitals, who had ischaemic stroke, whereas the frequency in 88 controls was about 5%.', 'We saw no increase in the frequency of protein Z deficiency in 56 patients with venous thrombophilia.', 'However, why protein Z deficiency was only observed in arterial thrombosis remains unknown.']\n",
            "unmatched tags:  [{'entity': 'deficiency', 'type': 'Disease', 'start': 533, 'end': 543}, {'entity': 'protein Z deficiency', 'type': 'Disease', 'start': 523, 'end': 543}, {'entity': 'venous thrombophilia', 'type': 'Disease', 'start': 488, 'end': 508}, {'entity': 'protein Z deficiency', 'type': 'Disease', 'start': 447, 'end': 467}]\n",
            "['Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population\\tPeople living with HIV have significantly lower HRQoL than do the general population, despite most HIV positive individuals in this study being virologically and immunologically stable.', 'Although this difference could in part be due to factors other than HIV, this study provides additional evidence of the loss of health that can be avoided through prevention of further HIV infections.']\n",
            "unmatched tags:  [{'entity': 'HIV infections', 'type': 'Disease', 'start': 530, 'end': 544}, {'entity': 'HIV', 'type': 'Virus', 'start': 413, 'end': 416}, {'entity': 'HIV', 'type': 'Virus', 'start': 258, 'end': 261}, {'entity': 'era', 'type': 'Gene', 'start': 228, 'end': 231}, {'entity': 'HIV', 'type': 'Virus', 'start': 178, 'end': 181}]\n",
            "['Self-assembled Star-shaped Chiroplasmonic Gold Nanoparticles for Ultrasensitive Chiro-immunosensor of Viruses\\tNear field optics and optical tunneling light-matter interaction in the superstructure of chiral nanostructures and semiconductor quantum dots exhibit strong optical rotation activity that may open a new window for chiral-based bioanalytes detection.', 'Herein we report an ultrasensitive, chiro-immunosensor using superstructure of chiral gold nanohybrids (CAu NPs) and quantum dots (QDs).', 'Self-assembling techniques were employed to create asymmetric plasmonic chiral nanostructures for extending the spectral range of circular dichroism (CD) response for obtaining superior plasmonic resonant coupling with the QDs excitonic state; this may help to achieve lower the limit of detection (LOD) values.', 'As a result, the designed probe exhibited avian influenza A (H5N1) viral concentration at picomolar level, a significant improvement in sensitivity in comparison to a non-assembled CAu NPs based chiroassay.', 'The practicability of the proposed sensing system was successfully demonstrated on several virus cultures including, avian influenza A (H4N6) virus, fowl adenovirus and coronavirus in blood samples.', 'The results of our study highlights that exciton-plasmon interaction changes chirality and the self-assembled nanostructures are an efficient strategy for enhancing the sensitivity of plasmonic nanosensors.']\n",
            "unmatched tags:  [{'entity': 'coronavirus', 'type': 'Virus', 'start': 1186, 'end': 1197}, {'entity': 'fowl adenovirus', 'type': 'Virus', 'start': 1166, 'end': 1181}]\n",
            "['Leptomeningeal malignancy of childhood: sharing learning between childhood leukaemia and brain tumour trials\\tLeptomeningeal malignancy complicates childhood cancers, including leukaemias, brain tumours, and solid tumours.', 'In leukaemia, such malignancy is thought to invade leptomeninges via the vascular route.', 'In brain tumours, dissemination from the primary tumour, before or after surgery, via CSF pathways is assumed; however, evidence exists to support the vascular route of dissemination.', 'Success in treating leptomeningeal malignancy represents a rate-limiting step to cure, which has been successfully overcome in leukaemia with intensified systemic therapy combined with intra-CSF therapy, which replaced cranial radiotherapy for many patients.']\n",
            "unmatched tags:  [{'entity': 'leukaemia', 'type': 'Disease', 'start': 622, 'end': 631}, {'entity': 'leptomeningeal malignancy', 'type': 'Disease', 'start': 515, 'end': 540}, {'entity': 'primary tumour', 'type': 'Disease', 'start': 352, 'end': 366}, {'entity': 'brain tumours', 'type': 'Disease', 'start': 314, 'end': 327}, {'entity': 'malignancy', 'type': 'Disease', 'start': 241, 'end': 251}, {'entity': 'leukaemia', 'type': 'Disease', 'start': 225, 'end': 234}, {'entity': 'solid tumours', 'type': 'Disease', 'start': 207, 'end': 220}, {'entity': 'brain tumours', 'type': 'Disease', 'start': 188, 'end': 201}, {'entity': 'leukaemias', 'type': 'Disease', 'start': 176, 'end': 186}]\n",
            "['Mechanisms of glutamate toxicity in multiple sclerosis: biomarker and therapeutic opportunities\\tResearch advances support the idea that excessive activation of the glutamatergic pathway plays an important part in the pathophysiology of multiple sclerosis.', 'Beyond the well established direct toxic effects on neurons, additional sites of glutamate-induced cell damage have been described, including effects in oligodendrocytes, astrocytes, endothelial cells, and immune cells.', 'Such toxic effects could provide a link between various pathological aspects of multiple sclerosis, such as axonal damage, oligodendrocyte cell death, demyelination, autoimmunity, and blood–brain barrier dysfunction.']\n",
            "unmatched tags:  [{'entity': 'dysfunction', 'type': 'Disease', 'start': 680, 'end': 691}]\n",
            "['Trends and mortality effects of vitamin A deficiency in children in 138 low-income and middle-income countries between 1991 and 2013: a pooled analysis of population-based surveys\\tVitamin A deficiency remains prevalent in south Asia and sub-Saharan Africa.', 'Deaths attributable to this deficiency have decreased over time worldwide, and have been almost eliminated in regions other than south Asia and sub-Saharan Africa.', \"This new evidence for both prevalence and absolute burden of vitamin A deficiency should be used to reconsider, and possibly revise, the list of priority countries for high-dose vitamin A supplementation such that a country's priority status takes into account both the prevalence of deficiency and the expected mortality benefits of supplementation.\"]\n",
            "unmatched tags:  [{'entity': 'deficiency', 'type': 'Disease', 'start': 705, 'end': 715}]\n",
            "['Oral diseases: a global public health challenge\\tOral diseases are among the most prevalent diseases globally and have serious health and economic burdens, greatly reducing quality of life for those affected.', 'The most prevalent and consequential oral diseases globally are dental caries (tooth decay), periodontal disease, tooth loss, and cancers of the lips and oral cavity.', 'In this first of two papers in a Series on oral health, we describe the scope of the global oral disease epidemic, its origins in terms of social and commercial determinants, and its costs in terms of population wellbeing and societal impact.']\n",
            "unmatched tags:  [{'entity': 'global oral disease', 'type': 'Disease', 'start': 460, 'end': 479}, {'entity': 'cancers', 'type': 'Disease', 'start': 338, 'end': 345}, {'entity': 'periodontal disease', 'type': 'Disease', 'start': 301, 'end': 320}, {'entity': 'tooth decay', 'type': 'Disease', 'start': 287, 'end': 298}, {'entity': 'dental caries', 'type': 'Disease', 'start': 272, 'end': 285}]\n",
            "['Psychiatric comorbidities in alcohol use disorder\\tAlcohol use disorder is a major contributor to the morbidity and mortality burden worldwide.', 'It often coexists with other psychiatric disorders; however, the nature of this comorbidity is still a matter of debate.', 'In this Series paper, we examine the main psychiatric disorders associated with alcohol use disorder, including the prevalence of co-occurring disorders, the temporal nature of the relationship, and mechanisms that might explain comorbidity across the lifespan.', 'Overall, this disorder co-occurs with a wide range of other psychiatric disorders, especially those disorders involving substance use and violent or aggressive behaviour.']\n",
            "unmatched tags:  [{'entity': 'violent', 'type': 'Disease', 'start': 664, 'end': 671}, {'entity': 'disorders', 'type': 'Disease', 'start': 626, 'end': 635}, {'entity': 'disorders', 'type': 'Disease', 'start': 598, 'end': 607}, {'entity': 'psychiatric disorders', 'type': 'Disease', 'start': 586, 'end': 607}, {'entity': 'disorders', 'type': 'Disease', 'start': 407, 'end': 416}]\n",
            "['Estimating the total incidence of global childhood cancer: a simulation-based analysis\\tChildhood cancer is substantially underdiagnosed, especially in south Asia and sub-Saharan Africa (including western, eastern, and southern Africa).', 'In addition to improving treatment for childhood cancer, health systems must be strengthened to accurately diagnose and effectively care for all children with cancer.', 'As countries expand universal health coverage, these estimates of total incidence will hopefully help guide efforts to appropriately increase health system capacity to ensure access to effective childhood cancer care.']\n",
            "unmatched tags:  [{'entity': 'childhood cancer', 'type': 'Disease', 'start': 598, 'end': 614}]\n",
            "['Promoting protection and pleasure: amplifying the effectiveness of barriers against sexually transmitted infections and pregnancy\\tThe global burden of morbidity and mortality associated with sexually transmitted infection (STI) and unwanted pregnancy is a prominent global public-health issue.', 'For example, HIV/AIDS and other STI cause 12·9% of the burden of disease in disability-adjusted life years.']\n",
            "unmatched tags:  [{'entity': 'STI', 'type': 'Disease', 'start': 326, 'end': 329}, {'entity': 'HIV/AIDS', 'type': 'Disease', 'start': 307, 'end': 315}, {'entity': 'global public-health', 'type': 'Chemical', 'start': 266, 'end': 286}, {'entity': 'STI', 'type': 'Disease', 'start': 223, 'end': 226}]\n",
            "['Severe disseminated tuberculosis in HIV-negative refugees\\tIn high-income countries, the presentation of tuberculosis is changing, primarily because of migration, and understanding the specific health needs of susceptible populations is becoming increasingly important.', 'Although disseminated tuberculosis is well documented in HIV-positive patients, the disease is poorly described and less expected in HIV-negative individuals.', 'In this Grand Round, we report eight HIV-negative refugees, who presented with extensively disseminated tuberculosis.', 'We discuss the multifactorial causes, such as deprivations during long journeys, precarious living conditions, and the experience of violence, which might add to nutritional factors and chronic disorders, eventually resulting in a state of predisposition to immune deficiency.']\n",
            "unmatched tags:  [{'entity': 'immune deficiency', 'type': 'Disease', 'start': 804, 'end': 821}, {'entity': 'chronic disorders', 'type': 'Disease', 'start': 732, 'end': 749}, {'entity': 'violence', 'type': 'Disease', 'start': 679, 'end': 687}]\n",
            "['Lipidome profiles of postnatal day 2 vaginal swabs reflect fat composition of gilt’s postnatal diet\\tWe hypothesized that postnatal development of the vagina is impacted by early nutritional environment.', 'Our objective was to determine if lipid profiles of vaginal swabs were different between gilts suckled by sow or fed milk replacer the first 48 h postpartum, with and without a lard-based fat supplement.', 'Gilts (>1.3 kg) were selected at birth across 8 litters and assigned to treatments: colostrum suckled (S, n=8); S plus fat supplement (SF, n=5); bottle-fed milk replacer (B, n=8); or B plus fat supplement (BF, n=7).', 'At 48 h postnatal, vaginal swabs were taken with a cytology brush, immersed in ultrapure water to burst cells, and lipids extracted for analysis using multiple reaction monitoring (MRM)-profiling.', 'Lipids extracted from serum collected at 48 h from gilts and milk collected from sows at 24 h were also analyzed with MRM-profiling.', 'Receiver operating characteristic curve analysis found 18 lipids highly distinguished [area-under-the-curve (AUC) > 0.9] between S and B gilts, including phosphatidylethanolamine with 34 carbon and four unsaturations in the fatty acyl residues [PE(34:4)].', 'Twelve lipids from vaginal swabs highly correlated ( r > 0.6; p < 0.01) with nutrition source.', 'Lipids more abundant in milk replacer drove association.', 'For example, mean intensity of PE (34:4) was 149-fold higher in milk replacer than colostrum, with 1.6- and 2.12-fold higher levels in serum and vaginal swab samples ( p < 0.001), respectively, of B versus S gilts.', 'Findings support that vaginal swabs can be used to noninvasively study effects of perinatal nutrition on tissue composition.', 'Summary sentence Vaginal swab lipidome profiles at 48 h reflect the fat composition of neonatal diet during first two days postnatal.']\n",
            "unmatched tags:  [{'entity': 'fat', 'type': 'Drug', 'start': 1769, 'end': 1772}]\n",
            "['Stroke prevention in atrial fibrillation\\tAtrial fibrillation is found in a third of all ischaemic strokes, even more after post-stroke atrial fibrillation monitoring.', 'Data from stroke registries show that both unknown and untreated or under treated atrial fibrillation is responsible for most of these strokes, which are often fatal or debilitating.', 'Most could be prevented if efforts were directed towards detection of atrial fibrillation before stroke occurs, through screening or case finding, and treatment of all patients with atrial fibrillation at increased risk of stroke with well-controlled vitamin K antagonists or non-vitamin K antagonist anticoagulants.']\n",
            "unmatched tags:  [{'entity': 'vitamin K antagonists', 'type': 'Drug', 'start': 601, 'end': 622}, {'entity': 'stroke', 'type': 'Disease', 'start': 573, 'end': 579}, {'entity': 'stroke', 'type': 'Disease', 'start': 447, 'end': 453}, {'entity': 'debilitating', 'type': 'Phenotype', 'start': 336, 'end': 348}]\n",
            "['Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial\\tThere is no evidence for a difference in efficacy and safety between epinephrine alone and norepinephrine plus dobutamine for the management of septic shock.']\n",
            "unmatched tags:  [{'entity': 'dobutamine', 'type': 'Drug', 'start': 218, 'end': 228}, {'entity': 'epinephrine', 'type': 'Drug', 'start': 201, 'end': 212}, {'entity': 'epinephrine', 'type': 'Drug', 'start': 176, 'end': 187}]\n",
            "['Care of diabetes in children and adolescents: controversies, changes, and consensus\\tDiabetes is one of the most common chronic medical disorders in children.', 'The management of diabetes remains a substantial burden on children with diabetes and their families, despite improvements in treatment and rates of morbidity and mortality.', 'Although most children with diabetes have type 1 diabetes, the increasing recognition of type 2 diabetes and genetic forms of diabetes in the paediatric population has important treatment implications.', 'Diabetes therapy focuses strongly on targets for good metabolic control to reduce the risk of long-term complications.']\n",
            "unmatched tags:  [{'entity': 'Diabetes', 'type': 'Disease', 'start': 534, 'end': 542}]\n",
            "['Full-length genome sequence of segmented RNA virus from ticks was obtained using small RNA sequencing data\\tIn 2014, A novel tick-borne virus of the genus Flavivirus was first reported from the Mogiana region in Brazil.', 'This virus was named the Mogiana tick virus (MGTV).', 'Later, MGTV was also named as Jingmen tick virus (JMTV), Kindia tick virus (KDTV), Guangxi tick virus (GXTV) etc.', 'In the present study, we used small RNA sequencing (sRNA-seq) to detect viruses in ticks and detected MGTV in Amblyomma testudinarium ticks, which had been captured in Yunnan province of China in the year of 2016.', 'The full-length genome sequence of a new MGTV strain Yunnan2016 (GenBank: MT080097 , MT080098 , MT080099 and MT080100 ) was obtained and recommended to be included into the NCBI RefSeq database for the future studies of MGTV.', 'Our phylogenetic analyses showed that viruses named MGTV, JMTV, KDTV and GXTV are monophyletic: the MGTV group (lineage) of viruses.', 'We show, for the first time, that 5′ and 3′ sRNAs can be used to obtain full-length sequences of the 5’ and 3’ ends of, but not limited to genome sequences of RNA viruses.', 'And we proved the feasibility of using the sRNA-seq based method for the detection of viruses in a sample containing miniscule RNA.']\n",
            "unmatched tags:  [{'entity': 'RNA', 'type': 'Gene', 'start': 1257, 'end': 1260}]\n",
            "['Computational prediction and\\tThe toxic manifestations of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), an environmental contaminant, primarily depend on its ability to activate aryl hydrocarbon receptor (AhR), which is a ligand-dependent transcription factor belonging to the superfamily of basic-helix-loop-helix DNA-binding proteins.', 'In the present study, we aimed to identify novel protein receptor targets for TCDD using computational and in vitro validation experiments.', 'Interestingly, results from computational methods predicted that Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) could be one of the potential targets for TCDD in both mouse and humans.', 'Results from molecular docking studies showed that human VEGFR1 (hVEGFR1) has less affinity towards TCDD compared to the mouse VEGFR1 (mVEGFR1).', 'In vitro validation results showed that TCDD can bind and phosphorylate hVEGFR1.', 'Further, results from molecular dynamic simulation studies showed that hVEGFR1 interaction with TCDD is stable throughout the simulation time.', 'Overall, the present study has identified VEGFR1 as a novel target for TCDD, which provides the basis for further elucidating the role of TCDD in angiogenesis.']\n",
            "unmatched tags:  [{'entity': 'TCDD', 'type': 'Drug', 'start': 1174, 'end': 1178}, {'entity': 'TCDD', 'type': 'Drug', 'start': 1107, 'end': 1111}, {'entity': 'VEGFR1', 'type': 'Gene', 'start': 1078, 'end': 1084}, {'entity': 'TCDD', 'type': 'Drug', 'start': 989, 'end': 993}]\n",
            "['Significant expression of FURIN and ACE2 on oral epithelial cells may facilitate the efficiency of SARS-CoV-2 entry\\tBackground Leading to a sustained epidemic spread with >2,000,000 confirmed human infections, including >100,000 deaths, COVID-19 was caused by SARS-CoV-2 and resulted in acute respiratory distress syndrome (ARDS) and sepsis, which brought more challenges to the patient’s treatment.', 'The S-glycoprotein, which recognized as the key factor for the entry of SARS-CoV-2 into the cell, contains two functional domains: an ACE2 receptor binding domain and a second domain necessary for fusion of the coronavirus and cell membranes.', 'FURIN activity, exposes the binding and fusion domains, is essential for the zoonotic transmission of SARS-CoV-2.', 'Moreover, it has been reported that ACE2 is likely to be the receptor for SARS-CoV-2.', 'In addition, FURIN enzyme and ACE2 receptor were expressed in airway epithelia, cardiac tissue, and enteric canals, which considered as the potential target organ of the virus.', 'However, report about the expression of FURIN and ACE2 in oral tissues was limited.', 'Methods In order to investigate the potential infective channel of new coronavirus in oral cavity, we analyze the expression of ACE2 and FURIN that mediate the new coronavirus entry into host cells in oral mucosa using the public single-cell sequence datasets.', 'Furthermore, immunohistochemical staining experiment was performed to confirm the expression of ACE2 and FURIN in the protein level.', 'Results The bioinformatics results indicated the differential expression of ACE2 and FURIN on epithelial cells of different oral mucosal tissues and the proportion of FURIN-positive cells was obviously higher than that of ACE2-positive cells.', 'IHC experiments revealed that both the ACE2-positive and FURIN-positive cells in the target tissues were mainly positioned in the epithelial layers, partly expressed in fibroblasts, which further confirm the bioinformatics results.', 'Conclusions Based on these findings, we speculated that SARS-CoV-2 could effectively invade oral mucosal cells though two possible routes: binding to the ACE2 receptor and fusion with cell membrane activated by FURIN protease.', 'Our results indicated that oral mucosa tissues are susceptible to SARS-CoV-2, which provides valuable information for virus-prevention strategy in clinical care as well as daily life.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 2266, 'end': 2276}, {'entity': 'FURIN protease', 'type': 'Gene', 'start': 2184, 'end': 2198}, {'entity': 'cell', 'type': 'Gene', 'start': 2157, 'end': 2161}, {'entity': 'receptor', 'type': 'Gene', 'start': 2132, 'end': 2140}, {'entity': 'ACE2 receptor', 'type': 'Gene', 'start': 2127, 'end': 2140}, {'entity': 'cell', 'type': 'Gene', 'start': 2078, 'end': 2082}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 2029, 'end': 2039}, {'entity': 'cell', 'type': 'Gene', 'start': 1813, 'end': 1817}, {'entity': 'ACE2-positive cells', 'type': 'Gene', 'start': 1720, 'end': 1739}, {'entity': 'cell', 'type': 'Gene', 'start': 1680, 'end': 1684}, {'entity': 'cell', 'type': 'Gene', 'start': 1603, 'end': 1607}, {'entity': 'FURIN', 'type': 'Gene', 'start': 1583, 'end': 1588}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1574, 'end': 1578}, {'entity': 'FURIN', 'type': 'Gene', 'start': 1470, 'end': 1475}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1461, 'end': 1465}, {'entity': 'cell', 'type': 'Gene', 'start': 1341, 'end': 1345}, {'entity': 'cell', 'type': 'Gene', 'start': 1296, 'end': 1300}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 1268, 'end': 1279}, {'entity': 'FURIN', 'type': 'Gene', 'start': 1241, 'end': 1246}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1232, 'end': 1236}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 1175, 'end': 1186}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1070, 'end': 1074}, {'entity': 'FURIN', 'type': 'Gene', 'start': 1060, 'end': 1065}, {'entity': 'ACE2 receptor', 'type': 'Gene', 'start': 873, 'end': 886}, {'entity': 'enzyme', 'type': 'Gene', 'start': 862, 'end': 868}, {'entity': 'FURIN', 'type': 'Gene', 'start': 856, 'end': 861}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 831, 'end': 841}, {'entity': 'receptor', 'type': 'Gene', 'start': 818, 'end': 826}, {'entity': 'ACE2', 'type': 'Gene', 'start': 793, 'end': 797}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 745, 'end': 755}, {'entity': 'FURIN', 'type': 'Gene', 'start': 643, 'end': 648}, {'entity': 'cell', 'type': 'Gene', 'start': 627, 'end': 631}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 611, 'end': 622}, {'entity': 'ACE2 receptor', 'type': 'Gene', 'start': 534, 'end': 547}, {'entity': 'cell', 'type': 'Gene', 'start': 492, 'end': 496}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 472, 'end': 482}, {'entity': 'S-glycoprotein', 'type': 'Gene', 'start': 404, 'end': 418}, {'entity': 'sepsis', 'type': 'Disease', 'start': 334, 'end': 340}, {'entity': 'ARDS', 'type': 'Disease', 'start': 324, 'end': 328}, {'entity': 'acute respiratory distress syndrome', 'type': 'Phenotype', 'start': 287, 'end': 322}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 260, 'end': 270}]\n",
            "['Chasing the ghost of infection past: identifying thresholds of change during the COVID-19 infection in Spain\\tCOVID-19 pandemic has spread worldwide rapidly from its first outbreak in China, with different impacts depending on the age and social structure of the populations, and the measures taken by each government.', 'Within Europe, the first countries to be strongly affected have been Italy and Spain.', 'In Spain, infection has expanded in highly populated areas, resulting in one of the largest nationwide bursts so far by early April.', 'We analyze the evolution of the growth curve of the epidemic in both the whole of Spain and Madrid Autonomous Region (the second largest conurbation in Europe), based on the cumulative numbers of reported cases and deaths.', 'We conducted segmented, linear regressions on log-transformed data to identify changes in the slope of these curves and/or sudden shifts in the number of cases (i.e.', 'changes in the intercept) at fitted breaking points, and compared their results with a timeline including both key events of the epidemic and containment measures taken by the national and regional governments.', 'Results were largely consistent in the four curves analyzed (reported infections and deaths for Spain and Madrid, respectively), showing two major shifts in slopes (growth rates) at 14-15 and 26-29 March that resulted in 37-65% reductions of slope, and originated in infection on 4-5 and 16-18 March (for case detections) and 14-23 February and 5-6 March (for deaths).', 'Small upward shifts in the progress of the disease in Madrid were not associated with significant changes in the intercept of the curve, and seem related with unevenness in case reporting.', 'These results evidence an early deceleration in the spread of COVID-19 coinciding with personal hygiene and social distancing recommendations, as well as the general awareness of the population; and a second, stronger decrease when harder isolation measures were enforced.', 'The combination of both breakpoints seemingly led to the start of the contention of the disease outbreak by early April, the limit of our time series.', 'This highlights the importance of adopting public health strategies that include disseminating basic knowledge on personal hygiene and reduced social contact at the onset of the epidemic, and the importance of early enforcement of hard contention measures for its subsequent contention.']\n",
            "unmatched tags:  [{'entity': 'breakpoints', 'type': 'Gene', 'start': 1992, 'end': 2003}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1757, 'end': 1765}, {'entity': 'intercept', 'type': 'Drug', 'start': 1619, 'end': 1628}, {'entity': 'Madrid', 'type': 'Chemical', 'start': 1560, 'end': 1566}, {'entity': 'Madrid', 'type': 'Chemical', 'start': 1243, 'end': 1249}]\n",
            "['Management of rheumatic diseases in the times of COVID-19 pandemic- perspectives of rheumatology practitioners from India\\tBackground.', 'The Coronavirus disease 19 (COVID-19) pandemic has led to widespread concerns about the risk of infection in patients with rheumatic diseases (RD) receiving disease modifying ant-rheumatic drugs (DMARDs) and other immunosuppressants (IS).', 'Methods.', 'A SurveyMonkey based electronic survey was conducted amongst members of the Indian Rheumatology Association to understand the need for changes in prevailing practices.', 'Results.', 'Of the 861 invitees, 221 responded.', 'In the wake of the pandemic, 47.5% would reduce biological DMARDs (bDMARDs) while only 12.2% would reduce the use of conventional synthetic DMARDs.', '64.2% were likely to defer change in IS, the reluctance being most with rituximab (58.3%) followed by cyclophosphamide (53.3%), anti-tumor necrosis factor alpha agents (52.4%) and Janus kinase inhibitors (34.39%).', 'Hydroxychloroquine was the preferred choice (81.9%) for the treatment of COVID-19 followed by protease inhibitors (22.1%) and intravenous immunoglobulin (8.1%).', 'Chloroquine was less preferred (19%).', 'More than two-thirds (70.5%) believed that  COVID-19 might trigger macrophage activation syndrome.', 'Social distancing (98.1%) and hand hygiene (74.6%) were recommended by majority.', '62.8% would avoid touch for clinical examination whenever feasible.', 'Conclusion.', 'Most rheumatologists perceived the need to change treatment of RDs during the COVID-19 pandemic; reduce immunosuppression and defer the usage of rituximab and bDMARDs.']\n",
            "unmatched tags:  [{'entity': 'DMARDs', 'type': 'Drug', 'start': 1588, 'end': 1594}, {'entity': 'rituximab', 'type': 'Gene', 'start': 1573, 'end': 1582}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1506, 'end': 1514}, {'entity': 'macrophage activation syndrome', 'type': 'Disease', 'start': 1232, 'end': 1262}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1209, 'end': 1217}, {'entity': 'Chloroquine', 'type': 'Drug', 'start': 1127, 'end': 1138}, {'entity': 'intravenous immunoglobulin', 'type': 'Gene', 'start': 1092, 'end': 1118}, {'entity': 'protease inhibitors', 'type': 'Drug', 'start': 1060, 'end': 1079}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1039, 'end': 1047}, {'entity': 'Hydroxychloroquine', 'type': 'Drug', 'start': 966, 'end': 984}, {'entity': 'anti-tumor necrosis factor alpha agents', 'type': 'Drug', 'start': 878, 'end': 917}, {'entity': 'cyclophosphamide', 'type': 'Drug', 'start': 852, 'end': 868}, {'entity': 'rituximab', 'type': 'Gene', 'start': 822, 'end': 831}]\n",
            "['Confronting the threat of bioterrorism: realities, challenges, and defensive strategies\\tGlobal terrorism is a rapidly growing threat to world security, and increases the risk of bioterrorism.', 'In this Review, we discuss the potential threat of bioterrorism, agents that could be exploited, and recent developments in technologies and policy for detecting and controlling epidemics that have been initiated intentionally.', 'The local and international response to infectious disease epidemics, such as the severe acute respiratory syndrome and west African Ebola virus epidemic, revealed serious shortcomings which bioterrorists might exploit when intentionally initiating an epidemic.']\n",
            "unmatched tags:  [{'entity': 'Ebola virus', 'type': 'Virus', 'start': 553, 'end': 564}, {'entity': 'acute respiratory syndrome', 'type': 'Disease', 'start': 509, 'end': 535}, {'entity': 'infectious disease', 'type': 'Disease', 'start': 460, 'end': 478}, {'entity': 'terrorism', 'type': 'Disease', 'start': 246, 'end': 255}, {'entity': 'terrorism', 'type': 'Disease', 'start': 181, 'end': 190}]\n",
            "['Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial\\tThese findings support the concept of neuroprotection with phenytoin in patients with acute optic neuritis at concentrations at which it blocks voltage-gated sodium channels selectively.', 'Further investigation in larger clinical trials in optic neuritis and in relapsing multiple sclerosis is warranted.']\n",
            "unmatched tags:  [{'entity': 'multiple sclerosis', 'type': 'Disease', 'start': 387, 'end': 405}, {'entity': 'optic neuritis', 'type': 'Disease', 'start': 355, 'end': 369}]\n",
            "['Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis\\tThe combination of moxifloxacin, pretomanid, and pyrazinamide, was safe, well tolerated, and showed superior bactericidal activity in drug-susceptible tuberculosis during 8 weeks of treatment.', 'Results were consistent between drug-susceptible and MDR tuberculosis.', 'This new regimen is ready to enter phase 3 trials in patients with drug-susceptible tuberculosis and MDR-tuberculosis, with the goal of shortening and simplifying treatment.']\n",
            "unmatched tags:  [{'entity': 'MDR-tuberculosis', 'type': 'Disease', 'start': 640, 'end': 656}, {'entity': 'tuberculosis', 'type': 'Disease', 'start': 623, 'end': 635}, {'entity': 'tuberculosis', 'type': 'Disease', 'start': 525, 'end': 537}, {'entity': 'tuberculosis', 'type': 'Disease', 'start': 426, 'end': 438}, {'entity': 'pyrazinamide', 'type': 'Drug', 'start': 324, 'end': 336}, {'entity': 'pretomanid', 'type': 'Drug', 'start': 308, 'end': 318}]\n",
            "['Incidence, clinical characteristics and prognostic factor of patients with COVID-19: a systematic review and meta-analysis\\tBackground: Recently, Coronavirus Disease 2019 (COVID-19) outbreak started in Wuhan, China.', 'Although the clinical features of COVID-19 have been reported previously, data regarding the risk factors associated with the clinical outcomes are lacking.', 'Objectives: To summary and analyze the clinical characteristics and identify the predictors of disease severity and mortality.', 'Methods: The PubMed, Web of Science Core Collection, Embase, Cochrane and MedRxiv databases were searched through February 25, 2020.', 'Meta-analysis of Observational Studies in Epidemiology (MOOSE) recommendations were followed.', 'We extracted and pooled data using random-effects meta-analysis to summary the clinical feature of the confirmed COVID-19 patients, and further identify risk factors for disease severity and death.', 'Heterogeneity was evaluated using the I2 method and explained with subgroup analysis and meta-regression.', 'Results: A total of 30 studies including 53000 patients with COVID-19 were included in this study, the mean age was 49.8 years (95% CI, 47.5-52.2 yrs) and 55.5% were male.', 'The pooled incidence of severity and mortality were 20.2% (95% CI, 15.1-25.2%) and 3.1% (95% CI, 1.9-4.2%), respectively.', 'The predictor for disease severity included old age (≥ 50 yrs, odds ratio [OR] = 2.61; 95% CI, 2.29-2.98), male (OR =1.348, 95% CI, 1.195-1.521), smoking (OR =1.734, 95% CI, 1.146-2.626) and any comorbidity (OR = 2.635, 95% CI, 2.098-3.309), especially chronic kidney disease (CKD, OR = 6.017; 95% CI, 2.192-16.514), chronic obstructive pulmonary disease (COPD, OR = 5.323; 95% CI, 2.613-10.847) and cerebrovascular disease (OR = 3.219; 95% CI, 1.486-6.972).', 'In terms of laboratory results, increased lactate dehydrogenase (LDH), C-reactive protein (CRP) and D-dimer and decreased blood platelet and lymphocytes count were highly associated with severe COVID-19 (all for P < 0.001).', 'Meanwhile, old age (≥ 60 yrs, RR = 9.45; 95% CI, 8.09-11.04), followed by cardiovascular disease (RR = 6.75; 95% CI, 5.40-8.43) hypertension (RR = 4.48; 95% CI, 3.69-5.45) and diabetes (RR = 4.43; 95% CI, 3.49-5.61) were found to be independent prognostic factors for the COVID-19 related death.', 'Conclusions: To our knowledge, this is the first evidence-based medicine research to explore the risk factors of prognosis in patients with COVID-19, which is helpful to identify early-stage patients with poor prognosis and adapt effective treatment.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2444, 'end': 2452}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2280, 'end': 2288}, {'entity': 'diabetes', 'type': 'Disease', 'start': 2184, 'end': 2192}, {'entity': 'hypertension', 'type': 'Disease', 'start': 2136, 'end': 2148}, {'entity': 'cardiovascular disease', 'type': 'Disease', 'start': 2082, 'end': 2104}, {'entity': 'yrs', 'type': 'Gene', 'start': 2033, 'end': 2036}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1978, 'end': 1986}, {'entity': 'C-reactive protein', 'type': 'Gene', 'start': 1855, 'end': 1873}, {'entity': 'LDH', 'type': 'Gene', 'start': 1849, 'end': 1852}, {'entity': 'lactate dehydrogenase', 'type': 'Gene', 'start': 1826, 'end': 1847}]\n",
            "[\"Down's syndrome\\tThe sequencing of chromosome 21 and the use of models of Down's syndrome in mice have allowed us to relate genes and sets of genes to the neuropathogenesis of this syndrome, and to better understand its phenotype.\", \"Research in prenatal screening and diagnosis aims to find methods to identify fetuses with Down's syndrome, and reduce or eliminate the need for amniocentesis.\", \"Other areas of active research and clinical interest include the association of Down's syndrome with coeliac disease and Alzheimer's disease, and improved median age of death.\"]\n",
            "unmatched tags:  [{'entity': \"Alzheimer's disease\", 'type': 'Disease', 'start': 511, 'end': 530}, {'entity': 'coeliac disease', 'type': 'Disease', 'start': 491, 'end': 506}, {'entity': 'syndrome', 'type': 'Disease', 'start': 477, 'end': 485}, {'entity': \"Down's syndrome\", 'type': 'Disease', 'start': 470, 'end': 485}, {'entity': \"Down's syndrome\", 'type': 'Disease', 'start': 321, 'end': 336}, {'entity': 'syndrome', 'type': 'Disease', 'start': 180, 'end': 188}, {'entity': 'neuropathogenesis', 'type': 'Disease', 'start': 154, 'end': 171}]\n",
            "['CAR T-cell product performance in haematological malignancies before and after marketing authorisation\\tChimeric antigen receptor (CAR) T cells represent a potent new approach to treat haematological malignancies.', 'Two CAR T-cell therapies, tisagenlecleucel and axicabtagene ciloleucel, have been approved in Europe and the USA, as well as several other countries, for the treatment of leukaemia and lymphoma.', 'These approvals marked a major milestone in the field of cell and gene therapies.', 'However, the clinical development and regulatory evaluation of these innovative therapies faced several challenges that are considered important lessons learned for future similar products.']\n",
            "unmatched tags:  [{'entity': 'cell', 'type': 'Gene', 'start': 465, 'end': 469}, {'entity': 'lymphoma', 'type': 'Disease', 'start': 398, 'end': 406}, {'entity': 'leukaemia', 'type': 'Disease', 'start': 384, 'end': 393}, {'entity': 'axicabtagene ciloleucel', 'type': 'Chemical', 'start': 260, 'end': 283}, {'entity': 'cell', 'type': 'Gene', 'start': 223, 'end': 227}]\n",
            "['MERS-CoV NSP16 necessary for IFN resistance and viral pathogenesis\\tCoronaviruses encode a mix of highly conserved and novel genes as well as genetic elements necessary for infection and pathogenesis, raising the possibility for common targets for attenuation and therapeutic design.', 'In this study, we focus on the highly conserved nonstructural protein (NSP) 16, a viral 2’O methyl-transferase (MTase) that encodes critical functions in immune modulation and infection.', 'Using reverse genetics, we disrupted a key motif in the conserved KDKE motif of MERS NSP16 (D130A) and evaluated the effect on viral infection and pathogenesis.', 'While the absence of 2’O MTase activity had only marginal impact on propagation and replication in Vero cells, the MERS dNSP16 mutant demonstrated significant attenuation relative to control both in primary human airway cultures and in vivo.', 'Further examination indicated the MERS dNSP16 mutant had a type I IFN based attenuation and was partially restored in the absence of IFIT molecules.', 'Importantly, the robust attenuation permitted use of MERS dNSP16 as a live attenuated vaccine platform protecting from challenge with a mouse adapted MERS-CoV strain.', 'These studies demonstrate the importance of the conserved 2’O MTase activity for CoV pathogenesis and highlight NSP16 as a conserved universal target for rapid live attenuated vaccine design in an expanding CoV outbreak setting.', 'Significance Coronavirus emergence in both human and livestock represents a significant threat to global public health, as evidenced by the sudden emergence of SARS-CoV, MERS-CoV, PEDV and swine delta coronavirus in the 21 st century.', 'These studies describe an approach that effectively targets the highly conserved 2’O methyl-transferase activity of coronaviruses for attenuation.', 'With clear understanding of the IFN/IFIT based mechanism, NSP16 mutants provide a suitable target for a live attenuated vaccine platform as well as therapeutic development for both current and future emergent CoV strains.', 'Importantly, other approaches targeting other conserved pan-coronavirus functions have not yet proven effective against MERS-CoV, illustrating the broad applicability of targeting viral 2’O MTase function across coronaviruses.']\n",
            "unmatched tags:  [{'entity': 'coronaviruses', 'type': 'Virus', 'start': 2234, 'end': 2247}, {'entity': 'MTase', 'type': 'Gene', 'start': 2212, 'end': 2217}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 2142, 'end': 2150}, {'entity': 'pan-coronavirus', 'type': 'Virus', 'start': 2078, 'end': 2093}, {'entity': 'CoV', 'type': 'Virus', 'start': 2009, 'end': 2012}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1920, 'end': 1927}, {'entity': 'NSP16', 'type': 'Gene', 'start': 1858, 'end': 1863}, {'entity': 'IFIT', 'type': 'Gene', 'start': 1836, 'end': 1840}, {'entity': 'IFN', 'type': 'Gene', 'start': 1832, 'end': 1835}, {'entity': 'coronaviruses', 'type': 'Virus', 'start': 1769, 'end': 1782}, {'entity': 'swine delta coronavirus', 'type': 'Virus', 'start': 1607, 'end': 1630}, {'entity': 'PEDV', 'type': 'Virus', 'start': 1598, 'end': 1602}, {'entity': 'CoV', 'type': 'Virus', 'start': 1593, 'end': 1596}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 1588, 'end': 1596}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 1578, 'end': 1586}, {'entity': 'Coronavirus', 'type': 'Virus', 'start': 1431, 'end': 1442}, {'entity': 'CoV', 'type': 'Virus', 'start': 1396, 'end': 1399}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1365, 'end': 1372}, {'entity': 'NSP16', 'type': 'Gene', 'start': 1301, 'end': 1306}, {'entity': 'NSP', 'type': 'Gene', 'start': 1301, 'end': 1304}, {'entity': 'CoV', 'type': 'Virus', 'start': 1270, 'end': 1273}, {'entity': 'MTase', 'type': 'Gene', 'start': 1251, 'end': 1256}, {'entity': 'CoV', 'type': 'Virus', 'start': 1177, 'end': 1180}, {'entity': 'MERS-CoV strain', 'type': 'Virus', 'start': 1172, 'end': 1187}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1108, 'end': 1115}]\n",
            "['Emergency diagnosis and treatment of adult meningitis\\tDespite the existence of antibiotic therapies against acute bacterial meningitis, patients with the disease continue to suffer significant morbidity and mortality in both high and low-income countries.', 'Dilemmas exist for emergency medicine and primary-care providers who need to accurately diagnose patients with bacterial meningitis and then rapidly administer antibiotics and adjunctive therapies for this life-threatening disease.', 'Physical examination may not perform well enough to accurately identify patients with meningitis, and traditionally described lumbar puncture results for viral and bacterial disease cannot always predict bacterial meningitis.']\n",
            "unmatched tags:  [{'entity': 'bacterial meningitis', 'type': 'Disease', 'start': 692, 'end': 712}, {'entity': 'bacterial disease', 'type': 'Disease', 'start': 652, 'end': 669}, {'entity': 'meningitis', 'type': 'Phenotype', 'start': 574, 'end': 584}]\n",
            "['Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study\\tCytomegalovirus viraemia is associated with an increased risk of overall mortality in the first year after haemopoietic stem cell transplantation, independent of the use of pre-emptive therapy, and with evidence of a positive dose-response relationship.', 'These data indicate the suitability of viral load as a surrogate clinical endpoint for clinical trials for cytomegalovirus vaccines, biologics, and drugs.']\n",
            "unmatched tags:  [{'entity': 'cytomegalovirus vaccines', 'type': 'Drug', 'start': 511, 'end': 535}, {'entity': 'era', 'type': 'Gene', 'start': 337, 'end': 340}, {'entity': 'era', 'type': 'Gene', 'start': 217, 'end': 220}, {'entity': 'Cytomegalovirus viraemia', 'type': 'Disease', 'start': 150, 'end': 174}]\n",
            "['SARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donors.', 'It is of paramount importance to evaluate the prevalence of both asymptomatic and symptomatic cases of SARS-CoV-2 infection and their antibody response profile.', 'Here, we performed a pilot study to assess the levels of anti-SARS-CoV-2 antibodies in samples taken from 491 pre- epidemic individuals, 51 patients from Hopital Bichat (Paris), 209 pauci-symptomatic individuals in the French Oise region and 200 contemporary Oise blood donors.', 'Two in-house ELISA assays, that recognize the full-length nucleoprotein (N) or trimeric Spike (S) ectodomain were implemented.', 'We also developed two novel assays: the S-Flow assay, which is based on the recognition of S at the cell surface by flow-cytometry, and the LIPS assay that recognizes diverse antigens (including S1 or N C- terminal domain) by immunoprecipitation.', 'Overall, the results obtained with the four assays were similar, with differences in sensitivity that can be attributed to the technique and the antigen in use.', 'High antibody titers were associated with neutralisation activity, assessed using infectious SARS-CoV- 2 or lentiviral-S pseudotypes.', 'In hospitalized patients, seroconversion and neutralisation occurred on 5-14 days post symptom onset, confirming previous studies.', 'Seropositivity was detected in 29% of pauci-symptomatic individuals within 15 days post-symptoms and 3 % of blood of healthy donors collected in the area of a cluster of COVID cases.', 'Altogether, our assays allow for a broad evaluation of SARS-CoV2 seroprevalence and antibody profiling in different population subsets.']\n",
            "unmatched tags:  [{'entity': 'COVID', 'type': 'Virus', 'start': 1524, 'end': 1529}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 1442, 'end': 1449}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 1398, 'end': 1405}, {'entity': 'Seropositivity', 'type': 'Disease', 'start': 1354, 'end': 1368}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 1310, 'end': 1317}, {'entity': 'post', 'type': 'Gene', 'start': 1305, 'end': 1309}, {'entity': 'SARS-CoV- 2', 'type': 'Virus', 'start': 1182, 'end': 1193}, {'entity': 'S1', 'type': 'Gene', 'start': 876, 'end': 878}, {'entity': 'flow-cytometry', 'type': 'Chemical', 'start': 797, 'end': 811}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 464, 'end': 471}, {'entity': 'Paris', 'type': 'Gene', 'start': 446, 'end': 451}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 197, 'end': 204}]\n",
            "['Genetic analysis of the novel SARS-CoV-2 host receptor TMPRSS2 in different populations.', 'The infection coronavirus disease 2019 (COVID-19) is caused by a virus classified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).', 'At cellular level, virus infection initiates with binding of viral particles to the host surface cellular receptor angiotensin converting enzyme 2 (ACE2).', 'SARS-CoV-2 engages ACE2 as the entry receptor and employs the cellular serine protease 2 (TMPRSS2) for S protein priming.', 'TMPRSS2 activity is essential for viral spread and pathogenesis in the infected host.', 'Understanding how TMPRSS2 protein expression in the lung varies in the population could reveal important insights into differential susceptibility to influenza and coronavirus infections.', 'Here, we systematically analyzed coding-region variants in TMPRSS2 and the eQTL variants, which may affect the gene expression, to compare the genomic characteristics of TMPRSS2 among different populations.', 'Our findings suggest that the lung-specific eQTL variants may confer different susceptibility or response to SARS-CoV-2 infection from different populations under the similar conditions.', 'In particular, we found that the eQTL variant rs35074065 is associated with high expression of TMPRSS2 but with a low expression of the interferon (IFN)-α/β-inducible gene, MX1, splicing isoform.', 'Thus, these subjects could account for a more susceptibility either to viral infection or to a decrease in cellular antiviral response.']\n",
            "unmatched tags:  [{'entity': 'viral infection', 'type': 'Virus', 'start': 1449, 'end': 1464}, {'entity': 'splicing isoform', 'type': 'Gene', 'start': 1360, 'end': 1376}, {'entity': 'MX1', 'type': 'Gene', 'start': 1355, 'end': 1358}, {'entity': 'TMPRSS2', 'type': 'Gene', 'start': 1277, 'end': 1284}, {'entity': 'eQTL', 'type': 'Gene', 'start': 1215, 'end': 1219}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1104, 'end': 1114}, {'entity': 'eQTL', 'type': 'Gene', 'start': 1039, 'end': 1043}, {'entity': 'lung-specific', 'type': 'Gene', 'start': 1025, 'end': 1038}, {'entity': 'TMPRSS2', 'type': 'Gene', 'start': 958, 'end': 965}, {'entity': 'eQTL', 'type': 'Gene', 'start': 863, 'end': 867}, {'entity': 'TMPRSS2', 'type': 'Gene', 'start': 847, 'end': 854}]\n",
            "['Mouse hepatitis virus nsp14 exoribonuclease activity is required for resistance to innate immunity\\tCoronaviruses (CoV) are positive-sense RNA viruses that infect numerous mammalian and avian species and are capable of causing severe and lethal disease in humans.', 'CoVs encode several innate immune antagonists that interact with the host innate immune response to facilitate efficient viral replication.', \"CoV non-structural protein 14 (nsp14) encodes 3'-to-5' exoribonuclease activity (ExoN), which performs a proofreading function and is required for high-fidelity replication.\", 'Outside of the order Nidovirales , arenaviruses are the only RNA viruses that encode an ExoN, which functions to degrade dsRNA replication intermediates.', 'In this study, we tested the hypothesis that CoV ExoN may also function to antagonize the innate immune response.', 'We demonstrate that viruses lacking ExoN activity [ExoN(-)] are sensitive to cellular pretreatment with interferon beta (IFN-β) in a dose-dependent manner.', 'In addition, ExoN(-) virus replication was attenuated in wild-type bone marrow-derived macrophages (BMMs) and partially restored in interferon alpha/beta receptor deficient (IFNAR-/-) BMMs.', 'ExoN(-) virus replication did not result in IFN-β gene expression, and in the presence of an IFN-β-mediated antiviral state, ExoN(-) viral RNA levels were not substantially reduced relative to untreated.', 'However, ExoN(-) virus generated from IFN-β pretreated cells had reduced specific infectivity and decreased relative fitness, suggesting that ExoN(-) virus generated during an antiviral state is less viable to establish a subsequent infection.', 'Overall, our data suggest MHV ExoN activity is required for resistance to the innate immune response and antiviral mechanisms affecting the viral RNA sequence and/or an RNA modification act on viruses lacking ExoN activity.']\n",
            "unmatched tags:  [{'entity': 'ExoN', 'type': 'Gene', 'start': 1848, 'end': 1852}, {'entity': 'RNA', 'type': 'Gene', 'start': 1808, 'end': 1811}, {'entity': 'RNA', 'type': 'Gene', 'start': 1785, 'end': 1788}, {'entity': 'viral RNA', 'type': 'Gene', 'start': 1779, 'end': 1788}, {'entity': 'ExoN', 'type': 'Gene', 'start': 1669, 'end': 1673}, {'entity': 'MHV', 'type': 'Chemical', 'start': 1665, 'end': 1668}, {'entity': 'antiviral state', 'type': 'Drug', 'start': 1571, 'end': 1586}, {'entity': 'ExoN(-)', 'type': 'Gene', 'start': 1537, 'end': 1544}, {'entity': 'IFN-β', 'type': 'Gene', 'start': 1433, 'end': 1438}, {'entity': 'ExoN(-)', 'type': 'Gene', 'start': 1404, 'end': 1411}, {'entity': 'viral RNA', 'type': 'Gene', 'start': 1324, 'end': 1333}, {'entity': 'ExoN(-)', 'type': 'Gene', 'start': 1316, 'end': 1323}, {'entity': 'antiviral state', 'type': 'Drug', 'start': 1299, 'end': 1314}, {'entity': 'IFN-β', 'type': 'Gene', 'start': 1235, 'end': 1240}, {'entity': 'ExoN(-)', 'type': 'Gene', 'start': 1191, 'end': 1198}, {'entity': 'IFNAR-/-', 'type': 'Gene', 'start': 1175, 'end': 1183}, {'entity': 'interferon alpha/beta receptor deficient', 'type': 'Gene', 'start': 1133, 'end': 1173}, {'entity': 'wild-type', 'type': 'Drug', 'start': 1058, 'end': 1067}, {'entity': 'ExoN(-)', 'type': 'Gene', 'start': 1014, 'end': 1021}, {'entity': 'IFN-β', 'type': 'Gene', 'start': 966, 'end': 971}, {'entity': 'interferon beta', 'type': 'Gene', 'start': 949, 'end': 964}, {'entity': 'ExoN(-)', 'type': 'Gene', 'start': 896, 'end': 903}, {'entity': 'ExoN', 'type': 'Gene', 'start': 881, 'end': 885}, {'entity': 'ExoN', 'type': 'Gene', 'start': 780, 'end': 784}]\n",
            "['Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts\\tRecent data for the global burden of disease reflect major demographic and lifestyle changes, leading to a rise in non-communicable diseases.', 'Most countries with high levels of tuberculosis face a large comorbidity burden from both non-communicable and communicable diseases.', 'Traditional disease-specific approaches typically fail to recognise common features and potential synergies in integration of care, management, and control of non-communicable and communicable diseases.', 'In resource-limited countries, the need to tackle a broader range of overlapping comorbid diseases is growing.']\n",
            "unmatched tags:  [{'entity': 'comorbid diseases', 'type': 'Disease', 'start': 682, 'end': 699}, {'entity': 'communicable diseases', 'type': 'Disease', 'start': 578, 'end': 599}, {'entity': 'communicable', 'type': 'Disease', 'start': 561, 'end': 573}, {'entity': 'communicable diseases', 'type': 'Disease', 'start': 375, 'end': 396}, {'entity': 'communicable', 'type': 'Disease', 'start': 358, 'end': 370}]\n",
            "['Guillain-Barré syndrome after exposure to influenza virus\\tGuillain-Barré syndrome (GBS) is an acute, acquired, monophasic autoimmune disorder of peripheral nerves that develops in susceptible individuals after infection and, in rare cases, after immunisation.', 'Exposure to influenza via infection or vaccination has been associated with GBS.', 'We review the relation between GBS and these routes of exposure.', 'Epidemiological studies have shown that, except for the 1976 US national immunisation programme against swine-origin influenza A H1N1 subtype A/NJ/76, influenza vaccine has probably not caused GBS or, if it has, rates have been extremely low (less than one case per million vaccine recipients).']\n",
            "unmatched tags:  [{'entity': 'vaccine', 'type': 'Drug', 'start': 680, 'end': 687}]\n",
            "['Evolving importance of kidney disease: from subspecialty to global health burden\\tIn the past decade, kidney disease diagnosed with objective measures of kidney damage and function has been recognised as a major public health burden.', 'The population prevalence of chronic kidney disease exceeds 10%, and is more than 50% in high-risk subpopulations.', 'Independent of age, sex, ethnic group, and comorbidity, strong, graded, and consistent associations exist between clinical prognosis and two hallmarks of chronic kidney disease: reduced glomerular filtration rate and increased urinary albumin excretion.']\n",
            "unmatched tags:  [{'entity': 'urinary albumin', 'type': 'Gene', 'start': 575, 'end': 590}]\n",
            "['Re-examining causes of surgical site infections following elective surgery in the era of asepsis\\tThe currently accepted assumption that most surgical site infections (SSIs) occurring after elective surgery under standard methods of antisepsis are due to an intraoperative contamination event, remains unproven.', 'We examined the available evidence in which microbial cultures of surgical wounds were taken at the conclusion of an operation and determined that such studies provide more evidence to refute that an SSI is due to intraoperative contamination than support it.', 'We propose that alternative mechanisms of SSI development should be considered, such as when a sterile postoperative wound becomes infected by a pathogen originating from a site remote from the operative wound—eg, from the gums or intestinal tract (ie, the Trojan Horse mechanism).']\n",
            "unmatched tags:  [{'entity': 'Trojan Horse', 'type': 'Chemical', 'start': 828, 'end': 840}, {'entity': 'era', 'type': 'Gene', 'start': 767, 'end': 770}, {'entity': 'era', 'type': 'Gene', 'start': 680, 'end': 683}, {'entity': 'SSI', 'type': 'Gene', 'start': 613, 'end': 616}, {'entity': 'era', 'type': 'Gene', 'start': 532, 'end': 535}, {'entity': 'SSI', 'type': 'Gene', 'start': 511, 'end': 514}, {'entity': 'era', 'type': 'Gene', 'start': 430, 'end': 433}, {'entity': 'surgical wounds', 'type': 'Disease', 'start': 377, 'end': 392}]\n",
            "['Hereditary spherocytosis\\tHereditary spherocytosis is a common inherited disorder that is characterised by anaemia, jaundice, and splenomegaly.', 'It is reported worldwide and is the most common inherited anaemia in individuals of northern European ancestry.', 'Clinical severity is variable with most patients having a well-compensated haemolytic anaemia.', 'Some individuals are asymptomatic, whereas others have severe haemolytic anaemia requiring erythrocyte transfusion.', 'The primary lesion in hereditary spherocytosis is loss of membrane surface area, leading to reduced deformability due to defects in the membrane proteins ankyrin, band 3, β spectrin, α spectrin, or protein 4.2.']\n",
            "unmatched tags:  [{'entity': 'protein', 'type': 'Gene', 'start': 664, 'end': 671}, {'entity': 'membrane proteins ankyrin', 'type': 'Gene', 'start': 602, 'end': 627}, {'entity': 'hereditary spherocytosis', 'type': 'Disease', 'start': 488, 'end': 512}, {'entity': 'primary lesion', 'type': 'Disease', 'start': 470, 'end': 484}]\n",
            "['A database resource for Genome-wide dynamics analysis of Coronaviruses on a historical and global scale\\tThe recent outbreak of a new zoonotic origin Coronavirus has ring the bell for the potential spread of epidemic Coronavirus crossing the species.', 'With the urgent needs to assist the control of the Coronavirus spread and to provide valuable scientific information, we developed a coronavirus database (CoVdb), an online genomics and proteomics analysis platform.', 'Based on public available coronavirus genomic information, the database annotates the genome of every strain and identifies 780 possible ORFs of all strains available in Genebank.', 'In addition, the comprehensive evaluation of all the published genomes of Coronavirus strains, including population genetics analysis, functional analysis and structural analysis on a historical and global scale were presented in the CoVdb.', 'In the database, the researcher can easily obtain the basic information of a Coronavirus gene with the distribution of the gene among strains, conserved or high mutation regions, possible subcellular location and topology of the gene.', 'Moreover, sliding windows for population genetics analysis results is provided, thereby facilitating genetics and evolutional analysis at the genomic level.', 'CoVdb can be accessed freely at http://covdb.popgenetics.net .']\n",
            "unmatched tags:  [{'entity': 'gene', 'type': 'Gene', 'start': 1327, 'end': 1331}, {'entity': 'gene', 'type': 'Gene', 'start': 1223, 'end': 1227}, {'entity': 'gene', 'type': 'Gene', 'start': 1163, 'end': 1167}, {'entity': 'sliding windows', 'type': 'Chemical', 'start': 1132, 'end': 1147}, {'entity': 'gene', 'type': 'Gene', 'start': 1116, 'end': 1120}, {'entity': 'strains', 'type': 'Disease', 'start': 1021, 'end': 1028}, {'entity': 'gene', 'type': 'Gene', 'start': 1010, 'end': 1014}]\n",
            "['Structure of M\\tA new coronavirus (CoV) identified as COVID-19 virus is the etiological agent responsible for the 2019-2020 viral pneumonia outbreak that commenced in Wuhan 1 – 4 .', 'Currently there is no targeted therapeutics and effective treatment options remain very limited.', 'In order to rapidly discover lead compounds for clinical use, we initiated a program of combined structure-assisted drug design, virtual drug screening and high-throughput screening to identify new drug leads that target the COVID-19 virus main protease (M pro ).', 'M pro is a key CoV enzyme, which plays a pivotal role in mediating viral replication and transcription, making it an attractive drug target for this virus 5 , 6 .', 'Here, we identified a mechanism-based inhibitor, N3, by computer-aided drug design and subsequently determined the crystal structure of COVID-19 virus M pro in complex with this compound.', 'Next, through a combination of structure-based virtual and high-throughput screening, we assayed over 10,000 compounds including approved drugs, drug candidates in clinical trials, and other pharmacologically active compounds as inhibitors of M pro .', 'Six of these inhibit M pro with IC 50 values ranging from 0.67 to 21.4 μM.', 'Ebselen also exhibited promising antiviral activity in cell-based assays.', 'Our results demonstrate the efficacy of this screening strategy, which can lead to the rapid discovery of drug leads with clinical potential in response to new infectious diseases where no specific drugs or vaccines are available.']\n",
            "unmatched tags:  [{'entity': 'vaccines', 'type': 'Drug', 'start': 1499, 'end': 1507}, {'entity': 'drug', 'type': 'Drug', 'start': 1490, 'end': 1494}, {'entity': 'infectious diseases', 'type': 'Disease', 'start': 1452, 'end': 1471}, {'entity': 'drug', 'type': 'Drug', 'start': 1398, 'end': 1402}, {'entity': 'screening strategy', 'type': 'Gene', 'start': 1337, 'end': 1355}, {'entity': 'cell-based assays', 'type': 'Gene', 'start': 1273, 'end': 1290}, {'entity': 'Ebselen', 'type': 'Drug', 'start': 1218, 'end': 1225}]\n",
            "['Clinical Characteristics of 24 Asymptomatic Infections with COVID-19 Screened among Close Contacts in Nanjing, China\\tBackground: Previous studies have showed clinical characteristics of patients with the 2019 novel coronavirus disease (COVID-19) and the evidence of person-to-person transmission.', 'Limited data are available for asymptomatic infections.', 'This study aims to present the clinical characteristics of 24 cases with asymptomatic infection screened from close contacts and to show the transmission potential of asymptomatic COVID-19 virus carriers.', 'Methods: Epidemiological investigations were conducted among all close contacts of COVID-19 patients (or suspected patients) in Nanjing, Jiangsu Province, China, from Jan 28 to Feb 9, 2020, both in clinic and in community.', 'Asymptomatic carriers were laboratory-confirmed positive for the COVID-19 virus by testing the nucleic acid of the pharyngeal swab samples.', 'Their clinical records, laboratory assessments, and chest CT scans were reviewed.', 'Findings: None of the 24 asymptomatic cases presented any obvious symptoms before nucleic acid screening.', 'Five cases (20.8%) developed symptoms (fever, cough, fatigue and etc.)', 'during hospitalization.', 'Twelve (50.0%) cases showed typical CT images of ground-glass chest and five (20.8%) presented stripe shadowing in the lungs.', 'The remaining seven (29.2%) cases showed normal CT image and had no symptoms during hospitalization.', 'These seven cases were younger (median age: 14.0 years; P = 0.012) than the rest.', 'None of the 24 cases developed severe COVID-19 pneumonia or died.', 'The median communicable period, defined as the interval from the first day of positive nucleic acid tests to the first day of continuous negative tests, was 9.5 days (up to 21 days among the 24 asymptomatic cases).', 'Through epidemiological investigation, we observed a typical asymptomatic transmission to the cohabiting family members, which even caused severe COVID-19 pneumonia.', 'Interpretation: The asymptomatic carriers identified from close contacts were prone to be mildly ill during hospitalization.', 'However, the communicable period could be up to three weeks and the communicated patients could develop severe illness.', 'These results highlighted the importance of close contact tracing and longitudinally surveillance via virus nucleic acid tests.', 'Further isolation recommendation and continuous nucleic acid tests may also be recommended to the patients discharged.']\n",
            "unmatched tags:  [{'entity': 'nucleic acid', 'type': 'Gene', 'start': 2386, 'end': 2398}, {'entity': 'nucleic acid', 'type': 'Gene', 'start': 2318, 'end': 2330}, {'entity': 'communicable', 'type': 'Disease', 'start': 2103, 'end': 2115}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1944, 'end': 1952}, {'entity': 'nucleic acid', 'type': 'Gene', 'start': 1670, 'end': 1682}, {'entity': 'communicable', 'type': 'Disease', 'start': 1594, 'end': 1606}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1555, 'end': 1563}, {'entity': 'ground-glass chest', 'type': 'Chemical', 'start': 1257, 'end': 1275}, {'entity': 'cough', 'type': 'Phenotype', 'start': 1159, 'end': 1164}, {'entity': 'fever', 'type': 'Phenotype', 'start': 1152, 'end': 1157}, {'entity': 'nucleic acid', 'type': 'Gene', 'start': 1089, 'end': 1101}, {'entity': 'nucleic acid', 'type': 'Gene', 'start': 877, 'end': 889}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 847, 'end': 855}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 642, 'end': 650}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 533, 'end': 541}]\n",
            "['Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)\\tTacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide was the most promising intervention, yielding the best GRFS; this regimen is thus being prospectively compared with tacrolimus and methotrexate in a phase 3 randomised trial.']\n",
            "unmatched tags:  [{'entity': 'methotrexate', 'type': 'Drug', 'start': 628, 'end': 640}, {'entity': 'tacrolimus', 'type': 'Drug', 'start': 613, 'end': 623}]\n",
            "['Transcriptional Difference between SARS-COV-2 and other Human Coronaviruses Revealed by Sub-genomic RNA Profiling\\tSARS-COV-2 and all other coronaviruses express its 3 prime genes by forming sub-genomic RNA.', 'As the genome of these virus exist in RNA form, only by profiling the relative abundance of these sgRNAs, can the viral transcriptome be revealed.', 'Utilizing publically available meta-transcriptomic data generated from patient samples, we were able to infer the viral transcriptome in vivo, which is distinct from the in vitro one derived from cell culture.', 'Inter-sample diversity was also observed and a sample specific transcript was identified.', 'By doing the same analysis to MERS and SARS data, we were able to compare the three in terms of transcription.', 'Among the differences, SARS-COV-2 has significantly elevated expression of the Spike gene, which may contribute to its high transmissibility.', 'Highlights The in vivo transcriptome of SARS-CoV-2 revealed by sgRNA profiling, for 25 patient samples around the globe.', 'The Spike protein expression is an order of magnitude higher in SARS-CoV-2 than MERS-CoV or SARS-CoV, possibly contributing to the virus’ elevated transmissibility.', 'The in vivo SARS-CoV-2 transcriptomes, as inferred from human patient data was distinct from the in vitro one derived from cell line culture, all the accessory genes were up-regulated in vivo , suggesting intricate expression regulation mechanism for the small viral genome.']\n",
            "unmatched tags:  [{'entity': 'transcript', 'type': 'Gene', 'start': 1216, 'end': 1226}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1205, 'end': 1215}, {'entity': 'virus’', 'type': 'Virus', 'start': 1159, 'end': 1165}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 1120, 'end': 1128}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 1108, 'end': 1116}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1092, 'end': 1102}, {'entity': 'Spike protein', 'type': 'Gene', 'start': 1032, 'end': 1045}, {'entity': 'patient samples', 'type': 'Chemical', 'start': 994, 'end': 1009}, {'entity': 'profiling', 'type': 'Gene', 'start': 976, 'end': 985}, {'entity': 'RNA', 'type': 'Gene', 'start': 972, 'end': 975}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 947, 'end': 957}, {'entity': 'transcript', 'type': 'Gene', 'start': 930, 'end': 940}, {'entity': 'SARS-COV-2', 'type': 'Virus', 'start': 788, 'end': 798}, {'entity': 'transcript', 'type': 'Gene', 'start': 750, 'end': 760}, {'entity': 'SARS', 'type': 'Disease', 'start': 693, 'end': 697}, {'entity': 'MERS', 'type': 'Disease', 'start': 684, 'end': 688}, {'entity': 'transcript', 'type': 'Gene', 'start': 627, 'end': 637}, {'entity': 'transcript', 'type': 'Gene', 'start': 474, 'end': 484}, {'entity': 'patient samples', 'type': 'Chemical', 'start': 425, 'end': 440}, {'entity': 'transcript', 'type': 'Gene', 'start': 390, 'end': 400}, {'entity': 'transcript', 'type': 'Gene', 'start': 327, 'end': 337}]\n",
            "['The impact of social distancing and epicenter lockdown on the COVID-19 epidemic in mainland China: A data-driven SEIQR model study\\tThe outbreak of coronavirus disease 2019 (COVID-19) which originated in Wuhan, China, constitutes a public health emergency of international concern with a very high risk of spread and impact at the global level.', 'We developed data-driven susceptible-exposed-infectious-quarantine-recovered (SEIQR) models to simulate the epidemic with the interventions of social distancing and epicenter lockdown.', 'Population migration data combined with officially reported data were used to estimate model parameters, and then calculated the daily exported infected individuals by estimating the daily infected ratio and daily susceptible population size.', 'As of Jan 01, 2020, the estimated initial number of latently infected individuals was 380.1 (95%-CI: 379.8~381.0).', 'With 30 days of substantial social distancing, the reproductive number in Wuhan and Hubei was reduced from 2.2 (95%-CI: 1.4~3.9) to 1.58 (95%-CI: 1.34~2.07), and in other provinces from 2.56 (95%-CI: 2.43~2.63) to 1.65 (95%-CI: 1.56~1.76).', 'We found that earlier intervention of social distancing could significantly limit the epidemic in mainland China.', 'The number of infections could be reduced up to 98.9%, and the number of deaths could be reduced by up to 99.3% as of Feb 23, 2020.', 'However, earlier epicenter lockdown would partially neutralize this favorable effect.', 'Because it would cause in situ deteriorating, which overwhelms the improvement out of the epicenter.', 'To minimize the epidemic size and death, stepwise implementation of social distancing in the epicenter city first, then in the province, and later the whole nation without the epicenter lockdown would be practical and cost-effective.']\n",
            "unmatched tags:  [{'entity': 'nation', 'type': 'Organization', 'start': 1717, 'end': 1723}]\n",
            "['Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders\\tSpinal cord involvement is an important cause of disability in patients with multiple sclerosis or neuromyelitis optica spectrum disorders (NMOSDs).', 'Multiple sclerosis and NMOSDs can be distinguished from other disorders that cause myelopathy by results from laboratory and radiological investigations.', 'However, limitations in the sensitivity and specificity of spinal cord imaging and poor correlation with disability megasures have impeded the understanding of the relationship between spinal cord involvement and clinical manifestations.']\n",
            "unmatched tags:  [{'entity': 'myelopathy', 'type': 'Disease', 'start': 322, 'end': 332}, {'entity': 'disorders', 'type': 'Disease', 'start': 301, 'end': 310}]\n",
            "['Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial\\tA two-dose regimen of an adjuvanted 10 μg inactivated whole-virion H5N1 vaccine met all European regulatory requirements for annual licensing of seasonal influenza vaccine.', 'Lower doses of this vaccine could achieve immune responses equivalent to those elicited by adjuvanted or non-adjuvanted split-virion vaccines.', 'The use of a whole virion vaccine could be more adaptable to the antigen-sparing strategy recommended by WHO for protection against an influenza pandemic.']\n",
            "unmatched tags:  [{'entity': 'influenza pandemic', 'type': 'Drug', 'start': 585, 'end': 603}]\n",
            "['Cell-intrinsic differences between human airway epithelial cells from children and adults\\tThe airway epithelium is a key protective barrier whose integrity is preserved by the self-renewal and differentiation of basal progenitor cells.', 'Epithelial cells are central to the pathogenesis of multiple lung diseases.', 'In chronic diseases, increasing age is a principle risk factor.', 'In acute diseases, such as COVID-19, children suffer less severe symptoms than adults and have a lower rate of mortality.', 'Few studies have explored differences between airway epithelial cells in children and adults to explain this age dependent variation in diseases.', 'Here, we perform bulk RNA sequencing studies in laser-capture microdissected whole epithelium, FACS-sorted basal cells and cultured basal cells, as well as in vitro cell proliferation experiments, to address the intrinsic molecular differences between paediatric and adult airway basal cells.', 'We find that, while the cellular composition of the paediatric and adult tracheobronchial epithelium is broadly similar, in cell culture, paediatric airway epithelial cells displayed higher colony forming ability, better in vitro growth and outcompeted adult cells in competitive proliferation assays.', 'In RNA sequencing experiments, we observed potentially important differences in airway epithelial gene expression between samples from children and adults.', 'However, genes known to be associated with SARS-CoV-2 infection were not differentially expressed between children and adults.', 'Our results chart cell-intrinsic differences in transcriptional profile and regenerative capacity between proximal airway epithelial cells of children and adults.']\n",
            "unmatched tags:  [{'entity': 'regenerative capacity', 'type': 'Disease', 'start': 1598, 'end': 1619}, {'entity': 'diseases', 'type': 'Disease', 'start': 634, 'end': 642}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 403, 'end': 411}]\n",
            "['A considerable proportion of individuals with asymptomatic SARS-CoV-2 infection in Tibetan population\\tSevere acute respiratory syndrome coronavirus 2 (SARS-Cov-2) quickly became a major epidemic threat in the whole China.', 'We analysed SARS-Cov-2 infected cases from Tibetan Autonomous Prefecture, and noted divergent characteristics of these Tibetans infected cases compared to Han Chinese, characterizing by a considerable proportion of asymptomatic carriers (21.7%), and few symptomatic patients with initial symptom of fever (7.7%).', 'Here, we did a descriptive study on clinical characteristics of 18 asymptomatic individuals with SARS-CoV-2 infection.', 'The median age of these asymptomatic carriers was 31 years and one third of them were students, aged under 20 years.', 'Notably, some of asymptomatic carriers had recognizable changes in radiological and laboratory indexes.', 'Our finding indicates a potentially big number of SARS-CoV-2 asymptomatic carriers in prevalent area, highlighting a necessity of screening individuals with close contact of infected patients, for a better control on the spread of SARS-CoV-2 infection.']\n",
            "unmatched tags:  [{'entity': 'symptom', 'type': 'Phenotype', 'start': 937, 'end': 944}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 789, 'end': 796}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 679, 'end': 686}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 603, 'end': 610}, {'entity': 'fever', 'type': 'Phenotype', 'start': 521, 'end': 526}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 510, 'end': 517}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 476, 'end': 483}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 438, 'end': 445}, {'entity': 'SARS-Cov-2', 'type': 'Virus', 'start': 234, 'end': 244}, {'entity': 'SARS-Cov-2', 'type': 'Virus', 'start': 151, 'end': 161}]\n",
            "['Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden\\tAutoimmune disorders are associated with a high risk of pulmonary embolism in the first year after hospital admission.', 'Our findings suggest that these disorders in general should be regarded as hypercoagulable disorders.']\n",
            "unmatched tags:  [{'entity': 'hypercoagulable disorders', 'type': 'Disease', 'start': 301, 'end': 326}, {'entity': 'disorders', 'type': 'Disease', 'start': 258, 'end': 267}]\n",
            "['Loss of smell and taste in combination with other symptoms is a strong predictor of COVID-19 infection\\tImportance: A strategy for preventing further spread of the ongoing COVID-19 epidemic is to detect infections and isolate infected individuals without the need of extensive bio-specimen testing.', 'Objectives: Here we investigate the prevalence of loss of smell and taste among COVID-19 diagnosed individuals and we identify the combination of symptoms, besides loss of smell and taste, most likely to correspond to a positive COVID-19 diagnosis in non-severe cases.', 'Design: Community survey.', 'Setting and Participants: Subscribers of RADAR COVID-19, an app that was launched for use among the UK general population asking about COVID-19 symptoms.', 'Main Exposure: Loss of smell and taste.', 'Main Outcome Measures: COVID-19.', 'Results: Between 24 and 29 March 2020, 1,573,103 individuals reported their symptoms via the app; 26% reported suffering from one or more symptoms of COVID-19.', 'Of those, n=1702 reported having had a RT-PCR COVID-19 test and gave full report on symptoms including loss of smell and taste; 579 were positive and 1123 negative.', 'In this subset, we find that loss of smell and taste were present in 59% of COVID-19 positive individuals compared to 18% of those negative to the test,  yielding an odds ratio (OR) of COVID-19 diagnosis of OR[95%CI]=6.59[5.25; 8.27], P= 1.90x10-59 .', 'We also find that a combination of loss of smell and taste, fever, persistent cough, fatigue, diarrhoea, abdominal pain and loss of appetite is predictive of COVID-19 positive test with sensitivity 0.54[0.44; 0.63], specificity 0.86[0.80; 0.90], ROC-AUC 0.77[0.72; 0.82] in the test set, and cross-validation ROC-AUC   0.75[0.72; 0.77].', 'When applied to the 410,598 individuals reporting symptoms but not formally tested, our model predicted that 13.06%[12.97%;13.15] of these might have been already infected by the virus.', 'Conclusions and Relevance: Our study suggests that loss of taste and smell is a strong predictor of having been infected by the COVID-19 virus.', 'Also, the combination of symptoms that could be used to identify and isolate individuals includes anosmia, fever, persistent cough, diarrhoea, fatigue, abdominal pain and loss of appetite.', 'This is particularly relevant to healthcare and other key workers in constant contact with the public who have not yet been tested for COVID-19.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2389, 'end': 2397}, {'entity': 'app', 'type': 'Gene', 'start': 2244, 'end': 2247}, {'entity': 'abdominal pain', 'type': 'Phenotype', 'start': 2217, 'end': 2231}, {'entity': 'diarrhoea', 'type': 'Drug', 'start': 2197, 'end': 2206}, {'entity': 'persistent cough', 'type': 'Phenotype', 'start': 2179, 'end': 2195}, {'entity': 'fever', 'type': 'Phenotype', 'start': 2172, 'end': 2177}, {'entity': 'anosmia', 'type': 'Phenotype', 'start': 2163, 'end': 2170}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2049, 'end': 2057}, {'entity': 'loss of taste', 'type': 'Phenotype', 'start': 1972, 'end': 1985}, {'entity': 'app', 'type': 'Gene', 'start': 1739, 'end': 1742}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1555, 'end': 1563}]\n",
            "[\"Changes in regional cerebral blood flow after a cold hand test in systemic lupus erythematosus patients with Raynaud's syndrome\\tThe appearance of vasospastic features in the central nervous system (CNS) after a cold stressor test was investigated through single photon emission computed tomography (SPECT) of regional cerebral blood flow in patients with systemic lupus erythematosus, with and without Raynaud's syndrome, and in scleroderma patients.\", \"We have shown that Raynaud's syndrome may occur in the CNS and that anticardiolipin or lupus anticoagulant positivity may favour perfusion defects.\"]\n",
            "unmatched tags:  [{'entity': 'positivity', 'type': 'Disease', 'start': 558, 'end': 568}, {'entity': 'anticoagulant', 'type': 'Drug', 'start': 544, 'end': 557}, {'entity': 'lupus', 'type': 'Disease', 'start': 538, 'end': 543}, {'entity': 'anticardiolipin', 'type': 'Drug', 'start': 519, 'end': 534}, {'entity': \"Raynaud's syndrome\", 'type': 'Disease', 'start': 470, 'end': 488}, {'entity': 'scleroderma', 'type': 'Disease', 'start': 429, 'end': 440}]\n",
            "['pH Dependent Differential Binding Behavior of Prtotease Inhibitor Molecular Drugs for SARS-COV-2\\tIn this research we used the structure of SARS-CoV-2 main protease (Mpro) for docking with Anti-HIV protease inhibitor drug molecules within pH 4-8.', 'By carrying out the variance analysis of binding energies at pH 4-8, it was revealed that the binding energy and mode of interaction of the potential ligands with SARS-CoV-2 Mpro, was dependent on variation of pH.', 'We found out that two of the selected protease inhibitors have differential binding characteristics with changing pH hence their binding energies and mode of interaction depends upon intracellular pH.', 'This differential binding behavior can lead to development of pH selective potent drug molecules for binding with viral protease at lowered intracellular pH of virus infected cell.']\n",
            "unmatched tags:  [{'entity': 'cell', 'type': 'Gene', 'start': 837, 'end': 841}, {'entity': 'cell', 'type': 'Gene', 'start': 807, 'end': 811}]\n",
            "['Heparin therapy improving hypoxia in COVID-19 patients - a case series\\tINTRODUCTION: Elevated D-dimer is predictor of severity and mortality in COVID-19 patients and heparin use during in hospital stay has been associated to decreased mortality.', 'COVID-19 patient autopsies have revealed thrombi in the microvasculature, suggesting intravascular coagulation as a prominent feature of organ failure in these patients.', 'Interestingly, in COVID-19, pulmonary compliance is preserved despite severe hypoxemia corroborating the hypothesis that perfusion mismatch may play a significant role in the development of respiratory failure.', 'METHODS:  We describe a series of 27 consecutive COVID-19 patients admitted to the Pulmonology service at Sirio-Libanes Hospital in Sao Paulo-Brazil treated with heparin in therapeutic doses tailored to clinical severity.', 'RESULTS: PaO2/FiO2 ratio increased significantly over the 72 hours following the start of anticoagulation, from 254(SD 90) to 325(SD 80), p=0.013, and over half of the patients were discharged home within an average time of 7.3 (SD 4.0) days.', 'Half of mechanically ventilated patients were extubated within 10.3 (SD 1.5) days.', 'The remaining patients showed progressive improvement and there were no bleeding complications or fatal events.', 'DISCUSSION: Even though this uncontrolled case series does not offer absolute proof of DIC as the underlying mechanism of respiratory failure in COVID-19, as well as patients positive response to tailored dose heparinization, it contributes to the understanding of the physiopathological mechanism of the disease and provides valuable information for the treatment of these very sick patients while we await the results of further prospective controlled studies']\n",
            "unmatched tags:  [{'entity': 'sick', 'type': 'Phenotype', 'start': 1668, 'end': 1672}]\n",
            "['Bipolar disorder diagnosis: challenges and future directions\\tBipolar disorder refers to a group of affective disorders, which together are characterised by depressive and manic or hypomanic episodes.', 'These disorders include: bipolar disorder type I (depressive and manic episodes: this disorder can be diagnosed on the basis of one manic episode); bipolar disorder type II (depressive and hypomanic episodes); cyclothymic disorder (hypomanic and depressive symptoms that do not meet criteria for depressive episodes); and bipolar disorder not otherwise specified (depressive and hypomanic-like symptoms that do not meet the diagnostic criteria for any of the aforementioned disorders).']\n",
            "unmatched tags:  [{'entity': 'disorders', 'type': 'Disease', 'start': 674, 'end': 683}, {'entity': 'depressive', 'type': 'Disease', 'start': 564, 'end': 574}, {'entity': 'bipolar disorder', 'type': 'Disease', 'start': 522, 'end': 538}, {'entity': 'depressive episodes', 'type': 'Disease', 'start': 496, 'end': 515}, {'entity': 'depressive symptoms', 'type': 'Phenotype', 'start': 446, 'end': 465}, {'entity': 'cyclothymic disorder', 'type': 'Disease', 'start': 410, 'end': 430}, {'entity': 'manic episodes', 'type': 'Disease', 'start': 393, 'end': 407}, {'entity': 'depressive', 'type': 'Disease', 'start': 374, 'end': 384}, {'entity': 'bipolar disorder type II', 'type': 'Disease', 'start': 348, 'end': 372}, {'entity': 'manic episode', 'type': 'Disease', 'start': 332, 'end': 345}, {'entity': 'manic episodes', 'type': 'Disease', 'start': 265, 'end': 279}, {'entity': 'depressive', 'type': 'Disease', 'start': 250, 'end': 260}, {'entity': 'bipolar disorder type I', 'type': 'Disease', 'start': 225, 'end': 248}, {'entity': 'disorders', 'type': 'Disease', 'start': 206, 'end': 215}]\n",
            "['Estimating cases of COVID-19 from Daily Death Data in Italy\\tCOVID-19 is an emerging infectious disease which has been declared a pan- demic by the World Health Organisation.', 'Due to limited testing capacity for this new virus, variable symptomatology the majority of infected showing non-specific mild or no symptoms it is likely current prevalence data is an underestimate.', 'Methods: We present an estimate of the number of cases of COVID-19 com- pared to the number of confirmed case in Italy based on the daily reported deaths and information about the incubation period, time from symptom on- set to death and reported case fatality rate.', 'Results: Our model predicts that on the 31st of January 2020 when the first 3 infected cases had been identified by Italian authorise there were already nearly 30 cases in Italy, and by the 24th of February 2020 only 0.5% cases had been detected and confirmed by Italian authorities.', 'While official statistics had 132 confirmed case we believe a more accurate estimate would be closer to 26000.', 'With a case-doubling period of about 2.5 days.']\n",
            "unmatched tags:  [{'entity': 'symptom', 'type': 'Phenotype', 'start': 583, 'end': 590}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 432, 'end': 440}, {'entity': 'underestimate', 'type': 'Organization', 'start': 359, 'end': 372}]\n",
            "['Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86)\\tAt diabetes onset, adults with latent autoimmune diabetes have a lower risk of microvascular complications followed by a later higher risk of complications than do adults with type 2 diabetes, secondary to worse glycaemic control.', 'Implementing strict glycaemic control from the time of diagnosis could reduce the later risk of microvascular complications in adults with latent autoimmune diabetes.']\n",
            "unmatched tags:  [{'entity': 'latent autoimmune diabetes', 'type': 'Disease', 'start': 594, 'end': 620}, {'entity': 'diabetes', 'type': 'Disease', 'start': 407, 'end': 415}, {'entity': 'type 2 diabetes', 'type': 'Disease', 'start': 400, 'end': 415}, {'entity': 'latent autoimmune diabetes', 'type': 'Disease', 'start': 255, 'end': 281}, {'entity': 'diabetes', 'type': 'Disease', 'start': 227, 'end': 235}]\n",
            "['Deducing the N- and O- glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2\\tThe current emergence of the novel coronavirus pandemic caused by SARS-CoV-2 demands the development of new therapeutic strategies to prevent rapid progress of mortalities.', 'The coronavirus spike (S) protein, which facilitates viral attachment, entry and membrane fusion is heavily glycosylated and plays a critical role in the elicitation of the host immune response.', 'The spike protein is comprised of two protein subunits (S1 and S2), which together possess 22 potential N-glycosylation sites.', 'Herein, we report the glycosylation mapping on spike protein subunits S1 and S2 expressed on human cells through high resolution mass spectrometry.', 'We have characterized the quantitative N-glycosylation profile on spike protein and interestingly, observed unexpected O-glycosylation modifications on the receptor binding domain (RBD) of spike protein subunit S1.', 'Even though O-glycosylation has been predicted on the spike protein of SARS-CoV-2, this is the first report of experimental data for both the site of O-glycosylation and identity of the O-glycans attached on the subunit S1.', 'Our data on the N- and O-glycosylation is strengthened by extensive manual interpretation of each glycopeptide spectra in addition to using bioinformatics tools to confirm the complexity of glycosylation in the spike protein.', 'The elucidation of the glycan repertoire on the spike protein provides insights into the viral binding studies and more importantly, propels research towards the development of a suitable vaccine candidate.']\n",
            "unmatched tags:  [{'entity': 'candidate', 'type': 'Gene', 'start': 1602, 'end': 1611}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1594, 'end': 1601}, {'entity': 'spike protein', 'type': 'Gene', 'start': 1454, 'end': 1467}, {'entity': 'glycan', 'type': 'Drug', 'start': 1429, 'end': 1435}, {'entity': 'spike protein', 'type': 'Gene', 'start': 1391, 'end': 1404}, {'entity': 'glycopeptide spectra', 'type': 'Gene', 'start': 1278, 'end': 1298}]\n",
            "['Energetics based epitope screening in SARS CoV-2 (COVID 19) spike glycoprotein by Immuno-informatic analysis aiming to a suitable vaccine development\\tThe recent outbreak by SARS-CoV-2 has generated a chaos in global health and economy and claimed/infected a large number of lives.', 'Closely resembling with SARS CoV, the present strain has manifested exceptionally higher degree of spreadability, virulence and stability possibly due to some unidentified mutations.', 'The viral spike glycoprotein is very likely to interact with host Angiotensin-Converting Enzyme 2 (ACE2) and transmits its genetic materials and hijacks host machinery with extreme fidelity for self propagation.', 'Few attempts have been made to develop a suitable vaccine or ACE2 blocker or virus-receptor inhibitor within this short period of time.', 'Here, attempt was taken to develop some therapeutic and vaccination strategies with a comparison of spike glycoproteins among SARS-CoV, MERS-CoV and the SARS-CoV-2.', 'We verified their structure quality (SWISS-MODEL, Phyre2, Pymol) topology (ProFunc), motifs (MEME Suite, GLAM2Scan), gene ontology based conserved domain (InterPro database) and screened several epitopes (SVMTrip) of SARS CoV-2 based on their energetics, IC50 and antigenicity with regard to their possible glycosylation and MHC/paratopic binding (Vaxigen v2.0, HawkDock, ZDOCK Server) effects.', 'We screened here few pairs of spike protein epitopic regions and selected their energetic, IC50, MHC II reactivity and found some of those to be very good target for vaccination.', 'A possible role of glycosylation on epitopic region showed profound effects on epitopic recognition.', 'The present work might be helpful for the urgent development of a suitable vaccination regimen against SARS CoV-2.']\n",
            "unmatched tags:  [{'entity': 'SARS', 'type': 'Disease', 'start': 1755, 'end': 1759}, {'entity': 'epitopic region', 'type': 'Organization', 'start': 1587, 'end': 1602}, {'entity': 'MHC II', 'type': 'Gene', 'start': 1469, 'end': 1475}, {'entity': 'epitopic region', 'type': 'Organization', 'start': 1416, 'end': 1431}, {'entity': 'spike protein', 'type': 'Gene', 'start': 1402, 'end': 1415}, {'entity': 'HawkDock', 'type': 'Gene', 'start': 1339, 'end': 1347}, {'entity': 'SARS', 'type': 'Disease', 'start': 1194, 'end': 1198}, {'entity': 'ProFunc', 'type': 'Disease', 'start': 1052, 'end': 1059}, {'entity': 'Phyre2', 'type': 'Gene', 'start': 1027, 'end': 1033}]\n",
            "[\"Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort study\\tImpaired glucose metabolism is a substantial burden on population health, and our findings emphasise the need for more effective prevention strategies, which should be implemented as soon in a person's life as possible.\", 'The substantial lifetime risk of prediabetes and diabetes in lean individuals also supports risk factor control in non-obese individuals.']\n",
            "unmatched tags:  [{'entity': 'diabetes', 'type': 'Disease', 'start': 414, 'end': 422}]\n",
            "['Distribution and genetic diversity of adeno-associated viruses in bats from coastal areas of Southeast China\\tBats are associated with several important zoonotic viruses from different families.', 'One example includes adeno-associated viruses (AAVs), that are extensively detected in several animals, especially primates.', 'To understand AAVs distribution and genetic diversity in the coastal areas of Southeast China, a total of 415 intestine samples were mostly collected from two provinces of southeast China, i.e., Zhejiang and Fujian province.', 'Intestine samples from five bat species were collected for AAVs detection.', 'The average prevalence rate for AAV detection among these samples was 18.6% (77 positives out of 415 samples) and ranged from 11.8 to 28.9% between the five bat species.', 'This suggests that AAVs are widely distributed in diverse bat populations in southeast coastal areas of China.', 'Based on the genome sequence of bat adeno-associated virus-CXC1(BtAAV-CXC1) from one AAV-positive sample, the genetic diversity of the detected AAVs were assessed and analyzed.', 'Phylogenetic analysis revealed that BtAAV-CXC1 was comparatively distant to other major AAVs from mammals and non-mammals, with only a 52.9~64.7% nucleotide identity.', 'However, they were phylogenetically closer to Rhinolophus sinicus bat adeno-associated virus (Rs-BtAAV1), with a 74.5% nt similarity.', 'Partial analysis of the rep and cap overlapping open reading frame (ORF) sequences from bat AAV samples revealed 48 partial rep sequences and 23 partial cap sequences from positive samples shared 86.9 to 100% and 72.3 to 98.8% nucleotide identities among themselves, respectively.', 'This suggests that the detected AAVs had a distinctly high genetic diversity.', 'These findings led us to conclude that diverse AAVs may be widely distributed in bat populations from the southeast regions of China.']\n",
            "unmatched tags:  [{'entity': 'AAVs', 'type': 'Organization', 'start': 1784, 'end': 1788}, {'entity': 'AAVs', 'type': 'Organization', 'start': 1691, 'end': 1695}, {'entity': 'nucleotide identities', 'type': 'Gene', 'start': 1605, 'end': 1626}, {'entity': 'AAV', 'type': 'Gene', 'start': 1470, 'end': 1473}, {'entity': 'open reading frame', 'type': 'Gene', 'start': 1426, 'end': 1444}]\n",
            "[\"Primary Sjögren's syndrome and deficiency of ICA69\\tICA69 is a new autoantigen in primary Sjögren's syndrome that has an important role in progression of disease and could be of diagnostic value.\", \"Immunotherapy of primary Sjögren's syndrome is promising, since autoimmunity in NOD mice with Sjögren's syndrome seems to be uniquely susceptible to such treatment even late in disease.\"]\n",
            "unmatched tags:  [{'entity': \"Sjögren's syndrome\", 'type': 'Disease', 'start': 289, 'end': 307}, {'entity': 'mice', 'type': 'Gene', 'start': 279, 'end': 283}, {'entity': 'NOD', 'type': 'Disease', 'start': 275, 'end': 278}]\n",
            "['Codon usage and evolutionary rates of the 2019-nCoV genes\\tSevere acute respiratory syndrome coronavirus 2 (2019-nCoV), which first broke out in Wuhan (China) in December of 2019, causes a severe acute respiratory illness with a mortality ranging from 3% to 6%.', 'To better understand the evolution of the newly emerging 2019-nCoV, in this paper, we analyze the codon usage pattern of 2019-nCoV.', 'For this purpose, we compare the codon usage of 2019-nCoV with that of other 30 viruses belonging to the subfamily of orthocoronavirinae.', 'We found that 2019-nCoV shows a rich composition of AT nucleotides that strongly influences its codon usage, which appears to be not optimized to human host.', 'Then, we study the evolutionary pressures influencing the codon usage and evolutionary rates of the sequences of five conserved genes that encode the corresponding proteins (viral replicase, spike, envelope, membrane and nucleocapsid) characteristic of coronaviruses.', 'We found different patterns of both mutational bias and nature selection that affect the codon usage of these genes at different extents.', 'Moreover, we show that the two integral membrane proteins proteins (matrix and envelope) tend to evolve slowly by accumulating nucleotide mutations on their genes.', 'Conversely, genes encoding nucleocapsid (N), viral replicase and spike proteins are important targets for the development of vaccines and antiviral drugs, tend to evolve faster as compared to other ones.', 'Taken together, our results suggest that the higher evolutionary rate observed for these two genes could represent a major barrier in the development of antiviral therapeutics 2019-nCoV.']\n",
            "unmatched tags:  [{'entity': '2019-nCoV', 'type': 'Virus', 'start': 1639, 'end': 1648}, {'entity': 'antiviral drugs', 'type': 'Drug', 'start': 1397, 'end': 1412}, {'entity': 'vaccines', 'type': 'Drug', 'start': 1384, 'end': 1392}, {'entity': 'spike proteins', 'type': 'Gene', 'start': 1324, 'end': 1338}, {'entity': 'viral replicase', 'type': 'Gene', 'start': 1304, 'end': 1319}, {'entity': 'nucleocapsid', 'type': 'Gene', 'start': 1286, 'end': 1298}]\n",
            "['Incidence of type 2 diabetes after bariatric surgery: population-based matched cohort study\\tBariatric surgery is associated with reduced incidence of clinical diabetes in obese participants without diabetes at baseline for up to 7 years after the procedure.']\n",
            "unmatched tags:  [{'entity': 'diabetes', 'type': 'Disease', 'start': 198, 'end': 206}]\n",
            "['Therapeutic Application of Chloroquine and Hydroxychloroquine in Clinical Trials for COVID-19: A systematic review\\tThe corona virus disease -2019 (COVID-19) pandemic has caused a massive global public health havoc.', 'Recent published clinical trials show conflicting data for use of chloroquine/hydroxychloroquine for COVID-19.', 'This study meticulously evaluated the various dosages of chloroquine and hydroxychloroquine utilized in clinical trials registered in Chinese and US clinical trial registries for the treatment of pneumonia caused by SARS-CoV-2.', 'Moreover, the results of published clinical trials and in vitro studies using chloroquine and hydroxychloroquine relevant to the disease are discussed.']\n",
            "unmatched tags:  [{'entity': 'hydroxychloroquine', 'type': 'Drug', 'start': 648, 'end': 666}, {'entity': 'chloroquine', 'type': 'Drug', 'start': 632, 'end': 643}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 542, 'end': 552}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 522, 'end': 531}, {'entity': 'hydroxychloroquine', 'type': 'Drug', 'start': 399, 'end': 417}, {'entity': 'chloroquine', 'type': 'Drug', 'start': 383, 'end': 394}]\n",
            "['Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study\\tDespite the limitations imposed by the suspension of the HPV vaccination, our findings lend support to the WHO recommendation of two doses, at least 6 months apart, for routine vaccination of young girls.', 'The short-term protection afforded by one dose of HPV vaccine against persistent infection with HPV 16, 18, 6, and 11 is similar to that afforded by two or three doses of vaccine and merits further assessment.']\n",
            "unmatched tags:  [{'entity': 'vaccine', 'type': 'Drug', 'start': 527, 'end': 534}]\n",
            "['Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study\\tTazemetostat showed a favourable safety profile and antitumour activity in patients with refractory B-cell non-Hodgkin lymphoma and advanced solid tumours, including epithelioid sarcoma.', 'Further clinical investigation of tazemetostat monotherapy is ongoing in phase 2 studies in adults and a phase 1 study for children, which are currently enrolling patients who have B-cell non-Hodgkin lymphoma and INI1-negative or SMARCA4-negative tumours.']\n",
            "unmatched tags:  [{'entity': 'B-cell non-Hodgkin lymphoma', 'type': 'Disease', 'start': 527, 'end': 554}]\n",
            "['Epidemiological features of chronic low-back pain\\tAlthough the literature is filled with information about the prevalence and incidence of back pain in general, there is less information about chronic back pain, partly because of a lack of agreement about definition.', 'Chronic back pain is sometimes defined as back pain that lasts for longer than 7–12 weeks.', 'Others define it as pain that lasts beyond the expected period of healing, and acknowledge that chronic pain may not have well-defined underlying pathological causes.', 'Others classify frequently recurring back pain as chronic pain since it intermittently affects an individual over a long period.']\n",
            "unmatched tags:  [{'entity': 'chronic pain', 'type': 'Phenotype', 'start': 576, 'end': 588}]\n",
            "['Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia\\tConventional chelation treatment with subcutaneous desferrioxamine does not prevent excess cardiac iron deposition in two-thirds of patients with thalassaemia major, placing them at risk of heart failure and its complications.', 'Oral deferiprone is more effective than desferrioxamine in removal of myocardial iron.']\n",
            "unmatched tags:  [{'entity': 'desferrioxamine', 'type': 'Drug', 'start': 422, 'end': 437}, {'entity': 'Oral deferiprone', 'type': 'Drug', 'start': 382, 'end': 398}, {'entity': 'heart failure', 'type': 'Phenotype', 'start': 345, 'end': 358}]\n",
            "['Off-label use of anticancer drugs\\tUse of a drug outside the terms of its official labelling is referred to as off-label prescription.', 'Many categories of use exist because labelling of anticancer agents is very precise in terms of type or subtype of tumour, association, line, and duration of treatment.', 'Off-label prescription of anticancer drugs is thought to be frequent but, in fact, very few surveys have been done to ascertain its real extent.', 'Findings of prospective studies undertaken between 1990 and 2002 showed proportions of off-label drug use in children and adults of 6·7–33·2%.']\n",
            "unmatched tags:  [{'entity': 'drug', 'type': 'Drug', 'start': 545, 'end': 549}, {'entity': 'drug', 'type': 'Drug', 'start': 340, 'end': 344}, {'entity': 'duration of', 'type': 'Drug', 'start': 280, 'end': 291}, {'entity': 'line', 'type': 'Gene', 'start': 270, 'end': 274}, {'entity': 'tumour', 'type': 'Disease', 'start': 249, 'end': 255}, {'entity': 'type', 'type': 'Gene', 'start': 241, 'end': 245}, {'entity': 'type', 'type': 'Gene', 'start': 230, 'end': 234}]\n",
            "['Neurodevelopmental disorders\\tNeurodevelopmental disorders such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder, although most commonly considered in childhood, can be lifelong conditions.', 'In this Personal View that is shaped by clinical experience and research, we adopt a conceptual approach.', 'First, we discuss what disorders are neurodevelopmental and why such a grouping is useful.', 'We conclude that both distinction and grouping are helpful and that it is important to take into account the strong overlap across neurodevelopmental disorders.']\n",
            "unmatched tags:  [{'entity': 'neurodevelopmental disorders', 'type': 'Disease', 'start': 548, 'end': 576}, {'entity': 'neurodevelopmental', 'type': 'Disease', 'start': 363, 'end': 381}, {'entity': 'disorders', 'type': 'Disease', 'start': 349, 'end': 358}, {'entity': 'autism spectrum disorder', 'type': 'Disease', 'start': 118, 'end': 142}, {'entity': 'ADHD', 'type': 'Disease', 'start': 108, 'end': 112}]\n",
            "['The first report of the prevalence of COVID-19 in Chronic myelogenous leukemia patients in the core epidemic area of China:multicentre, cross-sectional survey\\tBackground Since late December 2019, the outbreak of the novel coronavirus disease, COVID-19, that began in Wuhan, has become endemic in China and more than 100 countries and regions in the world.', 'So far, there is rare data on the prevalence of COVID-19 in patients with chronic myelogenous leukemia (CML).', 'We aimed to describe the clinical course, outcomes of CML patients with COVID-19 and prevalence of COVID-19 in CML patients.', 'Methods  In this multi-center survey, cross-sectional survey, observational study, the clinical data of CML patients with COVID-19 in each center were collected.', 'Simultaneously, an online survey was conducted for information about the CML patients under the management at each center by asking the CML patients to complete a questionnaire,from February 15, 2020 to February 21, 2020.', 'The questionnaire includes demographic data, place of residence, smoking status, CML diagnosis and treatment, comorbidities, combined medications, epidemiological history,  symptoms(fever, cough, shortness of breath, etc) during the epidemic.', 'Additional clinical data was collected on respondents suspected or confirmed to have COVID-19.', 'We described and analyzed the prevalence of COVID-19 in CML patients, and focus on the clinical characteristics and outcomes of COVID-19 patients.', 'Data were compared between the CML patients with optimal response and those with non-optimal response.', 'The primary outcome was prevalence of COVID-19 in CML patients, as of Feb 21, 2020.', 'Secondary outcomes included the history of epidemiology of CML patients, the clinical characteristics and outcomes of CML patients with COVID-19 .', 'Findings  Of 392 respondents, 223( 56.9%) were males, and 240( 61.2%) were 50 years or younger.', 'Only 10 patients took drugs irregularly due to the influence of the epidemic because of traffic control, pharmacies unable to operate normally, etc.', 'In the history of epidemiology, there were 4 patients with definite contact with COVID-19, of which 3 were remote contact and 1 was close contact.', '12 respondents had fever, cough or shortness of breath during the epidemic, 1 case (common type) was confirmed with COVID-19 and cured after treatment.', '1 patient was clinically diagnosed and succumbed.', '1 of 299 (0.3%) patients with an optimal response was diagnosed with COVID-19.', 'Of the 50 patients who failed to respond to CML treatment or had a poor response, 1 patient (2%) had a clinical diagnosis of COVID-19.', 'Interpretation While the 392 CML respondents required regular referrals to hospitals, they did not have much contact with COVID-19 patients during the outbreak.', 'Patients who failed to achieved an optimal response to CML therapy appear more likely to have a symptomatic infection with SARS-CoV-2.', 'Older patients with comorbidities are at increased risk of death.', \"Dan-Yu Wang, Jing-Ming Guo, Zhuang-Zhi Yang   Co first author Dan-Yu Wang,Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital, Guangdong Medical University, Shenzhen Guangdong, China,E-mail: 15818662864@139.com Jing-Ming Guo, Department of Hematology,Yi Chang Central People's Hospital, The First College of Clinical Medical Science, China Three Gorges University, Yichang Hubei, China,E-mail:gjm425@163.com Zhuang-Zhi Yang, Department of Hematology,Suizhou Central Hospital, Suizhou Hubei, China,E-mail:yzhzh88@163.com Correspondence author:  Guo-Lin Yuan, MD, Department of Hematology, Xiangyang Central Hospital, The Affiliated Hospital of Hubei University of Arts and Science, Xiangyang Hubei, China.\", 'E-mail: yuanguo1973@163.com Li Meng, MD, Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan Hubei, China.', 'E-mail: mengli@tjh.tjmu.edu.cn Wei-Ming Li, MD, Department of Hematology, Union hospital, Tongji Medical college, Huazhong University of science and Technology, Wuhan Hubei, China.', 'E-mail: lee937@126.com']\n",
            "unmatched tags:  [{'entity': 'Li', 'type': 'Gene', 'start': 3930, 'end': 3932}, {'entity': 'Tongji Hospital', 'type': 'Chemical', 'start': 3783, 'end': 3798}, {'entity': 'Li', 'type': 'Gene', 'start': 3744, 'end': 3746}]\n",
            "['A Toolkit for Rapid Modular Construction of Biological Circuits in Mammalian Cells\\tThe ability to rapidly assemble and prototype cellular circuits is vital for biological research and its applications in biotechnology and medicine.', 'Current methods that permit the assembly of DNA circuits in mammalian cells are laborious, slow, expensive and mostly not permissive of rapid prototyping of constructs.', 'Here we present the Mammalian ToolKit (MTK), a Golden Gate-based cloning toolkit for fast, reproducible and versatile assembly of large DNA vectors and their implementation in mammalian models.', 'The MTK consists of a curated library of characterized, modular parts that can be easily mixed and matched to combinatorially assemble one transcriptional unit with different characteristics, or a hierarchy of transcriptional units weaved into complex circuits.', 'MTK renders many cell engineering operations facile, as showcased by our ability to use the toolkit to generate single-integration landing pads, to create and deliver libraries of protein variants and sgRNAs, and to iterate through Cas9-based prototype circuits.', 'As a biological proof of concept, we used the MTK to successfully design and rapidly construct in mammalian cells a challenging multicistronic circuit encoding the Ebola virus (EBOV) replication complex.', 'This construct provides a non-infectious biosafety level 2 (BSL2) cellular assay for exploring the transcription and replication steps of the EBOV viral life cycle in its host.', 'Its construction also demonstrates how the MTK can enable important and time sensitive applications such as the rapid testing of pharmacological inhibitors of emerging BSL4 viruses that pose a major threat to human health.']\n",
            "unmatched tags:  [{'entity': 'MTK', 'type': 'Chemical', 'start': 1544, 'end': 1547}]\n",
            "['The role of institutional trust in preventive and treatment-seeking behaviors during the 2019 novel coronavirus (2019-nCoV) outbreak among residents in Hubei, China\\tBackground Since December 2019, pneumonia associated with the 2019 novel coronavirus (2019-nCoV) has emerged in Wuhan, China.', 'The exponential increase of the confirmed number of cases of 2019n-CoV is of great concern to the global community.', 'The fears and panic among residents in the epicenters have prompted diverse responses, which are understudied.', 'During such a crisis, community trust and support for the government and health authorities are important to contain the outbreak.', 'We aimed to investigate the influence of institutional trust on public responses to the 2019-nCoV outbreak.', 'Methods An anonymous Internet-based, cross-sectional survey was administered on  January 29, 2020.', 'The study population comprised all residents currently residing or working in the province of Hubei, where Wuhan is the capital city.', 'The level of trust in information provision and preventive instructions, individual preventive behaviors and treatment-seeking behaviors were queried.', 'Findings The majority of the participants expressed a great extent of trust in the information and preventive instructions provided by the central government than by the local government.', 'A high uptake of 2019-nCoV preventive measures was found, particularly among people who had been placed under quarantine.', 'Being under quarantine (adjusted odds ratio [OR] = 2.35, 95% confidence interval [CI] 1.80 to 3.08) and having a high institutional trust score (OR = 2.23, 95% CI 1.96 to 2.53) were both strong and significant determinants of higher preventive behavior scores.', 'The majority of study participants (85.7%, n = 3,640) reported that they would seek hospital treatment if they suspected themselves to have been infected with 2019 n-CoV.', 'Few of the participants from Wuhan (16.6%, n = 475) and those participants who were under quarantine (13.8%, n = 550) expressed an unwillingness to seek hospital treatment.', 'Similarly, being under quarantine (OR = 2.36, 95% CI 1.80 to 3.09) and having a high institutional trust score (OR = 2.20, 95% CI 1.96 to 2.49) were two strong significant determinants of hospital treatment-seeking.', 'Interpretation The results of this study suggest that institutional trust is an important factor influencing adequate preventive behavior and seeking formal medical care during an outbreak.', 'In view of the 2019-nCoV being highly pathogenic and extremely contagious, our findings also underscore the importance of public health intervention to reach individuals with poor adherence to preventive measures and who are reluctant to seek treatment at formal health services.', 'Funding National  Key  R&D  Program  of  China, Ningbo Health Branding Subject Fund,   Sanming Project of Medicine in Shenzhen, K.C.', 'Wong Magna Fund in Ningbo University, National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities,  China Postdoctoral Science Foundation, and Natural Science Basic Research Program of Shanxi Province.', 'Keywords: 2019-nCoV;  institutional trust; preventive behaviors']\n",
            "unmatched tags:  [{'entity': '2019-nCoV', 'type': 'Virus', 'start': 3130, 'end': 3139}, {'entity': 'Ningbo University', 'type': 'Organization', 'start': 2895, 'end': 2912}, {'entity': '2019-nCoV', 'type': 'Virus', 'start': 2478, 'end': 2487}, {'entity': '2019-nCoV', 'type': 'Virus', 'start': 1346, 'end': 1355}]\n",
            "['Seasonal affective disorder\\tSeasonal affective disorder (SAD) is a form of recurrent depressive or bipolar disorder, with episodes that vary in severity.', 'Seasonal patterns of depressive episodes are common, but SAD seems to be less common than such patterns suggest.', 'SAD was at first believed to be related to abnormal melatonin metabolism, but later findings did not support this hypothesis.', 'Studies of brain serotonin function support the hypothesis of disturbed activity.', 'The short-allele polymorphism for serotonin transporter is more common in patients with SAD than in healthy people.']\n",
            "unmatched tags:  [{'entity': 'serotonin transporter', 'type': 'Gene', 'start': 509, 'end': 530}, {'entity': 'disturbed', 'type': 'Disease', 'start': 455, 'end': 464}, {'entity': 'melatonin', 'type': 'Drug', 'start': 319, 'end': 328}, {'entity': 'depressive episodes', 'type': 'Disease', 'start': 175, 'end': 194}, {'entity': 'bipolar disorder', 'type': 'Disease', 'start': 99, 'end': 115}, {'entity': 'depressive', 'type': 'Disease', 'start': 85, 'end': 95}]\n",
            "['Typhoid and paratyphoid fever\\tTyphoid fever is estimated to have caused 21·6 million illnesses and 216\\u2008500 deaths globally in 2000, affecting all ages.', 'There is also one case of paratyphoid fever for every four of typhoid.', 'The global emergence of multidrug-resistant strains and of strains with reduced susceptibility to fluoroquinolones is of great concern.', 'We discuss the occurrence of poor clinical response to fluoroquinolones despite disc sensitivity.', 'Developments are being made in our understanding of the molecular pathogenesis, and genomic and proteomic studies reveal the possibility of new targets for diagnosis and treatment.']\n",
            "unmatched tags:  [{'entity': 'proteomic studies', 'type': 'Chemical', 'start': 553, 'end': 570}, {'entity': 'fluoroquinolones', 'type': 'Drug', 'start': 414, 'end': 430}, {'entity': 'fluoroquinolones', 'type': 'Drug', 'start': 321, 'end': 337}, {'entity': 'strains', 'type': 'Disease', 'start': 282, 'end': 289}, {'entity': 'multidrug-resistant strains', 'type': 'Disease', 'start': 247, 'end': 274}]\n",
            "['Comparative analysis of primer-probe sets for the laboratory confirmation of SARS-CoV-2\\tCoronavirus disease 2019 (COVID-19) is newly emerging human infectious diseases, which is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, also previously known as 2019-nCoV).', 'Within two months of the outbreak, more than 80,000 cases of COVID-19 have been confirmed worldwide.', 'Since the human to human transmission occurred easily and the human infection is rapidly increasing, the sensitive and early diagnosis is essential to prevent the global outbreak.', 'Recently, World Health Organization (WHO) announced various primer and probe sets for SARS-CoV-2 previously developed in China, Germany, Hong Kong, Japan, Thailand, and USA.', 'In this study, we compared the ability to detect SARS-CoV-2 RNA among the seven primer-probe sets for N gene and the three primer-probe sets for Orf1 gene.', 'The result of the comparative analysis represented that the ‘2019-nCoV_N2, N3’ of USA and the ‘ORF1ab’ of China are the most sensitive primer-probe sets for N and Orf1 genes, respectively.', 'Therefore, the appropriate combination from ORF1ab (China), 2019-nCoV_N2, N3 (USA), and NIID_2019-nCOV_N (Japan) sets should be selected for the sensitive and reliable laboratory confirmation of SARS-CoV-2.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1281, 'end': 1291}]\n",
            "['The effect of diet on risk of cancer\\tDiet-related factors are thought to account for about 30% of cancers in developed countries.', 'Obesity increases the risk of cancers in the oesophagus, colorectum, breast, endometrium, and kidney.', 'Alcohol causes cancers of the oral cavity, pharynx, larynx, oesophagus, and liver, and causes a small increase in the risk of breast cancer.', 'Adequate intakes of fruit and vegetables probably lower the risk for several types of cancer, especially cancers of the gastrointestinal tract.', 'The importance of other factors, including meat, fibre, and vitamins, is not yet clear.']\n",
            "unmatched tags:  [{'entity': 'vitamins', 'type': 'Drug', 'start': 577, 'end': 585}, {'entity': 'fibre', 'type': 'Drug', 'start': 566, 'end': 571}]\n",
            "['LY6E impairs coronavirus fusion and confers immune control of viral disease\\tZoonotic coronaviruses (CoVs) are significant threats to global health, as exemplified by the recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 1 .', 'Host immune responses to CoV are complex and regulated in part through antiviral interferons.', 'However, the interferon-stimulated gene products that inhibit CoV are not well characterized 2 .', 'Here, we show that interferon-inducible lymphocyte antigen 6 complex, locus E (LY6E) potently restricts cellular infection by multiple CoVs, including SARS-CoV, SARS-CoV-2, and Middle East respiratory syndrome coronavirus (MERS-CoV).', 'Mechanistic studies revealed that LY6E inhibits CoV entry into cells by interfering with spike protein-mediated membrane fusion.', 'Importantly, mice lacking Ly6e in hematopoietic cells were highly susceptible to murine CoV infection.', 'Exacerbated viral pathogenesis in Ly6e knockout mice was accompanied by loss of hepatic and splenic immune cells and reduction in global antiviral gene pathways.', 'Accordingly, we found that Ly6e directly protects primary B cells and dendritic cells from murine CoV infection.', 'Our results demonstrate that LY6E is a critical antiviral immune effector that controls CoV infection and pathogenesis.', 'These findings advance our understanding of immune-mediated control of CoV in vitro and in vivo , knowledge that could help inform strategies to combat infection by emerging CoV.']\n",
            "unmatched tags:  [{'entity': 'CoV', 'type': 'Virus', 'start': 1481, 'end': 1484}, {'entity': 'combat', 'type': 'Disease', 'start': 1452, 'end': 1458}, {'entity': 'CoV', 'type': 'Virus', 'start': 1378, 'end': 1381}, {'entity': 'CoV', 'type': 'Virus', 'start': 1275, 'end': 1278}, {'entity': 'LY6E', 'type': 'Gene', 'start': 1216, 'end': 1220}, {'entity': 'CoV', 'type': 'Virus', 'start': 1172, 'end': 1175}, {'entity': 'murine', 'type': 'Drug', 'start': 1165, 'end': 1171}, {'entity': 'Ly6e', 'type': 'Gene', 'start': 1101, 'end': 1105}, {'entity': 'mice', 'type': 'Gene', 'start': 960, 'end': 964}, {'entity': 'Ly6e', 'type': 'Gene', 'start': 946, 'end': 950}, {'entity': 'CoV', 'type': 'Virus', 'start': 897, 'end': 900}, {'entity': 'murine', 'type': 'Drug', 'start': 890, 'end': 896}, {'entity': 'Ly6e', 'type': 'Gene', 'start': 835, 'end': 839}, {'entity': 'mice', 'type': 'Gene', 'start': 822, 'end': 826}, {'entity': 'CoV', 'type': 'Virus', 'start': 728, 'end': 731}, {'entity': 'LY6E', 'type': 'Gene', 'start': 714, 'end': 718}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 669, 'end': 677}, {'entity': 'Middle East respiratory syndrome coronavirus', 'type': 'Virus', 'start': 623, 'end': 667}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 607, 'end': 617}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 597, 'end': 605}, {'entity': 'CoVs', 'type': 'Virus', 'start': 581, 'end': 585}, {'entity': 'LY6E', 'type': 'Gene', 'start': 525, 'end': 529}, {'entity': 'CoV', 'type': 'Virus', 'start': 411, 'end': 414}, {'entity': 'interferon-stimulated gene products', 'type': 'Gene', 'start': 362, 'end': 397}, {'entity': 'antiviral interferons', 'type': 'Gene', 'start': 326, 'end': 347}, {'entity': 'CoV', 'type': 'Virus', 'start': 280, 'end': 283}]\n",
            "['Low back pain in rural Tibet\\tIn a baseline assessment of 30 rural villages surrounding Shigatse City, Tibet, many people, especially women, identified low back pain as a serious health problem.', 'Consequently, we aimed to establish the prevalence of such pain and to develop appropriate interventions.', 'We did a cross-sectional study of the prevalence of low back pain and related functional disability using two-stage random cluster sampling.', 'We included 499 adults aged at least 15 years from 19 villages.', 'The point prevalence of low back pain was 34·1% (95% CI 27·9–40·3% [170 people]); the 12-month prevalence was 41·9% (35·5–48·3% [209 people]).']\n",
            "unmatched tags:  [{'entity': 'pain', 'type': 'Phenotype', 'start': 538, 'end': 542}]\n",
            "['Juvenile idiopathic arthritis\\tJuvenile idiopathic arthritis is a heterogeneous group of diseases characterised by arthritis of unknown origin with onset before age of 16 years.', 'Pivotal studies in the past 5 years have led to substantial progress in various areas, ranging from disease classification to new treatments.', 'Gene expression profiling studies have identified different immune mechanisms in distinct subtypes of the disease, and can help to redefine disease classification criteria.', 'Moreover, immunological studies have shown that systemic juvenile idiopathic arthritis is an acquired autoinflammatory disease, and have led to successful studies of both interleukin-1 and interleukin-6 blockade.']\n",
            "unmatched tags:  [{'entity': 'interleukin-6', 'type': 'Gene', 'start': 681, 'end': 694}, {'entity': 'interleukin-1', 'type': 'Gene', 'start': 663, 'end': 676}, {'entity': 'autoinflammatory disease', 'type': 'Disease', 'start': 594, 'end': 618}, {'entity': 'systemic juvenile idiopathic arthritis', 'type': 'Disease', 'start': 540, 'end': 578}, {'entity': 'arthritis', 'type': 'Disease', 'start': 114, 'end': 123}]\n",
            "['Cryo-electron microscopy structure of the SADS-CoV spike glycoprotein provides insights into an evolution of unique coronavirus spike proteins\\tThe current outbreak of Coronavirus Disease 2019 (COVID-19) by a novel betacoronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has aroused great public health concern.', 'Coronavirus has a history of causing epidemics in human and animals.', 'In 2017 an outbreak in piglets by a novel coronavirus was emerged designated as swine acute diarrhea syndrome coronavirus (SADS-CoV) which is originated from the same genus of horseshoe bats ( Rhinolophus ) as Severe Acute Respiratory Syndrome CoV (SARS-CoV) having a broad species tropism.', 'In addition to human cells, it can also infect cell lines from diverse species.', 'Coronavirus host range is determined by its spike glycoprotein (S).', 'Given the importance of S protein in viral entry to cells and host immune responses, here we report the cryo-EM structure of the SADS-CoV S in the prefusion conformation at a resolution of 3.55 Å.', 'Our study reveals that SADS-CoV S structure takes an intra-subunit quaternary packing mode where the NTD and CTD from the same subunit pack together by facing each other.', 'The comparison of NTD and CTD with that of the other four genera suggests the evolutionary process of the SADS-CoV S. Moreover, SADS-CoV S has several characteristic structural features, such as more compact architecture of S trimer, and masking of epitopes by glycan shielding, which may facilitate viral immune evasion.', 'These data provide new insights into the evolutionary relationships of SADS-CoV S and would extend our understanding of structural and functional diversity, which will facilitate to vaccine development.']\n",
            "unmatched tags:  [{'entity': 'vaccine', 'type': 'Drug', 'start': 1712, 'end': 1719}, {'entity': 'SADS-CoV', 'type': 'Virus', 'start': 1601, 'end': 1609}, {'entity': 'SADS-CoV', 'type': 'Virus', 'start': 1336, 'end': 1344}, {'entity': 'SADS-CoV', 'type': 'Virus', 'start': 1314, 'end': 1322}, {'entity': 'CTD', 'type': 'Gene', 'start': 1234, 'end': 1237}, {'entity': 'CTD', 'type': 'Gene', 'start': 1146, 'end': 1149}, {'entity': 'SADS-CoV', 'type': 'Virus', 'start': 1060, 'end': 1068}, {'entity': 'SADS-CoV', 'type': 'Virus', 'start': 969, 'end': 977}, {'entity': 'S protein', 'type': 'Gene', 'start': 864, 'end': 873}, {'entity': 'spike glycoprotein', 'type': 'Gene', 'start': 816, 'end': 834}, {'entity': 'Coronavirus', 'type': 'Virus', 'start': 772, 'end': 783}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 650, 'end': 658}, {'entity': 'Severe Acute Respiratory Syndrome CoV', 'type': 'Disease', 'start': 611, 'end': 648}, {'entity': 'SADS-CoV', 'type': 'Virus', 'start': 524, 'end': 532}, {'entity': 'swine acute diarrhea syndrome coronavirus', 'type': 'Chemical', 'start': 481, 'end': 522}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 443, 'end': 454}, {'entity': 'Coronavirus', 'type': 'Virus', 'start': 332, 'end': 343}]\n",
            "[\"Investigation of frailty as a moderator of the relationship between neuropathology and dementia in Alzheimer's disease: a cross-sectional analysis of data from the Rush Memory and Aging Project\\tThe degree of frailty among people of the same age modifies the association between Alzheimer's disease pathology and Alzheimer's dementia.\", \"That frailty is related to both odds of Alzheimer's dementia and disease expression has implications for clinical management, since individuals with even a low level of Alzheimer's disease pathology might be at risk for dementia if they have high amounts of frailty.\", 'Further research should assess how frailty and cognition change over time to better elucidate this complex relationship.']\n",
            "unmatched tags:  [{'entity': 'dementia', 'type': 'Disease', 'start': 554, 'end': 562}]\n",
            "['Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration\\tAccess to medicines and vaccines to prevent and treat non-communicable diseases (NCDs) is unacceptably low worldwide.', 'In the 2011 UN political declaration on the prevention and control of NCDs, heads of government made several commitments related to access to essential medicines, technologies, and vaccines for such diseases.', '30 years of experience with policies for essential medicines and 10 years of scaling up of HIV treatment have provided the knowledge needed to address barriers to long-term effective treatment and prevention of NCDs.']\n",
            "unmatched tags:  [{'entity': 'HIV', 'type': 'Virus', 'start': 547, 'end': 550}, {'entity': 'medicines', 'type': 'Drug', 'start': 507, 'end': 516}, {'entity': 'diseases', 'type': 'Disease', 'start': 446, 'end': 454}, {'entity': 'vaccines', 'type': 'Drug', 'start': 428, 'end': 436}, {'entity': 'medicines', 'type': 'Drug', 'start': 399, 'end': 408}, {'entity': 'government', 'type': 'Organization', 'start': 332, 'end': 342}]\n",
            "['COVID-19 Outbreak Situations in Bangladesh: An Empirical Analysis\\tCOVID-19 disease, as popularly known as Coronavirus 2019 disease, has been emerged from Wuhan, China in December 2019 and now is a pandemic for almost every nation in the earth.', \"It affects every country without considering country's race, nationality and economic status.\", 'This paper aims at analysing primarily the current situations of Bangladesh and predicting infections and deaths for moderated term intervals by a proposed projection technique called Infection Trajectory-Pathway Strategy (ITPS) and for short term intervals prediction for total infections, deaths along with total number of severe patients and Intensive Care Unit (ICU) patients by polynomial regression modeling approach.', 'Since April 7, Bangladesh has started to face critical situations as the number of infections has accelerated very fast in the following days.', 'However, the fatality rate decreases considerably from 15.7 on April 1 to 4.9 on April 14, which is still high among the south asian countries.', 'Of the 1012 cases reported on April 14, almost 70\\\\% are the male, 42\\\\% are from the capital Dhaka.', 'We have found that the potential pathway of infections for Bangldesh would be the similar pathways that are experienced by Austria, Netherlands, Israel, France and United Kingdom.', 'These countries are ahead a number of weeks and days in terms of infection cases since their 100-th confirmed cases.', 'Our proposed projection method ITPS suggests that by May 10, Bangladesh will cross 12000 incidences and 720 deaths which, by May 16 will be 27000 and 1644 respectively.', 'On the other hand, the regression model suggests that by the end of April, total number of infections, deaths, severe patients and ICU patients will be 5780, 347, 775, and 694 respectively.', 'This study will be favorable for the administrative units of Bangladesh to plan for the next few weeks and to consider various aspects related to the control of COVID-19 outspread in Bangladesh']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 1965, 'end': 1973}]\n",
            "['Aberrant pathogenic GM-CSF\\tPathogenic human coronavirus infections, such as severe acute respiratory syndrome CoV (SARS-CoV) and Middle East respiratory syndrome CoV (MERS-CoV), cause high morbidity and mortality 1 , 2 .', 'Recently, a severe pneumonia-associated respiratory syndrome caused by a new coronavirus was reported at December 2019 (2019-nCoV) in the city Wuhan, Hubei province, China 3 – 5 , which was also named as pneumonia-associated respiratory syndrome (PARS) 6 .', 'Up to 9th of February 2020, at least 37, 251 cases have been reported with 812 fatal cases according to the report from China CDC.', 'However, the immune mechanism that potential orchestrated acute mortality from patients of 2019-nCoV is still unknown.', 'Here we show that after the 2019-nCoV infection, CD4 + T lymphocytes are rapidly activated to become pathogenic T helper (Th) 1 cells and generate GM-CSF etc.', 'The cytokines environment induces inflammatory CD14 + CD16 + monocytes with high expression of IL-6 and accelerates the inflammation.', 'These aberrant and excessive immune cells may enter the pulmonary circulation in huge numbers and play an immune damaging role to causing lung functional disability and quick mortality.', 'Our results demonstrate that excessive non-effective host immune responses by pathogenic T cells and inflammatory monocytes may associate with severe lung pathology.', 'Therefore, we suggest that monoclonal antibody that targets the GM-CSF or interleukin 6 receptor may potentially curb immunopathology caused by 2019-nCoV and consequently win more time for virus clearance.']\n",
            "unmatched tags:  [{'entity': '2019-nCoV', 'type': 'Virus', 'start': 1517, 'end': 1526}, {'entity': 'interleukin 6 receptor', 'type': 'Gene', 'start': 1447, 'end': 1469}, {'entity': 'GM-CSF', 'type': 'Gene', 'start': 1437, 'end': 1443}, {'entity': 'monoclonal antibody', 'type': 'Drug', 'start': 1400, 'end': 1419}, {'entity': 'Th', 'type': 'Gene', 'start': 1373, 'end': 1375}, {'entity': 'Th', 'type': 'Gene', 'start': 1021, 'end': 1023}, {'entity': 'IL-6', 'type': 'Gene', 'start': 982, 'end': 986}, {'entity': 'CD16', 'type': 'Gene', 'start': 941, 'end': 945}, {'entity': 'CD14 +', 'type': 'Gene', 'start': 934, 'end': 940}]\n",
            "['Effect of mutated\\tactivation by genotoxic drugs can induce apoptosis or cell-cycle arrest.', 'Thus, whether the gene is mutated or wild type could affect the response of a tumour to chemotherapy.', 'Clinical data are unclear, possibly as a result of heterogeneity of tumours, drugs, methods of assessing response, or']\n",
            "unmatched tags:  [{'entity': 'tumours', 'type': 'Disease', 'start': 261, 'end': 268}]\n",
            "['Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action\\tThe Millennium Development Goal target for tuberculosis control is to halt the spread of tuberculosis by 2015, and begin to reverse the worldwide incidence.', 'After the introduction of standard control practices in 1995, 36 million people were cured and about 6 million deaths were averted.', 'However, substantial scientific advances and innovative solutions are urgently needed together with creative new strategies.', 'Strong international and national political commitment is essential.', 'Urgent action is needed by national governments to fund their own programmes, and for the G8 countries and other donor governments and organisations to support governmental and non-governmental efforts.']\n",
            "unmatched tags:  [{'entity': 'governmental', 'type': 'Organization', 'start': 782, 'end': 794}, {'entity': 'governmental', 'type': 'Organization', 'start': 761, 'end': 773}, {'entity': 'donor governments', 'type': 'Organization', 'start': 714, 'end': 731}]\n",
            "['A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein\\tSARS-CoV-2 is a zoonotic virus that has caused a pandemic of severe respiratory disease—COVID-19— within several months of its initial identification.', 'Comparable to the first SARS-CoV, this novel coronavirus’s surface Spike (S) glycoprotein mediates cell entry via the human ACE-2 receptor, and, thus, is the principal target for the development of vaccines and immunotherapeutics.', 'Molecular information on the SARS-CoV-2 S glycoprotein remains limited.', 'Here we report the crystal structure of the SARS-CoV-2 S receptor-binding-domain (RBD) at a the highest resolution to date, of 1.95 Å.', 'We identified a set of SARS-reactive monoclonal antibodies with cross-reactivity to SARS-CoV-2 RBD and other betacoronavirus S glycoproteins.', 'One of these antibodies, CR3022, was previously shown to synergize with antibodies that target the ACE-2 binding site on the SARS-CoV RBD and reduce viral escape capacity.', 'We determined the structure of CR3022, in complex with the SARS-CoV-2 RBD, and defined a broadly reactive epitope that is highly conserved across betacoronaviruses.', 'This epitope is inaccessible in the “closed” prefusion S structure, but is accessible in “open” conformations.', 'This first-ever resolution of a human antibody in complex with SARS-CoV-2 and the broad reactivity of this set of antibodies to a conserved betacoronavirus epitope will allow antigenic assessment of vaccine candidates, and provide a framework for accelerated vaccine, immunotherapeutic and diagnostic strategies against SARS-CoV-2 and related betacoronaviruses.', 'HIGHLIGHTS High resolution structure of the SARS-CoV-2 Receptor-Binding-Domain (RBD).', 'Recognition of the SARS-CoV-2 RBD by SARS-CoV antibodies.', 'Structure of the SARS-COV-2 RBD in complex with antibody CR3022.', 'Identification of a cryptic site of vulnerability on the SARS-CoV-2 Spike.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1907, 'end': 1917}, {'entity': 'cryptic site', 'type': 'Gene', 'start': 1870, 'end': 1882}, {'entity': 'CR3022', 'type': 'Gene', 'start': 1842, 'end': 1848}, {'entity': 'RBD', 'type': 'Gene', 'start': 1813, 'end': 1816}, {'entity': 'SARS-COV-2', 'type': 'Virus', 'start': 1802, 'end': 1812}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 1764, 'end': 1772}, {'entity': 'RBD', 'type': 'Gene', 'start': 1757, 'end': 1760}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1746, 'end': 1756}, {'entity': 'RBD', 'type': 'Gene', 'start': 1721, 'end': 1724}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1685, 'end': 1695}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 1626, 'end': 1637}, {'entity': 'betacoronaviruses', 'type': 'Virus', 'start': 1622, 'end': 1639}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1599, 'end': 1609}, {'entity': 'immunotherapeutic', 'type': 'Drug', 'start': 1547, 'end': 1564}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1538, 'end': 1545}, {'entity': 'candidates', 'type': 'Gene', 'start': 1486, 'end': 1496}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1478, 'end': 1485}, {'entity': 'conserved betacoronavirus epitope', 'type': 'Virus', 'start': 1409, 'end': 1442}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1342, 'end': 1352}]\n",
            "['Transmission of drug-resistant tuberculosis in HIV-endemic settings\\tThe emergence and expansion of the multidrug-resistant tuberculosis epidemic is a threat to the global control of tuberculosis.', 'Multidrug-resistant tuberculosis is the result of the selection of resistance-conferring mutations during inadequate antituberculosis treatment.', 'However, HIV has a profound effect on the natural history of tuberculosis, manifesting in an increased rate of disease progression, leading to increased transmission and amplification of multidrug-resistant tuberculosis.', 'Interventions specific to HIV-endemic areas are urgently needed to block tuberculosis transmission.']\n",
            "unmatched tags:  [{'entity': 'tuberculosis', 'type': 'Disease', 'start': 635, 'end': 647}, {'entity': 'block tuberculosis', 'type': 'Disease', 'start': 629, 'end': 647}, {'entity': 'multidrug-resistant tuberculosis', 'type': 'Disease', 'start': 528, 'end': 560}, {'entity': 'tuberculosis', 'type': 'Disease', 'start': 402, 'end': 414}, {'entity': 'HIV', 'type': 'Virus', 'start': 350, 'end': 353}, {'entity': 'tuberculosis', 'type': 'Disease', 'start': 317, 'end': 329}, {'entity': 'antituberculosis', 'type': 'Drug', 'start': 313, 'end': 329}, {'entity': 'drug-resistant tuberculosis', 'type': 'Disease', 'start': 201, 'end': 228}]\n",
            "['Chronic constipation: new insights, better outcomes?', 'Constipation is a symptom that affects around 11–20% of the adult population yearly.', 'Most physicians consider infrequency of defecation as a hallmark of constipation.', 'However, most patients view excessive straining as the biggest component of constipation and only a minority of patients with constipation have infrequent bowel movements.', 'Constipation might be due to many different medical conditions or occur as a side-effect of drug therapy.', 'When these medical conditions or drug therapies are not present, a diagnosis of functional constipation, chronic idiopathic constipation, or irritable bowel syndrome with constipation is often made.']\n",
            "unmatched tags:  [{'entity': 'constipation', 'type': 'Phenotype', 'start': 669, 'end': 681}]\n",
            "['The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice\\tSevere acute respiratory syndrome CoV-2 (SARS-CoV-2) caused the Corona Virus Disease 2019 (COVID-19) cases in China has become a public health emergency of international concern (PHEIC).', 'Based on angiotensin converting enzyme 2 (ACE2) as cell entry receptor of SARS-CoV, we used the hACE2 transgenic mice infected with SARS-CoV-2 to study the pathogenicity of the virus.', 'Weight loss and virus replication in lung were observed in hACE2 mice infected with SARS-CoV-2.', 'The typical histopathology was interstitial pneumonia with infiltration of significant lymphocytes and monocytes in alveolar interstitium, and accumulation of macrophages in alveolar cavities.', 'Viral antigens were observed in the bronchial epithelial cells, alveolar macrophages and alveolar epithelia.', 'The phenomenon was not found in wild type mice with SARS-CoV-2 infection.', 'The pathogenicity of SARS-CoV-2 in hACE2 mice was clarified and the Koch’s postulates were fulfilled as well, and the mouse model may facilitate the development of therapeutics and vaccines against SARS-CoV-2.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1098, 'end': 1108}, {'entity': 'vaccines', 'type': 'Drug', 'start': 1081, 'end': 1089}, {'entity': 'Koch’s', 'type': 'Gene', 'start': 968, 'end': 974}, {'entity': 'hACE2 mice', 'type': 'Gene', 'start': 935, 'end': 945}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 921, 'end': 931}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 878, 'end': 888}, {'entity': 'wild type mice', 'type': 'Gene', 'start': 858, 'end': 872}, {'entity': 'interstitial pneumonia', 'type': 'Disease', 'start': 555, 'end': 577}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 512, 'end': 522}]\n",
            "['Enisamium is a small molecule inhibitor of the influenza A virus and SARS-CoV-2 RNA polymerases\\tInfluenza A virus and coronavirus strains cause a mild to severe respiratory disease that can result in death.', 'Although vaccines exist against circulating influenza A viruses, such vaccines are ineffective against emerging pandemic influenza A viruses.', 'Currently, no vaccine exists against coronavirus infections, including pandemic SARS-CoV-2, the causative agent of the Coronavirus Disease 2019 (COVID-19).', 'To combat these RNA virus infections, alternative antiviral strategies are needed.', 'A key drug target is the viral RNA polymerase, which is responsible for viral RNA synthesis.', 'In January 2020, the World Health Organisation identified enisamium as a candidate therapeutic against SARS-CoV-2.', 'Enisamium is an isonicotinic acid derivative that is an inhibitor of multiple influenza B and A virus strains in cell culture and clinically approved in 11 countries.', 'Here we show using in vitro assays that enisamium and its putative metabolite, VR17-04, inhibit the activity of both the influenza virus RNA polymerase as well as the SARS-CoV-2 RNA polymerase complex.', 'These results suggest that enisamium is a broad-spectrum small molecule inhibitor of RNA virus RNA synthesis, and implicate it as a possible therapeutic option for treating SARS-CoV-2 infection.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1338, 'end': 1348}, {'entity': 'RNA', 'type': 'Gene', 'start': 1260, 'end': 1263}, {'entity': 'RNA virus', 'type': 'Virus', 'start': 1250, 'end': 1259}, {'entity': 'small molecule', 'type': 'Drug', 'start': 1222, 'end': 1236}, {'entity': 'enisamium', 'type': 'Drug', 'start': 1192, 'end': 1201}, {'entity': 'RNA', 'type': 'Gene', 'start': 1141, 'end': 1144}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1130, 'end': 1140}, {'entity': 'influenza virus RNA polymerase', 'type': 'Gene', 'start': 1084, 'end': 1114}, {'entity': 'enisamium', 'type': 'Drug', 'start': 1003, 'end': 1012}, {'entity': 'multiple influenza B', 'type': 'Drug', 'start': 865, 'end': 885}, {'entity': 'isonicotinic acid derivative', 'type': 'Drug', 'start': 812, 'end': 840}]\n",
            "['Serum-dependent and independent regulation of PARP2\\tPARP2 belongs to a family of proteins involved in cell differentiation, DNA damage repair, cellular energy expenditure, chromatin modeling and cell differentiation.', 'In addition to these overlapping functions with PARP1, PARP2 participates in spermatogenesis, T-cell maturation, extraembryonic endoderm formation and adipogenesis.', 'The function(s) of PARP2 is far from complete, and the mechanism(s) by which the gene and protein are regulated are unknown.', 'In this study, we found that two different mechanisms are used in vitro to regulate PARP2 levels.', 'In the presence of serum, PARP2 is degraded through the ubiquitin-proteasome pathway, however, when serum is removed, PARP2 is rapidly sequestered into an SDS- and urea-insoluble fraction.', 'This sequestration is relieved by serum in a dose-dependent manner, and again PARP2 is detected by immunoblotting.', 'Furthermore, and despite the presence of a putative serum response element in the PARP2 gene, transcription is not affected by serum deprivation.', 'These observations that PARP2 is tightly regulated by distinct pathways highlights the critical roles PARP2 plays under different physiological conditions.']\n",
            "unmatched tags:  [{'entity': 'PARP2', 'type': 'Gene', 'start': 1157, 'end': 1162}, {'entity': 'PARP2', 'type': 'Gene', 'start': 1079, 'end': 1084}, {'entity': 'PARP2 gene', 'type': 'Gene', 'start': 991, 'end': 1001}, {'entity': 'serum response element', 'type': 'Gene', 'start': 961, 'end': 983}, {'entity': 'PARP2', 'type': 'Gene', 'start': 872, 'end': 877}, {'entity': 'PARP2', 'type': 'Gene', 'start': 723, 'end': 728}, {'entity': 'PARP2', 'type': 'Gene', 'start': 631, 'end': 636}, {'entity': 'PARP2', 'type': 'Gene', 'start': 591, 'end': 596}, {'entity': 'protein', 'type': 'Gene', 'start': 472, 'end': 479}]\n",
            "['Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome\\tTherapy-related augmentation of the symptoms of restless legs syndrome (RLS) is an important clinical problem reported in up to 60% of patients treated with levodopa and, to a lesser extent, with dopamine agonists.', 'The efficacy of low-dose dopaminergic drugs for RLS has been established, but the mode of action is unknown.', 'Here, we review the existing data and conclude that augmentation is a syndrome characterised by a severely increased dopamine concentration in the CNS; overstimulation of the dopamine D1 receptors compared with D2 receptors in the spinal cord may lead to D1-related pain and generate periodic limb movements; iron deficiency may be a main predisposing factor of augmentation, probably caused by a reduced function of the dopamine transporter; therapy with levodopa or dopamine agonists should remain at low doses and; iron supplementation and opiates are the therapy of choice to counter augmentation.']\n",
            "unmatched tags:  [{'entity': 'opiates', 'type': 'Drug', 'start': 968, 'end': 975}, {'entity': 'dopamine agonists', 'type': 'Drug', 'start': 893, 'end': 910}, {'entity': 'levodopa', 'type': 'Gene', 'start': 881, 'end': 889}, {'entity': 'dopamine transporter', 'type': 'Gene', 'start': 846, 'end': 866}, {'entity': 'iron deficiency', 'type': 'Disease', 'start': 734, 'end': 749}, {'entity': 'D2 receptors', 'type': 'Gene', 'start': 636, 'end': 648}, {'entity': 'dopamine D1 receptors', 'type': 'Gene', 'start': 600, 'end': 621}, {'entity': 'dopamine', 'type': 'Drug', 'start': 542, 'end': 550}, {'entity': 'syndrome', 'type': 'Disease', 'start': 495, 'end': 503}, {'entity': 'RLS', 'type': 'Disease', 'start': 364, 'end': 367}, {'entity': 'dopaminergic drugs', 'type': 'Drug', 'start': 341, 'end': 359}, {'entity': 'dopamine agonists', 'type': 'Drug', 'start': 297, 'end': 314}, {'entity': 'levodopa', 'type': 'Gene', 'start': 258, 'end': 266}]\n",
            "['First estimates of the global and regional incidence of neonatal herpes infection\\tThese neonatal herpes estimates mark the first attempt to quantify the global burden of this rare but serious condition.', 'Better collection of primary data for neonatal herpes is crucially needed to reduce uncertainty and refine future estimates.', 'These data are particularly important in resource-poor settings where we may have underestimated cases.', 'Nevertheless, these first estimates suggest development of new HSV prevention measures such as vaccines could have additional benefits beyond reducing genital ulcer disease and HSV-associated HIV transmission, through prevention of neonatal herpes.']\n",
            "unmatched tags:  [{'entity': 'neonatal herpes', 'type': 'Disease', 'start': 664, 'end': 679}, {'entity': 'HIV', 'type': 'Virus', 'start': 624, 'end': 627}, {'entity': 'genital ulcer disease', 'type': 'Disease', 'start': 583, 'end': 604}, {'entity': 'vaccines', 'type': 'Drug', 'start': 527, 'end': 535}, {'entity': 'HSV', 'type': 'Virus', 'start': 495, 'end': 498}]\n",
            "['Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial\\tWBRT and ASCT are both feasible and effective as consolidation therapies after high-dose methotrexate-based chemoimmunotherapy in patients aged 70 years or younger with primary CNS lymphoma.', 'The risks and implications of cognitive impairment after WBRT should be considered at the time of therapeutic decision.']\n",
            "unmatched tags:  [{'entity': 'cognitive impairment', 'type': 'Phenotype', 'start': 513, 'end': 533}]\n",
            "['Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study\\tOur results suggest that prognosis is poor for patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia owing to both therapy-resistant disease and treatment-related toxicities.', 'Improved surveillance algorithms and risk stratification tools, studies of clonal evolution, and prospective trials are needed to inform effective prevention and treatment strategies for leukaemia predisposition in patients with Shwachman-Diamond syndrome.']\n",
            "unmatched tags:  [{'entity': 'Shwachman-Diamond syndrome', 'type': 'Disease', 'start': 622, 'end': 648}, {'entity': 'leukaemia', 'type': 'Disease', 'start': 580, 'end': 589}, {'entity': 'clonal evolution', 'type': 'Disease', 'start': 468, 'end': 484}, {'entity': 'treatment-related toxicities', 'type': 'Disease', 'start': 363, 'end': 391}]\n",
            "['SARS-CoV-2 is sensitive to type I interferon pretreatment\\tSARS-CoV-2, a novel coronavirus (CoV), has recently emerged causing an ongoing outbreak of viral pneumonia around the world.', 'While genetically distinct from the original SARS-CoV, both group 2B CoVs share similar genome organization and origins to coronaviruses harbored in bats.', 'Importantly, initial guidance has used insights from SARS-CoV infection to inform treatment and public health strategies.', 'In this report, we evaluate type-I Interferon (IFN-I) sensitivity of SARS-CoV-2 relative to the original SARS-CoV.', 'Our results indicate that while SARS-CoV-2 maintains similar viral replication kinetics to SARS-CoV in Vero cell, the novel CoV is much more sensitive to IFN-I pretreatment.', 'Examining transcriptional factor activation and interferon stimulated gene (ISG) induction, SARS-CoV-2 in the context of type I IFN induces phosphorylation of STAT1 and increased ISG proteins.', 'In contrast, the original SARS-CoV has no evidence for STAT1 phosphorylation or ISG protein increases even in the presence of type I IFN pretreatment.', 'Next, we examined IFN competent Calu3 2B4 cells finding SARS-CoV-2 had reduced viral replication relative to SARS-CoV and induced STAT1 phosphorylation late during infection.', 'Finally, we examined homology between SARS-CoV and SARS-CoV-2 in viral proteins shown to be interferon antagonist.', 'The absence of open reading frame (ORF) 3b and significant changes to ORF6 suggest the two key IFN antagonists may not maintain equivalent function in SARS-CoV-2.', 'Together, the results identify key differences in susceptibility to the IFN-I response between SARS-CoV and SARS-CoV-2.', 'that could help inform disease progression, treatment options, and animal model development.', 'Importance With the ongoing outbreak of COVID-19 disease, differences between the SARS-CoV-2 and the original SARS-CoV could be leveraged to inform disease progression and eventual treatment options.', 'In addition, these findings could have key implications for animal model development as well as further research into how SARS-CoV-2 modulates the type I IFN response early during infection.']\n",
            "unmatched tags:  [{'entity': 'IFN', 'type': 'Gene', 'start': 2113, 'end': 2116}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 2081, 'end': 2091}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 1869, 'end': 1877}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1841, 'end': 1851}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1654, 'end': 1664}, {'entity': 'CoV', 'type': 'Virus', 'start': 1646, 'end': 1649}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 1641, 'end': 1649}, {'entity': 'IFN-I', 'type': 'Chemical', 'start': 1618, 'end': 1623}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1534, 'end': 1544}, {'entity': 'IFN', 'type': 'Gene', 'start': 1478, 'end': 1481}, {'entity': 'ORF6', 'type': 'Gene', 'start': 1453, 'end': 1457}, {'entity': 'open reading frame', 'type': 'Gene', 'start': 1398, 'end': 1416}, {'entity': 'interferon antagonist', 'type': 'Gene', 'start': 1360, 'end': 1381}, {'entity': 'viral proteins', 'type': 'Gene', 'start': 1333, 'end': 1347}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1319, 'end': 1329}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 1306, 'end': 1314}, {'entity': 'STAT1', 'type': 'Gene', 'start': 1223, 'end': 1228}, {'entity': 'CoV', 'type': 'Virus', 'start': 1207, 'end': 1210}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 1202, 'end': 1210}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1149, 'end': 1159}, {'entity': 'Calu3 2B4 cells', 'type': 'Gene', 'start': 1125, 'end': 1140}, {'entity': 'IFN', 'type': 'Gene', 'start': 1111, 'end': 1114}, {'entity': 'IFN', 'type': 'Gene', 'start': 1075, 'end': 1078}]\n",
            "['Stapled versus excision haemorrhoidectomy: long-term follow up of a randomised controlled trial\\tAdvantages of the stapling procedure for haemorrhoids include reduced postoperative pain and shortened convalescence; however, there are few data with respect to functional and symptomatic outcome.', 'At a dedicated clinic, we reviewed patients between Dec, 2001, and March, 2002, who had taken part in a randomised controlled trial undertaken at the unit in 1999, which compared outcomes after open or stapled haemorrhoidectomy.', 'We noted the presence or absence of haemorrhoid specific symptoms, and assessed overall satisfaction, continence, and quality of life.']\n",
            "unmatched tags:  [{'entity': 'continence', 'type': 'Disease', 'start': 625, 'end': 635}, {'entity': 'haemorrhoid', 'type': 'Disease', 'start': 559, 'end': 570}, {'entity': 'haemorrhoid', 'type': 'Disease', 'start': 504, 'end': 515}, {'entity': 'postoperative pain', 'type': 'Phenotype', 'start': 166, 'end': 184}]\n",
            "['Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis\\tAutosomal dominant cerebellar ataxias are hereditary neurodegenerative disorders that are known as spinocerebellar ataxias (SCA) in genetic nomenclature.', 'In the pregenomic era, ataxias were some of the most poorly understood neurological disorders; the unravelling of their molecular basis enabled precise diagnosis in vivo and explained many clinical phenomena such as anticipation and variable phenotypes even within one family.', 'However, the discovery of many ataxia genes and loci in the past decade threatens to cause more confusion than optimism among clinicians.']\n",
            "unmatched tags:  [{'entity': 'confusion', 'type': 'Disease', 'start': 612, 'end': 621}, {'entity': 'ataxia genes', 'type': 'Phenotype', 'start': 547, 'end': 559}, {'entity': 'neurological disorders', 'type': 'Disease', 'start': 310, 'end': 332}, {'entity': 'ataxias', 'type': 'Phenotype', 'start': 262, 'end': 269}, {'entity': 'SCA', 'type': 'Disease', 'start': 209, 'end': 212}, {'entity': 'spinocerebellar ataxias', 'type': 'Disease', 'start': 184, 'end': 207}]\n",
            "['SARS-CoV-2, an evolutionary perspective of interaction with human ACE2 reveals undiscovered amino acids necessary for complex stability\\tThe emergence of SARS-CoV-2 has resulted in more than 200,000 infections and nearly 9,000 deaths globally so far.', 'This novel virus is thought to have originated from an animal reservoir, and acquired the ability to infect human cells using the SARS-CoV cell receptor hACE2.', 'In the wake of a global pandemic it is essential to improve our understanding of the evolutionary dynamics surrounding the origin and spread of a novel infectious disease.', 'One way theory predicts selection pressures should shape viral evolution is to enhance binding with host cells.', 'We first assessed evolutionary dynamics in select betacoronavirus spike protein genes to predict where these genomic regions are under directional or purifying selection between divergent viral lineages at various scales of relatedness.', 'With this analysis, we determine a region inside the receptor-binding domain with putative sites under positive selection interspersed among highly conserved sites, which are implicated in structural stability of the viral spike protein and its union with human receptor hACE2.', 'Next, to gain further insights into factors associated with coronaviruses recognition of the human host receptor, we performed modeling studies of five different coronaviruses and their potential binding to hACE2.', 'Modeling results indicate that interfering with the salt bridges at hot spot 353 could be an effective strategy for inhibiting binding, and hence for the prevention of coronavirus infections.', 'We also propose that a glycine residue at the receptor binding domain of the spike glycoprotein can have a critical role in permitting bat variants of the coronaviruses to infect human cells.']\n",
            "unmatched tags:  [{'entity': 'coronaviruses', 'type': 'Virus', 'start': 1770, 'end': 1783}, {'entity': 'spike glycoprotein', 'type': 'Gene', 'start': 1692, 'end': 1710}, {'entity': 'coronavirus infections', 'type': 'Disease', 'start': 1591, 'end': 1613}, {'entity': 'salt bridges', 'type': 'Chemical', 'start': 1475, 'end': 1487}, {'entity': 'hACE2', 'type': 'Chemical', 'start': 1416, 'end': 1421}, {'entity': 'coronaviruses', 'type': 'Virus', 'start': 1371, 'end': 1384}, {'entity': 'host receptor', 'type': 'Gene', 'start': 1308, 'end': 1321}, {'entity': 'coronaviruses recognition', 'type': 'Virus', 'start': 1269, 'end': 1294}]\n",
            "['Alcohol use disorders\\tAlcohol use disorders consist of disorders characterised by compulsive heavy alcohol use and loss of control over alcohol intake.', 'Alcohol use disorders are some of the most prevalent mental disorders globally, especially in high-income and upper-middle-income countries; and are associated with high mortality and burden of disease, mainly due to medical consequences, such as liver cirrhosis or injury.', 'Despite their high prevalence, alcohol use disorders are undertreated partly because of the high stigma associated with them, but also because of insufficient systematic screening in primary health care, although effective and cost-effective psychosocial and pharmacological interventions do exist.']\n",
            "unmatched tags:  [{'entity': 'alcohol use disorders', 'type': 'Disease', 'start': 457, 'end': 478}, {'entity': 'injury', 'type': 'Disease', 'start': 418, 'end': 424}, {'entity': 'liver cirrhosis', 'type': 'Disease', 'start': 399, 'end': 414}, {'entity': 'upper-middle-income countries', 'type': 'Gene', 'start': 262, 'end': 291}, {'entity': 'high-income', 'type': 'Gene', 'start': 246, 'end': 257}, {'entity': 'disorders', 'type': 'Disease', 'start': 212, 'end': 221}, {'entity': 'mental disorders', 'type': 'Disease', 'start': 205, 'end': 221}, {'entity': 'Alcohol use disorders', 'type': 'Disease', 'start': 152, 'end': 173}]\n",
            "['Microbial and autoantibody immunogenic repertoires in TIF1γ autoantibody positive dermatomyositis\\tWe investigate the accumulated microbial and autoantigen antibody repertoire in adult-onset dermatomyositis patients sero-positive for TIF1γ (TRIM33) autoantibodies.', 'We use an untargeted high-throughput approach which combines immunoglobulin disease-specific epitope-enrichment and identification of microbial and human antigens.', 'Increased microbial diversity was observed in dermatomyositis.', 'Viruses were over-represented and species of the Poxviridae family were significantly enriched.', 'The autoantibodies identified recognised a large portion of the human proteome, including interferon regulated proteins; these proteins were clustered in specific biological processes.', 'Apart from TRIM33, autoantibodies against eleven further TRIM proteins, including TRIM21, were identified.', 'Some of these TRIM proteins shared epitope homology with specific viral species including poxviruses.', 'Our data suggest antibody accumulation in dermatomyositis against an expanded diversity of microbial and human proteins and evidence of non-random targeting of specific signalling pathways.', 'Our findings indicate that molecular mimicry and epitope spreading events may play a significant role in the pathogenesis of dermatomyositis.']\n",
            "unmatched tags:  [{'entity': 'dermatomyositis', 'type': 'Disease', 'start': 1296, 'end': 1311}, {'entity': 'human proteins', 'type': 'Gene', 'start': 1086, 'end': 1100}, {'entity': 'dermatomyositis', 'type': 'Disease', 'start': 1023, 'end': 1038}, {'entity': 'poxviruses', 'type': 'Virus', 'start': 969, 'end': 979}, {'entity': 'proteins', 'type': 'Gene', 'start': 898, 'end': 906}, {'entity': 'TRIM proteins', 'type': 'Gene', 'start': 893, 'end': 906}, {'entity': 'TRIM21', 'type': 'Gene', 'start': 854, 'end': 860}, {'entity': 'TRIM proteins', 'type': 'Gene', 'start': 829, 'end': 842}, {'entity': 'autoantibodies', 'type': 'Gene', 'start': 791, 'end': 805}, {'entity': 'TRIM33', 'type': 'Gene', 'start': 783, 'end': 789}, {'entity': 'proteins', 'type': 'Gene', 'start': 714, 'end': 722}, {'entity': 'proteins', 'type': 'Gene', 'start': 698, 'end': 706}, {'entity': 'proteome', 'type': 'Gene', 'start': 657, 'end': 665}, {'entity': 'autoantibodies', 'type': 'Gene', 'start': 591, 'end': 605}, {'entity': 'Poxviridae family', 'type': 'Virus', 'start': 540, 'end': 557}, {'entity': 'Viruses', 'type': 'Virus', 'start': 491, 'end': 498}, {'entity': 'dermatomyositis', 'type': 'Disease', 'start': 474, 'end': 489}, {'entity': 'autoantibodies', 'type': 'Gene', 'start': 248, 'end': 262}, {'entity': 'TRIM33', 'type': 'Gene', 'start': 240, 'end': 246}, {'entity': 'TIF1γ', 'type': 'Gene', 'start': 233, 'end': 238}]\n",
            "[\"MHC class II region, CTLA4 gene, and ophthalmopathy in patients with Graves' disease\\tUp to half of patients with Graves' hyperthyroidism have signs of thyroid associated ophthalmopathy, but the factors that cause this disorder are unknown.\", \"We investigated two major genetic susceptibility loci for Graves' disease in ophthalmopathy; the MHC class II region and the cytotoxic T lymphocyte antigen-4 (CTLA4) gene.\", \"Allelic frequencies of these genes in patients with Graves' disease who did and did not have concurrent thyroid-associated ophthalmopathy did not differ, and are, therefore, unlikely to contribute to its development.\"]\n",
            "unmatched tags:  [{'entity': 'thyroid-associated ophthalmopathy', 'type': 'Disease', 'start': 516, 'end': 549}, {'entity': \"Graves' disease\", 'type': 'Disease', 'start': 464, 'end': 479}, {'entity': 'gene', 'type': 'Gene', 'start': 406, 'end': 410}, {'entity': 'cytotoxic T lymphocyte antigen-4', 'type': 'Gene', 'start': 365, 'end': 397}]\n",
            "[\"Beyond wasted and stunted—a major shift to fight child undernutrition\\tChild undernutrition refers broadly to the condition in which food intake is inadequate to meet a child's needs for physiological function, growth, and the capacity to respond to illness.\", 'Since the 1970s, nutritionists have categorised undernutrition in two major ways, either as wasted (ie, low weight for height, or small mid-upper arm circumference) or stunted (ie, low height for age).', 'This approach, although useful for identifying populations at risk of undernutrition, creates several problems: the focus is on children who have already become undernourished, and this approach draws an artificial distinction between two idealised types of undernourished children that are widely interpreted as indicative of either acute or chronic undernutrition.']\n",
            "unmatched tags:  [{'entity': 'chronic undernutrition', 'type': 'Disease', 'start': 803, 'end': 825}, {'entity': 'undernourished', 'type': 'Disease', 'start': 718, 'end': 732}, {'entity': 'undernourished', 'type': 'Disease', 'start': 621, 'end': 635}, {'entity': 'undernutrition', 'type': 'Disease', 'start': 530, 'end': 544}]\n",
            "['Metastatic epidural spinal cord compression\\tMetastatic epidural spinal cord compression (MESCC) occurs when cancer metastasises to the spine or epidural space and causes secondary compression of the spinal cord.', 'MESCC is a common complication of malignancy that affects almost 5% of patients with cancer.', 'The most common symptom is back pain.', 'MESCC is a medical emergency that needs rapid diagnosis and treatment if permanent paralysis is to be prevented: the diagnosis of MESCC is best made with MRI; and corticosteroids, radiation therapy, and surgery are all established treatments.']\n",
            "unmatched tags:  [{'entity': 'corticosteroids', 'type': 'Drug', 'start': 506, 'end': 521}, {'entity': 'MESCC', 'type': 'Disease', 'start': 473, 'end': 478}, {'entity': 'permanent paralysis', 'type': 'Disease', 'start': 416, 'end': 435}, {'entity': 'MESCC', 'type': 'Disease', 'start': 343, 'end': 348}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 321, 'end': 328}, {'entity': 'cancer', 'type': 'Disease', 'start': 297, 'end': 303}, {'entity': 'malignancy', 'type': 'Disease', 'start': 246, 'end': 256}, {'entity': 'MESCC', 'type': 'Disease', 'start': 212, 'end': 217}, {'entity': 'cancer metastasises', 'type': 'Disease', 'start': 108, 'end': 127}, {'entity': 'MESCC', 'type': 'Disease', 'start': 89, 'end': 94}]\n",
            "['Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy\\tThe introduction of HIV-1 protease inhibitors and non-nucleoside reverse transcriptase inhibitors in 1996 began an era described as that of highly active antiretroviral therapy.', 'In addition, the more recent development and availability of HIV-1 genotypic and phenotypic resistance tests and advances in pharmacological assays that support therapeutic drug monitoring (TDM) have created tools that may help clinicians to provide more individualised treatment with HIV-1 protease inhibitors.', 'All current treatment guidelines provide fixed doses of protease inhibitors with vague recommendations for the use of TDM in selected clinical situations.']\n",
            "unmatched tags:  [{'entity': 'clinical situations', 'type': 'Chemical', 'start': 736, 'end': 755}, {'entity': 'protease inhibitors', 'type': 'Drug', 'start': 658, 'end': 677}, {'entity': 'HIV-1 protease inhibitors', 'type': 'Drug', 'start': 575, 'end': 600}, {'entity': 'era', 'type': 'Gene', 'start': 453, 'end': 456}, {'entity': 'HIV-1', 'type': 'Virus', 'start': 351, 'end': 356}, {'entity': 'era', 'type': 'Gene', 'start': 283, 'end': 286}, {'entity': 'era', 'type': 'Gene', 'start': 227, 'end': 230}]\n",
            "['Fluoroquinolones, tuberculosis, and resistance\\tAlthough the fluoroquinolones are presently used to treat tuberculosis primarily in cases involving resistance or intolerance to first-line antituberculosis therapy, these drugs are potential first-line agents and are under study for this indication.', 'However, there is concern about the development of fluoroquinolone resistance in']\n",
            "unmatched tags:  [{'entity': 'fluoroquinolone', 'type': 'Drug', 'start': 349, 'end': 364}]\n",
            "['Estimation of incubation period distribution of COVID-19 using disease onset forward time: a novel cross-sectional and forward follow-up study\\tBackground:  The current outbreak of coronavirus disease 2019 (COVID-19) has quickly spread across countries and become a global crisis.', 'However, one of the most important clinical characteristics in epidemiology, the distribution of the incubation period, remains unclear.', 'Different estimates of the incubation period of COVID-19 were reported in recent published studies, but all have their own limitations.', 'In this study, we propose a novel low-cost and accurate method to estimate the incubation distribution.', 'Methods: We have conducted a cross-sectional and forward follow-up study by identifying those asymptomatic individuals at their time of departure from Wuhan and then following them until their symptoms developed.', 'The renewal process is hence adopted by considering the incubation period as a renewal and the duration between departure and symptom onset as a forward recurrence time.', 'Under mild assumptions, the observations of selected forward times can be used to consistently estimate the parameters in the distribution of the incubation period.', 'Such a method enhances the accuracy of estimation by reducing recall bias and utilizing the abundant and readily available forward time data.', 'Findings:  The estimated distribution of forward time fits the observations in the collected data well.', 'The estimated median of incubation period is 8.13 days (95% confidence interval [CI]: 7.37-8.91), the mean is 8.62 days (95% CI: 8.02-9.28), the 90th percentile is 14.65 days (95% CI: 14.00-15.26), and the 99th percentile is 20.59 days (95% CI: 19.47, 21.62).', 'Compared with results in other studies, the incubation period estimated in this study is longer.', 'Interpretation: Based on the estimated incubation distribution in this study, about 10% of patients with COVID-19 would not develop symptoms until 14 days after infection.', 'Further study of the incubation distribution is warranted to directly estimate the proportion with long incubation periods.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 1918, 'end': 1926}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 998, 'end': 1005}]\n",
            "['Cytogenetics of myelodysplasia and acute myeloid leukaemia in aircrew and people treated with radiotherapy\\tIncreased risk of acute myeloid leukaemia has been reported in aircrew, possibly in association with cosmic radiation.', 'We studied the cytogenetics of seven aircrew members who had acute myeloid leukaemia or myelodysplasia and found deletion or loss of chromosome 7 in four.', 'The same abnormality was found in eight of 19 patients with leukaemia after radiotherapy alone.', 'By comparison, only 81 of 761 unselected cases of myelodysplasia or acute myeloid leukaemia had the same cytogenetic abnormalities.']\n",
            "unmatched tags:  [{'entity': 'acute myeloid leukaemia', 'type': 'Disease', 'start': 545, 'end': 568}]\n",
            "['Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events\\tAspirin is widely used for the prevention of recurrent stroke in patients with transient ischaemic attack (TIA) and ischaemic stroke of arterial origin, because it is effective and inexpensive.', 'Clopidogrel and the combination of aspirin and extended-release dipyridamole are more effective than aspirin, but are also much more expensive.', 'No other antithrombotic regimens provide significant advantages over aspirin, although cilostazol and the novel platelet protease activated receptor-1 antagonist, SCH 530348, are currently being evaluated.']\n",
            "unmatched tags:  [{'entity': 'SCH', 'type': 'Disease', 'start': 631, 'end': 634}, {'entity': 'cilostazol', 'type': 'Drug', 'start': 555, 'end': 565}, {'entity': 'aspirin', 'type': 'Drug', 'start': 537, 'end': 544}, {'entity': 'antithrombotic regimens', 'type': 'Drug', 'start': 477, 'end': 500}, {'entity': 'aspirin', 'type': 'Drug', 'start': 425, 'end': 432}, {'entity': 'dipyridamole', 'type': 'Drug', 'start': 388, 'end': 400}, {'entity': 'aspirin', 'type': 'Drug', 'start': 359, 'end': 366}, {'entity': 'Clopidogrel', 'type': 'Drug', 'start': 324, 'end': 335}, {'entity': 'ischaemic stroke', 'type': 'Disease', 'start': 246, 'end': 262}, {'entity': 'TIA', 'type': 'Disease', 'start': 237, 'end': 240}]\n",
            "['Aquaporin 4 and neuromyelitis optica\\tNeuromyelitis optica is an inflammatory demyelinating disorder of the CNS.', 'The discovery of circulating IgG1 antibodies against the astrocyte water channel protein aquaporin 4 (AQP4) and the evidence that AQP4-IgG is involved in the development of neuromyelitis optica revolutionised our understanding of the disease.', 'However, important unanswered questions remain—for example, we do not know the cause of AQP4-IgG-negative disease, how astrocyte damage causes demyelination, the role of T cells, why peripheral AQP4-expressing organs are undamaged, and how circulating AQP4-IgG enters neuromyelitis optica lesions.']\n",
            "unmatched tags:  [{'entity': 'neuromyelitis optica', 'type': 'Disease', 'start': 623, 'end': 643}]\n",
            "['Mosaic effectiveness: measuring the impact of novel PrEP methods\\tVarious ongoing trials seek to evaluate long-acting pre-exposure prophylaxis (PrEP) agents by showing that they are non-inferior to daily oral tenofovir disoproxil fumarate and emtricitabine.', 'Trials comparing oral PrEP to new methods examine effectiveness in a setting where only one or the other is provided; however, a new product will probably be delivered in a context where oral PrEP is also available.', 'The effectiveness of a new PrEP product is best measured by its potential effect in a context that also includes oral tenofovir disoproxil fumarate and emtricitabine as an option.']\n",
            "unmatched tags:  [{'entity': 'emtricitabine', 'type': 'Gene', 'start': 625, 'end': 638}]\n",
            "['BCG protects against COVID-19?', 'A word of caution\\tThe COVID-19 pandemic, caused by type 2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2), puts all of us to the test.', 'Epidemiologic observations could critically aid the development of protective measures to combat this devastating viral outbreak.', 'A recent publication, linked nation based universal Bacillus Calmette-Guerin (BCG) vaccination to potential protection against morbidity and mortality from SARS-CoV-2, and received much attention in public media, even before its peer review.', 'We wished to validate the findings by examining the association between daily rates of COVID-19 case fatality (i.e.', 'Death Per Case /Days of the endemic [dpc/d]) and the presence of universal BCG vaccination before 1980, or the year of the establishment of universal vaccination.', 'There was no significant association in either analysis.', 'In this work we emphasize caution amidst the publication surge on COVID-19, and highlight the political/economical-, arbitrary selection-, and fear/anxiety related biases, which may obscure scientific rigor.', 'It is underscored that physical (social) distancing (i.e.', 'quarantine) and use of personal protective equipment (PPE) are the only epidemiologic measures (Iceland being a great example, where universal BCG vaccination policy was never in place), which consistently associate with successful counteraction of morbidity and mortality during the pandemic.']\n",
            "unmatched tags:  [{'entity': 'counteraction', 'type': 'Drug', 'start': 1383, 'end': 1396}, {'entity': 'nation', 'type': 'Organization', 'start': 1303, 'end': 1309}, {'entity': 'PPE', 'type': 'Gene', 'start': 1205, 'end': 1208}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 951, 'end': 959}, {'entity': 'nation', 'type': 'Organization', 'start': 820, 'end': 826}, {'entity': 'nation', 'type': 'Organization', 'start': 749, 'end': 755}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 636, 'end': 644}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 463, 'end': 473}]\n",
            "['Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial\\tPostoperative radiotherapy in stage-1 endometrial carcinoma reduces locoregional recurrence but has no impact on overall survival.', 'Radiotherapy increases treatment-related morbidity.', 'Postoperative radiotherapy is not indicated in patients with stage-1 endometrial carcinoma below 60 years and patients with grade-2 tumours with superficial invasion.']\n",
            "unmatched tags:  [{'entity': 'stage-1 endometrial carcinoma', 'type': 'Disease', 'start': 382, 'end': 411}, {'entity': 'treatment-related morbidity', 'type': 'Disease', 'start': 292, 'end': 319}]\n",
            "['Social anxiety disorder\\tOur understanding of social anxiety disorder (also known as social phobia) has moved from rudimentary awareness that it is not merely shyness to a much more sophisticated appreciation of its prevalence, its chronic and pernicious nature, and its neurobiological underpinnings.', 'Social anxiety disorder is the most common anxiety disorder; it has an early age of onset—by age 11 years in about 50% and by age 20 years in about 80% of individuals—and it is a risk factor for subsequent depressive illness and substance abuse.']\n",
            "unmatched tags:  [{'entity': 'substance abuse', 'type': 'Disease', 'start': 530, 'end': 545}, {'entity': 'depressive illness', 'type': 'Disease', 'start': 507, 'end': 525}, {'entity': 'anxiety disorder', 'type': 'Disease', 'start': 344, 'end': 360}, {'entity': 'Social anxiety disorder', 'type': 'Disease', 'start': 301, 'end': 324}, {'entity': 'pernicious', 'type': 'Disease', 'start': 243, 'end': 253}]\n",
            "['Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial\\tSupplementation with fibre as ispaghula husk may have adverse effects on colorectal adenoma recurrence, especially in patients with high dietary calcium intake.', 'Calcium supplementation was associated with a modest but not significant reduction in the risk of adenoma recurrence.']\n",
            "unmatched tags:  [{'entity': 'adenoma', 'type': 'Disease', 'start': 373, 'end': 380}]\n",
            "['Impact of the introduction of pneumococcal conjugate vaccination on pneumonia in The Gambia: population-based surveillance and case-control studies\\tThe introduction of PCV in The Gambia was associated with a moderate impact on the incidence of radiological pneumonia, a small reduction in cases of hospitalised pneumonia, and substantial reductions of pneumococcal and hypoxic pneumonia in young children.', 'Low-income countries that introduce PCV13 with reasonable coverage can expect modest reductions in hospitalised cases of pneumonia and a marked impact on the incidence of severe childhood pneumonia.']\n",
            "unmatched tags:  [{'entity': 'pneumonia', 'type': 'Disease', 'start': 594, 'end': 603}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 527, 'end': 536}, {'entity': 'PCV13', 'type': 'Drug', 'start': 442, 'end': 447}, {'entity': 'Low-income countries', 'type': 'Gene', 'start': 406, 'end': 426}, {'entity': 'hypoxic pneumonia', 'type': 'Disease', 'start': 369, 'end': 386}]\n",
            "['AN EPIDEMIOLOGICAL MODEL TO AID DECISION-MAKING FOR COVID-19 CONTROL IN SRI LANKA\\tBackground: Sri Lanka diagnosed its first local case of COVID-19 on 11 March 2020.', 'The government acted swiftly to contain transmission, with extensive public health measures.', 'At the end of 30 days, Sri Lanka had 197 cases, 54 recovered and 7 deaths; a staged relaxing of the lockdown is now underway.', 'This paper proposes a theoretical basis for estimating the limits within which transmission should be constrained in order to ensure that the case load remains within the capacity of the health system.', 'Methods: We used the Susceptible, Infected, Recovered (SIR) model to explore the number of new infections and estimate ICU bed requirement at different levels of R0 values after lockout.', 'We developed a web-based application that enables visualization of cases and ICU bed requirements with time, with adjustable parameters that include: population exposed; proportion asymptomatic; number of active and recovered cases; infectious period; R0 or doubling time; proportion critically ill; available ICU beds; duration of ICU stay; and uncertainty of projection.', 'Results: The three-day moving average of the caseload suggested two waves of transmission from Day 0 to 17 (R0=3.32, 95% CI 1.85 - 5.41) and from Day 18 - 30 (R=1.25, 95%CI: 0.93 - 1.63).', 'We estimate that if there are 156 active cases with 91 recovered at the time of lockout, and R increases to 1.5 (doubling time 19 days), under the standard parameters for Sri Lanka, the ICU bed capacity of 300 is likely to be saturated by about 100 days days, signalled by 18 new infections (95% CI 15 - 22) on Day 14 after lockout.', 'Conclusion: Our model suggests that to ensure that the case load remains within the available capacity of the health system after lockout, transmission should not exceed R=1.5.', 'This model and the web-based application may be useful in other low and middle income countries which have similar constraints on health resources.']\n",
            "unmatched tags:  [{'entity': 'middle income countries', 'type': 'Disease', 'start': 1923, 'end': 1946}, {'entity': 'bed', 'type': 'Disease', 'start': 1529, 'end': 1532}, {'entity': 'R0', 'type': 'Organization', 'start': 1259, 'end': 1261}, {'entity': 'three-day', 'type': 'Disease', 'start': 1164, 'end': 1173}, {'entity': 'bed', 'type': 'Disease', 'start': 1089, 'end': 1092}, {'entity': 'critically ill', 'type': 'Phenotype', 'start': 1059, 'end': 1073}, {'entity': 'R0', 'type': 'Organization', 'start': 1027, 'end': 1029}, {'entity': 'bed', 'type': 'Disease', 'start': 856, 'end': 859}, {'entity': 'R0', 'type': 'Organization', 'start': 750, 'end': 752}, {'entity': 'bed', 'type': 'Disease', 'start': 711, 'end': 714}, {'entity': 'government', 'type': 'Organization', 'start': 170, 'end': 180}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 138, 'end': 146}]\n",
            "['Errors in the approval process and post-marketing evaluation of drotrecogin alfa (activated) for the treatment of severe sepsis\\tRegulatory agencies take responsibility for the safety and efficacy of the drugs they license.', 'Over the past few years, however, several serious failings in the approval procedure have raised widespread concern that the present process of drug regulation is inadequate to guarantee the defence of public health.', 'We discuss the approval process of drotrecogin alfa (activated), a non-antibacterial drug for the treatment of severe sepsis.', 'The US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) approved drotrecogin alfa following a phase III trial that showed efficacy of the drug.']\n",
            "unmatched tags:  [{'entity': 'drug', 'type': 'Drug', 'start': 731, 'end': 735}, {'entity': 'drotrecogin alfa', 'type': 'Gene', 'start': 658, 'end': 674}, {'entity': 'EMEA', 'type': 'Chemical', 'start': 643, 'end': 647}, {'entity': 'European Medicines Agency', 'type': 'Chemical', 'start': 616, 'end': 641}, {'entity': 'sepsis', 'type': 'Disease', 'start': 558, 'end': 564}]\n",
            "['Future clinical applications of genomics for acute respiratory distress syndrome\\tAcute respiratory distress syndrome remains a substantial cause of morbidity and mortality in intensive care units, yet no specific pharmacotherapy has proven useful in reducing the duration of mechanical ventilation or improving survival.', 'One factor that might hamper the development of treatment for acute respiratory distress syndrome is the heterogeneous nature of the population who present with the syndrome.', 'In this Review, the potential of genomic approaches—genetic association, gene expression, metabolomic, proteomic, and systems biology applications—for the identification of molecular endotypes within acute respiratory distress syndrome and potentially for the prediction, diagnosis, prognosis, and treatment of this difficult disorder are discussed.']\n",
            "unmatched tags:  [{'entity': 'acute respiratory distress syndrome', 'type': 'Phenotype', 'start': 696, 'end': 731}]\n",
            "['Biased and unbiased estimation of the average lengths of stay in intensive care units in the COVID-19 pandemic\\tBackground: The average length of stay (LOS) in the intensive care unit (ICU_ALOS) is a helpful parameter summarizing critical bed occupancy.', 'During the outbreak of a novel virus, estimating early a reliable ICU_ALOS estimate of infected patients is critical to accurately parameterize models examining mitigation and preparedness scenarios.', 'Methods: Two estimation methods of ICU ALOS were compared: the average LOS of already discharged patients at the date of estimation (DPE), and a standard parametric method used for analyzing time-to-event data which fits a given distribution to observed data and includes the censored stays of patients still treated in the ICU at the date of estimation (CPE).', 'Methods were compared on a series of all COVID-19 consecutive cases (n=59) admitted in an ICU devoted to such patients.', 'At the last follow-up date, 99 days after the first admission, all patients but one had been discharged.', \"A simulation study investigated the generalizability of the methods' patterns.\", 'CPE and DPE estimates were also compared to COVID-19 estimates reported to date.', 'Findings: LOS ≥ 30 days concerned 14 out of the 59 patients (24%), including 8 of the 21 deaths observed.', 'Two months after the first admission, 38 (64%) patients had been discharged, with corresponding DPE and CPE estimates of ICU_ALOS (95%CI) at 13.0 days (10.4, 15.6) and 23.1 days (18.1, 29.7), respectively.', \"Series' true ICU_ALOS was greater than 21 days, well above reported estimates to date.\", 'Interpretation: Discharges of short stays are more likely observed earlier during the course of an outbreak.', 'Cautious unbiased ICU_ALOS estimates suggest parameterizing a higher burden of ICU bed occupancy than that adopted to date in COVID-19 forecasting models.', 'Funding: Support by the National Natural Science Foundation of China (81900097 to Dr. Zhou) and the Emergency Response Project of Hubei Science and Technology Department (2020FCA023 to Pr.', 'Zhao).']\n",
            "unmatched tags:  [{'entity': 'Pr', 'type': 'Gene', 'start': 2048, 'end': 2050}, {'entity': 'Pr', 'type': 'Gene', 'start': 1982, 'end': 1984}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1834, 'end': 1842}, {'entity': 'LOS', 'type': 'Organization', 'start': 1731, 'end': 1734}, {'entity': 'LOS', 'type': 'Organization', 'start': 1529, 'end': 1532}, {'entity': 'LOS', 'type': 'Organization', 'start': 1431, 'end': 1434}, {'entity': 'CPE', 'type': 'Gene', 'start': 1409, 'end': 1412}, {'entity': 'DPE', 'type': 'Drug', 'start': 1401, 'end': 1404}, {'entity': 'LOS', 'type': 'Organization', 'start': 1209, 'end': 1212}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1162, 'end': 1170}, {'entity': 'DPE', 'type': 'Drug', 'start': 1126, 'end': 1129}, {'entity': 'CPE', 'type': 'Gene', 'start': 1118, 'end': 1121}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 855, 'end': 863}, {'entity': 'CPE', 'type': 'Gene', 'start': 808, 'end': 811}, {'entity': 'DPE', 'type': 'Drug', 'start': 586, 'end': 589}, {'entity': 'LOS', 'type': 'Organization', 'start': 524, 'end': 527}]\n",
            "['Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study\\tOur findings suggest that for people with virological failure of a first-line regimen containing efavirenz plus tenofovir and lamivudine or emtricitabine, the WHO-recommended switch to a ritonavir-boosted protease inhibitor plus zidovudine (a thymidine analogue nucleoside reverse transcriptase inhibitor) and lamivudine might come at the cost of peripheral lipoatrophy.', 'Further study could help to define specific groups of people who might benefit from a switch to an N(t)RTI-sparing second-line ART regimen.']\n",
            "unmatched tags:  [{'entity': 'peripheral lipoatrophy', 'type': 'Disease', 'start': 712, 'end': 734}, {'entity': 'lamivudine', 'type': 'Gene', 'start': 675, 'end': 685}, {'entity': 'thymidine analogue nucleoside reverse transcriptase inhibitor', 'type': 'Drug', 'start': 608, 'end': 669}]\n",
            "['Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses\\tThe new coronavirus (2019-nCoV) outbreak from December 2019 in Wuhan, Hubei, China, has been declared a global public health emergency.', 'Angiotensin I converting enzyme 2 (ACE2), is the host receptor by 2019-nCov to infect human cells.', 'Although ACE2 is reported to be expressed in lung, liver, stomach, ileum, kidney and colon, its expressing levels are rather low, especially in the lung.', '2019-nCoV may use co-receptors/auxiliary proteins as ACE2 partner to facilitate the virus entry.', 'To identify the potential candidates, we explored the single cell gene expression atlas including 119 cell types of 13 human tissues and analyzed the single cell co-expression spectrum of 51 reported RNA virus receptors and 400 other membrane proteins.', 'Consistent with other recent reports, we confirmed that ACE2 was mainly expressed in lung AT2, liver cholangiocyte, colon colonocytes, esophagus keratinocytes, ileum ECs, rectum ECs, stomach epithelial cells, and kidney proximal tubules.', 'Intriguingly, we found that the candidate co-receptors, manifesting the most similar expression patterns with ACE2 across 13 human tissues, are all peptidases, including ANPEP, DPP4 and ENPEP.', 'Among them, ANPEP and DPP4 are the known receptors for human CoVs, suggesting ENPEP as another potential receptor for human CoVs.', 'We also conducted “CellPhoneDB” analysis to understand the cell crosstalk between CoV-targets and their surrounding cells across different tissues.', 'We found that macrophages frequently communicate with the CoVs targets through chemokine and phagocytosis signaling, highlighting the importance of tissue macrophages in immune defense and immune pathogenesis.']\n",
            "unmatched tags:  [{'entity': 'chemokine', 'type': 'Gene', 'start': 1631, 'end': 1640}, {'entity': 'CoVs', 'type': 'Virus', 'start': 1610, 'end': 1614}, {'entity': 'CoVs', 'type': 'Virus', 'start': 1398, 'end': 1402}, {'entity': 'receptor', 'type': 'Gene', 'start': 1379, 'end': 1387}, {'entity': 'ENPEP', 'type': 'Gene', 'start': 1352, 'end': 1357}, {'entity': 'CoVs', 'type': 'Virus', 'start': 1335, 'end': 1339}, {'entity': 'receptors', 'type': 'Gene', 'start': 1315, 'end': 1324}, {'entity': 'DPP4', 'type': 'Gene', 'start': 1296, 'end': 1300}, {'entity': 'ANPEP', 'type': 'Gene', 'start': 1286, 'end': 1291}, {'entity': 'ENPEP', 'type': 'Gene', 'start': 1267, 'end': 1272}, {'entity': 'DPP4', 'type': 'Gene', 'start': 1258, 'end': 1262}, {'entity': 'ANPEP', 'type': 'Gene', 'start': 1251, 'end': 1256}, {'entity': 'peptidases', 'type': 'Gene', 'start': 1229, 'end': 1239}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1191, 'end': 1195}]\n",
            "['Fatal toxic epidermal necrolysis associated with mefloquine antimalarial prophylaxis\\tMefloquine is the recommended antimalarial for the prevention of falciparum malaria for visitors from the UK to chloroquine-resistant endemic areas.']\n",
            "unmatched tags:  [{'entity': 'malaria', 'type': 'Disease', 'start': 161, 'end': 168}]\n",
            "[\"Human monoclonal thyroid stimulating autoantibody\\tA monoclonal autoantibody (MAb) with powerful thyroid stimulating activity has been produced from lymphocytes from a patient with Graves' disease.\", 'The autoantibody and its Fab fragment bind to the thyroid stimulating hormone (TSH) receptor (TSHR) with high affinity, inhibit labelled TSH binding to the receptor and stimulate cyclic AMP production in Chinese hamster ovary cells transfected with TSHR.', \"TSHR autoantibodies with TSH agonist or antagonist activities from patients' serum samples are effective inhibitors of labelled monoclonal autoantibody binding to TSHR.\"]\n",
            "unmatched tags:  [{'entity': 'TSHR', 'type': 'Gene', 'start': 615, 'end': 619}, {'entity': 'monoclonal autoantibody binding', 'type': 'Gene', 'start': 580, 'end': 611}]\n",
            "['Development and Evaluation of A CRISPR-based Diagnostic For 2019-novel Coronavirus\\tBackground: The recent outbreak of infections by the 2019 novel coronavirus (2019-nCoV), the third zoonotic CoV has raised great public health concern.', 'The demand for rapid and accurate diagnosis of this novel pathogen brought significant clinical and technological challenges.', 'Currently, metagenomic next-generation sequencing (mNGS) and reverse-transcription PCR (RT-PCR) are the most widely used molecular diagnostics.', 'Methods: 2019-nCoV infections were confirmed in 52 specimens by mNGS.', 'Genomic information was analyzed and used for the design and development of an isothermal, CRISPR-based diagnostic for this novel virus.', 'The diagnostic performance of CRISPR-nCoV was assessed and compared across three technology platforms (mNGS, RT-PCR and CRISPR).', 'Results: 2019-nCoVs sequenced in our study were conserved with the Wuhan strain, and shared certain genetic similarity with SARS-CoV.', 'A high degree of variation in the level of viral RNA was observed in clinical specimens.', 'CRISPR-nCoV demonstrated a near single-copy sensitivity and great clinical sensitivity with a shorter turn-around time than RT-PCR.', 'Conclusion: CRISPR-nCoV presents as a promising diagnostic option for the emerging pathogen.']\n",
            "unmatched tags:  [{'entity': 'viral RNA', 'type': 'Gene', 'start': 1021, 'end': 1030}]\n",
            "['Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial\\tRhabdomyosarcoma is an aggressive tumour that can develop in almost any part of the body.', 'Doxorubicin is an effective drug against rhabdomyosarcoma, but its role in combination with an established multidrug regimen remains controversial.', 'Therefore, we aimed to evaluate the possible benefit of early dose intensification with doxorubicin in patients with non-metastatic rhabdomyosarcoma.']\n",
            "unmatched tags:  [{'entity': 'non-metastatic rhabdomyosarcoma', 'type': 'Disease', 'start': 524, 'end': 555}, {'entity': 'doxorubicin', 'type': 'Drug', 'start': 495, 'end': 506}]\n",
            "['New drugs for aggressive B-cell and T-cell lymphomas\\tOver the past decade an unprecedented number of new drugs for lymphomas have been developed.', 'Most of these new drugs target molecules or pathways that are important for the growth and proliferation of lymphomas.', 'The introduction of the B-lymphoma specific monoclonal anti-CD20 antibody, rituximab, has improved the prognosis of patients with B-cell lymphomas more than any other drug in the past 50 years; today less than half of the patients with aggressive B-cell lymphomas die of their disease than in the pre-rituximab era.']\n",
            "unmatched tags:  [{'entity': 'era', 'type': 'Gene', 'start': 576, 'end': 579}, {'entity': 'pre-rituximab', 'type': 'Gene', 'start': 562, 'end': 575}, {'entity': 'lymphomas', 'type': 'Disease', 'start': 519, 'end': 528}, {'entity': 'aggressive B-cell lymphomas', 'type': 'Disease', 'start': 501, 'end': 528}, {'entity': 'drug', 'type': 'Drug', 'start': 432, 'end': 436}, {'entity': 'B-cell lymphomas', 'type': 'Disease', 'start': 395, 'end': 411}, {'entity': 'rituximab', 'type': 'Gene', 'start': 340, 'end': 349}, {'entity': 'B-lymphoma', 'type': 'Disease', 'start': 289, 'end': 299}, {'entity': 'lymphomas', 'type': 'Disease', 'start': 254, 'end': 263}, {'entity': 'era', 'type': 'Gene', 'start': 243, 'end': 246}, {'entity': 'drug', 'type': 'Drug', 'start': 164, 'end': 168}, {'entity': 'lymphomas', 'type': 'Disease', 'start': 115, 'end': 124}, {'entity': 'drug', 'type': 'Drug', 'start': 105, 'end': 109}]\n",
            "['Prevention of chronic diseases: a call to action\\tChronic (non-communicable) diseases—principally cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes—are leading causes of death and disability but are surprisingly neglected elements of the global-health agenda.', 'They are underappreciated as development issues and underestimated as diseases with profound economic effects.', 'Achievement of the global goal for prevention and control of chronic diseases would avert 36 million deaths by 2015 and would have major economic benefits.']\n",
            "unmatched tags:  [{'entity': 'chronic diseases', 'type': 'Disease', 'start': 457, 'end': 473}, {'entity': 'diseases', 'type': 'Disease', 'start': 355, 'end': 363}]\n",
            "['Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010\\tRates of YLDs per 100\\u2008000 people have remained largely constant over time but rise steadily with age.', 'Population growth and ageing have increased YLD numbers and crude rates over the past two decades.', 'Prevalences of the most common causes of YLDs, such as mental and behavioural disorders and musculoskeletal disorders, have not decreased.', 'Health systems will need to address the needs of the rising numbers of individuals with a range of disorders that largely cause disability but not mortality.', 'Quantification of the burden of non-fatal health outcomes will be crucial to understand how well health systems are responding to these challenges.']\n",
            "unmatched tags:  [{'entity': 'non-fatal', 'type': 'Disease', 'start': 689, 'end': 698}]\n",
            "['ACE2shedding and furin abundance in target organs may influence the efficiency of SARS-CoV-2 entry\\tSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently identified lineage Bcoronavirus, causing rapid worldwide outbreak of Corona Virus Disease 2019 (COVID-19).', 'Despitegenetically closed to SARS-CoV, SARS-CoV-2 seems to possess enhanced infectivity and subtledifferent clinical features, which may hamper the early screening of suspected patients as wellas the control of virus transmission.', 'Unfortunately, there are few tools to predict thepotential target organ damage and possible clinical manifestations caused by such novelcoronavirus.', 'To solve this problem, we investigate the potential host cell entry mechanisms ofSARS-CoV-2 through bioinformatics.', 'Using the online single-cell sequence datasets, we analyzethe expression of major receptor in host cells that mediates the virus entry, includingangiotensin converting enzyme 2 (ACE2), and its co-expressed membrane endopeptidases.', 'Theresults indicated the differential expression of ADAM10 and ADAM17 might contribute to the ACE2shedding and affect the membrane ACE2 abundance.', 'We further confirm a putative furin-cleavagesite reported recently in the spike protein of SARS-CoV-2, which may facilitate the virus-cellfusion.', 'Based on these findings, we develop a novel approach that comprehensively analyzed thevirus receptor expression, ACE2 shedding, membrane fusion activity, virus uptake and virusreplication to evaluate the infectivity of SARS-CoV-2 to different human organs.', 'Our resultsindicate that, in addition to airway epithelia, cardiac tissue and enteric canals aresusceptible to SARS-CoV-2 as well.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1669, 'end': 1679}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1520, 'end': 1530}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1414, 'end': 1418}, {'entity': 'thevirus receptor', 'type': 'Gene', 'start': 1384, 'end': 1401}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1246, 'end': 1256}, {'entity': 'spike protein', 'type': 'Gene', 'start': 1229, 'end': 1242}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1139, 'end': 1143}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1102, 'end': 1106}, {'entity': 'ADAM17', 'type': 'Gene', 'start': 1071, 'end': 1077}, {'entity': 'ADAM10', 'type': 'Gene', 'start': 1060, 'end': 1066}, {'entity': 'membrane endopeptidases', 'type': 'Gene', 'start': 983, 'end': 1006}, {'entity': 'ACE2', 'type': 'Gene', 'start': 955, 'end': 959}]\n",
            "['Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention\\tMuch is now known about the carcinogens in cigarette smoke, their conversion to forms that react with DNA, and the miscoding properties of the resulting DNA adducts that cause the many genetic changes known to exist in human lung cancer.', 'The chronic exposure of pulmonary DNA to a multitude of metabolically activated carcinogens is consistent with our current understanding of cancer as a disease resulting from many changes in key genes regulating growth.', 'This review illustrates how this solid foundation of knowledge can be used to find new ways to prevent lung cancer.']\n",
            "unmatched tags:  [{'entity': 'lung cancer', 'type': 'Disease', 'start': 645, 'end': 656}, {'entity': 'solid foundation', 'type': 'Organization', 'start': 575, 'end': 591}, {'entity': 'cancer', 'type': 'Disease', 'start': 462, 'end': 468}, {'entity': 'carcinogens', 'type': 'Chemical', 'start': 402, 'end': 413}]\n",
            "['An Efficient Ethanol-Vacuum Method for the Decontamination and Restoration of Polypropylene Microfiber Medical Masks & Respirators\\tA critical shortage of respirators, masks and other personal protective equipment (PPE) exists across all sectors of society afflicted by the COVID-19 pandemic, placing medical staff and service workers at heightened risk and hampering efforts to reduce transmission rates.', 'Of particular need are the N95 medical face respirators that filter 95% of all airborne particles at and above 0.3 um in diameter, many of which use meltblown microfibers of charged polypropylene (e.g, the 3M 8200).', 'An intensive search is underway to find reliable methods to lengthen the useful life of these normally disposable units.', 'It is currently believed that these masks and respirators cannot be cleaned with 70 to 75% alcohol-water solutions, as past wet/dry experiments show that filtration efficiency can drop by ~40% after the first such treatment.', 'This has been interpreted as the liquids disrupting the surface charge on the fibers and has led to a recent CDC/NIOSH advisory against using alcohol for their decontamination.', 'We have replicated the drop in efficiency after alcohol treatment.', 'However, we find that the efficiency can be recovered by more effective drying, which we achieve with a vacuum chamber.', 'Drying at pressures of < ~6 mBar (0.6 kPa) restores the measured filtering efficiency to within 2% or so of the pre-washing value, which we have sustained for 5 cleaning-drying cycles so far in three models of N95 masks.', 'The mechanism seems to be the removal of water molecules adsorbed on the fiber surfaces, a hypothesis which is supported by two independent observations: (A) the filtering efficiency increases non-linearly with the weight loss during drying, and (B) filtration efficiency shows an abrupt recovery as the vacuum pressure drops from 13 to 6 mBar, the range physically attributable to the removal of adsorbed water.', 'These results are not compatible with the electrostatic discharge hypothesis, and rather suggest that water molecules adsorbed to the fiber surface are reducing the filtration efficiency via surface tension interactions (e.g., wicking between the fibers and coating their surfaces with a film).', 'Such a degradation mechanism has two implications: (A) Respirators decontaminated by a soak in 70% v/v ethanol regain their filtration efficiency once they are fully dry.', 'We employ vacuum chambers in this study, which are inexpensive and commonly available.', '(B) This mechanism presents the possibility that mask filtration performance may be subject to degradation by other sources of moisture, and that the mask would continue to be compromised even if it appears dry.', 'The mask would need to be vacuum-dried to restore its performance.', 'This study introduces a number of methods which could be developed and validated for use in resource-limited settings.', 'As the pandemic spreads to rural areas and developing nations, these would allow for local efforts to decontaminate, restore, monitor, and test medical masks.']\n",
            "unmatched tags:  [{'entity': 'ethanol', 'type': 'Drug', 'start': 2374, 'end': 2381}, {'entity': 'fiber', 'type': 'Drug', 'start': 2222, 'end': 2227}, {'entity': 'fiber', 'type': 'Drug', 'start': 2109, 'end': 2114}, {'entity': 'adsorbed', 'type': 'Gene', 'start': 2093, 'end': 2101}, {'entity': 'adsorbed', 'type': 'Gene', 'start': 1958, 'end': 1966}, {'entity': 'fiber', 'type': 'Drug', 'start': 1634, 'end': 1639}, {'entity': 'adsorbed', 'type': 'Gene', 'start': 1618, 'end': 1626}, {'entity': 'alcohol treatment', 'type': 'Drug', 'start': 1198, 'end': 1215}, {'entity': 'alcohol', 'type': 'Drug', 'start': 1114, 'end': 1121}, {'entity': 'fiber', 'type': 'Drug', 'start': 1050, 'end': 1055}, {'entity': 'charged polypropylene', 'type': 'Drug', 'start': 580, 'end': 601}, {'entity': 'fiber', 'type': 'Drug', 'start': 570, 'end': 575}, {'entity': 'society', 'type': 'Organization', 'start': 248, 'end': 255}]\n",
            "['Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme\\tDespite advances in the molecular pathogenesis of glioblastoma multiforme, no reliable prognostic markers have been identified.', 'We analysed telomerase activity and telomere lengths in glioblastoma multiformes from 77 patients.', '19 patients (25%) had tumours with the alternative-lengthening-of-telomere (ALT) phenotype.', 'Median survival for patients with this phenotype was 542 days (95% CI 114–970) compared with 247 days (224–270) for glioblastoma multiformes with normal telomeres (p=0·0003).', \"Cox's regression analysis showed that this association is independent of age.\"]\n",
            "unmatched tags:  [{'entity': 'multiformes', 'type': 'Disease', 'start': 539, 'end': 550}, {'entity': 'glioblastoma multiforme', 'type': 'Disease', 'start': 526, 'end': 549}, {'entity': 'ALT', 'type': 'Gene', 'start': 394, 'end': 397}, {'entity': 'tumours', 'type': 'Disease', 'start': 340, 'end': 347}]\n",
            "['Monogenic autoimmune diseases of the endocrine system\\tThe most common endocrine diseases, type 1 diabetes, hyperthyroidism, and hypothyroidism, are the result of autoimmunity.', 'Clustering of autoimmune endocrinopathies can result from polygenic predisposition, or more rarely, may present as part of a wider syndrome due to a mutation within one of seven genes.', 'These monogenic autoimmune diseases show highly variable phenotypes both within and between families with the same mutations.', 'The average age of onset of the monogenic forms of autoimmune endocrine disease is younger than that of the common polygenic forms, and this feature combined with the manifestation of other autoimmune diseases, specific hallmark features, or both, can inform clinicians as to the relevance of genetic testing.']\n",
            "unmatched tags:  [{'entity': 'autoimmune diseases', 'type': 'Disease', 'start': 677, 'end': 696}]\n",
            "['Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial\\tWe found no evidence of benefit of lithium on survival in patients with ALS, but nor were there safety concerns, which had been identified in previous studies with less conventional designs.', 'This finding emphasises the importance of pursuing adequately powered trials with clear endpoints when testing new treatments.']\n",
            "unmatched tags:  [{'entity': 'ALS', 'type': 'Gene', 'start': 211, 'end': 214}]\n",
            "['Host and infectivity prediction of Wuhan 2019 novel coronavirus using deep learning algorithm\\tThe recent outbreak of pneumonia in Wuhan, China caused by the 2019 Novel Coronavirus (2019-nCoV) emphasizes the importance of detecting novel viruses and predicting their risks of infecting people.', 'In this report, we introduced the VHP (Virus Host Prediction) to predict the potential hosts of viruses using deep learning algorithm.', 'Our prediction suggests that 2019-nCoV has close infectivity with other human coronaviruses, especially the severe acute respiratory syndrome coronavirus (SARS-CoV), Bat SARS-like Coronaviruses and the Middle East respiratory syndrome coronavirus (MERS-CoV).', 'Based on our prediction, compared to the Coronaviruses infecting other vertebrates, bat coronaviruses are assigned with more similar infectivity patterns with 2019-nCoVs.', 'Furthermore, by comparing the infectivity patterns of all viruses hosted on vertebrates, we found mink viruses show a closer infectivity pattern to 2019-nCov.', 'These consequences of infectivity pattern analysis illustrate that bat and mink may be two candidate reservoirs of 2019-nCov.These results warn us to beware of 2019-nCoV and guide us to further explore the properties and reservoir of it.', 'One Sentence Summary It is of great value to identify whether a newly discovered virus has the risk of infecting human.', 'Guo et al.', 'proposed a virus host prediction method based on deep learning to detect what kind of host a virus can infect with DNA sequence as input.', 'Applied to the Wuhan 2019 Novel Coronavirus, our prediction demonstrated that several vertebrate-infectious coronaviruses have strong potential to infect human.', 'This method will be helpful in future viral analysis and early prevention and control of viral pathogens.']\n",
            "unmatched tags:  [{'entity': 'coronaviruses', 'type': 'Virus', 'start': 1632, 'end': 1645}, {'entity': 'Coronavirus', 'type': 'Virus', 'start': 1556, 'end': 1567}, {'entity': 'virus host', 'type': 'Virus', 'start': 1397, 'end': 1407}, {'entity': '2019-nCoV', 'type': 'Virus', 'start': 1177, 'end': 1186}, {'entity': '2019-nCov', 'type': 'Virus', 'start': 1132, 'end': 1141}, {'entity': 'mink', 'type': 'Gene', 'start': 1092, 'end': 1096}, {'entity': '2019-nCov', 'type': 'Virus', 'start': 1006, 'end': 1015}, {'entity': 'mink', 'type': 'Gene', 'start': 956, 'end': 960}, {'entity': '2019-nCoV', 'type': 'Virus', 'start': 846, 'end': 855}, {'entity': 'bat coronaviruses', 'type': 'Virus', 'start': 771, 'end': 788}, {'entity': 'Coronaviruses', 'type': 'Virus', 'start': 728, 'end': 741}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 676, 'end': 684}, {'entity': 'Middle East respiratory syndrome coronavirus', 'type': 'Virus', 'start': 630, 'end': 674}, {'entity': 'Coronaviruses', 'type': 'Virus', 'start': 608, 'end': 621}]\n",
            "['The deubiquitinating activity of Middle East respiratory syndrome coronavirus papain-like protease delays the innate immune response and enhances virulence in a mouse model\\tMiddle East respiratory syndrome coronavirus (MERS-CoV) continues to cause zoonotic infections and serious disease, primarily in the Arabian Peninsula, due to repeated spill-over from dromedary camels and subsequent nosocomial transmission.', 'Approved MERS vaccines for use in animals or humans are not currently available.', 'MERS-CoV replication requires the virus-encoded papain-like protease (PL pro ) to cleave multiple sites in the viral replicase polyproteins, thereby releasing functional non-structural proteins.', 'Additionally, PL pro is a deubiquitinating enzyme (DUB) that can remove ubiquitin(-like) moieties from substrates, presumably to counteract host antiviral responses.', 'In previous work, we determined the crystal structure of MERS-CoV PL pro in complex with ubiquitin, facilitating the design of PL pro mutations that impair DUB activity without affecting viral polyprotein cleavage.', 'Here, we introduced these DUB-inactivating mutations into the viral genome and examined their impact on MERS-CoV infection both in cell culture and in a lethal mouse model.', 'Although overall replication of DUB-negative and wild-type (wt) recombinant MERS-CoV was comparable in multiple cell lines, infection with DUB-negative virus markedly increased mRNA levels for interferon (IFN)-β and IFN-stimulated genes.', 'Moreover, compared to a wt virus infection, the survival rate was significantly increased when DUB-negative MERS-CoV was used to infect transgenic mice expressing a human MERS-CoV receptor.', 'Interestingly, DUB-negative and wt MERS-CoV replicated to the same titers in lungs of infected mice, but the DUB-negative virus was cleared faster, likely due to the observed accelerated and better-regulated innate immune responses, in contrast to delayed and subsequently excessive responses in wt virus-infected mice.', 'This study provides the first direct evidence that the DUB activity of a coronaviral protease contributes to innate immune evasion and can profoundly enhance virulence in an animal model.', 'Thus, reduction or removal of the innate immune-suppressive DUB activity of PL pro s is a promising strategy for coronavirus attenuation in the context of rational vaccine development.', 'Author Summary Although zoonotic coronaviruses such as Middle East respiratory coronavirus (MERS-CoV) have pandemic potential, therapeutics and vaccines that counteract this public health threat are not currently available.', 'Coronaviruses typically employ multiple strategies to evade the host’s innate immune response, which may enhance clinical disease and/or reduce the efficacy of modified live vaccines.', 'The MERS-CoV-encoded papain-like protease (PL pro ) is not only crucial for the expression of functional replicase proteins, but has also been postulated to antagonize ubiquitination-dependent steps during the activation of the innate immune response.', 'Here, we report the generation of engineered MERS-CoVs mutants in which PL pro ’s deubiquitinating (DUB) activity was specifically disrupted without affecting virus viability.', 'In this manner, we could demonstrate that the DUB activity of PL pro suppresses the interferon response in MERS-CoV-infected cells.', 'Strikingly, in the lungs of mice infected with DUB-negative MERS-CoV, innate immune responses were induced at an earlier stage of infection than in wt virus-infected mice.', 'This group also showed a clearly increased survival, indicating that the DUB activity is an important MERS-CoV virulence factor.', 'This proof-of-concept study establishes that the engineering of DUB-negative coronaviruses, which elicit a more effective immune response in the host, is a viable strategy for vaccine development.']\n",
            "unmatched tags:  [{'entity': 'vaccine', 'type': 'Drug', 'start': 3810, 'end': 3817}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 3711, 'end': 3722}, {'entity': 'DUB-negative', 'type': 'Organization', 'start': 3698, 'end': 3710}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 3607, 'end': 3615}, {'entity': 'DUB', 'type': 'Organization', 'start': 3578, 'end': 3581}, {'entity': 'virus-infected mice', 'type': 'Disease', 'start': 3484, 'end': 3503}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 3393, 'end': 3401}, {'entity': 'DUB-negative', 'type': 'Organization', 'start': 3380, 'end': 3392}, {'entity': 'mice', 'type': 'Gene', 'start': 3361, 'end': 3365}, {'entity': 'DUB', 'type': 'Organization', 'start': 3247, 'end': 3250}, {'entity': 'DUB', 'type': 'Organization', 'start': 3125, 'end': 3128}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 3070, 'end': 3078}, {'entity': 'functional replicase proteins', 'type': 'Gene', 'start': 2867, 'end': 2896}, {'entity': 'vaccines', 'type': 'Drug', 'start': 2763, 'end': 2771}, {'entity': 'Coronaviruses', 'type': 'Virus', 'start': 2589, 'end': 2602}, {'entity': 'vaccines', 'type': 'Drug', 'start': 2509, 'end': 2517}]\n",
            "['Revealing variants in SARS-CoV-2 interaction domain of ACE2 and loss of function intolerance through analysis of >200,000 exomes\\tOur researchers took a look at a sequence of DNA known as the ACE2 gene.', 'This gene is most well known for its role in regulating blood pressure.', 'But in recent times, it’s drawn a lot of attention from the scientific community because it may also serve as a doorway of sorts, enabling viruses like SARS-CoV-2 to infect cells.', 'Our researchers looked at the ACE2 gene in more than 200,000 people, comparing their exact DNA sequences to see where there are differences among people.', 'Variation in the DNA sequence of a gene is common and is sometimes meaningless.', 'But other times, small changes in the DNA sequence can alter the protein that is made from that gene.', 'In this case the ACE2 gene makes the ACE2 protein, which is what the SARS-CoV-2 virus interacts with.', 'We found a lot of variation between individuals and checked to see if that variation coincided with any traits (i.e., people with variant X tend to have high blood pressure more often than people without variant X).', 'All of the traits we looked at were non-COVID-19-related traits, meaning we haven’t asked these people anything about COVID-19 yet (this is because these DNA sequences were collected before the pandemic).', 'We found that there are a number of variations observed among people in a specific part of the ACE2 gene.', 'These variations are expected to alter the shape or functionality of a specific part of the ACE2 protein: The part that interacts with the SARS-CoV-2 virus.', 'We don’t yet know what the real-life significance of this variation is, but it’s possible that these variants decrease the protein’s ability to interact with the SARS-CoV-2 virus, thus decreasing the person’s likelihood of being infected.', 'We can speculate that there will be a spectrum of vulnerability to COVID-19 among people, where some people are more vulnerable than others, and that variants in this part of the ACE2 gene may be one of the reasons.', 'The research we presented here shines a light on this part of the ACE2 gene and may give future researchers a direction to go in as they try to figure out what makes people vulnerable to COVID-19 and similar viruses.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2218, 'end': 2226}, {'entity': 'gene', 'type': 'Gene', 'start': 2102, 'end': 2106}, {'entity': 'ACE2 gene', 'type': 'Gene', 'start': 2097, 'end': 2106}, {'entity': 'ACE2 gene', 'type': 'Gene', 'start': 1994, 'end': 2003}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1882, 'end': 1890}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1738, 'end': 1748}, {'entity': 'protein’s', 'type': 'Gene', 'start': 1699, 'end': 1708}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1558, 'end': 1568}, {'entity': 'protein', 'type': 'Gene', 'start': 1516, 'end': 1523}, {'entity': 'ACE2 protein', 'type': 'Gene', 'start': 1511, 'end': 1523}, {'entity': 'gene', 'type': 'Gene', 'start': 1413, 'end': 1417}, {'entity': 'ACE2 gene', 'type': 'Gene', 'start': 1408, 'end': 1417}, {'entity': 'DNA', 'type': 'Gene', 'start': 1262, 'end': 1265}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1226, 'end': 1234}, {'entity': 'traits', 'type': 'Gene', 'start': 1165, 'end': 1171}, {'entity': 'traits', 'type': 'Gene', 'start': 1119, 'end': 1125}, {'entity': 'high blood pressure', 'type': 'Disease', 'start': 1045, 'end': 1064}, {'entity': 'traits', 'type': 'Gene', 'start': 996, 'end': 1002}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 859, 'end': 869}, {'entity': 'ACE2', 'type': 'Gene', 'start': 827, 'end': 831}, {'entity': 'ACE2 protein', 'type': 'Gene', 'start': 827, 'end': 839}, {'entity': 'ACE2 gene', 'type': 'Gene', 'start': 807, 'end': 816}, {'entity': 'gene', 'type': 'Gene', 'start': 784, 'end': 788}, {'entity': 'protein', 'type': 'Gene', 'start': 753, 'end': 760}, {'entity': 'DNA', 'type': 'Gene', 'start': 726, 'end': 729}, {'entity': 'gene', 'type': 'Gene', 'start': 643, 'end': 647}, {'entity': 'DNA', 'type': 'Gene', 'start': 625, 'end': 628}]\n",
            "['Multiple known and a novel parvovirus associated with an outbreak of feline diarrhea and vomiting\\tAn unexplained outbreak of feline diarrhea and vomiting, negative for common enteric viral and bacterial pathogens, was subjected to viral metagenomics and PCR.', 'We characterized from fecal samples the genome of a novel chapparvovirus we named fechavirus that was shed by 8/17 affected cats and different feline bocaviruses shed by 9/17 cats.', 'Also detected were nucleic acids from attenuated vaccine viruses, members of the normal feline virome, viruses found in only one or two cases, and viruses likely derived from ingested food products.', 'Epidemiological investigation of disease signs, time of onset, and transfers of affected cats between three facilities support a possible role for this new chapparvovirus in a highly contagious feline diarrhea and vomiting disease.']\n",
            "unmatched tags:  [{'entity': 'vomiting disease', 'type': 'Disease', 'start': 853, 'end': 869}, {'entity': 'feline diarrhea', 'type': 'Phenotype', 'start': 833, 'end': 848}]\n",
            "['Reassessment of the prevalence of soil-transmitted helminth infections in Sri Lanka to enable a more focused control programme: a cross-sectional national school survey with spatial modelling\\tOur survey findings indicate that the national prevalence of soil-transmitted helminth infection has continued to decline in Sri Lanka.', 'On the basis of WHO guidelines, we recommend discontinuation of routine deworming in low-risk areas, continuation of annual deworming in high-risk areas, and deworming once every 2 years in intermediate-risk areas, for at least 4 years.']\n",
            "unmatched tags:  [{'entity': 'helminth infection', 'type': 'Disease', 'start': 270, 'end': 288}]\n",
            "['HIV-1/AIDS and the control of other infectious diseases in Africa\\tThe effect of HIV-1 on other infectious diseases in Africa is an increasing public health concern.', 'In this review, we describe the role that three major infectious diseases—malaria, sexually transmitted diseases (STDs), and tuberculosis—have had in the HIV-1 epidemic.', 'The high prevalence of untreated STD infections has been a major factor facilitating the spread of HIV-1 in Africa; with the synergistic interaction between HIV-1 transmission and genital herpes being of especial concern for control of both diseases.']\n",
            "unmatched tags:  [{'entity': 'diseases', 'type': 'Disease', 'start': 576, 'end': 584}, {'entity': 'genital herpes', 'type': 'Disease', 'start': 515, 'end': 529}, {'entity': 'HIV-1', 'type': 'Virus', 'start': 492, 'end': 497}, {'entity': 'HIV-1', 'type': 'Virus', 'start': 434, 'end': 439}, {'entity': 'STD', 'type': 'Disease', 'start': 368, 'end': 371}, {'entity': 'HIV-1', 'type': 'Virus', 'start': 319, 'end': 324}, {'entity': 'tuberculosis', 'type': 'Disease', 'start': 290, 'end': 302}, {'entity': 'STDs', 'type': 'Disease', 'start': 279, 'end': 283}, {'entity': 'diseases', 'type': 'Disease', 'start': 269, 'end': 277}, {'entity': 'sexually transmitted diseases', 'type': 'Disease', 'start': 248, 'end': 277}, {'entity': 'malaria', 'type': 'Disease', 'start': 239, 'end': 246}]\n",
            "['lectin LecB impairs keratinocyte fitness by abrogating growth factor signalling\\tLectins are glycan-binding proteins with no catalytic activity and ubiquitously expressed in nature.', 'Numerous bacteria employ lectins to efficiently bind to epithelia, thus facilitating tissue colonisation.', 'Wounded skin is one of the preferred niches for Pseudomonas aeruginosa , which has developed diverse strategies to impair tissue repair processes and promote infection.', 'Here, we analyse the effect of the P. aeruginosa fucose-binding lectin LecB on human keratinocytes and demonstrate that it triggers events in the host, upon binding to fucosylated residues on cell membrane receptors, that extend beyond its role as an adhesion molecule.', 'We found that LecB associates with several growth factor receptors and dampens their signalling pathways, leading to the arrest of cell cycle.', 'Additionally, we describe a novel LecB-triggered mechanism to downregulate host cell receptors by showing that LecB leads to insulin-like growth factor receptor 1 internalisation, without receptor activation, and subsequent missorting towards intracellular endosomal compartments.', 'Overall, these data highlight that LecB is a multitask virulence factor that, through subversion of several host pathways, has a profound impact on keratinocyte proliferation and survival.']\n",
            "unmatched tags:  [{'entity': 'virulence factor', 'type': 'Drug', 'start': 1205, 'end': 1221}, {'entity': 'LecB', 'type': 'Chemical', 'start': 1185, 'end': 1189}, {'entity': 'insulin-like growth factor receptor 1', 'type': 'Gene', 'start': 994, 'end': 1031}, {'entity': 'LecB', 'type': 'Chemical', 'start': 980, 'end': 984}, {'entity': 'host cell receptors', 'type': 'Gene', 'start': 944, 'end': 963}, {'entity': 'growth factor receptors', 'type': 'Gene', 'start': 769, 'end': 792}, {'entity': 'LecB', 'type': 'Chemical', 'start': 740, 'end': 744}, {'entity': 'adhesion molecule', 'type': 'Gene', 'start': 707, 'end': 724}]\n",
            "['Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial\\tThis study suggests that active and modifiable disease processes might be ongoing in patients with mild to moderate, persistent asthma receiving ICS.', 'Although the lung function improvement observed does not warrant use of benralizumab in this population because it did not reach the minimum clinically important difference of 10%, further studies to assess this finding should be considered.']\n",
            "unmatched tags:  [{'entity': 'benralizumab', 'type': 'Drug', 'start': 359, 'end': 371}]\n",
            "['Is there a role for second-line chemotherapy in advanced gastric cancer?', 'Gastric cancer remains one of the most common forms of cancer worldwide.', 'Unfortunately, most patients will present with advanced-stage disease, and will therefore need palliative chemotherapy.', 'Some chemotherapy regimens have been well established as first-line therapy, and have been shown to increase survival; however, almost all patients with metastatic gastric cancer will develop progressive disease after first-line therapy.', 'With the availability of several active chemotherapy drugs, many patients who retain a good performance status after the initial treatment remain good candidates for additional therapy; however, no standard approach for second-line therapy exists.']\n",
            "unmatched tags:  [{'entity': 'progressive disease', 'type': 'Disease', 'start': 458, 'end': 477}, {'entity': 'metastatic gastric cancer', 'type': 'Disease', 'start': 419, 'end': 444}]\n",
            "['Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial\\tSulfadoxine/pyrimethamine, amodiaquine, and amodiaquine/sulfadoxine/pyrimethamine were all effective for treatment of uncomplicated falciparum malaria in Uganda.', 'The amodiaquine/sulfadoxine/ pyrimethamine combination was the most effective, and could be the optimum low-cost alternative to chloroquine in Africa.']\n",
            "unmatched tags:  [{'entity': 'chloroquine', 'type': 'Drug', 'start': 443, 'end': 454}, {'entity': 'low-cost', 'type': 'Gene', 'start': 419, 'end': 427}, {'entity': 'pyrimethamine', 'type': 'Drug', 'start': 344, 'end': 357}, {'entity': 'amodiaquine', 'type': 'Drug', 'start': 319, 'end': 330}, {'entity': 'malaria', 'type': 'Disease', 'start': 296, 'end': 303}, {'entity': 'falciparum', 'type': 'Disease', 'start': 285, 'end': 295}]\n",
            "['Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial\\tDose-dense weekly paclitaxel plus carboplatin improved survival compared with the conventional regimen and represents a new treatment option in women with advanced epithelial ovarian cancer.']\n",
            "unmatched tags:  [{'entity': 'epithelial ovarian cancer', 'type': 'Disease', 'start': 324, 'end': 349}, {'entity': 'carboplatin', 'type': 'Drug', 'start': 194, 'end': 205}]\n",
            "['Messenger RNAs transcribed from yeast linear cytoplasmic plasmids possess unconventional 5’ and 3’ UTRs and suggest a novel mechanism of translation\\tLinear plasmids with almost identical compact genetic organization have been found in the cytoplasm of yeast species from nine genera.', 'We employed pGKL1,2 plasmids from Kluyveromyces lactis as a model to investigate the previously unstudied transcriptome of yeast cytoplasmic linear plasmids.', 'We performed 5’ and 3’ RACE analysis of all the pGKL1,2 mRNAs and found them not 3’ polyadenylated and containing mostly uncapped 5’ poly(A) leaders that are not complementary to the plasmid DNA.', 'The degree of 5’ capping and/or 5’ polyadenylation is specific to each gene and is controlled by the corresponding promoter regions.', 'We refined the description of the pGKL1,2 promoters and found new alternative promoters of several genes.', 'We also provide evidence that K2ORF3 encodes an mRNA cap guanine-N 7 -methyltransferase and that 5’ capped pGKL1,2 transcripts contain N 7 -methylated caps.', 'Translation of pGKL1,2 transcripts is enhanced in Ism1Δ and pab1Δ strains and is independent of eIF4E and Pab1 translation factors.', 'We suggested a model of a primitive regulation of pGKL1,2 plasmids gene expression where degree of 5’ mRNA capping, degree of 5’ non-template polyadenylation and presence of negative regulators as PAB1 and Lsm1 play an important role.', 'Our data also suggest a close relationship between linear plasmids and poxviruses.']\n",
            "unmatched tags:  [{'entity': 'poxviruses', 'type': 'Virus', 'start': 1472, 'end': 1482}, {'entity': 'linear plasmids', 'type': 'Gene', 'start': 1452, 'end': 1467}, {'entity': 'Lsm1', 'type': 'Gene', 'start': 1372, 'end': 1376}, {'entity': 'PAB1', 'type': 'Gene', 'start': 1363, 'end': 1367}, {'entity': 'mRNA', 'type': 'Gene', 'start': 1268, 'end': 1272}, {'entity': 'gene', 'type': 'Gene', 'start': 1233, 'end': 1237}, {'entity': 'translation factors', 'type': 'Gene', 'start': 1145, 'end': 1164}, {'entity': 'Pab1', 'type': 'Gene', 'start': 1140, 'end': 1144}, {'entity': 'eIF4E', 'type': 'Gene', 'start': 1130, 'end': 1135}, {'entity': 'transcripts', 'type': 'Gene', 'start': 1057, 'end': 1068}, {'entity': 'transcripts', 'type': 'Gene', 'start': 992, 'end': 1003}, {'entity': 'mRNA', 'type': 'Gene', 'start': 925, 'end': 929}, {'entity': 'promoters', 'type': 'Gene', 'start': 849, 'end': 858}, {'entity': 'promoters', 'type': 'Gene', 'start': 813, 'end': 822}, {'entity': 'promoter regions', 'type': 'Gene', 'start': 753, 'end': 769}, {'entity': 'gene', 'type': 'Gene', 'start': 709, 'end': 713}, {'entity': 'plasmid DNA', 'type': 'Gene', 'start': 625, 'end': 636}, {'entity': 'polyadenylated', 'type': 'Gene', 'start': 526, 'end': 540}]\n",
            "['Multicentre search for genetic susceptibility loci in sporadic epilepsy syndrome and seizure types: a case-control study\\tThe underlying genetic component to sporadic epilepsy is clearly complex.', 'Results suggest that many SNPs contribute to disease predisposition in an apparently population-specific manner.', 'However, subtle differences in phenotyping across cohorts, combined with a poor understanding of how the underlying genetic component to epilepsy aligns with current phenotypic classifications, might also account for apparent population-specific genetic risk factors.', 'Variations across five genes warrant further study in independent cohorts to clarify the tentative association.']\n",
            "unmatched tags:  [{'entity': 'epilepsy', 'type': 'Disease', 'start': 445, 'end': 453}]\n",
            "['Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins\\tThe glycoprotein spike (S) on the surface of SARS-CoV-2 is a determinant for viral invasion and host immune response.', 'Herein, we characterized the site-specific N-glycosylation of S protein at the level of intact glycopeptides.', 'All 22 potential N-glycosites were identified in the S-protein protomer and were found to be preserved among the 753 SARS-CoV-2 genome sequences.', 'The glycosite occupancy by different glycoforms exhibited remarkable heterogeneity in human cell-expressed protein subunits, including up to 157 N-glycans, mainly of the complex type.', 'In contrast, the insect cell-expressed S protein contained 38 N-glycans, primarily of the high-mannose type.', 'Our results revealed that the glycan types were highly determined by the differential processing of N-glycans among human and insect cells.', 'This N-glycosylation landscape and the differential N-glycan patterns among distinct host cells are expected to shed light on the infection mechanism and present a positive view for the development of vaccines and targeted drugs.']\n",
            "unmatched tags:  [{'entity': 'vaccines', 'type': 'Drug', 'start': 1096, 'end': 1104}, {'entity': 'glycan', 'type': 'Drug', 'start': 949, 'end': 955}, {'entity': 'N-glycan', 'type': 'Gene', 'start': 947, 'end': 955}, {'entity': 'insect', 'type': 'Drug', 'start': 881, 'end': 887}, {'entity': 'N-glycans', 'type': 'Gene', 'start': 855, 'end': 864}, {'entity': 'glycan', 'type': 'Drug', 'start': 785, 'end': 791}, {'entity': 'glycan', 'type': 'Drug', 'start': 710, 'end': 716}, {'entity': 'N-glycans', 'type': 'Gene', 'start': 708, 'end': 717}, {'entity': 'S protein', 'type': 'Gene', 'start': 685, 'end': 694}, {'entity': 'insect', 'type': 'Drug', 'start': 663, 'end': 669}, {'entity': 'N-glycans', 'type': 'Gene', 'start': 607, 'end': 616}, {'entity': 'glycosite', 'type': 'Drug', 'start': 466, 'end': 475}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 433, 'end': 443}]\n",
            "['Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial\\tThe baricitinib 4 mg dose, but not the 2 mg dose, significantly improved the signs and symptoms of active systemic lupus erythematosus in patients who were not adequately controlled despite standard of care therapy, with a safety profile consistent with previous studies of baricitinib.', 'This study provides the foundation for future phase 3 trials of JAK1/2 inhibition with baricitinib as a new potential oral therapy for systemic lupus erythematosus.']\n",
            "unmatched tags:  [{'entity': 'systemic lupus erythematosus', 'type': 'Disease', 'start': 530, 'end': 558}, {'entity': 'baricitinib', 'type': 'Drug', 'start': 482, 'end': 493}]\n",
            "['Mono-ADP-ribosylation by ARTD10 restricts Chikungunya virus replication by interfering with the proteolytic activity of nsP2\\tA subset of intracellular mono-ADP-ribosyltransferases diphtheria toxin-like (ARTDs, aka mono-PARPs) is induced by type I interferons.', 'Some of these mono-ARTDs feature antiviral activity while certain RNA viruses, including Chikungunya virus (CHIKV), encode mono-ADP-ribosylhydrolases, suggesting a role for mono-ADP-ribosylation (MARylation) in host-virus conflicts.', 'CHIKV expresses four non-structural proteins (nsP1-nsP4), with nsP3 containing a macrodomain that hydrolyzes and thereby reverses protein MARylation in vitro and in cells.', 'This de-MARylation activity is essential as hydrolase inactivating mutations result in replication defective virus.', 'However, the substrates of MARylation during CHIKV infection are unknown and thus it is unclear how the macrodomain contributes to virus replication and how mono-ARTD-dependent MARylation confers antiviral immunity.', 'We identified ARTD10 and ARTD12 as restriction factors for CHIKV replication in a catalytic activity-dependent manner.', 'CHIKV replication requires processing of the non-structural polyprotein nsP1-4 by the nsP2-encoded protease and the assembly of the four individual nsPs into a functional replication complex.', 'Expression of ARTD10 and ARTD12 resulted in a reduction of processed nsPs.', 'Similarly, MAR hydrolase inactive CHIKV replicon mutants revealed a decrease in processed nsPs, comparable to an nsP2 protease defective mutant.', 'This suggested that the macrodomain contributes to nsP2 protease activity.', 'In support, a hydrolase-deficient virus was complemented by a protease-deficient virus.', 'We hypothesized that MARylation regulates the proteolytic function of nsP2.', 'Indeed, we found that nsP2 is MARylated by ARTD10.', 'This inhibited nsP2 protease activity, thereby preventing polyprotein processing and consequently virus replication.', 'This inhibition was antagonized by the MAR hydrolase activity of nsP3.', 'Together, our findings provide a mechanistic explanation for the need of the viral MAR hydrolase for efficient replication of CHIKV.', 'Author Summary Infectious diseases still pose major health threats.', 'Especially fast evolving viruses find ever new strategies to manipulate the immune response.', 'With climate warming and increased human mobility vector-borne pathogens like Chikungunya virus (CHIKV) spread and cause world-wide epidemics.', 'Beyond the acute phase, CHIKV patients regularly suffer from chronic rheumatism.', 'This entails a decline in life quality and an economic burden.', 'To date no drugs are approved and the mode of pathogenesis remains elusive.', 'Here we describe a mechanistic function of the CHIKV nsP3 macrodomain.', 'We found that the viral nsP2 is mono-ADP-ribosylated interfering with its auto-proteolytic function.', 'The nsP3 macrodomain removes this modification and restores the protease activity that is essential for replication.', 'Because macrodomains are highly conserved they might represent broad antiviral targets.']\n",
            "unmatched tags:  [{'entity': 'macrodomain', 'type': 'Gene', 'start': 2960, 'end': 2971}, {'entity': 'macrodomain', 'type': 'Gene', 'start': 2844, 'end': 2855}, {'entity': 'nsP3 macrodomain', 'type': 'Disease', 'start': 2839, 'end': 2855}, {'entity': 'proteolytic function', 'type': 'Gene', 'start': 2813, 'end': 2833}, {'entity': 'nsP2', 'type': 'Gene', 'start': 2758, 'end': 2762}, {'entity': 'viral nsP2', 'type': 'Gene', 'start': 2752, 'end': 2762}, {'entity': 'nsP3 macrodomain', 'type': 'Disease', 'start': 2716, 'end': 2732}, {'entity': 'CHIKV', 'type': 'Organization', 'start': 2710, 'end': 2715}, {'entity': 'chronic rheumatism', 'type': 'Disease', 'start': 2504, 'end': 2522}, {'entity': 'CHIKV', 'type': 'Organization', 'start': 2467, 'end': 2472}, {'entity': 'CHIKV', 'type': 'Organization', 'start': 2397, 'end': 2402}, {'entity': 'Chikungunya virus', 'type': 'Virus', 'start': 2378, 'end': 2395}, {'entity': 'Author Summary Infectious diseases', 'type': 'Disease', 'start': 2139, 'end': 2173}, {'entity': 'CHIKV', 'type': 'Organization', 'start': 2132, 'end': 2137}, {'entity': 'hydrolase', 'type': 'Gene', 'start': 2093, 'end': 2102}, {'entity': 'viral MAR hydrolase', 'type': 'Gene', 'start': 2083, 'end': 2102}, {'entity': 'nsP3', 'type': 'Gene', 'start': 2000, 'end': 2004}, {'entity': 'MAR hydrolase', 'type': 'Gene', 'start': 1974, 'end': 1987}, {'entity': 'nsP2 protease', 'type': 'Gene', 'start': 1833, 'end': 1846}, {'entity': 'ARTD10', 'type': 'Gene', 'start': 1810, 'end': 1816}, {'entity': 'nsP2', 'type': 'Gene', 'start': 1789, 'end': 1793}, {'entity': 'nsP2', 'type': 'Gene', 'start': 1761, 'end': 1765}, {'entity': 'proteolytic function', 'type': 'Gene', 'start': 1737, 'end': 1757}, {'entity': 'nsP2 protease', 'type': 'Gene', 'start': 1579, 'end': 1592}, {'entity': 'macrodomain', 'type': 'Gene', 'start': 1552, 'end': 1563}, {'entity': 'nsP2 protease', 'type': 'Gene', 'start': 1496, 'end': 1509}, {'entity': 'replicon', 'type': 'Gene', 'start': 1423, 'end': 1431}, {'entity': 'CHIKV', 'type': 'Organization', 'start': 1417, 'end': 1422}, {'entity': 'MAR hydrolase', 'type': 'Gene', 'start': 1394, 'end': 1407}, {'entity': 'ARTD12', 'type': 'Gene', 'start': 1333, 'end': 1339}, {'entity': 'ARTD10', 'type': 'Gene', 'start': 1322, 'end': 1328}, {'entity': 'CHIKV', 'type': 'Organization', 'start': 1116, 'end': 1121}, {'entity': 'CHIKV', 'type': 'Organization', 'start': 1056, 'end': 1061}, {'entity': 'ARTD12', 'type': 'Gene', 'start': 1022, 'end': 1028}, {'entity': 'ARTD10', 'type': 'Gene', 'start': 1011, 'end': 1017}, {'entity': 'macrodomain', 'type': 'Gene', 'start': 885, 'end': 896}, {'entity': 'CHIKV', 'type': 'Organization', 'start': 826, 'end': 831}, {'entity': 'replication defective virus', 'type': 'Virus', 'start': 752, 'end': 779}, {'entity': 'hydrolase', 'type': 'Gene', 'start': 709, 'end': 718}, {'entity': 'macrodomain', 'type': 'Gene', 'start': 574, 'end': 585}, {'entity': 'nsP3', 'type': 'Gene', 'start': 556, 'end': 560}, {'entity': 'nsP1-nsP4', 'type': 'Gene', 'start': 539, 'end': 548}]\n",
            "['Tension-type headache in childhood and adolescence\\tThe prevalence of non-migrainous headache is 10–25% in childhood and adolescence.', 'Although tension-type headache and migraine are the two most common types of headache in children and adolescents, most articles address migraine headache.', 'The distinction of tension-type headache from migraine can be difficult; use of']\n",
            "unmatched tags:  [{'entity': 'migraine', 'type': 'Disease', 'start': 335, 'end': 343}, {'entity': 'headache', 'type': 'Phenotype', 'start': 321, 'end': 329}, {'entity': 'tension-type headache', 'type': 'Disease', 'start': 308, 'end': 329}, {'entity': 'migraine headache', 'type': 'Disease', 'start': 270, 'end': 287}]\n",
            "['Acute lung injury and the acute respiratory distress syndrome: a clinical review\\tAcute respiratory distress syndrome and acute lung injury are well defined and readily recognised clinical disorders caused by many clinical insults to the lung or because of predispositions to lung injury.', 'That this process is common in intensive care is well established.', 'The mainstay of treatment for this disorder is provision of excellent supportive care since these patients are critically ill and frequently have coexisting conditions including sepsis and multiple organ failure.', 'Refinements in ventilator and fluid management supported by data from prospective randomised trials have increased the methods available to effectively manage this disorder.']\n",
            "unmatched tags:  [{'entity': 'sepsis', 'type': 'Disease', 'start': 533, 'end': 539}, {'entity': 'critically ill', 'type': 'Phenotype', 'start': 466, 'end': 480}, {'entity': 'lung injury', 'type': 'Disease', 'start': 275, 'end': 286}]\n",
            "['Clinical analysis and early differential diagnosis of suspected pediatric patients with 2019 novel coronavirus infection\\tAbstract Background: Early differential diagnosis of suspected pediatric patients is difficult during the 2019-nCoV epidemic.', 'Objective: To identify clinical characteristics and key points of early differential diagnosis.', 'Methods: A retrospective analysis was performed on suspected pediatric cases.', 'Results:A total of 77 suspected cases were admitted from Jan 22nd to Mar 1st.', 'Compared with non-2019-nCoV group (n=33),2019-nCoV confirmed group (n=35) had fewer fever (OR[95% CI] 0.39[0.242 to 0.628];P<.001) and symptoms of ARI (0.454[0.287 to 0.719];P<.001),more asymptomatic (15.086[2.117 to 107.475];P<.001), and more family cluster infections (5.469[2.405 to 12.433]; P<.001),while chest CT had more positive findings of viral pneumonia (1.813[1.131 to 2.908];P=.014).There were significant statistical differences between the two groups in age (7.2[3.9 to 11.4] vs 5[2.1 to 7.8];P=.031),body temperature (36.7[36.2 to 36.9] vs 37[36.7 to 37.9];P=.001), heart rate ([97.1 and 16.8] vs [109.7 and 15.6];P=.002),percentage ([39.4 and 14.9] vs [52.5 and 17.5]; P=.001) and count (2.25[1.43 to 3.53] vs 3.33[2.8 to 5.18];P=.007) of neutrophil, percentage (45.3[39.2 to 56.6] vs 33.2[22.7 to 42.5];P=.001) of lymphocyte,hs-CRP (5.52[1.1 to 9.04] vs 9.04[7.35 to 9.54];P=.002) and PCT (0.05[0.03 to 0.08] vs 0.1[0.05 to 0.21];P<.001),while gender (42.9% vs 57.6%;P=.332),respiratory rate (22[20 to 22] vs 22[20 to 24];P=.092),WBC (5.37[4.67 to 8.08] vs 6.94[5.72 to 8.87];P=.198), lymphocyte count (2.68[1.99 to 4.01] vs 2.26[1.66 to 2.92];P=.096),Hb (128[124 to 142] vs 130[119 to 137];P=.572) and PLT ([279.1 and 77.5] vs [263.4 and 65.1];P=.37) were statistically insignificant.', 'Conclusions: Asymptoms or mild symptoms,positive CT findings and family cluster infection are the main clinical characteristics of infected pediatric patients.', 'The CBC, hs-CRP and PCT can provide an important basis for early differential diagnosis.', 'Compared with other non-bacterial infections,hs-CRP and PCT in 2019-nCoV infection are reduced,but further evidence is needed to support whether their reduction is specific.', 'Keywords: 2019 novel coronavirus;acute respiratory infection; pediatric;differential diagnosis;suspected infection.', 'Abbreviations:2019-nCoV,2019 novel coronavirus;CT,computed tomography; RT-PCR,real-time reverse transcriptase polymerase chain reaction;IQR,interquartile range;OR,odds ratio;CI,confidence interval;SD,standard deviation;ARI,acute respiratory infection; CAP,community-acquired pneumonia;RSV, respiratory syncytial virus; MP, mycoplasma pneumoniae; INF A,B,influenza A,B;CBC,complete blood count;WBC,white blood cell;N%, percentage of neutrophil; L%, percentage of lymphocyte; Hb, Hemoglobin;PLT, platelet; hs-CRP,high sensitivity C-reactive protein; PCT, procalcitonin.']\n",
            "unmatched tags:  [{'entity': 'procalcitonin', 'type': 'Gene', 'start': 2894, 'end': 2907}, {'entity': 'PCT', 'type': 'Disease', 'start': 2889, 'end': 2892}, {'entity': 'C-reactive protein', 'type': 'Gene', 'start': 2869, 'end': 2887}, {'entity': 'hs-CRP', 'type': 'Chemical', 'start': 2845, 'end': 2851}, {'entity': 'Hb', 'type': 'Gene', 'start': 2815, 'end': 2817}, {'entity': 'influenza A', 'type': 'Drug', 'start': 2695, 'end': 2706}, {'entity': 'INF', 'type': 'Drug', 'start': 2687, 'end': 2690}, {'entity': 'MP', 'type': 'Disease', 'start': 2660, 'end': 2662}, {'entity': 'respiratory syncytial virus', 'type': 'Virus', 'start': 2631, 'end': 2658}, {'entity': 'community-acquired pneumonia;RSV', 'type': 'Disease', 'start': 2597, 'end': 2629}, {'entity': 'respiratory infection', 'type': 'Disease', 'start': 2570, 'end': 2591}, {'entity': 'acute respiratory infection', 'type': 'Disease', 'start': 2564, 'end': 2591}, {'entity': 'ARI', 'type': 'Gene', 'start': 2560, 'end': 2563}, {'entity': 'coronavirus;CT', 'type': 'Virus', 'start': 2376, 'end': 2390}, {'entity': 'acute respiratory infection', 'type': 'Disease', 'start': 2258, 'end': 2285}, {'entity': 'PCT', 'type': 'Disease', 'start': 2107, 'end': 2110}, {'entity': 'hs-CRP', 'type': 'Chemical', 'start': 2096, 'end': 2102}, {'entity': 'non-bacterial infections', 'type': 'Disease', 'start': 2071, 'end': 2095}, {'entity': 'PCT', 'type': 'Disease', 'start': 1982, 'end': 1985}, {'entity': 'hs-CRP', 'type': 'Chemical', 'start': 1971, 'end': 1977}, {'entity': 'Asymptoms', 'type': 'Phenotype', 'start': 1815, 'end': 1824}, {'entity': 'Hb', 'type': 'Gene', 'start': 1668, 'end': 1670}, {'entity': 'PCT', 'type': 'Disease', 'start': 1401, 'end': 1404}, {'entity': 'hs-CRP', 'type': 'Chemical', 'start': 1341, 'end': 1347}]\n",
            "['Alcohol consumption and risk of non-Hodgkin lymphoma: a pooled analysis\\tPeople who drink alcoholic beverages might have a lower risk of NHL than those who do not, and this risk might vary by NHL subtype.', 'Further study designs are needed to determine whether confounding lifestyle factors or immunomodulatory effects of alcohol explain this association.']\n",
            "unmatched tags:  [{'entity': 'alcohol', 'type': 'Drug', 'start': 319, 'end': 326}]\n",
            "['Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies\\tIn patients with recent ischaemic stroke or transient ischaemic attack, cerebral microbleeds are associated with a greater relative hazard (aHR) for subsequent intracranial haemorrhage than for ischaemic stroke, but the absolute risk of ischaemic stroke is higher than that of intracranial haemorrhage, regardless of cerebral microbleed presence, antomical distribution, or burden.']\n",
            "unmatched tags:  [{'entity': 'intracranial haemorrhage', 'type': 'Disease', 'start': 433, 'end': 457}, {'entity': 'stroke', 'type': 'Disease', 'start': 403, 'end': 409}, {'entity': 'ischaemic stroke', 'type': 'Disease', 'start': 393, 'end': 409}, {'entity': 'ischaemic stroke', 'type': 'Disease', 'start': 350, 'end': 366}, {'entity': 'intracranial haemorrhage', 'type': 'Disease', 'start': 316, 'end': 340}, {'entity': 'aHR', 'type': 'Gene', 'start': 296, 'end': 299}]\n",
            "['ISG15 drives immune pathology and respiratory failure during viral infection\\tCytokine storm during respiratory viral infection is an indicator of disease severity and poor prognosis.', 'Type 1 interferon (IFN-I) production and signaling has been reported to be causal in cytokine storm-associated pathology in several respiratory viral infections, however, the mechanisms by which IFN-I promotes disease pathogenesis remain poorly understood.', 'Here, using Usp18- deficient, USP18 enzymatic-inactive and Isg15 -deficient mouse models, we report that lack of deISGylation during persistent viral infection leads to severe immune pathology characterized by hematological disruptions, cytokine amplification, lung vascular leakage and death.', 'This pathology requires T cells but not T cell-intrinsic deletion of Usp18 .', 'However, lack of Usp18 in myeloid cells mimicked the pathological manifestations observed in Usp18 -/- or Usp18 C61A mice which were dependent on Isg15 .', 'We further mechanistically demonstrate that interrupting the ISGylation/deISGylation circuit increases extracellular levels of ISG15 which is accompanied by inflammatory neutrophil accumulation to the lung.', 'Importantly, neutrophil depletion reversed morbidity and mortality in Usp18 C61A mice.', 'In summary, we reveal that the enzymatic function of Usp18 is crucial for regulating extracellular release of ISG15.', 'This is accompanied by altered neutrophil differentiation, cytokine amplification and mortality following persistent viral infection.', 'Moreover, our results suggest that extracellular ISG15 may drive the inflammatory pathology observed and could be both a prospective predictor of disease outcome and a therapeutic target during severe respiratory viral infections.']\n",
            "unmatched tags:  [{'entity': 'respiratory viral infections', 'type': 'Disease', 'start': 1711, 'end': 1739}, {'entity': 'ISG15', 'type': 'Gene', 'start': 1559, 'end': 1564}, {'entity': 'viral infection', 'type': 'Virus', 'start': 1493, 'end': 1508}, {'entity': 'cytokine', 'type': 'Gene', 'start': 1435, 'end': 1443}, {'entity': 'ISG15', 'type': 'Gene', 'start': 1369, 'end': 1374}, {'entity': 'Usp18', 'type': 'Gene', 'start': 1312, 'end': 1317}, {'entity': 'Usp18', 'type': 'Gene', 'start': 1242, 'end': 1247}, {'entity': 'ISG15', 'type': 'Gene', 'start': 1092, 'end': 1097}, {'entity': 'Isg15', 'type': 'Gene', 'start': 957, 'end': 962}, {'entity': 'Usp18', 'type': 'Gene', 'start': 917, 'end': 922}, {'entity': 'Usp18', 'type': 'Gene', 'start': 904, 'end': 909}, {'entity': 'Usp18', 'type': 'Gene', 'start': 828, 'end': 833}, {'entity': 'Usp18', 'type': 'Gene', 'start': 803, 'end': 808}, {'entity': 'cytokine', 'type': 'Gene', 'start': 677, 'end': 685}, {'entity': 'viral infection', 'type': 'Virus', 'start': 584, 'end': 599}, {'entity': 'Isg15', 'type': 'Gene', 'start': 499, 'end': 504}, {'entity': 'USP18', 'type': 'Gene', 'start': 470, 'end': 475}]\n",
            "['A proposal of alternative primers for the ARTIC Network’s multiplex PCR to improve coverage of SARS-CoV-2 genome sequencing\\tA group of biologists, ARTIC Network, has proposed a multiplexed PCR primer set for whole-genome analysis of the novel coronavirus, SARS-CoV-2, soon after the start of COVID-19 epidemics was realized.', 'The primer set was adapted by many researchers worldwide and has already contributed to the high-quality and prompt genome epidemiology of this rapidly spreading viral disease.', 'We have also seen the great performance of their primer set and protocol; the primer set amplifies all desired 98 PCR amplicons with fairly small amplification bias from clinical samples with relatively high viral load.', 'However, we also observed an acute drop of reads derived from some amplicons especially amplicon 18 and 76 in “pool 2” as a sample’s viral load decreases.', 'We suspected this low coverage issue was due to dimer formation between primers targeting those two amplicons.', 'Indeed, replacement of just one of those primers, nCoV-2019_76_RIGHT, to a newly designed primer resulted in a drastic improvement of coverages at both regions targeted by the amplicons 18 and 76.', 'Given this result, we further replaced four primers in “pool 1” with each respective alternative.', 'These modifications also improved coverage in eight amplicons particularly in samples with low viral load.', 'The results of our experiments clearly indicate that primer dimer formation is one critical cause of coverage bias in ARTIC protocol.', 'Importantly, some of the problematic primers are detectable by observing primer dimers in raw NGS sequence reads and replacing them with alternatives as shown in this study.', 'We expect a continuous improvement of the ARTIC primer set will extend the limit for completion of SARS-CoV-2 genomes to samples with lower viral load, that supports better genomic epidemiology and mitigation of spread of this pathogen.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1797, 'end': 1807}, {'entity': 'primer set', 'type': 'Gene', 'start': 1746, 'end': 1756}, {'entity': 'NGS', 'type': 'Organization', 'start': 1618, 'end': 1621}, {'entity': 'primer dimer', 'type': 'Gene', 'start': 1597, 'end': 1609}, {'entity': 'primer dimer', 'type': 'Gene', 'start': 1443, 'end': 1455}, {'entity': 'amplicon', 'type': 'Organization', 'start': 1335, 'end': 1343}, {'entity': 'amplicon', 'type': 'Organization', 'start': 1164, 'end': 1172}, {'entity': 'primer', 'type': 'Gene', 'start': 1078, 'end': 1084}, {'entity': 'nCoV-2019_76_RIGHT', 'type': 'Gene', 'start': 1038, 'end': 1056}, {'entity': 'amplicon', 'type': 'Organization', 'start': 977, 'end': 985}, {'entity': 'amplicon', 'type': 'Organization', 'start': 810, 'end': 818}]\n",
            "['Probing the unfolded protein response to mouse hepatitis coronavirus infection through RNA sequencing and ribosome profiling\\tCoronaviruses (CoVs) are enveloped, positive-sense RNA viruses with an unusually large RNA genome and a unique replication strategy.', 'They cause important diseases in mammals and birds ranging from enteritis in cows and pigs and upper respiratory disease in chickens, to potentially lethal human respiratory infections.', 'Here, we apply ribosome profiling and parallel RNA sequencing to analyse global changes in host cell transcriptome and translatome upon infection with mouse hepatitis virus strain A59 (MHV-A59), a model murine coronavirus in the same genus as the human pathogens severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV).', 'Amongst differentially-regulated cellular genes, we observed up-regulation of all arms of the unfolded protein response (UPR), including translational activation of transcription factors ATF4, ATF5 and Chop.', 'Polysome profiling of infected-cells revealed an accumulation of empty 80S ribosomes, consistent with increased phosphorylation of eIF2α leading to translational shut-off via inhibited initiation.', 'Ribosomal footprints on phosphorylated-eIF2α-resistant mRNAs revealed unambiguous upstream open reading frame (uORF) occupancy consistent with host maintenance of the UPR.', 'Unexpectedly, an inhibitor of PERK that blocks the UPR and relieves translation inhibition was found to attenuate virus growth suggesting that MHV may subvert the UPR to its own advantage.', 'This study sheds new light on the complex interactions between MHV and host during infection and provides new potential targets for antiviral intervention.']\n",
            "unmatched tags:  [{'entity': 'MHV', 'type': 'Chemical', 'start': 1654, 'end': 1657}, {'entity': 'MHV', 'type': 'Chemical', 'start': 1545, 'end': 1548}, {'entity': 'PERK', 'type': 'Gene', 'start': 1432, 'end': 1436}, {'entity': 'uORF', 'type': 'Gene', 'start': 1341, 'end': 1345}, {'entity': 'upstream open reading frame', 'type': 'Gene', 'start': 1312, 'end': 1339}, {'entity': 'mRNAs', 'type': 'Gene', 'start': 1285, 'end': 1290}, {'entity': 'infected-cells', 'type': 'Gene', 'start': 1055, 'end': 1069}, {'entity': 'ATF5', 'type': 'Gene', 'start': 1018, 'end': 1022}, {'entity': 'ATF4', 'type': 'Gene', 'start': 1012, 'end': 1016}, {'entity': 'transcription factors', 'type': 'Gene', 'start': 990, 'end': 1011}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 814, 'end': 822}]\n",
            "['Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials\\tIn the era of treatment with tyrosine-kinase inhibitors, patients diagnosed with CML-CP can expect a 5-year survival that is only slightly lower than that of the general population.', 'With access to tyrosine-kinase inhibitors, most patients with chronic myeloid leukaemia could enjoy a near normal life expectancy.']\n",
            "unmatched tags:  [{'entity': 'chronic myeloid leukaemia', 'type': 'Disease', 'start': 419, 'end': 444}, {'entity': 'tyrosine-kinase inhibitors', 'type': 'Drug', 'start': 372, 'end': 398}, {'entity': 'era', 'type': 'Gene', 'start': 340, 'end': 343}, {'entity': 'tyrosine-kinase inhibitors', 'type': 'Drug', 'start': 204, 'end': 230}, {'entity': 'era', 'type': 'Gene', 'start': 182, 'end': 185}, {'entity': 'era', 'type': 'Gene', 'start': 108, 'end': 111}]\n",
            "['Lung cancer in Europe in 2000: epidemiology, prevention, and early detection\\tLung cancer is the most common cancer in the world.', 'In men, the highest incidence rates are seen in Europe (especially eastern Europe) and North America.', 'In women, high incidence rates are found in North America and in Europe, particularly in northern and western Europe.', 'It is estimated that there were about 375\\u2008000 cases of lung cancer in Europe in 2000; 303\\u2008000 in men and 72\\u2008000 in women.', 'The number of resulting deaths was about 347\\u2008000 (280\\u2008000 in men and 67\\u2008000 in women).', 'Tobacco smoking is well established as the main cause of lung cancer and about 90% of cases are thought to be tobacco related.']\n",
            "unmatched tags:  [{'entity': 'cancer', 'type': 'Disease', 'start': 620, 'end': 626}, {'entity': 'lung cancer', 'type': 'Disease', 'start': 615, 'end': 626}]\n",
            "['Membrane proteins with high N-glycosylation, high expression, and multiple interaction partners were preferred by mammalian viruses as receptors\\tReceptor mediated entry is the first step for viral infection.', 'However, the relationship between viruses and receptors is still obscure.', 'Here, by manually curating a high-quality database of 268 pairs of mammalian virus-host receptor interaction, which included 128 unique viral species or sub-species and 119 virus receptors, we found the viral receptors were structurally and functionally diverse, yet they had several common features when compared to other cell membrane proteins: more protein domains, higher level of N-glycosylation, higher ratio of self-interaction and more interaction partners, and higher expression in most tissues of the host.', 'Additionally, the receptors used by the same virus tended to co-evolve.', 'Further correlation analysis between viral receptors and the tissue and host specificity of the virus shows that the virus receptor similarity was a significant predictor for mammalian virus cross-species.', 'This work could deepen our understanding towards the viral receptor selection and help evaluate the risk of viral zoonotic diseases.']\n",
            "unmatched tags:  [{'entity': 'viral zoonotic diseases', 'type': 'Disease', 'start': 1185, 'end': 1208}, {'entity': 'viral receptor', 'type': 'Gene', 'start': 1130, 'end': 1144}, {'entity': 'cross-species', 'type': 'Chemical', 'start': 1062, 'end': 1075}, {'entity': 'virus receptor', 'type': 'Gene', 'start': 988, 'end': 1002}, {'entity': 'viral receptors', 'type': 'Gene', 'start': 908, 'end': 923}, {'entity': 'receptors', 'type': 'Gene', 'start': 817, 'end': 826}]\n",
            "['Deaths due to absence of an affordable antitoxin for plant poisoning\\tThere is a severe shortage of affordable antivenoms and antitoxins in the developing world.', 'An anti-digoxin antitoxin for oleander poisoning was introduced in Sri Lanka in July, 2001, but because of its cost, stocks ran out in July, 2002.', 'We looked at the effect of its introduction and withdrawal on case fatality, and determined its cost-effectiveness.', 'The antitoxin strikingly reduced the case fatality; its absence resulted in a three-fold rise in deaths.', 'At the present price of US$2650 per course, every life saved cost $10\\u2008209 and every life year cost $248.']\n",
            "unmatched tags:  [{'entity': 'antitoxin', 'type': 'Drug', 'start': 428, 'end': 437}]\n",
            "['Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial\\tTopical application of imiquimod before intradermal trivalent influenza vaccine significantly improved immunogenicity against the vaccine influenza strains in young healthy individuals and increased immunogenicity against the non-vaccine strains, especially the antigenically drifted H3N2 strain of 2015, which was not included in the 2013–14 recommended vaccine.', 'Further studies should be done to establish the efficacy and safety of this approach for other injectable vaccines to augment the onset and range of protection.']\n",
            "unmatched tags:  [{'entity': 'injectable vaccines', 'type': 'Drug', 'start': 678, 'end': 697}, {'entity': 'vaccine', 'type': 'Drug', 'start': 574, 'end': 581}, {'entity': 'vaccine', 'type': 'Drug', 'start': 449, 'end': 456}, {'entity': 'vaccine influenza strains', 'type': 'Drug', 'start': 349, 'end': 374}]\n",
            "['A Multicentre Study of 2019 Novel Coronavirus Disease Outcomes of Cancer Patients in Wuhan, China\\tBackground: At present, there is a global pandemic of coronavirus disease 2019 (COVID-19) pneumonia.', 'Two previous case series from China have suggested that cancer patients are at a higher risk of COVID-19 pneumonia, but the reports were limited by small numbers and few clinical information.', 'Objective: To study clinical characteristics and outcomes of cancer patients infected with COVID-19.', 'Design: Retrospective study.', 'Setting: Four designated COVID-16 hospitals in Wuhan, Hubei province, China.', 'Participants: Medical records of 67 cancer patients admitted to hospitals between Jan 5, 2020 to Feb 18, 2020 were included.', 'Measurements: Demographic, clinical, laboratory, radiological and treatment data were collected.', 'Survival data of the cohort was cut-off on Mar 10, 2020.', 'Results: Of the 67 patients (median age: 66 years), the median age of patients who had severe illness was older than that of patients who had mild symptoms (P<0.001).', 'Forty-three (64.2%) patients had other concurrent chronic diseases, and the proportion of severe patients had co-morbidities was higher than patients with mild disease (P=0.004).', 'Twenty-three (34.3%) patients were still at the anticancer treatment phase, but no tumour progression and recurrence was observed for all the patients during the treatment of COVID-19 pneumonia.', 'About 70% of these patients had fever (n=53, 79.1%) and/or cough (n=50, 74.6%).', 'Lymphocytopenia was the main laboratory finding accompanying increased C-reactive protein and procalcitonin in cancer patients, especially in severe cases.', 'By Mar 10, 2020, 18 (26.9%) patients died from COVID-19, and 39 (58.2%) patients have been discharged.', 'The median age of survivors was younger than that of deaths (P=0.014).', 'Lung cancer (n=15, 22.4%) with COVID-19 was the most common cancer type and accounted for the highest proportion COVID-19 resulted deaths (33.3%, 5/15).', 'We observed a tendency that patients at the follow-up phase had a better prognosis than that at anticancer treatment phase (P=0.095).', 'Limitation: This is a retrospective study with only 67 cases from four hospitals.', 'And some specific clinical information was insufficient.', 'Conclusion: This study showed COVID-19 patients with cancer seem to have a higher proportion of severe cases and poorer prognosis.', 'The tendency of poor prognosis was more obvious in patients at anticancer treatment phase.', 'We should pay more intensive attentions to cancer patients infected with COVID-19.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2551, 'end': 2559}, {'entity': 'cancer', 'type': 'Disease', 'start': 2521, 'end': 2527}, {'entity': 'cancer', 'type': 'Disease', 'start': 2454, 'end': 2460}, {'entity': 'cancer', 'type': 'Disease', 'start': 2309, 'end': 2315}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2286, 'end': 2294}, {'entity': 'cancer', 'type': 'Disease', 'start': 2082, 'end': 2088}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1942, 'end': 1950}, {'entity': 'cancer', 'type': 'Disease', 'start': 1889, 'end': 1895}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1860, 'end': 1868}, {'entity': 'Lung cancer', 'type': 'Disease', 'start': 1829, 'end': 1840}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1702, 'end': 1710}, {'entity': 'cancer', 'type': 'Disease', 'start': 1610, 'end': 1616}, {'entity': 'procalcitonin', 'type': 'Gene', 'start': 1593, 'end': 1606}, {'entity': 'C-reactive protein', 'type': 'Gene', 'start': 1570, 'end': 1588}, {'entity': 'cough', 'type': 'Phenotype', 'start': 1478, 'end': 1483}, {'entity': 'fever', 'type': 'Phenotype', 'start': 1451, 'end': 1456}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 1408, 'end': 1417}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1399, 'end': 1407}]\n",
            "['Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial\\tFingolimod 0·5 mg once-daily was not better than placebo for the treatment of CIDP.', 'Future trial designs should take account of the possibility that if IVIg is stopped abruptly, some patients might relapse soon afterwards whereas others might remain in remission.']\n",
            "unmatched tags:  [{'entity': 'IVIg', 'type': 'Gene', 'start': 304, 'end': 308}, {'entity': 'CIDP', 'type': 'Disease', 'start': 230, 'end': 234}]\n",
            "['Analysis of meteorological conditions and prediction of epidemic trend of 2019-nCoV infection in 2020\\tObjective: To investigate the meteorological condition for incidence and spread of 2019-nCoV infection, to predict the epidemiology of the infectious disease, and to provide a scientific basis for prevention and control measures against the new disease.', 'Methods: The meteorological factors during the outbreak period of the novel coronavirus pneumonia in Wuhan in 2019 were collected and analyzed, and were confirmed with those of Severe Acute Respiratory Syndrome (SARS) in China in 2003.', 'Data of patients infected with 2019-nCoV and SARS coronavirus were collected from WHO website and other public sources.', 'Results: This study found that the suitable temperature range for 2019-nCoV coronavirus survival is (13-24 degree Celsius), among which 19 degree Celsius lasting about 60 days is conducive to the spread between the vector and humans; the humidity range is 50%-80%, of which about 75% humidity is conducive to the survival of the coronavirus; the suitable precipitation range is below 30 mm/ month.', 'Cold air and continuous low temperature over one week are helpful for the elimination of the virus.', 'The prediction results show that with the approach of spring, the temperature in north China gradually rises, and the coronavirus spreads to middle and high latitudes along the temperature line of 13-18 degree Celsius.', 'The population of new coronavirus infections is concentrated in Beijing, Tianjin, Hebei, Jiangsu, Zhejiang, Shanghai and other urban agglomerations.', 'Starting from May 2020, the Beijing-Tianjin-Hebei urban agglomeration, the Central China Zhengzhou-Wuhan urban agglomeration, the eastern Jiangsu-Zhejiang-Shanghai urban agglomeration, and the southern Pearl River Delta urban agglomeration are all under a high temperature above 24 degree Celsius, which is not conducive to the survival and reproduction of coronaviruses, so the epidemic is expected to end.', 'Conclusions: A wide range of continuous warm and dry weather is conducive to the survival of 2019-nCoV.', 'The coming of spring, in addition to the original Wuhan-Zhengzhou urban agglomeration in central China, means that the prevention and control measures in big cities located in mid-latitude should be strengthened, especially the monitoring of transportation hubs.', 'The Pearl River Delta urban agglomeration is a concentrated area of population in south China, with a faster temperature rise than those in mid-high latitudes, and thus the prevention in this area should be prioritized.', 'From a global perspective, cities with a mean temperature below 24 degree Celsius are all high-risk cities for 2019-nCoV transmission before June.']\n",
            "unmatched tags:  [{'entity': '2019-nCoV', 'type': 'Virus', 'start': 2685, 'end': 2694}, {'entity': 'agglomeration', 'type': 'Disease', 'start': 2382, 'end': 2395}, {'entity': 'Pearl River Delta', 'type': 'Gene', 'start': 2358, 'end': 2375}, {'entity': 'transportation hubs', 'type': 'Organization', 'start': 2333, 'end': 2352}, {'entity': 'agglomeration', 'type': 'Disease', 'start': 2163, 'end': 2176}, {'entity': '2019-nCoV', 'type': 'Virus', 'start': 2080, 'end': 2089}, {'entity': 'coronaviruses', 'type': 'Virus', 'start': 1936, 'end': 1949}, {'entity': 'agglomeration', 'type': 'Disease', 'start': 1805, 'end': 1818}, {'entity': 'Pearl River Delta', 'type': 'Gene', 'start': 1781, 'end': 1798}, {'entity': 'agglomeration', 'type': 'Disease', 'start': 1749, 'end': 1762}, {'entity': 'agglomeration', 'type': 'Disease', 'start': 1690, 'end': 1703}, {'entity': 'agglomeration', 'type': 'Disease', 'start': 1635, 'end': 1648}]\n",
            "['The metabolic syndrome\\tThe metabolic syndrome is a common metabolic disorder that results from the increasing prevalence of obesity.', 'The disorder is defined in various ways, but in the near future a new definition(s) will be applicable worldwide.', 'The pathophysiology seems to be largely attributable to insulin resistance with excessive flux of fatty acids implicated.', 'A proinflammatory state probably contributes to the syndrome.', 'The increased risk for type 2 diabetes and cardiovascular disease demands therapeutic attention for those at high risk.']\n",
            "unmatched tags:  [{'entity': 'cardiovascular disease', 'type': 'Disease', 'start': 474, 'end': 496}, {'entity': 'type 2 diabetes', 'type': 'Disease', 'start': 454, 'end': 469}, {'entity': 'syndrome', 'type': 'Disease', 'start': 421, 'end': 429}, {'entity': 'fatty acids', 'type': 'Drug', 'start': 345, 'end': 356}, {'entity': 'obesity', 'type': 'Phenotype', 'start': 124, 'end': 131}]\n",
            "['ACE2 Homo-dimerization, Human Genomic variants and Interaction of Host Proteins Explain High Population Specific Differences in Outcomes of COVID19\\tSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive single stranded RNA virus that causes a highly contagious Corona Virus Disease (COVID19).', 'Entry of SARS-CoV-2 in human cells depends on binding of the viral spike (S) proteins to cellular receptor Angiotensin-converting enzyme 2 (ACE2) and on S protein priming by host cell serine protease TMPRSS2.', 'Recently COVID19 has been declared pandemic by World Health Organization yet high differences in disease outcomes across countries have been seen.', 'We provide evidences based on analyses of existing public datasets and by using various in-silico approaches to explain some of these as factors that may explain population level differences.', 'One of the key factors might be entry of virus in host cells due to differential interaction of viral proteins with host cell proteins due to different genetic backgrounds.', 'Based on our findings, we conclude that higher expression of ACE2 facilitated by natural variations, acting as Expression quantitative trait loci (eQTLs) and with different frequencies in different populations, results in ACE2 homo-dimerization which is disadvantageous for TMPRSS2 mediated cleavage of ACE2 and becomes more difficult in presence of broad neutral amino acid transporter, B0AT1 (coded by SLC6A19), that usually does not express in Lungs.', 'We also propose that the monomeric ACE2 has higher preferential binding with SARS-CoV-2 S-Protein vis-a-vis its dimerized counterpart.', 'Further, eQTLs in TMPRSS2 and natural structural variations in the gene may also result in differential outcomes towards priming of viral S-protein, a critical step for entry of Virus in host cells.', 'In addition, we suggest some other potential key host genes like ADAM17, RPS6, HNRNPA1, SUMO1, NACA, BTF3 and some other proteases as Cathepsins, that might have a critical role.', 'Understanding these population specific differences may help in developing appropriate management strategies.']\n",
            "unmatched tags:  [{'entity': 'Cathepsins', 'type': 'Gene', 'start': 1956, 'end': 1966}, {'entity': 'proteases', 'type': 'Gene', 'start': 1943, 'end': 1952}, {'entity': 'BTF3', 'type': 'Gene', 'start': 1923, 'end': 1927}, {'entity': 'NACA', 'type': 'Gene', 'start': 1917, 'end': 1921}, {'entity': 'SUMO1', 'type': 'Gene', 'start': 1910, 'end': 1915}, {'entity': 'HNRNPA1', 'type': 'Gene', 'start': 1901, 'end': 1908}, {'entity': 'RPS6', 'type': 'Gene', 'start': 1895, 'end': 1899}, {'entity': 'ADAM17', 'type': 'Gene', 'start': 1887, 'end': 1893}, {'entity': 'gene', 'type': 'Gene', 'start': 1876, 'end': 1880}, {'entity': 'Virus', 'type': 'Virus', 'start': 1801, 'end': 1806}, {'entity': 'viral S-protein', 'type': 'Gene', 'start': 1755, 'end': 1770}, {'entity': 'gene', 'type': 'Gene', 'start': 1690, 'end': 1694}, {'entity': 'TMPRSS2', 'type': 'Gene', 'start': 1641, 'end': 1648}, {'entity': 'eQTLs', 'type': 'Chemical', 'start': 1632, 'end': 1637}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1565, 'end': 1575}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1523, 'end': 1527}, {'entity': 'SLC6A19', 'type': 'Gene', 'start': 1438, 'end': 1445}, {'entity': 'neutral amino acid transporter', 'type': 'Gene', 'start': 1390, 'end': 1420}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1337, 'end': 1341}, {'entity': 'TMPRSS2', 'type': 'Gene', 'start': 1308, 'end': 1315}, {'entity': 'ACE2', 'type': 'Gene', 'start': 1256, 'end': 1260}, {'entity': 'eQTLs', 'type': 'Chemical', 'start': 1181, 'end': 1186}, {'entity': 'quantitative trait loci', 'type': 'Gene', 'start': 1156, 'end': 1179}]\n",
            "['Acute appendicitis: modern understanding of pathogenesis, diagnosis, and management\\tAcute appendicitis is one of the most common abdominal emergencies worldwide.', 'The cause remains poorly understood, with few advances in the past few decades.', 'To obtain a confident preoperative diagnosis is still a challenge, since the possibility of appendicitis must be entertained in any patient presenting with an acute abdomen.', 'Although biomarkers and imaging are valuable adjuncts to history and examination, their limitations mean that clinical assessment is still the mainstay of diagnosis.', 'A clinical classification is used to stratify management based on simple (non-perforated) and complex (gangrenous or perforated) inflammation, although many patients remain with an equivocal diagnosis, which is one of the most challenging dilemmas.']\n",
            "unmatched tags:  [{'entity': 'gangrenous', 'type': 'Disease', 'start': 685, 'end': 695}, {'entity': 'acute abdomen', 'type': 'Disease', 'start': 401, 'end': 414}]\n",
            "[\"Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma\\tAreas within the HLA class I and class III regions are associated with susceptibility to Hodgkin's lymphoma, the association with class I being specific for EBV-positive disease.\", \"This finding strongly suggests that antigenic presentation of EBV-derived peptides is involved in the pathogenesis of EBV-involved Hodgkin's lymphoma.\"]\n",
            "unmatched tags:  [{'entity': \"EBV-involved Hodgkin's lymphoma\", 'type': 'Disease', 'start': 430, 'end': 461}, {'entity': 'peptides', 'type': 'Gene', 'start': 386, 'end': 394}, {'entity': \"Hodgkin's lymphoma\", 'type': 'Disease', 'start': 222, 'end': 240}]\n",
            "[\"Vascular dementia\\tVascular dementia is one of the most common causes of dementia after Alzheimer's disease, causing around 15% of cases.\", \"However, unlike Alzheimer's disease, there are no licensed treatments for vascular dementia.\", 'Progress in the specialty has been difficult because of uncertainties over disease classification and diagnostic criteria, controversy over the exact nature of the relation between cerebrovascular pathology and cognitive impairment, and the paucity of identifiable tractable treatment targets.']\n",
            "unmatched tags:  [{'entity': 'cognitive impairment', 'type': 'Phenotype', 'start': 441, 'end': 461}, {'entity': 'vascular dementia', 'type': 'Disease', 'start': 211, 'end': 228}, {'entity': \"Alzheimer's disease\", 'type': 'Disease', 'start': 153, 'end': 172}]\n",
            "['Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries\\tCancer in children and adolescents is rare and biologically very different from cancer in adults.', 'It accounts for 1·4% of all cancers worldwide, although this proportion ranges from 0·5% in Europe to 4·8% in Africa, largely because of differences in age composition and life expectancy.', 'In high-income countries, survival from childhood cancer has reached 80% through a continuous focus on the integration of clinical research into front-line care for nearly all children affected by malignant disease.']\n",
            "unmatched tags:  [{'entity': 'malignant disease', 'type': 'Disease', 'start': 595, 'end': 612}]\n",
            "['Forecasting ultra-early intensive care strain from COVID-19 in England\\tThe COVID-19 pandemic has led to unprecedented strain on intensive care unit (ICU) admission in parts of the world.', 'Strategies to create surge ICU capacity requires complex local and national service reconfiguration and reduction or cancellation of elective activity.', 'Theses measures require time to implement and have an inevitable lag before additional capacity comes on-line.', 'An accurate short-range forecast would be helpful in guiding such difficult, costly and ethically challenging decisions.', 'At the time this work began, cases in England were starting to increase.', 'Here we present an attempt at an agile short-range forecast based on published real-time COVID-19 case data from the seven National Health Service commissioning regions in England (East of England, London, Midlands, North East and Yorkshire, North West, South East and South West).', 'We use a Monte Carlo approach to model the likely impact of current diagnoses on regional ICU capacity over a 14 day horizon.', 'Our model is designed to be parsimonious and based on plausible epidemiological data from the literature available.', 'On the basis of the modelling assumptions made, ICU occupancy is likely to increase dramatically in the the days following the time of modelling.', 'If the current exponential growth continues, 5 out of 7 commissioning regions will have more critically ill COVID-19 patients than there are ICU beds within two weeks\\\\todo{last thing to do}.', 'Despite variable growth in absolute patients, all commissioning regions are forecast to be heavily burdened under the assumptions used.', 'Whilst, like any forecast model, there remain uncertainties both in terms of model specification and robust epidemiological data in this early prospective phase, it would seem that surge capacity will be required in the very near future.', 'We hope that our model will help policy decision makers with their preparations.', 'The uncertainties in the data highlight the urgent need for ongoing real-time surveillance to allow forecasts to be constantly updated using high quality local patient-facing data as it emerges.']\n",
            "unmatched tags:  [{'entity': 'ill', 'type': 'Phenotype', 'start': 2046, 'end': 2049}, {'entity': 'decision makers', 'type': 'Gene', 'start': 1922, 'end': 1937}, {'entity': 'ill', 'type': 'Phenotype', 'start': 1906, 'end': 1909}, {'entity': 'ill', 'type': 'Phenotype', 'start': 1841, 'end': 1844}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1424, 'end': 1432}]\n",
            "['Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial\\tMaraviroc had no significant effect on development of IRIS after ART initiation.', 'Inclusion of this CCR5 inhibitor in an initial treatment regimen does not confer a meaningful protection from the occurrence of IRIS in people with advanced HIV infection.']\n",
            "unmatched tags:  [{'entity': 'HIV infection', 'type': 'Phenotype', 'start': 414, 'end': 427}, {'entity': 'IRIS', 'type': 'Drug', 'start': 385, 'end': 389}, {'entity': 'CCR5', 'type': 'Gene', 'start': 275, 'end': 279}, {'entity': 'IRIS', 'type': 'Drug', 'start': 230, 'end': 234}]\n",
            "['Immunogenicity and safety of measles-rubella vaccine co-administered with attenuated Japanese encephalitis SA 14–14–2 vaccine in infants aged 8 months in China: a non-inferiority randomised controlled trial\\tThe evidence of similar seroconversion and safety with co-administered LJEV and measles-rubella vaccines supports the co-administration of these vaccines to infants aged 8 months.', 'These results will be important for measles and rubella elimination and the expansion of Japanese encephalitis vaccination in countries where it is endemic.']\n",
            "unmatched tags:  [{'entity': 'encephalitis', 'type': 'Disease', 'start': 485, 'end': 497}, {'entity': 'Japanese encephalitis', 'type': 'Disease', 'start': 476, 'end': 497}, {'entity': 'rubella elimination', 'type': 'Disease', 'start': 435, 'end': 454}, {'entity': 'measles', 'type': 'Disease', 'start': 423, 'end': 430}]\n",
            "['Novel Function of Bluetongue Virus NS3 Protein in Regulation of the MAPK/ERK Signaling Pathway\\tBluetongue virus (BTV) is an arbovirus transmitted by blood-feeding midges to a wide range of wild and domestic ruminants.', 'In this report, we showed that BTV, through its virulence non-structural protein NS3 (BTV-NS3), is able to activate the MAPK/ERK pathway.', 'In response to growth factors, the MAPK/ERK pathway activates cell survival, differentiation, proliferation and protein translation but can also lead to the production of several inflammatory cytokines.', 'By combining immunoprecipitation of BTV-NS3 and mass spectrometry analysis from both BTV-infected and NS3-transfected cells, we identified the serine/threonine-protein kinase B-Raf (BRAF), a crucial player of the MAPK/ERK pathway, as a new cellular interactor of BTV-NS3.', 'BRAF silencing led to a significant decrease of the MAPK/ERK activation by BTV supporting a model where BTV-NS3 interacts with BRAF to activate this signaling cascade.', 'Furthermore, the intrinsic ability of BTV-NS3 to bind BRAF and activate the MAPK/ERK pathway is conserved throughout multiple serotypes/strains but appears to be specific to BTV compared to other members of Orbivirus genus.', 'Inhibition of MAPK/ERK pathway with U0126 reduced viral titers, suggesting that BTV manipulates this pathway for its own replication.', 'Therefore, the activation of the MAPK/ERK pathway by BTV-NS3 could benefit to BTV replication by promoting its own viral protein synthesis but could also explain the deleterious inflammation associated with tissue damages as already observed in severe cases of BT disease.', 'Altogether, our data provide molecular mechanisms to explain the role of BTV-NS3 as a virulence factor and determinant of pathogenesis.', 'Importance Bluetongue Virus (BTV) is responsible of the non-contagious arthropod-borne disease Bluetongue (BT) transmitted to ruminants by blood-feeding midges.', 'Despite the fact that BTV has been extensively studied, we still have little understanding of the molecular determinants of BTV virulence.', 'In this report, we found that the virulence protein NS3 interacts with BRAF, a key component of the MAPK/ERK pathway.', 'In response to growth factors, this pathway promotes cell survival, increases protein translation but also contributes to the production of inflammatory cytokines.', 'We showed that BTV-NS3 enhances the MAPK/ERK pathway and this activation is BRAF-dependent.', 'Our results demonstrate, at the molecular level, how a single virulence factor has evolved to target a cellular function to ensure its viral replication.', 'On the other hand, our findings could also explain the deleterious inflammation associated with tissue damages as already observed in severe cases of BT disease.']\n",
            "unmatched tags:  [{'entity': 'BT disease', 'type': 'Disease', 'start': 2744, 'end': 2754}, {'entity': 'tissue damages', 'type': 'Disease', 'start': 2690, 'end': 2704}, {'entity': 'virulence factor', 'type': 'Drug', 'start': 2502, 'end': 2518}, {'entity': 'MAPK/ERK pathway', 'type': 'Gene', 'start': 2384, 'end': 2400}, {'entity': 'BTV-NS3', 'type': 'Chemical', 'start': 2363, 'end': 2370}, {'entity': 'growth factors', 'type': 'Gene', 'start': 2199, 'end': 2213}, {'entity': 'MAPK/ERK pathway', 'type': 'Gene', 'start': 2166, 'end': 2182}, {'entity': 'BRAF', 'type': 'Gene', 'start': 2137, 'end': 2141}, {'entity': 'NS3', 'type': 'Disease', 'start': 2118, 'end': 2121}, {'entity': 'BTV', 'type': 'Gene', 'start': 2051, 'end': 2054}, {'entity': 'molecular determinants', 'type': 'Gene', 'start': 2025, 'end': 2047}, {'entity': 'BTV', 'type': 'Gene', 'start': 1949, 'end': 1952}, {'entity': 'BTV', 'type': 'Gene', 'start': 1795, 'end': 1798}, {'entity': 'Bluetongue Virus', 'type': 'Virus', 'start': 1777, 'end': 1793}, {'entity': 'virulence factor', 'type': 'Drug', 'start': 1716, 'end': 1732}, {'entity': 'BTV-NS3', 'type': 'Chemical', 'start': 1703, 'end': 1710}, {'entity': 'BT disease', 'type': 'Disease', 'start': 1618, 'end': 1628}, {'entity': 'tissue damages', 'type': 'Disease', 'start': 1564, 'end': 1578}, {'entity': 'BTV', 'type': 'Gene', 'start': 1435, 'end': 1438}, {'entity': 'NS3', 'type': 'Disease', 'start': 1414, 'end': 1417}, {'entity': 'BTV-NS3', 'type': 'Chemical', 'start': 1410, 'end': 1417}, {'entity': 'MAPK/ERK pathway', 'type': 'Gene', 'start': 1390, 'end': 1406}, {'entity': 'BTV', 'type': 'Gene', 'start': 1303, 'end': 1306}, {'entity': 'U0126', 'type': 'Drug', 'start': 1259, 'end': 1264}, {'entity': 'MAPK/ERK pathway', 'type': 'Gene', 'start': 1237, 'end': 1253}, {'entity': 'Orbivirus genus', 'type': 'Virus', 'start': 1206, 'end': 1221}, {'entity': 'BTV', 'type': 'Gene', 'start': 1173, 'end': 1176}, {'entity': 'MAPK/ERK pathway', 'type': 'Gene', 'start': 1075, 'end': 1091}, {'entity': 'BRAF', 'type': 'Gene', 'start': 1053, 'end': 1057}, {'entity': 'BTV-NS3', 'type': 'Chemical', 'start': 1037, 'end': 1044}, {'entity': 'BRAF', 'type': 'Gene', 'start': 958, 'end': 962}, {'entity': 'NS3', 'type': 'Disease', 'start': 939, 'end': 942}, {'entity': 'BTV-NS3', 'type': 'Chemical', 'start': 935, 'end': 942}, {'entity': 'BTV', 'type': 'Gene', 'start': 906, 'end': 909}, {'entity': 'MAPK/ERK activation', 'type': 'Gene', 'start': 883, 'end': 902}, {'entity': 'BRAF', 'type': 'Gene', 'start': 831, 'end': 835}, {'entity': 'BTV-NS3', 'type': 'Chemical', 'start': 822, 'end': 829}, {'entity': 'MAPK/ERK pathway', 'type': 'Gene', 'start': 772, 'end': 788}, {'entity': 'BRAF', 'type': 'Gene', 'start': 741, 'end': 745}, {'entity': 'serine/threonine-protein kinase B-Raf', 'type': 'Gene', 'start': 702, 'end': 739}]\n",
            "['Human infection with avian influenza A H6N1 virus: an epidemiological analysis\\tThis is the first report of human infection with a wild avian influenza A H6N1 virus.', 'A unique clade of H6N1 viruses with a G228S substitution of haemagglutinin have circulated persistently in poultry in Taiwan.', 'These viruses continue to evolve and accumulate changes, increasing the potential risk of human-to-human transmission.', 'Our report highlights the continuous need for preparedness for a pandemic of unpredictable and complex avian influenza.']\n",
            "unmatched tags:  [{'entity': 'complex avian influenza', 'type': 'Disease', 'start': 505, 'end': 528}]\n",
            "['Acute ischaemic stroke and infection: recent and emerging concepts\\tThe relation between acute ischaemic stroke and infection is complex.', 'Infection appears to be an important trigger that precedes up to a third of ischaemic strokes and can bring about stroke through a range of potential mechanisms.', 'Infections that present subsequent to stroke also complicate up to a third of cases of stroke and might worsen outcome.', 'Inflammatory responses, which are a defence mechanism against infection but can also be a pathogenic mechanism that precipitates stroke and neurological sequelae, are important features.']\n",
            "unmatched tags:  [{'entity': 'stroke', 'type': 'Disease', 'start': 548, 'end': 554}, {'entity': 'stroke', 'type': 'Disease', 'start': 386, 'end': 392}, {'entity': 'stroke', 'type': 'Disease', 'start': 337, 'end': 343}, {'entity': 'stroke', 'type': 'Disease', 'start': 251, 'end': 257}]\n",
            "['Pathogenesis of filoviral haemorrhagic fevers\\tThe filoviruses, marburgvirus and ebolavirus, cause epidemics of haemorrhagic fever with high casefatality rates.', 'The severe illness results from a complex of pathogenetic mechanisms that enable the virus to suppress innate and adaptive immune responses, infect and kill a broad variety of cell types, and elicit strong inflammatory responses and disseminated intravascular coagulation, producing a syndrome resembling septic shock.', 'Most experimental data have been obtained on Zaire ebolavirus, which causes uniformly lethal disease in experimentally infected non-human primates but produces a broader range of outcomes in naturally infected human beings.']\n",
            "unmatched tags:  [{'entity': 'non-human', 'type': 'Gene', 'start': 607, 'end': 616}, {'entity': 'lethal disease', 'type': 'Disease', 'start': 565, 'end': 579}, {'entity': 'Zaire ebolavirus', 'type': 'Virus', 'start': 524, 'end': 540}, {'entity': 'syndrome', 'type': 'Disease', 'start': 445, 'end': 453}, {'entity': 'intravascular coagulation', 'type': 'Phenotype', 'start': 406, 'end': 431}, {'entity': 'haemorrhagic fever', 'type': 'Disease', 'start': 111, 'end': 129}, {'entity': 'ebolavirus', 'type': 'Virus', 'start': 80, 'end': 90}, {'entity': 'marburgvirus', 'type': 'Virus', 'start': 63, 'end': 75}]\n",
            "['Three new human herpesviruses (HHV6, 7, and 8)\\tThree new human herpesviruses have been recognised in the past decade, and add further to our knowledge of human diseases with potential viral aetiologies.', 'These viruses can be included with the other known human herpesviruses found in normal body secretions, particularly sallva.', 'HHV6 and HHV7 have been associated with febrile illnesses and the childhood disease, exanthem subitum.', \"HHV8 seems to resemble Epstein-Barr virus in its possible transforming properties and poses challenging questions for researchers directed at determining its potential role in lymphomas and Kaposl's sarcoma.\"]\n",
            "unmatched tags:  [{'entity': \"Kaposl's sarcoma\", 'type': 'Disease', 'start': 621, 'end': 637}, {'entity': 'lymphomas', 'type': 'Disease', 'start': 607, 'end': 616}, {'entity': 'Epstein-Barr virus', 'type': 'Virus', 'start': 454, 'end': 472}, {'entity': 'HHV8', 'type': 'Disease', 'start': 431, 'end': 435}, {'entity': 'exanthem subitum', 'type': 'Disease', 'start': 413, 'end': 429}, {'entity': 'childhood disease', 'type': 'Disease', 'start': 394, 'end': 411}, {'entity': 'febrile illnesses', 'type': 'Phenotype', 'start': 368, 'end': 385}, {'entity': 'HHV7', 'type': 'Gene', 'start': 337, 'end': 341}, {'entity': 'HHV6', 'type': 'Virus', 'start': 328, 'end': 332}, {'entity': 'human herpesviruses', 'type': 'Virus', 'start': 254, 'end': 273}]\n",
            "['Psychogenic movement disorders\\tDiagnosis and treatment of psychogenic movement disorders are challenging for both neurologists and psychiatrists.', 'Symptoms can mimic the full range of organic abnormal involuntary movements, affect gait and speech, or present as unusual undifferentiated movements.', 'Typical clinical characteristics of these disorders are acute onset, fast progression, movement patterns incongruent with organic movement disorders, distractibility, variability, and simultaneous occurrence of various abnormal movements and dysfunctions.']\n",
            "unmatched tags:  [{'entity': 'organic movement disorders', 'type': 'Disease', 'start': 419, 'end': 445}, {'entity': 'disorders', 'type': 'Disease', 'start': 339, 'end': 348}]\n",
            "['Moving towards causality in attention-deficit hyperactivity disorder: overview of neural and genetic mechanisms\\tAttention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterised by developmentally inappropriate levels of inattention and hyperactivity or impulsivity.', 'The heterogeneity of its clinical manifestations and the differential responses to treatment and varied prognoses have long suggested myriad underlying causes.', 'Over the past decade, clinical and basic research efforts have uncovered many behavioural and neurobiological alterations associated with ADHD, from genes to higher order neural networks.']\n",
            "unmatched tags:  [{'entity': 'ADHD', 'type': 'Disease', 'start': 594, 'end': 598}, {'entity': 'hyperactivity', 'type': 'Disease', 'start': 266, 'end': 279}, {'entity': 'inattention', 'type': 'Disease', 'start': 250, 'end': 261}]\n",
            "['Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine\\tPrecision medicine has emerged as a mantra for therapeutic approaches to complex diseases.', 'The defining concept relies on a detailed insight into disease pathogenesis and therapeutic mechanism.', 'Although the type 1 diabetes field has gained new insights into disease endotypes and indications of efficacy for several therapies, none of these is yet licensed, partly because of immune suppressive side-effects beyond control of islet autoimmunity.', 'New strategies designed to regulate the immune system continue to emerge as basic science discoveries are made, including the use of antigen-based immunotherapies.']\n",
            "unmatched tags:  [{'entity': 'era', 'type': 'Gene', 'start': 692, 'end': 695}, {'entity': 'era', 'type': 'Gene', 'start': 409, 'end': 412}, {'entity': 'era', 'type': 'Gene', 'start': 402, 'end': 405}, {'entity': 'type 1 diabetes field', 'type': 'Disease', 'start': 298, 'end': 319}, {'entity': 'era', 'type': 'Gene', 'start': 264, 'end': 267}, {'entity': 'complex diseases', 'type': 'Disease', 'start': 164, 'end': 180}, {'entity': 'era', 'type': 'Gene', 'start': 140, 'end': 143}]\n",
            "['Loss of health professionals from sub-Saharan Africa: the pivotal role of the UK\\tThe already inadequate health systems of sub-Saharan Africa have been badly damaged by the emigration of their health professionals, a process in which the UK has played a prominent part.', 'In 2005, there are special opportunities for the UK to take the lead in addressing that damage, and in focusing the attention of the G8 on the wider problems of health-professional migration from poor to rich countries.', 'We suggest some practical measures to these ends.', 'These include action the UK could take on its own, with the African countries most affected, and with other developed countries and WHO.']\n",
            "unmatched tags:  [{'entity': 'G8', 'type': 'Gene', 'start': 402, 'end': 404}]\n",
            "['Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2\\tHuman coronaviruses (HCoVs), including severe acute respiratory syndrome coronavirus (SARS-CoV) and 2019 novel coronavirus (2019-nCoV, also known as SARS-CoV-2), lead global epidemics with high morbidity and mortality.', 'However, there are currently no effective drugs targeting 2019-nCoV/SARS-CoV-2.', 'Drug repurposing, representing as an effective drug discovery strategy from existing drugs, could shorten the time and reduce the cost compared to de novo drug discovery.', 'In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoVâ\\x80\\x93host interactome and drug targets in the human proteinâ\\x80\\x93protein interaction network.', 'Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV/SARS-CoV-2 shares the highest nucleotide sequence identity with SARS-CoV (79.7%).', 'Specifically, the envelope and nucleocapsid proteins of 2019-nCoV/SARS-CoV-2 are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV.', 'Using network proximity analyses of drug targets and HCoVâ\\x80\\x93host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs (e.g., melatonin, mercaptopurine, and sirolimus) that are further validated by enrichment analyses of drug-gene signatures and HCoV-induced transcriptomics data in human cell lines.', 'We further identify three potential drug combinations (e.g., sirolimus plus dactinomycin, mercaptopurine plus melatonin, and toremifene plus emodin) captured by the â\\x80\\x9cComplementary Exposureâ\\x80\\x9d pattern: the targets of the drugs both hit the HCoVâ\\x80\\x93host subnetwork, but target separate neighborhoods in the human interactome network.', 'In summary, this study offers powerful network-based methodologies for rapid identification of candidate repurposable drugs and potential drug combinations targeting 2019-nCoV/SARS-CoV-2.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 2031, 'end': 2041}, {'entity': '2019-nCoV', 'type': 'Virus', 'start': 2021, 'end': 2030}, {'entity': 'drug combinations', 'type': 'Drug', 'start': 1993, 'end': 2010}, {'entity': 'HCoV', 'type': 'Virus', 'start': 1763, 'end': 1767}, {'entity': 'emodin', 'type': 'Drug', 'start': 1663, 'end': 1669}, {'entity': 'toremifene', 'type': 'Drug', 'start': 1647, 'end': 1657}, {'entity': 'melatonin', 'type': 'Drug', 'start': 1632, 'end': 1641}, {'entity': 'mercaptopurine', 'type': 'Drug', 'start': 1612, 'end': 1626}, {'entity': 'dactinomycin', 'type': 'Gene', 'start': 1598, 'end': 1610}, {'entity': 'sirolimus', 'type': 'Drug', 'start': 1583, 'end': 1592}, {'entity': 'drug combinations', 'type': 'Drug', 'start': 1558, 'end': 1575}, {'entity': 'sirolimus', 'type': 'Drug', 'start': 1378, 'end': 1387}, {'entity': 'mercaptopurine', 'type': 'Drug', 'start': 1358, 'end': 1372}, {'entity': 'melatonin', 'type': 'Drug', 'start': 1347, 'end': 1356}, {'entity': 'HCoV', 'type': 'Virus', 'start': 1316, 'end': 1320}, {'entity': 'HCoV', 'type': 'Virus', 'start': 1233, 'end': 1237}, {'entity': 'SARS-CoV.', 'type': 'Virus', 'start': 1170, 'end': 1179}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1042, 'end': 1052}, {'entity': '2019-nCoV', 'type': 'Virus', 'start': 1032, 'end': 1041}, {'entity': 'nucleocapsid proteins', 'type': 'Gene', 'start': 1007, 'end': 1028}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 958, 'end': 966}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 894, 'end': 904}, {'entity': '2019-nCoV', 'type': 'Virus', 'start': 884, 'end': 893}, {'entity': 'HCoV', 'type': 'Virus', 'start': 853, 'end': 857}, {'entity': 'proteinâ\\x80\\x93protein', 'type': 'Gene', 'start': 786, 'end': 803}, {'entity': 'HCoV', 'type': 'Virus', 'start': 732, 'end': 736}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 361, 'end': 371}, {'entity': '2019-nCoV', 'type': 'Virus', 'start': 351, 'end': 360}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 223, 'end': 233}, {'entity': '2019-nCoV', 'type': 'Virus', 'start': 198, 'end': 207}]\n",
            "['Reliability of diagnosis of melanoma in situ\\tEarly and correct diagnosis of malignant melanoma is of utmost importance to ensure adequate treatment and the best outcome.', 'Prompted by the death of a patient with an apparent metastasising melanoma in situ, we reassessed 104 people with this malignant disorder, whose diagnosis had been histopathologically verified.', 'We did immuno-histochemical analysis of cells with the melanocytic marker melan-A/MART-1, and results of this analysis showed that 30 (29%) of 104 patients had invasive melanomas.', 'One patient died of distant metastases, and the tumour recurred in another.']\n",
            "unmatched tags:  [{'entity': 'tumour', 'type': 'Disease', 'start': 592, 'end': 598}, {'entity': 'distant metastases', 'type': 'Disease', 'start': 564, 'end': 582}]\n",
            "['Preventing chronic diseases: how many lives can we save?', '35 million people will die in 2005 from heart disease, stroke, cancer, and other chronic diseases.', 'Only 20% of these deaths will be in high-income countries—while 80% will occur in low-income and middle-income countries.', 'The death rates from these potentially preventable diseases are higher in low-income and middle-income countries than in high-income countries, especially among adults aged 30–69 years.', 'The impact on men and women is similar.', 'We propose a new goal for reducing deaths from chronic disease to focus prevention and control efforts among those concerned about international health.']\n",
            "unmatched tags:  [{'entity': 'chronic disease', 'type': 'Disease', 'start': 551, 'end': 566}, {'entity': 'middle-income countries', 'type': 'Disease', 'start': 367, 'end': 390}, {'entity': 'low-income', 'type': 'Gene', 'start': 352, 'end': 362}]\n",
            "['Early prediction of mortality risk among severe COVID-19 patients using machine learning\\tAbstract Background Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been spreading globally.', 'The number of deaths has increased with the increase in the number of infected patients.', 'We aimed to develop a clinical model to predict the outcome of severe COVID-19 patients early.', 'Methods Epidemiological, clinical, and first laboratory findings after admission of 183 severe COVID-19 patients (115 survivors and 68 nonsurvivors) from the Sino-French New City Branch of Tongji Hospital were used to develop the predictive models.', \"Five machine learning approaches (logistic regression, partial least squares regression, elastic net, random forest, and bagged flexible discriminant analysis) were used to select the features and predict the patients' outcomes.\", \"The area under the receiver operating characteristic curve (AUROC) was applied to compare the models' performance.\", 'Sixty-four severe COVID-19 patients from the Optical Valley Branch of Tongji Hospital were used to externally validate the final predictive model.', 'Results The baseline characteristics and laboratory tests were significantly different between the survivors and nonsurvivors.', 'Four variables (age, high-sensitivity C-reactive protein level, lymphocyte count, and d-dimer level) were selected by all five models.', 'Given the similar performance among the models, the logistic regression model was selected as the final predictive model because of its simplicity and interpretability.', 'The AUROCs of the derivation and external validation sets were 0.895 and 0.881, respectively.', 'The sensitivity and specificity were 0.892 and 0.687 for the derivation set and 0.839 and 0.794 for the validation set, respectively, when using a probability of death of 50% as the cutoff.', 'The individual risk score based on the four selected variables and the corresponding probability of death can serve as indexes to assess the mortality risk of COVID-19 patients.', 'The predictive model is freely available at https://phenomics.fudan.edu.cn/risk_scores/.', \"Conclusions Age, high-sensitivity C-reactive protein level, lymphocyte count, and d-dimer level of COVID-19 patients at admission are informative for the patients' outcomes.\"]\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2264, 'end': 2272}, {'entity': 'predictive model', 'type': 'Chemical', 'start': 2079, 'end': 2095}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2056, 'end': 2064}]\n",
            "['Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort\\tDespite the availability of free treatment and care in the UK, AIDS continues to account for the majority of deaths in HIV-positive people, and mortality remains higher in HIV-positive people than in the general population.', 'These findings highlight the importance of prompt diagnosis, care engagement, and optimum management of comorbidities in reducing mortality in people with HIV.']\n",
            "unmatched tags:  [{'entity': 'HIV', 'type': 'Virus', 'start': 574, 'end': 577}, {'entity': 'era', 'type': 'Gene', 'start': 402, 'end': 405}, {'entity': 'HIV-positive', 'type': 'Gene', 'start': 367, 'end': 379}, {'entity': 'HIV-positive', 'type': 'Gene', 'start': 314, 'end': 326}, {'entity': 'AIDS', 'type': 'Disease', 'start': 258, 'end': 262}, {'entity': 'era', 'type': 'Gene', 'start': 131, 'end': 134}]\n",
            "['Haemozoin: from melatonin pigment to drug target, diagnostic tool, and immune modulator\\tspp produce a pigment (haemozoin) to detoxify the free haem that is generated by haemoglobin degradation.', 'Haemozoin was originally thought to be an inert waste byproduct of the parasite.', 'However, recent research has led to the recognition that haemozoin is possibly of great importance in various aspects of malaria.', 'Haemozoin is the target of many antimalarial drugs, and the unravelling of the exact modes of action may allow the design of novel antimalarial compounds.', 'The detection of haemozoin in erythrocytes or leucocytes facilitates the diagnosis of malaria.']\n",
            "unmatched tags:  [{'entity': 'malaria', 'type': 'Disease', 'start': 646, 'end': 653}]\n",
            "['The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections\\tCoronaviruses belong to a group of enveloped, positive-single stranded RNA viruses that are known to cause severe respiratory distress in animals and humans.', 'The current SARS coronavirus-2 (SARS CoV-2) pandemic has caused more than 2,000,000 infections globally and nearly 200,000 deaths.', 'Coronaviruses enter susceptible cells via fusion of the viral envelope with the plasma membrane and/or via fusion of the viral envelope with endosomal membranes after endocytosis of the virus into endosomes.', 'Previous results with SARS and MERS CoV have shown that the Spike (S) glycoprotein is a major determinant of virus infectivity and immunogenicity.', 'Herein, we show that expression of SARS CoV-2 S (S-n) glycoprotein after transient transfection of African green monkey kidney (Vero) cells caused extensive cell fusion in comparison to limited cell fusion caused by the SARS S (S-o) glycoprotein.', 'S-n expression was detected intracellularly and on transfected Vero cell surfaces and caused the formation of very large multinucleated cells (syncytia) by 48 hours post transfection.', 'These results are in agreement with published pathology observations of extensive syncytial formation in lung tissues of COVID-19 patients.', 'This differential S-n versus S-o-mediated cell fusion suggests that SARS-CoV-2 is able to spread from cell-to-cell much more efficiently than SARS effectively avoiding extracellular spaces and neutralizing antibodies.', 'A systematic screening of several drugs for ability to inhibit S-n and S-o cell fusion revealed that the FDA approved HIV-protease inhibitor, nelfinavir mesylate (Viracept) drastically inhibited S-n and S-o-mediated cell fusion in a dose-dependent manner.', 'Complete inhibition of cell fusion was observed at a 10 micromolar concentration.', 'Computational modeling and in silico docking experiments suggested the possibility that nelfinavir may bind inside the S trimer structure, proximal to the S2 amino terminus directly inhibiting S-n and S-o-mediated membrane fusion.', 'Also, it is possible that nelfinavir mesylate acts on cellular processes to inhibit S proteolytic processing.', 'These results warrant further investigations of the potential of nelfinavir mesylate as an antiviral drug, especially at early times after SARS-CoV-2 symptoms appear.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 2459, 'end': 2469}, {'entity': 'antiviral drug', 'type': 'Drug', 'start': 2411, 'end': 2425}]\n",
            "['Risk of subsequent primary neoplasms in survivors of adolescent and young adult cancer (Teenage and Young Adult Cancer Survivor Study): a population-based, cohort study\\tOur finding that a small number of specific subsequent primary neoplasms account for a large percentage of the total excess number of neoplasms in long-term survivors of cervical, breast, and testicular cancer, and Hodgkin lymphoma provides an evidence base to inform priorities for clinical long-term follow-up.', 'The prominence of lung cancer after each of these AYA cancers indicates the need for further work aimed at preventing and reducing the burden of this cancer in future survivors of AYA cancer.']\n",
            "unmatched tags:  [{'entity': 'cancer', 'type': 'Disease', 'start': 666, 'end': 672}, {'entity': 'AYA', 'type': 'Organization', 'start': 662, 'end': 665}, {'entity': 'cancer', 'type': 'Disease', 'start': 632, 'end': 638}, {'entity': 'cancers', 'type': 'Disease', 'start': 536, 'end': 543}, {'entity': 'AYA', 'type': 'Organization', 'start': 532, 'end': 535}, {'entity': 'cancer', 'type': 'Disease', 'start': 505, 'end': 511}, {'entity': 'lung cancer', 'type': 'Disease', 'start': 500, 'end': 511}, {'entity': 'Hodgkin lymphoma', 'type': 'Disease', 'start': 384, 'end': 400}, {'entity': 'testicular cancer', 'type': 'Disease', 'start': 361, 'end': 378}]\n",
            "['Cervicogenic headache: an assessment of the evidence on clinical diagnosis, invasive tests, and treatment\\tCervicogenic headache is characterised by pain referred to the head from the cervical spine.', 'Although the International Headache Society recognises this type of headache as a distinct disorder, some clinicians remain sceptical.', 'Laboratory and clinical studies have shown that pain from upper cervical joints and muscles can be referred to the head.', 'Clinical diagnostic criteria have not proved valid, but a cervical source of pain can be established by use of fluoroscopically guided, controlled, diagnostic nerve blocks.']\n",
            "unmatched tags:  [{'entity': 'pain', 'type': 'Phenotype', 'start': 532, 'end': 536}, {'entity': 'pain', 'type': 'Phenotype', 'start': 382, 'end': 386}]\n",
            "['Coagulopathy and haemorrhagic progression in traumatic brain injury: advances in mechanisms, diagnosis, and management\\tNormal haemostasis depends on an intricate balance between mechanisms of bleeding and mechanisms of thrombosis, and this balance can be altered after traumatic brain injury (TBI).', 'Impaired haemostasis could exacerbate the primary insult with risk of initiation or aggravation of bleeding; anticoagulant use at the time of injury can also contribute to bleeding risk after TBI.', 'Many patients with TBI have abnormalities on conventional coagulation tests at admission to the emergency department, and the presence of coagulopathy is associated with increased morbidity and mortality.']\n",
            "unmatched tags:  [{'entity': 'coagulopathy', 'type': 'Disease', 'start': 634, 'end': 646}, {'entity': 'TBI', 'type': 'Disease', 'start': 515, 'end': 518}, {'entity': 'TBI', 'type': 'Disease', 'start': 491, 'end': 494}, {'entity': 'injury', 'type': 'Disease', 'start': 441, 'end': 447}]\n",
            "['Confirmedasymptomatic carrier of SARS-CoV-2\\tHere we reported a case of asymptomatic carrier of SARS-CoV-2 infection.', 'A 50-year old woman,lived with her husband in Anqing(Anhui, China) with no significant past medical history, travelhistory to Wuhan or adjacent area, or exposure to wild animals.', 'She took throat swab test forSARS-CoV-2 nucleic acid due to her husband’s close contact with patients who had SARS-CoV-2infection.', 'Her results were confirmed positive on February 6, 2020.', 'But she did not reportelevation of temperature measurement, nor respiratory or gastrointestinal symptoms and her chestCT scan showed no significant abnormalities.', 'She was hospitalized on February 6 and treated withantiviral agents.', 'During her hospitalization, apart from a mild elevation of liver enzymes after10-day treatment of lopinavir/ritonavir, she was asymptomatic, with her blood cell count, liveand renal function largely normal.', 'Her subcutaneous oxygen saturation stayed above 97%.', 'Chest CTscan was repeated on February 11 and 20, and both were negative for signs of viral pneumonia.Notably, a second set of throat swabs and anal swabs were sent to test for SARS-CoV-2 onFebruary 19, and the results were still confirmed positive.', 'This is a confirmed case ofasymptomatic carrier of SARS-CoV-2 infection.', 'Her persistent positive findings in both throatand anal swabs suggested the possibility of healthy carrier of the virus, which adds to thedifficulty in preventing transmission of the disease.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1276, 'end': 1286}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1152, 'end': 1162}, {'entity': 'viral pneumonia', 'type': 'Disease', 'start': 1061, 'end': 1076}, {'entity': 'lopinavir/ritonavir', 'type': 'Drug', 'start': 814, 'end': 833}, {'entity': 'withantiviral agents', 'type': 'Drug', 'start': 694, 'end': 714}]\n",
            "['Difference in nature of ruptured and unruptured cerebral aneurysms\\tAlthough small aneurysms have an extremely low probability of rupture, most aneurysms that rupture are found to be less than 10 mm in diameter.', 'Histological study of aneurysms and epidemiological analysis of subarachnoid haemorrhage revealed that ruptured and unruptured aneurysms are of a different nature.']\n",
            "unmatched tags:  [{'entity': 'unruptured aneurysms', 'type': 'Disease', 'start': 327, 'end': 347}, {'entity': 'rupture', 'type': 'Disease', 'start': 314, 'end': 321}, {'entity': 'subarachnoid haemorrhage', 'type': 'Disease', 'start': 275, 'end': 299}, {'entity': 'aneurysms', 'type': 'Disease', 'start': 233, 'end': 242}, {'entity': 'rupture', 'type': 'Disease', 'start': 158, 'end': 165}, {'entity': 'aneurysms', 'type': 'Disease', 'start': 143, 'end': 152}, {'entity': 'rupture', 'type': 'Disease', 'start': 129, 'end': 136}, {'entity': 'aneurysms', 'type': 'Disease', 'start': 82, 'end': 91}]\n",
            "['Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data\\tPatients with newly diagnosed myeloma who received lenalidomide had an increased risk of developing haematological second primary malignancies, driven mainly by treatment strategies that included a combination of lenalidomide and oral melphalan.', 'These results suggest that alternatives, such as cyclophosphamide or alkylating-free combinations, should be considered instead of oral melphalan in combination with lenalidomide for myeloma.']\n",
            "unmatched tags:  [{'entity': 'lenalidomide', 'type': 'Drug', 'start': 538, 'end': 550}]\n",
            "['Are inhaled longacting β\\tPossible adverse effects of adrenergic bronchodilators in asthma have been the subject of discussion for more than half a century, with recent intense debate about the safety of longacting β agonists (LABAs).', 'In this Debate, we consider the issues of bronchodilator and bronchoprotective tolerance resulting from the frequent use of bronchodilators, which is noted particularly with shortacting drugs, but has also been shown to occur quicker and to a greater extent with LABAs.', 'Increased allergen responsiveness and masking allowing inflammation to increase, while symptoms and lung function remain apparently controlled, have also been observed.']\n",
            "unmatched tags:  [{'entity': 'LABAs', 'type': 'Chemical', 'start': 497, 'end': 502}, {'entity': 'bronchodilators', 'type': 'Drug', 'start': 358, 'end': 373}, {'entity': 'bronchodilator', 'type': 'Drug', 'start': 276, 'end': 290}, {'entity': 'LABAs', 'type': 'Chemical', 'start': 226, 'end': 231}]\n",
            "['Chronic lymphocytic leukaemia\\tImportant advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome.', 'Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years.', 'The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms.', 'For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care.']\n",
            "unmatched tags:  [{'entity': 'monoclonal antibodies', 'type': 'Drug', 'start': 619, 'end': 640}, {'entity': 'anti-CD20', 'type': 'Gene', 'start': 609, 'end': 618}, {'entity': 'chronic lymphocytic leukaemia', 'type': 'Disease', 'start': 546, 'end': 575}, {'entity': 'Rai', 'type': 'Gene', 'start': 444, 'end': 447}, {'entity': 'leukaemia', 'type': 'Disease', 'start': 315, 'end': 324}]\n",
            "['Knowledge and Beliefs towards Universal Safety Precautions to flatten the curve during Novel Coronavirus Disease (nCOVID-19) Pandemic among general Public in India: Explorations from a National Perspective\\tBackground: The novel Coronavirus disease (COVID-19) is being considered as the most serious health threat that the world has never witnessed in the recent times and significantly affecting the daily routine of mankind by emerging as a global pandemic.', 'Yet, as there is no treatment nor a vaccine that was approved so far, universal safety precautions (USPs) and mitigating strategies are the only way to deal with this emergency crisis.', 'However, knowledge and beliefs towards USPs among the general public in countries such as India with a large population are lacking.', 'Methods: A prospective, cross-sectional, web-based online survey was conducted among the general public in India during March 2020.', 'A 20-items self-administered survey questionnaire was developed and randomly distributed among the public using google document forms through social media networks.', 'Descriptive statistics were used in representing the study characteristics, and the Chi-square test was used in assessing the associations among the study variables with a p-value of < 0.05 was considered as statistically significant.', 'Results: Of 1287 participants, 1117 have given their consent of willingness and completed the questionnaire with a response rate of 86.8%.', 'The mean age of the study participants was 28.8 ± 10.9 years, where the majority of them belong to the age category <25 years, and sex was equally distributed.', 'Based upon the socio-demographic information, the majority were post-graduates (32.9%), professional job holders (45%) and belonged to the upper-middle (40%) economic class.', 'Overall, the knowledge and beliefs towards USPs and mitigating strategies among participants varied between moderate to high, with statistically significant associations with their socio-demographic characteristics.', 'Conclusions: Although the knowledge and beliefs of the general public in India towards USPs are encouraging, there is a need for long-term educational interventions as the dynamics and severity of COVID-19 have been changing day-by-day rapidly.', 'The findings of this study could guide the public health authorities in making and implementing decisions to combat this pandemic.', 'Keywords:  Coronavirus, COVID-19, outbreak, Pandemic, universal precautions, SARS-CoV-2.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 2459, 'end': 2469}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2406, 'end': 2414}, {'entity': 'Coronavirus', 'type': 'Virus', 'start': 2393, 'end': 2404}, {'entity': 'combat', 'type': 'Disease', 'start': 2355, 'end': 2361}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2198, 'end': 2206}, {'entity': 'socio-demographic', 'type': 'Organization', 'start': 1966, 'end': 1983}, {'entity': 'socio-demographic', 'type': 'Organization', 'start': 1626, 'end': 1643}, {'entity': 'vaccine', 'type': 'Drug', 'start': 495, 'end': 502}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 249, 'end': 257}]\n",
            "['Establishment of a Replicon System for Bourbon Virus and Identification of Small Molecules that Efficiently Inhibit Virus Replication\\tBourbon virus (BRBV) was first isolated from a patient hospitalized at the University of Kansas Hospital in 2014.', 'Since then, several deaths have been reported to be caused by BRBV infection in the Midwest and Southern United States.', 'BRBV is a tick-borne virus that is widely carried by lone star ticks.', 'It belongs to genus Thogotovirus of the Orthomyxoviridae family.', 'Currently, there are no treatments or vaccines available for BRBV or thogotovirus infection caused diseases.', \"In this study, we reconstituted a replicon reporter system, composed of plasmids expressing the RNA-dependent RNA polymerase (RdRP) complex (PA, PB1 and PB2), nucleocapsid (NP) protein, and a reporter gene flanked by the 3' and 5' UTR of the envelope glycoprotein (GP) genome segment.\", 'By using the luciferase reporter, we screened a few small molecule compounds of anti-endonuclease that inhibited the nicking activity by parvovirus B19 (B19V) NS1, as well as FDA-approved drugs targeting the RdRP of influenza virus.', 'Our results demonstrated that myricetin, and an anti-B19V NS1 nicking inhibitor, efficiently inhibited the RdRP activity of BRBV and virus replication.', 'The IC50 and EC50 of myricetin are 2.22 uM and 4.6 uM, respectively, in cells.', 'Myricetin had minimal cytotoxicity in cells, and therefore the therapeutic index of the compound is high.', 'In conclusion, the BRBV replicon system is a useful tool to study viral RNA replication and to develop antivirals, and myricetin may hold promise in treatment of BRBV infected patients.']\n",
            "unmatched tags:  [{'entity': 'BRBV', 'type': 'Chemical', 'start': 1629, 'end': 1633}, {'entity': 'myricetin', 'type': 'Drug', 'start': 1586, 'end': 1595}, {'entity': 'antivirals', 'type': 'Drug', 'start': 1570, 'end': 1580}, {'entity': 'viral RNA', 'type': 'Gene', 'start': 1533, 'end': 1542}, {'entity': 'BRBV', 'type': 'Chemical', 'start': 1486, 'end': 1490}, {'entity': 'compound', 'type': 'Chemical', 'start': 1449, 'end': 1457}, {'entity': 'Myricetin', 'type': 'Drug', 'start': 1361, 'end': 1370}, {'entity': 'myricetin', 'type': 'Drug', 'start': 1303, 'end': 1312}, {'entity': 'EC50', 'type': 'Gene', 'start': 1295, 'end': 1299}, {'entity': 'BRBV', 'type': 'Chemical', 'start': 1254, 'end': 1258}, {'entity': 'NS1', 'type': 'Disease', 'start': 1188, 'end': 1191}, {'entity': 'B19V', 'type': 'Chemical', 'start': 1183, 'end': 1187}, {'entity': 'myricetin', 'type': 'Drug', 'start': 1160, 'end': 1169}, {'entity': 'influenza virus', 'type': 'Virus', 'start': 1113, 'end': 1128}, {'entity': 'NS1', 'type': 'Disease', 'start': 1056, 'end': 1059}, {'entity': 'B19V', 'type': 'Chemical', 'start': 1050, 'end': 1054}, {'entity': 'parvovirus B19', 'type': 'Virus', 'start': 1034, 'end': 1048}]\n",
            "['Second-line therapies in advanced biliary tract cancers\\tBiliary tract cancers constitute approximately 3% of gastrointestinal malignancies with poor prognosis.', 'Surgical therapy is the main form of treatment in localised disease; however, for patients with advanced stage or unresectable disease, locoregional and systemic chemotherapeutics are primary treatment options.', 'Although the combination of gemcitabine and cisplatin is a standard regimen of choice, there are no consensus guidelines that help in choosing an appropriate second-line therapy.', 'Substantial progress has been made in the past decade to understand the tumorigenesis and genetic landscape of each biliary tract cancer subtype, which facilitates precision medicine for this cancer.']\n",
            "unmatched tags:  [{'entity': 'cancer', 'type': 'Disease', 'start': 742, 'end': 748}, {'entity': 'cancer', 'type': 'Disease', 'start': 680, 'end': 686}, {'entity': 'tumorigenesis', 'type': 'Disease', 'start': 622, 'end': 635}, {'entity': 'cisplatin', 'type': 'Drug', 'start': 415, 'end': 424}, {'entity': 'gemcitabine', 'type': 'Drug', 'start': 399, 'end': 410}, {'entity': 'systemic chemotherapeutics', 'type': 'Drug', 'start': 313, 'end': 339}, {'entity': 'localised disease', 'type': 'Disease', 'start': 210, 'end': 227}]\n",
            "['Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial\\tCoformulated elvitegravir, cobicistat, emtricitabine, and tenofovir seems to be efficacious and well tolerated in virologically suppressed adults with HIV and might be a suitable alternative for patients on an NNRTI with emtricitabine and tenofovir regimen considering a regimen modification or simplification.']\n",
            "unmatched tags:  [{'entity': 'tenofovir', 'type': 'Gene', 'start': 561, 'end': 570}]\n",
            "['Familial Mediterranean fever\\tFamilial Mediterranean fever (FMF; recurrent polyserositis, periodic disease) is an autosomal recessive hereditary disease which primarily affects populations surrounding the Mediterranean basin.', 'It is characterised by recurrent attacks of fever and peritonitis, pleuritis, arthritis, or erysipelas-like skin disease.']\n",
            "unmatched tags:  [{'entity': 'arthritis', 'type': 'Disease', 'start': 303, 'end': 312}, {'entity': 'pleuritis', 'type': 'Disease', 'start': 292, 'end': 301}, {'entity': 'fever', 'type': 'Phenotype', 'start': 269, 'end': 274}, {'entity': 'periodic disease', 'type': 'Disease', 'start': 89, 'end': 105}, {'entity': 'polyserositis', 'type': 'Disease', 'start': 74, 'end': 87}]\n",
            "['Efficient high throughput SARS-CoV-2 testing to detect asymptomatic carriers\\tThe COVID-19 pandemic is rapidly spreading throughout the world.', 'Recent reports suggest that 10-30% of SARS-CoV-2 infected patients are asymptomatic.', 'Other studies report that some subjects have significant viral shedding prior to symptom onset.', 'Since both asymptomatic and pre-symptomatic subjects can spread the disease, identifying such individuals is critical for effective control of the SARS-CoV-2 pandemic.', 'Therefore, there is an urgent need to increase diagnostic testing capabilities in order to also screen asymptomatic carriers.', 'In fact, such tests will be routinely required until a vaccine is developed.', 'Yet, a major bottleneck of managing the COVID-19 pandemic in many countries is diagnostic testing, due to limited laboratory capabilities as well as limited access to genome-extraction and Polymerase Chain Reaction (PCR) reagents.', 'We developed P-BEST - a method for Pooling-Based Efficient SARS-CoV-2 Testing, using a non-adaptive group-testing approach, which significantly reduces the number of tests required to identify all positive subjects within a large set of samples.', 'Instead of testing each sample separately, samples are pooled into groups and each pool is tested for SARS-CoV-2 using the standard clinically approved PCR-based diagnostic assay.', 'Each sample is part of multiple pools, using a combinatorial pooling strategy based on compressed sensing designed for maximizing the ability to identify all positive individuals.', 'We evaluated P-BEST using leftover samples that were previously clinically tested for COVID-19.', 'In our current proof-of-concept study we pooled 384 patient samples into 48 pools providing an 8-fold increase in testing efficiency.', 'Five sets of 384 samples, containing 1-5 positive carriers were screened and all positive carriers in each set were correctly identified.', 'P-BEST provides an efficient and easy-to-implement solution for increasing testing capacity that will work with any clinically approved genome-extraction and PCR-based diagnostic methodologies.']\n",
            "unmatched tags:  [{'entity': 'patient samples', 'type': 'Chemical', 'start': 1679, 'end': 1694}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1617, 'end': 1625}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1273, 'end': 1283}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 984, 'end': 994}, {'entity': 'reagents', 'type': 'Chemical', 'start': 915, 'end': 923}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 734, 'end': 742}, {'entity': 'vaccine', 'type': 'Drug', 'start': 672, 'end': 679}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 595, 'end': 602}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 470, 'end': 480}, {'entity': 'pre-symptomatic', 'type': 'Disease', 'start': 351, 'end': 366}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 335, 'end': 342}, {'entity': 'symptom', 'type': 'Phenotype', 'start': 308, 'end': 315}]\n",
            "['Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL\\tDonepezil had no effect on the primary endpoint, the V-ADAS-cog score in CADASIL patients with cognitive impairment.', 'Improvements were noted on several measures of executive function, but the clinical relevance of these findings is not clear.', 'Our findings may have implications for future trial design in subcortical vascular cognitive impairment.']\n",
            "unmatched tags:  [{'entity': 'subcortical vascular cognitive impairment', 'type': 'Disease', 'start': 418, 'end': 459}, {'entity': 'cognitive impairment', 'type': 'Phenotype', 'start': 208, 'end': 228}, {'entity': 'CADASIL', 'type': 'Disease', 'start': 186, 'end': 193}, {'entity': 'primary endpoint', 'type': 'Chemical', 'start': 144, 'end': 160}, {'entity': 'Donepezil', 'type': 'Drug', 'start': 113, 'end': 122}]\n",
            "['Fast assessment of human receptor-binding capability of 2019 novel coronavirus (2019-nCoV)\\tThe outbreaks of 2002/2003 SARS, 2012/2015 MERS and 2019/2020 Wuhan respiratory syndrome clearly indicate that genome evolution of an animal coronavirus (CoV) may enable it to acquire human transmission ability, and thereby to cause serious threats to global public health.', 'It is widely accepted that CoV human transmission is driven by the interactions of its spike protein (S-protein) with human receptor on host cell surface; so, quantitative evaluation of these interactions may be used to assess the human transmission capability of CoVs.', 'However, quantitative methods directly using viral genome data are still lacking.', 'Here, we perform large-scale protein-protein docking to quantify the interactions of 2019-nCoV S-protein receptor-binding domain (S-RBD) with human receptor ACE2, based on experimental SARS-CoV S-RBD-ACE2 complex structure.', 'By sampling a large number of thermodynamically probable binding conformations with Monte Carlo algorithm, this approach successfully identified the experimental complex structure as the lowest-energy receptor-binding conformations, and hence established an experiment-based strength reference for evaluating the receptor-binding affinity of 2019-nCoV via comparison with SARS-CoV.', 'Our results show that this binding affinity is about 73% of that of SARS-CoV, supporting that 2019-nCoV may cause human transmission similar to that of SARS-CoV.', 'Thus, this study presents a method for rapidly assessing the human transmission capability of a newly emerged CoV and its mutant strains, and demonstrates that post-genome analysis of protein-protein interactions may provide early scientific guidance for viral prevention and control.']\n",
            "unmatched tags:  [{'entity': 'strains', 'type': 'Disease', 'start': 1614, 'end': 1621}, {'entity': 'CoV', 'type': 'Virus', 'start': 1595, 'end': 1598}, {'entity': 'CoV', 'type': 'Virus', 'start': 1480, 'end': 1483}, {'entity': 'SARS-CoV.', 'type': 'Virus', 'start': 1475, 'end': 1484}, {'entity': '2019-nCoV', 'type': 'Virus', 'start': 1417, 'end': 1426}, {'entity': 'CoV', 'type': 'Virus', 'start': 1396, 'end': 1399}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 1391, 'end': 1399}, {'entity': 'SARS-CoV.', 'type': 'Virus', 'start': 1313, 'end': 1322}, {'entity': 'CoV', 'type': 'Virus', 'start': 1289, 'end': 1292}, {'entity': '2019-nCoV', 'type': 'Virus', 'start': 1283, 'end': 1292}, {'entity': 'receptor-binding', 'type': 'Gene', 'start': 1254, 'end': 1270}, {'entity': 'receptor-binding', 'type': 'Gene', 'start': 1142, 'end': 1158}, {'entity': 'ACE2', 'type': 'Gene', 'start': 917, 'end': 921}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 902, 'end': 910}, {'entity': 'ACE2', 'type': 'Gene', 'start': 874, 'end': 878}, {'entity': 'human receptor', 'type': 'Gene', 'start': 859, 'end': 873}, {'entity': 'receptor-binding', 'type': 'Gene', 'start': 822, 'end': 838}]\n",
            "['Prevalence of pulmonary tuberculosis in western China in 2010–11: a population-based, cross-sectional survey\\tDespite progress in other parts of China, the prevalence of pulmonary tuberculosis in Xinjiang remains high.', 'The very low PDR suggests poor access to diagnosis and care.', 'Further studies are needed to understand the barriers to diagnosis and care of this population, and efforts are urgently needed to enhance tuberculosis screening in this area.']\n",
            "unmatched tags:  [{'entity': 'tuberculosis', 'type': 'Disease', 'start': 418, 'end': 430}]\n",
            "['Bipolar disorder\\tBipolar, or manic-depressive, disorder is a frequent, severe, mostly recurrent mood disorder associated with great morbidity.', 'The lifetime prevalence of bipolar disorder is 1·3 to 1·6%.', 'The mortality rate of the disease is two to three times higher than that of the general population.', 'About 10–20% of individuals with bipolar disorder take their own life, and nearly one third of patients admit to at least one suicide attempt.', 'The clinical manifestations of the disease are exceptionally diverse.', 'They range from mild hypomania or mild depression to severe forms of mania or depression accompanied by profound psychosis.']\n",
            "unmatched tags:  [{'entity': 'psychosis', 'type': 'Disease', 'start': 629, 'end': 638}, {'entity': 'depression', 'type': 'Disease', 'start': 594, 'end': 604}, {'entity': 'mania', 'type': 'Disease', 'start': 585, 'end': 590}]\n",
            "['Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial\\tThese data show that a progressive improvement in disease activity is associated with correction of pro-inflammatory T-cell lineage specification in patients with active systemic lupus erythematosus during 12 months of sirolimus treatment.', 'Follow-up placebo-controlled clinical trials in diverse patient populations are warranted to further define the role of mTOR blockade in treatment of systemic lupus erythematosus.']\n",
            "unmatched tags:  [{'entity': 'systemic lupus erythematosus', 'type': 'Disease', 'start': 564, 'end': 592}, {'entity': 'mTOR', 'type': 'Gene', 'start': 534, 'end': 538}]\n",
            "['CCN proteins: multifunctional signalling regulators\\tAlthough little is known as yet about the processes that coordinate cell-signalling pathways, matrix proteins are probably major players in this type of global control.', 'The CCN (cyr61, ctgf, nov) proteins are an important family of matri-cellular regulatory factors involved in internal and external cell signalling.', 'This family participates in angiogenesis, chondro-genesis, and osteogenesis, and they are probably involved in the control of cell proliferation and differentiation.']\n",
            "unmatched tags:  [{'entity': 'proteins', 'type': 'Gene', 'start': 248, 'end': 256}, {'entity': 'ctgf', 'type': 'Gene', 'start': 237, 'end': 241}, {'entity': 'cyr61', 'type': 'Gene', 'start': 230, 'end': 235}]\n",
            "['Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial\\tIn patients with CLL, ruxolitinib was associated with significant improvements in disease-related symptoms as measured by BFI, MDASI, and symptom interference scores.', 'Further studies to test the therapeutic efficacy of ruxolitinib in CLL are warranted.']\n",
            "unmatched tags:  [{'entity': 'CLL', 'type': 'Disease', 'start': 344, 'end': 347}, {'entity': 'ruxolitinib', 'type': 'Drug', 'start': 329, 'end': 340}]\n",
            "['Functional connectivity of large-scale brain networks in patients with anti-NMDA receptor encephalitis: an observational study\\tThis study reveals a characteristic pattern of whole-brain functional connectivity alterations in anti-NMDAR encephalitis that is well suited to explain the major clinical symptoms of the disorder.', 'These observations advance the pathophysiological understanding of NMDAR dysfunction in the human brain and could be similarly relevant for other neuropsychiatric disorders, such as schizophrenia.']\n",
            "unmatched tags:  [{'entity': 'schizophrenia', 'type': 'Disease', 'start': 507, 'end': 520}, {'entity': 'neuropsychiatric disorders', 'type': 'Disease', 'start': 471, 'end': 497}, {'entity': 'dysfunction', 'type': 'Disease', 'start': 398, 'end': 409}, {'entity': 'NMDAR', 'type': 'Gene', 'start': 392, 'end': 397}]\n",
            "['Recombinant vector vaccines and within-host evolution\\tMany recombinant vector vaccines are capable of replication within the host.', 'They consist of a fully competent vector backbone engineered to express an antigen from a foreign transgene.', 'From the perspective of viral replication, the transgene is not only dispensable but may even be intrinsically detrimental.', 'Thus vaccine revertants that delete the transgene may evolve to dominate the within-host population and in doing so reduce the antigenicity of the vaccine.', 'We apply mathematical and computational models to study this process, including the dynamics of vaccine and revertant growth plus the dynamics of innate and adaptive immunity.', 'Although the selective basis of vaccine evolution is easy to comprehend, the immunological consequences are not.', 'One complication is that, despite possible fitness differences between vaccine and revertant, the opportunity for vaccine evolution is limited by the short period of growth before the viral population is cleared.', 'Even less obvious, revertant per se does not interfere with immunity to vaccine except as the revertant suppresses vaccine abundance; the magnitude of this interference depends on mechanisms and timing of viral suppression.', 'Adaptive immunity targeting the foreign antigen is also a possible basis of vaccine inferiority, but it is not worsened by vaccine evolution.', 'Overall, we find that within-host vaccine evolution can sometimes matter to the adaptive immune response targeting the foreign antigen, but even when it does matter, simple principles of vaccine design and the control of inoculum composition can largely mitigate the effects.', 'Author Summary Recombinant vector vaccines are live replicating viruses that are engineered to carry extra genes derived from a pathogen – and these produce proteins against which we want to generate immunity.', 'These genes may evolve to be lost during the course of replication within an individual, and there is a concern that this can severely limit the vaccine’s efficacy.', 'The dynamics of this process are studied here with mathematical models.', 'The potential for vaccine evolution is somewhat reduced by the short-term growth of the vaccine population before it is suppressed by the immune response.', 'Even when within-host evolution can be a problem, the models show that increasing the vaccine inoculum size or ensuring that the inoculum is mostly pure vaccine can largely avoid the loss of immunity arising from evolution.']\n",
            "unmatched tags:  [{'entity': 'vaccine', 'type': 'Drug', 'start': 2419, 'end': 2426}, {'entity': 'vaccine', 'type': 'Drug', 'start': 2352, 'end': 2359}, {'entity': 'vaccine', 'type': 'Drug', 'start': 2199, 'end': 2206}, {'entity': 'vaccine', 'type': 'Drug', 'start': 2129, 'end': 2136}, {'entity': 'vaccine', 'type': 'Drug', 'start': 2019, 'end': 2026}, {'entity': 'proteins', 'type': 'Gene', 'start': 1821, 'end': 1829}, {'entity': 'Recombinant vector vaccines', 'type': 'Gene', 'start': 1679, 'end': 1706}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1575, 'end': 1582}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1422, 'end': 1429}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1369, 'end': 1376}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1322, 'end': 1329}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1137, 'end': 1144}, {'entity': 'revertant', 'type': 'Gene', 'start': 1116, 'end': 1125}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1094, 'end': 1101}, {'entity': 'revertant', 'type': 'Gene', 'start': 1041, 'end': 1050}, {'entity': 'vaccine', 'type': 'Drug', 'start': 923, 'end': 930}, {'entity': 'revertant', 'type': 'Gene', 'start': 892, 'end': 901}, {'entity': 'vaccine', 'type': 'Drug', 'start': 880, 'end': 887}, {'entity': 'vaccine', 'type': 'Drug', 'start': 728, 'end': 735}, {'entity': 'revertant', 'type': 'Gene', 'start': 628, 'end': 637}, {'entity': 'vaccine', 'type': 'Drug', 'start': 616, 'end': 623}, {'entity': 'vaccine', 'type': 'Drug', 'start': 511, 'end': 518}]\n",
            "['Thyroid cancer\\tThyroid cancer is the fifth most common cancer in women in the USA, and an estimated over 62\\u2008000 new cases occurred in men and women in 2015.', 'The incidence continues to rise worldwide.', 'Differentiated thyroid cancer is the most frequent subtype of thyroid cancer and in most patients the standard treatment (surgery followed by either radioactive iodine or observation) is effective.', 'Patients with other, more rare subtypes of thyroid cancer—medullary and anaplastic—are ideally treated by physicians with experience managing these malignancies.']\n",
            "unmatched tags:  [{'entity': 'malignancies', 'type': 'Disease', 'start': 546, 'end': 558}, {'entity': 'thyroid cancer', 'type': 'Disease', 'start': 441, 'end': 455}, {'entity': 'radioactive iodine', 'type': 'Drug', 'start': 349, 'end': 367}, {'entity': 'cancer', 'type': 'Disease', 'start': 270, 'end': 276}, {'entity': 'thyroid cancer', 'type': 'Disease', 'start': 262, 'end': 276}]\n",
            "['Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial\\tCamrelizumab showed antitumour activity in pretreated Chinese patients with advanced hepatocellular carcinoma, with manageable toxicities, and might represent a new treatment option for these patients.']\n",
            "unmatched tags:  [{'entity': 'toxicities', 'type': 'Disease', 'start': 280, 'end': 290}]\n",
            "['Death in children with febrile seizures: a population-based cohort study\\tLong-term mortality is not increased in children with febrile seizures, but there seems to be a small excess mortality during the 2 years after complex febrile seizures.', 'Parents should be reassured that death after febrile seizures is very rare, even in high-risk children.']\n",
            "unmatched tags:  [{'entity': 'seizures', 'type': 'Phenotype', 'start': 296, 'end': 304}]\n",
            "['Influence of maternal obesity on the association between common pregnancy complications and risk of childhood obesity: an individual participant data meta-analysis\\tAlthough lowering maternal risk of gestational diabetes, gestational hypertension, and pre-eclampsia is important in relation to maternal and fetal pregnancy outcomes, such interventions are unlikely to have a direct impact on childhood obesity.', 'Preventive strategies for reducing childhood obesity should focus on maternal BMI rather than on pregnancy complications.']\n",
            "unmatched tags:  [{'entity': 'childhood obesity', 'type': 'Disease', 'start': 445, 'end': 462}]\n",
            "['Headache arising from idiopathic changes in CSF pressure\\tNew onset of sudden or progressive headache can have various causes, including disorders of intracranial pressure (ICP).', 'Headache is the most common—and often the presenting—symptom of both intracranial hypertension and intracranial hypotension syndromes, which can be symptomatic or idiopathic.', 'Despite the widespread availability of diagnostic tests, including ocular ophthalmoscopy, neuroimaging, and measurement of CSF pressure, delays in diagnosis or misdiagnosis of idiopathic intracranial hypertension and spontaneous intracranial hypotension remain common.']\n",
            "unmatched tags:  [{'entity': 'spontaneous intracranial hypotension', 'type': 'Disease', 'start': 570, 'end': 606}, {'entity': 'idiopathic intracranial hypertension', 'type': 'Disease', 'start': 529, 'end': 565}]\n",
            "['Lung cancer after treatment for breast cancer\\tBreast cancer is the most common cancer in women, and the second most common cause of cancer death after lung cancer.', 'Improvements in the outcome of breast cancer mean that more patients are living longer and are, therefore, at risk of developing a second malignancy.', 'The aim of this review is to present the current understanding of the risk of lung cancer arising in patients previously treated for early stage breast cancer.', 'We review data on the effect of treatment factors (ie, surgery type, radiotherapy technique, and adjuvant chemotherapy) and patient factors (ie, age and smoking) on the risk of developing a subsequent lung cancer.']\n",
            "unmatched tags:  [{'entity': 'lung cancer', 'type': 'Disease', 'start': 675, 'end': 686}, {'entity': 'cancer', 'type': 'Disease', 'start': 466, 'end': 472}, {'entity': 'breast cancer', 'type': 'Disease', 'start': 459, 'end': 472}, {'entity': 'lung cancer', 'type': 'Disease', 'start': 392, 'end': 403}, {'entity': 'malignancy', 'type': 'Disease', 'start': 302, 'end': 312}, {'entity': 'cancer', 'type': 'Disease', 'start': 202, 'end': 208}, {'entity': 'breast cancer', 'type': 'Disease', 'start': 195, 'end': 208}, {'entity': 'lung cancer', 'type': 'Disease', 'start': 151, 'end': 162}, {'entity': 'cancer', 'type': 'Disease', 'start': 132, 'end': 138}, {'entity': 'cancer', 'type': 'Disease', 'start': 79, 'end': 85}]\n",
            "['A Web-based, Mobile Responsive Application to Screen Healthcare Workers for COVID Symptoms: Descriptive Study\\tBackground: The COVID-19 pandemic has impacted over 1 million people across the globe, with over 330,000 cases in the United States.', 'To help limit the spread in Massachusetts, the Department of Public Health required that all healthcare workers must be screened for symptoms daily - individuals with symptoms may not work.', 'We rapidly created a digital COVID-19 symptom screening tool for a large, academic, integrated healthcare delivery system, Partners HealthCare, in Boston, Massachusetts.', 'Objective: We describe the design and development of the COVID-19 symptom screening application and report on aggregate usage data from the first week of use across the organization.', 'Methods: Using agile principles, we designed, tested and implemented a solution over the span of a week using progressively custom development approaches as the requirements and use case become more solidified.', 'We developed the minimum viable product (MVP) of a mobile responsive, web-based self-service application using REDCap (Research Electronic Data Capture).', 'For employees without access to a computer or mobile device to use the self-service application, we established a manual process where in-person, socially distanced screeners asked employees entering the site if they have symptoms and then manually recorded the responses in an Office 365 Form.', 'A custom .NET Framework application was developed solution as COVID Pass was scaled.', 'We collected log data from the .NET application, REDCap and Office 365 from the first week of full enterprise deployment (March 30, 2020 - April 5, 2020).', 'Aggregate descriptive statistics including overall employee attestations by day and site, employee attestations by application method (COVID Pass automatic screening vs. manual screening), employee attestations by time of day, and percentage of employees reporting COVID-19 symptoms  Results: We rapidly created the MVP and gradually deployed it across the hospitals in our organization.', 'By the end of the first week of enterprise deployment, the screening application was being used by over 25,000 employees each weekday.', 'Over the first full week of deployment, 154,730 employee attestation logs were processed across the system.', 'Over this 7-day period, 558 (0.36%) employees reported positive symptoms.', 'In most clinical locations, the majority of employees (~80-90%) used the self-service application, with a smaller percentage (~10-20%) using manual attestation.', 'Hospital staff continued to work around the clock, but as expected, staff attestations peaked during shift changes between 7-8am, 2-3pm, 4-6pm, and 11pm-midnight.', 'Conclusions: Using rapid, agile development, we quickly created and deployed a dedicated employee attestation application that gained widespread adoption and use within our health system.', 'Further, we have identified over 500 symptomatic employees that otherwise would have possibly come to work, potentially putting others at risk.', 'We share the story of our implementation, lessons learned, and source code (via GitHub) for other institutions who may want to implement similar solutions.']\n",
            "unmatched tags:  [{'entity': 'GitHub', 'type': 'Organization', 'start': 3146, 'end': 3152}]\n",
            "['Sphingolipid Biosynthesis Inhibition As A Host Strategy Against Diverse Pathogens\\tChloroquine is an anti-malarial and immunosuppressant drug that has cationic amphipathic chemical properties.', 'We performed genome-wide screens in human cells with chloroquine and several other widely used cationic amphipathic drugs (CADs) including the anti-depressants, sertraline (Zoloft) and fluoxetine (Prozac), the analgesic nortriptyline (Pamelor), the anti-arrhythmic amiodarone (Cordarone), and the anti-hypertensive verapamil (Calan) to characterize their molecular similarities and differences.', 'Despite CADs having different disease indications but consistent with them sharing key chemical properties, we found CADs to have remarkably similar phenotypic profiles compared with non-CADs we and others have previously screened ( 1 – 5 ).', 'The most significant genetic interaction for all CADs was the initiating step in sphingolipid biosynthesis catalyzed by serine palmitoyltransferase (SPT).', 'A comparison of genome-wide screens performed with diverse pathogens from viruses, bacteria, plants, and parasites including Ebola ( 6 ), adeno-associated virus AAV2 ( 7 ), HIV ( 8 ), Rotavirus ( 9 ), Influenza A ( 10 ), Zika virus ( 11 ), Picornavirus ( 12 ), Exotoxin A ( 13 ), Cholera toxin ( 14 ), Type III secretion system and Shiga toxin ( 15 , 16 ), Ricin toxin ( 17 ), and Toxoplasma gondii ( 18 ) showed SPT as a top common host factor and 80% overlap overall in top hits specifically with CADs.', 'Potential sphingolipid-mediated mechanisms for the host response- and virulence-modulating effects of CADs involve autophagy and SERPINE1/PAI-1 (plasminogen activator inhibitor-1).', 'Chloroquine has recently shown potential as an anti-viral agent for the novel coronavirus SARS-CoV-2, the causative agent of COVID-19 respiratory disease ( 19 , 20 ).', 'Our study demonstrates that numerous readily available drugs molecularly function highly similar to chloroquine, which suggests they might be considered for further pre-clinical investigation in the context of SARS-CoV-2.', 'More generally, our work suggests the diverse pathogen mitigating potential of drugs that inhibit host sphingolipid biosynthesis such as CADs.', 'Brief Summary Our study demonstrates that numerous readily available drugs molecularly function highly similar to chloroquine, which suggests they might be considered for further pre-clinical investigation in the context of SARS-CoV-2.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 2426, 'end': 2436}, {'entity': 'chloroquine', 'type': 'Drug', 'start': 2316, 'end': 2327}, {'entity': 'CADs', 'type': 'Gene', 'start': 2196, 'end': 2200}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 2047, 'end': 2057}, {'entity': 'chloroquine', 'type': 'Drug', 'start': 1937, 'end': 1948}, {'entity': 'COVID-19 respiratory disease', 'type': 'Disease', 'start': 1795, 'end': 1823}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1760, 'end': 1770}]\n",
            "['Multivariate Analyses of Codon Usage of SARS-CoV-2 and other betacoronaviruses\\tCoronavirus disease 2019 (COVID-19) is a global health concern as it continues to spread within China and beyond.', 'The causative agent of this disease, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), belongs to the genus Betacoronavirus which also includes severe acute respiratory syndrome related coronavirus (SARSr-CoV) and Middle East respiratory syndrome related coronavirus (MERSr-CoV).', 'Codon usage of viral genes are believed to be subjected to different selection pressures in different host environments.', 'Previous studies on codon usage of influenza A viruses can help identify viral host origins and evolution trends, however, similar studies on coronaviruses are lacking.', 'In this study, global correspondence analysis (CA), within-group correspondence analysis (WCA) and between-group correspondence analysis (BCA) were performed among different genes in coronavirus viral sequences.', 'The amino acid usage pattern of SARS-CoV-2 was generally found similar to bat and human SARSr-CoVs.', 'However, we found greater synonymous codon usage differences between SARS-CoV-2 and its phylogenetic relatives on spike and membrane genes, suggesting these two genes of SARS-CoV-2 are subjected to different evolutionary pressures.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1257, 'end': 1267}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1156, 'end': 1166}, {'entity': 'SARSr-CoVs', 'type': 'Virus', 'start': 1075, 'end': 1085}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1019, 'end': 1029}, {'entity': 'amino acid', 'type': 'Gene', 'start': 991, 'end': 1001}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 958, 'end': 969}, {'entity': 'CA', 'type': 'Drug', 'start': 914, 'end': 916}, {'entity': 'BCA', 'type': 'Gene', 'start': 913, 'end': 916}, {'entity': 'WCA', 'type': 'Gene', 'start': 865, 'end': 868}, {'entity': 'CA', 'type': 'Drug', 'start': 822, 'end': 824}, {'entity': 'coronaviruses', 'type': 'Virus', 'start': 748, 'end': 761}, {'entity': 'influenza A viruses', 'type': 'Virus', 'start': 641, 'end': 660}, {'entity': 'viral genes', 'type': 'Gene', 'start': 500, 'end': 511}, {'entity': 'MERSr-CoV', 'type': 'Virus', 'start': 473, 'end': 482}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 460, 'end': 471}, {'entity': 'Middle East respiratory syndrome', 'type': 'Disease', 'start': 419, 'end': 451}, {'entity': 'SARSr-CoV', 'type': 'Virus', 'start': 404, 'end': 413}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 391, 'end': 402}, {'entity': 'acute respiratory syndrome', 'type': 'Disease', 'start': 356, 'end': 382}]\n",
            "['Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression\\tAdults with type 2 diabetes are at an increased risk of developing certain brain or mental disorders, including stroke, dementia, and depression.', 'Although these disorders are not usually considered classic microvascular complications of diabetes, evidence is growing that microvascular dysfunction is one of the key underlying mechanisms.', 'Microvascular dysfunction is a widespread phenomenon in people with diabetes, including effects on the brain.', 'Cerebral microvascular dysfunction is also apparent in adults with prediabetes, suggesting that cerebral microvascular disease processes start before the onset of diabetes.']\n",
            "unmatched tags:  [{'entity': 'diabetes', 'type': 'Disease', 'start': 715, 'end': 723}, {'entity': 'cerebral microvascular disease', 'type': 'Disease', 'start': 648, 'end': 678}, {'entity': 'prediabetes', 'type': 'Disease', 'start': 619, 'end': 630}, {'entity': 'Cerebral microvascular dysfunction', 'type': 'Disease', 'start': 552, 'end': 586}, {'entity': 'diabetes', 'type': 'Disease', 'start': 510, 'end': 518}, {'entity': 'diabetes', 'type': 'Disease', 'start': 340, 'end': 348}, {'entity': 'disorders', 'type': 'Disease', 'start': 264, 'end': 273}, {'entity': 'depression', 'type': 'Disease', 'start': 237, 'end': 247}, {'entity': 'dementia', 'type': 'Disease', 'start': 223, 'end': 231}, {'entity': 'stroke', 'type': 'Disease', 'start': 215, 'end': 221}]\n",
            "['Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study\\tOur findings suggest that the oral cholera vaccine offers both direct and indirect (herd) protection in a sub-Saharan African setting.', 'Mass oral cholera immunisation campaigns have the potential to provide not only protection for vaccinated individuals but also for the unvaccinated members of the community and should be strongly considered for wider use.', 'Because this is an internationally-licensed vaccine, we could not undertake a randomised placebo-controlled trial, but the absence of vaccine effectiveness against non-cholera diarrhoea indicates that the noted protection against cholera could not be explained by bias.']\n",
            "unmatched tags:  [{'entity': 'cholera', 'type': 'Drug', 'start': 714, 'end': 721}, {'entity': 'non-cholera diarrhoea', 'type': 'Phenotype', 'start': 648, 'end': 669}, {'entity': 'vaccine', 'type': 'Drug', 'start': 618, 'end': 625}]\n",
            "['Pathophysiology and treatment of stroke in sickle-cell disease: present and future\\tSickle-cell anaemia is the most common cause of stroke in children, and stroke is one of the most devastating complications of sickle-cell disease.', 'Overt strokes are typically due to large-artery vasculopathy affecting the intracranial internal carotid arteries and proximal middle cerebral arteries, whereas silent strokes typically occur in the territory of penetrating arteries.', 'The sickled red blood cell can contribute to the pathogenesis of stroke via abnormal adherence to the vascular endothelium and by haemolysis, which results in endothelial cell activation, a hypercoaguable state, and alterations in vasomotor tone.']\n",
            "unmatched tags:  [{'entity': 'hypercoaguable state', 'type': 'Disease', 'start': 655, 'end': 675}]\n",
            "['Androgen insensitivity syndrome\\tAndrogen insensitivity syndrome in its complete form is a disorder of hormone resistance characterised by a female phenotype in an individual with an XY karyotype and testes producing age-appropriate normal concentrations of androgens.', 'Pathogenesis is the result of mutations in the X-linked androgen receptor gene, which encodes for the ligand-activated androgen receptor—a transcription factor and member of the nuclear receptor superfamily.', 'This Seminar describes the clinical manifestations of androgen insensitivity syndrome from infancy to adulthood, reviews the mechanism of androgen action, and shows examples of how mutations of the androgen receptor gene cause the syndrome.']\n",
            "unmatched tags:  [{'entity': 'syndrome', 'type': 'Disease', 'start': 707, 'end': 715}, {'entity': 'androgen receptor gene', 'type': 'Gene', 'start': 674, 'end': 696}, {'entity': 'androgen action', 'type': 'Drug', 'start': 614, 'end': 629}, {'entity': 'androgen insensitivity syndrome', 'type': 'Disease', 'start': 530, 'end': 561}, {'entity': 'nuclear receptor superfamily', 'type': 'Gene', 'start': 446, 'end': 474}, {'entity': 'transcription factor', 'type': 'Gene', 'start': 407, 'end': 427}, {'entity': 'X-linked androgen receptor gene', 'type': 'Gene', 'start': 315, 'end': 346}]\n",
            "['Chloroquine Kills Hair Cells in Zebrafish Lateral Line and Murine Cochlear Cultures: Implications for Ototoxicity\\tHearing and balance deficits have been reported during and following treatment with the antimalarial drug chloroquine.', 'However, experimental work examining the direct actions of chloroquine on mechanoreceptive hair cells in common experimental models is lacking.', 'This study examines the effects of chloroquine on hair cells using two common experimental models: the zebrafish lateral line and neonatal mouse cochlear cultures.', 'Zebrafish larvae were exposed to varying concentrations of chloroquine phosphate or hydroxychloroquine for 1 hr or 24 hr, and hair cells assessed by antibody staining.', 'A significant, dose-dependent reduction in the number of surviving hair cells was seen across conditions for both exposure periods.', 'Hydroxycholroquine showed similar toxicity.', 'In mouse cochlear cultures, chloroquine damage was specific to outer hair cells in tissue from the cochlear basal turn, consistent with susceptibility to other ototoxic agents.', 'These findings suggest a need for future studies employing hearing and balance monitoring during exposure to chloroquine and related compounds, particularly with interest in these compounds as therapeutics against viral infections including coronavirus.']\n",
            "unmatched tags:  [{'entity': 'coronavirus', 'type': 'Virus', 'start': 1303, 'end': 1314}, {'entity': 'viral infections', 'type': 'Disease', 'start': 1276, 'end': 1292}, {'entity': 'compounds', 'type': 'Drug', 'start': 1242, 'end': 1251}, {'entity': 'compounds', 'type': 'Drug', 'start': 1195, 'end': 1204}, {'entity': 'chloroquine', 'type': 'Drug', 'start': 1171, 'end': 1182}, {'entity': 'chloroquine damage', 'type': 'Drug', 'start': 913, 'end': 931}, {'entity': 'Hydroxycholroquine', 'type': 'Drug', 'start': 841, 'end': 859}, {'entity': 'surviving', 'type': 'Gene', 'start': 766, 'end': 775}]\n",
            "['Sensitive one-step isothermal detection of pathogen-derived RNAs\\tThe recent outbreaks of Ebola, Zika, MERS, and SARS-CoV-2 (2019-nCoV) require fast, simple, and sensitive onsite nucleic acid diagnostics that can be developed rapidly to prevent the spread of diseases.', 'We have developed a SENsitive Splint-based one-step isothermal RNA detection (SENSR) method for rapid and straightforward onsite detection of pathogen RNAs with high sensitivity and specificity.', 'SENSR consists of two simple enzymatic reactions: a ligation reaction by SplintR ligase and subsequent transcription by T7 RNA polymerase.', 'The resulting transcript forms an RNA aptamer that induces fluorescence.', 'Here, we demonstrate that SENSR is an effective and highly sensitive method for the detection of the current epidemic pathogen, (SARS-CoV-2).', 'We also show that the platform can be extended to the detection of five other pathogens.', 'Overall, SENSR is a molecular diagnostic method that can be developed rapidly for onsite uses requiring high sensitivity, specificity, and short assaying times.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 804, 'end': 814}, {'entity': 'RNA aptamer', 'type': 'Gene', 'start': 636, 'end': 647}, {'entity': 'transcript', 'type': 'Gene', 'start': 616, 'end': 626}]\n",
            "['Infections associated with haemophagocytic syndrome\\tHaemophagocytic syndrome or haemophagocytic lymphohistiocytosis is a rare disease that is often fatal despite treatment.', 'Haemophagocytic syndrome is caused by a dysregulation in natural killer T-cell function, resulting in activation and proliferation of lymphocytes or histiocytes with uncontrolled haemophagocytosis and cytokine overproduction.', 'The syndrome is characterised by fever, hepatosplenomegaly, cytopenias, liver dysfunction, and hyperferritinaemia.', 'Haemophagocytic syndrome can be either primary, with a genetic aetiology, or secondary, associated with malignancies, autoimmune diseases, or infections.']\n",
            "unmatched tags:  [{'entity': 'autoimmune diseases', 'type': 'Disease', 'start': 632, 'end': 651}, {'entity': 'malignancies', 'type': 'Disease', 'start': 618, 'end': 630}, {'entity': 'Haemophagocytic syndrome', 'type': 'Disease', 'start': 514, 'end': 538}, {'entity': 'hyperferritinaemia', 'type': 'Disease', 'start': 494, 'end': 512}, {'entity': 'hepatosplenomegaly', 'type': 'Phenotype', 'start': 439, 'end': 457}, {'entity': 'fever', 'type': 'Phenotype', 'start': 432, 'end': 437}, {'entity': 'syndrome', 'type': 'Disease', 'start': 403, 'end': 411}, {'entity': 'haemophagocytosis', 'type': 'Disease', 'start': 352, 'end': 369}, {'entity': 'Haemophagocytic syndrome', 'type': 'Disease', 'start': 173, 'end': 197}]\n",
            "['Modelling and analysis of COVID-19 epidemic in India.', 'COVID-19 epidemic is declared as the public health emergency of international concern by the World Health Organisation in the second week of March 2020.', 'This disease originated from China in December 2019 has already caused havoc around the world, including India.', 'The first case in India was reported on 30th January 2020, with the cases crossing 6000 on the day paper was written.', 'Complete lockdown of the nation for 21 days and immediate isolation of infected cases are the proactive steps taken by the authorities.', 'For a better understanding of the evolution of COVID-19 in the country, Susceptible-Infectious-Quarantined-Recovered (SIQR) model is used in this paper.', 'It is predicted that actual infectious population is ten times the reported positive case (quarantined) in the country.', 'Also, a single case can infect 1.5 more individuals of the population.', 'Epidemic doubling time is estimated to be around 4.1 days.', 'All indicators are compared with Brazil and Italy as well.', 'SIQR model has also predicted that India will see the peak with 22,000 active cases during the last week of April followed by reduction in active cases.', 'It may take complete July for India to get over with COVID-19.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 1241, 'end': 1249}, {'entity': 'indicators', 'type': 'Chemical', 'start': 980, 'end': 990}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 620, 'end': 628}, {'entity': 'nation', 'type': 'Organization', 'start': 462, 'end': 468}]\n",
            "['HIV/AIDS treatment and HIV vaccines for Africa\\tIncreased support from the global HIV/AIDS community is driving advances in HIV treatment and vaccine development in the developing world.', 'Care of patients with AIDS includes many biomedical, nutritional, psychosocial, and behavioural interventions.', 'In resource-poor settings, antiretroviral drugs should be given with use of standardised treatment regimens and streamlined algorithms for monitoring use.', 'A safe and effective HIV vaccine will supplement prevention efforts to protect uninfected people against infection, or might possibly be able to modify the course of HIV infection.']\n",
            "unmatched tags:  [{'entity': 'HIV infection', 'type': 'Phenotype', 'start': 618, 'end': 631}, {'entity': 'HIV vaccine', 'type': 'Drug', 'start': 473, 'end': 484}, {'entity': 'antiretroviral drugs', 'type': 'Drug', 'start': 324, 'end': 344}, {'entity': 'resource-poor settings', 'type': 'Gene', 'start': 300, 'end': 322}, {'entity': 'AIDS', 'type': 'Disease', 'start': 208, 'end': 212}, {'entity': 'vaccine', 'type': 'Drug', 'start': 141, 'end': 148}, {'entity': 'HIV', 'type': 'Virus', 'start': 123, 'end': 126}, {'entity': 'HIV/AIDS', 'type': 'Disease', 'start': 81, 'end': 89}]\n",
            "['Structural and biochemical characterization of nsp12-nsp7-nsp8 core polymerase complex from COVID-19 virus\\tThe ongoing global pandemic of coronavirus disease 2019 (COVID-19) has caused huge number of human deaths.', 'Currently, there are no specific drugs or vaccines available for this virus.', 'The viral polymerase is a promising antiviral target.', 'However, the structure of COVID-19 virus polymerase is yet unknown.', 'Here, we describe the near-atomic resolution structure of its core polymerase complex, consisting of nsp12 catalytic subunit and nsp7-nsp8 cofactors.', 'This structure highly resembles the counterpart of SARS-CoV with conserved motifs for all viral RNA-dependent RNA polymerases, and suggests the mechanism for activation by cofactors.', 'Biochemical studies revealed reduced activity of the core polymerase complex and lower thermostability of individual subunits of COVID-19 virus as compared to that of SARS-CoV.', 'These findings provide important insights into RNA synthesis by coronavirus polymerase and indicate a well adaptation of COVID-19 virus towards humans with relatively lower body temperatures than the natural bat hosts.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 1044, 'end': 1052}, {'entity': 'coronavirus polymerase', 'type': 'Virus', 'start': 987, 'end': 1009}, {'entity': 'RNA', 'type': 'Gene', 'start': 970, 'end': 973}, {'entity': 'SARS-CoV.', 'type': 'Virus', 'start': 913, 'end': 922}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 875, 'end': 883}, {'entity': 'subunits', 'type': 'Gene', 'start': 863, 'end': 871}]\n",
            "['Tuning antiviral CD8 T-cell response via proline-altered peptide ligand vaccination\\tViral escape from CD8 + cytotoxic T lymphocyte responses correlates with disease progression and represents a significant challenge for vaccination.', 'Here, we demonstrate that CD8 + T cell recognition of the naturally occurring MHC-I-restricted LCMV-associated immune escape variant Y4F is restored following vaccination with a proline-altered peptide ligand (APL).', 'The APL increases MHC/peptide (pMHC) complex stability, rigidifies the peptide and facilitates T cell receptor (TCR) recognition through reduced entropy costs.', 'Structural analyses of pMHC complexes before and after TCR binding, combined with biophysical analyses, revealed that although the TCR binds similarly to all complexes, the p3P modification alters the conformations of a very limited amount of specific MHC and peptide residues, facilitating efficient TCR recognition.', 'This approach can be easily introduced in peptides restricted to other MHC alleles, and can be combined with currently available and future vaccination protocols in order to prevent viral immune escape.', 'Author Summary Viral escape mutagenesis correlates often with disease progression and represents a major hurdle for vaccination-based therapies.', 'Here, we have designed and developed a novel generation of altered epitopes that re-establish and enhance significantly CD8 + T cell recognition of a naturally occurring viral immune escape variant.', 'Biophysical and structural analyses provide a clear understanding of the molecular mechanisms underlying this reestablished recognition.', 'We believe that this approach can be implemented to currently available or novel vaccination approaches to efficiently restore T cell recognition of virus escape variants to control disease progression.']\n",
            "unmatched tags:  [{'entity': 'structural analyses', 'type': 'Gene', 'start': 1490, 'end': 1509}, {'entity': 'Viral escape', 'type': 'Gene', 'start': 1145, 'end': 1157}, {'entity': 'MHC', 'type': 'Gene', 'start': 998, 'end': 1001}, {'entity': 'peptides', 'type': 'Gene', 'start': 969, 'end': 977}, {'entity': 'TCR', 'type': 'Gene', 'start': 910, 'end': 913}, {'entity': 'peptide', 'type': 'Gene', 'start': 869, 'end': 876}, {'entity': 'MHC', 'type': 'Gene', 'start': 861, 'end': 864}, {'entity': 'alters', 'type': 'Disease', 'start': 799, 'end': 805}, {'entity': 'p3P', 'type': 'Gene', 'start': 782, 'end': 785}]\n",
            "['Socioeconomic differences in mortality in the antiretroviral therapy era in Agincourt, rural South Africa, 2001–13: a population surveillance analysis\\tThe poorest people in the population continue to bear a high burden of HIV/AIDS and tuberculosis mortality, despite free antiretroviral therapy being made available from public health facilities.', 'Associations between socioeconomic status and increasing burden of mortality from non-communicable diseases is likely to become prominent.', 'Integrated strategies are needed to improve access to and uptake of HIV testing, care, and treatment, and management of non-communicable diseases in the poorest populations.']\n",
            "unmatched tags:  [{'entity': 'non-communicable diseases', 'type': 'Disease', 'start': 606, 'end': 631}, {'entity': 'non-communicable diseases', 'type': 'Disease', 'start': 429, 'end': 454}, {'entity': 'era', 'type': 'Gene', 'start': 289, 'end': 292}, {'entity': 'tuberculosis', 'type': 'Disease', 'start': 235, 'end': 247}, {'entity': 'HIV/AIDS', 'type': 'Disease', 'start': 222, 'end': 230}]\n",
            "['Treatment of systemic lupus erythematosus: from cod-liver oil to cyclosporin\\tWe now think of systemic lupus erythematosus (SLE) as a multisystemic disease that may include specific, more or less extensive, skin lesions.', 'In the the 19th century (discoid) lupus erythematosus (DLE) was solely a skin disease and was studied largely by dermatologists whose main interest was in differentiating these lesions from lupus vulgaris (cutaneous tuberculosis).', '“Disseminated LE” initially meant that the skin lesions were extensive, but this term became ambiguous when it was subsequently applied to patients with both cutaneous and visceral symptoms.']\n",
            "unmatched tags:  [{'entity': 'skin lesions', 'type': 'Disease', 'start': 494, 'end': 506}, {'entity': 'cutaneous tuberculosis', 'type': 'Disease', 'start': 426, 'end': 448}, {'entity': 'lupus vulgaris', 'type': 'Disease', 'start': 410, 'end': 424}, {'entity': 'skin disease', 'type': 'Disease', 'start': 293, 'end': 305}, {'entity': 'DLE', 'type': 'Disease', 'start': 275, 'end': 278}, {'entity': 'lupus erythematosus', 'type': 'Disease', 'start': 254, 'end': 273}, {'entity': 'skin lesions', 'type': 'Disease', 'start': 206, 'end': 218}, {'entity': 'multisystemic disease', 'type': 'Disease', 'start': 133, 'end': 154}]\n",
            "['Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial\\tA short course of twice-daily oral zidovudine was safe and well tolerated and, in the absence of breastfeeding, can lessen the risk for mother-to-child HIV-1 transmission by half.', 'This regimen could prevent many HIV-1 infections during late pregnancy and labour in less-developed countries unable to implement the full 076 regimen.']\n",
            "unmatched tags:  [{'entity': 'HIV-1 infections', 'type': 'Virus', 'start': 321, 'end': 337}, {'entity': 'HIV-1', 'type': 'Virus', 'start': 261, 'end': 266}]\n",
            "['Acute pneumonia and the cardiovascular system\\tAlthough traditionally regarded as a disease confined to the lungs, acute pneumonia has important effects on the cardiovascular system at all severities of infection.', 'Pneumonia tends to affect individuals who are also at high cardiovascular risk.', 'Results of recent studies show that about a quarter of adults admitted to hospital with pneumonia develop a major acute cardiac complication during their hospital stay, which is associated with a 60% increase in short-term mortality.', 'These findings suggest that outcomes of patients with pneumonia can be improved by prevention of the development and progression of associated cardiac complications.']\n",
            "unmatched tags:  [{'entity': 'pneumonia', 'type': 'Disease', 'start': 581, 'end': 590}, {'entity': 'pneumonia', 'type': 'Disease', 'start': 381, 'end': 390}]\n",
            "['Targeting SARS-CoV-2 Spike Protein of COVID-19 with Naturally Occurring Phytochemicals: An in Silco Study for Drug Development\\tSpike glycoprotein found on the surface of SARS-CoV-2 (SARS-CoV-2S) is a class I fusion protein which helps the virus in its initial attachment with human Angiotensin converting enzyme 2 (ACE2) receptor and its consecutive fusion with the host cells.', 'The attachment is mediated by the S1 subunit of the protein via its receptor binding domain.', 'Upon binding with the receptor the protein changes its conformation from a pre-fusion to a post-fusion form.', 'The membrane fusion and internalization of the virus is brought about by the S2 domain of the spike protein.', 'From ancient times people have relied on naturally occurring substances like phytochemicals to fight against diseases and infection.', 'Among these phytochemicals, flavonoids and non-flavonoids have been found to be the active source of different anti-microbial agents.', 'Recently, studies have shown that these phytochemicals have essential anti-viral activities.', 'We performed a molecular docking study using 10 potential naturally occurring flavonoids/non-flavonoids against the SARS-CoV-2 spike protein and compared their affinity with the FDA approved drug hydroxychloroquine (HCQ).', 'Interestingly, the docking analysis suggested that C-terminal of S1 domain and S2 domain of the spike protein are important for binding with these compounds.', 'Kamferol, curcumin, pterostilbene, and HCQ interact with the C-terminal of S1 domain with binding energies of -7.4, -7.1, -6.7 and -5.6 Kcal/mol, respectively.', 'Fisetin, quercetin, isorhamnetin, genistein, luteolin, resveratrol']\n",
            "unmatched tags:  [{'entity': 'luteolin', 'type': 'Drug', 'start': 1636, 'end': 1644}, {'entity': 'genistein', 'type': 'Drug', 'start': 1625, 'end': 1634}, {'entity': 'isorhamnetin', 'type': 'Drug', 'start': 1611, 'end': 1623}, {'entity': 'quercetin', 'type': 'Drug', 'start': 1600, 'end': 1609}, {'entity': 'Fisetin', 'type': 'Drug', 'start': 1591, 'end': 1598}, {'entity': 'HCQ', 'type': 'Drug', 'start': 1470, 'end': 1473}, {'entity': 'pterostilbene', 'type': 'Drug', 'start': 1451, 'end': 1464}, {'entity': 'curcumin', 'type': 'Drug', 'start': 1441, 'end': 1449}, {'entity': 'compounds', 'type': 'Drug', 'start': 1420, 'end': 1429}, {'entity': 'spike protein', 'type': 'Gene', 'start': 1369, 'end': 1382}, {'entity': 'HCQ', 'type': 'Drug', 'start': 1267, 'end': 1270}, {'entity': 'drug hydroxychloroquine', 'type': 'Drug', 'start': 1242, 'end': 1265}, {'entity': 'protein', 'type': 'Gene', 'start': 1184, 'end': 1191}, {'entity': 'spike protein', 'type': 'Gene', 'start': 1178, 'end': 1191}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1167, 'end': 1177}, {'entity': 'flavonoids/non-flavonoids', 'type': 'Drug', 'start': 1129, 'end': 1154}, {'entity': 'phytochemicals', 'type': 'Drug', 'start': 998, 'end': 1012}, {'entity': 'anti-microbial agents', 'type': 'Drug', 'start': 934, 'end': 955}, {'entity': 'non-flavonoids', 'type': 'Drug', 'start': 866, 'end': 880}, {'entity': 'flavonoids', 'type': 'Drug', 'start': 851, 'end': 861}, {'entity': 'phytochemicals', 'type': 'Drug', 'start': 835, 'end': 849}, {'entity': 'diseases', 'type': 'Disease', 'start': 798, 'end': 806}, {'entity': 'phytochemicals', 'type': 'Drug', 'start': 766, 'end': 780}, {'entity': 'spike protein', 'type': 'Gene', 'start': 674, 'end': 687}, {'entity': 'pre-fusion', 'type': 'Organization', 'start': 546, 'end': 556}, {'entity': 'protein', 'type': 'Gene', 'start': 506, 'end': 513}, {'entity': 'receptor', 'type': 'Gene', 'start': 493, 'end': 501}, {'entity': 'receptor', 'type': 'Gene', 'start': 446, 'end': 454}, {'entity': 'protein', 'type': 'Gene', 'start': 430, 'end': 437}, {'entity': 'receptor', 'type': 'Gene', 'start': 321, 'end': 329}]\n",
            "['Acute kidney injury\\tAcute kidney injury (AKI) is defined by a rapid increase in serum creatinine, decrease in urine output, or both.', 'AKI occurs in approximately 10–15% of patients admitted to hospital, while its incidence in intensive care has been reported in more than 50% of patients.', 'Kidney dysfunction or damage can occur over a longer period or follow AKI in a continuum with acute and chronic kidney disease.', 'Biomarkers of kidney injury or stress are new tools for risk assessment and could possibly guide therapy.']\n",
            "unmatched tags:  [{'entity': 'kidney injury', 'type': 'Disease', 'start': 430, 'end': 443}, {'entity': 'chronic kidney disease', 'type': 'Disease', 'start': 392, 'end': 414}]\n",
            "['Significance of hydrophobic and charged sequence similarities in sodium-bile acid cotransporter and vitamin D-binding protein macrophage activating factor\\tSodium-bile acid cotransporter, also denominated sodium-taurocholate cotransporting polypeptide (NTCP) is an integral membrane protein with multiple hydrophobic transmembrane domains.', 'The third extracellular domain of NTCP presents a stretch of nine aminoacids (KGIVISLVL) that is characterized by pronounced hydrophobicity and serves as receptor for a protein, preS1, showing the hydrophobic epta-peptide sequence NPLGFFP.', 'Vitamin D-binding protein macrophage activating factor (DBP-MAF) is a multifunctional protein that is characterized by two hydrophobic regions able to bind fatty acids and vitamin D, respectively.', 'Here we demonstrate that NTCP and DBP-MAF show significant sequence similarities as far as hydrophobic stretches of aminoacids are concerned.', 'Alignment of the sequence of seven aminoacids preceding the 157-KGIVISLVL-165 stretch of NTCP shows four aminoacids that are identical to those of the corresponding sequence of DBP-MAF, and two that are conserved substitutions.', 'In addition, in the sequence of DBP-MAF that is aligned with the sequence YKGIVISLVL of NTCP, there are two contiguous negatively charged aminoacids (ED) and, in the preceding epta-peptide sequence, there are three negatively charged aminoacids (D-ED), whereas in the corresponding sequence of NTCP there are only two (D--D) that are not contiguous.', 'This concentration of negatively charged aminoacids may be involved in binding of protein inserts characterized by high density of positively charges residues.', 'The alternating hydrophobic and electrostatic interactions described in this paper may help elucidating the biological roles of these proteins as far as protein-protein interactions are concerned.']\n",
            "unmatched tags:  [{'entity': 'protein', 'type': 'Gene', 'start': 1817, 'end': 1824}, {'entity': 'proteins', 'type': 'Gene', 'start': 1790, 'end': 1798}, {'entity': 'high density', 'type': 'Gene', 'start': 1611, 'end': 1623}, {'entity': 'protein', 'type': 'Gene', 'start': 1578, 'end': 1585}, {'entity': 'charged aminoacids', 'type': 'Gene', 'start': 1529, 'end': 1547}, {'entity': 'NTCP', 'type': 'Gene', 'start': 1440, 'end': 1444}, {'entity': 'aminoacids', 'type': 'Gene', 'start': 1380, 'end': 1390}, {'entity': 'charged aminoacids', 'type': 'Gene', 'start': 1372, 'end': 1390}, {'entity': 'charged aminoacids', 'type': 'Gene', 'start': 1276, 'end': 1294}, {'entity': 'NTCP', 'type': 'Gene', 'start': 1234, 'end': 1238}, {'entity': 'KGIVISLVL', 'type': 'Disease', 'start': 1221, 'end': 1230}, {'entity': 'DBP-MAF', 'type': 'Gene', 'start': 1178, 'end': 1185}, {'entity': 'DBP-MAF', 'type': 'Gene', 'start': 1095, 'end': 1102}, {'entity': 'aminoacids', 'type': 'Gene', 'start': 1023, 'end': 1033}, {'entity': 'NTCP', 'type': 'Gene', 'start': 1007, 'end': 1011}, {'entity': 'aminoacids', 'type': 'Gene', 'start': 953, 'end': 963}, {'entity': 'aminoacids', 'type': 'Gene', 'start': 892, 'end': 902}, {'entity': 'DBP-MAF', 'type': 'Gene', 'start': 810, 'end': 817}, {'entity': 'NTCP', 'type': 'Gene', 'start': 801, 'end': 805}, {'entity': 'vitamin D', 'type': 'Drug', 'start': 751, 'end': 760}, {'entity': 'fatty acids', 'type': 'Drug', 'start': 735, 'end': 746}, {'entity': 'protein', 'type': 'Gene', 'start': 665, 'end': 672}, {'entity': 'multifunctional protein', 'type': 'Gene', 'start': 649, 'end': 672}, {'entity': 'DBP-MAF', 'type': 'Gene', 'start': 635, 'end': 642}, {'entity': 'Vitamin D-binding protein macrophage activating factor', 'type': 'Gene', 'start': 579, 'end': 633}, {'entity': 'preS1', 'type': 'Gene', 'start': 517, 'end': 522}, {'entity': 'protein', 'type': 'Gene', 'start': 508, 'end': 515}]\n",
            "['Relation between sympathetic vasoconstrictor activity and pain and hyperalgesia in complex regional pain syndromes: a case-control study\\tWe have shown that in complex regional pain syndromes with SMP, physiological activation of cutaneous vasoconstrictor neurons projecting to the painful arm or leg enhances spontaneous pain and hyperalgesia.', 'We postulate that there is a pathological interaction between sympathetic and afferent neurons within the skin.', 'Published online April 23, 2002 http://image.thelancet.com/extras/01art6027web.pdf']\n",
            "unmatched tags:  [{'entity': 'hyperalgesia', 'type': 'Phenotype', 'start': 330, 'end': 342}, {'entity': 'pain', 'type': 'Phenotype', 'start': 321, 'end': 325}, {'entity': 'painful arm', 'type': 'Phenotype', 'start': 281, 'end': 292}, {'entity': 'vasoconstrictor', 'type': 'Drug', 'start': 239, 'end': 254}]\n",
            "['Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials\\tIntensive lowering of systolic blood pressure increased the risk of incident chronic kidney disease in people with and without type 2 diabetes.', 'However, the absolute risk of incident chronic kidney disease was higher in people with type 2 diabetes.', 'Our findings suggest the need for vigilance in monitoring kidney function during intensive antihypertensive drug treatment, particularly in adults with diabetes.', 'Long-term studies are needed to understand the clinical implications of antihypertensive treatment-related reductions in eGFR.']\n",
            "unmatched tags:  [{'entity': 'antihypertensive', 'type': 'Drug', 'start': 662, 'end': 678}, {'entity': 'diabetes', 'type': 'Disease', 'start': 580, 'end': 588}]\n",
            "['Decodingevolution and transmissions of novel pneumonia coronavirus using the whole genomic data\\tBackground.', 'The outbreak of COVID-19 started in mid-December 2019 in Wuhan, Central China.', 'Up toFebruary 18, 2020, SARS-CoV-2 has infected more than 70,000 people in China, and another 25countries across five continents.', 'In this study, we used 93 complete genomes of SARS-CoV-2 fromthe GISAID EpiFluTM database to decode the evolution and human-to-human transmissions ofSARS-CoV-2 in the recent two months.Methods.', 'Alignment of coding-regions was conducted haplotype analyses using DnaSP.', 'Substitutionsites were analyzed in codon.', 'Evolutionary analysis of haplotypes used NETWORK.', 'Population sizechanges were estimated using both DnaSP and Arlequin.', 'Expansion date of population size wascalculated based on the expansion parameter tau (τ) using the formula t=τ/2u.Findings.', 'Eight coding-regions have 120 substitution sites, including 79 non-synonymous and 40synonymous substitutions.', 'Forty-two non-synonymous substitutions changed the biochemicalproperty of amino acids.', 'No evident combination was found.', 'Fifty-eight haplotypes wereclassified as five groups, and 31 haplotypes were found in samples from both China and othercountries, respectively.', 'The rooted network suggested H13 and H35 to be ancestral haplotypes,and H1 (and its descendent haplotypes including all samples from the Hua Nan market) was derivedH3 haplotype.', 'Population size of SARS-CoV-2 were estimated to have a recent expansion on 6January 2020, and an early expansion on 8 December 2019.Interpretation.', 'Genomic variations of SARS-CoV-2 are still low in comparisons with publishedgenomes of SARS-CoV and MERS-CoV.', 'Phyloepidemiologic analyses indicated the SARS-CoV-2 source atthe Hua Nan market should be imported from other places.', 'The crowded market boosted SARS-CoV-2rapid circulations in the market and spread it to the whole city in early December 2019.Furthermore, phyloepidemiologic approaches have recovered specific direction of human-to-humantransmissions, and the import sources of international infectious cases.']\n",
            "unmatched tags:  [{'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1827, 'end': 1837}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1723, 'end': 1733}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 1658, 'end': 1666}, {'entity': 'genomes', 'type': 'Gene', 'start': 1647, 'end': 1654}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1593, 'end': 1603}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1442, 'end': 1452}, {'entity': 'H1', 'type': 'Gene', 'start': 1317, 'end': 1319}, {'entity': 'H1', 'type': 'Gene', 'start': 1274, 'end': 1276}, {'entity': 'amino acids', 'type': 'Gene', 'start': 1054, 'end': 1065}, {'entity': 'coding-regions', 'type': 'Disease', 'start': 876, 'end': 890}]\n",
            "['COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning\\tTo ultimately combat the emerging COVID-19 pandemic, it is desired to develop an effective and safe vaccine against this highly contagious disease caused by the SARS-CoV-2 coronavirus.', 'Our literature and clinical trial survey showed that the whole virus, as well as the spike (S) protein, nucleocapsid (N) protein, and membrane (M) protein, have been tested for vaccine development against SARS and MERS.', 'However, these vaccine candidates might lack the induction of complete protection and have safety concerns.', 'We then applied the Vaxign reverse vaccinology tool and the newly developed Vaxign-ML machine learning tool to predict COVID-19 vaccine candidates.', 'By investigating the entire proteome of SARS-CoV-2, six proteins, including the S protein and five non-structural proteins (nsp3, 3CL-pro, and nsp8-10), were predicted to be adhesins, which are crucial to the viral adhering and host invasion.', 'The S, nsp3, and nsp8 proteins were also predicted by Vaxign-ML to induce high protective antigenicity.', 'Besides the commonly used S protein, the nsp3 protein has not been tested in any coronavirus vaccine studies and was selected for further investigation.', 'The nsp3 was found to be more conserved among SARS-CoV-2, SARS-CoV, and MERS-CoV than among 15 coronaviruses infecting human and other animals.', 'The protein was also predicted to contain promiscuous MHC-I and MHC-II T-cell epitopes, and linear B-cell epitopes localized in specific locations and functional domains of the protein.', 'By applying reverse vaccinology and machine learning, we predicted potential vaccine targets for effective and safe COVID-19 vaccine development.', 'We then propose that an “Sp/Nsp cocktail vaccine” containing a structural protein(s) (Sp) and a non-structural protein(s) (Nsp) would stimulate effective complementary immune responses.']\n",
            "unmatched tags:  [{'entity': 'Nsp', 'type': 'Gene', 'start': 1843, 'end': 1846}, {'entity': 'protein', 'type': 'Gene', 'start': 1831, 'end': 1838}, {'entity': 'protein', 'type': 'Gene', 'start': 1794, 'end': 1801}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1761, 'end': 1768}, {'entity': 'Nsp', 'type': 'Gene', 'start': 1748, 'end': 1751}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1699, 'end': 1706}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1651, 'end': 1658}, {'entity': 'reverse vaccinology', 'type': 'Gene', 'start': 1586, 'end': 1605}, {'entity': 'protein', 'type': 'Gene', 'start': 1565, 'end': 1572}, {'entity': 'MHC-I', 'type': 'Gene', 'start': 1452, 'end': 1457}, {'entity': 'MHC-I', 'type': 'Gene', 'start': 1442, 'end': 1447}, {'entity': 'protein', 'type': 'Gene', 'start': 1392, 'end': 1399}, {'entity': 'coronaviruses', 'type': 'Virus', 'start': 1339, 'end': 1352}, {'entity': 'MERS-CoV', 'type': 'Virus', 'start': 1316, 'end': 1324}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 1302, 'end': 1310}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1290, 'end': 1300}, {'entity': 'nsp3', 'type': 'Gene', 'start': 1248, 'end': 1252}, {'entity': 'vaccine', 'type': 'Drug', 'start': 1184, 'end': 1191}, {'entity': 'nsp3 protein', 'type': 'Gene', 'start': 1132, 'end': 1144}, {'entity': 'protein', 'type': 'Gene', 'start': 1119, 'end': 1126}, {'entity': 'S protein', 'type': 'Gene', 'start': 1117, 'end': 1126}, {'entity': 'proteins', 'type': 'Gene', 'start': 1009, 'end': 1017}, {'entity': 'nsp3', 'type': 'Gene', 'start': 994, 'end': 998}, {'entity': 'adhesins', 'type': 'Gene', 'start': 918, 'end': 926}, {'entity': 'nsp3', 'type': 'Gene', 'start': 868, 'end': 872}]\n",
            "['The porcine deltacoronavirus replication organelle comprises double membrane vesicles and zippered endoplasmic reticulum with double membrane spherules\\tPorcine deltacoronavirus (PDCoV) was first identified in Hong Kong in 2012 from samples taken from pigs in 2009.', 'PDCoV was subsequently identified in the USA in 2014 in pigs with a history of severe diarrhea and the virus has now been detected in pigs in several countries around the world.', 'Following the development of tissue culture adapted strains of PDCoV, it is now possible to begin to address questions regarding virus-host cell interactions for this genera of coronavirus.', 'Here we present a detailed study of PDCoV induced replication organelles.', 'All positive strand RNA viruses induce the rearrangement of cellular membranes during virus replication to support viral RNA synthesis, forming the replication organelle.', 'Replication organelles for the Alpha -, Beta - and Gammacoronavirus genera have been characterized.', 'However the structures induced by deltacoronaviruses, in particular the presence of convoluted membranes or double membrane spherules, are unknown.', 'Initially, the dynamics of PDCoV strain OH-FD22 replication were assessed with the onset of viral RNA synthesis, protein synthesis and progeny particle release determined.', 'Subsequently, virus induced membrane rearrangements were identified in infected cells by electron microscopy.', 'As has been observed for all other coronaviruses studied to date, PDCoV replication was found to induce the formation of double membrane vesicles.', 'Significantly however, PDCoV replication was also found to induce the formation of regions of zippered endoplasmic reticulum and small associated tethered vesicles, double membrane spherules.', 'These structures strongly resemble the replication organelle induced by avian Gammacoronavirus infectious bronchitis virus.']\n",
            "unmatched tags:  [{'entity': 'coronavirus', 'type': 'Virus', 'start': 1830, 'end': 1841}, {'entity': 'Gammacoronavirus infectious bronchitis virus', 'type': 'Virus', 'start': 1825, 'end': 1869}, {'entity': 'double membrane spherules', 'type': 'Chemical', 'start': 1720, 'end': 1745}, {'entity': 'PDCoV', 'type': 'Chemical', 'start': 1578, 'end': 1583}, {'entity': 'PDCoV', 'type': 'Chemical', 'start': 1474, 'end': 1479}, {'entity': 'coronaviruses', 'type': 'Virus', 'start': 1443, 'end': 1456}, {'entity': 'viral RNA', 'type': 'Gene', 'start': 1218, 'end': 1227}, {'entity': 'PDCoV', 'type': 'Chemical', 'start': 1153, 'end': 1158}, {'entity': 'double membrane spherules', 'type': 'Chemical', 'start': 1086, 'end': 1111}, {'entity': 'convoluted membranes', 'type': 'Chemical', 'start': 1062, 'end': 1082}, {'entity': 'deltacoronaviruses', 'type': 'Virus', 'start': 1012, 'end': 1030}, {'entity': 'Gammacoronavirus genera', 'type': 'Virus', 'start': 929, 'end': 952}, {'entity': 'viral RNA', 'type': 'Gene', 'start': 822, 'end': 831}, {'entity': 'positive strand RNA viruses', 'type': 'Virus', 'start': 711, 'end': 738}, {'entity': 'PDCoV', 'type': 'Chemical', 'start': 669, 'end': 674}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 620, 'end': 631}, {'entity': 'PDCoV', 'type': 'Chemical', 'start': 506, 'end': 511}, {'entity': 'strains', 'type': 'Disease', 'start': 495, 'end': 502}, {'entity': 'pigs', 'type': 'Gene', 'start': 399, 'end': 403}, {'entity': 'diarrhea', 'type': 'Phenotype', 'start': 351, 'end': 359}, {'entity': 'pigs', 'type': 'Gene', 'start': 321, 'end': 325}, {'entity': 'PDCoV', 'type': 'Chemical', 'start': 265, 'end': 270}]\n",
            "['Effects of cognitive behaviour therapy for worry on persecutory delusions in patients with psychosis (WIT): a parallel, single-blind, randomised controlled trial with a mediation analysis\\tTo our knowledge, this is the first large trial focused on persecutory delusions.', 'We have shown that long-standing delusions were significantly reduced by a brief intervention targeted on worry, although the limitations for our study include no determination of the key elements within the intervention.', 'Our results suggest that worry might cause paranoia, and that worry intervention techniques might be a beneficial addition to the standard treatment of psychosis.']\n",
            "unmatched tags:  [{'entity': 'psychosis', 'type': 'Disease', 'start': 644, 'end': 653}, {'entity': 'paranoia', 'type': 'Disease', 'start': 535, 'end': 543}]\n",
            "['Implementation of a Novel Remote Physician SBRT Coverage Process during the Coronavirus Pandemic\\tINTRODUCTION: During the COVID-19 pandemic, alternative methods of care are needed to reduce the relative risk of transmission in departments.', 'Also needed is the ability to provide vital radiation oncological care if radiation oncologists (RO) are reallocated to other departments.', 'We implemented a novel remote RO SBRT coverage practice, requiring it to be reliable, of high audio and visual quality, timely, and the same level of specialty care as our current in-person treatment coverage practice.', 'METHODS: All observed failure modes were recorded during implementation over the first 15 sequential fractions.', 'The time from CBCT to treatment was calculated before and after implementation to determine timeliness of remote coverage.', 'Image quality metrics were calculated between the imaging console screen and the RO′s shared screen.', 'Comfort levels with audio/visual communication as well as overall comfort in comparison to in-person RO coverage was evaluated using Likert scale surveys after treatment.', 'RESULTS: Remote RO SBRT coverage was successfully implemented in 14/15 fractions with 3 observed process failures that were all corrected before treatment.', 'Average times of pre-treatment coverage before and after implementation were 8.74 and 8.51min, respectively.', 'The cross correlation between the imaging console screen and RO′s shared screen was r=0.96 and lag was 0.05s.', 'The average value for all survey questions was above 4.5, approaching in-person RO coverage comfort levels.', 'CONCLUSIONS: Our novel method of remote RO SBRT coverage permits reduced personnel and patient interactions surrounding RT procedures.', 'This may help to reduce transmission of COVID-19 in our department and provides a means for SBRT coverage if ROs are reallocated to other areas of the hospital for COVID-19 support.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 1888, 'end': 1896}, {'entity': 'ROs', 'type': 'Gene', 'start': 1833, 'end': 1836}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1764, 'end': 1772}, {'entity': 'RO', 'type': 'Gene', 'start': 1629, 'end': 1631}, {'entity': 'RO', 'type': 'Gene', 'start': 1561, 'end': 1563}, {'entity': 'RO', 'type': 'Gene', 'start': 1432, 'end': 1434}, {'entity': 'pre-treatment', 'type': 'Gene', 'start': 1279, 'end': 1292}, {'entity': 'RO', 'type': 'Gene', 'start': 1122, 'end': 1124}, {'entity': 'RO', 'type': 'Gene', 'start': 1036, 'end': 1038}, {'entity': 'RO', 'type': 'Gene', 'start': 915, 'end': 917}, {'entity': 'RO', 'type': 'Gene', 'start': 409, 'end': 411}, {'entity': 'departments', 'type': 'Organization', 'start': 366, 'end': 377}, {'entity': 'RO', 'type': 'Gene', 'start': 337, 'end': 339}]\n",
            "['A nematode-specific gene underlies bleomycin-response variation in\\tBleomycin is a powerful chemotherapeutic drug used to treat a variety of cancers.', 'However, individual patients vary in their responses to bleomycin.', 'The identification of genetic differences that underlie this response variation could improve treatment outcomes by tailoring bleomycin dosages to each patient.', 'We used the model organism Caenorhabditis elegans to identify genetic determinants of bleomycin-response differences by performing linkage mapping on recombinants derived from a cross between the laboratory strain (N2) and a wild strain (CB4856).', 'This approach identified a small genomic region on chromosome V that underlies bleomycin-response variation.', 'Using near-isogenic lines and strains with CRISPR-Cas9 mediated deletions and allele replacements, we discovered that a novel nematode-specific gene ( scb-1 ) is required for bleomycin resistance.', 'Although the mechanism by which this gene causes variation in bleomycin responses is unknown, we suggest that a rare variant present in the CB4856 strain might cause differences in the potential stress-response function of scb-1 between the N2 and CB4856 strains, thereby leading to differences in bleomycin resistance.', 'Article summary We performed linkage mapping on a panel of recombinant lines generated between two genetically divergent strains of Caenorhabditis elegans and identified a bleomycin-response QTL.', 'We generated CRISPR-Cas9 deletions and reciprocal allele-replacement strains for all six candidate genes across the QTL confidence interval.', 'Deletions of one gene, H19N07.3 , caused increased bleomycin sensitivity in both divergent genetic backgrounds.', 'This gene might act in stress responses and detoxification in nematodes.', 'We further compared our linkage mapping to a genome-wide association mapping and showed that a rare expression variant in the CB4856 strain likely underlies bleomycin-response differences.']\n",
            "unmatched tags:  [{'entity': 'CB4856', 'type': 'Chemical', 'start': 1898, 'end': 1904}, {'entity': 'gene', 'type': 'Gene', 'start': 1704, 'end': 1708}, {'entity': 'gene', 'type': 'Gene', 'start': 1678, 'end': 1682}, {'entity': 'bleomycin', 'type': 'Drug', 'start': 1638, 'end': 1647}, {'entity': 'gene', 'type': 'Gene', 'start': 1604, 'end': 1608}, {'entity': 'QTL', 'type': 'Gene', 'start': 1562, 'end': 1565}, {'entity': 'strains', 'type': 'Disease', 'start': 1515, 'end': 1522}, {'entity': 'CRISPR-Cas9', 'type': 'Chemical', 'start': 1459, 'end': 1470}, {'entity': 'gene', 'type': 'Gene', 'start': 1449, 'end': 1453}, {'entity': 'QTL', 'type': 'Gene', 'start': 1441, 'end': 1444}, {'entity': 'strains', 'type': 'Disease', 'start': 1371, 'end': 1378}, {'entity': 'genetically', 'type': 'Gene', 'start': 1349, 'end': 1360}, {'entity': 'gene', 'type': 'Gene', 'start': 1327, 'end': 1331}, {'entity': 'bleomycin', 'type': 'Drug', 'start': 1228, 'end': 1237}, {'entity': 'strains', 'type': 'Disease', 'start': 1185, 'end': 1192}, {'entity': 'CB4856', 'type': 'Chemical', 'start': 1178, 'end': 1184}]\n",
            "['Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study\\tPatients who have survived acute myocardial infarction or unstable angina have a similar long-term prognosis, a high occurrence of subsequent unstable angina, and benefit similarly from therapy with pravastatin.']\n",
            "unmatched tags:  [{'entity': 'pravastatin', 'type': 'Drug', 'start': 290, 'end': 301}]\n",
            "['Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes\\tThe HIV epidemic has led to large increases in the frequency of smear-negative pulmonary tuberculosis, which has poor treatment outcomes and excessive early mortality compared with smear-positive disease.', 'We used a combination of systematic review, document analysis, and global expert opinion to review the extent of this problem.', 'We also looked at policies of national tuberculosis control programmes for the diagnosis of smear-negative pulmonary tuberculosis to assess their coverage, identify the diagnostic difficulties, and find ways to improve the diagnosis of this type of tuberculosis, with a focus on resource-constrained settings with high HIV infection rates.']\n",
            "unmatched tags:  [{'entity': 'HIV infection', 'type': 'Phenotype', 'start': 805, 'end': 818}, {'entity': 'tuberculosis', 'type': 'Disease', 'start': 735, 'end': 747}, {'entity': 'smear-negative pulmonary tuberculosis', 'type': 'Disease', 'start': 578, 'end': 615}, {'entity': 'control programmes', 'type': 'Organization', 'start': 538, 'end': 556}, {'entity': 'tuberculosis', 'type': 'Disease', 'start': 525, 'end': 537}, {'entity': 'national tuberculosis', 'type': 'Disease', 'start': 516, 'end': 537}, {'entity': 'pulmonary tuberculosis', 'type': 'Disease', 'start': 233, 'end': 255}, {'entity': 'smear-negative pulmonary tuberculosis', 'type': 'Disease', 'start': 218, 'end': 255}, {'entity': 'HIV', 'type': 'Virus', 'start': 158, 'end': 161}]\n",
            "[\"A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy\\tWe identified four prognostic factors that can be used to obtain an accurate prognostic index at diagnosis of AIDS-associated Kaposi's sarcoma.\", 'This index is widely applicable and can be used to guide therapeutic options.']\n",
            "unmatched tags:  [{'entity': 'era', 'type': 'Gene', 'start': 310, 'end': 313}, {'entity': \"AIDS-associated Kaposi's sarcoma\", 'type': 'Disease', 'start': 217, 'end': 249}]\n",
            "['Immune mechanisms and development of childhood asthma\\tEarly life influences are crucial for the development of distinct childhood asthma phenotypes, which are currently included under the term asthma syndrome.', 'Improved characterisation of different childhood asthma phenotypes will help to elucidate specific underlying immune mechanisms—namely, endotypes.', 'Besides genetics, epigenetics and environmental factors have an effect on innate and adaptive immune regulatory networks.', 'Crucial determining factors for complex immune regulation and barrier function include family history of atopy, respiratory infections, microbiome, and nutrition.']\n",
            "unmatched tags:  [{'entity': 'respiratory infections', 'type': 'Disease', 'start': 591, 'end': 613}, {'entity': 'immune regulation', 'type': 'Drug', 'start': 519, 'end': 536}, {'entity': 'asthma', 'type': 'Phenotype', 'start': 259, 'end': 265}, {'entity': 'childhood asthma', 'type': 'Disease', 'start': 249, 'end': 265}]\n",
            "['A governance framework for development and assessment of national action plans on antimicrobial resistance\\tStrengthening governance is an essential strategy to tackling antimicrobial resistance (AMR) at all levels: global, national, regional, and local.', 'To date, no systematic approach to governance of national action plans on AMR exists.', 'To address this issue, we aimed to develop the first governance framework to offer guidance for both the development and assessment of national action plans on AMR.', 'We reviewed health system governance framework reviews to inform the basic structure of our framework, international guidance documents from WHO, the Food and Agriculture Organization, the World Organisation for Animal Health, and the European Commission, and sought the input of 25 experts from international organisations, government ministries, policy institutes, and academic institutions to develop and refine our framework.']\n",
            "unmatched tags:  [{'entity': 'government ministries', 'type': 'Organization', 'start': 830, 'end': 851}, {'entity': 'national', 'type': 'Organization', 'start': 806, 'end': 814}]\n",
            "['Haemoglobin E β thalassaemia in Sri Lanka\\tHaemoglobin E β thalassaemia is the commonest form of severe thalassaemia in many Asian countries, but little is known about its natural history, the reasons for clinical diversity, or its management.', 'We studied 109 Sri Lankan patients with the disorder over 5 years.', '25 patients were not receiving transfusion; transfusion was stopped with no deleterious effect in a further 37.', 'We identified several genetic and environmental factors that might contribute to the phenotypic diversity of the disorder, including modifiers of haemoglobin F production, malaria, and age-related changes in adaptive function.']\n",
            "unmatched tags:  [{'entity': 'malaria', 'type': 'Disease', 'start': 594, 'end': 601}, {'entity': 'haemoglobin F', 'type': 'Gene', 'start': 568, 'end': 581}]\n",
            "['Hypocretin (orexin) deficiency in human narcolepsy\\tAlterations in the hypocretin receptor 2 and preprohypocretin genes produce narcolepsy in animal models.', 'Hypocretin was undetectable in seven out of nine people with narcolepsy, indicating abnormal hypocretin transmission.']\n",
            "unmatched tags:  [{'entity': 'hypocretin', 'type': 'Gene', 'start': 249, 'end': 259}, {'entity': 'narcolepsy', 'type': 'Disease', 'start': 217, 'end': 227}, {'entity': 'Hypocretin', 'type': 'Gene', 'start': 156, 'end': 166}]\n",
            "['A virus that has gone viral: Amino acid mutation in S protein of Indian isolate of Coronavirus COVID-19 might impact receptor binding and thus infectivity\\tSince 2002, beta coronaviruses (CoV) have caused three zoonotic outbreaks, SARS-CoV in 2002, MERS-CoV in 2012, and the recent outbreak of SARS-CoV-2 late in 2019 (also named as COVID-19 or novel coronavirus 2019 or nCoV2019.', 'Spike(S) protein, one of the structural proteins of this virus plays key role in receptor (ACE2) binding and thus virus entry.', 'Thus, this protein has attracted scientists for detailed study and therapeutic targeting.', 'As the 2019 novel coronavirus takes its course throughout the world, more and more sequence analyses are been done and genome sequences getting deposited in various databases.', 'From India two clinical isolates have been sequenced and the full genome deposited in GenBank.', 'We have performed sequence analyses of the spike protein of the Indian isolates and compared with that of the Wuhan, China (where the outbreak was first reported).', 'While all the sequences of Wuhan isolates are identical, we found point mutations in the Indian isolates.', 'Out of the two isolates one was found to harbour a mutation in its Receptor binding domain (RBD) at position 407.', 'At this site arginine (a positively charged amino acid) was replaced by isoleucine (a hydrophobic amino acid that is also a C-beta branched amino acid).', 'This mutation has been seen to change the secondary structure of the protein at that region and this can potentially alter receptor ding of the virus.', 'Although this finding needs further validation and more sequencing, the information might be useful in rational drug designing and vaccine engineering.']\n",
            "unmatched tags:  [{'entity': 'vaccine', 'type': 'Drug', 'start': 1687, 'end': 1694}, {'entity': 'receptor ding', 'type': 'Gene', 'start': 1528, 'end': 1541}, {'entity': 'protein', 'type': 'Gene', 'start': 1474, 'end': 1481}, {'entity': 'hydrophobic amino acid', 'type': 'Chemical', 'start': 1338, 'end': 1360}, {'entity': 'isoleucine', 'type': 'Gene', 'start': 1324, 'end': 1334}, {'entity': 'site arginine', 'type': 'Gene', 'start': 1260, 'end': 1273}, {'entity': 'RBD', 'type': 'Gene', 'start': 1230, 'end': 1233}, {'entity': 'spike protein', 'type': 'Gene', 'start': 911, 'end': 924}, {'entity': 'coronavirus', 'type': 'Virus', 'start': 615, 'end': 626}, {'entity': 'protein', 'type': 'Gene', 'start': 518, 'end': 525}, {'entity': 'ACE2', 'type': 'Gene', 'start': 471, 'end': 475}, {'entity': 'receptor', 'type': 'Gene', 'start': 461, 'end': 469}, {'entity': 'structural proteins', 'type': 'Gene', 'start': 409, 'end': 428}, {'entity': 'protein', 'type': 'Gene', 'start': 389, 'end': 396}]\n",
            "['Healthcare worker mask reuse in a global pandemic: Using idle resources to create an inexpensive, scalable, and accessible UV system for N95 sterilization\\tAs the current COVID-19 pandemic illustrates, not all hospitals and other facilities are equipped with enough personal protective equipment to meet the demand in a crisis.', 'Healthcare workers around the world utilize N95 masks to protect themselves and their patients, yet during this global pandemic they are forced to re-wear what is intended to be single-use masks.', 'This poses significant risk to these healthcare workers along with the populations they are trying to protect.', 'Ultraviolet germicidal irradiation (UVGI) has been validated previously as a way to effectively sterilize these masks between use, however, not all facilities have access to the high cost commercial UV-C lamp sterilization equipment.', 'However, UV-C bulbs are sitting idle in biosafety cabinets (BSCs) at universities and research facilities around the globe that have been shuttered to slow the spread of COVID-19.', 'These bulbs may also be available in existing medical centers where infectious diseases are commonly treated.', 'Therefore, we have developed a method to modify existing light fixtures, or create custom light fixtures compatible with new or existing common UV-C bulbs.', 'This system is scalable and can be created for less than 50 US dollars, on site, at the point of need, and leverages resources that are currently untapped and sitting unused in public and private research facilities.', 'The freely-accessible design can be easily modified for use around the world.', 'Hospitals can obtain this potentially life-saving UVGI resource with minimal funds, via collaboration between research facilities to obtain the UV-C meters and limited availability UVGI bulbs.', 'While mask reuse is not ideal, we must do what we can in emergency situations to protect our frontline healthcare workers and the communities they serve.']\n",
            "unmatched tags:  [{'entity': 'protect', 'type': 'Gene', 'start': 1883, 'end': 1890}, {'entity': 'infectious diseases', 'type': 'Disease', 'start': 1116, 'end': 1135}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1038, 'end': 1046}]\n",
            "['Treatment and control of arterial hypertension in a rural community in Ecuador\\tCardiovascular diseases are widespread in developing countries, but little is known about cardiovascular risk profiles in rural communities.', 'To assess the importance of arterial hypertension in a rural district of Ecuador, we screened 4284 of the 8876 adults who lived in the area.', '1542 (36%) individuals had hypertension, only four (0·3%) of whom were well controlled by treatment.', 'We monitored all deaths for 2·5 years, and noted that cardiovascular diseases were the primary cause of death in the adult population.']\n",
            "unmatched tags:  [{'entity': 'cardiovascular diseases', 'type': 'Disease', 'start': 516, 'end': 539}]\n",
            "['Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins\\tThe ongoing outbreak of viral pneumonia in China and beyond is associated with a novel coronavirus, SARS-CoV-21.', 'This outbreak has been tentatively associated with a seafood market in Wuhan, China, where the sale of wild animals may be the source of zoonotic infection2.', 'Although bats are likely reservoir hosts for SARS-CoV-2, the identity of any intermediate host that might have facilitated transfer to humans is unknown.', 'Here, we report the identification of SARS-CoV-2-related coronaviruses in Malayan pangolins (Manis javanica) seized in anti-smuggling operations in southern China.', 'Metagenomic sequencing identified pangolin-associated coronaviruses that belong to two sub-lineages of SARS-CoV-2-related coronaviruses, including one that exhibits strong similarity to SARS-CoV-2 in the receptor-binding domain.', 'The discovery of multiple lineages of pangolin coronavirus and their similarity to SARS-CoV-2 suggests that pangolins should be considered as possible hosts in the emergence of novel coronaviruses and should be removed from wet markets to prevent zoonotic transmission.']\n",
            "unmatched tags:  [{'entity': 'zoonotic', 'type': 'Disease', 'start': 1131, 'end': 1139}, {'entity': 'wet markets', 'type': 'Gene', 'start': 1108, 'end': 1119}, {'entity': 'coronaviruses', 'type': 'Virus', 'start': 1067, 'end': 1080}]\n",
            "['Cutaneous leishmaniasis\\tCutaneous leishmaniasis is endemic in the tropics and neotropics.', 'It is often referred to as a group of diseases because of the varied spectrum of clinical manifestations, which range from small cutaneous nodules to gross mucosal tissue destruction.', 'Cutaneous leishmaniasis can be caused by several']\n",
            "unmatched tags:  [{'entity': 'Cutaneous leishmaniasis', 'type': 'Disease', 'start': 274, 'end': 297}, {'entity': 'diseases', 'type': 'Disease', 'start': 128, 'end': 136}]\n",
            "['Sexually transmissible infections other than HIV\\tSexually transmitted infections (STIs) are notable for their fastidious requirements for transmission and growth in the laboratory and for their high physical and psychosocial morbidity.', 'The combination of subtle or absent symptoms and stigma preventing the seeking of health care, leaves many infections undiagnosed.', 'The development of nucleic-acid amplification tests heralded a new era in sensitive and robust diagnostic procedures for STIs.', 'Unfortunately, many of these tests are not commercially available or are too expensive for the populations that need them most.']\n",
            "unmatched tags:  [{'entity': 'STIs', 'type': 'Disease', 'start': 488, 'end': 492}]\n",
            "['Immune Cell Profiling of COVID-19 Patients in the Recovery Stage by Single-Cell Sequencing\\tCOVID-19 caused by SARS-CoV-2 has recently affected over 200,000 people and killed more than 8000.', 'Immune system dysregulation such as lymphopenia and inflammatory cytokine storm has been observed in COVID-19 patients, but it remains unclear for the change of key immune cell subsets and their states during COVID-19.', 'Here, we applied single-cell technology to comprehensively characterize transcriptional changes of peripheral blood mononuclear cells in ten patients recovered from COVID-19.', 'Compared with healthy control, COVID-19 induced a unique signature of immune cells in humans, especially in the early recovery stage (ERS).', 'In ERS patients, T cells were decreased remarkably, while monocytes were increased.', 'A detailed analysis of monocytes showed that there was an increased ratio of classical CD14++ monocytes with highly inflammatory genes expression, as well as a greater abundance of CD14++IL1B+ monocytes.', 'For nature killer (NK) cells and T cells, CD4+ T cells were significantly decreased and expressed high level of inflammatory markers, while NK cells were increased.', 'In addition, T cells were highly expanded clone, especially in CD4+ T memory cells and CD8+ T cells.', 'Among B cells, plasma cells were increased remarkably, and naïve B cells were reduced.', 'Our study also identified several novel B cell receptor (BCR) changes (such as IGHV1-8 and IGHV3-7), and confirmed isotypes (IGKV3-11 and IGHV3-21) previously used for virus vaccine development.', 'The strongest pairing frequencies, IGHV3-23+IGHJ4, indicated a monoclonal state associated with SARS-CoV-2 specificity.', 'Furthermore, integrated analysis predicated that IL-1B and M-CSF may be novel candidate target gene for inflammatory storm, and TNFSF13, IL-18 and IL-4 may be benefit for the recovery of COVID-19 patients.', 'Our study provides the first evidence of inflammatory immune signature in early recovery stage, suggesting that the COVID-19 patients are still vulnerable after hospital discharge.', 'Our identification of novel BCR signaling may lead to the development of vaccine and antibodies for the treatment of COVID-19.']\n",
            "unmatched tags:  [{'entity': 'COVID-19', 'type': 'Disease', 'start': 2184, 'end': 2192}, {'entity': 'vaccine', 'type': 'Drug', 'start': 2140, 'end': 2147}, {'entity': 'BCR', 'type': 'Gene', 'start': 2095, 'end': 2098}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 2002, 'end': 2010}, {'entity': 'COVID-19', 'type': 'Disease', 'start': 1867, 'end': 1875}, {'entity': 'IL-4', 'type': 'Gene', 'start': 1827, 'end': 1831}, {'entity': 'IL-18', 'type': 'Gene', 'start': 1817, 'end': 1822}, {'entity': 'TNFSF13', 'type': 'Gene', 'start': 1808, 'end': 1815}, {'entity': 'gene', 'type': 'Gene', 'start': 1775, 'end': 1779}, {'entity': 'M-CSF', 'type': 'Gene', 'start': 1739, 'end': 1744}, {'entity': 'IL-1B', 'type': 'Gene', 'start': 1729, 'end': 1734}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1656, 'end': 1666}, {'entity': 'virus vaccine', 'type': 'Drug', 'start': 1533, 'end': 1546}, {'entity': 'isotypes', 'type': 'Gene', 'start': 1480, 'end': 1488}, {'entity': 'BCR', 'type': 'Gene', 'start': 1422, 'end': 1425}]\n",
            "['The host antiviral ribonuclease L protein supports Zika virus replication factory formation to enhance infectious virus production\\tThe flavivirus Zika virus (ZIKV) activates ribonuclease L (RNase L) catalytic antiviral function during infection, yet deletion of RNase L decreases ZIKV production, suggesting a proviral role of RNase L. In this study, we reveal that latent RNase L supports ZIKV replication factory (RF) assembly.', 'Deletion of RNase L induced broader cellular distribution of ZIKV dsRNA and NS3 compared with densely concentrated RFs detected in WT cells.', 'An inactive form of RNase L was sufficient to contain ZIKV genome and dsRNA within a smaller area, which increased levels of viral RNA within RFs as well as infectious ZIKV released from the cell.', 'We used a microtubule stabilization drug to demonstrate that RNase L deletion impaired the cytoskeleton rearrangements that are required for proper generation of RFs.', 'During infection with dengue or West Nile Kunjin viruses, RNase L decreased virus production, suggesting that RNase L proviral function is specific to ZIKV.']\n",
            "unmatched tags:  [{'entity': 'ZIKV', 'type': 'Virus', 'start': 1086, 'end': 1090}, {'entity': 'proviral', 'type': 'Virus', 'start': 1053, 'end': 1061}, {'entity': 'RNase L', 'type': 'Gene', 'start': 1045, 'end': 1052}, {'entity': 'RNase L', 'type': 'Gene', 'start': 993, 'end': 1000}, {'entity': 'West Nile Kunjin viruses', 'type': 'Virus', 'start': 967, 'end': 991}, {'entity': 'dengue', 'type': 'Disease', 'start': 957, 'end': 963}, {'entity': 'RFs', 'type': 'Disease', 'start': 930, 'end': 933}, {'entity': 'RNase L deletion', 'type': 'Gene', 'start': 829, 'end': 845}, {'entity': 'cell', 'type': 'Gene', 'start': 762, 'end': 766}, {'entity': 'ZIKV', 'type': 'Virus', 'start': 739, 'end': 743}, {'entity': 'RFs', 'type': 'Disease', 'start': 713, 'end': 716}, {'entity': 'viral RNA', 'type': 'Gene', 'start': 696, 'end': 705}, {'entity': 'dsRNA', 'type': 'Gene', 'start': 641, 'end': 646}, {'entity': 'ZIKV', 'type': 'Virus', 'start': 625, 'end': 629}, {'entity': 'RNase L', 'type': 'Gene', 'start': 591, 'end': 598}, {'entity': 'cell', 'type': 'Gene', 'start': 564, 'end': 568}, {'entity': 'RFs', 'type': 'Disease', 'start': 545, 'end': 548}, {'entity': 'NS3', 'type': 'Disease', 'start': 506, 'end': 509}]\n",
            "['Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges\\tProgressive supranuclear palsy (PSP) is a clinical syndrome comprising supranuclear palsy, postural instability, and mild dementia.', 'Neuropathologically, PSP is defined by the accumulation of neurofibrillary tangles.', 'Since the first description of PSP in 1963, several distinct clinical syndromes have been described that are associated with PSP; this discovery challenges the traditional clinicopathological definition and complicates diagnosis in the absence of a reliable, disease-specific biomarker.']\n",
            "unmatched tags:  [{'entity': 'PSP', 'type': 'Gene', 'start': 428, 'end': 431}, {'entity': 'PSP', 'type': 'Gene', 'start': 334, 'end': 337}, {'entity': 'PSP', 'type': 'Gene', 'start': 240, 'end': 243}, {'entity': 'mild dementia', 'type': 'Disease', 'start': 204, 'end': 217}]\n",
            "['Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk\\tOur results show interactions between coding polymorphisms in fibrinogen and factor XIII and fibrinogen concentrations that modify fibrin and explain the apparent paradox between epidemiological studies of factor XIII 34Leu and reported in-vitro effects on fibrin structure and function.', 'We suggest a potential complexity of gene-gene and gene-environment interactions in determining cardiovascular risk.']\n",
            "unmatched tags:  [{'entity': 'fibrin', 'type': 'Gene', 'start': 375, 'end': 381}, {'entity': 'factor XIII', 'type': 'Gene', 'start': 324, 'end': 335}]\n",
            "['Fever, genes, and epilepsy\\tAbout 13% of patients with epilepsy have a history of febrile seizures (FS).', 'Studies of familial forms suggest a genetic component to the epidemiological link.', 'Indeed, in certain monogenic forms of FS, for which several loci have been reported, some patients develop epilepsy with a higher risk than in the general population.', 'Patients with generalised epilepsy with febrile seizures plus (GEFS+) can have typical and isolated FS, FS lasting more beyond age 6 years, and subsequent afebrile (typically generalised) seizures.']\n",
            "unmatched tags:  [{'entity': 'seizures', 'type': 'Phenotype', 'start': 542, 'end': 550}, {'entity': 'FS', 'type': 'Gene', 'start': 458, 'end': 460}, {'entity': 'FS', 'type': 'Gene', 'start': 454, 'end': 456}]\n",
            "['The monoamine neurotransmitter disorders: an expanding range of neurological syndromes\\tThe monoamine neurotransmitter disorders consist of a rapidly expanding heterogeneous group of neurological syndromes characterised by primary and secondary defects in the biosynthesis degradation, or transport of dopamine, norepinephrine, epinephrine, and serotonin.', 'Disease onset can occur any time from infancy onwards.', 'Clinical presentation depends on the pattern and severity of neurotransmitter abnormalities, and is predominated by neurological features (encephalopathy, epilepsy, and pyramidal and extrapyramidal motor disorders) that are primarily attributed to deficiency of cerebral dopamine, serotonin, or both.']\n",
            "unmatched tags:  [{'entity': 'serotonin', 'type': 'Drug', 'start': 691, 'end': 700}, {'entity': 'cerebral dopamine', 'type': 'Drug', 'start': 672, 'end': 689}, {'entity': 'deficiency', 'type': 'Disease', 'start': 658, 'end': 668}, {'entity': 'epilepsy', 'type': 'Disease', 'start': 565, 'end': 573}, {'entity': 'serotonin', 'type': 'Drug', 'start': 344, 'end': 353}]\n",
            "['Loss of IKK subunits limits NF-κB signaling in reovirus infected cells\\tViruses commonly antagonize innate immune pathways that are primarily driven by Nuclear Factor-κB (NF-κB), Interferon Regulatory Factor (IRF) and Signal Transducer and Activator of Transcription (STAT) family of transcription factors.', 'Such a strategy allows viruses to evade immune surveillance and maximize their replication.', 'Using an unbiased RNA-seq based approach to measure gene expression induced by transfected viral genomic RNA (vgRNA) and reovirus infection, we discovered that mammalian reovirus inhibits host cell innate immune signaling.', 'We found that while vgRNA and reovirus infection both induce a similar IRF dependent gene expression program, gene expression driven by the NF-κB family of transcription factors is lower in infected cells.', 'Potent agonists of NF-κB, such as Tumor Necrosis Factor alpha (TNFα) and vgRNA, failed to induce NF-κB dependent gene expression in infected cells.', 'We demonstrate that NF-κB signaling is blocked due to loss of critical members of the Inhibitor of KappaB Kinase (IKK) complex, NF-κB Essential MOdifier (NEMO) and IKKβ.', 'The loss of the IKK complex components prevents nuclear translocation and phosphorylation of NF-κB, thereby preventing gene expression.', 'Our studies demonstrate that reovirus infection selectively blocks NF-κB, likely to counteract its antiviral effects and promote efficient viral replication.', 'IMPORTANCE Host cells mount a response to curb virus replication in infected cells and prevent infection of neighboring, as yet uninfected cells.', 'The NF-κB family of proteins is important for the cell to mediate this response.', 'In this study, we show that in cells infected with mammalian reovirus, NF-κB is inactive.', 'Further, we demonstrate that NF-κB is rendered inactive because virus infection results in reduced levels of upstream intermediaries (called IKKs) that are needed for NF-κB function.', 'Based on previous evidence that active NF-κB limits reovirus infection, we conclude that inactivating NF-κB is a viral strategy to produce a cellular environment that is favorable for virus replication.']\n",
            "unmatched tags:  [{'entity': 'cell', 'type': 'Gene', 'start': 2080, 'end': 2084}, {'entity': 'reovirus infection', 'type': 'Disease', 'start': 1991, 'end': 2009}, {'entity': 'virus infection', 'type': 'Disease', 'start': 1820, 'end': 1835}, {'entity': 'mammalian reovirus', 'type': 'Virus', 'start': 1717, 'end': 1735}, {'entity': 'cell', 'type': 'Gene', 'start': 1697, 'end': 1701}, {'entity': 'cell', 'type': 'Gene', 'start': 1635, 'end': 1639}, {'entity': 'proteins', 'type': 'Gene', 'start': 1605, 'end': 1613}, {'entity': 'cell', 'type': 'Gene', 'start': 1578, 'end': 1582}, {'entity': 'cell', 'type': 'Gene', 'start': 1516, 'end': 1520}, {'entity': 'cell', 'type': 'Gene', 'start': 1455, 'end': 1459}, {'entity': 'reovirus infection', 'type': 'Disease', 'start': 1310, 'end': 1328}, {'entity': 'IKKβ', 'type': 'Gene', 'start': 1139, 'end': 1143}, {'entity': 'NEMO', 'type': 'Gene', 'start': 1129, 'end': 1133}, {'entity': 'NF-κB Essential MOdifier', 'type': 'Gene', 'start': 1103, 'end': 1127}, {'entity': 'KappaB Kinase', 'type': 'Gene', 'start': 1074, 'end': 1087}, {'entity': 'cell', 'type': 'Gene', 'start': 968, 'end': 972}, {'entity': 'TNFα', 'type': 'Gene', 'start': 890, 'end': 894}, {'entity': 'Tumor Necrosis Factor alpha', 'type': 'Gene', 'start': 861, 'end': 888}, {'entity': 'agonists', 'type': 'Drug', 'start': 834, 'end': 842}, {'entity': 'cell', 'type': 'Gene', 'start': 820, 'end': 824}, {'entity': 'transcription factors', 'type': 'Gene', 'start': 777, 'end': 798}, {'entity': 'virus infection', 'type': 'Disease', 'start': 654, 'end': 669}, {'entity': 'reovirus infection', 'type': 'Disease', 'start': 651, 'end': 669}, {'entity': 'innate immune signaling', 'type': 'Chemical', 'start': 596, 'end': 619}, {'entity': 'cell', 'type': 'Gene', 'start': 591, 'end': 595}, {'entity': 'reovirus', 'type': 'Virus', 'start': 568, 'end': 576}, {'entity': 'mammalian reovirus', 'type': 'Virus', 'start': 558, 'end': 576}, {'entity': 'reovirus infection', 'type': 'Disease', 'start': 519, 'end': 537}, {'entity': 'transcription factors', 'type': 'Gene', 'start': 283, 'end': 304}, {'entity': 'Activator of Transcription', 'type': 'Gene', 'start': 239, 'end': 265}, {'entity': 'Interferon Regulatory Factor', 'type': 'Gene', 'start': 178, 'end': 206}, {'entity': 'Nuclear Factor-κB', 'type': 'Gene', 'start': 151, 'end': 168}]\n",
            "['Distribution of rotavirus strains and strain-specific effectiveness of the rotavirus vaccine after its introduction: a systematic review and meta-analysis\\tRV1 and RV5 exert similar effectiveness against homotypic and heterotypic rotavirus strains.', 'Persistence of specific strains was not recorded, suggesting vaccine-induced selective pressure did not occur.', 'Expansion of rotavirus surveillance efforts to low-income countries and ongoing surveillance are crucial to identify emergence of new strains and to assess strain-specific vaccine effectiveness in various settings.']\n",
            "unmatched tags:  [{'entity': 'strains', 'type': 'Disease', 'start': 493, 'end': 500}, {'entity': 'low-income countries', 'type': 'Gene', 'start': 406, 'end': 426}]\n",
            "['Novel paradigms in systemic lupus erythematosus\\tThe heterogeneity of systemic lupus erythematosus (SLE), long recognised by clinicians, is now challenging the entire lupus community, from geneticists to clinical investigators.', 'Although the outlook for patients with SLE has greatly improved, many unmet needs remain, chief of which is the development of safer and more efficacious therapies.', 'To develop innovative therapies, a far better understanding of SLE pathogenesis as it relates to the array of clinical phenotypes is needed.', 'Additionally, to efficiently achieve these goals, the lupus community needs to refine existing clinical research tools and better adapt them to overcome the obstacles created by the heterogeneity of manifestations.']\n",
            "unmatched tags:  [{'entity': 'lupus', 'type': 'Disease', 'start': 587, 'end': 592}, {'entity': 'SLE', 'type': 'Disease', 'start': 455, 'end': 458}]\n",
            "['Management of primary melanoma of the female urogenital tract\\tPrimary melanoma of the urogenital tract in women is rare, but biologically aggressive.', 'They usually affect elderly women and account for less than 10% of all cancer of the urogenital tract in women and less than 10% of all melanoma diagnosed in women.', 'Tumours originate from melanocytes that are present in the urogenital mucosal epithelium of about 3% of women.', 'Tumour staging can be challenging; however, the American Joint Committee on Cancer melanoma staging system has been recommended for use in vulvar and vaginal melanoma.']\n",
            "unmatched tags:  [{'entity': 'vaginal melanoma', 'type': 'Disease', 'start': 576, 'end': 592}, {'entity': 'melanoma', 'type': 'Disease', 'start': 509, 'end': 517}, {'entity': 'Tumours', 'type': 'Disease', 'start': 315, 'end': 322}, {'entity': 'melanoma', 'type': 'Disease', 'start': 286, 'end': 294}]\n",
            "['Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial\\tThe tested chimeric haemagglutinin-based, universal influenza virus vaccine regimens elicited cross-reactive serum IgG antibodies that targeted the conserved haemagglutinin stalk domain.', 'This is the first proof-of-principle study to show that high anti-stalk titres can be induced by a rationally designed vaccine in humans and opens up avenues for further development of universal influenza virus vaccines.', 'On the basis of the blinded study group, the vaccine regimens were tolerable and no safety concerns were observed.']\n",
            "unmatched tags:  [{'entity': 'vaccine', 'type': 'Drug', 'start': 624, 'end': 631}]\n",
            "['Nucleotide Analogues as Inhibitors of SARS-CoV Polymerase\\tSARS-CoV-2, a member of the coronavirus family, has caused a global public health emergency.', '1 Based on our analysis of hepatitis C virus and coronavirus replication, and the molecular structures and activities of viral inhibitors, we previously reasoned that the FDA-approved heptatitis C drug EPCLUSA (Sofosbuvir/Velpatasvir) should inhibit coronaviruses, including SARS-CoV-2.', '2 Here, using model polymerase extension experiments, we demonstrate that the activated triphosphate form of Sofosbuvir is incorporated by low-fidelity polymerases and SARS-CoV RNA-dependent RNA polymerase (RdRp), and blocks further incorporation by these polymerases; the activated triphosphate form of Sofosbuvir is not incorporated by a host-like high-fidelity DNA polymerase.', 'Using the same molecular insight, we selected two other anti-viral agents, Alovudine and AZT (an FDA approved HIV/AIDS drug) for evaluation as inhibitors of SARS-CoV RdRp.', 'We demonstrate the ability of two HIV reverse transcriptase inhibitors, 3’-fluoro-3’-deoxythymidine triphosphate and 3’-azido-3’-deoxythymidine triphosphate (the active triphosphate forms of Alovudine and AZT), to be incorporated by SARS-CoV RdRp where they also terminate further polymerase extension.', 'Given the 98% amino acid similarity of the SARS-CoV and SARS-CoV-2 RdRps, we expect these nucleotide analogues would also inhibit the SARS-CoV-2 polymerase.', 'These results offer guidance to further modify these nucleotide analogues to generate more potent broad-spectrum anti-coronavirus agents.']\n",
            "unmatched tags:  [{'entity': 'nucleotide analogues', 'type': 'Gene', 'start': 1503, 'end': 1523}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1427, 'end': 1437}, {'entity': 'nucleotide analogues', 'type': 'Gene', 'start': 1383, 'end': 1403}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1349, 'end': 1359}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 1336, 'end': 1344}, {'entity': 'amino acid', 'type': 'Gene', 'start': 1307, 'end': 1317}, {'entity': 'polymerase extension', 'type': 'Gene', 'start': 1271, 'end': 1291}, {'entity': 'SARS-CoV RdRp', 'type': 'Virus', 'start': 1223, 'end': 1236}, {'entity': 'AZT', 'type': 'Gene', 'start': 1195, 'end': 1198}, {'entity': 'Alovudine', 'type': 'Gene', 'start': 1181, 'end': 1190}]\n",
            "['Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial\\tI338 can safely improve glycaemic control in insulin-naive patients with type 2 diabetes with no evidence of a difference compared with insulin glargine, a widely used subcutaneously administered basal insulin.', 'Further development of this particular oral insulin project was discontinued because I338 doses were high and, therefore, production of the required quantities of I338 for wide public use was deemed not commercially viable.', \"Improvement of technologies involved in the product's development is the focus of ongoing research.\"]\n",
            "unmatched tags:  [{'entity': 'basal insulin', 'type': 'Gene', 'start': 337, 'end': 350}]\n",
            "['Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia\\tThe data support the future co-administration of IPV, measles–rubella, and yellow fever vaccines within the Expanded Programme on Immunization schedule at 9 months.', 'The administration of single fractional intradermal doses of IPV by needle and syringe or disposable-syringe jet injector compromises the immunity generated, although it results in a high post-vaccination poliovirus seroprevalence.']\n",
            "unmatched tags:  [{'entity': 'post-vaccination', 'type': 'Organization', 'start': 598, 'end': 614}, {'entity': 'IPV', 'type': 'Disease', 'start': 471, 'end': 474}]\n",
            "['Presence of simian virus 40 DNA sequences in human lymphomas\\tSimian virus 40 (SV40)—a potent oncogenic virus—has been associated previously with some types of human tumours, but not with lymphomas.', 'We examined human tumours for the presence of specific SV40 DNA sequences by PCR and Southern blotting.', \"Viral sequences were present in 29 (43%) of 68 non-Hodgkin lymphomas, and in three (9%) of 31 of Hodgkin's lymphomas.\", 'Viral sequences were detected at low frequencies (about 5%) in 235 epithelial tumours of adult and paediatric origin, and were absent in 40 control tissues.']\n",
            "unmatched tags:  [{'entity': 'epithelial tumours', 'type': 'Disease', 'start': 487, 'end': 505}]\n",
            "['Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein\\tThe recent emergence of a novel coronavirus associated with an ongoing outbreak of pneumonia (Covid-2019) resulted in infections of more than 72,000 people and claimed over 1,800 lives.', 'Coronavirus spike (S) glycoprotein trimers promote entry into cells and are the main target of the humoral immune response.', 'We show here that SARS-CoV-2 S mediates entry in VeroE6 cells and in BHK cells transiently transfected with human ACE2, establishing ACE2 as a functional receptor for this novel coronavirus.', 'We further demonstrate that the receptor-binding domains of SARS-CoV-2 S and SARS-CoV S bind with similar affinities to human ACE2, which correlates with the efficient spread of SARS-CoV-2 among humans.', 'We found that the SARS-CoV-2 S glycoprotein harbors a furin cleavage site at the boundary between the S 1 /S 2 subunits, which is processed during biogenesis and sets this virus apart from SARS-CoV and other SARS-related CoVs.', 'We determined a cryo-electron microscopy structure of the SARS-CoV-2 S ectodomain trimer, demonstrating spontaneous opening of the receptor-binding domain, and providing a blueprint for the design of vaccines and inhibitors of viral entry.', 'Finally, we demonstrate that SARS-CoV S murine polyclonal sera potently inhibited SARS-CoV-2 S-mediated entry into target cells, thereby indicating that cross-neutralizing antibodies targeting conserved S epitopes can be elicited upon vaccination.']\n",
            "unmatched tags:  [{'entity': 'cross-neutralizing antibodies', 'type': 'Gene', 'start': 1398, 'end': 1427}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1327, 'end': 1337}, {'entity': 'polyclonal sera', 'type': 'Gene', 'start': 1292, 'end': 1307}, {'entity': 'SARS-CoV S murine', 'type': 'Virus', 'start': 1274, 'end': 1291}, {'entity': 'vaccines', 'type': 'Drug', 'start': 1205, 'end': 1213}, {'entity': 'receptor-binding domain', 'type': 'Gene', 'start': 1136, 'end': 1159}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 1063, 'end': 1073}, {'entity': 'SARS-CoV', 'type': 'Virus', 'start': 967, 'end': 975}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 796, 'end': 806}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 753, 'end': 763}, {'entity': 'ACE2', 'type': 'Gene', 'start': 701, 'end': 705}]\n",
            "['Management of vertebral radiotherapy dose in paediatric patients with cancer: consensus recommendations from the SIOPE radiotherapy working group\\tInhomogeneities in radiotherapy dose distributions covering the vertebrae in children can produce long-term spinal problems, including kyphosis, lordosis, scoliosis, and hypoplasia.', 'In the published literature, many often interrelated variables have been reported to affect the extent of potential radiotherapy damage to the spine.', 'Articles published in the 2D and 3D radiotherapy era instructed radiation oncologists to avoid dose inhomogeneity over growing vertebrae.', 'However, in the present era of highly conformal radiotherapy, steep dose gradients over at-risk structures can be generated and thus less harm is caused to patients.']\n",
            "unmatched tags:  [{'entity': 'era', 'type': 'Gene', 'start': 733, 'end': 736}, {'entity': 'era', 'type': 'Gene', 'start': 671, 'end': 674}, {'entity': 'era', 'type': 'Gene', 'start': 640, 'end': 643}, {'entity': 'era', 'type': 'Gene', 'start': 527, 'end': 530}, {'entity': 'era', 'type': 'Gene', 'start': 521, 'end': 524}, {'entity': 'era', 'type': 'Gene', 'start': 451, 'end': 454}, {'entity': 'era', 'type': 'Gene', 'start': 348, 'end': 351}, {'entity': 'lordosis', 'type': 'Disease', 'start': 291, 'end': 299}, {'entity': 'spinal problems', 'type': 'Disease', 'start': 254, 'end': 269}, {'entity': 'era', 'type': 'Gene', 'start': 172, 'end': 175}, {'entity': 'era', 'type': 'Gene', 'start': 126, 'end': 129}]\n",
            "['SARS-CoV-2 might manipulate against its host the immunity RNAi/Dicer/Ago system\\tThe role of the RNAi/Dicer/Ago system to degrade RNA viruses has been elusive, which prompt authors to think that interferon (IFN) synthesis is essential, relegating the dsRNAs as accessory function.', 'We investigate SARS-CoV-2 genome responsible of the new deadly COVID-19 pandemic for the theoretical possibilities to engage intra pairing within the viral RNA and also hybrid pairing with human transcriptome.', 'Segmental pieces of RNAs that originate from SARS-CoV-2 were computationally searched as a potential source of one strand, the complementary strand being from the host transcriptome.', 'We therefore considered perfect complementarity of host RNA with any piece of SARS-CoV-2 RNA as a collection of theoretical siRNAs potentially Dicer substrates.', 'Few human genes seems targeted by SARS-CoV-2 RNA, among them mitochondrial deubiquitinase USP30 and a subunit of ubiquitin protein ligase complex FBXO21 could explain premature death of infected cell by the collapse of mitochondria.']\n",
            "unmatched tags:  [{'entity': 'cell', 'type': 'Gene', 'start': 1029, 'end': 1033}, {'entity': 'ubiquitin protein ligase complex FBXO21', 'type': 'Gene', 'start': 947, 'end': 986}, {'entity': 'USP30', 'type': 'Gene', 'start': 924, 'end': 929}, {'entity': 'RNA', 'type': 'Gene', 'start': 879, 'end': 882}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 868, 'end': 878}, {'entity': 'siRNAs', 'type': 'Gene', 'start': 797, 'end': 803}, {'entity': 'RNA', 'type': 'Gene', 'start': 762, 'end': 765}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 751, 'end': 761}, {'entity': 'RNA', 'type': 'Gene', 'start': 729, 'end': 732}, {'entity': 'complementarity', 'type': 'Gene', 'start': 705, 'end': 720}, {'entity': 'complementary strand', 'type': 'Gene', 'start': 617, 'end': 637}, {'entity': 'SARS-CoV-2', 'type': 'Virus', 'start': 535, 'end': 545}]\n",
            "['The MAPK signalling pathways and colorectal cancer\\tThere are three major subfamilies of mitogen-activated protein kinases (MAPK): the extracellular-signal-regulated kinases (ERK MAPK); the c-jun N-terminal kinase or stress-activated protein kinases (JNK or SAPK); and MAPK14.', 'The ERK MAPK pathway is one of the most important for cell proliferation.', 'The MAPK pathways are located downstream of many growth-factor receptors, including that for epidermal growth factor.', 'Overexpression and activation of this receptor are commonly detected in colorectal cancer, and several lines of evidence indicate that overexpression and activation of ERK MAPK play an important part in progression of this cancer.']\n",
            "unmatched tags:  [{'entity': 'cancer', 'type': 'Disease', 'start': 691, 'end': 697}]\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "gef3ckFc0LkM",
        "colab_type": "code",
        "colab": {}
      },
      "source": [
        "train_inputs_embeds = prepare_embedding(datas)"
      ],
      "execution_count": null,
      "outputs": []
    }
  ]
}